FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Stewart, SE
Hu, YP
Hezel, DM
Proujansky, R
Lamstein, A
Walsh, C
Ben-Joseph, EP
Gironda, C
Jenike, M
Geller, DA
Pauls, DL
AF Stewart, S. Evelyn
Hu, Yu-Pei
Hezel, Dianne M.
Proujansky, Rachel
Lamstein, Abby
Walsh, Casey
Ben-Joseph, Elana Pearl
Gironda, Christina
Jenike, Michael
Geller, Daniel A.
Pauls, David L.
TI Development and Psychometric Properties of the OCD Family Functioning
(OFF) Scale
SO JOURNAL OF FAMILY PSYCHOLOGY
LA English
DT Article
DE obsessive-compulsive disorder; family; accommodation; functioning; scale
ID OBSESSIVE-COMPULSIVE DISORDER; ACCOMMODATION; CHILDREN; RELIABILITY;
ADOLESCENTS; IMPAIRMENT; PREDICTORS; SYMPTOMS; GUILT; AGE
AB Obsessive-compulsive disorder (OCD) influences not only patients but also family members. Although the construct of family accommodation has received attention in OCD literature, no measures of overall family functioning are currently available. The OCD Family Functioning (OFF) Scale was developed to explore the context, extent, and perspectives of functional impairment in families affected by OCD. It is a three-part, self-report measure capturing independent perspectives of patients and relatives. A total of 400 subjects were enrolled between 2008 and 2010 from specialized OCD clinics and OCD research studies. Psychometric properties of this scale were examined including internal consistency, test-retest reliability, convergent and divergent validity, and exploratory factor analyses. Both patient and relative versions of the OFF Scale demonstrated excellent internal consistency (Cronbach's alpha coefficient = 0.96). The test-retest reliability was also adequate (ICC = 0.80). Factor analyses determined that the OFF Scale comprises a family functioning impairment factor and four OCD symptom factors that were consistent with previously reported OCD symptom dimension studies. The OFF Scale demonstrated excellent convergent validity with the Family Accommodation Scale and the Work and Social Adjustment Scale. Information gathered regarding emotional impact and family role-specific impairment was novel and not captured by other examined scales. The OFF Scale is a reliable and valid instrument for the clinical and research assessment of family functioning in pediatric and adult OCD. This will facilitate the exploration of family functioning impairment as a potential risk factor, as a moderator and as a treatment outcome measure in OCD.
C1 [Stewart, S. Evelyn] Univ British Columbia, OCD Res Program, Vancouver, BC V5Z 1M9, Canada.
[Stewart, S. Evelyn] Harvard Univ, Sch Med, Vancouver, BC, Canada.
[Hu, Yu-Pei; Lamstein, Abby; Gironda, Christina] Mclean Hosp, OCD Inst, Belmont, MA USA.
[Hezel, Dianne M.; Proujansky, Rachel; Walsh, Casey; Ben-Joseph, Elana Pearl] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Jenike, Michael] Harvard Univ, Sch Med, Belmont, MA 02178 USA.
[Jenike, Michael] McLean Hosp, OCD Inst, Belmont, MA 02178 USA.
[Geller, Daniel A.; Pauls, David L.] Harvard Univ, Med School, Cambridge, MA 02138 USA.
RP Stewart, SE (reprint author), BC Childrens Hosp, Child & Family Res Inst, 938 W28th Ave,Room A3-118, Vancouver, BC V5Z 4H4, Canada.
EM sevelynstewart@gmail.com
OI Stewart, S. Evelyn/0000-0002-0994-6383
FU NIMH NIH HHS [R01 MH079489, R01MH79489-4]
NR 37
TC 12
Z9 12
U1 3
U2 9
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0893-3200
J9 J FAM PSYCHOL
JI J. Fam. Psychol.
PD JUN
PY 2011
VL 25
IS 3
BP 434
EP 443
DI 10.1037/a0023735
PG 10
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA 776AS
UT WOS:000291507500012
PM 21553962
ER
PT J
AU Rowe, LS
Doss, BD
Hsueh, AC
Libet, J
Mitchell, AE
AF Rowe, Lorelei Simpson
Doss, Brian D.
Hsueh, Annie C.
Libet, Julian
Mitchell, Alexandra E.
TI Coexisting Difficulties and Couple Therapy Outcomes: Psychopathology and
Intimate Partner Violence
SO JOURNAL OF FAMILY PSYCHOLOGY
LA English
DT Article
DE couple therapy; relationship satisfaction; psychopathology; intimate
partner violence; marriage
ID MARITAL SATISFACTION; QUALITY
AB Couples presenting for treatment of relationship distress often experience additional problems, including individual psychopathology and intimate partner violence (IPV). Both issues are associated with current and future poor relationship functioning in nontreatment samples, but relatively little is understood about their association with initial presentation and outcomes in couple therapy. The current study examined these associations in a sample of 177 heterosexual couples who received therapy at two Veteran's Affairs clinics. Unlike most studies of couple therapy outcomes, couples were not excluded from treatment specifically because of high levels of psychopathology or IPV. Results of Actor Partner Interdependence Model (APIM) analyses revealed actor and partner effects of depression, actor effects of anxiety, and partner effects of IPV on initial relationship satisfaction, such that greater coexisting difficulties were associated with poorer initial satisfaction. However, improvement in relationship satisfaction over the course of therapy was not associated with psychopathology, and, contrary to hypothesis, was positively associated with men's IPV prior to treatment, even when initial level of satisfaction was controlled. The results suggest that coexisting symptoms of psychopathology or IPV may not necessarily interfere with therapy outcomes and, indeed, therapy may have positive effects for couples with these problems.
C1 [Rowe, Lorelei Simpson; Mitchell, Alexandra E.] So Methodist Univ, Dept Psychol, Dallas, TX 75275 USA.
[Doss, Brian D.] Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA.
[Hsueh, Annie C.] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA.
[Libet, Julian] Ralph H Johnson VA Med Ctr, Psychol Serv, Charleston, SC USA.
RP Rowe, LS (reprint author), So Methodist Univ, Dept Psychol, POB 750442, Dallas, TX 75275 USA.
EM lsimpson@smu.edu
NR 8
TC 4
Z9 4
U1 1
U2 7
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0893-3200
J9 J FAM PSYCHOL
JI J. Fam. Psychol.
PD JUN
PY 2011
VL 25
IS 3
BP 455
EP 458
DI 10.1037/a0023696
PG 4
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA 776AS
UT WOS:000291507500015
PM 21534671
ER
PT J
AU Webb, ML
Rosen, H
Taghinia, A
McCarty, ER
Cerrato, F
Upton, J
Labow, BI
AF Webb, Michelle L.
Rosen, Heather
Taghinia, Amir
McCarty, Erika R.
Cerrato, Felecia
Upton, Joseph
Labow, Brian I.
TI Incidence of Fanconi Anemia in Children with Congenital Thumb Anomalies
Referred for Diepoxybutane Testing
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Congenital; Fanconi anemia; radius; hypoplasia; thumb
ID BONE-MARROW FAILURE; REGISTRY; DIAGNOSIS; CANCER; RISKS
AB Purpose Fanconi anemia (FA) is a rare genetic disorder of DNA repair that with near uniformity leads to bone marrow failure and resulting morbidity and mortality. Approximately 50% of FA patients are born with anomalies of the thumb or thumb and radius, and it has been recommended that all patients born with thumb anomalies undergo testing. However, the risk of FA in this population is unknown. We determined the incidence of FA in children with congenital thumb anomalies referred for FA testing and characterized those who tested positive.
Methods We queried our database for patients who presented with congenital thumb anomalies and who underwent diepoxybutane (DEB) testing for FA between 1999 and 2008 at Children's Hospital Boston and the Dana-Farber Cancer Institute.
Results During this time period, 543 congenital thumb anomaly patients (235 with thumb hypoplasia) presented to our institution. A total of 81 patients with thumb abnormalities underwent DEB testing. Six patients (7% of those tested; 1% of the total; 3% of thumb hypoplasia patients) had a positive DEB test consistent with the diagnosis of FA; all had other non-upper-extremity anomalies associated with FA. Of 6 FA patients, 5 had bilateral involvement; all had some degree of thumb hypoplasia (3 also had radial dysplasia). Mean age at testing was 2.6 years (SD 4.3). Most of the patients tested had multiple physical anomalies (n = 66). The anomaly distribution was: thumb hypoplasia and radial dysplasia (n = 29), thumb hypoplasia (n = 26), radial polydactyly (n = 12), radial polydactyly and radial dysplasia (n = 1), and proximally placed thumb and radial dysplasia (n = 1). Twelve patients had other thumb anomalies.
Conclusions Although the incidence of FA in patients with thumb anomalies may be low, patients with thumb hypoplasia and other physical findings associated with FA, specifically cafe au lait spots and short stature, appear to have an increased risk of FA. Because hand surgeons see these patients early in life, they have the opportunity to refer these patients for FA testing to initiate early education, family genetic counseling, and treatment if warranted. (J Hand Surg 2011;36A: 1052-1057. Copyright (C) 2011 by the American Society for Surgery of the Hand. All rights reserved.) Type of study/level of evidence Prognostic IV.
C1 [Labow, Brian I.] Childrens Hosp, Dept Plast & Oral Surg, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
Childrens Hosp, Fanconi Anemia & Bone Marrow Failure Multidiscipl, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Labow, BI (reprint author), Childrens Hosp, Dept Plast & Oral Surg, 300 Longwood Ave,Enders 1, Boston, MA 02115 USA.
EM brian.labow@childrens.harvard.edu
NR 22
TC 7
Z9 7
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD JUN
PY 2011
VL 36A
IS 6
BP 1052
EP 1057
DI 10.1016/j.jhsa.2011.02.018
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 776XD
UT WOS:000291572900016
PM 21514743
ER
PT J
AU Fusco, DN
Chung, RT
AF Fusco, Dahlene N.
Chung, Raymond T.
TI New protease inhibitors for HCV - Help is on the way
SO JOURNAL OF HEPATOLOGY
LA English
DT Editorial Material
ID NUCLEOSIDE POLYMERASE R7128; HEPATITIS-C; INFECTION; TELAPREVIR;
PHARMACOKINETICS; PEGINTERFERON; COMBINATION; RIBAVIRIN; INFORM-1;
SAFETY
C1 [Fusco, Dahlene N.; Chung, Raymond T.] Massachusetts Gen Hosp, GI Unit, Boston, MA 02114 USA.
RP Chung, RT (reprint author), Massachusetts Gen Hosp, GI Unit, 55 Fruit St,Warren 1007, Boston, MA 02114 USA.
EM rtchung@partners.org
NR 20
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD JUN
PY 2011
VL 54
IS 6
BP 1087
EP 1089
DI 10.1016/j.jhep.2010.12.016
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 776GR
UT WOS:000291523000002
PM 21232563
ER
PT J
AU Bieganski, RM
Yarmush, ML
AF Bieganski, Robert M.
Yarmush, Martin L.
TI Novel ligands that target the mitochondrial membrane protein mitoNEET
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE Mitoneet; Autodock; Docking; Fluorescence; Iron-sulfur;
Thiazolidinedione
ID AMYOTROPHIC-LATERAL-SCLEROSIS; PPAR-GAMMA; TRANSGENIC MICE;
PIOGLITAZONE; DOCKING; THIAZOLIDINEDIONE; CELLS; SYSTEM;
NEURODEGENERATION; STABILIZATION
AB Ligands of the thiazolidinedione (TZD) class of compounds, pioglitazone (Actos (TM)) and rosiglitazone (Avandia (TM)) are currently approved for treatment of type 2 diabetes and are known to bind to the PPAR-gamma gamma nuclear receptor subtype. Recent evidence suggesting PPAR-gamma independent action of the TZDs led to the discovery of a novel integral outer mitochondrial membrane protein, mitoNEET. In spite of the several reported X-ray crystal structures of the unbound form cif mitoNEET, the location and nature of the mitoNEET ligand binding sites (LBS) remain unknown. In this study, a molecular blind docking (BD) method was used to discover potential mitoNEET LBS and novel ligands, utilizing the program AutoDock Vina (v 1.0.2). Validation of BD was performed on the PPAR-gamma receptor (PDB ID: 1ZGY) with the test compound rosiglitazone, demonstrating that the binding conformation of rosiglitazone determined by AutoDock Vina matches well with that of the cocrystallized ligand (root mean square deviation of the heavy atoms 1.45 angstrom). The locations and a general ligand binding interaction model for the LBS were determined, leading to the discovery of novel mitoNEET ligands. An in vitro fluorescence binding assay utilizing purified recombinant mitoNEET protein was used to determine the binding affinity of a predicted mitoNEET ligand, and the data obtained is in good agreement with AutoDock Vina results. The discovery of potential mitoNEET ligand binding sites and novel ligands, opens up the possibility for detailed structural studies of mitoNEET-ligand complexes, as well as rational design of novel ligands specifically targeted for mitoNEET. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Bieganski, Robert M.; Yarmush, Martin L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA.
[Bieganski, Robert M.; Yarmush, Martin L.] Shriners Hosp Children, Dept Surg, Boston, MA 02114 USA.
[Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA.
RP Yarmush, ML (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, 51 Blossom St, Boston, MA 02114 USA.
EM rbieg2008@gmail.com
FU National Institute Of Diabetes And Digestive And Kidney Diseases
[R01DK059766]
FX The project described was supported by Award Number R01DK059766 from the
National Institute Of Diabetes And Digestive And Kidney Diseases. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute Of
Diabetes And Digestive And Kidney Diseases or the National Institutes of
Health. We wish to gratefully acknowledge Max R. Bieganski for creating
graphical content and providing technical support, and Dr. Sandra Wiley,
from the Department of Pharmacology at the University of California, San
Diego, for providing purified recombinant mitoNEET protein samples, as
well as Prof. JoAnne Stubbe, from the Departments of Biology and
Chemistry at the Massachusetts Institute of Technology, for providing
access to the QM-4-SE fluorimeter used in this study.
NR 41
TC 18
Z9 19
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD JUN
PY 2011
VL 29
IS 7
BP 965
EP 973
DI 10.1016/j.jmgm.2011.04.001
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
Science, Interdisciplinary Applications; Crystallography; Mathematical &
Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
Mathematical & Computational Biology
GA 774VL
UT WOS:000291414700009
PM 21531159
ER
PT J
AU Jackson, VA
Back, AL
AF Jackson, Vicki A.
Back, Anthony L.
TI Teaching Communication Skills Using Role-Play: An Experience-Based Guide
for Educators
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID PALLIATIVE CARE; FACULTY-DEVELOPMENT; BAD-NEWS; ONCOLOGISTS; PHYSICIANS;
PROGRAM
AB Teaching advanced communication skills requires educators who are not only excellent communicators themselves but have the ability to deconstruct the components of the interaction and develop a cognitive approach that can be used across a variety of learners, diverse content, and under different time constraints while helping the learner develop the skill of self-reflection in a 'safe' and effective learning environment. The use of role-play in small groups is an important method to help learners cultivate the skills required to engage in nuanced, often difficult conversations with seriously ill patients. To be effective, educators utilizing role-play must help learners set realistic goals and know when and how to provide feedback to the learners in a way that allows a deepening of skills and a promotion of self-awareness. The challenge is to do this in a manner that does not cause too much anxiety for the learner. In this article we outline an approach to teaching communication skills to advanced learners through the use of different types of role-play, feedback, and debriefing.
C1 [Jackson, Vicki A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Palliat Care Unit, Boston, MA 02115 USA.
[Back, Anthony L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
RP Jackson, VA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Palliat Care Unit, Founders 600,55 Fruit St, Boston, MA 02115 USA.
EM VJackson@partners.org
FU NIH [R25 119019]
FX Dr. Back was supported by NIH R25 119019.
NR 22
TC 23
Z9 23
U1 0
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN
PY 2011
VL 14
IS 6
BP 775
EP 780
DI 10.1089/jpm.2010.0493
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 775CC
UT WOS:000291433700019
PM 21651366
ER
PT J
AU Hopwood, CJ
Malone, JC
Ansell, EB
Sanislow, CA
Gill, CM
McGlashan, TH
Pinto, A
Markowitz, JC
Shea, MT
Skodol, AE
Gunderson, JG
Zanarini, MC
Morey, LC
AF Hopwood, Christopher J.
Malone, Johanna C.
Ansell, Emily B.
Sanislow, Charles A.
Gill, Carlos M.
McGlashan, Thomas H.
Pinto, Anthony
Markowitz, John C.
Shea, M. Tracie
Skodol, Andrew E.
Gunderson, John G.
Zanarini, Mary C.
Morey, Leslie C.
TI PERSONALITY ASSESSMENT IN DSM-5: EMPIRICAL SUPPORT FOR RATING SEVERITY,
STYLE, AND TRAITS
SO JOURNAL OF PERSONALITY DISORDERS
LA English
DT Article
ID 5-FACTOR MODEL; DISCRIMINANT VALIDITY; DIMENSIONAL MODELS; CLINICAL
UTILITY; DISORDERS; IV; CLASSIFICATION; RELIABILITY; BORDERLINE;
PSYCHOPATHOLOGY
AB Despite a general consensus that dimensional models are superior to the categorical representations of personality disorders in DSM-IV, proposals for how to depict personality pathology dimensions vary substantially. One important question involves how to separate clinical severity from the style of expression through which personality pathology manifests. This study empirically distinguished stylistic elements of personality pathology symptoms from the overall severity of personality disorder in a large, longitudinally assessed clinical sample (N = 605). Data suggest that generalized severity is the most important single predictor of current and prospective dysfunction, but that stylistic elements also indicate specific areas of difficulty. Normative personality traits tend to relate to the general propensity for personality pathology, but not stylistic elements of personality disorders. Overall, findings support a three-stage diagnostic strategy involving a global rating of personality disorder severity, ratings of parsimonious and discriminant valid stylistic elements of personality disorder, and ratings of normative personality traits.
C1 [Hopwood, Christopher J.] Michigan State Univ, E Lansing, MI 48824 USA.
[Ansell, Emily B.; Gill, Carlos M.; McGlashan, Thomas H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ansell, Emily B.; Gill, Carlos M.; McGlashan, Thomas H.; Gunderson, John G.; Zanarini, Mary C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Ansell, Emily B.; Gill, Carlos M.; McGlashan, Thomas H.] Yale Univ, Sch Med, New Haven, CT 06520 USA.
[Pinto, Anthony; Markowitz, John C.; Skodol, Andrew E.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Pinto, Anthony] Columbia Coll Phys & Surg, New York, NY USA.
[Markowitz, John C.] Cornell Univ, Ithaca, NY 14853 USA.
[Shea, M. Tracie] Brown Univ, Warren Alpert Med Sch, Dept Vet Affairs, Providence, RI 02912 USA.
[Shea, M. Tracie] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA.
[Gunderson, John G.; Zanarini, Mary C.] McLean Hosp, Belmont, MA USA.
[Morey, Leslie C.] Texas A&M Univ, College Stn, TX 77843 USA.
[Sanislow, Charles A.] Wesleyan Univ, Middletown, CT 06459 USA.
RP Hopwood, CJ (reprint author), Michigan State Univ, 107A Psychol, E Lansing, MI 48824 USA.
EM hopwood2@msu.edu
RI Morey, Leslie/B-5617-2008; Pinto, Anthony/D-2718-2017
OI Morey, Leslie/0000-0001-7711-5568; Pinto, Anthony/0000-0002-6078-7242
NR 44
TC 81
Z9 82
U1 2
U2 15
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 0885-579X
J9 J PERS DISORD
JI J. Pers. Disord.
PD JUN
PY 2011
VL 25
IS 3
BP 305
EP 320
PG 16
WC Psychiatry
SC Psychiatry
GA 774FG
UT WOS:000291369900003
PM 21699393
ER
PT J
AU Apfel, BA
Otte, C
Inslicht, SS
McCaslin, SE
Henn-Haase, C
Metzler, TJ
Makotkine, I
Yehuda, R
Neylan, TC
Marmar, CR
AF Apfel, Brigitte A.
Otte, Christian
Inslicht, Sabra S.
McCaslin, Shannon E.
Henn-Haase, Clare
Metzler, Thomas J.
Makotkine, Iouri
Yehuda, Rachel
Neylan, Thomas C.
Marmar, Charles R.
TI Pretraumatic prolonged elevation of salivary MHPG predicts peritraumatic
distress and symptoms of post-traumatic stress disorder
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Neuroendocrinology; Post-traumatic stress disorder; Stress test;
Salivary MHPG; Prospective study; Police
ID HEART-RATE; PSYCHOLOGICAL STRESS; PTSD SYMPTOMS; PSYCHOBIOLOGICAL
RESPONSES; PSYCHOMETRIC PROPERTIES; EMERGENCY-DEPARTMENT; CHILDHOOD
TRAUMA; MEMORY STORAGE; PLASMA-LEVELS; NOREPINEPHRINE
AB Post-traumatic stress disorder (PTSD) is associated with elevated catecholamines and increased sympathetic arousal. However, it is unknown whether this condition is a pre-existing vulnerability factor for PTSD or an acquired result of either trauma exposure or the development of FTSD symptoms. We sought to examine if salivary 3-methoxy-4-hydroxy-phenylglycol (MHPG) in response to a laboratory stressor prior to critical incident exposure predicts the development of PTSD symptoms and if early childhood trauma influences this relationship. In a prospective cohort study, 349 urban police officers were assessed during academy training (baseline) and 243 were reassessed 12 months after the start of active duty (follow-up). At baseline, participants observed a video consisting of police critical incidents. Salivary MHPG was measured before and immediately after the challenge, and after 20 min recovery. At follow-up, peritraumatic distress and PTSD symptoms were assessed in relationship to the worst critical incident during the past year. Participants with childhood trauma showed a trend towards higher MHPG increase to the challenge. Higher MHPG levels after 20 min recovery were associated with both higher levels of peritraumatic distress and PTSD symptoms at follow-up. In a path analysis, elevated MHPG levels predicted higher peritraumatic distress which in turn predicted higher levels of PTSD symptoms while the direct effect of elevated MHPG levels on PTSD symptoms was no longer significant. Prolonged elevation of salivary MHPG in response to a laboratory stressor marks a predisposition to experience higher levels of peritraumatic distress and subsequently more PTSD symptoms following critical incident exposure. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Apfel, Brigitte A.; Inslicht, Sabra S.; McCaslin, Shannon E.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Apfel, Brigitte A.; Inslicht, Sabra S.; McCaslin, Shannon E.; Metzler, Thomas J.; Neylan, Thomas C.] Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA.
[Otte, Christian] Univ Hosp Hamburg Eppendorf, Dept Psychiat, Hamburg, Germany.
[Makotkine, Iouri; Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Henn-Haase, Clare; Marmar, Charles R.] NYU, Dept Psychiat, New York, NY 10016 USA.
RP Apfel, BA (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, 116D,4150 Clement St, San Francisco, CA 94121 USA.
EM brigitte.apfel@ucsf.edu
FU Glaxo Smith Kline; Actelion; NIMH [5R01-MH056350-10]
FX Dr. Neylan has served on the Pfizer-Advisory Panel and received research
support from Glaxo Smith Kline and Actelion. Dr. Marmar has served on
the Pfizer-Advisory Panel. All other authors declare that they have no
conflicts of interest.; Funding for this study was provided by NIMH
Grant 5R01-MH056350-10; the NIMH had no further role in study design; in
the collection, analysis and interpretation of data; in the writing of
the report; and in the decision to submit the paper for publication.
NR 67
TC 9
Z9 9
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2011
VL 45
IS 6
BP 735
EP 741
DI 10.1016/j.jpsychires.2010.11.016
PG 7
WC Psychiatry
SC Psychiatry
GA 776XH
UT WOS:000291573400004
PM 21196013
ER
PT J
AU Goodman, M
Hazlett, EA
Avedon, JB
Siever, DR
Chu, KW
New, AS
AF Goodman, Marianne
Hazlett, Erin A.
Avedon, Jennifer B.
Siever, Daniel R.
Chu, King-Wai
New, Antonia S.
TI Anterior cingulate volume reduction in adolescents with borderline
personality disorder and co-morbid major depression
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Borderline personality disorder; Adolescent; Structural neuroimaging;
MRI; anterior cingulate; Major depression
ID CORTEX; AGGRESSION; SYMPTOMS; OUTCOMES; MATTER; GRAY; MRI
AB Borderline Personality Disorder (BPD) is a serious illness characterized by emotional dysregulation, impulsivity, and impaired interpersonal relationships. Prior work shows the anterior cingulate gyrus (ACG)-a region primarily involved in assessing the salience of emotional information and regulating emotional responses-is smaller in adults with BPD. We tested the hypothesis that, similar to adults, adolescents with BPD would have reduced Brodmann area (BA)-24 volume. Thirteen adolescent inpatients with co-morbid BPD and Major Depressive Disorder (MDD) and 13 matched healthy controls received 3T-MRI scans. Using a cytoarchitecturally-derived approach measuring gray and white matter volume, we observed a Group x Cingulate BA (25,24,31,23,29) x Matter (gray, white) type interaction indicating the BPD/MDD adolescents had smaller BA24 volume in gray but not white matter. Greater number of suicide attempts and BPD symptom severity measured by the Diagnostic Interview for BPD-revised (DIB-R) total score but not depressive symptoms measured by the Beck Depression Inventory (BDI) was associated with smaller BA24 volume. Our preliminary findings suggest that BPD-related abnormalities in BA24 volume may occur early in the developmental course of BPD with MDD. Future studies examining samples of MDD patients with and without BPD co-morbidity will be needed to clarify whether BA24 volume reductions are specific to BPD. Published by Elsevier Ltd.
C1 [Goodman, Marianne; Hazlett, Erin A.; Avedon, Jennifer B.; New, Antonia S.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
RP Goodman, M (reprint author), James J Peters Dept Vet Adm Med Ctr, 130 W Kingsbridge Rd,Off 3B-20B, Bronx, NY 10468 USA.
EM Marianne.goodman@va.gov
FU VA; NIMH [R01MH073911]; National Center for Research Resources (NCRR)
[M01-Patient Care RR-0071]; Mental Illness Research and ClinicalCenter;
VISN 3 Veterans Heath Administration
FX This work was supported by a VA Career Development grant to MG and NIMH
grant R01MH073911 to EAH. Other support came from grant M01-Patient Care
RR-0071 from the National Center for Research Resources (NCRR) and the
Mental Illness Research and ClinicalCenter, VISN 3 Veterans Heath
Administration. These funding sources had no further role in study
design; in the collection, analysis and interpretation of data; in the
writing of the report; and in the decision to submit the paper for
publication.
NR 27
TC 31
Z9 31
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2011
VL 45
IS 6
BP 803
EP 807
DI 10.1016/j.jpsychires.2010.11.011
PG 5
WC Psychiatry
SC Psychiatry
GA 776XH
UT WOS:000291573400013
PM 21145068
ER
PT J
AU Farwell, WR
D'Avolio, LW
Scranton, RE
Lawler, EV
Gaziano, JM
AF Farwell, Wildon R.
D'Avolio, Leonard W.
Scranton, Richard E.
Lawler, Elizabeth V.
Gaziano, J. Michael
TI Statins and Prostate Cancer Diagnosis and Grade in a Veterans Population
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID CHOLESTEROL-LOWERING DRUGS; RISK; ASSOCIATION; COHORT; HEALTH;
CAVEOLIN-1; TRIAL; CELLS
AB Background Although prostate cancer is commonly diagnosed, few risk factors for high-grade prostate cancer are known and few prevention strategies exist. Statins have been proposed as a possible treatment to prevent prostate cancer.
Methods Using electronic and administrative files from the Veterans Affairs New England Healthcare System, we identified 55 875 men taking either a statin or antihypertensive medication. We used age-and multivariable-adjusted Cox proportional hazard models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for prostate cancer incidence among patients taking statins (n = 41 078) compared with patients taking antihypertensive medications (n = 14 797). We performed similar analyses for all lipid parameters including total cholesterol examining each lipid parameter as a continuous variable and by quartiles. All statistical tests were two-sided.
Results Compared with men taking an antihypertensive medication, statin users were 31% less likely (HR = 0.69, 95% CI = 0.52 to 0.90) to be diagnosed with prostate cancer. Furthermore, statin users were 14% less likely (HR = 0.86, 95% CI = 0.62 to 1.20) to be diagnosed with low-grade prostate cancer and 60% less likely (HR = 0.40, 95% CI = 0.24 to 0.65) to be diagnosed with high-grade prostate cancer compared with antihypertensive medication users. Increased levels of total cholesterol were also associated with both total (HR = 1.02, 95% CI = 1.00 to 1.05) and high-grade (HR = 1.06, 95% CI = 1.02 to 1.10) prostate cancer incidence but not with low-grade prostate cancer incidence (HR = 1.01, 95% CI = 0.98 to 1.04).
Conclusions Statin use is associated with statistically significantly reduced risk for total and high-grade prostate cancer, and increased levels of serum cholesterol are associated with higher risk for total and high-grade prostate cancer. These findings indicate that clinical trials of statins for prostate cancer prevention are warranted.
C1 [Farwell, Wildon R.] VA Boston Healthcare Syst, Boston Div MAV 151, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02130 USA.
[Farwell, Wildon R.; Scranton, Richard E.; Lawler, Elizabeth V.; Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Lawler, Elizabeth V.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
RP Farwell, WR (reprint author), VA Boston Healthcare Syst, Boston Div MAV 151, Massachusetts Vet Epidemiol Res & Informat Ctr, 150 S Huntington Ave, Boston, MA 02130 USA.
EM wfarwell@partners.org
FU Department of Defense [W81XWH-08-2-0168]; Department of Veterans Affairs
Office of Research and Development [601, 96]
FX Research award W81XWH-08-2-0168 from the Department of Defense and
grants 601 and 96 from the Cooperative Studies Program, Department of
Veterans Affairs Office of Research and Development.
NR 24
TC 44
Z9 44
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD JUN
PY 2011
VL 103
IS 11
BP 885
EP 892
DI 10.1093/jnci/djr108
PG 8
WC Oncology
SC Oncology
GA 775VG
UT WOS:000291490900010
PM 21498780
ER
PT J
AU Newgard, CD
Nelson, MJ
Kampp, M
Saha, S
Zive, D
Schmidt, T
Daya, M
Jui, J
Wittwer, L
Warden, C
Sahni, R
Stevens, M
Gorman, K
Koenig, K
Gubler, D
Rosteck, P
Lee, J
Hedges, JR
AF Newgard, Craig D.
Nelson, Maria J.
Kampp, Michael
Saha, Somnath
Zive, Dana
Schmidt, Terri
Daya, Mohamud
Jui, Jonathan
Wittwer, Lynn
Warden, Craig
Sahni, Ritu
Stevens, Mark
Gorman, Kyle
Koenig, Karl
Gubler, Dean
Rosteck, Pontine
Lee, Jan
Hedges, Jerris R.
TI Out-of-Hospital Decision Making and Factors Influencing the Regional
Distribution of Injured Patients in a Trauma System
SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE
LA English
DT Article; Proceedings Paper
CT 10th Annual Academic Emergency Medicine Consensus Conference/Annual
Meeting of the Society-for-Academic-Emergency-Medicine
CY MAY 13, 2009
CL New Orleans, LA
SP Soc Acad Emergency Med
DE Triage; Cognitive reasoning; Emergency medical services; Trauma
ID EMERGENCY MEDICAL-SERVICES; PARAMEDIC JUDGMENT; PROBABILISTIC LINKAGE;
NATIONAL EVALUATION; FIELD TRIAGE; MORTALITY; SEVERITY; THINKING; CARE
AB Background: The decision-making processes used for out-of-hospital trauma triage and hospital selection in regionalized trauma systems remain poorly understood. The objective of this study was to assess the process of field triage decision making in an established trauma system.
Methods: We used a mixed methods approach, including emergency medical services (EMS) records to quantify triage decisions and reasons for hospital selection in a population-based, injury cohort (2006-2008), plus a focused ethnography to understand EMS cognitive reasoning in making triage decisions. The study included 10 EMS agencies providing service to a four-county regional trauma system with three trauma centers and 13 nontrauma hospitals. For qualitative analyses, we conducted field observation and interviews with 35 EMS field providers and a round table discussion with 40 EMS management personnel to generate an empirical model of out-of-hospital decision making in trauma triage.
Results: A total of 64,190 injured patients were evaluated by EMS, of whom 56,444 (88.0%) were transported to acute care hospitals and 9,637 (17.1% of transports) were field trauma activations. For nontrauma activations, patient/family preference and proximity accounted for 78% of destination decisions. EMS provider judgment was cited in 36% of field trauma activations and was the sole criterion in 23% of trauma patients. The empirical model demonstrated that trauma triage is driven primarily by EMS provider "gut feeling" (judgment) and relies heavily on provider experience, mechanism of injury, and early visual cues at the scene.
Conclusions: Provider cognitive reasoning for field trauma triage is more heuristic than algorithmic and driven primarily by provider judgment, rather than specific triage criteria.
C1 [Newgard, Craig D.; Nelson, Maria J.; Kampp, Michael; Zive, Dana; Schmidt, Terri; Daya, Mohamud; Jui, Jonathan; Warden, Craig; Sahni, Ritu] Oregon Hlth & Sci Univ, Dept Emergency Med, Ctr Policy & Res Emergency Med, Portland, OR 97239 USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
[Schmidt, Terri] Clackamas Cty Amer Med Response, Clackamas, OR USA.
[Daya, Mohamud; Stevens, Mark] Tualatin Valley Fire & Rescue, Aloha, OR USA.
[Jui, Jonathan] Multnomah Cty Emergency Med Serv, Multnomah Cty Hlth Dept, Portland, OR USA.
[Wittwer, Lynn] Clark Cty Emergency Med Serv, Vancouver, WA USA.
[Warden, Craig; Gorman, Kyle; Koenig, Karl] Clackamas Cty Fire Dist 1, Clackamas, OR USA.
[Sahni, Ritu] EMS & Trauma Syst, Oregon Dept Human Serv, Publ Hlth Div, Portland, OR USA.
[Gubler, Dean] Legacy Emanuel Trauma Program, Portland, OR USA.
[Rosteck, Pontine] NW Amer Med Response, Portland, OR USA.
[Lee, Jan] Metrowest Ambulance, Hillsboro, OR USA.
[Hedges, Jerris R.] Univ Hawaii Manoa, Dept Med, John A Burns Sch Med, Honolulu, HI 96822 USA.
RP Newgard, CD (reprint author), Oregon Hlth & Sci Univ, Dept Emergency Med, Ctr Policy & Res Emergency Med, 3181 SW Sam Jackson Pk Rd,Mail Code CR-114, Portland, OR 97239 USA.
EM newgardc@ohsu.edu
FU NCRR NIH HHS [UL1 RR024140, UL1 RR024140-01]; NIMHD NIH HHS [U54
MD007584]
NR 30
TC 22
Z9 22
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-5282
J9 J TRAUMA
JI J. Trauma-Injury Infect. Crit. Care
PD JUN
PY 2011
VL 70
IS 6
BP 1345
EP 1353
DI 10.1097/TA.0b013e3182191a1b
PG 9
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 775QR
UT WOS:000291478500013
PM 21817971
ER
PT J
AU Aranson, NJ
Ergul, E
Patel, VI
LaMuraglia, GM
Kwolek, CJ
Cambria, RP
Conrad, MF
AF Aranson, Nathan J.
Ergul, Emel
Patel, Virendra I.
LaMuraglia, Glenn M.
Kwolek, Christopher J.
Cambria, Richard P.
Conrad, Mark F.
TI Timing of TEVAR Does Not Influence Mortality After Hybrid Repair of
Thoracoabdominal Aneurysms
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 16-18, 2011
CL Chicago, IL
SP Soc Vasc Surg
C1 [Aranson, Nathan J.; Ergul, Emel; Patel, Virendra I.; LaMuraglia, Glenn M.; Kwolek, Christopher J.; Cambria, Richard P.; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
OI Aranson, Nathan/0000-0001-8833-4643
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2011
VL 53
SU S
BP 12S
EP 12S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 774TY
UT WOS:000291410700020
ER
PT J
AU Blazick, E
Haurani, MJ
Patel, VI
LaMuraglia, GM
Kwolek, CJ
Conrad, MF
AF Blazick, Elizabeth
Haurani, Mounir J.
Patel, Virendra I.
LaMuraglia, Glenn M.
Kwolek, Christopher J.
Conrad, Mark F.
TI Results of an Aggressive Surveillance and Retrieval Protocol for
Inferior Vena Cava (IVC) Filter Removal
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 16-18, 2011
CL Chicago, IL
SP Soc Vasc Surg
C1 [Blazick, Elizabeth; Haurani, Mounir J.; Patel, Virendra I.; LaMuraglia, Glenn M.; Kwolek, Christopher J.; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2011
VL 53
SU S
BP 13S
EP 14S
PG 2
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 774TY
UT WOS:000291410700022
ER
PT J
AU Lombardi, JV
Nienaber, CA
Cambria, R
Chiesa, R
Teebken, O
Lee, A
Mossop, P
Bharadwaj, P
AF Lombardi, Joseph V.
Nienaber, Christoph A.
Cambria, Richard
Chiesa, Roberto
Teebken, Omke
Lee, Anthony
Mossop, Peter
Bharadwaj, Priya
TI Endovascular Treatment of Complicated Type B Aortic Dissection Using a
Composite Device Design: Initial Results of a Prospective Multicenter
Clinical Trial (STABLE)
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 16-18, 2011
CL Chicago, IL
SP Soc Vasc Surg
C1 [Lombardi, Joseph V.] Cooper Univ Hosp, Camden, NJ USA.
[Nienaber, Christoph A.] Univ Hosp Rostock, Rostock, Germany.
[Cambria, Richard] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chiesa, Roberto] Hosp San Raffaele, I-20132 Milan, Italy.
[Teebken, Omke] Hannover Med Sch, Hannover, Germany.
[Lee, Anthony] Christine E Lynn Heart & Vasc Inst, Boca Raton, FL USA.
[Mossop, Peter] St Vincents Hosp, Melbourne, Vic, Australia.
[Bharadwaj, Priya] Inst Med, Bloomington, IN USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2011
VL 53
SU S
BP 25S
EP 25S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 774TY
UT WOS:000291410700046
ER
PT J
AU Danczyk, RC
Mitchell, EL
Kryger, SG
Burk, C
Singh, S
Liem, TK
Landry, GJ
Edwards, JM
Petersen, BD
Moneta, GL
AF Danczyk, Rachel C.
Mitchell, Erica L.
Kryger, Sharon G.
Burk, Chad
Singh, Sarguni
Liem, Timothy K.
Landry, Gregory J.
Edwards, James M.
Petersen, Bryan D.
Moneta, Gregory L.
TI Comparing Patency and Salvage Rates between Multiple Ipsilateral Iliac
Artery Stents and Isolated Iliac Artery Stents: Beyond TASC II
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 16-18, 2011
CL Chicago, IL
SP Soc Vasc Surg
C1 [Danczyk, Rachel C.; Mitchell, Erica L.; Kryger, Sharon G.; Burk, Chad; Singh, Sarguni; Liem, Timothy K.; Landry, Gregory J.; Moneta, Gregory L.] Oregon Hlth & Sci Univ, Div Vasc Surg, Portland, OR 97201 USA.
[Edwards, James M.] Portland VA Med Ctr, Portland, OR USA.
[Petersen, Bryan D.] Oregon Hlth & Sci Univ, Dotter Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2011
VL 53
SU S
BP 63S
EP 63S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 774TY
UT WOS:000291410700120
ER
PT J
AU Patel, VI
Mukhopadhyay, S
Ergul, E
Aranson, NJ
Conrad, MF
Kwolek, CJ
Cambria, RP
AF Patel, Virendra I.
Mukhopadhyay, Shankha
Ergul, Emel
Aranson, Nathan J.
Conrad, Mark F.
Kwolek, Christopher J.
Cambria, Richard P.
TI Surgery for Descending Thoracic Aneurysms: Impact of Hospital Type on
Operative Techniques and Outcomes in the US Medicare Population
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 16-18, 2011
CL Chicago, IL
SP Soc Vasc Surg
C1 [Patel, Virendra I.; Mukhopadhyay, Shankha; Ergul, Emel; Aranson, Nathan J.; Conrad, Mark F.; Kwolek, Christopher J.; Cambria, Richard P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2011
VL 53
SU S
BP 93S
EP 94S
PG 2
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 774TY
UT WOS:000291410700180
ER
PT J
AU Goodney, PP
Scali, ST
Stone, DH
Patel, V
Eslami, M
Wallaert, J
Shaw, P
Cronenwett, JL
AF Goodney, Philip P.
Scali, Salvatore T.
Stone, David H.
Patel, Virenda
Eslami, Mohammad
Wallaert, Jessica
Shaw, Palma
Cronenwett, Jack L.
TI Impact of Surgeon Practice Pattern in Shunt Use during CEA for
Contralateral Carotid Occlusion
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 16-18, 2011
CL Chicago, IL
SP Soc Vasc Surg
C1 [Goodney, Philip P.; Stone, David H.; Wallaert, Jessica; Cronenwett, Jack L.] Dartmouth Hitchcock Med Ctr, Vasc Surg Sect, Lebanon, NH 03766 USA.
[Patel, Virenda] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Shaw, Palma] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Scali, Salvatore T.] Univ Florida, Gainesville, FL USA.
[Eslami, Mohammad] Univ Massachusetts, Worcester, MA 01605 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2011
VL 53
SU S
BP 94S
EP 95S
PG 2
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 774TY
UT WOS:000291410700182
ER
PT J
AU Patel, VI
Ergul, E
Conrad, MF
Cambria, M
LaMuraglia, GM
Kwolek, CJ
Brewster, DC
Cambria, RP
AF Patel, Virendra I.
Ergul, Emel
Conrad, Mark F.
Cambria, Matthew
LaMuraglia, Glenn M.
Kwolek, Christopher J.
Brewster, David C.
Cambria, Richard P.
TI Continued favorable results with open surgical repair of type IV
thoracoabdominal aortic aneurysms
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 10-14, 2010
CL Boston, MA
SP Soc Vasc Surg
ID CEREBROSPINAL-FLUID DRAINAGE; REDUCES PARAPLEGIA; EVOKED-POTENTIALS;
RENAL-FAILURE; MORTALITY; SURGERY; TRIAL; OPERATIONS; EVOLUTION;
PERFUSION
AB Objectives: Type IV thoracoabdominal aortic aneurysm (TAAA) repair, despite low risk of spinal cord ischemia (SCI), is reported to have significant morbidity and mortality. This has led some to apply adjuncts (eg, extracorporeal circulation) used in more extensive TAAA repair or to consider alternative approaches, such as hybrid operations. We have used a consistent, simplified surgical approach to type IV TAAA, and the goal of the present study is to review experience over 2 decades with such treatment and to identify correlates of surgical morbidity.
Methods: All type IV repairs at Massachusetts General Hospital from January 1989 through September 2009 were evaluated for clinical features, technical operative details, and 30-day outcomes. Logistic regression identified predictors of morbidity. Survival was assessed using Kaplan-Meier analysis.
Results: A total of 179 patients underwent type IV repair, with elective repair in 156 (87%) and urgent in 23 (13%). The clamp-and-sew technique was used for all operations, with routine hypothermic renal perfusion. Clinical features were age 73 +/- 8 years, coronary artery disease in 89 (50%), and creatinine level > 1.8 mg/dL defining chronic renal insufficiency (CRI) in 32 (18%). Operative reconstruction in 166 (93%) consisted of one beveled proximal anastomosis incorporating the descending thoracic aorta, celiac, superior mesenteric artery, and right renal arteries origins (mean visceral clamp time, 36 +/- 12 minutes) and a side-arm graft to the left renal artery. Technical details included previous abdominal aortic aneurysm (AAA) repair in 52 (29%), operative time of 290 +/- 90 min, estimated blood loss of 2.7 +/- 1.4 L, and splenectomy in 57 (32%). The 30-day outcomes were death in 5 (2.8%), myocardial infarction in 6 (3.4%), hemodialysis in 5 (2.8%), and any degree of SCI in 4 (2.2%). Regression analysis identified a history of CRI as an independent predictor of postoperative complication or death (odds ratio, 3.4; 95% confidence interval, 1.4-8). Survival rates at 1, 5, and 10 years were 89% +/- 2%, 62% +/- 4%, and 36% +/- 5%, respectively.
Conclusions: A simplified operative approach for type IV TAAA repair is associated with favorable perioperative results. These data refute the need for surgical adjuncts commonly applied in more extensive TAAA and indicate that the hybrid operation is an illogical posture. CRI should figure prominently in clinical decision making. Long-term survival equates that observed after routine AAA repair. (J Vase Surg 2011;53:1492-8.)
C1 [Patel, Virendra I.; Ergul, Emel; Conrad, Mark F.; Cambria, Matthew; LaMuraglia, Glenn M.; Kwolek, Christopher J.; Brewster, David C.; Cambria, Richard P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA.
RP Patel, VI (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, 15 Parkman St,Wang ACC 440, Boston, MA 02114 USA.
EM vpatel4@partners.org
NR 41
TC 13
Z9 13
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2011
VL 53
IS 6
BP 1492
EP 1498
DI 10.1016/j.jvs.2011.01.070
PG 7
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 774TX
UT WOS:000291410600007
PM 21514769
ER
PT J
AU Kennealey, PT
Elias, N
Hertl, M
Ko, DSC
Saidi, RF
Markmann, JF
Smoot, EE
Schoenfeld, DA
Kawai, T
AF Kennealey, Peter T.
Elias, Nahel
Hertl, Martin
Ko, Dicken S. C.
Saidi, Reza F.
Markmann, James F.
Smoot, Elizabeth E.
Schoenfeld, David A.
Kawai, Tatsuo
TI A prospective, randomized comparison of bovine carotid artery and
expanded polytetrafluoroethylene for permanent hemodialysis vascular
access
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID GRAFT ARTERIOVENOUS-FISTULA; WALL EPTFE GRAFTS; 3-YEAR FOLLOW-UP;
MULTICENTER EVALUATION; PTFE GRAFT; HETEROGRAFT; EXPERIENCE;
APPLICATIONS/; STANDARD; PATENCY
AB Background: Many patients on hemodialysis do not have adequate anatomy for native arteriovenous fistulas. In these patients, synthetic conduits remain an alternative option for permanent hemodialysis access. We sought to compare the standard cuffed expanded polytetrafluoroethylene (ePTFE) graft with the bovine carotid artery (BCA) graft.
Methods: This was a prospective, randomized controlled trial that was set in an academic medical center. We enrolled 26 patients in the BCA group and 27 patients in the ePTFE group. Primary, assisted primary, and secondary patency were calculated using the Kaplan-Meier method. Complications were monitored and are reported.
Results: Although there was no significant difference in secondary patency rates, primary and assisted primary patency rates were significantly higher in BCA than in the ePTFE grafts (60.5% vs 10.1% and 60.5% vs 20.8% at I year, respectively). The BCA graft survival advantage was most profound in the upper arm grafts with significantly higher primary and assisted patency rates (P < .0001 and .0005, respectively). The total number of interventions (upper arm grafts) and total number of angioplasties (overall and upper arm) required to maintain patency were significantly fewer in the BCA group. The most common complication was graft thrombosis which occurred 0.34 +/- 0.09 times per patient year in the BCA group compared to 0.77 +/- 0.16 times per patient year in the ePTFE group, P = .01.
Conclusion: The BCA graft is an excellent option for patients on hemodialysis that are not suitable for native arteriovenous fistulas, as these grafts required fewer interventions than the ePTFE grafts to maintain patency. (J Vase Surg 2011;53:1640-8.)
C1 [Kennealey, Peter T.; Elias, Nahel; Hertl, Martin; Ko, Dicken S. C.; Saidi, Reza F.; Markmann, James F.; Kawai, Tatsuo] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Div Transplantat, Boston, MA 02115 USA.
[Smoot, Elizabeth E.; Schoenfeld, David A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Biostat, Boston, MA 02115 USA.
RP Kennealey, PT (reprint author), 2555 S Downing St,Suite 130, Denver, CO 80210 USA.
EM pkennealey@gmail.com
FU Artegraft, NCT [01021839]
FX This work was funded in part by a research grant from Artegraft, NCT#
01021839.
NR 33
TC 13
Z9 14
U1 0
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2011
VL 53
IS 6
BP 1640
EP 1648
DI 10.1016/j.jvs.2011.02.008
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 774TX
UT WOS:000291410600028
PM 21609797
ER
PT J
AU Glide-Hurst, CK
Ionascu, D
Berbeco, R
Yan, D
AF Glide-Hurst, Carri K.
Ionascu, Dan
Berbeco, Ross
Yan, Di
TI Coupling surface cameras with on-board fluoroscopy: A feasibility study
SO MEDICAL PHYSICS
LA English
DT Article
DE surface imaging; respiratory gating; fluoroscopy; respiratory motion;
lung cancer
ID 4-DIMENSIONAL COMPUTED-TOMOGRAPHY; TUMOR-TRACKING SYSTEM; CELL
LUNG-CANCER; MULTILEAF COLLIMATOR; GATED RADIOTHERAPY; EXTERNAL MARKERS;
ORGAN MOTION; ACCURACY; CT; INTRAFRACTION
AB Purpose: To investigate the feasibility of using three-dimensional surface imaging cameras as an external surrogate of tumor motion through a temporal synchronization with kV imaging.
Methods: To obtain an "x-ray on" signal from the on-board kV fluoroscopy system (XVI, Elekta), a hardware controller (Gate Controller) was interfaced between the kV fluoroscopy and Gate CT (VisionRT Ltd., London) computers. First, phantom experiments were performed using a programmable respiratory motion platform (sinusoidal motion, period = 3-5 s). The platform included a chest-wall component (A-P amplitude = 1 cm) tracked with the surface camera, while tumorlike objects translated in the superior-inferior direction were tracked using kV fluoroscopy (300 frames, frequency similar to 5.5 fps). Accuracy of tracking the chest-wall platform was assessed, and the latency of the system was characterized by performing linear regression between the peak times obtained from Gate CT and fluoroscopy. Increasing the complexity of experiments, tumor displacement curves from three patients were simulated using synchronous tumor-abdomen data (RTRT). Our approach was further validated by imaging four free-breathing lung cancer patients with simultaneous Gate CT and kV fluoroscopy for approximately 55 s. Consideration was also given to varied sizes and locations of the tracked region of interest on the patient surface.
Results: For simple sinusoidal curves, measured amplitude (peak-to-peak) was 1.005 +/- 0.003 cm, 1.013 +/- 0.003 cm, and 1.003 +/- 0.005 cm for periods of 5, 4, and 3.3 s, respectively, demonstrating an excellent agreement with the actual chest platform amplitude of 1.0 cm. Period measurements were within 0.2% of actual using the surface cameras and within 0.9% of actual value using fluoroscopy. For the sinusoidal motion, the system latency was 0.64 +/- 0.02 s. This was further validated for the simulated tumor motion from three patients (latency = 0.65 +/- 0.03 s). Five of the nine patient fractions studied showed the associations between the abdomen and tumor were equivalent or better (Pearson r = 0.93-0.98) than those observed between the diaphragm and tumor (Pearson r = 0.89-0.95). A repeat analysis of five different tracked surfaces on the same patient further demonstrated strong agreement with the diaphragm and tumor, although no improvement in association strength was observed with increased size of region of interest.
Conclusions: The feasibility of using surface imaging cameras to track the patient's abdomen as an external surrogate, while using kV imaging to track internal anatomy in synchrony, has been demonstrated. With further validation through additional patient studies to confirm these findings, gated radiation therapy treatments using surface imaging cameras as the external surrogate can be facilitated. (C) 2011 American Association of Physicists in Medicine. [DOI: 10.1118/1.3581057]
C1 [Glide-Hurst, Carri K.] Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI 48202 USA.
[Ionascu, Dan; Yan, Di] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48073 USA.
[Berbeco, Ross] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
[Berbeco, Ross] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Glide-Hurst, CK (reprint author), Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI 48202 USA.
EM churst2@hfhs.org
NR 28
TC 10
Z9 10
U1 0
U2 6
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2011
VL 38
IS 6
BP 2937
EP 2947
DI 10.1118/1.3581057
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 774RZ
UT WOS:000291405200012
PM 21815367
ER
PT J
AU Guerin, B
Cho, S
Chun, SY
Zhu, X
Alpert, NM
El Fakhri, G
Reese, T
Catana, C
AF Guerin, B.
Cho, S.
Chun, S. Y.
Zhu, X.
Alpert, N. M.
El Fakhri, G.
Reese, T.
Catana, C.
TI Nonrigid PET motion compensation in the lower abdomen using simultaneous
tagged-MRI and PET imaging
SO MEDICAL PHYSICS
LA English
DT Article
DE fully 3D reconstruction; motion correction; simultaneous PET-MRI
acquisitions; tagged-MRI
ID GATED PET; ATTENUATION CORRECTION; MAGNETIC-RESONANCE; SPATIAL
MODULATION; OPTICAL-FLOW; 3D PET; IMAGES; RECONSTRUCTION; REDUCTION;
TRACKING
AB Purpose: We propose a novel approach for PET respiratory motion correction using tagged-MRI and simultaneous PET-MRI acquisitions.
Methods: We use a tagged-MRI acquisition followed by motion tracking in the phase domain to estimate the nonrigid deformation of biological tissues during breathing. In order to accurately estimate motion even in the presence of noise and susceptibility artifacts, we regularize the traditional HARP tracking strategy using a quadratic roughness penalty on neighboring displacement vectors (R-HARP). We then incorporate the motion fields estimated with R-HARP in the system matrix of an MLEM PET reconstruction algorithm formulated both for sinogram and list-mode data representations. This approach allows reconstruction of all detected coincidences in a single image while modeling the effect of motion both in the emission and the attenuation maps. At present, tagged-MRI does not allow estimation of motion in the lungs and our approach is therefore limited to motion correction in soft tissues. Since it is difficult to assess the accuracy of motion correction approaches in vivo, we evaluated the proposed approach in numerical simulations of simultaneous PET-MRI acquisitions using the NCAT phantom. We also assessed its practical feasibility in PET-MRI acquisitions of a small deformable phantom that mimics the complex deformation pattern of a lung that we imaged on a combined PET-MRI brain scanner.
Results: Simulations showed that the R-HARP tracking strategy accurately estimated realistic respiratory motion fields for different levels of noise in the tagged-MRI simulation. In simulations of tumors exhibiting increased uptake, contrast estimation was 20% more accurate with motion correction than without. Signal-to-noise ratio (SNR) was more than 100% greater when performing motion-corrected reconstruction which included all counts, compared to when reconstructing only coincidences detected in the first of eight gated frames. These results were confirmed in our proof-of-principle PET-MRI acquisitions, indicating that our motion correction strategy is accurate, practically feasible, and is therefore ready to be tested in vivo.
Conclusions: This work shows that PET motion correction using motion fields measured with tagged-MRI in simultaneous PET-MRI acquisitions can be made practical for clinical application and that doing so has the potential to remove motion blur in whole-body PET studies of the torso. (C) 2011 American Association of Physicists in Medicine. [DOI: 10.1118/1.3589136]
C1 [Guerin, B.; Cho, S.; Chun, S. Y.; Zhu, X.; Alpert, N. M.; El Fakhri, G.] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Reese, T.; Catana, C.] Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP El Fakhri, G (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, 55 Fruit St, Boston, MA 02114 USA.
EM elfakhri@pet.mgh.harvard.edu
RI Chun, Se Young/B-6653-2013; Guerin, Bastien/P-1412-2014;
OI Chun, Se Young/0000-0001-8739-8960
NR 54
TC 59
Z9 60
U1 0
U2 10
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2011
VL 38
IS 6
BP 3025
EP 3038
DI 10.1118/1.3589136
PG 14
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 774RZ
UT WOS:000291405200021
PM 21815376
ER
PT J
AU Winey, B
Wagar, M
Ebe, K
Popple, R
Lingos, T
Sher, D
Court, L
AF Winey, Brian
Wagar, Matthew
Ebe, Kazuyu
Popple, Richard
Lingos, Tania
Sher, David
Court, Laurence
TI Effect of respiratory trace shape on optimal treatment margin
SO MEDICAL PHYSICS
LA English
DT Article
DE internal margins; respiratory motion; IMRT; VMAT
ID MOTION; RADIOTHERAPY; ERRORS
AB Purpose: To evaluate the effect of target trajectory shape on the optimal treatment margin.
Methods: Intensity-modulated radiation therapy and volumetric modulated arc therapy plans were created for three spherical targets (3, 5, and 7 cm diameter) simulated in exhalation phases, each with margins of 2, 4, 6, 8, and 10 mm to account for motion. The plans were delivered to a stationary 2D ion chamber array, and dose movies were obtained of the delivered doses. The dose movie frames were then displaced to simulate different respiratory traces. Five traces were used: sin(2), sin(4), sin(6), and two patient traces. The optimal margin was defined as the margin for which the dose delivered to 95% of the target was closest to that obtained with no margin or motion. The equivalent uniform dose was also investigated as an alternative cost function.
Results: The optimal margin was always smaller than the peak-to-peak motion. When the respiratory trace spent less time in the inhale phases, the optimal margin was consistently smaller than when more time was spent in the inhale phases. The target size and treatment modality also affected the optimal margin.
Conclusions: The necessary margin for targets that spend less time in the exhale phase (sin(6)) is 2-4 mm smaller than for targets that spend equal time in the inhale and exhale phases (sin). (C) 2011 American Association of Physicists in Medicine. [DOI: 10.1118/1.3592649]
C1 [Winey, Brian; Wagar, Matthew; Lingos, Tania; Sher, David; Court, Laurence] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
[Winey, Brian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA.
[Ebe, Kazuyu] JA Jouetsu Hosp, Joetsu 9430171, Japan.
[Popple, Richard] Univ Alabama, Dept Radiat Oncol, Birmingham, AL 35249 USA.
[Court, Laurence] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA.
RP Winey, B (reprint author), Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
EM winey.brian@mgh.harvard.edu
OI Popple, Richard/0000-0003-1252-738X
NR 11
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2011
VL 38
IS 6
BP 3125
EP 3129
DI 10.1118/1.3592649
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 774RZ
UT WOS:000291405200031
PM 21815386
ER
PT J
AU Yue, Y
Aristophanous, M
Rottmann, J
Berbeco, RI
AF Yue, Yong
Aristophanous, Michalis
Rottmann, Joerg
Berbeco, Ross I.
TI 3-D fiducial motion tracking using limited MV projections in arc therapy
SO MEDICAL PHYSICS
LA English
DT Article
DE VMAT; maximum a posteriori; maximum likelihood; prostate; statistical
method; image guidance
ID INTENSITY-MODULATED RADIOTHERAPY; REAL-TIME; IMRT
AB Purpose: In-treatment fiducial tracking has recently received attention as a method for improving treatment accuracy, dose conformity, and sparing of healthy tissue. 3-D fiducial localization in arc-radiotherapy remains challenging due to the motion of targets and the complexity of arc deliveries. We propose a novel statistical method for estimating 3-D fiducial motion using limited 2-D mega-voltage (MV) projections.
Methods: 3-D fiducial motion was estimated by a maximum a posteriori (MAP) approach to integrating information of fiducial projections with prior knowledge of target motion. To obtain the imaging geometries, short sequences of MV projections were selected in which fiducials were continuously visible. The MAP algorithm estimated the 3-D motion by maximizing the probability of displacement of fiducials in the sequences. Prior knowledge of target motion from a large statistical sample was built into the model to enhance the accuracy of estimation. In the case that a motion prior was unavailable, the algorithm can be simplified to the maximum likelihood (ML) approach. To compare tracking performance, a multiprojection geometric method was also presented by extending the typical two-project ion geometric estimation approach. The algorithms were evaluated using clinical prostate motion traces, and the performance was measured in quality indices and statistical evaluation.
Results: The results showed that the MAP method significantly outperforms the geometric method in all measures. In our simulations, the MAP method achieved an accuracy of less than 1 mm RMS error using only five continuous projections, whereas the geometric method required 15 projections to achieve a similar result.
Conclusions: The approach presented can accurately estimate tumor motion using a limited number of continuous projections. The MAP motion estimation is superior to both the ML and geometric estimation methods. (C) 2011 American Association of Physicists in Medicine. [DOI: 10.1118/1.3584197]
C1 [Yue, Yong; Aristophanous, Michalis; Rottmann, Joerg; Berbeco, Ross I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp,Dept Radiat Oncol, Boston, MA 02115 USA.
RP Yue, Y (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp,Dept Radiat Oncol, 44 Binney St, Boston, MA 02115 USA.
EM yyue@lroc.harvard.edu
FU Varian Medical Systems, Inc.
FX The authors would like to thank Dr. Katja Langen for generously
providing the clinical prostate motion traces used in this study. This
project was supported, in part, by a research grant from Varian Medical
Systems, Inc.
NR 17
TC 4
Z9 5
U1 0
U2 3
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2011
VL 38
IS 6
BP 3222
EP 3231
DI 10.1118/1.3584197
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 774RZ
UT WOS:000291405200042
PM 21815397
ER
PT J
AU Hernandez-Davies, JE
Zape, JP
Landaw, EM
Tan, XL
Presnell, A
Griffith, D
Heinrich, MC
Glaser, KB
Sakamoto, KM
AF Hernandez-Davies, Jenny E.
Zape, Joan P.
Landaw, Elliot M.
Tan, Xiaolin
Presnell, Ajia
Griffith, Diana
Heinrich, Michael C.
Glaser, Keith B.
Sakamoto, Kathleen M.
TI The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869)
Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3
beta-Dependent Pathway
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID LEUKEMIC-CELLS; DOWN-REGULATION; AML CELLS; FLT3; ACTIVATION; MCL-1;
PHOSPHORYLATION; TRANSFORMATION; DAUNORUBICIN; CYTARABINE
AB The FMS-like receptor tyrosine kinase 3 (FLT3) plays an important role in controlling differentiation and proliferation of hematopoietic cells. Activating mutations in FLT3 occur in patients with acute myeloid leukemia (AML; 15%-35%), resulting in abnormal cell proliferation. Furthermore, both adult and pediatric patients with AML harboring the FLT3 internal tandem duplication (ITD) mutation have a poor prognosis. Several inhibitors have been developed to target mutant FLT3 for the treatment of AML, yet the molecular pathways affected by drug inhibition of the mutated FLT3 receptor alone have not been characterized as yet. Linifanib (ABT-869) is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. In this article, we show that treatment with linifanib inhibits proliferation and induces apoptosis in ITD mutant cells in vitro and in vivo. We show that treatment with linifanib reduces phosphorylation of Akt and glycogen synthase kinase 3 beta (GSK3 beta). In addition, we show that inhibition of GSK3b decreases linifanib-induced apoptosis. This study shows the importance of GSK3 beta as a potential target for AML therapy, particularly in patients with FLT3 ITD mutations. Mol Cancer Ther; 10(6); 949-59. (C)2011 AACR.
C1 [Hernandez-Davies, Jenny E.; Zape, Joan P.; Sakamoto, Kathleen M.] Univ Calif Los Angeles, Mattel Childrens Hosp UCLA, Jonsson Comprehens Canc Ctr, Div Hematol Oncol,Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA.
[Hernandez-Davies, Jenny E.; Sakamoto, Kathleen M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Sakamoto, Kathleen M.] Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA 90095 USA.
[Sakamoto, Kathleen M.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.
[Landaw, Elliot M.] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA.
[Tan, Xiaolin] Univ Calif Irvine, Dept Med, Div Infect Dis, Irvine, CA 92717 USA.
[Presnell, Ajia; Griffith, Diana; Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA.
[Presnell, Ajia; Griffith, Diana; Heinrich, Michael C.] OHSU Knight Canc Inst, Portland, OR USA.
[Glaser, Keith B.] Abbott Labs, Abbott Pk, IL 60064 USA.
RP Sakamoto, KM (reprint author), Univ Calif Los Angeles, Mattel Childrens Hosp UCLA, Jonsson Comprehens Canc Ctr, Div Hematol Oncol,Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA.
EM ksakamoto@mednet.ucla.edu
FU Abbott Laboratories, Inc.; Genentech, Inc.; NIH [HL75826, HL83077];
William Lawrence and Blanche Hughes Foundation; St. Baldrick's
Foundation; Department of Veterans Affairs; Leukemia and Lymphoma
Society
FX K.M. Sakamoto received a commercial research grant from Abbott
Laboratories, Inc., and received other commercial research support from
Genentech, Inc. M.C. Heinrich has equity interest in Molecular M.D.;
K.M. Sakamoto is supported by NIH grants HL75826 and HL83077, the
William Lawrence and Blanche Hughes Foundation, and the St. Baldrick's
Foundation. K.M. Sakamoto is a scholar of the Leukemia and Lymphoma
Society. M.C. Heinrich is supported, in part, by a Merit Review grant
from the Department of Veterans Affairs and a SCOR grant from the
Leukemia and Lymphoma Society.
NR 34
TC 11
Z9 13
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUN
PY 2011
VL 10
IS 6
BP 949
EP 959
DI 10.1158/1535-7163.MCT-10-0904
PG 11
WC Oncology
SC Oncology
GA 775AI
UT WOS:000291428000004
PM 21471285
ER
PT J
AU DeFeo, EM
Wu, CL
McDougal, WS
Cheng, LL
AF DeFeo, Elita M.
Wu, Chin-Lee
McDougal, W. Scott
Cheng, Leo L.
TI A decade in prostate cancer: from NMR to metabolomics
SO NATURE REVIEWS UROLOGY
LA English
DT Review
ID MAGNETIC-RESONANCE-SPECTROSCOPY; HR-MAS SPECTROSCOPY; PROTON MR
SPECTROSCOPY; HORMONE-DEPRIVATION THERAPY; DIGITAL RECTAL EXAMINATION;
PRIOR NEGATIVE BIOPSY; HUMAN SEMINAL FLUID; IN-VIVO; ENDORECTAL MR;
RADICAL PROSTATECTOMY
AB Over the past 30 years, continuous progress in the application of nuclear magnetic resonance (NMR) spectroscopy and magnetic resonance spectroscopic imaging (MRSI) to the detection, diagnosis and characterization of human prostate cancer has turned what began as scientific curiosity into a useful clinical option. In vivo MRSI technology has been integrated into the daily care of prostate cancer patients, and innovations in ex vivo methods have helped to establish NMR-based prostate cancer metabolomics. Metabolomic and multimodality imaging could be the future of the prostate cancer clinic-particularly given the rationale that more accurate interrogation of a disease as complex as human prostate cancer is most likely to be achieved through paradigms involving multiple, instead of single and isolated, parameters. The research and clinical results achieved through in vivo MRSI and ex vivo NMR investigations during the first 11 years of the 21st century illustrate areas where these technologies can be best translated into clinical practice.
C1 [DeFeo, Elita M.; Cheng, Leo L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Wu, Chin-Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA.
[McDougal, W. Scott] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA 02114 USA.
RP Cheng, LL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM cheng@nmr.mgh.harvard.edu
FU NIH [CA115746, CA115746S2, CA141139]
FX We thank Ms J. Fordham for editorial assistance. Grant funding support:
NIH CA115746, CA115746S2, and CA141139.
NR 166
TC 27
Z9 27
U1 0
U2 33
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4812
J9 NAT REV UROL
JI Nat. Rev. Urol.
PD JUN
PY 2011
VL 8
IS 6
BP 301
EP 311
DI 10.1038/nrurol.2011.53
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA 776OO
UT WOS:000291546200004
PM 21587223
ER
PT J
AU Ringman, JM
Taylor, K
Teng, E
Coppola, G
Gylys, K
AF Ringman, J. M.
Taylor, K.
Teng, E.
Coppola, G.
Gylys, K.
TI LONGITUDINAL CHANGE IN CSF BIOMARKERS IN A PRESYMPTOMATIC CARRIER OF AN
APP MUTATION
SO NEUROLOGY
LA English
DT Editorial Material
ID ALZHEIMER-DISEASE; MARKERS
C1 [Ringman, J. M.] Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, Dept Neurol, Los Angeles, CA 90095 USA.
[Taylor, K.; Gylys, K.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90095 USA.
[Teng, E.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
RP Ringman, JM (reprint author), Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, Dept Neurol, 10911 Weyburn Ave,200, Los Angeles, CA 90095 USA.
EM jringman@mednet.ucla.edu
FU NCATS NIH HHS [UL1 TR000124]; NCRR NIH HHS [UL1 RR033176, M01-RR00865];
NIA NIH HHS [K08 AG-22228, P50 AG-16570]
NR 7
TC 10
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUN
PY 2011
VL 76
IS 24
BP 2124
EP 2125
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 777BR
UT WOS:000291588800018
PM 21562250
ER
PT J
AU Jensen, JH
Falangola, MF
Hu, CX
Tabesh, A
Rapalino, O
Lo, C
Helpern, JA
AF Jensen, Jens H.
Falangola, Maria F.
Hu, Caixia
Tabesh, Ali
Rapalino, Otto
Lo, Calvin
Helpern, Joseph A.
TI Preliminary observations of increased diffusional kurtosis in human
brain following recent cerebral infarction
SO NMR IN BIOMEDICINE
LA English
DT Article
DE ischemia; stroke; diffusion; brain; kurtosis; DKI; DTI; MRI
ID GAUSSIAN WATER DIFFUSION; ENDOPLASMIC-RETICULUM; ISCHEMIC-STROKE;
NEURONAL DEATH; RAT-BRAIN; MODEL; TISSUES
AB By application of the MRI method of diffusional kurtosis imaging, a substantially increased diffusional kurtosis was observed within the cerebral ischemic lesions of three stroke subjects, 13-26 h following the onset of symptoms. This increase is interpreted as probably reflecting a higher degree of diffusional heterogeneity in the lesions when compared with normal-appearing contralateral tissue. In addition, for two of the subjects with white matter infarcts, the increase had a strong fiber tract orientational dependence. It is proposed that this effect is consistent with a large drop in the intra-axonal diffusivity, possibly related to either axonal varicosities or alterations associated with the endoplasmic reticulum. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Jensen, Jens H.; Falangola, Maria F.; Hu, Caixia; Tabesh, Ali; Lo, Calvin; Helpern, Joseph A.] NYU, Sch Med, Dept Radiol, Ctr Biomed Imaging, New York, NY 10016 USA.
[Jensen, Jens H.; Helpern, Joseph A.] NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA.
[Falangola, Maria F.; Hu, Caixia; Helpern, Joseph A.] Nathan S Kline Inst Psychiat Res, Ctr Adv Brain Imaging, Orangeburg, NY 10962 USA.
[Rapalino, Otto] Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Div, Boston, MA 02114 USA.
[Helpern, Joseph A.] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA.
RP Jensen, JH (reprint author), NYU, Sch Med, Dept Radiol, Ctr Biomed Imaging, 660 1st Ave,4th Floor, New York, NY 10016 USA.
EM jj33@nyu.edu
FU National Institutes of Health [1R01AG027852, 1R01EB007656]; Litwin
Foundation for Alzheimer's Research
FX We thank Dr Steven Levine for helpful comments. This work was supported
by the National Institutes of Health (contract/grant numbers
1R01AG027852 and 1R01EB007656) and the Litwin Foundation for Alzheimer's
Research.
NR 27
TC 72
Z9 82
U1 2
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0952-3480
J9 NMR BIOMED
JI NMR Biomed.
PD JUN
PY 2011
VL 24
IS 5
BP 452
EP 457
DI 10.1002/nbm.1610
PG 6
WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
GA 777EA
UT WOS:000291597200002
PM 20960579
ER
PT J
AU Traugott, KA
Echevarria, K
Maxwell, P
Green, K
Lewis, JS
AF Traugott, Kristi A.
Echevarria, Kelly
Maxwell, Pamela
Green, Kay
Lewis, James S., II
TI Monotherapy or Combination Therapy? The Pseudomonas aeruginosa Conundrum
SO PHARMACOTHERAPY
LA English
DT Review
DE Pseudomonas aeruginosa; combination therapy; bacteremia;
ventilator-associated pneumonia; monotherapy
ID VENTILATOR-ASSOCIATED PNEUMONIA; BLOOD-STREAM INFECTIONS; BETA-LACTAM
MONOTHERAPY; GRAM-NEGATIVE BACTEREMIA; INTENSIVE-CARE UNITS;
ANTIMICROBIAL THERAPY; ANTIBIOTIC-THERAPY; TIME-KILL; RETROSPECTIVE
ANALYSIS; STAPHYLOCOCCUS-AUREUS
AB The use of combination antibiotic therapy for severe pseudomonal infections is a standard practice in many hospitals; however, the data supporting its use are somewhat unclear. Possible benefits of combination therapy for Pseudomonas aeruginosa infections include in vitro antibiotic synergy, prevention of the emergence of bacterial resistance while receiving therapy, and improved adequacy of empiric therapy. Unfortunately, the potential disadvantages are also considerable, the most worrisome of which are drug toxicity and creation of multidrug-resistant organisms in the environment. Many in vitro and animal studies have attempted to shed light on this clinically challenging issue; however, these studies have often yielded conflicting results and used different study methods, which limits the clinical utility of the results. Clinical studies have also attempted to clarify this issue, particularly in patients with serious pseudomonal infections such as bacteremia and ventilator-associated pneumonia, but again, often resulted in conflicting conclusions. Thus, we performed a MEDLINE search (1950-May 2010) of clinical and in vitro studies evaluating the use of antibiotic combination therapy and monotherapy for bacteremia and pneumonia due to P. aeruginosa. Although a clear answer still eludes this controversy, combination therapy for seriously ill patients suspected of having pseudomonal infection has been shown, with considerable evidence, to improve the likelihood of an active agent being included in the initial antibiotic regimen of these patients. The clinical status of the patient and true likelihood of encountering a multidrug-resistant organism should be evaluated before deciding on empiric combination therapy. Future research may be able to better identify which patient populations might receive the most benefit from combination therapy rather than using combination therapy for everyone at risk for these infections.
C1 [Maxwell, Pamela; Green, Kay; Lewis, James S., II] Univ Hlth Syst, Dept Pharm Serv, San Antonio, TX 78229 USA.
[Echevarria, Kelly] S Texas Vet Hlth Care Syst, Dept Pharm Serv, San Antonio, TX USA.
[Traugott, Kristi A.] Ochsner Med Ctr, Dept Pharm Serv, New Orleans, LA USA.
RP Lewis, JS (reprint author), Univ Hlth Syst, Dept Pharm Serv, 4502 Med Dr,MS 102-1, San Antonio, TX 78229 USA.
EM James.Lewis@uhs-sa.com
NR 57
TC 28
Z9 29
U1 0
U2 12
PU PHARMACOTHERAPY PUBLICATIONS INC
PI BOSTON
PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA
SN 0277-0008
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD JUN
PY 2011
VL 31
IS 6
BP 598
EP 608
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 774HE
UT WOS:000291375500009
PM 21923444
ER
PT J
AU Kleespies, PM
Van Orden, KA
Bongar, B
Bridgeman, D
Bufka, LF
Galper, DI
Hillbrand, M
Yufit, RI
AF Kleespies, Phillip M.
Van Orden, Kimberly A.
Bongar, Bruce
Bridgeman, Diane
Bufka, Lynn F.
Galper, Daniel I.
Hillbrand, Marc
Yufit, Robert I.
TI Psychologist Suicide: Incidence, Impact, and Suggestions for Prevention,
Intervention, and Postvention
SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
LA English
DT Article
DE psychologist suicide; colleague suicide; impact of psychologist suicide;
colleague assistance; self-care
ID OCCUPATION; IMPAIRMENT; DOCTORS; ASSOCIATION; EXPERIENCES; DEPRESSION;
THERAPISTS; US
AB Psychologist practitioners are not immune to certain mental health problems, including suicidality, for which they provide services. In the aftermath of two recent psychologist suicides, the American Psychological Association's Advisory Committee on Colleague Assistance (ACCA) initiated the formation of a conjoint ad hoc committee consisting of members from ACCA, the American Psychological Association (APA) Practice Directorate, and the Section on Clinical Emergencies and Crises (Section VII of APA's Division 12) to investigate the incidence of psychologist suicide and its impact on colleagues, students or interns, patients or clients, and the profession. The committee reviewed the extant empirical literature on suicide rates for psychologists, evaluated unpublished data on psychologist suicide provided by the National Institute of Occupational Safety and Health (NIOSH), interviewed colleague survivors, reviewed published case reports of the impact of therapist suicides, and linked their findings to the literature on professional distress, impairment, and self-care. The committee concluded that there is evidence suggestive of an elevated risk of suicide for psychologists in past decades. It further concluded that there is a need for further research to confirm if there is a heightened risk of suicide for psychologists in the present day and to determine factors that might contribute to such risk. Accounts from colleague-survivors suggest that the impact of a psychologist's suicide can affect many people including family, colleagues, students, and patients or clients. This article offers suggestions for possible preventive approaches, for intervention with potentially at-risk colleagues, and for postvention efforts in the wake of a colleague suicide.
C1 [Kleespies, Phillip M.] VA Boston Healthcare Syst, Psychol Serv 116 B, Boston, MA 02130 USA.
[Van Orden, Kimberly A.] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14627 USA.
[Bongar, Bruce] Palo Alto Univ, Pacific Grad Sch Psychol, Palo Alto, CA USA.
[Bridgeman, Diane] Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA.
[Bufka, Lynn F.; Galper, Daniel I.] Amer Psychol Assoc, Practice Directorate, Washington, DC 20036 USA.
[Hillbrand, Marc] Connecticut Valley Hosp, Middletown, CT USA.
[Yufit, Robert I.] Northwestern Univ, Sch Med, Evanston, IL 60208 USA.
RP Kleespies, PM (reprint author), VA Boston Healthcare Syst, Psychol Serv 116 B, 150 S Huntington Ave, Boston, MA 02130 USA.
EM phillip.kleespies@va.gov
OI Van Orden, Kimberly/0000-0001-9439-401X
FU NIMH NIH HHS [T32 MH020061, T32 MH020061-10]
NR 49
TC 4
Z9 4
U1 0
U2 14
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7028
EI 1939-1323
J9 PROF PSYCHOL-RES PR
JI Prof. Psychol.-Res. Pract.
PD JUN
PY 2011
VL 42
IS 3
BP 244
EP 251
DI 10.1037/a0022805
PG 8
WC Psychology, Multidisciplinary
SC Psychology
GA 776DY
UT WOS:000291515900006
PM 21731175
ER
PT J
AU Grudzen, CR
Meeker, D
Torres, JM
Du, QL
Morrison, RS
Andersen, RM
Gelberg, L
AF Grudzen, Corita R.
Meeker, Daniella
Torres, Jacqueline M.
Du, Qingling
Morrison, R. Sean
Andersen, Ronald M.
Gelberg, Lillian
TI Comparison of the Mental Health of Female Adult Film Performers and
Other Young Women in California
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID GREATER SYDNEY AREA; SEX WORKERS; SUBSTANCE-ABUSE; PUBLIC-HEALTH;
LOS-ANGELES; VIOLENCE; INFECTIONS; DEPRESSION; OCCUPATION; INDUSTRY
AB Objective: This study compared self-reported mental health status and current depression of female adult film performers and other young women. Methods: A cross-sectional structured online survey adapted from the California Women's Health Survey (CWHS) was self-administered to a convenience sample of 134 current female adult film performers via the Internet. Bivariate and multivariate analyses were used to compare data for these women with data for 1,773 women of similar ages who responded to the 2007 CWHS. Main outcome measures were self-reported mental health status, measured with the Behavioral Risk Factor Surveillance Survey core-instrument quality-of-life questions, and current depression, measured with the Patient Health Questionnaire-8. Results: Performers reported a mean of 7.2 days of poor mental health in the past 30 days, compared with 4.8 days for CWHS respondents, and 33% met criteria for current depression, compared with 13% of CWHS respondents (p<.01). As children, the adult film performers were more likely to have been victims of forced sex (37% compared with 13% of CWHS respondents), to have lived in poverty (24% and 12%), and to have been placed in foster care (21% and 4%) (p<.01). In the past 12 months, 50% of the performers reported living in poverty and 34% reported experiencing domestic violence, compared with 36% and 6%, respectively, of CWHS respondents (p<.01). As adults, 27% had experienced forced sex, compared with 9% of CWHS respondents (p<.01). Conclusions: Female adult film performers have significantly worse mental health and higher rates of depression than other California women of similar ages. (Psychiatric Services 62: 639-645, 2011)
C1 [Grudzen, Corita R.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA.
[Grudzen, Corita R.; Du, Qingling; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Morrison, R. Sean] James J Peters VA Med Ctr, Bronx, NY USA.
[Meeker, Daniella] RAND Corp, Santa Monica, CA USA.
[Torres, Jacqueline M.; Andersen, Ronald M.; Gelberg, Lillian] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Gelberg, Lillian] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA.
RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, 1 Gustave Levy Pl,Box 1620, New York, NY 10029 USA.
EM corita.grudzen@mssm.edu
OI Meeker, Daniella/0000-0002-1034-7628; Grudzen,
Corita/0000-0003-3039-8497
FU University of California Office of the President; National Institute on
Aging [K24 AG022345]
FX This project was supported by an Innovative, Developmental, Exploratory
Award (IDEA) from the California HIV/AIDS Research Program, University
of California Office of the President. The funding entity had no role in
the design and conduct of the study; collection, management, analysis,
and interpretation of data; and preparation, review, or approval of the
manuscript. Dr. Morrison was supported by a Mid-Career Investigator
Award in Patient Oriented Research (K24 AG022345) from the National
Institute on Aging. The authors thank the California Women's Health
Survey Work-group for providing access to the 2007 CWHS data set.
NR 44
TC 3
Z9 3
U1 3
U2 7
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2011
VL 62
IS 6
BP 639
EP 645
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 774SL
UT WOS:000291406600012
PM 21632733
ER
PT J
AU Barkley, RA
Knouse, LE
Murphy, KR
AF Barkley, Russell A.
Knouse, Laura E.
Murphy, Kevin R.
TI Correspondence and Disparity in the Self- and Other Ratings of Current
and Childhood ADHD Symptoms and Impairment in Adults With ADHD
SO PSYCHOLOGICAL ASSESSMENT
LA English
DT Article
DE attention-deficit/hyperactivity disorder (ADHD); symptom rating;
impairment rating; self- other disparity; adults
ID DEFICIT-HYPERACTIVITY DISORDER;
ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; RELIABILITY; DEFINITION;
VALIDITY; STUDENTS
AB Experts recommend that clinicians evaluating adults for attention-deficit/hyperactivity disorder (ADHD) obtain information from others who know the patient well. The authors examined correspondence between the self- and other-ratings of ADHD symptoms and impairment using 3 groups of adults recruited on the basis of their severity of ADHD: ADHD diagnosis (n = 146), clinical controls self-referring for ADHD but not diagnosed (n = 97), and community controls (n = 109). The influences of diagnostic group, informant relationship, sex of participant, IQ, and comorbid anxiety and depression on self-informant disparities were also examined. Results indicated moderate to high agreement (.59-.80) between self and others on current functioning and slightly lower levels (.53-.75) between self- and parent ratings of childhood functioning. Examination of difference scores between self- and other ratings revealed small mean disparities (-0.1 to +5.0 points) but substantial variation (SDs = -2.4 to 8.9 points) for both current and childhood ratings. Clinic referrals not diagnosed with ADHD, particularly women, had higher disparities than was evident in the ADHD and community groups. Age, IQ, and education were not associated with disparities in most ratings. Higher anxiety, in contrast, was associated with greater disparities on all current and childhood measures of both ADHD and impairment.
C1 [Barkley, Russell A.] Med Univ S Carolina, Dept Psychiat, Charleston, SC USA.
[Knouse, Laura E.] Massachusetts Gen Hosp, Behav Med Serv, Boston, MA 02114 USA.
[Knouse, Laura E.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA.
[Murphy, Kevin R.] Adult ADHD Ctr Cent Massachusetts, Northborough, MA USA.
RP Barkley, RA (reprint author), 1752 Greenspoint Court, Mt Pleasant, SC 29466 USA.
EM drbarkley@russellbarkley.org
FU NIMH NIH HHS [MH54509]
NR 35
TC 26
Z9 27
U1 2
U2 25
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1040-3590
J9 PSYCHOL ASSESSMENT
JI Psychol. Assess.
PD JUN
PY 2011
VL 23
IS 2
BP 437
EP 446
DI 10.1037/a0022172
PG 10
WC Psychology, Clinical
SC Psychology
GA 774HY
UT WOS:000291377500014
PM 21381833
ER
PT J
AU Ciernik, IF
Niemierko, A
Harmon, DC
Kobayashi, W
Chen, YL
Yock, T
Ebb, DH
Raskin, KA
Liebsch, N
Horniceck, FJ
DeLaney, TF
AF Ciernik, I. F.
Niemierko, A.
Harmon, D. C.
Kobayashi, W.
Chen, Y-L
Yock, T.
Ebb, D. H.
Raskin, K. A.
Liebsch, N.
Horniceck, F. J.
DeLaney, T. F.
TI Proton-based radiotherapy for unresectable or incompletely resected
osteosarcoma
SO STRAHLENTHERAPIE UND ONKOLOGIE
LA English
DT Meeting Abstract
CT 17th Annual Meeting of the German-Society-for-Radiation-Oncology
CY JUN 02-05, 2011
CL Wiesbaden, GERMANY
SP German Soc Radiat Oncol
C1 [Ciernik, I. F.] Stadt Klinikum Dessau, Dessau, Germany.
[DeLaney, T. F.] Massachusetts Gen Hosp, Francis H Burr Proton Ctr, Boston, MA 02114 USA.
[Niemierko, A.; Harmon, D. C.; Yock, T.; Ebb, D. H.; Raskin, K. A.; Horniceck, F. J.; DeLaney, T. F.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0179-7158
J9 STRAHLENTHER ONKOL
JI Strahlenther. Onkol.
PD JUN
PY 2011
VL 187
SU 1
BP 6
EP 6
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 772LU
UT WOS:000291236200007
ER
PT J
AU Niemeyer, E
Kamoun, WS
Han, HS
Gillissen, M
Martin, J
Lanning, R
Bawendi, MG
Munn, LL
Fukuruma, D
Duda, DG
Dunst, J
Jain, RK
AF Niemeyer, E.
Kamoun, W. S.
Han, H. -S
Gillissen, M.
Martin, J.
Lanning, R.
Bawendi, M. G.
Munn, L. L.
Fukuruma, D.
Duda, D. G.
Dunst, J.
Jain, R. K.
TI Hematopoietic Stem cells are located in Niches normoxic
SO STRAHLENTHERAPIE UND ONKOLOGIE
LA German
DT Meeting Abstract
CT 17th Annual Meeting of the German-Society-for-Radiation-Oncology
CY JUN 02-05, 2011
CL Wiesbaden, GERMANY
SP German Soc Radiat Oncol
C1 [Niemeyer, E.; Dunst, J.] Med Univ Lubeck, Klin Strahlentherapie, D-23538 Lubeck, Germany.
[Niemeyer, E.; Kamoun, W. S.; Gillissen, M.; Martin, J.; Lanning, R.; Munn, L. L.; Fukuruma, D.; Duda, D. G.; Jain, R. K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.
[Niemeyer, E.; Kamoun, W. S.; Gillissen, M.; Martin, J.; Lanning, R.; Munn, L. L.; Fukuruma, D.; Duda, D. G.; Jain, R. K.] Harvard Univ, Sch Med, Boston, MA USA.
[Han, H. -S; Bawendi, M. G.] MIT, Dept Chem, Cambridge, MA 02139 USA.
RI Munn, Lance/L-3950-2016
OI Munn, Lance/0000-0003-0698-7232
NR 0
TC 0
Z9 0
U1 0
U2 1
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0179-7158
J9 STRAHLENTHER ONKOL
JI Strahlenther. Onkol.
PD JUN
PY 2011
VL 187
SU 1
BP 128
EP 128
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 772LU
UT WOS:000291236200365
ER
PT J
AU Basham, C
Denneson, LM
Millet, L
Shen, X
Duckart, J
Dobscha, SK
AF Basham, Chandra
Denneson, Lauren M.
Millet, Lisa
Shen, Xun
Duckart, Jonathan
Dobscha, Steven K.
TI Characteristics and VA Health Care Utilization of U.S. Veterans Who
Completed Suicide in Oregon Between 2000 and 2005
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID DEATH REPORTING SYSTEM; MENTAL-HEALTH; PHYSICAL ILLNESS; FIREARM
SUICIDE; MARITAL-STATUS; DEPRESSION; AFFAIRS; VALIDITY; PREDICTORS;
PREVENTION
AB Oregon Violent Death Reporting System data were linked with Veterans Affairs (VA) administrative data to identify and describe veterans who completed suicide in Oregon from 2000 to 2005 (n = 968), and to describe their VA health care utilization in the year prior to death. Twenty-two percent had received health care in the VA system. Of these, 57% did not have mental health diagnoses and 58% had not seen mental health professionals. A larger proportion of those who accessed care were VA-enrolled and received service-connected disability benefits. Fifty-five veterans were hospitalized during the year prior to death. Of these, 33% completed suicide within 30 days of a hospitalization. Further development of suicide prevention strategies for veterans in the community, including general medical treatment settings, is indicated.
C1 [Denneson, Lauren M.; Duckart, Jonathan; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97207 USA.
[Basham, Chandra] ZoomCare PC, Hillsboro, OR USA.
[Denneson, Lauren M.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Millet, Lisa; Shen, Xun] Oregon Publ Hlth Div, Portland, OR USA.
RP Denneson, LM (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, POB 1034 P3DEP PC, Portland, OR 97207 USA.
EM lauren.denneson@va.gov
NR 33
TC 9
Z9 9
U1 2
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0363-0234
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD JUN
PY 2011
VL 41
IS 3
BP 287
EP 296
DI 10.1111/j.1943-278X.2011.00028.x
PG 10
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 774OG
UT WOS:000291395300004
PM 21463353
ER
PT J
AU Bahn, RS
Burch, HB
Cooper, DS
Garber, JR
Greenlee, MC
Klein, I
Laurberg, P
McDougall, IR
Montori, VM
Rivkees, SA
Ross, DS
Sosa, JA
Stan, MN
AF Bahn, Rebecca S.
Burch, Henry B.
Cooper, David S.
Garber, Jeffrey R.
Greenlee, M. Carol
Klein, Irwin
Laurberg, Peter
McDougall, I. Ross
Montori, Victor M.
Rivkees, Scott A.
Ross, Douglas S.
Sosa, Julie Ann
Stan, Marius N.
TI Hyperthyroidism and Other Causes of Thyrotoxicosis: Management
Guidelines of the American Thyroid Association and American Association
of Clinical Endocrinologists
SO THYROID
LA English
DT Article
ID ENDOGENOUS SUBCLINICAL HYPERTHYROIDISM; ANTINEUTROPHIL CYTOPLASMIC
ANTIBODY; AMIODARONE-INDUCED THYROTOXICOSIS; PERCUTANEOUS ETHANOL
INJECTION; HUMAN CHORIONIC-GONADOTROPIN; DRUG-INDUCED AGRANULOCYTOSIS;
RADIOACTIVE IODINE THERAPY; MULTINODULAR TOXIC GOITER; QUALITY-OF-LIFE;
PARATHYROID-HORMONE ASSAY
AB Background: Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This article describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist and subspeciality physicians and others providing care for patients with this condition.
Methods: The development of these guidelines was commissioned by the American Thyroid Association in association with the American Association of Clinical Endocrinologists. The American Thyroid Association and American Association of Clinical Endocrinologists assembled a task force of expert clinicians who authored this report. The task force examined relevant literature using a systematic PubMed search supplemented with additional published materials. An evidence-based medicine approach that incorporated the knowledge and experience of the panel was used to develop the text and a series of specific recommendations. The strength of the recommendations and the quality of evidence supporting each was rated according to the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation Group.
Results: Clinical topics addressed include the initial evaluation and management of thyrotoxicosis; management of Graves' hyperthyroidism using radioactive iodine, antithyroid drugs, or surgery; management of toxic multinodular goiter or toxic adenoma using radioactive iodine or surgery; Graves' disease in children, adolescents, or pregnant patients; subclinical hyperthyroidism; hyperthyroidism in patients with Graves' ophthalmopathy; and management of other miscellaneous causes of thyrotoxicosis.
Conclusions: One hundred evidence-based recommendations were developed to aid in the care of patients with thyrotoxicosis and to share what the task force believes is current, rational, and optimal medical practice.
C1 [Bahn, Rebecca S.; Montori, Victor M.; Stan, Marius N.] Mayo Clin, Div Endocrinol Metab & Nutr, Rochester, MN 55905 USA.
[Burch, Henry B.] Walter Reed Army Med Ctr, Div Endocrinol & Metab, Washington, DC 20307 USA.
[Cooper, David S.] Johns Hopkins Univ, Sch Med, Div Endocrinol, Baltimore, MD USA.
[Garber, Jeffrey R.] Harvard Vanguard Med Associates, Div Endocrine, Boston, MA USA.
[Greenlee, M. Carol] Western Slope Endocrinol, Grand Junction, CO USA.
[Klein, Irwin] N Shore Univ Hosp, Thyroid Unit, Manhasset, NY USA.
[Laurberg, Peter] Aarhus Univ Hosp, Dept Endocrinol, Aalborg, Denmark.
[McDougall, I. Ross] Stanford Univ, Sch Med, Dept Radiol, Div Nucl Med, Stanford, CA 94305 USA.
[McDougall, I. Ross] Stanford Univ, Dept Med, Sch Med, Div Endocrinol, Stanford, CA 94305 USA.
[Rivkees, Scott A.] Yale Pediat Thyroid Ctr, Dept Pediat, New Haven, CT USA.
[Ross, Douglas S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sosa, Julie Ann] Yale Univ, Sch Med, Div Endocrine Surg, New Haven, CT USA.
[Sosa, Julie Ann] Yale Univ, Sch Med, Div Surg Oncol, New Haven, CT USA.
RP Bahn, RS (reprint author), Mayo Clin, Div Endocrinol Metab & Nutr, 200 1st St SW, Rochester, MN 55905 USA.
EM bahn.rebecca@mayo.edu
OI Stan, Marius/0000-0002-1408-8125; Montori, Victor/0000-0003-0595-2898
FU Genzyme
FX D.R. is a consultant for Abbott Laboratories and has received research
grant support from Genzyme. For all other authors, no competing
financial interests exist.
NR 358
TC 151
Z9 170
U1 3
U2 32
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD JUN
PY 2011
VL 21
IS 6
BP 593
EP 646
DI 10.1089/thy.2010.0417
PG 54
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 775LM
UT WOS:000291461000005
PM 21510801
ER
PT J
AU De, S
AF De, Subhajyoti
TI Somatic mosaicism in healthy human tissues
SO TRENDS IN GENETICS
LA English
DT Review
ID COPY-NUMBER-VARIATION; MITOCHONDRIAL-DNA MUTATIONS; L1
RETROTRANSPOSITION; CELL COMPETITION; CHROMOSOMAL MOSAICISM; MONOZYGOTIC
TWINS; HUMAN-DISEASE; HUMAN GENOME; HUMAN BRAIN; GENE-EXPRESSION
AB From the fertilization of an egg until the death of an individual, somatic cells can accumulate genetic changes, such that cells from different tissues or even within the same tissue differ genetically. The presence of multiple cell clones with distinct genotypes in the same individual is referred to as 'somatic mosaicism'. Many endogenous factors such as mobile elements, DNA polymerase slippage, DNA double-strand break, inefficient DNA repair, unbalanced chromosomal segregation and some exogenous factors such as nicotine and UV exposure can contribute to the generation of somatic mutations, thereby leading to somatic mosaicism. Such changes can potentially affect the epigenetic patterns and levels of gene expression, and ultimately the phenotypes of cells. Although recent studies suggest that somatic mosaicism is widespread during normal development and aging, its implications for heightened disease risks are incompletely understood. Here, I discuss the origins, prevalence and implications of somatic mosaicism in healthy human tissues.
C1 [De, Subhajyoti] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[De, Subhajyoti] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
RP De, S (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
EM subho@jimmy.harvard.edu
FU Human Frontier Science Program
FX SD thanks Franziska Michor, Elizabeth Murchison, Frank McCaughan and the
anonymous reviewers for insightful discussions and critical comments. SD
is a recipient of Human Frontier Science Program Long-term Fellowship
and also a Fellow at King's College, Cambridge, UK.
NR 90
TC 55
Z9 59
U1 0
U2 10
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0168-9525
J9 TRENDS GENET
JI Trends Genet.
PD JUN
PY 2011
VL 27
IS 6
BP 217
EP 223
DI 10.1016/j.tig.2011.03.002
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 776VS
UT WOS:000291567400002
PM 21496937
ER
PT J
AU Saeidi, N
Sander, EA
Zareian, R
Ruberti, JW
AF Saeidi, Nima
Sander, Edward A.
Zareian, Ramin
Ruberti, Jeffrey W.
TI Production of highly aligned collagen lamellae by combining shear force
and thin film confinement
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Collagen; Corneal tissue engineering; Extracellular matrix; Shear
stress; Spin coating
ID CORNEAL STROMA; ROTATING-DISK; LIQUID-FILMS; CONTACT GUIDANCE; IN-VITRO;
X-RAY; FLOW; DYNAMICS; STABILITY; TISSUE
AB Load-bearing tissues owe their mechanical strength to their highly anisotropic collagenous structure. To date attempts to engineer mechanically strong connective tissue have failed, mainly due to a lack of ability to reproduce the native collagen organization in constructs synthesized by cultured cells in vitro. The ability to influence the orientation of self-assembling collagen molecules to produce highly anisotropic structures has applications ranging from de novo engineering of complex tissues to the production of organized scaffolds for cell culture contact guidance. In this investigation we have used the simple technique of spin-coating to produce highly aligned arrays of collagen fibrils. By a simple modification of the method we have also successfully produced orthogonal collagen lamellae. Alternating collagen lamellae are frequently seen in load-bearing tissues such as cornea, annulus fibrosus, and cortical bone. Culturing of corneal fibroblasts on aligned collagen shows that the cells adopt the organization of fibrils. In this investigation we observed the reversal of fibrillar growth direction or "hook" formation similar to that seen previously in a microfluidic shear flow chamber. Although the results of this investigation clearly show that it is possible to produce small areas (1 cm(2)) of collagen fibrils with enough alignment to guide fibroblasts, there is evidence that thin film instabilities are likely to be a significant barrier to producing organized collagen fibrils over larger areas. Successful application of this method to produce highly controlled and organized collagenous structures will require the development of techniques to control thin film instability and will be the subject of future work. (C) 2011 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Zareian, Ramin; Ruberti, Jeffrey W.] Northeastern Univ, Dept Mech & Ind Engn, Boston, MA 02115 USA.
[Saeidi, Nima] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA.
[Sander, Edward A.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA.
RP Ruberti, JW (reprint author), Northeastern Univ, Dept Mech & Ind Engn, Boston, MA 02115 USA.
EM j.ruberti@neu.edu
FU NEI NIH HHS [R01 EY015500-05, R01 EY015500-01A1S1, R01 EY015500-03, R01
EY015500-06, R01 EY015500-01A1, R01 EY015500-02, R01 EY015500-04, R01
EY015500]
NR 51
TC 8
Z9 8
U1 4
U2 35
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUN
PY 2011
VL 7
IS 6
BP 2437
EP 2447
DI 10.1016/j.actbio.2011.02.038
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 771SU
UT WOS:000291181800009
PM 21362500
ER
PT J
AU Goldfarb, I
Panda, B
Wylie, B
Riley, L
AF Goldfarb, Ilona
Panda, Britta
Wylie, Blair
Riley, Laura
TI Uptake of influenza vaccine in pregnant women during the 2009 H1N1
influenza pandemic
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE H1N1; influenza; pregnancy; vaccination
ID IMMUNIZATION; ATTITUDES
AB The goals of this study were to define the uptake of H1N1 and seasonal influenza vaccination during pregnancy among women delivering during the 2009 H1N1 pandemic and explore barriers to vaccination. All postpartum women at the Massachusetts General Hospital from January 2010 through March 2010 were invited to complete an anonymous questionnaire about demographics, vaccination status, and attitudes about vaccination during pregnancy. Among 370 participants (53% response rate), 81% accepted both the H1N1 and seasonal influenza vaccines during pregnancy. Patients who declined one or both vaccines cited concerns over safety as a major deterrent. Of the 36% of participants who reported having flu-like symptoms during this pregnancy only 8.6% took oseltamivir. While a high vaccination rate was identified in this study, further education is needed to reassure patients regarding vaccine safety. Education for providers and patients emphasizing the benefits of early treatment of pregnant women with flu-like symptoms should be a priority.
C1 [Goldfarb, Ilona; Panda, Britta; Wylie, Blair; Riley, Laura] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Dept Obstet & Gynecol, Boston, MA USA.
RP Goldfarb, I (reprint author), 55 Fruit St, Boston, MA 02114 USA.
EM igoldfarb@partners.org
FU Centers for Disease Control and Prevention; Association of Maternal and
Child Health Programs
FX Publication of this article was supported by the Centers for Disease
Control and Prevention and the Association of Maternal and Child Health
Programs.
NR 23
TC 40
Z9 40
U1 0
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD JUN
PY 2011
VL 204
IS 6
SU 1
BP S112
EP S115
DI 10.1016/j.ajog.2011.01.007
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 772AF
UT WOS:000291201100019
PM 21345408
ER
PT J
AU Surman, CBH
Biederman, J
Spencer, T
Yorks, D
Miller, CA
Petty, CR
Faraone, SV
AF Surman, Craig B. H.
Biederman, Joseph
Spencer, Thomas
Yorks, Dayna
Miller, Carolyn A.
Petty, Carter R.
Faraone, Stephen V.
TI Deficient Emotional Self-Regulation and Adult Attention Deficit
Hyperactivity Disorder: A Family Risk Analysis
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID PEDIATRIC BIPOLAR DISORDER; SUBTHRESHOLD DIAGNOSES; LATE-ONSET;
DEFICIT/HYPERACTIVITY DISORDER; ADHD ADULTS; TRAITS
AB Objective: A growing body of research suggests that deficient emotional self-regulation (DESR) is prevalent and morbid among patients with attention deficit hyperactivity disorder (ADHD). Family studies provide a method of clarifying the co-occurrence of clinical features, but no family studies have yet addressed ADHD and DESR.
Method: Participants were 83 probands with and without ADHD and 128 siblings. All were assessed for axis I DSM-IV conditions with structured diagnostic interviews. The authors defined DESR in adult probands and siblings using items from the Barkley Current Behavior Scale. Analyses tested hypotheses about the familial relationship between ADHD and DESR.
Results: Siblings of ADHD probands were at elevated risk of having ADHD, irrespective of the presence or absence of DESR in the proband. The risk for DESR was elevated in siblings of ADHD plus DESR probands but not in siblings of ADHD probands. ADHD and DESR cosegregated in siblings. The risk for other psychiatric disorders was similar in siblings of the ADHD proband groups.
Conclusions: The pattern of inheritance of ADHD with DESR preliminarily suggests that DESR may be a familial subtype of ADHD. Our data suggest that DESR is not an expression of other axis I DSM-IV disorders or of nonfamilial environmental factors. The authors cannot exclude contribution of non-axis-I DSM-IV disorders to risk for DESR and cannot determine whether the cosegregation of ADHD in DESR within families is a result of genes or familial environmental risk factors. Further investigation of DESR and its correlates and treatment both in and outside the context of ADHD is warranted.
C1 [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat & Neurosci, Syracuse, NY 13210 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Physiol, Syracuse, NY 13210 USA.
Massachusetts Gen Hosp, Yawkey Ctr Outpatient Care, Pediat Psychopharmacol Unit, Clin & Res Program Pediat Psychopharmacol & Adult, Boston, MA 02114 USA.
RP Faraone, SV (reprint author), SUNY Upstate Med Univ, Dept Psychiat & Neurosci, Syracuse, NY 13210 USA.
EM sfaraone@childpsychresearch.org
OI Faraone, Stephen/0000-0002-9217-3982
FU Abbott; Alza; Cephalon; Eli Lilly; Hilda; Preston Davis Foundation;
McNeil; Merck; National Institutes of Health [R01MH-57934]; New River;
Organon; Pfizer; Shire; Takeda; Janssen-Ortho; Novartis; Elminda;
Janssen; Fundacion Areces; Medice Pharmaceuticals; Spanish Child
Psychiatry Association; AstraZeneca; Bristol-Myers Squibb; Celltech;
Esai; Forest; GlaxoSmithKline; Gliatech; NARSAD; National Institute of
Child Health and Human Development; National Institute on Drug Abuse;
National Institute of Mental Health; Neurosearch; Noven; Otsuka;
Pharmacia; Prechter Foundation; Stanley Foundation; UCB Pharma; Wyeth;
Shire Pharmaceuticals
FX Dr. Surman has received research support from Abbott, Alza, Cephalon,
Eli Lilly, the Hilda and Preston Davis Foundation, McNeil, Merck, the
National Institutes of Health, New River, Organon, Pfizer, Shire, and
Takeda; he has been sponsored by Janssen-Ortho, McNeil, Novartis, and
Shire for speaking and educational activities and has been a
consultant/advisor to McNeil, Shire, and Takeda; and he has received
honoraria from Reed Medical Education ( a logistics collaborator for the
Massachusetts General Hospital Psychiatry Academy [commercial entities
supporting the Massachusetts General Hospital Psychiatry Academy are
listed on the Academy's website, http://www.mghcme.org]). Dr. Biederman
is currently receiving research support from Elminda, Janssen, McNeil,
and Shire; in 2010, he received a speaker's fee from Fundacion Dr.
Manuel Camelo A. C. and honoraria from the Massachusetts General
Hospital Psychiatry Academy for a tuition-funded CME course; in 2009, he
received speaker's fees from Fundacion Areces, Medice Pharmaceuticals,
and the Spanish Child Psychiatry Association; in previous years, he
received research support, consultation fees, or speaker's fees from
Abbott, Alza, AstraZeneca, Bristol-Myers Squibb, Celltech, Cephalon, Eli
Lilly, Esai, Forest, GlaxoSmithKline, Gliatech, Janssen, McNeil, Merck,
NARSAD, the National Institute of Child Health and Human Development,
the National Institute on Drug Abuse, the National Institute of Mental
Health, Neurosearch, New River, Novartis, Noven, Organon, Otsuka,
Pfizer, Pharmacia, the Prechter Foundation, Shire, the Stanley
Foundation, UCB Pharma, and Wyeth. Dr. Spencer has received research
support from, has served as a speaker or on a speaker's bureau for, or
has been an advisor or served on an advisory board for Cephalon, Eli
Lilly, Glaxo-SmithKline, Janssen, McNeil, the National Institutes of
Mental Health, Novartis, Pfizer, and Shire. In the past year, Dr.
Faraone has received consulting fees from and served on advisory boards
for Shire Development in addition to receiving research support from the
National Institutes of Health and Shire; in previous years, he received
consulting fees from or served on advisory boards of or participated in
continuing medical education programs sponsored by Eli Lilly, Janssen,
McNeil, Novartis, Pfizer, and Shire; he has also received research
support from Eli Lilly, the National Institutes of Health, Pfizer, and
Shire; and he receives royalties from a book published by Guilford
Press. Ms. Yorks, Ms. Miller, and Mr. Petty report no financial
relationships with commercial interests.; Supported in part by National
Institutes of Health grant R01MH-57934 (Dr. Faraone) and a grant from
Shire Pharmaceuticals.
NR 24
TC 42
Z9 42
U1 2
U2 10
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD JUN
PY 2011
VL 168
IS 6
BP 617
EP 623
DI 10.1176/appi.ajp.2010.10081172
PG 7
WC Psychiatry
SC Psychiatry
GA 772OJ
UT WOS:000291242900010
PM 21498464
ER
PT J
AU Andreola, G
Chittenden, M
Shaffer, J
Cosimi, AB
Kawai, T
Cotter, P
LoCascio, SA
Morokata, T
Dey, BR
Tolkoff-Rubin, NT
Preffer, F
Bonnefoix, T
Kattleman, K
Spitzer, TR
Sachs, DH
Sykes, M
AF Andreola, G.
Chittenden, M.
Shaffer, J.
Cosimi, A. B.
Kawai, T.
Cotter, P.
LoCascio, S. A.
Morokata, T.
Dey, B. R.
Tolkoff-Rubin, N. T.
Preffer, F.
Bonnefoix, T.
Kattleman, K.
Spitzer, T. R.
Sachs, D. H.
Sykes, M.
TI Mechanisms of Donor-Specific Tolerance in Recipients of Haploidentical
Combined Bone Marrow/Kidney Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Bone marrow transplantation; kidney transplantation; mixed chimerism;
tolerance
ID REGULATORY T-CELLS; ANTIGEN-SPECIFIC HYPOREACTIVITY;
MARROW-TRANSPLANTATION; MIXED CHIMERISM; MAINTENANCE IMMUNOSUPPRESSION;
HOMEOSTATIC PROLIFERATION; IMMUNE RECONSTITUTION; ALLOGRAFT TOLERANCE;
THYMOCYTE GLOBULIN; GRAFT-REJECTION
AB We recently reported long-term organ allograft survival without ongoing immunosuppression in four of five patients receiving combined kidney and bone marrow transplantation from haploidentical donors following nonmyeloablative conditioning. In vitro assays up to 18 months revealed donor-specific unresponsiveness. We now demonstrate that T cell recovery is gradual and is characterized by memory-type cell predominance and an increased proportion of CD4+CD25+CD127-FOXP3+ Treg during the lymphopenic period. Complete donor-specific unresponsiveness in proliferative and cytotoxic assays, and in limiting dilution analyses of IL-2-producing and cytotoxic cells, developed and persisted for the 3-year follow-up in all patients, and extended to donor renal tubular epithelial cells. Assays in two of four patients were consistent with a role for a suppressive tolerance mechanism at 6 months to 1 year, but later (>= 18 months) studies on all four patients provided no evidence for a suppressive mechanism. Our studies demonstrate, for the first time, long-term, systemic donor-specific unresponsiveness in patients with HLA-mismatched allograft tolerance. While regulatory cells may play an early role, long-term tolerance appears to be maintained by a deletion or anergy mechanism.
C1 [Andreola, G.; Chittenden, M.; Shaffer, J.; Cotter, P.; LoCascio, S. A.; Morokata, T.; Kattleman, K.; Sachs, D. H.; Sykes, M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02115 USA.
[Cosimi, A. B.; Kawai, T.; Tolkoff-Rubin, N. T.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Transplant Unit, Boston, MA 02115 USA.
[Dey, B. R.; Spitzer, T. R.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Bone Marrow Transplant Uni, Boston, MA USA.
[Preffer, F.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Bonnefoix, T.] Inst Albert Bonniot, INSERM, U823, Grenoble 9, France.
[Bonnefoix, T.] CHU Grenoble, Plateforme Hosp Genet Mol Tumeurs, Pole Rech & Pole Biol, Grenoble 9, France.
[Sykes, M.] Columbia Univ, Med Ctr, Columbia Ctr Translat Immunol, New York, NY USA.
[Bonnefoix, T.] CHU Grenoble, Plateforme Hosp Genet Mol Tumeurs, Cellular & Mol Haematol Unit, Grenoble 9, France.
RP Sykes, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02115 USA.
EM megan.sykes@columbia.edu
FU NIH [R01AI084074, ITN N01AI15416]; Multiple Myeloma Research Foundation;
American Society of Transplantation and Umberto Veronesi Foundation
FX American Recovery and Reinvestment Act funding NIH R01AI084074, NIH ITN
N01AI15416, Multiple Myeloma Research Foundation.; G.A. was supported by
the American Society of Transplantation and Umberto Veronesi Foundation.
Author contributions: G.A. wrote the manuscript, performed flow
cytometry and in vitro assays, analyzed data and prepared specimens.
M.C., J.S. and P.C. coordinated sample acquisition, prepared specimens,
performed in vitro assays. S.A.L. and T.M. performed in vitro assays and
assisted with data analysis. F.I.P. provided expert advice on and
performed flow cytometry. K.K. supervised and coordinated research
sample acquisition. T.B. aided in the analysis and interpretation of
limiting dilution assays. A. B.C. T.K., B.R.D., N.T.R., T.S. and D.H.S.
designed, supervised and carried out the clinical protocol and patient
care. M.S. participated in the design of the clinical protocol, cowrote
the paper and participated in and oversaw design of all laboratory
studies, data analysis and interpretation, and preparation of the
manuscript.
NR 44
TC 50
Z9 52
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2011
VL 11
IS 6
BP 1236
EP 1247
DI 10.1111/j.1600-6143.2011.03566.x
PG 12
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 772ZV
UT WOS:000291277700020
PM 21645255
ER
PT J
AU Dutta, P
Dart, M
Roenneburg, DA
Torrealba, JR
Burlingham, WJ
AF Dutta, P.
Dart, M.
Roenneburg, D. A.
Torrealba, J. R.
Burlingham, W. J.
TI Pretransplant Immune-Regulation Predicts Allograft Tolerance
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE NIMA; regulatory T cells; transplantation tolerance
ID NONINHERITED MATERNAL ANTIGENS; CELLS; IMMUNOSUPPRESSION;
TRANSPLANTATION; MECHANISM; SURVIVAL; HUMANS; FETAL; MICE
AB CD4+ Tregs specific for noninherited maternal antigens (NIMAd) are detectable in some but not all B6 x BDF(1) backcross, H-2b homozygous offspring, and their presence is strongly correlated with extent of maternal (BDF(1)) microchimerism. We hypothesized that the level of pretransplant donor antigen-specific Tregs could predict allograft tolerance. To test this idea, mice were screened for bystander suppression in a DTH assay, followed 1 week later by DBA/2 heterotopic heart transplantation. NIMAd-exposed, H-2b offspring that failed to suppress DTH uniformly rejected heart allografts (12/12) by d15. In contrast, 5/6 NIMAd-exposed DTH 'regulators' accepted their allografts > 100 days. The defect in 'nonregulator" offspring could be corrected by transfer of CD4+CD25+, but not CD4+CD25neg or CD8+T cells from transplant acceptor mice. In conclusion, donor-specific T reg screening of F1 backcross offspring correctly predicted which recipients would accept a heart allograft. If translated to the clinic, similar pretransplant Treg screening could greatly enhance the effectiveness of tolerance as a clinical strategy in transplantation between family members.
C1 [Dutta, P.; Dart, M.; Roenneburg, D. A.; Burlingham, W. J.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Dutta, P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Cambridge, MA 02138 USA.
[Torrealba, J. R.] Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA.
RP Burlingham, WJ (reprint author), Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI 53706 USA.
EM burlingham@surgery.wisc.edu
FU NIH [5R01AI066219-05, R01 AI066229]
FX We would like to thank Steve Schumacher for technical assistance in
typing mice, DNA extraction and qPCR. P.D. designed experiments, and
performed all experiments (except DTH assay) and heterotopic heart
transplantation, analyzed data and prepared manuscript. M.D. performed
DTH assay and manuscript editing. D.A.R. and J.R.T. helped with
immunohistochemistry. W.J.B. was responsible for overall experimental
design and manuscript editing. This work was supported by
5R01AI066219-05 from the NIH (to W.J.B.).; The research was supported by
National Institute of Health Grant R01 AI066229.
NR 18
TC 9
Z9 9
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2011
VL 11
IS 6
BP 1296
EP 1301
DI 10.1111/j.1600-6143.2011.03484.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 772ZV
UT WOS:000291277700026
PM 21449933
ER
PT J
AU Chan, JA
Blaszkowsky, LS
Enzinger, PC
Ryan, DP
Abrams, TA
Zhu, AX
Temel, JS
Schrag, D
Bhargava, P
Meyerhardt, JA
Wolpin, BM
Fidias, P
Zheng, H
Florio, S
Regan, E
Fuchs, CS
AF Chan, J. A.
Blaszkowsky, L. S.
Enzinger, P. C.
Ryan, D. P.
Abrams, T. A.
Zhu, A. X.
Temel, J. S.
Schrag, D.
Bhargava, P.
Meyerhardt, J. A.
Wolpin, B. M.
Fidias, P.
Zheng, H.
Florio, S.
Regan, E.
Fuchs, C. S.
TI A multicenter phase II trial of single-agent cetuximab in advanced
esophageal and gastric adenocarcinoma
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE cetuximab; esophageal adenocarcinoma; gastric adenocarcinoma
ID GROWTH-FACTOR RECEPTOR; ADVANCED ESOPHAGOGASTRIC CANCER; METASTATIC
COLORECTAL-CANCER; GASTROESOPHAGEAL JUNCTION; CLINICAL-RESPONSE;
LUNG-CANCER; COMBINATION; GEFITINIB; PLUS; CISPLATIN
AB Background: Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of esophageal and gastric carcinomas. Although previous studies have examined tyrosine kinase inhibitors of EGFR, there remains limited data regarding the role of EGFR-directed monoclonal antibody therapy in these malignancies. We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma.
Patients and Methods: Thirty-five patients with previously treated metastatic esophageal or gastric adenocarcinoma were treated with weekly cetuximab, at an initial dose of 400 mg/m(2) followed by weekly infusions at 250 mg/m(2). Patients were followed for toxicity, treatment response, and survival.
Results: Treatment with cetuximab was well tolerated; no patients were taken off study due to drug-related adverse events. One (3%) partial treatment response was noted. Two (6%) patients had stable disease after 2 months of treatment. Median progression-free survival and overall survival were 1.6 and 3.1 months, respectively.
Conclusion: Although well tolerated, cetuximab administered as a single agent had minimal clinical activity in patients with metastatic esophageal and gastric adenocarcinoma. Ongoing studies of EGFR inhibitors in combination with other agents may define a role for these agents in the treatment of esophageal and gastric cancer.
C1 [Chan, J. A.; Enzinger, P. C.; Abrams, T. A.; Schrag, D.; Bhargava, P.; Meyerhardt, J. A.; Wolpin, B. M.; Florio, S.; Regan, E.; Fuchs, C. S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Chan, J. A.; Enzinger, P. C.; Abrams, T. A.; Schrag, D.; Bhargava, P.; Meyerhardt, J. A.; Wolpin, B. M.; Fuchs, C. S.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Chan, J. A.; Blaszkowsky, L. S.; Enzinger, P. C.; Ryan, D. P.; Abrams, T. A.; Zhu, A. X.; Temel, J. S.; Schrag, D.; Bhargava, P.; Meyerhardt, J. A.; Wolpin, B. M.; Fidias, P.; Zheng, H.; Fuchs, C. S.] Harvard Univ, Sch Med, Dept Hematol Oncol, Boston, MA USA.
[Blaszkowsky, L. S.; Ryan, D. P.; Zhu, A. X.; Temel, J. S.; Fidias, P.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA.
[Zheng, H.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
RP Chan, JA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM jang@partners.org
FU Bristol-Myers Squibb
FX Bristol-Myers Squibb provided cetuximab and clinical trial funding
support.
NR 35
TC 59
Z9 61
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
IS 6
BP 1367
EP 1373
DI 10.1093/annonc/mdq604
PG 7
WC Oncology
SC Oncology
GA 770BA
UT WOS:000291060800018
PM 21217058
ER
PT J
AU Jonker, DJ
Rosen, LS
Sawyer, MB
de Braud, F
Wilding, G
Sweeney, CJ
Jayson, GC
McArthur, GA
Rustin, G
Goss, G
Kantor, J
Velasquez, L
Syed, S
Mokliatchouk, O
Feltquate, DM
Kollia, G
Nuyten, DSA
Galbraith, S
AF Jonker, D. J.
Rosen, L. S.
Sawyer, M. B.
de Braud, F.
Wilding, G.
Sweeney, C. J.
Jayson, G. C.
McArthur, G. A.
Rustin, G.
Goss, G.
Kantor, J.
Velasquez, L.
Syed, S.
Mokliatchouk, O.
Feltquate, D. M.
Kollia, G.
Nuyten, D. S. A.
Galbraith, S.
TI A phase I study to determine the safety, pharmacokinetics and
pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in
patients with advanced or metastatic solid tumors
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE antiangiogenesis; brivanib; fibroblast growth factor; vascular
endothelial growth
ID RENAL-CELL CARCINOMA; ADVANCED HEPATOCELLULAR-CARCINOMA; GROWTH-FACTOR
RECEPTOR; COLORECTAL-CANCER; TYROSINE KINASES; SORAFENIB; BEVACIZUMAB;
THERAPY; PTK787/ZK-222584; ANGIOGENESIS
AB Background: This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors.
Patients and methods: Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate. The primary objectives of this study were (in part A) dose-limiting toxicity, maximum tolerated dose (MTD) and the lowest biologically active dose level and (in part B) the optimal dose/dose range. The secondary objectives of this study were preliminary evidence of antitumor activity, PK and PD.
Results: Across part A (open-label dose escalation and MTD) and part B (open-label dose optimization), 68 patients received brivanib alaninate. Brivanib demonstrated a manageable toxicity profile at doses of 180-800 mg. Most toxic effects were mild. Systemic exposure of the active moiety brivanib increased linearly <= 1000 mg/day. The MTD was 800 mg/day. Forty-four patients were treated at the MTD: 20 with 800 mg continuously, 11 with 800 mg intermittently and 13 with 400 mg b.i.d. doses. Partial responses were confirmed in two patients receiving brivanib 600 mg. Dynamic contrast-enhanced magnetic resonance imaging demonstrated statistically significant decreases in parameters reflecting tumor vascularity and permeability after multiple doses in the 800-mg continuous q.d. and 400-mg b.i.d. dose cohorts.
Conclusion: In patients with advanced/metastatic cancer, brivanib demonstrates promising antiangiogenic and antitumor activity and manageable toxicity at doses <= 800 mg orally q.d., the recommended phase II study dose.
C1 [Jonker, D. J.; Goss, G.] Univ Ottawa, Ottawa Hosp Canc Ctr, Div Med Oncol, Ottawa, ON K1H 8L6, Canada.
[Rosen, L. S.] Premiere Oncol, Dept Oncol, Santa Monica, CA USA.
[Sawyer, M. B.] Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada.
[de Braud, F.] European Inst Oncol, Dept Med, Div Clin Pharmacol & New Drugs, Milan, Italy.
[Wilding, G.] Univ Wisconsin Carbone Canc Ctr, Dept Oncol, Madison, WI USA.
[Sweeney, C. J.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.
[Jayson, G. C.] Univ Manchester, Dept Oncol, Christie Hosp, Manchester, Lancs, England.
[McArthur, G. A.] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia.
[Rustin, G.] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, Middx, England.
[Kantor, J.; Velasquez, L.; Syed, S.; Mokliatchouk, O.; Feltquate, D. M.; Kollia, G.; Nuyten, D. S. A.; Galbraith, S.] Bristol Myers Squibb Co, Res & Dev, Princeton, NJ USA.
RP Jonker, DJ (reprint author), Univ Ottawa, Ottawa Hosp Canc Ctr, Div Med Oncol, 501 Smyth Rd,Box 912, Ottawa, ON K1H 8L6, Canada.
EM djonker@ottawahospital.on.ca
RI Jayson, Gordon/O-8224-2015; de Braud, Filippo/B-9997-2017
OI Jayson, Gordon/0000-0002-8515-8944; de Braud,
Filippo/0000-0003-0103-730X
FU Bristol-Myers Squibb [CA182002]
FX This work was supported by research funding from Bristol-Myers Squibb
(Study No. CA182002). This trial is registered at www.clinicaltrials.gov
as NCT00207051.
NR 31
TC 46
Z9 49
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
IS 6
BP 1413
EP 1419
DI 10.1093/annonc/mdq599
PG 7
WC Oncology
SC Oncology
GA 770BA
UT WOS:000291060800023
PM 21131369
ER
PT J
AU Albasanz-Puig, A
Murray, J
Preusch, M
Coan, D
Namekata, M
Patel, Y
Dong, ZM
Rosenfeld, ME
Wijelath, ES
AF Albasanz-Puig, Adaia
Murray, Jacqueline
Preusch, Michael
Coan, Daniel
Namekata, Mayumi
Patel, Yatin
Dong, Zhao Ming
Rosenfeld, Michael E.
Wijelath, Errol S.
TI Oncostatin M is expressed in atherosclerotic lesions: A role for
Oncostatin M in the pathogenesis of atherosclerosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Oncostatin M; Smooth muscle cell; Atherosclerosis; Carotid plaques;
ApoE(-/-); STAT-1; STAT-3
ID SMOOTH-MUSCLE-CELLS; IN-VITRO; ENDOTHELIAL-CELLS; SIGNALING PATHWAY;
CAROTID PLAQUE; ED-B; ANGIOGENESIS; INDUCTION; CYTOKINES; DISEASE
AB Objective: Chronic inflammation plays a pivotal role in the development and progression of atherosclerosis. The inflammatory response is mediated by cytokines. The aim of this study was to determine if OncostatinM(OSM), a monocyte and T-lymphocyte specific cytokine is present in atherosclerotic lesions. We also investigated the roles of signal transducer and activator of transcription (STAT)-1 and STAT-3 in regulating OSM-induced smooth muscle cell (SMC) proliferation, migration and cellular fibronectin (cFN) synthesis.
Methods and results: Immunostaining of atherosclerotic lesions from human carotid plaques demonstrated the expression of OSM antigen in both macrophages and SMCs. Explanted SMCs from human carotid plaques expressed OSM mRNA and protein as determined by RT-PCR and Western blotting. Using the chow-fed ApoE-/- mouse model of atherosclerosis, we observed that OSM was initially expressed in the intima at 20 weeks of age. By 30 weeks, OSM was expressed in both the intima and media. In vitro studies show that OSM promotes SMC proliferation, migration and cFN synthesis. Lentivirus mediated-inhibition of STAT-1 and STAT-3 prevented OSM-induced SMC proliferation, migration and cellular fibronectin synthesis.
Conclusions: These findings demonstrate that OSM is expressed in atherosclerotic lesions and may contribute to the progression of atherosclerosis by promoting SMC proliferation, migration and extracellular matrix protein synthesis through the STAT pathway. Published by Elsevier Ireland Ltd.
C1 [Preusch, Michael; Dong, Zhao Ming; Rosenfeld, Michael E.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
[Albasanz-Puig, Adaia; Murray, Jacqueline; Coan, Daniel; Namekata, Mayumi; Dong, Zhao Ming; Wijelath, Errol S.] VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA USA.
[Patel, Yatin] Kings Coll London, Sch Med London, Div Cardiovasc, Dept Cardiol, London, England.
RP Wijelath, ES (reprint author), Dept Vet Affairs Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM errolw@u.washington.edu
FU U.S. Department of Veterans Affairs, Office of Research and Development,
Biomedical Laboratory
FX This study was supported by the U.S. Department of Veterans Affairs,
Office of Research and Development, Biomedical Laboratory Research
Program. We thank Dr. Michael Sobel for providing carotid endarterectomy
specimens and for critical review of the manuscript.
NR 40
TC 18
Z9 20
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2011
VL 216
IS 2
BP 292
EP 298
DI 10.1016/j.atherosclerosis.2011.02.003
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 773XA
UT WOS:000291343600009
PM 21376322
ER
PT J
AU Haspel, J
Shaik, RS
Ifedigbo, E
Nakahira, K
Dolinay, T
Englert, JA
Choi, AMK
AF Haspel, Jeffrey
Shaik, Rahamthulla S.
Ifedigbo, Emeka
Nakahira, Kiichi
Dolinay, Tamas
Englert, Joshua A.
Choi, Augustine M. K.
TI Characterization of macroautophagic flux in vivo using a leupeptin-based
assay
SO AUTOPHAGY
LA English
DT Article
DE macroautophagy; autophagy; flux; mice; in vivo; LC3; GABARAP; GATE-16;
leupeptin; cycloheximide
ID ISOLATED RAT HEPATOCYTES; AUTOPHAGIC DEGRADATION; MORPHOMETRIC-ANALYSIS;
MAMMALIAN AUTOPHAGY; ELECTRON-MICROSCOPY; CELL BIOLOGY; MOUSE-LIVER;
TNF-ALPHA; LC3; PROTEIN
AB Macroautophagy is a highly conserved catabolic process that is crucial for organ homeostasis in mammals. However, methods to directly measure macroautophagic activity (or flux) in vivo are limited. In this study we developed a quantitative macroautophagic flux assay based on measuring LC3b protein turnover in vivo after administering the protease inhibitor leupeptin. Using this assay we then characterized basal macroautophagic flux in different mouse organs. We found that the rate of LC3b accumulation after leupeptin treatment was greatest in the liver and lowest in spleen. Interestingly we found that LC3a, an ATG8/LC3b homologue and the LC3b-interacting protein p62 were degraded with similar kinetics to LC3b. However, the LC3b-related proteins GABARAP and GATE-16 were not rapidly turned over in mouse liver, implying that different LC3b homologues may contribute to macroautophagy via distinct mechanisms. Nutrient starvation augmented macroautophagic flux as measured by our assay, while refeeding the animals after a period of starvation significantly suppressed flux. We also confirmed that beclin 1 heterozygous mice had reduced basal macroautophagic flux compared to wild-type littermates. These results illustrate the usefulness of our leupeptin-based assay for studying the dynamics of macroautophagy in mice.
C1 [Haspel, Jeffrey; Shaik, Rahamthulla S.; Ifedigbo, Emeka; Nakahira, Kiichi; Englert, Joshua A.; Choi, Augustine M. K.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Haspel, Jeffrey] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA.
[Dolinay, Tamas] Univ Tennessee, Coll Med, Dept Med, Chattanooga, TN USA.
[Choi, Augustine M. K.] Kyung Hee Univ, Coll Med, Seoul, South Korea.
RP Choi, AMK (reprint author), Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.
EM amchoi@rics.bwh.harvard.edu
FU NIH [T32 HL007633, R03HL097005]; FAMRI
FX We thank Beth Levine for the generous gift of beclin 1 heterozygous mice
and Tamotsu Yoshimori for his GST-LC3b expression construct. We also
thank Louise Trakimas for her technical assistance with electron
microscopy and Stefan Ryter and Robyn Haspel for their critique of this
manuscript. This work was funded by NIH T32 HL007633, NIH R03HL097005
and a FAMRI Clinical Innovator Award.
NR 75
TC 44
Z9 45
U1 0
U2 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD JUN
PY 2011
VL 7
IS 6
BP 629
EP 642
DI 10.4161/auto.7.6.15100
PG 14
WC Cell Biology
SC Cell Biology
GA 771JP
UT WOS:000291153300007
PM 21460622
ER
PT J
AU Pike, LS
Smift, AL
Croteau, NJ
Ferrick, DA
Wu, M
AF Pike, Lisa S.
Smift, Amy L.
Croteau, Nicole J.
Ferrick, David A.
Wu, Min
TI Inhibition of fatty acid oxidation by etomoxir impairs NADPH production
and increases reactive oxygen species resulting in ATP depletion and
cell death in human glioblastoma cells
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article
DE Fatty acid oxidation; NADPH; ROS; Oxidative stress; Mitochondrial
dysfunction
ID NADP(+)-DEPENDENT ISOCITRATE DEHYDROGENASE; CANCER-CELLS;
GLUTAMINE-METABOLISM; AEROBIC GLYCOLYSIS; TRANSFORMED-CELLS;
HYDROGEN-PEROXIDE; TUMOR-CELLS; STRESS; APOPTOSIS; BIOLOGY
AB Normal differentiated cells rely primarily on mitochondrial oxidative phosphorylation to produce adenosine triphosphate (ATP) to maintain their viability and functions by using three major bioenergetic fuels: glucose, glutamine and fatty acids. Many cancer cells, however, rely on aerobic glycolysis for their growth and survival, and recent studies indicate that some cancer cells depend on glutamine as well. This altered metabolism in cancers occurs through oncogene activation or loss of tumor suppressor genes in multiple signaling pathways, including the phosphoinositide 3-kinase and Myc pathways. Relatively little is known, however, about the role of fatty acids as a bioenergetic fuel in growth and survival of cancer cells. Here, we report that human glioblastoma SF188 cells oxidize fatty acids and that inhibition of fatty acid beta-oxidation by etomoxir, a carnitine palmitoyltransferase 1 inhibitor, markedly reduces cellular ATP levels and viability. We also found that inhibition of fatty acid oxidation decreases nicotinamide adenine dinucleotide phosphate (NADPH) levels and the reduced glutathione (GSH) content and elevates intracellular reactive oxygen species. These results suggest that modulation of fatty acid oxidation controls the NADPH level. In the presence of reactive oxygen species scavenger tiron, however, ATP depletion is prevented without restoring fatty acid oxidation. This suggests that oxidative stress may lead to bioenergetic failure and cell death. Our work provides evidence that mitochondrial fatty acid oxidation may provide NADPH for defense against oxidative stress and prevent ATP loss and cell death. This article is part of a Special Issue entitled: Bioenergetics of Cancer. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Pike, Lisa S.; Smift, Amy L.; Ferrick, David A.; Wu, Min] Seahotse Biosci, N Billerica, MA 01862 USA.
[Croteau, Nicole J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Wu, M (reprint author), Seahotse Biosci, N Billerica, MA 01862 USA.
EM mwu@seahorsebio.com
NR 34
TC 105
Z9 107
U1 1
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2728
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD JUN
PY 2011
VL 1807
IS 6
SI SI
BP 726
EP 734
DI 10.1016/j.bbabio.2010.10.022
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 772MH
UT WOS:000291237500022
PM 21692241
ER
PT J
AU Armand, P
Kim, HT
Rhodes, J
Sainvil, MM
Cutler, C
Ho, VT
Koreth, J
Alyea, EP
Hearsey, D
Neufeld, EJ
Fleming, MD
Steen, H
Anderson, D
Kwong, RY
Soiffer, R
Antin, JH
AF Armand, Philippe
Kim, Haesook T.
Rhodes, Joanna
Sainvil, Marie-Michele
Cutler, Corey
Ho, Vincent T.
Koreth, John
Alyea, Edwin P.
Hearsey, Doreen
Neufeld, Ellis J.
Fleming, Mark D.
Steen, Hanno
Anderson, Damon
Kwong, Raymond Y.
Soiffer, Robert.
Antin, Joseph H.
TI Iron Overload in Patients with Acute Leukemia or MDS Undergoing
Myeloablative Stem Cell Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Iron overload; Acute myeloid leukemia; Acute lymphoblastic leukemia;
Myelodysplastic syndromes; Stem cell transplantation
ID PRETRANSPLANTATION SERUM FERRITIN; RISK-FACTOR; MYELODYSPLASTIC
SYNDROME; PROGNOSTIC IMPACT; CHELATING THERAPY; MEASUREMENT-ERROR;
THALASSEMIA; LIVER; QUANTIFICATION; MALIGNANCIES
AB Patients with hematologic malignancies undergoing allogeneic stem cell transplantation (HSCT) commonly have an elevated serum ferritin prior to HSCT, which has been associated with increased mortality after transplantation. This has led to the suggestion that iron overload is common and deleterious in this patient population. However, the relationship between serum ferritin and parenchymal iron overload in such patients is unknown. We report a prospective study of 48 patients with acute leukemia (AL) or myelodysplastic syndromes (MDS) undergoing myeloablative HSCT, using magnetic resonance imaging (MRI) to estimate liver iron content (LIC) and cardiac iron. The median (and range) pre-HSCT value of serum ferritin was 1549 ng/mL (20-6989); serum hepcidin, 59 ng/mL (10-468); labile plasma iron, 0 LPI units (0.0-0.9). Eighty-five percent of patients had hepatic iron overload (HIO), and 42% had significant HIO (LIC >= 5.0 mg/gdw). Only I patient had cardiac iron overload. There was a strong correlation between pre-HSCT serum ferritin and estimated LIC (r = .75), which was mostly dependent on prior transfusion history. Serum hepcidin was appropriately elevated in patients with HIO. Labile plasma iron elevation was rare. A regression calibration analysis supported the hypothesis that elevated pre-HSCT LIC is significantly associated with inferior post-HSCT survival. These results contribute to our understanding of the prevalence, mechanism, and consequences of iron overload in HSCT. Biol Blood Marrow Transplant 17: 852-860 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
C1 [Armand, Philippe; Sainvil, Marie-Michele; Cutler, Corey; Ho, Vincent T.; Koreth, John; Alyea, Edwin P.; Hearsey, Doreen; Soiffer, Robert.; Antin, Joseph H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
[Rhodes, Joanna] SUNY Stony Brook, Dept Med, Sch Med, Stony Brook, NY 11794 USA.
[Neufeld, Ellis J.] Childrens Hosp, Dept Pediat Hematol Oncol, Boston, MA 02115 USA.
[Fleming, Mark D.; Steen, Hanno; Anderson, Damon] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Kwong, Raymond Y.] Brigham & Womens Hosp, Dept Cardiovasc Med, Boston, MA 02115 USA.
RP Armand, P (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM parmand@partners.org
RI Neufeld, Ellis/F-9331-2011
FU Novartis Oncology; Jock and Bunny Adams Research and Education
Endowment; National Institutes of Health [CA142106-06]; Leukemia and
Lymphoma Society
FX This work was funded in part by grants from Novartis Oncology, the Jock
and Bunny Adams Research and Education Endowment, and the National
Institutes of Health, CA142106-06. P.A. is a recipient of a Special
Fellowship in Clinical Research from the Leukemia and Lymphoma Society.
NR 30
TC 38
Z9 42
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JUN
PY 2011
VL 17
IS 6
BP 852
EP 860
DI 10.1016/j.bbmt.2010.09.006
PG 9
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 771XM
UT WOS:000291194000008
PM 20854920
ER
PT J
AU Declercq, E
Young, R
Cabral, H
Ecker, J
AF Declercq, Eugene
Young, Robin
Cabral, Howard
Ecker, Jeffrey
TI Is a Rising Cesarean Delivery Rate Inevitable? Trends in Industrialized
Countries, 1987 to 2007
SO BIRTH-ISSUES IN PERINATAL CARE
LA English
DT Article
DE cesarean delivery rates; cesarean trends; cross-national analysis; trend
analysis
ID PELVIC FLOOR; SECTION; RISKS
AB Background:
Cesarean delivery rates have been rising rapidly in many countries in the last decade. The objective of this research is to examine cesarean rates in industrialized countries and assess patterns in the trends toward increasing rates.
Methods:
We examined cesarean delivery rates per 1,000 live births from 1987 to 2007 in 22 industrialized countries. To enhance comparability, the inclusion criteria were at least 50,000 births annually and a per capita gross domestic product of at least U.S.$10,000 in 2007. Poisson regression was selected to model the cesarean delivery rates of countries across time.
Results:
We examined overall cesarean delivery rates, absolute changes in these rates, and changes in trend lines for cesarean rates for the period from 1987 to 2007. In 2007, 11 of the 21 countries reported overall cesarean rates of more than 25 percent, led by Italy (39%), Portugal (35%), the United States (32%), and Switzerland (32%). Five countries, the Slovak Republic, Czech Republic, Ireland, Austria, and Hungary more than doubled their cesarean delivery rate between 1992 and 2007. Comparing changes in rates across time periods, 14 countries experienced a greater increase in rates in the period between 1998 and 2002 compared with the period between 1993 and 1997. Comparing trends from 2003-2007 to 1998-2002, eighteen countries experienced a slowing down of rate increases across these two periods.
Conclusion:
Although cesarean delivery rates continue to rise, the rate of increase appears to be slowing down in most industrialized countries. (BIRTH 38:2 June 2011).
C1 [Declercq, Eugene] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA.
[Young, Robin] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
[Young, Robin] Harvard Univ, Sch Med, Brigham & Womens Hosp, Osteoarthritis & Arthrit Ctr Outcomes Res,Dept Or, Cambridge, MA 02138 USA.
[Ecker, Jeffrey] Massachusetts Gen Hosp, Maternal Fetal Med Residency Program, Boston, MA 02114 USA.
RP Declercq, E (reprint author), Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, 801 Massachusetts Ave,CT-4, Boston, MA 02118 USA.
OI Declercq, Eugene/0000-0001-5411-3033; Cabral, Howard/0000-0002-1185-8331
NR 30
TC 64
Z9 70
U1 1
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0730-7659
J9 BIRTH-ISS PERINAT C
JI Birth-Issue Perinat. Care
PD JUN
PY 2011
VL 38
IS 2
BP 99
EP 104
DI 10.1111/j.1523-536X.2010.00459.x
PG 6
WC Nursing; Obstetrics & Gynecology; Pediatrics
SC Nursing; Obstetrics & Gynecology; Pediatrics
GA 766SW
UT WOS:000290807800002
PM 21599731
ER
PT J
AU Mawardi, H
Elad, S
Correa, ME
Stevenson, K
Woo, SB
Almazrooa, S
Haddad, R
Antin, JH
Soiffer, R
Treister, N
AF Mawardi, H.
Elad, S.
Correa, M. E.
Stevenson, K.
Woo, S-B
Almazrooa, S.
Haddad, R.
Antin, J. H.
Soiffer, R.
Treister, N.
TI Oral epithelial dysplasia and squamous cell carcinoma following
allogeneic hematopoietic stem cell transplantation: clinical
presentation and treatment outcomes
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE hematopoietic; oral epithelial dysplasia; squamous cell carcinoma;
allogeneic; transplantation
ID BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; CHILDHOOD
ACUTE-LEUKEMIA; SEVERE APLASTIC-ANEMIA; SECONDARY MALIGNANCIES;
RISK-FACTORS; FANCONI-ANEMIA; SOLID CANCERS; TOPICAL APPLICATION;
GENOMIC ALTERATIONS
AB Late complications of allogeneic hematopoietic stem cell transplantation (HSCT) include a risk of secondary malignancies. Optimization for early diagnosis and treatment of oral premalignant or malignant lesions requires an assessment of potential predisposing risk factors. The medical records of patients who developed oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC) following allogeneic-HSCT were reviewed. Data on HSCT course, chronic graft-versus-host disease (cGVHD), and clinical outcome were recorded; landmark survival was calculated. Twenty-six patients with OED (n = 8) and OSCC (n = 18) were identified with a median follow-up of 26.5 and 21.5 months, respectively. Premalignant and malignant oral lesions were diagnosed at a median time of 2.5 and 8 years after HSCT, respectively. Chronic GVHD was present in 96% of patients and of these, 96% had oral involvement. Multifocal oral cancer was found in 28% of cases, and localized recurrence was observed in 44% of cases. These results suggest that oral cGVHD may be considered a potential risk factor for the development of OSCC following allogeneic-HSCT. The observation that oral cancers were frequently multifocal and recurred locally suggests that these cancers may be more aggressive. Vigilant follow-up and coordination of care are critical. Bone Marrow Transplantation (2011) 46, 884-891; doi: 10.1038/bmt.2011.77; published online 4 April 2011
C1 [Mawardi, H.; Woo, S-B; Almazrooa, S.; Treister, N.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Elad, S.] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral Biol, IL-91010 Jerusalem, Israel.
[Correa, M. E.] Univ Estadual Campinas, Dent Ambulatory Hematol & Blood Transfus Ctr, Sao Paulo, Brazil.
[Stevenson, K.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Mawardi, H.; Woo, S-B; Treister, N.] Brigham & Womens Hosp, Div Oral Med & Dent, Boston, MA 02115 USA.
[Haddad, R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Antin, J. H.; Soiffer, R.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
[Mawardi, H.; Almazrooa, S.] King Abdulaziz Univ, Fac Dent, Dept Oral Med, Jeddah 21413, Saudi Arabia.
RP Mawardi, H (reprint author), Brigham & Womens Hosp, Div Oral Med & Dent, 75 Francis St, Boston, MA 02115 USA.
EM hmawardi@partners.org
RI Sangue, Inct/I-1919-2013; Pizzigatti Correa, Maria Elvira/J-4389-2012
OI Pizzigatti Correa, Maria Elvira/0000-0001-5714-4089
FU NIH [CA142106]
FX The oral medicine specialists (HM, SE, MEC, S-BW and NT) thank the
Hematopoietic Cell Transplantation and Head and Neck Oncology
departments at their respective institutions for their daily
collaboration in the management of these patients. We also extend our
gratitude to our patients and their families. Supported in part by NIH
Grant CA142106.
NR 61
TC 19
Z9 20
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUN
PY 2011
VL 46
IS 6
BP 884
EP 891
DI 10.1038/bmt.2011.77
PG 8
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 774KC
UT WOS:000291383100018
PM 21460866
ER
PT J
AU Drzezga, A
Becker, JA
Van Dijk, KRA
Sreenivasan, A
Talukdar, T
Sullivan, C
Schultz, AP
Sepulcre, J
Putcha, D
Greve, D
Johnson, KA
Sperling, RA
AF Drzezga, Alexander
Becker, J. Alex
Van Dijk, Koene R. A.
Sreenivasan, Aishwarya
Talukdar, Tanveer
Sullivan, Caroline
Schultz, Aaron P.
Sepulcre, Jorge
Putcha, Deepti
Greve, Doug
Johnson, Keith A.
Sperling, Reisa A.
TI Neuronal dysfunction and disconnection of cortical hubs in non-demented
subjects with elevated amyloid burden
SO BRAIN
LA English
DT Article
DE amyloid; cortical hubs; functional connectivity; metabolism; mild
cognitive impairment; positron emission tomography; magnetic resonance
imaging
ID MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; RESTING-STATE
NETWORKS; PITTSBURGH COMPOUND-B; ALZHEIMERS-DISEASE; FUNCTIONAL
CONNECTIVITY; FDG-PET; HUMAN BRAIN; AEROBIC GLYCOLYSIS; COMPONENT
ANALYSIS
AB Disruption of functional connectivity between brain regions may represent an early functional consequence of beta-amyloid pathology prior to clinical Alzheimer's disease. We aimed to investigate if non-demented older individuals with increased amyloid burden demonstrate disruptions of functional whole-brain connectivity in cortical hubs (brain regions typically highly connected to multiple other brain areas) and if these disruptions are associated with neuronal dysfunction as measured with fluorodeoxyglucose-positron emission tomography. In healthy subjects without cognitive symptoms and patients with mild cognitive impairment, we used positron emission tomography to assess amyloid burden and cerebral glucose metabolism, structural magnetic resonance imaging to quantify atrophy and novel resting state functional magnetic resonance imaging processing methods to calculate whole-brain connectivity. Significant disruptions of whole-brain connectivity were found in amyloid-positive patients with mild cognitive impairment in typical cortical hubs (posterior cingulate cortex/precuneus), strongly overlapping with regional hypometabolism. Subtle connectivity disruptions and hypometabolism were already present in amyloid-positive asymptomatic subjects. Voxel-based morphometry measures indicate that these findings were not solely a consequence of regional atrophy. Whole-brain connectivity values and metabolism showed a positive correlation with each other and a negative correlation with amyloid burden. These results indicate that disruption of functional connectivity and hypometabolism may represent early functional consequences of emerging molecular Alzheimer's disease pathology, evolving prior to clinical onset of dementia. The spatial overlap between hypometabolism and disruption of connectivity in cortical hubs points to a particular susceptibility of these regions to early Alzheimer's-type neurodegeneration and may reflect a link between synaptic dysfunction and functional disconnection.
C1 [Drzezga, Alexander; Becker, J. Alex; Van Dijk, Koene R. A.; Talukdar, Tanveer; Sepulcre, Jorge; Johnson, Keith A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Drzezga, Alexander; Becker, J. Alex; Van Dijk, Koene R. A.; Talukdar, Tanveer; Sepulcre, Jorge; Johnson, Keith A.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Drzezga, Alexander; Van Dijk, Koene R. A.; Sreenivasan, Aishwarya; Talukdar, Tanveer; Sullivan, Caroline; Schultz, Aaron P.; Sepulcre, Jorge; Putcha, Deepti; Greve, Doug] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Sullivan, Caroline; Schultz, Aaron P.; Putcha, Deepti; Johnson, Keith A.; Sperling, Reisa A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment,Dept Neurol, Boston, MA 02115 USA.
[Van Dijk, Koene R. A.; Sepulcre, Jorge] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Van Dijk, Koene R. A.; Sepulcre, Jorge] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Sreenivasan, Aishwarya; Johnson, Keith A.; Sperling, Reisa A.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Drzezga, A (reprint author), Tech Univ Munich, Dept Nucl Med, Klinikum Rechts Isar, Ismaningerstr 22, D-81675 Munich, Germany.
EM a.drzezga@lrz.tum.de
FU German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) [DR
445/3-1, 4-1]; National Institute on Aging [R01AG027435]; Alzheimer's
Disease Research Center (ADRC) [P50AG005134, P01 AG036694]; Anonymous
Medical Foundation; Alzheimer's Association
FX Funding for this study has been provided by: The German Research
Foundation (Deutsche Forschungsgemeinschaft, DFG) (DR 445/3-1, 4-1 to
A.D.), the National Institute on Aging (R01AG027435 to R.A.S. and
K.A.J.), the Alzheimer's Disease Research Center (ADRC) (P50AG005134 to
R.A.S. and K.A.J., P01 AG036694 to R.A.S.), an Anonymous Medical
Foundation (to R.A.S. and K.A.J.) and the Alzheimer's Association (to
R.A.S.).
NR 61
TC 146
Z9 148
U1 1
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD JUN
PY 2011
VL 134
BP 1635
EP 1646
DI 10.1093/brain/awr066
PN 6
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 770CF
UT WOS:000291063900007
PM 21490054
ER
PT J
AU Thliveris, AT
Clipson, L
White, A
Waggoner, J
Plesh, L
Skinner, BL
Zahm, CD
Sullivan, R
Dove, WF
Newton, MA
Halberg, RB
AF Thliveris, Andrew T.
Clipson, Linda
White, Alanna
Waggoner, Jesse
Plesh, Lauren
Skinner, Bridget L.
Zahm, Christopher D.
Sullivan, Ruth
Dove, William F.
Newton, Michael A.
Halberg, Richard B.
TI Clonal Structure of Carcinogen-Induced Intestinal Tumors in Mice
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID CHIMERIC MICE; APC MUTATIONS; ORIGIN; ADENOMAS; TUMORIGENESIS;
MULTIPLICITY; RESISTANCE; PLA2G2A; DNA
AB Previous studies have shown that intestinal tumors from Apc(Min/+) (Min) mice and familial adenomatous polyposis (FAP) patients are often polyclonal. We sought to determine whether polyclonality is unique to tumors arising from hereditary predispositions or, instead, is a common feature of intestinal tumorigenesis in other pathways to tumorigenesis. Ethylnitrosourea-induced intestinal tumors from mice wild type at the Apc locus and chimeric for the Rosa26 lineage marker were analyzed. Many were overtly polyclonal, being composed of a mixture of Rosa26(+) and Rosa26(-) neoplastic cells. Statistical analyses revealed that polyclonality could be explained by interactions between two initiated clones separated by a very short distance. The frequency of overtly polyclonal tumors and the range of interactions estimated in this model are similar to those observed when analyzing familial tumors from Min mice. Thus, polyclonality does not depend on the familial pathway to tumorigenesis. Interactions between two initiated clones might provide a selective advantage during the early stages of intestinal tumorigenesis. Cancer Prev Res; 4(6); 916-23. (C) 2011 AACR.
C1 [Thliveris, Andrew T.] Univ Wisconsin Madison, Dept Ophthalmol & Visual Sci, Madison, WI USA.
[Clipson, Linda; White, Alanna; Waggoner, Jesse; Dove, William F.] Univ Wisconsin Madison, Dept Oncol, Madison, WI USA.
[Newton, Michael A.] Univ Wisconsin Madison, Dept Stat, Madison, WI USA.
[Newton, Michael A.] Univ Wisconsin Madison, Dept Biostat & Med Informat, Madison, WI USA.
[Plesh, Lauren; Skinner, Bridget L.; Zahm, Christopher D.; Halberg, Richard B.] Univ Wisconsin Madison, Div Gastroenterol & Hepatol, Dept Med, Madison, WI USA.
[Sullivan, Ruth] Univ Wisconsin Madison, Res Anim Resource Ctr, Madison, WI USA.
[Dove, William F.] Univ Wisconsin Madison, Genet Lab, Madison, WI USA.
[Sullivan, Ruth; Dove, William F.; Newton, Michael A.; Halberg, Richard B.] Univ Wisconsin Madison, UW Carbone Canc Ctr, Madison, WI USA.
[Thliveris, Andrew T.] William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI USA.
RP Halberg, RB (reprint author), K4 532 Clin Sci Ctr, MC 5124,600 Highland Ave, Madison, WI 53792 USA.
EM rbhalberg@medicine.wisc.edu
OI Zahm, Christopher/0000-0002-2117-7003
FU National Cancer Institute [R01 CA123438, R37 CA63677, P30 CA014520]; UW
Division of Gastroenterology and Hepatology; UW Department of Medicine;
UW School of Medicine and Public Health
FX The study was supported by National Cancer Institute grants R01 CA123438
(R.B. Halberg), R37 CA63677 (W.F. Dove), P30 CA014520 (UW Carbone Cancer
Center Core Grant), and start-up funds to RBH from the UW Division of
Gastroenterology and Hepatology, the UW Department of Medicine, and the
UW School of Medicine and Public Health.
NR 24
TC 6
Z9 6
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD JUN
PY 2011
VL 4
IS 6
BP 916
EP 923
DI 10.1158/1940-6207.CAPR-11-0022
PG 8
WC Oncology
SC Oncology
GA 771ZR
UT WOS:000291199700017
PM 21636550
ER
PT J
AU Kim, H
Catana, C
Ratai, EM
Andronesi, OC
Jennings, DL
Batchelor, TT
Jain, RK
Sorensen, AG
AF Kim, Heisoog
Catana, Ciprian
Ratai, Eva-Maria
Andronesi, Ovidiu C.
Jennings, Dominique L.
Batchelor, Tracy T.
Jain, Rakesh K.
Sorensen, A. Gregory
TI Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect
of Cediranib in Glioblastoma
SO CANCER RESEARCH
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PROTON MR SPECTROSCOPY; HUMAN BRAIN-TUMORS;
IN-VIVO; ANTIANGIOGENIC THERAPY; H-1-NMR SPECTROSCOPY; KINASE INHIBITOR;
GLIAL TUMORS; ANGIOGENESIS; RADIATION
AB Proton magnetic resonance spectroscopy is increasingly used in clinical studies of brain tumor to provide information about tissue metabolic profiles. In this study, we evaluated changes in the levels of metabolites predominant in recurrent glioblastoma multiforme (rGBM) to characterize the response of rGBM to antiangiogenic therapy. We examined 31 rGBM patients treated with daily doses of cediranib, acquiring serial chemical shift imaging data at specific time points during the treatment regimen. We defined spectra from three regions of interest (ROI)-enhancing tumor (ET), peritumoral tissue, and normal tissue on the contralateral side (cNT)-in post-contrast T1-weighted images, and normalized the concentrations of N-acetylaspartate (NAA) and choline (Cho) in each ROI to the concentration of creatine in cNT (norCre). We analyzed the ratios of these normalized metabolites (i.e., NAA/Cho, NAA/norCre, and Cho/norCre) by averaging all patients and categorizing two different survival groups. Relative to pretreatment values, NAA/Cho in ET was unchanged through day 28. However, after day 28, NAA/Cho significantly increased in relation to a significant increase in NAA/norCre and a decrease in Cho/norCre; interestingly, the observed trend was reversed after day 56, consistent with the clinical course of GBM recurrence. Notably, receiver operating characteristic analysis indicated that NAA/Cho in tumor shows a high prediction to 6-month overall survival. These metabolic changes in these rGBM patients strongly suggest a direct metabolic effect of cediranib and might also reflect an antitumor response to antiangiogenic treatment during the first 2 months of treatment. Further study is needed to confirm these findings. Cancer Res; 71(11); 3745-52. (C)2011 AACR.
C1 [Kim, Heisoog; Catana, Ciprian; Ratai, Eva-Maria; Andronesi, Ovidiu C.; Jennings, Dominique L.; Sorensen, A. Gregory] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
[Kim, Heisoog] MIT, Dept Nucl Sci & Engn Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Batchelor, Tracy T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Kim, H (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, 149 13th St, Charlestown, MA 02129 USA.
EM heisoog@nmr.mgh.harvard.edu
FU NIH [R21, K24]; Harvard Catalyst
FX The work was financially supported by NIH grants R21 and K24, and by the
Harvard Catalyst grant.
NR 51
TC 25
Z9 25
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2011
VL 71
IS 11
BP 3745
EP 3752
DI 10.1158/0008-5472.CAN-10-2991
PG 8
WC Oncology
SC Oncology
GA 771JR
UT WOS:000291153500003
PM 21507932
ER
PT J
AU Simpson, DR
Yu, M
Zheng, SY
Zhao, ZM
Muthuswamy, SK
Tansey, WP
AF Simpson, David R.
Yu, Min
Zheng, Siyuan
Zhao, Zhongming
Muthuswamy, Senthil K.
Tansey, William P.
TI Epithelial Cell Organization Suppresses Myc Function by Attenuating Myc
Expression
SO CANCER RESEARCH
LA English
DT Article
ID C-MYC; BREAST-CANCER; ESSENTIAL COFACTOR; LUMEN FORMATION; IN-VIVO;
POLARITY; PROTEIN; ACINI; PHOSPHORYLATION; OVEREXPRESSION
AB c-Myc is an oncogene transcription factor that causes cancer in many settings, including solid tumors that arise in the context of organized tissue structures. Given that disruption of tissue architecture frequently occurs in cancer, there is considerable interest in how cell organization impacts oncogene function. A previous report found that organization of mammary epithelial cells into defined 3-dimensional structures renders them insensitive to the effects of retrovirus-mediated overexpression of Myc, leading to the notion that organization tempers the sensitivity of individual cells to Myc activity. In this article, we report that epithelial cell organization does not profoundly alter Myc activity but, instead, suppresses Myc by modulating its expression. We show that the morphogenesis of mammary epithelial cells into organized acinar structures in vitro is accompanied by widespread changes in gene expression patterns, including a substantial decrease in the expression of Myc. Concomitant with the decrease in endogenous Myc expression, we observe a decrease in transcription from retroviral vectors during morphogenesis and find that Myc transgene expression in acini is much lower than in unorganized cells. This decrease in Myc transgene activity is responsible for the apparent recalcitrance of organized cells to ectopic Myc, as adenovirus-mediated expression of Myc in organized structures potently induces apoptosis. These observations reveal that organization does not alter the inherent response of epithelial cells to Myc and suggest that other tumor suppression mechanisms, apart from structure, antagonize Myc in the development of solid tumors. Cancer Res; 71(11); 3822-30. (C) 2011 AACR.
C1 [Simpson, David R.; Tansey, William P.] Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, Nashville, TN 37232 USA.
[Zheng, Siyuan; Zhao, Zhongming] Vanderbilt Univ, Dept Biomed Informat, Sch Med, Nashville, TN 37232 USA.
[Simpson, David R.] Watson Sch Biol Sci, Cold Spring Harbor, NY USA.
[Simpson, David R.; Yu, Min; Muthuswamy, Senthil K.; Tansey, William P.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
[Yu, Min] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.
[Yu, Min] Harvard Univ, Sch Med, Charlestown, MA USA.
[Muthuswamy, Senthil K.] Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada.
RP Tansey, WP (reprint author), Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, 465 21st Ave S, Nashville, TN 37232 USA.
EM william.p.tansey@vanderbilt.edu
FU Department of Defense [W81XWH-06-1-0731, BC075024]; Vanderbilt Ingram
Cancer Center [CA68465]; Cold Spring Harbor Laboratory Cancer Center
[CA45508]; U.S. Public Health Service [CA098830, CA13106]
FX This study was supported by Department of Defense Traineeship Award
W81XWH-06-1-0731 (D.R. Simpson), Vanderbilt Ingram Cancer Center support
grant CA68465 (Z. Zhao and W.P. Tansey), Cold Spring Harbor Laboratory
Cancer Center support grant CA45508 (S.K. Muthuswamy and W.P. Tansey),
and Department of Defense grant BC075024 (S.K. Muthuswamy). U.S. Public
Health Service grants CA098830 (S.K. Muthuswamy) and CA13106 (W.P.
Tansey).
NR 35
TC 7
Z9 7
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2011
VL 71
IS 11
BP 3822
EP 3830
DI 10.1158/0008-5472.CAN-10-3782
PG 9
WC Oncology
SC Oncology
GA 771JR
UT WOS:000291153500011
PM 21610111
ER
PT J
AU Permuth-Wey, J
Kim, D
Tsai, YY
Lin, HY
Chen, YA
Barnholtz-Sloan, J
Birrer, MJ
Bloom, G
Chanock, SJ
Chen, ZH
Cramer, DW
Cunningham, JM
Dagne, G
Ebbert-Syfrett, J
Fenstermacher, D
Fridley, BL
Garcia-Closas, M
Gayther, SA
Ge, W
Gentry-Maharaj, A
Gonzalez-Bosquet, J
Goode, EL
Iversen, E
Jim, H
Kong, W
McLaughlin, J
Menon, U
Monteiro, ANA
Narod, SA
Pharoah, PDP
Phelan, CM
Qu, XT
Ramus, SJ
Risch, H
Schildkraut, JM
Song, HL
Stockwell, H
Sutphen, R
Terry, KL
Tyrer, J
Vierkant, RA
Wentzensen, N
Lancaster, JM
Cheng, JQ
Sellers, TA
AF Permuth-Wey, Jennifer
Kim, Donghwa
Tsai, Ya-Yu
Lin, Hui-Yi
Chen, Y. Ann
Barnholtz-Sloan, Jill
Birrer, Michael J.
Bloom, Gregory
Chanock, Stephen J.
Chen, Zhihua
Cramer, Daniel W.
Cunningham, Julie M.
Dagne, Getachew
Ebbert-Syfrett, Judith
Fenstermacher, David
Fridley, Brooke L.
Garcia-Closas, Montserrat
Gayther, Simon A.
Ge, William
Gentry-Maharaj, Aleksandra
Gonzalez-Bosquet, Jesus
Goode, Ellen L.
Iversen, Edwin
Jim, Heather
Kong, William
McLaughlin, John
Menon, Usha
Monteiro, Alvaro N. A.
Narod, Steven A.
Pharoah, Paul D. P.
Phelan, Catherine M.
Qu, Xiaotao
Ramus, Susan J.
Risch, Harvey
Schildkraut, Joellen M.
Song, Honglin
Stockwell, Heather
Sutphen, Rebecca
Terry, Kathryn L.
Tyrer, Jonathan
Vierkant, Robert A.
Wentzensen, Nicolas
Lancaster, Johnathan M.
Cheng, Jin Q.
Sellers, Thomas A.
CA OCAC
TI LIN28B Polymorphisms Influence Susceptibility to Epithelial Ovarian
Cancer
SO CANCER RESEARCH
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; MICRORNA-RELATED GENES; RISK; LOCI; CARCINOMA;
VARIANTS; PATHWAYS; IDENTIFICATION; TRANSFORMATION; METAANALYSIS
AB Defective microRNA (miRNA) biogenesis contributes to the development and progression of epithelial ovarian cancer (EOC). In this study, we examined the hypothesis that single nucleotide polymorphisms (SNP) in miRNA biogenesis genes may influence EOC risk. In an initial investigation, 318 SNPs in 18 genes were evaluated among 1,815 EOC cases and 1,900 controls, followed up by a replicative joint meta-analysis of data from an additional 2,172 cases and 3,052 controls. Of 23 SNPs from 9 genes associated with risk (empirical P < 0.05) in the initial investigation, the meta-analysis replicated 6 SNPs from the DROSHA, FMR1, LIN28, and LIN28B genes, including rs12194974 (G>A), an SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR = 0.90, 95% CI: 0.82-0.98; P = 0.015) which has been recently implicated in age of menarche and other phenotypes. Consistent with reports that LIN28B overexpression in EOC contributes to tumorigenesis by repressing tumor suppressor let-7 expression, we provide data from luciferase reporter assays and quantitative RT-PCR to suggest that the inverse association among rs12194974 A allele carriers may be because of reduced LIN28B expression. Our findings suggest that variants in LIN28B and possibly other miRNA biogenesis genes may influence EOC susceptibility. Cancer Res; 71(11); 3896-903. (C) 2011 AACR.
C1 [Permuth-Wey, Jennifer; Tsai, Ya-Yu; Phelan, Catherine M.; Sellers, Thomas A.] Univ S Florida, H Lee Moffitt Canc Ctr, Canc Epidemiol Program, Div Populat Sci, Tampa, FL 33682 USA.
[Kim, Donghwa; Kong, William; Cheng, Jin Q.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Interdisciplinary Oncol, Tampa, FL 33682 USA.
[Lin, Hui-Yi; Chen, Y. Ann] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Biostat, Tampa, FL 33682 USA.
[Bloom, Gregory; Chen, Zhihua; Fenstermacher, David; Ge, William; Qu, Xiaotao] Univ S Florida, H Lee Moffitt Canc Ctr, Dept iomed Informat, Tampa, FL 33682 USA.
[Ebbert-Syfrett, Judith; Gonzalez-Bosquet, Jesus; Lancaster, Johnathan M.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Womens Oncol, Tampa, FL 33682 USA.
[Jim, Heather] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Hlth Outcomes & Behav, Tampa, FL 33682 USA.
[Permuth-Wey, Jennifer; Dagne, Getachew; Stockwell, Heather] Univ S Florida, Dept Epidemiol & Biostat, Coll Publ Hlth, Tampa, FL 33682 USA.
[Sutphen, Rebecca] Univ S Florida, Pediat Epidemiol Ctr, Coll Med, Tampa, FL 33682 USA.
Case Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA.
[Birrer, Michael J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Barnholtz-Sloan, Jill; Cramer, Daniel W.; Terry, Kathryn L.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Epidemiol Ctr, Boston, MA 02115 USA.
[Chanock, Stephen J.; Wentzensen, Nicolas] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA.
[Cunningham, Julie M.] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN USA.
[Fridley, Brooke L.; Goode, Ellen L.; Vierkant, Robert A.] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA.
[Garcia-Closas, Montserrat] UCL, EGA Inst Womens Hlth, Inst Canc Res, Sect Epidemiol, London, England.
[Garcia-Closas, Montserrat] UCL, EGA Inst Womens Hlth, Inst Canc Res, Sect Genet, London, England.
[Garcia-Closas, Montserrat] UCL, EGA Inst Womens Hlth, Breakthrough Breast Canc Res Ctr, London, England.
[Gentry-Maharaj, Aleksandra; Menon, Usha] UCL, EGA Inst Womens Hlth, Dept Gynecol Oncol, London, England.
[Gayther, Simon A.; Ramus, Susan J.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Iversen, Edwin] Duke Univ, Dept Stat Sci, Durham, NC USA.
[Schildkraut, Joellen M.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA.
[McLaughlin, John] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Narod, Steven A.] Ctr Res Womens Hlth, Toronto, ON, Canada.
[Pharoah, Paul D. P.; Song, Honglin; Tyrer, Jonathan] Univ Cambridge, Dept Oncol, Cambridge, England.
[Risch, Harvey] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
RP Sellers, TA (reprint author), MRC CANCONT, Moffitt Res Inst, Dept Epidemiol & Genet, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM thomas.sellers@moffitt.org
RI McLaughlin, John/E-4577-2013; Fridley, Brooke/D-8315-2015;
Garcia-Closas, Montserrat /F-3871-2015;
OI Fridley, Brooke/0000-0001-7739-7956; Garcia-Closas, Montserrat
/0000-0003-1033-2650; Monteiro, Alvaro/0000-0002-8448-4801; Vierkant,
Robert/0000-0001-6242-5221; Ramus, Susan/0000-0003-0005-7798
FU Moffitt Cancer Center/University of South Florida; Cancer Center
[P30-CA0762-92]; Mayo Foundation; American Cancer Society
[CRTG-00-196-01-CCE]; Advanced Cancer Detection Center, Department of
Defense [DAMD-17-98-1-8659]; Canadian Cancer Society; NIH [R01-CA-63682,
R01-CA-63678]; National Cancer Institute [P30-CA-15083]; NIH, National
Cancer Institute, Division of Cancer Epidemiology and Genetics; Center
for Cancer Research; Cancer Research U.K.; Eve Appeal; OAK Foundation;
Department of Health's NIHR Biomedical Research Centre;
[R01-CA-114343]; [R01-CA114343-S1]; [R01-CA-122443]; [P50-CA-136393];
[R01-CA-76016]; [R01-CA-106414]; [CA-54419]; [P50 CA105009]
FX The genotyping, bioinformatic, and biostatistical data analysis for
stage 1 was supported by R01-CA-114343 and R01-CA114343-S1 and the
Moffitt Cancer Center/University of South Florida Anna Valentine Fund
and Cancer Center Support Grant P30-CA0762-92. The MAY study is
supported by R01-CA-122443 and P50-CA-136393 and funding from the Mayo
Foundation. The NCO study is supported by R01-CA-76016. The TBO study is
supported by R01-CA-106414, the American Cancer Society
(CRTG-00-196-01-CCE), and the Advanced Cancer Detection Center Grant,
Department of Defense (DAMD-17-98-1-8659). The TOR study is supported by
grants from the Canadian Cancer Society and the NIH (R01-CA-63682 and
R01-CA-63678). The Mayo Clinic Genotyping Shared Resource is supported
by the National Cancer Institute (P30-CA-15083).; Of studies that
participated in stage 2, the NEC study is supported by grants CA-54419
and P50 CA105009. The POL study was supported by the Intramural Research
Program of the NIH, National Cancer Institute, Division of Cancer
Epidemiology and Genetics, and the Center for Cancer Research. The SEA
study is funded by a program grant from Cancer Research U.K. The UKO
study is supported by funding from Cancer Research U.K., the Eve Appeal,
and the OAK Foundation. Some of this work was undertaken at UCLH/UCL,
who received some funding from the Department of Health's NIHR
Biomedical Research Centre funding scheme. U.K. genotyping and data
analysis was supported by a project grant from Cancer Research U.K. U.K.
studies also make use of data generated by the Wellcome Trust
Case-Control consortium. A list of investigators who contributed to the
generation of data is available at www.wtccc.org.uk.
NR 40
TC 50
Z9 52
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2011
VL 71
IS 11
BP 3896
EP 3903
DI 10.1158/0008-5472.CAN-10-4167
PG 8
WC Oncology
SC Oncology
GA 771JR
UT WOS:000291153500019
PM 21482675
ER
PT J
AU Alam, M
Siddiqui, S
Lee, VV
Elayda, MA
Nambi, V
Yang, EY
Jneid, HM
Wilson, JM
Ballantyne, CM
Virani, SS
AF Alam, Mahboob
Siddiqui, Sahar
Lee, Vei-Vei
Elayda, McArthur A.
Nambi, Vijay
Yang, Eric Y.
Jneid, Hani M.
Wilson, James M.
Ballantyne, Christie M.
Virani, Salim S.
TI Isolated Coronary Artery Bypass Grafting in Obese Individuals - A
Propensity Matched Analysis of Outcomes
SO CIRCULATION JOURNAL
LA English
DT Article
DE Coronary artery bypass grafting; Morbidity; Mortality; Obesity; Outcomes
ID BODY-MASS INDEX; THORACIC-SURGEONS DATABASE; IN-HOSPITAL MORTALITY;
LONG-TERM OUTCOMES; CARDIAC-SURGERY; EXTREME OBESITY; RISK-FACTOR;
POSTOPERATIVE MORBIDITY; METABOLIC SYNDROME; HEART-FAILURE
AB Background: There is conflicting data regarding the impact of obesity on morbidity and mortality in patients undergoing isolated coronary artery bypass grafting (CABG).
Methods and Results: Retrospective cohort analysis of patients who underwent CABG from January 1, 1995, through July 31, 2010 was performed. Patients were classified as obese or non-obese (body mass index >= 30.0 kg/m(2) and <30.0 kg/m(2), respectively). The primary outcome was in-hospital mortality. Secondary outcomes included postoperative respiratory failure, postoperative stroke, postoperative myocardial infarction, sternal and leg wound infections, postoperative atrial fibrillation, postoperative ventricular tachycardia, postoperative renal failure and length of hospital stay. Propensity-matched stepwise multivariable logistic regression was performed. Of 13,115 patients, 4,619 (35.2%) were obese. In the propensity-matched logistic regression models (n=8,442), obesity was not associated with postoperative mortality (odds ratio=1.13, 95% confidence interval 0.86-1.48). However, obesity was associated with postoperative respiratory failure, postoperative renal insufficiency, sternal wound infection, and leg wound infection. Obesity was also associated with a decreased risk of postoperative bleeding and re-operation from bleeding.
Conclusions: Obesity was associated with an increased risk of postoperative respiratory failure, postoperative renal failure, and surgical site infections. However, obesity was not associated with in-hospital mortality in patients undergoing CABG. (Circ J 2011; 75: 1378-1385)
C1 [Alam, Mahboob; Nambi, Vijay; Jneid, Hani M.; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA.
[Lee, Vei-Vei; Elayda, McArthur A.; Wilson, James M.; Virani, Salim S.] Baylor Coll Med, Texas Heart Inst, Houston, TX 77030 USA.
[Nambi, Vijay; Yang, Eric Y.; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Methodist DeBakey Heart & Vasc Ctr, Houston, TX 77030 USA.
[Jneid, Hani M.; Virani, Salim S.] Baylor Coll Med, Methodist Hosp, Houston, TX 77030 USA.
[Jneid, Hani M.; Virani, Salim S.] Baylor Coll Med, Hlth Policy & Qual Program, Houston, TX 77030 USA.
[Siddiqui, Sahar] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA.
[Siddiqui, Sahar] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Siddiqui, Sahar] Univ Florida, Sch Publ Hlth, Gainesville, FL USA.
RP Alam, M (reprint author), Baylor Coll Med, Dept Med, Cardiol Sect, 1709 Dryden Rd,Suite 9-90,BCM 620, Houston, TX 77030 USA.
EM malam@bcm.tmc.edu
RI Yang, Eric/C-1170-2010;
OI Yang, Eric/0000-0003-2234-3269; Virani, Salim/0000-0001-9541-6954
FU St. Luke's Episcopal Hospital; Department of Veterans Affairs Health
Services Research and Development Service (Health Service Research
Development) [CDA-09-028]
FX The authors thank Ms. Joanna A. Brooks, BA, for her editorial
assistance. This work was supported by the Muller Fund for
Cardiovascular Research at St. Luke's Episcopal Hospital. Dr. Virani is
also supported via a Department of Veterans Affairs Health Services
Research and Development Service (Health Service Research & Development)
Career Development Award (Grant number: CDA-09-028).
NR 68
TC 11
Z9 12
U1 0
U2 2
PU JAPANESE CIRCULATION SOC
PI KYOTO
PA KINKI INVENTION CENTER, 14 YOSHIDA KAWAHARACHO, SAKYO-KU, KYOTO,
606-8305, JAPAN
SN 1346-9843
J9 CIRC J
JI Circ. J.
PD JUN
PY 2011
VL 75
IS 6
BP 1378
EP 1385
DI 10.1253/circj.CJ-10-1129
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 771RH
UT WOS:000291177900018
PM 21498907
ER
PT J
AU Hall, AL
Peterson, CL
Kautz, SA
Neptune, RR
AF Hall, A. L.
Peterson, C. L.
Kautz, S. A.
Neptune, R. R.
TI Relationships between muscle contributions to walking subtasks and
functional walking status in persons with post-stroke hemiparesis
SO CLINICAL BIOMECHANICS
LA English
DT Article
DE Forward dynamics simulation; Modeling; Biomechanics; Gait; Muscle
function
ID MECHANICAL-PROPERTIES; GAIT SPEED; STROKE; SUPPORT; PROGRESSION; WORK;
CLASSIFICATION; OPTIMIZATION; FLEXORS; FORCES
AB Background: Persons with post-stroke hemiparesis usually walk slowly and asymmetrically. Stroke severity and functional walking status are commonly predicted by post-stroke walking speed. The mechanisms that limit walking speed, and by extension functional walking status, need to be understood to improve post-stroke rehabilitation methods.
Methods: Three-dimensional forward dynamics walking simulations of hemiparetic subjects (and speed-matched controls) with different levels of functional walking status were developed to investigate the relationships between muscle contributions to walking subtasks and functional walking status. Muscle contributions to forward propulsion, swing initiation and power generation were analyzed during the pre-swing phase of the gait cycle and compared between groups.
Findings: Contributions from the paretic leg muscles (i.e., soleus, gastrocnemius and gluteus medius) to forward propulsion increased with improved functional walking status, with the non-paretic leg muscles (i.e., rectus femoris and vastii) compensating for reduced paretic leg propulsion in the limited community walker. Contributions to swing initiation from both paretic (i.e., gastrocnemius, iliacus and psoas) and non-paretic leg muscles (i.e., hamstrings) also increased as functional walking status improved. Power generation was also an important indicator of functional walking status, with reduced paretic leg power generation limiting the paretic leg contribution to forward propulsion and leg swing initiation.
Interpretation: These results suggest that deficits in muscle contributions to the walking subtasks of forward propulsion, swing initiation and power generation are directly related to functional walking status and that improving output in these muscle groups may be an effective rehabilitation strategy for improving post-stroke hemiparetic walking. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Hall, A. L.; Peterson, C. L.; Neptune, R. R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA.
[Kautz, S. A.] Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL USA.
[Kautz, S. A.] Med Univ S Carolina, Div Phys Therapy, Dept Hlth Sci & Res, Charleston, SC USA.
[Kautz, S. A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, 1 Univ Stn C2200, Austin, TX 78712 USA.
EM rneptune@mail.utexas.edu
RI Kinney, Allison/J-5814-2013; Peterson, Carrie/C-6007-2016;
OI Kinney, Allison/0000-0003-3553-0733; Peterson,
Carrie/0000-0002-7169-2089; Kautz, Steven/0000-0003-3151-8235
FU NIH [RO1 HD46820]; Rehabilitation Research & Development Service of the
VA
FX The authors would like to thank Erin Carr, Dr. Mark Bowden, Dr. Bhavana
Raja, Dr. Cameron Nott, Dr. Chitra Balasubramanian, Kelly Rooney and
Ryan Knight for help with the data collection and processing and the
members of the Neuromuscular Biomechanics Lab at The University of Texas
at Austin for their insightful comments on the manuscript. This work was
funded by NIH grant RO1 HD46820 and the Rehabilitation Research &
Development Service of the VA. The contents are solely the
responsibility of the authors and do not necessarily represent the
official views of the NIH, NICHD or VA.
NR 27
TC 32
Z9 32
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0268-0033
J9 CLIN BIOMECH
JI Clin. Biomech.
PD JUN
PY 2011
VL 26
IS 5
BP 509
EP 515
DI 10.1016/j.clinbiomech.2010.12.010
PG 7
WC Engineering, Biomedical; Orthopedics; Sport Sciences
SC Engineering; Orthopedics; Sport Sciences
GA 771RN
UT WOS:000291178500013
PM 21251738
ER
PT J
AU Liu, JQ
Liao, S
Huang, YH
Samuel, R
Shi, T
Naxerova, K
Huang, PG
Kamoun, W
Jain, RK
Fukumura, D
Xu, L
AF Liu, Jieqiong
Liao, Shan
Huang, Yuhui
Samuel, Rekha
Shi, Tony
Naxerova, Kamila
Huang, Peigen
Kamoun, Walid
Jain, Rakesh K.
Fukumura, Dai
Xu, Lei
TI PDGF-D Improves Drug Delivery and Efficacy via Vascular Normalization,
But Promotes Lymphatic Metastasis by Activating CXCR4 in Breast Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR-D; HUMAN OVARIAN-CARCINOMA; ANTI-VEGF TREATMENT;
RECEPTOR-BETA; DOWN-REGULATION; PROTEIN-KINASE; IN-SITU; EXPRESSION;
ANGIOGENESIS; CELLS
AB Purpose: Unlike platelet-derived growth factor-B (PDGF-B), the role of PDGF-D in tumor progression or treatment is largely unknown. To this end, we determined the role of PDGF-D in breast cancer progression, metastasis, and response to chemotherapy.
Experimental Design: We first examined PDGF-D expression in human breast carcinomas by immunohistochemical (IHC) staining. To mimic high PDGF-D expressing tumors, we stably transfected the breast cancer cell lines MDA-MB-231 and 4T1 with pdgf-d cDNA, and implanted these tumor cells orthtopically into nude mice. We monitored tumor growth by caliper measurement and bioluminescence imaging. We also used short hairpin RNA interference (shRNAi) and imatinib to block PDGF-D/PDGFR beta signaling. Finally, we studied the effect of PDGF-D on doxorubicin delivery and efficacy.
Results: Human breast cancers express high levels of PDGF-D. Overexpression of PDGF-D promoted tumor growth and lymph node metastasis through increased proliferation, decreased apoptosis, and induction of CXCR4 expression. Blockade of CXCR4 signaling abolished PDGF-D-induced lymph node metastasis. Furthermore, overexpression of PDGF-D increased perivascular cell coverage and normalized tumor blood vessels. As a result, PDGF-D overexpression facilitated tissue penetration of doxorubicin and enhanced its treatment efficacy.
Conclusions: PDGF-D is highly expressed in human breast cancer and facilitates tumor growth and lymph node metastasis, making it a potential target in breast cancer. At the same time, PDGF-D increases drug delivery and hence improves the efficacy of chemotherapy through vessel normalization. Therefore, judicious use of PDGF-D/PDGFR beta blockers would be necessary to minimize the adverse effects on concomitantly administered cytotoxic therapies. Clin Cancer Res; 17(11); 3638-48. (C)2011 AACR.
C1 [Liu, Jieqiong; Liao, Shan; Huang, Yuhui; Samuel, Rekha; Naxerova, Kamila; Huang, Peigen; Kamoun, Walid; Jain, Rakesh K.; Fukumura, Dai; Xu, Lei] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.
[Liu, Jieqiong] Cent S Univ, Xiangya Hosp 2, Dept Breast Surg, Changsha, Hunan, Peoples R China.
[Shi, Tony] NYU, Coll Arts & Sci, New York, NY USA.
RP Xu, L (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.
EM lei@steele.mgh.harvard.edu
RI Huang, Yuhui/E-5046-2010;
OI Huang, Yuhui/0000-0002-6226-2028; Naxerova, Kamila/0000-0001-7744-5110;
Huang, Yuhui/0000-0003-1985-3575
FU Clafflin Distinguished Scholar Award; Harvard Medical School; US
National Cancer Institute [P01-CA80124, R01-CA85140, R01-CA96915,
R01-CA115767, R01-CA126642]; US Department of Defense [W81XWH-10-1-0016]
FX This study was supported in part by Clafflin Distinguished Scholar
Award, Harvard Medical School (L. Xu), US National Cancer Institute
grants P01-CA80124 (R. K. Jain and D. Fukumura), R01-CA85140 (R. K.
Jain), R01-CA96915 (D. Fukumura), R01-CA115767 (R. K. Jain),
R01-CA126642 (R. K. Jain), and US Department of Defense Breast Cancer
Research Innovator Award-W81XWH-10-1-0016 (R.K. Jain).
NR 37
TC 38
Z9 41
U1 5
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2011
VL 17
IS 11
BP 3638
EP 3648
DI 10.1158/1078-0432.CCR-10-2456
PG 11
WC Oncology
SC Oncology
GA 772AC
UT WOS:000291200800015
PM 21459800
ER
PT J
AU Andersson, A
Srivastava, MK
Harris-White, M
Huang, M
Zhu, L
Elashoff, D
Strieter, RM
Dubinett, SM
Sharma, S
AF Andersson, Asa
Srivastava, Minu K.
Harris-White, Marni
Huang, Min
Zhu, Li
Elashoff, David
Strieter, Robert M.
Dubinett, Steven M.
Sharma, Sherven
TI Role of CXCR3 Ligands in IL-7/IL-7R alpha-Fc-Mediated Antitumor Activity
in Lung Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CYTOTOXIC T-LYMPHOCYTES; ANGIOGENESIS IN-VIVO; X-C-CHEMOKINE; DENDRITIC
CELLS; MACROPHAGE POLARIZATION; INTERFERON-GAMMA; TUMOR-ANTIGENS;
INTERLEUKIN-7; IL-7; CARCINOMA
AB Purpose: We evaluated the utility of chimeric gamma c homeostatic cytokine, IL-7/IL-7R alpha-Fc, to restore host APC (antigen presenting cell) and T cell activities in lung cancer.
Experimental Design: Utilizing murine lung cancer models we determined the antitumor efficacy of IL-7/IL-7R alpha-Fc. APC, T cell, cytokine analyses, neutralization of CXCL9, CXCL10, and IFN gamma were carried out to evaluate the mechanistic differences in the antitumor activity of IL-7/IL-7R alpha-Fc in comparison to controls.
Results: IL-7/IL-7R alpha-Fc administration inhibited tumor growth and increased survival in lung cancer. Accompanying the tumor growth inhibition were increases in APC and T cell activities. In comparison to controls, IL-7/IL-7R alpha-Fc treatment of tumor bearing mice led to increased: (i) levels of CXCL9, CXCL10, IFN gamma, IL-12 but reduced IL-10 and TGF beta, (ii) tumor macrophage infiltrates characteristic of M1 phenotype with increased IL-12, iNOS but reduced IL-10 and arginase, (iii) frequencies of T and NK cells, (iv) T cell activation markers CXCR3, CD69 and CD127(low), (v) effector memory T cells, and (vi) T cell cytolytic activity against parental tumor cells. IL-7/IL-7R alpha-Fc treatment abrogated the tumor induced reduction in splenic functional APC activity to T responder cells. The CXCR3 ligands played an important role in IL-7/IL-7R alpha-Fc-mediated antitumor activity. Neutralization of CXCL9, CXCL10, or IFN gamma reduced CXCR3 expressing activated T cells infiltrating the tumor and abrogated IL-7/IL-7R alpha-Fc-mediated tumor growth inhibition.
Conclusions: Our findings show that IL-7/IL-7R alpha-Fc promotes afferent and efferent antitumor responses in lung cancer. Clin Cancer Res; 17(11); 3660-72. (C)2011 AACR.
C1 [Harris-White, Marni; Huang, Min; Zhu, Li; Dubinett, Steven M.; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA 90073 USA.
[Strieter, Robert M.] Univ Virginia, Dept Med, Charlottesville, VA USA.
[Harris-White, Marni] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Huang, Min; Zhu, Li; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Andersson, Asa; Srivastava, Minu K.; Huang, Min; Zhu, Li; Elashoff, David; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, UCLA Lung Canc Res Program, Dept Med, Los Angeles, CA 90095 USA.
RP Sharma, S (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA 90073 USA.
EM ssharma@mednet.ucla.edu
FU NIH [RO1 CA95686, RO1 CA126944]; University of California Los Angeles
Lung Cancer Program; Department of Veterans Affairs; University of
California [18FT-0165, 15RT-0207]
FX This work was supported by: NIH Grants (RO1 CA95686 and RO1 CA126944),
University of California Los Angeles Lung Cancer Program, Department of
Veterans Affairs Medical Research Funds, and Tobacco Related Disease
Program Award Program of University of California (18FT-0165 and
15RT-0207).
NR 56
TC 15
Z9 17
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2011
VL 17
IS 11
BP 3660
EP 3672
DI 10.1158/1078-0432.CCR-10-3346
PG 13
WC Oncology
SC Oncology
GA 772AC
UT WOS:000291200800017
PM 21636553
ER
PT J
AU Kanai, R
Wakimoto, H
Martuza, RL
Rabkin, SD
AF Kanai, Ryuichi
Wakimoto, Hiroaki
Martuza, Robert L.
Rabkin, Samuel D.
TI A Novel Oncolytic Herpes Simplex Virus that Synergizes with
Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma
Stem Cells
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MALIGNANT GLIOMA-CELLS; U(S)3 PROTEIN-KINASE; IN-VIVO; CANCER; MUTANT;
VECTORS; APOPTOSIS; TUMORS; US3; HERPES-SIMPLEX-VIRUS-1
AB Purpose: To develop a new oncolytic herpes simplex virus (oHSV) for glioblastoma (GBM) therapy that will be effective in glioblastoma stem cells (GSC), an important and untargeted component of GBM. One approach to enhance oHSV efficacy is by combination with other therapeutic modalities.
Experimental Design: MG18L, containing a U(S)3 deletion and an inactivating LacZ insertion in U(L)39, was constructed for the treatment of brain tumors. Safety was evaluated after intracerebral injection in HSV-susceptible mice. The efficacy of MG18L in human GSCs and glioma cell lines in vitro was compared with other oHSVs, alone or in combination with phosphoinositide-3-kinase (PI3K)/Akt inhibitors (LY294002, triciribine, GDC-0941, and BEZ235). Cytotoxic interactions between MG18L and PI3K/Akt inhibitors were determined using Chou-Talalay analysis. In vivo efficacy studies were conducted using a clinically relevant mouse model of GSC-derived GBM.
Results: MG18L was severely neuroattenuated in mice, replicated well in GSCs, and had anti-GBM activity in vivo. PI3K/Akt inhibitors displayed significant but variable antiproliferative activities in GSCs, whereas their combination with MG18L synergized in killing GSCs and glioma cell lines, but not human astrocytes, through enhanced induction of apoptosis. Importantly, synergy was independent of inhibitor sensitivity. In vivo, the combination of MG18L and LY294002 significantly prolonged survival of mice, as compared with either agent alone, achieving 50% long-term survival in GBM-bearing mice.
Conclusions: This study establishes a novel therapeutic strategy: oHSV manipulation of critical oncogenic pathways to sensitize cancer cells to molecularly targeted drugs. MG18L is a promising agent for the treatment of GBM, being especially effective when combined with PI3K/Akt pathway-targeted agents. Clin Cancer Res; 17(11); 3686-96. (C)2011 AACR.
C1 [Rabkin, Samuel D.] Massachusetts Gen Hosp, Brain Tumor Res Ctr, Dept Neurosurg, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Rabkin, SD (reprint author), Massachusetts Gen Hosp, Brain Tumor Res Ctr, Dept Neurosurg, 185 Cambridge St,CPZN-3800, Boston, MA 02114 USA.
EM rabkin@helix.mgh.harvard.edu
RI rabkin, samuel/C-2443-2012
OI rabkin, samuel/0000-0003-2344-2795
FU NIH [NS-032677]; Department of Defense [W81XWH-07-1-0359]
FX The study was supported by NIH grant NS-032677 (R.L. Martuza) and
Department of Defense grant W81XWH-07-1-0359 (S.D. Rabkin).
NR 47
TC 30
Z9 30
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2011
VL 17
IS 11
BP 3686
EP 3696
DI 10.1158/1078-0432.CCR-10-3142
PG 11
WC Oncology
SC Oncology
GA 772AC
UT WOS:000291200800019
PM 21505062
ER
PT J
AU Pharoah, PDP
Palmieri, RT
Ramus, SJ
Gayther, SA
Andrulis, IL
Anton-Culver, H
Antonenkova, N
Antoniou, AC
Goldgar, D
Beattie, MS
Beckmann, MW
Birrer, MJ
Bogdanova, N
Bolton, KL
Brewster, W
Brooks-Wilson, A
Brown, R
Butzow, R
Caldes, T
Caligo, MA
Campbell, I
Chang-Claude, J
Chen, YA
Cook, LS
Couch, FJ
Cramer, DW
Cunningham, JM
Despierre, E
Doherty, JA
Dork, T
Durst, M
Eccles, DM
Ekici, AB
Easton, D
Fasching, PA
de Fazio, A
Fenstermacher, DA
Flanagan, JM
Fridley, BL
Friedman, E
Gao, B
Sinilnikova, O
Gentry-Maharaj, A
Godwin, AK
Goode, EL
Goodman, MT
Gross, J
Hansen, TVO
Harnett, P
Rookus, M
Heikkinen, T
Hein, R
Hogdall, C
Hogdall, E
Iversen, ES
Jakubowska, A
Johnatty, SE
Karlan, BY
Kauff, ND
Kaye, SB
Chenevix-Trench, G
Kelemen, LE
Kiemeney, LA
Kjaer, SK
Lambrechts, D
LaPolla, JP
Lazaro, C
Le, ND
Leminen, A
Leunen, K
Levine, DA
Lu, Y
Lundvall, L
Macgregor, S
Marees, T
Massuger, LF
McLaughlin, JR
Menon, U
Montagna, M
Moysich, KB
Narod, SA
Nathanson, KL
Nedergaard, L
Ness, RB
Nevanlinna, H
Nickels, S
Osorio, A
Paul, J
Pearce, CL
Phelan, CM
Pike, MC
Radice, P
Rossing, MA
Schildkraut, JM
Sellers, TA
Singer, CF
Song, HL
Stram, DO
Sutphen, R
Lindblom, A
Terry, KL
Tsai, YY
van Altena, AM
Vergote, I
Vierkant, RA
Vitonis, AF
Walsh, C
Wang-Gohrke, S
Wappenschmidt, B
Wu, AH
Ziogas, A
Berchuck, A
Risch, HA
AF Pharoah, Paul D. P.
Palmieri, Rachel T.
Ramus, Susan J.
Gayther, Simon A.
Andrulis, Irene L.
Anton-Culver, Hoda
Antonenkova, Natalia
Antoniou, Antonis C.
Goldgar, David
Beattie, Mary S.
Beckmann, Matthias W.
Birrer, Michael J.
Bogdanova, Natalia
Bolton, Kelly L.
Brewster, Wendy
Brooks-Wilson, Angela
Brown, Robert
Butzow, Ralf
Caldes, Trinidad
Caligo, Maria Adelaide
Campbell, Ian
Chang-Claude, Jenny
Chen, Y. Ann
Cook, Linda S.
Couch, Fergus J.
Cramer, Daniel W.
Cunningham, Julie M.
Despierre, Evelyn
Doherty, Jennifer A.
Doerk, Thilo
Duerst, Matthias
Eccles, Diana M.
Ekici, Arif B.
Easton, Douglas
Fasching, Peter A.
de Fazio, Anna
Fenstermacher, David A.
Flanagan, James M.
Fridley, Brooke L.
Friedman, Eitan
Gao, Bo
Sinilnikova, Olga
Gentry-Maharaj, Aleksandra
Godwin, Andrew K.
Goode, Ellen L.
Goodman, Marc T.
Gross, Jenny
Hansen, Thomas V. O.
Harnett, Paul
Rookus, Matti
Heikkinen, Tuomas
Hein, Rebecca
Hogdall, Claus
Hogdall, Estrid
Iversen, Edwin S.
Jakubowska, Anna
Johnatty, Sharon E.
Karlan, Beth Y.
Kauff, Noah D.
Kaye, Stanley B.
Chenevix-Trench, Georgia
Kelemen, Linda E.
Kiemeney, Lambertus A.
Kjaer, Susanne Krueger
Lambrechts, Diether
LaPolla, James P.
Lazaro, Conxi
Le, Nhu D.
Leminen, Arto
Leunen, Karin
Levine, Douglas A.
Lu, Yi
Lundvall, Lene
Macgregor, Stuart
Marees, Tamara
Massuger, Leon F.
McLaughlin, John R.
Menon, Usha
Montagna, Marco
Moysich, Kirsten B.
Narod, Steven A.
Nathanson, Katherine L.
Nedergaard, Lotte
Ness, Roberta B.
Nevanlinna, Heli
Nickels, Stefan
Osorio, Ana
Paul, Jim
Pearce, Celeste Leigh
Phelan, Catherine M.
Pike, Malcolm C.
Radice, Paolo
Rossing, Mary Anne
Schildkraut, Joellen M.
Sellers, Thomas A.
Singer, Christian F.
Song, Honglin
Stram, Daniel O.
Sutphen, Rebecca
Lindblom, Annika
Terry, Kathryn L.
Tsai, Ya-Yu
van Altena, Anne M.
Vergote, Ignace
Vierkant, Robert A.
Vitonis, Allison F.
Walsh, Christine
Wang-Gohrke, Shan
Wappenschmidt, Barbara
Wu, Anna H.
Ziogas, Argyrios
Berchuck, Andrew
Risch, Harvey A.
CA BCFR Investigators
EMBRACE Investigators
GEMO Study Collaborators
HEBON Investigators
KConFab Investigators
Consortium Investigators Modifiers
SWE-BRCA Investigators
Ovarian Canc Assoc Consortium
TI The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer:
Implications for Clinical Testing
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; MUTATION CARRIERS;
BREAST-CANCER; RISK; CONSORTIUM; SURVIVAL
AB Purpose: An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'-UTR miRNA binding site of the KRAS oncogene and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one published article, analyzing fewer than 1,000 subjects in total, has examined this association.
Experimental Design: Risk association was evaluated in 8,669 cases of invasive EOC and 10,012 controls from 19 studies participating in the Ovarian Cancer Association Consortium, and in 683 cases and 2,044 controls carrying BRCA1 mutations from studies in the Consortium of Investigators of Modifiers of BRCA1/2. Prognosis association was also examined in a subset of five studies with progression-free survival (PFS) data and 18 studies with all-cause mortality data.
Results: No evidence of association was observed between genotype and risk of unselected EOC (OR = 1.02, 95% CI: 0.95-1.10), serous EOC (OR = 1.08, 95% CI: 0.98-1.18), familial EOC (OR = 1.09, 95% CI: 0.78-1.54), or among women carrying deleterious mutations in BRCA1 (OR = 1.09, 95% CI: 0.88-1.36). There was little evidence for association with survival time among unselected cases (HR = 1.10, 95% CI: 0.99-1.22), among serous cases (HR = 1.12, 95% CI = 0.99-1.28), or with PFS in 540 cases treated with carboplatin and paclitaxel (HR = 1.18, 95% CI: 0.93-1.52).
Conclusions: These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer. Use of this SNP for ovarian cancer clinical risk prediction, therefore, seems unwarranted. Clin Cancer Res; 17(11); 3742-50. (C)2011 AACR.
C1 [Risch, Harvey A.] Yale Univ, Dept Epidemiol & Publ Hlth, Sch Publ Hlth, Sch Med, New Haven, CT 06520 USA.
[Wappenschmidt, Barbara] Univ Cologne, Dept Obstet & Gynaecol, Ctr Familial Breast & Ovarian Canc, Cologne, Germany.
[Wappenschmidt, Barbara] Univ Cologne, CIO, Cologne, Germany.
[Wang-Gohrke, Shan] Univ Ulm, Dept Obstet & Gynaecol, Ulm, Germany.
[Lindblom, Annika; SWE-BRCA Investigators] Karolinska Univ Hosp, Stockholm, Sweden.
[Singer, Christian F.] Med Univ Vienna, Div Special Gynecol, Vienna, Austria.
[Radice, Paolo] Fdn Ist FIRC Oncol Mol, IFOM, Milan, Italy.
[Radice, Paolo] Fdn IRCCS Ist Nazl Tumori INT, Dept Prevent & Predict Med, Unit Mol Bases Genet Risk & Genet Testing, Milan, Italy.
[Paul, Jim] Univ Glasgow, Canc Res UK Clin Trials Unit, Glasgow, Lanark, Scotland.
[Ness, Roberta B.] Univ Texas Sch Publ Hlth, Houston, TX USA.
[Nathanson, Katherine L.] Univ Penn, Sch Med, Dept Med, Med Genet & Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Moysich, Kirsten B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
[Montagna, Marco] IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy.
[Lazaro, Conxi] Inst Catalan Oncol, Hereditary Canc Program, Barcelona, Spain.
[LaPolla, James P.] Bayfront Med Ctr, Obstet & Gynecol Residency Program, St Petersburg, FL USA.
[LaPolla, James P.] Womens Canc Associates, St Petersburg, FL USA.
[Lambrechts, Diether] Vesalius Res Ctr VIB, Louvain, Belgium.
[Lambrechts, Diether] Univ Leuven, Louvain, Belgium.
[Massuger, Leon F.; van Altena, Anne M.] Radboud Univ Nijmegen, Med Ctr, Dept Gynecol, NL-6525 ED Nijmegen, Netherlands.
[Kiemeney, Lambertus A.; Marees, Tamara] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6525 ED Nijmegen, Netherlands.
[Kelemen, Linda E.] Alberta Hlth Serv Canc Care, Dept Populat Hlth Res, Calgary, AB, Canada.
[Chenevix-Trench, Georgia; KConFab Investigators] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Kaye, Stanley B.] Inst Canc Res, Med Sect, Sutton, Surrey, England.
[Kauff, Noah D.] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, New York, NY 10021 USA.
[Levine, Douglas A.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA.
[Pike, Malcolm C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
[Johnatty, Sharon E.; Lu, Yi; Macgregor, Stuart; Consortium Investigators Modifiers] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[Jakubowska, Anna] Pomeranian Med Univ, Dept Genet & Pathol, Int Hereditary Canc Ctr, Szczecin, Poland.
[Rookus, Matti; HEBON Investigators] Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands.
[Nedergaard, Lotte] Univ Copenhagen, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark.
[Hogdall, Estrid] Herlev Hosp, Mol Unit, Dept Pathol, Herlev, Denmark.
[Hogdall, Estrid; Kjaer, Susanne Krueger] Danish Canc Soc, Inst Canc Epidemiol, Dept Viruses Hormones & Canc, Copenhagen, Denmark.
[Hogdall, Claus; Kjaer, Susanne Krueger; Lundvall, Lene] Univ Copenhagen, Rigshosp, Juliane Marie Ctr, Gynecol Clin, DK-2100 Copenhagen, Denmark.
[Hansen, Thomas V. O.] Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, Copenhagen, Denmark.
[Goodman, Marc T.] Univ Hawaii, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA.
[Godwin, Andrew K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA.
[Sinilnikova, Olga; GEMO Study Collaborators] Federat Natl Ctr Lutte Canc, Canc Genet Network Grp Genet & Canc, Lyon, France.
[Friedman, Eitan] Chaim Sheba Med Ctr, Oncogenet Unit, IL-52621 Tel Hashomer, Israel.
[Friedman, Eitan] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
[de Fazio, Anna; Gao, Bo; Harnett, Paul] Westmead Hosp, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
[de Fazio, Anna; Gao, Bo; Harnett, Paul] Univ Sydney, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.
[de Fazio, Anna; Gao, Bo] Westmead Hosp, Dept Gynaecol Oncol, Westmead, NSW 2145, Australia.
[Easton, Douglas; EMBRACE Investigators] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge, England.
[Eccles, Diana M.] Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England.
[Duerst, Matthias] Univ Jena, Clin Obstet & Gynaecol, Jena, Germany.
[Doherty, Jennifer A.; Rossing, Mary Anne] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98104 USA.
[Despierre, Evelyn; Leunen, Karin; Vergote, Ignace] Univ Leuven, Univ Hosp Leuven, Dept Obstet & Gynaecol, Div Gynaecol Oncol, Leuven, Belgium.
[Goode, Ellen L.] Mayo Clin, Coll Med, Div Epidemiol, Rochester, MN USA.
[Fridley, Brooke L.; Vierkant, Robert A.] Mayo Clin, Coll Med, Div Biostat, Dept Hlth Sci Res, Rochester, MN USA.
[Cunningham, Julie M.] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN USA.
[Cook, Linda S.] Univ New Mexico, Dept Internal Med, Div Epidemiol & Biostat, Albuquerque, NM 87131 USA.
[Sutphen, Rebecca] Univ S Florida, Coll Med, Dept Pediat, Tampa, FL 33612 USA.
[Chen, Y. Ann; Fenstermacher, David A.; Phelan, Catherine M.; Sellers, Thomas A.; Tsai, Ya-Yu] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Chang-Claude, Jenny; Hein, Rebecca; Nickels, Stefan] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
[Campbell, Ian] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.
[Campbell, Ian] Peter MacCallum Canc Ctr, Ctr Canc Genom & Predict Med, Melbourne, Vic, Australia.
[Caligo, Maria Adelaide] Univ Hosp Pisa, Sect Genet Oncol, Pisa, Italy.
[Osorio, Ana] Spanish Natl Canc Ctr, Human Canc Genet Programme, Human Genet Grp, Madrid, Spain.
[Caldes, Trinidad] Hosp Clin San Carlos, Mol Oncol Lab, Madrid, Spain.
[Butzow, Ralf] Univ Helsinki, Dept Pathol, Helsinki, Finland.
[Butzow, Ralf; Heikkinen, Tuomas; Leminen, Arto; Nevanlinna, Heli] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland.
[Menon, Usha] UCL, EGA Inst Womens Hlth, Dept Gynaecol Oncol, London, England.
[Brown, Robert; Flanagan, James M.; Gentry-Maharaj, Aleksandra] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London SW7 2AZ, England.
[Brooks-Wilson, Angela] British Columbia Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada.
[Brewster, Wendy] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC USA.
[Bolton, Kelly L.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Bogdanova, Natalia] Hannover Med Sch, Clin Radiat Oncol, D-3000 Hannover, Germany.
[Bogdanova, Natalia; Doerk, Thilo] Hannover Med Sch, Clin Obstet & Gynaecol, D-3000 Hannover, Germany.
[Cramer, Daniel W.; Terry, Kathryn L.; Vitonis, Allison F.] Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA.
[Birrer, Michael J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Ekici, Arif B.] Friedrich Alexander Univ Erlangen Nuremberg, Inst Human Genet, Erlangen, Bavaria, Germany.
[Beckmann, Matthias W.] Univ Hosp Erlangen, Dept Gynecol & Obstet, Erlangen, Germany.
[Beattie, Mary S.] Univ Calif San Francisco, Dept Med, Canc Risk Program, San Francisco, CA USA.
[Beattie, Mary S.] Univ Calif San Francisco, Dept Epidemiol, Canc Risk Program, San Francisco, CA 94143 USA.
[Beattie, Mary S.] Univ Calif San Francisco, Dept Biostat, Canc Risk Program, San Francisco, CA 94143 USA.
[Goldgar, David; BCFR Investigators] NCI, Breast Canc Family Registry, Epidemiol & Genet Res Program, DCCPS, Rockville, MD USA.
[Antonenkova, Natalia] Byelorussian Inst Oncol & Med Radiol Aleksandrov, Minsk, Byelarus.
[Anton-Culver, Hoda; Ziogas, Argyrios] Univ Calif Irvine, Sch Med, Dept Epidemiol, Irvine, CA 92717 USA.
[Narod, Steven A.] Univ Toronto, Womens Coll Res Inst, Toronto, ON, Canada.
[Andrulis, Irene L.] Canc Care Ontario, Ontario Canc Genet Network, Toronto, ON, Canada.
[Andrulis, Irene L.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, New York, NY USA.
[Gross, Jenny; Karlan, Beth Y.; Walsh, Christine] Cedars Sinai Med Ctr, Samual Oschin Comprehens Canc Inst, Womens Canc Res Inst, Los Angeles, CA 90048 USA.
[Fasching, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
[Ramus, Susan J.; Gayther, Simon A.; Pearce, Celeste Leigh; Pike, Malcolm C.; Stram, Daniel O.; Wu, Anna H.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Ramus, Susan J.; Gayther, Simon A.; Pearce, Celeste Leigh; Pike, Malcolm C.; Stram, Daniel O.; Wu, Anna H.] Univ So Calif, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.
[Iversen, Edwin S.] Duke Univ, Dept Stat Sci, Durham, NC USA.
[Berchuck, Andrew] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA.
[Palmieri, Rachel T.; Schildkraut, Joellen M.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA.
[Pharoah, Paul D. P.; Song, Honglin] Univ Cambridge, Dept Oncol, Cambridge, England.
RP Risch, HA (reprint author), Yale Univ, Dept Epidemiol & Publ Hlth, Sch Publ Hlth, Sch Med, 60 Coll St, New Haven, CT 06520 USA.
EM harvey.risch@yale.edu
RI Tang, Macy/B-9798-2014; Harnett, Paul/D-4090-2014; deFazio,
Anna/D-3939-2013; Marees, Tamara/D-9867-2011; Lester, Jenny/B-5933-2012;
montagna, marco/E-2225-2012; Verdrengh, Evelien/H-4571-2012; Macgregor,
Stuart/C-6442-2009; Ekici, Arif/C-3971-2013; Andrulis,
Irene/E-7267-2013; McLaughlin, John/E-4577-2013; Radice,
Paolo/O-3119-2013; Kiemeney, Lambertus/D-3357-2009; Brooks-Wilson,
Angela/E-9399-2012; Osorio, Ana/I-4324-2014; Massuger, Leon/H-8072-2014;
Jakubowska, Anna/O-8050-2014; campbell, Ian/F-6006-2011; Fridley,
Brooke/D-8315-2015; van Altena, Anne/B-9824-2016; Dork,
Thilo/J-8620-2012; Johnatty, Sharon/R-8890-2016;
OI Harnett, Paul/0000-0001-7021-0642; deFazio, Anna/0000-0003-0057-4744;
montagna, marco/0000-0002-4929-2150; Macgregor,
Stuart/0000-0001-6731-8142; Kiemeney, Lambertus/0000-0002-2368-1326;
Brooks-Wilson, Angela/0000-0003-1009-6408; Osorio,
Ana/0000-0001-8124-3984; Fridley, Brooke/0000-0001-7739-7956; Johnatty,
Sharon/0000-0002-7888-1966; Vierkant, Robert/0000-0001-6242-5221;
Nathanson, Katherine/0000-0002-6740-0901; Kjaer,
Susanne/0000-0002-8347-1398; Ramus, Susan/0000-0003-0005-7798; Kauff,
Noah/0000-0001-7242-6156; Nevanlinna, Heli/0000-0002-0916-2976
FU Ovarian Cancer Research Fund; Breast Cancer Family Registry including
Cancer Care Ontario; US NIH [5U01-CA069467, 5U01-CA069398,
5U01-CA069631, 5U01-CA069446, 5U01-CA069417, 5U01-CA069638,
N02-PC45022]; National Cancer Plan-Action 29; NIH [5R01-CA054419,
5P50-CA105009, 5R01-CA112523]; Ligue National Contre le Cancer;
Association Le cancer du sein, parlonsen; Association for International
Cancer Research [AICR-07-0454]; German Federal Ministry of Education and
Research; Programme of Clinical Biomedical Research [01 GB 9401]; state
of Baden-Wurttemberg through the University of Ulm Medical [P.685];
German Cancer Research Center; Helsinki University Central Hospital;
Academy of Finland; Finnish Cancer Society; US Army MRMC [DAMD
17-02-1-0669]; Ovarian Cancer Research Foundation; Roswell Park Alliance
Foundation; Cancer Australia [628333]; National Breast Cancer
Foundation; National Health and Medical Research Council (NHMRC);
Queensland Cancer Fund; Cancer Council of New South Wales; Cancer
Council of Victoria; Cancer Council of Tasmania; Cancer Council of South
Australia; Cancer Foundation of Western Australia; American Cancer
Society [SIOP-06-258-01-CCE, CRTG-00-196-01-CCE]; L & S Milken
Foundation; Mermaid 1; Danish Cancer Society; National Cancer Institute
[5R01-CA061107, 5R01-CA122443, 5R01-CA076016, 5R01-CA058860,
5K07-CA092044]; Radboud University Nijmegen Medical Centre; Canadian
Institutes of Health Research (CIHR); Workers' Compensation Board of
British Columbia; Cancer Research UK [A6689]; Experimental Cancer
Research Centres; Advanced Cancer Detection Center; Department of
Defense [DAMD 17-98-1-8659]; Celma Mastry Ovarian Cancer Foundation;
Canadian Institutes for Health Research; National Cancer Institute of
Canada; Canadian Cancer Society; Lon V Smith Foundation [LVS-39420]; Eve
Appeal; OAK Foundation; Department of Health's NIHR Biomedical Research
Centre; California Cancer Research Program [00-01389V-20170, 2110200];
California Department of Health Services [050-E8709]; Wellcome Trust
[076113]; Breast Cancer Research Foundation; Susan G. Komen for the
Cure; Eileen Stein Jacoby Fund; Neve Foundation; Project Hope for
Ovarian Cancer Research and Education; Australian National Breast Cancer
Foundation; National Health and Medical Research Council of Australia
FX The Ovarian Cancer Association Consortium is supported by a grant from
the Ovarian Cancer Research Fund. Funding for the individual
participating studies was provided by: cooperative agreements with the
Breast Cancer Family Registry including Cancer Care Ontario, and US NIH
grants 5U01-CA069467, 5U01-CA069398, 5U01-CA069631, 5U01-CA069446,
5U01-CA069417, 5U01-CA069638, and N02-PC45022 (BCFR); the National
Cancer Plan-Action 29 for the support of Translational Research (BEL);
NIH grants 5R01-CA054419 and 5P50-CA105009 (BWH); NIH grants
5R01-CA112523 and 5R01-CA087538 (DOV); the Ligue National Contre le
Cancer, the Association "Le cancer du sein, parlonsen!" and research
grant AICR-07-0454 from the Association for International Cancer
Research (GEMO); the German Federal Ministry of Education and Research,
the Programme of Clinical Biomedical Research grant 01 GB 9401, the
state of Baden-Wurttemberg through the University of Ulm Medical Faculty
grant P.685, and the German Cancer Research Center (GER); the Helsinki
University Central Hospital Research Fund, Academy of Finland and the
Finnish Cancer Society (HOC); NIH grants 5R01-CA095023, 5R01-CA126841,
and 5R03-CA121881, US Army MRMC grant DAMD 17-02-1-0669, and grants from
the Ovarian Cancer Research Foundation and the Roswell Park Alliance
Foundation (HOP); grant 628333 from Cancer Australia and grants from the
National Breast Cancer Foundation, the National Health and Medical
Research Council (NHMRC), the Queensland Cancer Fund, the Cancer
Councils of New South Wales, Victoria, Tasmania and South Australia, and
the Cancer Foundation of Western Australia (kConFab); American Cancer
Society Early Detection Professorship grant SIOP-06-258-01-CCE and the L
& S Milken Foundation (LAX); Mermaid 1, The Danish Cancer Society and
the National Cancer Institute 5R01-CA061107 (MAL); National Cancer
Institute 5R01-CA122443 (MAY); National Cancer Institute 5R01-CA076016
(NCO); an Investment Grant of the Radboud University Nijmegen Medical
Centre (NTH); grants from the Canadian Institutes of Health Research
(CIHR) and the Workers' Compensation Board of British Columbia (OVA);
Cancer Research UK (SEA); Experimental Cancer Research Centres and
Cancer Research UK A6689 (SRO); NIH grant 5R01-CA106414, American Cancer
Society grant CRTG-00-196-01-CCE and an Advanced Cancer Detection Center
Grant, Department of Defense grant DAMD 17-98-1-8659, and funding from
the Celma Mastry Ovarian Cancer Foundation (TBO); Canadian Institutes
for Health Research, the National Cancer Institute of Canada, the
Canadian Cancer Society and the NIH grants 5R01-CA063682 and
5R01-CA063678 (TOR); National Cancer Institute grants 5R01-CA058860 and
5K07-CA092044 and the Lon V Smith Foundation LVS-39420 (UCI); Cancer
Research UK, the Eve Appeal, the OAK Foundation and the Department of
Health's NIHR Biomedical Research Centre funding scheme (UKO); the
California Cancer Research Program grants 00-01389V-20170 and 2110200,
NIH grants 5P30-CA014089, 5P01-CA017054, 5R01-CA061132, 5R01-CA063464,
N01-PC67010, and 5R03-CA113148, and California Department of Health
Services sub-contract 050-E8709 (USC); Wellcome Trust award 076113
(WTCCC). Additional support for the TOR, NCO, MAY, TBO, and NCI studies
was provided by NIH grant 5R01-CA114343. The Consortium of Investigators
of Modifiers of BRCA1/2 GWAS and its participating studies were funded
by: the Breast Cancer Research Foundation, Susan G.; Komen for the Cure,
the Ovarian Cancer Research Fund, the Eileen Stein Jacoby Fund, NIH
grants 5R01-CA128978 and 1R01-CA140323, Cancer Research UK, he Neve
Foundation, Project Hope for Ovarian Cancer Research and Education, the
Australian National Breast Cancer Foundation, the National Health and
Medical Research Council of Australia.
NR 16
TC 31
Z9 33
U1 0
U2 17
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2011
VL 17
IS 11
BP 3742
EP 3750
DI 10.1158/1078-0432.CCR-10-3405
PG 9
WC Oncology
SC Oncology
GA 772AC
UT WOS:000291200800025
PM 21385923
ER
PT J
AU Abdelsamie, SA
Li, YC
Huang, Y
Lee, MH
Klein, RL
Virella, G
Lopes-Virella, MF
AF Abdelsamie, Souzan A.
Li, Yanchun
Huang, Yan
Lee, Mi-Hye
Klein, Richard L.
Virella, Gabriel
Lopes-Virella, Maria F.
TI Oxidized LDL immune complexes stimulate collagen IV production in
mesangial cells via Fc gamma receptors I and III
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Collagen; Low-density lipoprotein; Immune complexes; Nephropathy;
Mesangial cells
ID LOW-DENSITY-LIPOPROTEIN; DIABETIC-NEPHROPATHY; CULTURED RAT;
EXTRACELLULAR-MATRIX; PATHOGENESIS; MACROPHAGES; DISEASE; PROGRESSION;
EXPRESSION; ANTIBODIES
AB Diabetic nephropathy is characterized by progressive mesangial expansion. Although we have reported that circulating oxidized LDL-containing immune complexes (oxLDL-IC) are associated with abnormal levels of albuminuria, the underlying mechanisms have not been investigated. In this study, we have studied the effect of oxLDL-IC on collagen IV expression by mesangial cells. We found that oxLDL-IC markedly stimulated collagen IV expression in a concentration- and time-dependent fashion while oxLDL only had moderate effect. We also found that oxLDL-IC stimulated collagen IV expression by engaging Fc gamma receptor (Fc gamma R) I and III, but not Fc gamma RII, and that p38 MAPK, JNK and PKC pathways were involved in collagen IV expression. Furthermore, we found that oxLDL-IC stimulated Fc gamma RI expression, suggesting a positive feedback mechanism involved in oxLDL-IC-stimulated collagen IV expression. Taken together, this study showed that oxLDL-IC stimulated collagen IV in mesangial cells via Fc gamma RI and Fc gamma RIII, and the expression of Fc gamma RI was increased by oxLDL-IC. Published by Elsevier Inc.
C1 [Huang, Yan; Klein, Richard L.; Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Abdelsamie, Souzan A.; Li, Yanchun; Huang, Yan; Lee, Mi-Hye; Klein, Richard L.; Lopes-Virella, Maria F.] Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA.
[Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA.
EM virellam@musc.edu
FU Department of Veterans Affairs; National Institutes of Health/NHLBI [PO1
HL 55782]; NIH/NIDDK [R01 DK081352]; Juvenile Diabetes Foundation
[2006-49]
FX This work was supported by a Merit Review Grant from the Department of
Veterans Affairs. This work was also supported by a Program Project
funded by the National Institutes of Health/NHLBI (PO1 HL 55782), by a
RO1 Grant funded by NIH/NIDDK (R01 DK081352) and by a Juvenile Diabetes
Foundation Grant (2006-49).
NR 42
TC 15
Z9 15
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2011
VL 139
IS 3
BP 258
EP 266
DI 10.1016/j.clim.2011.01.016
PG 9
WC Immunology
SC Immunology
GA 771QX
UT WOS:000291176900006
PM 21439910
ER
PT J
AU Xu, YH
Li, H
Gao, RL
Adeyemo, O
Itkin, M
Kaplan, DE
AF Xu, Yanhui
Li, Hong
Gao, Rui Lin
Adeyemo, Oluwasayo
Itkin, Maxim
Kaplan, David E.
TI Expansion of interferon-gamma-producing multifunctional CD4+T-cells and
dysfunctional CD8+T-cells by glypican-3 peptide library in
hepatocellular carcinoma patients
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Hepatocellular carcinoma; T-cells; Interferon-gamma; PD-1; CTLA-4
ID T-CELL RESPONSES; HEPATITIS-B-VIRUS; ALPHA-FETOPROTEIN; POSTOPERATIVE
RECURRENCE; EFFECTOR FUNCTION; EX-VIVO; LIVER; EXPRESSION; CIRRHOSIS;
CANCER
AB Glypican-3 is a promising target for immunotherapy for hepatocellular carcinoma, but limited data exist regarding its immunogenicity in patients with diverse HLA types, immunogenicity for CD4(+) T-cells, and the impact of inhibitory co-stimulation on glypican-3-specific T-cells. Using a 15mer overlapping peptide library for glypican-3, PBMC from patients with HCC were assessed ex vivo and after short-term in vitro expansion for tumor antigen-specific T-cell responses with and without blockade of PD-1/PD-L1 and CTLA-4 signaling. Glypican-3-specific T-cells were undetectable ex vivo, but primarily IFN gamma(+)TNF alpha(+) CD4(+) T-cells expanded with short-term in vitro stimulation in 10/19 (52%) patients. Glypican-3-specific CD8(+) T-cells predominantly produced TNF alpha, but did not secrete IFN gamma nor degranulate. CTLA-4 and PD-1 blockade minimally impacted the cytokine secretion and proliferation of glypican-3-specific T-cells. These data suggest that CD8(+). T-cell-directed tumor vaccines in HCC may have limited potential for efficacy unless optimal co-stimulation conditions can be identified but CD4(+)-directed vaccines merit consideration. Published by Elsevier Inc.
C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Med & Res Serv, Philadelphia, PA 19104 USA.
[Xu, Yanhui; Li, Hong; Gao, Rui Lin; Adeyemo, Oluwasayo; Kaplan, David E.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
[Itkin, Maxim] Univ Penn, Philadelphia VA Med Ctr, Serv Radiol, Philadelphia, PA 19104 USA.
[Itkin, Maxim] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
RP Kaplan, DE (reprint author), Philadelphia VA Med Ctr, Med & Res Serv, Res Bldg 21,A402A,3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM dakaplan@mail.med.upenn.edu
OI Kaplan, David E./0000-0002-3839-336X
FU Veterans Health Administration; University of Pennsylvania
FX This work was supported by the Research Career Development Award from
the Veterans Health Administration (DEK) and academic development funds
from the University of Pennsylvania. The content of this article does
not reflect the views of the VA or of the US Government.
NR 53
TC 8
Z9 10
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2011
VL 139
IS 3
BP 302
EP 313
DI 10.1016/j.clim.2011.02.014
PG 12
WC Immunology
SC Immunology
GA 771QX
UT WOS:000291176900011
PM 21419713
ER
PT J
AU Liverant, GI
Kamholz, BW
Sloan, DM
Brown, TA
AF Liverant, Gabrielle I.
Kamholz, Barbara W.
Sloan, Denise M.
Brown, Timothy A.
TI Rumination in Clinical Depression: A Type of Emotional Suppression?
SO COGNITIVE THERAPY AND RESEARCH
LA English
DT Article
DE Rumination; Depression; Emotion regulation; Acceptance
ID GENERALIZED ANXIETY DISORDER; DSM-IV ANXIETY; STRESS SCALES DASS; MOOD
DISORDERS; THOUGHT SUPPRESSION; COGNITIVE THERAPY; NEGATIVE AFFECT;
STRUCTURAL RELATIONSHIPS; PSYCHOMETRIC PROPERTIES; REGULATION STRATEGIES
AB This study examined the relationship between rumination and the use of other emotion-regulation strategies in a depressed sample. Sixty outpatients diagnosed with unipolar depression completed questionnaires and participated in a sad mood induction. The mood induction was used to investigate the relationship between the use of rumination and each of two theoretically relevant emotion-regulation strategies-suppression and acceptance. Findings demonstrated that rumination was positively associated with other types of suppression and negatively related to acceptance. Results offer tentative support for the conceptualization of rumination as a maladaptive, cognitive emotion-regulation strategy utilized by depressed individuals in an attempt to suppress their experience of negative emotion. Findings also suggest a potential mechanism of action for efficacious mindfulness and acceptance-based treatments for depression.
C1 [Liverant, Gabrielle I.; Sloan, Denise M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
[Liverant, Gabrielle I.; Kamholz, Barbara W.; Sloan, Denise M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Liverant, GI (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
EM Gabrielle.Liverant@va.gov
NR 74
TC 19
Z9 19
U1 6
U2 21
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0147-5916
J9 COGNITIVE THER RES
JI Cogn. Ther. Res.
PD JUN
PY 2011
VL 35
IS 3
BP 253
EP 265
DI 10.1007/s10608-010-9304-4
PG 13
WC Psychology, Clinical
SC Psychology
GA 771OD
UT WOS:000291169300008
ER
PT J
AU Moon, HS
Matarese, G
Brennan, AM
Chamberland, JP
Liu, XW
Fiorenza, CG
Mylvaganam, GH
Abanni, L
Carbone, F
Williams, CJ
De Paoli, AM
Schneider, BE
Mantzoros, CS
AF Moon, Hyun-Seuk
Matarese, Giuseppe
Brennan, Aoife M.
Chamberland, John P.
Liu, Xiaowen
Fiorenza, Christina G.
Mylvaganam, Geetha H.
Abanni, Luisa
Carbone, Fortunata
Williams, Catherine J.
De Paoli, Alex M.
Schneider, Benjamin E.
Mantzoros, Christos S.
TI Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular
and Molecular Pathways Underlying Leptin Tolerance
SO DIABETES
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; BLOOD-BRAIN-BARRIER; EXPRESSION; RECEPTOR;
INSULIN; HUMANS; RESISTANCE; ADIPOSITY; THERAPY; TISSUES
AB OBJECTIVE-Metreleptin has been efficacious in improving metabolic control in patients with lipodystrophy, but its efficacy has not been tested in obese patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS-We studied the role of leptin in regulating the endocrine adaptation to long-term caloric deprivation and weight loss in obese diabetic subjects over 16 weeks in the context of a double-blinded, placebo-controlled, randomized trial. We then performed detailed interventional and mechanistic signaling studies in humans in vivo, ex vivo, and in vitro.
RESULTS-In obese patients with diabetes, metreleptin administration for 16 weeks did not alter body weight or circulating inflammatory markers but reduced HbA(1c) marginally (8.01 +/- 0.93-7.96 +/- 1.12, P = 0.03). Total leptin, leptin-binding protein, and antileptin antibody levels increased, limiting free leptin availability and resulting in circulating free leptin levels of similar to 50 ng/mL. Consistent with clinical observations, all metreleptin signaling pathways studied in human adipose tissue and peripheral blood mononuclear cells were saturable at similar to 50 ng/mL, with no major differences in timing or magnitude of leptin-activated STAT3 phosphorylation in tissues from male versus female or obese versus lean humans in vivo, ex vivo, or in vitro. We also observed for the first time that endoplasmic reticulum (ER) stress in human primary adipocytes inhibits leptin signaling.
CONCLUSIONS-In obese patients with diabetes, metreleptin administration did not alter body weight or circulating inflammatory markers but reduced HbA(1c) marginally. ER stress and the saturable nature of leptin signaling pathways play a key role in the development of leptin tolerance in obese patients with diabetes. Diabetes 60:1647-1656, 2011
C1 [Moon, Hyun-Seuk; Brennan, Aoife M.; Chamberland, John P.; Liu, Xiaowen; Fiorenza, Christina G.; Mylvaganam, Geetha H.; Williams, Catherine J.; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
[Matarese, Giuseppe; Abanni, Luisa; Carbone, Fortunata] Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Ist Endoctinol & Oncol Spetimentale, Immunol Lab, Naples, Italy.
[De Paoli, Alex M.] Amgen Inc, Thousand Oaks, CA USA.
[Schneider, Benjamin E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Minimally Invas Surg, Boston, MA 02215 USA.
[Mantzoros, Christos S.] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Sect Endocrinol, Boston, MA 02215 USA.
RP Mantzoros, CS (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
EM cmantzor@bidmc.harvard.edu
RI Moon, Hyun-Seuk/G-8576-2015; Carbone, Fortunata/K-3176-2016;
OI Moon, Hyun-Seuk/0000-0002-5216-2090; Carbone,
Fortunata/0000-0003-4299-6515; Chamberland, John/0000-0002-7862-1371;
Matarese, Giuseppe/0000-0001-9429-0616
FU National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases [DK081913, DK79929, DK58785, AG032030];
Veterans Affairs Merit Review grant; Beth Israel Deaconess Medical
Center (BIDMC); EU; Telethon-Juvenile Diabetes Research Foundation
[GJT08004]; ERC [202579]; Amgen [UL1-RR-025758, M01-RR-01032]; Harvard
Clinical and Translational Science Center, from the National Center for
Research Resources; [F32-DK64550-01A1]
FX The current study was supported by grant F32-DK64550-01A1 (G.K.S.); the
National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases grants DK081913, DK79929, DK58785, and
AG032030 (C.S.M.); and a Veterans Affairs Merit Review grant (C.S.M.).
The Mantzoros Laboratory is also supported by a discretionary grant from
the Beth Israel Deaconess Medical Center (BIDMC). G.M. is supported by
grants from the EU Ideas Programme, ERC-Starting Independent Grant
"LeptinMS" 202579, and Telethon-Juvenile Diabetes Research Foundation
Grant GJT08004. The studies were also supported by Amgen and grants
UL1-RR-025758 and M01-RR-01032, Harvard Clinical and Translational
Science Center, from the National Center for Research Resources.
NR 27
TC 52
Z9 52
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD JUN
PY 2011
VL 60
IS 6
BP 1647
EP 1656
DI 10.2337/db10-1791
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 774FE
UT WOS:000291369600001
PM 21617185
ER
PT J
AU Navaratna, D
Guo, SZ
Hayakawa, K
Wang, XY
Gerhardinger, C
Lo, EH
AF Navaratna, Deepti
Guo, Shu-zhen
Hayakawa, Kazhuhide
Wang, Xiaoying
Gerhardinger, Chiara
Lo, Eng H.
TI Decreased Cerebrovascular Brain-Derived Neurotrophic Factor-Mediated
Neuroprotection in the Diabetic Brain
SO DIABETES
LA English
DT Article
ID ENDOTHELIAL-CELLS; ISCHEMIC-STROKE; ADVANCED GLYCATION; FACTOR BDNF;
CORTEX CAPILLARIES; ALZHEIMERS-DISEASE; MELLITUS; DEMENTIA; RISK;
HYPERGLYCEMIA
AB OBJECTIVE-Diabetes is an independent risk fact or for stroke. However, the underlying mechanism of how diabetes confers that this risk is not fully understood. We hypothesize that secretion of neurotrophic factors by the cerebral endothelium, such as brain-derived neurotrophic factor (BDNF), is suppressed in diabetes. Consequently, such accrued neuroprotective deficits make neurons more vulnerable to injury.
RESEARCH DESIGN AND METHODS-We examined BDNF protein levels in a streptozotocin-induced rat model of diabetes by Western blotting and immunohistochemistry. Levels of total and secreted BDNF protein were quantified in human brain microvascular endothelial cells after exposure to advanced glycation end product (AGE)-BSA by enzyme-linked immunosorbent assay and immunocytochemistry. In media transfer experiments, the neuroprotective efficacy of conditioned media from normal healthy endothelial cells was compared with AGE-treated endothelial cells in an in vitro hypoxic injury model.
RESULTS-Cerebrovascular BDNF protein was reduced in the cortical endothelium in 6-month diabetic rats. Immunohistochemical analysis of 6-week diabetic brain sections showed that the reduction of BDNF occurs early after induction of diabetes. Treatment of brain microvascular endothelial cells with AGE caused a similar reduction in BDNF protein and secretion in an extracellular signal-related kinase-dependent manner. In media transfer experiments, conditioned media from AGE-treated endothelial cells were less neuroprotective against hypoxic injury because of a decrease in secreted BDNF.
CONCLUSIONS-Taken together, our findings suggest that a progressive depletion of microvascular neuroprotection in diabetes elevates the risk of neuronal injury for a variety of central nervous system diseases, including stroke and neuro-degeneration. Diabetes 60:1789-1796, 2011
C1 [Navaratna, Deepti; Guo, Shu-zhen; Hayakawa, Kazhuhide; Wang, Xiaoying; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA USA.
[Gerhardinger, Chiara] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
RP Lo, EH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA USA.
EM lo@helix.mgh.edu
FU National Institutes of Health [R37-NS-37074, R01-NS-56530, RC2-NS-69335,
P01-NS-55014]; American Heart Association
FX This work was supported by National Institutes of Health grants
R37-NS-37074, R01-NS-56530, RC2-NS-69335, and P01-NS-55014, and a Bugher
award and postdoctoral fellowship from the American Heart Association.
NR 50
TC 32
Z9 34
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD JUN
PY 2011
VL 60
IS 6
BP 1789
EP 1796
DI 10.2337/db10-1371
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 774FE
UT WOS:000291369600017
PM 21562076
ER
PT J
AU Shields, RK
Kwak, EJ
Potoski, BA
Doi, Y
Adams-Haduch, JM
Silviera, FP
Toyoda, Y
Pilewski, JM
Crespo, M
Pasculle, AW
Clancy, CJ
Nguyen, MH
AF Shields, Ryan K.
Kwak, Eun J.
Potoski, Brian A.
Doi, Yohei
Adams-Haduch, Jennifer M.
Silviera, Fernando. P.
Toyoda, Yoshiya
Pilewski, Joseph M.
Crespo, Maria
Pasculle, A. William
Clancy, Cornelius J.
Nguyen, M. Hong
TI High mortality rates among solid organ transplant recipients infected
with extensively drug-resistant Acinetobacter baumannii: using in vitro
antibiotic combination testing to identify the combination of a
carbapenem and colistin as an effective treatment regimen
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE Acinetobacter; Synergy; Colistin; Doripenem; Transplant
ID POLYMYXIN-B; TIGECYCLINE; SYNERGY; PNEUMONIA
AB Extensively drug-resistant (XDR) Acinetobacter baumannii infections caused 91% (10/11) mortality in transplant recipients. Isolates were colistin-susceptible initially, but susceptibility decreased during therapy in 40% (4/10). We tested antibiotic combinations against XDR Acinetobacter in vitro and demonstrated positive interactions for carbapenem colistin. Subsequently, 80% (4/5) of transplant patients were treated successfully with carbepenem-colistin regimens. Published by Elsevier Inc.
C1 [Shields, Ryan K.; Kwak, Eun J.; Potoski, Brian A.; Doi, Yohei; Adams-Haduch, Jennifer M.; Silviera, Fernando. P.; Toyoda, Yoshiya; Pilewski, Joseph M.; Crespo, Maria; Pasculle, A. William; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Pittsburgh, PA 15213 USA.
[Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Pittsburgh, PA 15213 USA.
EM cjc76@pitt.edu
RI Doi, Yohei/C-7110-2013
FU University of Pittsburgh School of Pharmacy; University of Pittsburgh,
Department of Medicine
FX The study was funded by the University of Pittsburgh School of Pharmacy
and by seed support from the University of Pittsburgh, Department of
Medicine to the Transplant Infectious Diseases Program (MHN and CJC).
NR 26
TC 35
Z9 36
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD JUN
PY 2011
VL 70
IS 2
BP 246
EP 252
DI 10.1016/j.diagmicrobio.2010.12.023
PG 7
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 771CQ
UT WOS:000291135200014
PM 21353436
ER
PT J
AU Nair, G
Kim, M
Nagaoka, T
Olson, DE
Thule, PM
Pardue, MT
Duong, TQ
AF Nair, Govind
Kim, Moon
Nagaoka, Tsukasa
Olson, Darin E.
Thule, Peter M.
Pardue, Machelle T.
Duong, Timothy Q.
TI Effects of common anesthetics on eye movement and electroretinogram
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Anesthesia; Eye movement; ERG; fMRI; Magnetic resonance imaging
ID DARK-ADAPTED ELECTRORETINOGRAM; OPTICAL COHERENCE TOMOGRAPHY; PEAK
VELOCITY; PHYSIOPHARMACOLOGICAL INVESTIGATIONS; RAT ELECTRORETINOGRAM;
URETHANE ANESTHESIA; SCATTERING CHANGES; RETINAL RESPONSES;
NITROUS-OXIDE; BLOOD-FLOW
AB High-resolution magnetic resonance imaging (MRI) provides non-invasive images of retinal anatomy, physiology, and function with depth-resolved laminar resolution. Eye movement and drift, however, could limit high spatial resolution imaging, and anesthetics that minimize eye movement could significantly attenuate retinal function. The aim of this study was to determine the optimal anesthetic preparations to minimize eye movement and maximize visual-evoked retinal response in rats. Eye movements were examined by imaging of the cornea with a charge-coupled device (CCD) camera under isoflurane, urethane, ketamine/xylazine, and propofol anesthesia at typical dosages in rats. Combination of the paralytic pancuronium bromide with isoflurane or ketamine/xylazine anesthesia was also examined for the eye movement studies. Visual-evoked retinal responses were evaluated using full-field electroretinography (ERG) under isoflurane, ketamine/xylazine, urethane, and ketamine/xylazine + pancuronium anesthesia in rats. The degree of eye movement, measured as displacement per unit time, was the smallest under 1% isoflurane + pancuronium anesthesia. The ketamine/xylazine groups showed larger dark-adapted ERG a- and b-waves than other anesthetics tested. The isoflurane group showed the shortest b-wave implicit times. Photopic ERGs in the ketamine/xylazine groups showed the largest b-waves with the isoflurane group showing slightly shorter implicit times at the higher flash intensities. Oscillatory potentials revealed an early peak in the isoflurane group compared with ketamine/xylazine and urethane groups. Pancuronium did not affect the a- and b-wave, but did increase oscillatory potential amplitudes. Compared with the other anesthetics tested here, ketamine/xylazine + pancuronium was the best combination to minimize eye movement and maximize retinal function. These findings should set the stage for further development and application of high-resolution functional imaging techniques, such as MRI, to study retinal anatomy, physiology, and function in anesthetized rats.
C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Physiol, San Antonio, TX 78229 USA.
[Nair, Govind; Nagaoka, Tsukasa] Emory Univ, Div Neurosci, Yerkes Imaging Ctr, Atlanta, GA 30322 USA.
[Nair, Govind] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Worcester, MA USA.
[Nair, Govind] Worcester Polytech Inst, Worcester, MA 01609 USA.
[Nair, Govind; Kim, Moon; Nagaoka, Tsukasa; Olson, Darin E.; Thule, Peter M.; Pardue, Machelle T.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
[Olson, Darin E.; Thule, Peter M.] Emory Univ, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.
[Pardue, Machelle T.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA.
[Pardue, Machelle T.] Atlanta VA Med Ctr, Rehab R&D Ctr, Decatur, GA USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM mpardue@emory.edu; duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU NIH/NEI [R01 EY014211, EY018855]; Department of Veterans Affairs;
Research to Prevent Blindness; NEI [P30EY006360]; Rehabilitation,
Research and Development Service, Department of Veterans Affairs
FX This work was supported by the NIH/NEI (R01 EY014211 and EY018855 to
TQD) and MERIT awards from the Department of Veterans Affairs (TQD, MTP,
DEO). We also thank Research to Prevent Blindness; NEI (P30EY006360);
and Rehabilitation, Research and Development Service, Department of
Veterans Affairs for their supports.
NR 66
TC 18
Z9 18
U1 2
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD JUN
PY 2011
VL 122
IS 3
BP 163
EP 176
DI 10.1007/s10633-011-9271-4
PG 14
WC Ophthalmology
SC Ophthalmology
GA 774NC
UT WOS:000291392300005
PM 21519880
ER
PT J
AU Oberaigner, W
Siebert, U
AF Oberaigner, Willi
Siebert, Uwe
TI Do women with cancer have better survival as compared to men after
adjusting for staging distribution?
SO EUROPEAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE cancer; gender; population based; prognosis; survival
ID GENDER-DIFFERENCES; RELATIVE SURVIVAL; RECORD LINKAGE; RATES; ERRORS
AB Background: Gender aspects in medicine are receiving increasing attention, namely also in oncology. For this reason, we decided to investigate whether for solid cancer sites women have better survival outcome than do men in the population of Tyrol, Austria. Methods: We conducted an observational population-based study in Tyrol. All solid cancer sites excluding non-melanoma skin cancer and sex-specific sites were analysed in total and all specific sites with more than 500 patients in the analysis. By the end of 2006, follow-up was ended. We applied a relative excess risk model, thus correcting for differences in life expectancy between women and men. Results: For all cancer sites combined, after adjusting for case mix, women had a relative excess risk of 0.95 (95% CI 0.91-0.99). For the following sites our analysis resulted in a relative excess risk statistically different from 1, namely for women as compared to men: head and neck without larynx 0.72 (95% CI 0.56-0.93), stomach 0.86 (95% CI 0.75-0.97) and lung 0.82 (95% CI 0.75-0.90). Conclusion: In a healthcare system with free access to diagnostics and therapy, after adjusting for staging distribution female cancer patients have a lesser excess mortality risk than do men for lung, stomach and head and neck cancer and also for all cancer sites combined after adjusting for case mix.
C1 [Oberaigner, Willi] Tyrolean State Hosp Ltd, Dept Clin Epidemiol, Canc Registry Tyrol, Innsbruck, Austria.
[Oberaigner, Willi; Siebert, Uwe] Univ Hlth Sci Med Informat & Technol, UMIT, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Informat Syst & Hlth Technol Asses, Hall In Tirol, Austria.
[Oberaigner, Willi; Siebert, Uwe] Ctr Personalized Canc Med, Innsbruck, Austria.
[Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
[Siebert, Uwe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
[Siebert, Uwe] Harvard Univ, Inst Technol Assessment, Sch Med, Boston, MA USA.
RP Oberaigner, W (reprint author), TILAK GmbH, Canc Registry Tyrol, Anichstr 35, Innsbruck, Austria.
EM willi.oberaigner@iet.at
FU ONCOTYROL Center for Personalized Cancer Medicine; Federal Ministry for
Transport Innovation and Technology (BMVIT); Federal Ministry of
Economics and Labour/the Federal Ministry of Economy, Family and Youth
(BMWA/BMWFJ); Tyrolean Future Foundation (TZS); UMIT, University for
Health Sciences, Medical Informatics and Technology; TILAK-Hospital
Holding Company
FX This work was supported by the ONCOTYROL Center for Personalized Cancer
Medicine. ONCOTYROL is a K1-COMET Center and funded by the Federal
Ministry for Transport Innovation and Technology (BMVIT) and the Federal
Ministry of Economics and Labour/the Federal Ministry of Economy, Family
and Youth (BMWA/BMWFJ), the Tyrolean Future Foundation (TZS) and the
State of Styria represented by the Styrian Business Promotion Agency
(SFG) and supported by UMIT, University for Health Sciences, Medical
Informatics and Technology and TILAK-Hospital Holding Company.
NR 27
TC 5
Z9 5
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1101-1262
J9 EUR J PUBLIC HEALTH
JI Eur. J. Public Health
PD JUN
PY 2011
VL 21
IS 3
BP 387
EP 391
DI 10.1093/eurpub/ckq099
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 766UT
UT WOS:000290812700029
PM 20650944
ER
PT J
AU Mortensen, EM
AF Mortensen, E. M.
TI Potential causes of increased long-term mortality after pneumonia
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Editorial Material
ID COMMUNITY-ACQUIRED PNEUMONIA; HOSPITALIZATION; INTERLEUKIN-6; COHORT
C1 [Mortensen, E. M.] Univ Texas Hlth Ctr San Antonio, Dept Med, S Texas Vet Hlth Care Syst, VERDICT Res Program, San Antonio, TX USA.
RP Mortensen, EM (reprint author), VERDICT Res Program 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM mortensene@uthscsa.edu
OI Mortensen, Eric/0000-0002-3880-5563
NR 20
TC 6
Z9 6
U1 0
U2 1
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
J9 EUR RESPIR J
JI Eur. Resp. J.
PD JUN
PY 2011
VL 37
IS 6
BP 1306
EP 1307
DI 10.1183/09031936.00194110
PG 2
WC Respiratory System
SC Respiratory System
GA 771JE
UT WOS:000291152200002
PM 21632829
ER
PT J
AU Kwon, JY
Ellington, JK
Marsland, D
Gupta, S
AF Kwon, John Y.
Ellington, J. Kent
Marsland, Daniel
Gupta, Sanjeev
TI Calcaneal Traction Pin Placement Simplified: A Cadaveric Study
SO FOOT & ANKLE INTERNATIONAL
LA English
DT Article
DE Calcaneal Traction; Transcalcaneal Pin Placement
ID ANATOMIC CONSIDERATIONS; ANKLE
AB Background: The tibial neurovascular bundle and sural nerve are at risk with errant pin placement during transcalcaneal pin placement. The purpose of this study was to determine a relative safe zone using a single osseous landmark to establish a technique applicable in the presence of trauma. We describe the neural anatomy anatomically and radiographically, giving surgeons a reliable and relatively safe technique for transcalcaneal pin placement. Materials and Methods: Twenty-four cadavers were dissected for the major medial neurovascular structures and the sural nerve. The closest distance from the neurovascular structures to the posterior inferior calcaneus was measured. Results: The mean distance from the posterior inferior calcaneus to the closest major medial neurovascular structure was 3.4 cm (SD +/- 0.36; range, 2.6 to 4.1 cm). The mean distance to the sural nerve was 3.4 cm (SD +/- 0.54; range, 2.3 to 4.6 cm). According to the 95% confidence intervals, a relative safe zone of 3.1 cm as a radius from the posterior inferior calcaneus was determined. Conclusion: A relatively safe zone of 3.1 cm based on 95% confidence intervals as described as a radius from the posterior inferior calcaneus can be used for transcalcaneal pin placement in most cases without injury to the medial neurovascular bundle or sural nerve. However anatomic variation may result in the neurovascular bundle being within this zone. Clinical Relevance: We describe a surgical technique for reliable placement of a transcalcaneal pin within this relative safe zone and a safe distance from the closest neurovascular structure.
C1 [Kwon, John Y.] Harvard Univ, Sch Med, Dept Orthoped Surg, Massachussetts Gen Hosp, Boston, MA 02115 USA.
[Ellington, J. Kent] Ortho Carolina Foot & Ankle Inst, Charlotte, NC USA.
[Marsland, Daniel] Johns Hopkins Univ, Int Ctr Orthopaed Adv, Dept Orthopaed Surg, Johns Hopkins Bayview Med Ctr, Baltimore, MD USA.
[Gupta, Sanjeev] Royal Prince Alfred Hosp, Sydney, NSW, Australia.
RP Kwon, JY (reprint author), 300 W Lombard St,Apt 1308, Baltimore, MD 21201 USA.
EM johnkwonmd@gmail.com
NR 21
TC 2
Z9 2
U1 0
U2 1
PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC
PI SEATTLE
PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA
SN 1071-1007
J9 FOOT ANKLE INT
JI Foot Ankle Int.
PD JUN
PY 2011
VL 32
IS 6
BP 651
EP 655
DI 10.3113/FAI.2011.0651
PG 5
WC Orthopedics
SC Orthopedics
GA 773IL
UT WOS:000291300100016
PM 21733432
ER
PT J
AU Namjou, B
Kothari, PH
Kelly, JA
Glenn, SB
Ojwang, JO
Adler, A
Alarcon-Riquelme, ME
Gallant, CJ
Boackle, SA
Criswell, LA
Kimberly, RP
Brown, E
Edberg, J
Stevens, AM
Jacob, CO
Tsao, BP
Gilkeson, GS
Kamen, DL
Merrill, JT
Petri, M
Goldman, RR
Vila, LM
Anaya, JM
Niewold, TB
Martin, J
Pons-Estel, BA
Sabio, JM
Callejas, JL
Vyse, TJ
Bae, SC
Perrino, FW
Freedman, BI
Scofield, RH
Moser, KL
Gaffney, PM
James, JA
Langefeld, CD
Kaufman, KM
Harley, JB
Atkinson, JP
AF Namjou, B.
Kothari, P. H.
Kelly, J. A.
Glenn, S. B.
Ojwang, J. O.
Adler, A.
Alarcon-Riquelme, M. E.
Gallant, C. J.
Boackle, S. A.
Criswell, L. A.
Kimberly, R. P.
Brown, E.
Edberg, J.
Stevens, A. M.
Jacob, C. O.
Tsao, B. P.
Gilkeson, G. S.
Kamen, D. L.
Merrill, J. T.
Petri, M.
Goldman, R. R.
Vila, L. M.
Anaya, J-M
Niewold, T. B.
Martin, J.
Pons-Estel, B. A.
Sabio, J. M.
Callejas, J. L.
Vyse, T. J.
Bae, S-C
Perrino, F. W.
Freedman, B. I.
Scofield, R. H.
Moser, K. L.
Gaffney, P. M.
James, J. A.
Langefeld, C. D.
Kaufman, K. M.
Harley, J. B.
Atkinson, J. P.
CA BIOLUPUS Network
GENLES Collaboration
TI Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort
SO GENES AND IMMUNITY
LA English
DT Article
DE autoimmunity; SLE; TREX1
ID AICARDI-GOUTIERES-SYNDROME; GENOME-WIDE ASSOCIATION; DNA EXONUCLEASE
TREX1; ERYTHEMATOSUS PATIENTS; AUTOIMMUNE-DISEASE; MUTATIONS;
INTERFERONS; PROTEIN
AB Systemic lupus erythematosus (SLE) is a prototypic autoimmune disorder with a complex pathogenesis in which genetic, hormonal and environmental factors have a role. Rare mutations in the TREX1 gene, the major mammalian 3'-5' exonuclease, have been reported in sporadic SLE cases. Some of these mutations have also been identified in a rare pediatric neurological condition featuring an inflammatory encephalopathy known as Aicardi-Goutieres syndrome (AGS). We sought to investigate the frequency of these mutations in a large multi-ancestral cohort of SLE cases and controls. A total of 40 single-nucleotide polymorphisms (SNPs), including both common and rare variants, across the TREX1 gene, were evaluated in similar to 8370 patients with SLE and similar to 7490 control subjects. Stringent quality control procedures were applied, and principal components and admixture proportions were calculated to identify outliers for removal from analysis. Population-based case-control association analyses were performed. P-values, false-discovery rate q values, and odds ratios (OR) with 95% confidence intervals (CI) were calculated. The estimated frequency of TREX1 mutations in our lupus cohort was 0.5%. Five heterozygous mutations were detected at the Y305C polymorphism in European lupus cases but none were observed in European controls. Five African cases incurred heterozygous mutations at the E266G polymorphism and, again, none were observed in the African controls. A rare homozygous R114H mutation was identified in one Asian SLE patient, whereas all genotypes at this mutation in previous reports for SLE were heterozygous. Analysis of common TREX1 SNPs (minor allele frequency (MAF)>10%) revealed a relatively common risk haplotype in European SLE patients with neurological manifestations, especially seizures, with a frequency of 58% in lupus cases compared with 45% in normal controls (P = 0.0008, OR = 1.73, 95% CI = 1.25-2.39). Finally, the presence or absence of specific autoantibodies in certain populations produced significant genetic associations. For example, a strong association with anti-nRNP was observed in the European cohort at a coding synonymous variant rs56203834 (P = 2.99E-13, OR = 5.2, 95% CI = 3.18-8.56). Our data confirm and expand previous reports and provide additional support for the involvement of TREX1 in lupus pathogenesis. Genes and Immunity (2011) 12, 270-279; doi:10.1038/gene.2010.73; published online 27 January 2011
C1 [Namjou, B.; Kelly, J. A.; Glenn, S. B.; Ojwang, J. O.; Adler, A.; Alarcon-Riquelme, M. E.; Merrill, J. T.; Scofield, R. H.; Moser, K. L.; Gaffney, P. M.; James, J. A.; Kaufman, K. M.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[Kothari, P. H.; Atkinson, J. P.] Washington Univ, Sch Med, St Louis, MI USA.
[Alarcon-Riquelme, M. E.; Gallant, C. J.] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Uppsala, Sweden.
[Alarcon-Riquelme, M. E.] Univ Granada Junta de Andalucia, Ctr Genom & Oncol Res Pfizer, Granada, Spain.
[Boackle, S. A.] Univ Colorado Denver, Sch Med, Aurora, CO USA.
[Criswell, L. A.] Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA USA.
[Kimberly, R. P.; Brown, E.; Edberg, J.] Univ Alabama, Birmingham, AL USA.
[Stevens, A. M.] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Jacob, C. O.] Univ So Calif, Lupus Genet Grp, Los Angeles, CA USA.
[Tsao, B. P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA.
[Gilkeson, G. S.; Kamen, D. L.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Petri, M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Goldman, R. R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Anaya, J-M] Univ Rosario, Ctr Autoimmune Dis Res CREA, Bogota, Colombia.
[Vila, L. M.] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA.
[Niewold, T. B.] Univ Chicago, Rheumatol Sect, Chicago, IL 60637 USA.
[Pons-Estel, B. A.] Sanatorio Parque, Rosario, Argentina.
[Martin, J.] Inst Biomed & Parasitol Lopez Neyra, Armilla, Spain.
[Sabio, J. M.] Hosp Virgen Nieves, Dept Internal Med, Granada, Spain.
[Callejas, J. L.] Hosp Clin San Cecilio, Dept Internal Med, Granada, Spain.
[Vyse, T. J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England.
[Bae, S-C] Hanyang Univ, Hosp Rheumat Dis, Seoul 133791, South Korea.
[Bae, S-C] Hanyang Univ, Dept Internal Med, Div Rheumatol, Seoul 133791, South Korea.
[Perrino, F. W.; Freedman, B. I.; Langefeld, C. D.] Wake Forest Univ Hlth Sci, Winston Salem, NC USA.
[Kaufman, K. M.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Harley, J. B.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA.
RP Namjou, B (reprint author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.
EM namjoub@omrf.org
RI Vyse, Tim/G-3887-2011; Martin, Javier/B-8141-2008; Anaya,
Juan-Manuel/J-1960-2016;
OI Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario,
Biblioteca/0000-0003-3491-9392; Kimberly, Robert/0000-0002-5330-3086;
Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Niewold,
Timothy/0000-0003-3532-6660
FU NIH [AR042460, RR015577, AR048940, RR020143, AI24717, AR62277,
R21AI070304, AR044804, AR02175, AR052300, K24 AR 002138, P60 2 AR30692,
PO1 AR49084, UL1RR025741, CA141700-01]; Lupus Foundation of America;
Alliance for Lupus Research; US Department of Veterans Affairs; Cerebral
Retinal Vasculopathy Fund; National Center for Research Resources (NCRR)
[NIH AR43727, UL1RR025005, UL1RR029882]; Kirkland Scholar Award; US
Public Health Service National Center for Research Resources [M01
RR-00079]; European Science Foundation; Swedish Research Council;
Swedish Association against Rheumatism; Swedish International
Development Agency (SIDA); Gustaf Vth-80th jubilee Foundation;
[HL083822]; [NS062069]; [AR33062]; [AR49084]; [5UL1RR02777];
[R01GM069962]; [67692]
FX The cooperation of patients and normal control individuals involved in
this study as well as physicians that provide samples is gratefully
acknowledged. At the Oklahoma Medical Research Foundation, the work was
supported by the NIH (AR042460, RR015577, AR048940, RR020143, AI24717,
AR62277), Lupus Foundation of America, the Alliance for Lupus Research,
the US Department of Veterans Affairs. At the Washington University
School of Medicine (St Louis, MO, USA), the work was supported by grants
(HL083822 (PHK), and NS062069 (JPA)), and the Cerebral Retinal
Vasculopathy Fund. At the University of Alabama at Birmingham, the work
was supported by grants AR33062 (RPK), AR49084 (RPK) and 5UL1RR02777. At
the Johns Hopkins University School of Medicine, the work was supported
by The Hopkins Lupus Cohort (NIH AR43727) and UL1RR025005 from the
National Center for Research Resources (NCRR). At the University of
Colorado, Denver School of Medicine, the work was supported by a NIH
grant R21AI070304. At the Medical University of South Carolina,
Charleston, USA, the project was supported by award number UL1RR029882
from the National Center for Research Resources. (The content is solely
the responsibility of the authors and does not necessarily represent the
official views of the National Center for Research Resources or the
National Institutes of Health). At the Rosalind Russell Medical Research
Center for Arthritis, University of California, San Francisco, USA, the
work was supported by Kirkland Scholar Award, US Public Health Service
National Center for Research Resources, M01 RR-00079 and NIH grants
AR044804, AR02175 and AR052300. At the Northwestern University, Feinberg
School of Medicine, Chicago, IL, USA, the work was supported by NIH
grants K24 AR 002138, P60 2 AR30692, PO1 AR49084 and UL1RR025741. At the
Wake Forest University Health Sciences, Department of Biochemistry, the
work was supported by R01GM069962 and Alliance for Lupus Research
(67692) awards. We acknowledge grants from the European Science
Foundation for the BIOLUPUS network, the Swedish Research Council,
Swedish Association against Rheumatism, the Swedish International
Development Agency (SIDA) and Gustaf Vth-80th jubilee Foundation to MEAR
and the NIH grant CA141700-01. For GENLES: Argentina: Hugo R Scherbarth,
MD; Pilar C Marino, MD; Estela L Motta, MD at Servicio de Reumatologia,
Hospital Interzonal General de Agudos 'Dr Oscar Alende', Mar del Plata,
Argentina. Susana Gamron, MD; Cristina Drenkard, MD; Emilia Menso, MD at
Servicio de Reumatologia de la UHMI 1, Hospital Nacional de Clinicas,
Universidad Nacional de Cordoba, Cordoba, Argentina. Alberto Allievi,
MD; Guillermo A Tate, MD at Organizacion Medica de Investigacion, Buenos
Aires, Argentina. Jose L Presas, MD at Hospital General de Agudos Dr
Juan A Fernandez, Buenos Aires, Argentina. Simon A Palatnik, MD; Marcelo
Abdala, MD; Mariela Bearzotti, PhD at Facultad de Ciencias Medicas,
Universidad Nacional de Rosario y Hospital Provincial del Centenario,
Rosario, Argentina. Alejandro Alvarellos, MD; Francisco Caeiro, MD; Ana
Bertoli, MD at Servicio de Reumatologia, Hospital Privado, Centro Medico
de Cordoba, Cordoba, Argentina. Sergio Paira, MD; Susana Roverano, MD at
Hospital Jose M. Cullen, Santa Fe, Argentina. Cesar E Graf, MD; Estela
Bertero, PhD at Hospital San Martin, Parana. Cesar Caprarulo, MD;
Griselda Buchanan, PhD at Hospital Felipe Heras, Concordia, Entre Rios,
Argentina.; Carolina Guilleron, MD; Sebastian Grimaudo, PhD; Jorge
Manni, MD at Departamento de Inmunologia, Instituto de Investigaciones
Medicas 'Alfredo Lanri', Buenos Aires, Argentina. Luis J Catoggio, MD;
Enrique R Soriano, MD; Carlos D Santos, MD at Seccion Reumatologia,
Servicio de Clinica Medica, Hospital Italiano de Buenos Aires y
Fundacion Dr Pedro M Catoggio para el Progreso de la Reumatologia,
Buenos Aires, Argentina. Cristina Prigione, MD; Fernando A Ramos, MD;
Sandra M Navarro, MD at Servicio de Reumatologia, Hospital Provincial de
Rosario, Rosario, Argentina. Guillermo A Berbotto, MD; Marisa Jorfen,
MD; Elisa J Romero, PhD at Servicio de Reumatologia Hospital Escuela Eva
Peron. Granadero Baigorria, Rosario, Argentina. Mercedes A Garcia, MD;
Juan C Marcos MD; Ana I Marcos, MD at Servicio de Reumatologia, Hospital
Interzonal General de Agudos General San Martin, La Plata. Carlos E
Perandones, MD; Alicia Eimon, MD at Centro de Educacion Medica e
Investigaciones Clinicas (CEMIC), Buenos Aires, Argentina. Cristina G
Battagliotti, MD at Hospital de Ninos Dr Orlando Alassia, Santa Fe,
Argentina. Peru is represented by: Dr Eduardo Acevedo and Dr Mariano
Cucho, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru. Mexico
is represented by Dr Ignacio Garcia de la Torre, Hospital General de
Occidente, Zapopan, Jalisco; Dr Mario Cardiel Rios, Hospital General Dr
Miguel Silva, Morelia, Michoacan; Dr Jose Francisco Moctezuma, Hospital
General de Mexico, Mexico, DF; Dr Marco Maradiaga Cecena, Hospital
General de Culiacan, Culiacan, Sinaloa. The members of the BIOLUPUS
network are: Sandra D'Alfonso, Department of Medical Sciences and IRCAD,
University of Eastern Piedmont, Novara, Italy; Bernard R. Lauwerys,
Cliniques Universitaires Saint-Luc, Universite catholique de Louvain,
Bruxells, Belgium; Emoke Endreffy, Department of Pediatrics and Health
Center, University of Szeged, Szeged, Hungary; Laszlo Kovacs, Department
of Rheumatology, Albert Szent-Gyorgyi Clinical Centre, University of
Szeged, Szeged, Hungary; Carlos Vasconcelos, Hospital Santo Antonio and
ICBAS, Porto, Portugal; Berta Martins da Silva, UMIB/ICBAS,
Immunogenetics laboratory, Universidado do Porto, Porto, Portugal; Inigo
Rua Figueroa, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain.
Sandra D'Alfonso, Nadia Barizzone (Department of Medical Sciences and
IRCAD, University of Eastern Piedmont, Novara, Italy); Gian Domenico
Sebastiani (Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy);
Mauro Galeazzi, (Siena University, Siena, Italy) Maria Giovanna Danieli
(Clinica Medica di Scienze Mediche e Chirurgiche, Universita Politecnica
delle Marche, Ancona, Italy); Giovanni La Montagna (Rheumatology Unit
Second University of Naples, Naples, Italy) and Maria Grazia Sabbadini
(Vita-Salute San Raffaele University of Milan, Italy).
NR 35
TC 100
Z9 102
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUN
PY 2011
VL 12
IS 4
BP 270
EP 279
DI 10.1038/gene.2010.73
PG 10
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 772BU
UT WOS:000291206100004
PM 21270825
ER
PT J
AU Dai, N
Rapley, J
Angel, M
Yanik, MF
Blower, MD
Avruch, J
AF Dai, Ning
Rapley, Joseph
Angel, Matthew
Yanik, M. Fatih
Blower, Michael D.
Avruch, Joseph
TI mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal
ribosomal entry
SO GENES & DEVELOPMENT
LA English
DT Article
DE mTOR; IMP2; amino acid-dependent phosphorylation; IGF2; mRNA
translation; internal ribosome entry; type 2 diabetes
ID GENOME-WIDE ASSOCIATION; K562 LEUKEMIA-CELLS; BINDING PROTEIN; DEPENDENT
TRANSLATION; MAMMALIAN TARGET; GROWTH; RAPTOR; IDENTIFICATION;
EXPRESSION; PATHWAY
AB Variants in the IMP2 (insulin-like growth factor 2 [IGF2] mRNA-binding protein 2) gene are implicated in susceptibility to type 2 diabetes. We describe the ability of mammalian target of rapamycin (mTOR) to regulate the cap-independent translation of IGF2 mRNA through phosphorylation of IMP2, an oncofetal RNA-binding protein. IMP2 is doubly phosphorylated in a rapamycin-inhibitable, amino acid-dependent manner in cells and by mTOR in vitro. Double phosphorylation promotes IMP2 binding to the IGF2 leader 3 mRNA 5' untranslated region, and the translational initiation of this mRNA through eIF-4E- and 5' cap-independent internal ribosomal entry. Unexpectedly, the interaction of IMP2 with mTOR complex 1 occurs through mTOR itself rather than through raptor. Whereas depletion of mTOR strongly inhibits IMP2 phosphorylation in cells, comparable depletion of raptor has no effect; moreover, the ability of mTOR to phosphorylate IMP2 in vitro is unaffected by the elimination of raptor. Dual phosphorylation of IMP2 at the mTOR sites is evident in the mouse embryo, likely coupling nutrient sufficiency to IGF2 expression and fetal growth. Doubly phosphorylated IMP2 is also widely expressed in adult tissues, including islets of Langerhans.
C1 [Dai, Ning; Rapley, Joseph; Blower, Michael D.; Avruch, Joseph] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Dai, Ning; Rapley, Joseph; Avruch, Joseph] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
[Dai, Ning; Rapley, Joseph; Avruch, Joseph] Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA.
[Dai, Ning; Rapley, Joseph; Avruch, Joseph] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Angel, Matthew; Yanik, M. Fatih] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
[Blower, Michael D.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
RP Avruch, J (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM avruch@molbio.mgh.harvard.edu
RI wang, hua/H-3345-2011
FU NIH [CA73818, DK17776, DK057521]; ARRA funds
FX We thank T. Ding, Dr. S. Jacobs, Dr. O. Peroni, and Dr. D. Wrighting for
assistance with mice; M. Lynch and Dr. E. Schmidt for assistance in
sucrose density gradient methods; Dr. S. Vasudevan for suggestions
regarding streptavidin-tagged mRNA isolation; Dr. N. Oshiro for
discussions; Dr. F. C. Nielsen for IMP1, IMP2, and IMP3 antibodies; and
Dr. J. Christiansen for the plasmids pcDNA-IGF-II-L3-luciferase and
pcDNA-IGF-II-L4-luciferase. Torin1 was kindly provided by Drs. N. S.
Gray and D. M. Sabatini. Human islets were a gift from Dr. J. Markmann
and Dr. J. Lei. This work was supported by grants from the NIH (CA73818,
DK17776, and DK057521) and ARRA funds.
NR 53
TC 54
Z9 54
U1 1
U2 5
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
J9 GENE DEV
JI Genes Dev.
PD JUN 1
PY 2011
VL 25
IS 11
BP 1159
EP 1172
DI 10.1101/gad.2042311
PG 14
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 771JL
UT WOS:000291152900007
PM 21576258
ER
PT J
AU Durrett, R
Foo, J
Leder, K
Mayberry, J
Michor, F
AF Durrett, Rick
Foo, Jasmine
Leder, Kevin
Mayberry, John
Michor, Franziska
TI Intratumor Heterogeneity in Evolutionary Models of Tumor Progression
SO GENETICS
LA English
DT Article
ID CLONAL EXPANSION; ESCHERICHIA-COLI; WAITING TIME; CANCER; MUTATIONS;
POPULATIONS; RESISTANCE; DIVERSITY; SUBPOPULATION; ADAPTATION
AB With rare exceptions, human tumors arise from single cells that have accumulated the necessary number and types of heritable alterations. Each such cell leads to dysregulated growth and eventually the formation of a tumor. Despite their monoclonal origin, at the time of diagnosis most tumors show a striking amount of intratumor heterogeneity in all measurable phenotypes; such heterogeneity has implications for diagnosis, treatment efficacy, and the identification of drug targets. An understanding of the extent and evolution of intratumor heterogeneity is therefore of direct clinical importance. In this article, we investigate the evolutionary dynamics of heterogeneity arising during exponential expansion of a tumor cell population, in which heritable alterations confer random fitness changes to cells. We obtain analytical estimates for the extent of heterogeneity and quantify the effects of system parameters on this tumor trait. Our work contributes to a mathematical understanding of intratumor heterogeneity and is also applicable to organisms like bacteria, agricultural pests, and other microbes.
C1 [Durrett, Rick] Duke Univ, Dept Math, Durham, NC 27708 USA.
[Foo, Jasmine; Leder, Kevin; Michor, Franziska] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Foo, Jasmine; Leder, Kevin; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Mayberry, John] Univ Pacific, Dept Math, Stockton, CA 95211 USA.
RP Durrett, R (reprint author), Duke Univ, Dept Math, Durham, NC 27708 USA.
EM rtd@math.duke.edu; michor@jimmy.harvard.edu
FU National Cancer Institute [U54CA143798]; National Science Foundation
(NSF) [DMS 0704996, DMS 0739164]
FX The authors thank Theresa Edmonds for exceptional research assistance.
This work is supported by National Cancer Institute grant U54CA143798
(to J.F., K.L., and F.M.), National Science Foundation (NSF) grant DMS
0704996 (to R.D.), and NSF RTG grant DMS 0739164 (to J.M.).
NR 47
TC 42
Z9 45
U1 1
U2 10
PU GENETICS SOC AM
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 0016-6731
J9 GENETICS
JI Genetics
PD JUN
PY 2011
VL 188
IS 2
BP 461
EP 477
DI 10.1534/genetics.110.125724
PG 17
WC Genetics & Heredity
SC Genetics & Heredity
GA 773XM
UT WOS:000291344900018
PM 21406679
ER
PT J
AU Rauh-Hain, JA
Growdon, WB
Rodriguez, N
Goodman, AK
Boruta, DM
Schorge, JO
Horowitz, NS
del Carmen, MG
AF Rauh-Hain, J. Alejandro
Growdon, Whitfield B.
Rodriguez, Noah
Goodman, A. K.
Boruta, David M., II
Schorge, John O.
Horowitz, Neil S.
del Carmen, Marcela G.
TI Carcinosarcoma of the ovary: A case-control study
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Ovarian cancer; Carcinosarcoma
ID MIXED MESODERMAL TUMORS; MULLERIAN TUMORS; PLATINUM; CANCER;
CHEMOTHERAPY; EXPERIENCE; FEATURES
AB Introduction. Carcinosarcoma of the ovary is a rare tumor with a grim prognosis. Chemotherapy for these tumors is chosen according to guidelines established for epithelial ovarian cancer (EOC). The purpose of this study is to compare response to chemotherapy and survival in patients with advanced stage carcinosarcoma of the ovary.
Methods. We identified women with advanced carcinosarcoma of the ovary who underwent first-line platinum and taxane-based chemotherapy. Each case was matched to two women with serous EOC. Cases and controls were matched by age, stage, and year of diagnosis. The Kaplan-Meier method was used to generate overall survival (OS) data. Factors predictive of outcome were compared using the log-rank test and Cox proportional hazards model.
Results. Fifty women treated with first line platinum and taxane-based chemotherapy had advanced carcinosarcoma of the ovary and were selected as cases. The response rates to chemotherapy for cases and controls were 62% and 83% (P = 0.03), respectively. Median progression-free survival was 11 months (95% CI, 8 to 14 months) versus 16 months (95% CI, 12 to 21 months; P = 0.02) and median overall survival was 24 months (95% CI, 18 to 29 months) versus 41 months (95% CI, 33 to 49 months; P = 0.002) for cases and controls, respectively.
Conclusion. Patients with advanced carcinosarcoma of the ovary have a poorer response to platinum and taxane-based first-line chemotherapy and worse survival, compared to patients with serous EOC. Aggressive surgical treatment may play an important role. However, other alternative systemic therapeutic approaches should be sought for patients with carcinosarcoma of the ovary. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Rauh-Hain, J. Alejandro; Growdon, Whitfield B.; Goodman, A. K.; Boruta, David M., II; Schorge, John O.; del Carmen, Marcela G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol, Boston, MA 02114 USA.
[Rauh-Hain, J. Alejandro; Rodriguez, Noah; Horowitz, Neil S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gynecol Oncol, Boston, MA 02115 USA.
RP del Carmen, MG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol, 55 Fruit St,Yawkey 9 E, Boston, MA 02114 USA.
EM mdelcarmen@partners.org
NR 22
TC 16
Z9 16
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JUN 1
PY 2011
VL 121
IS 3
BP 477
EP 481
DI 10.1016/j.ygyno.2011.02.023
PG 5
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 772NN
UT WOS:000291240700010
PM 21420726
ER
PT J
AU Carchman, EH
Rao, J
Loughran, PA
Rosengart, MR
Zuckerbraun, BS
AF Carchman, Evie H.
Rao, Jayashree
Loughran, Patricia A.
Rosengart, Matthew R.
Zuckerbraun, Brian S.
TI Heme Oxygenase-1-Mediated Autophagy Protects Against Hepatocyte Cell
Death and Hepatic Injury from Infection/Sepsis in Mice
SO HEPATOLOGY
LA English
DT Article
ID NF-KAPPA-B; HOST-DEFENSE; APOPTOSIS; INHIBITION; SEPSIS; SHOCK;
MITOCHONDRIA; DYSFUNCTION; SURVIVAL; FAILURE
AB Adaptive responses to sepsis are necessary to prevent organ failure and death. Cellular signaling responses that limit cell death and structural damage allow a cell to withstand insult from sepsis to prevent irreversible organ dysfunction. One such protective pathway to reduce hepatocellular injury is the up-regulation of heme oxygenase-1 (HO-1) signaling. HO-1 is up-regulated in the liver in response to multiple stressors, including sepsis and lipopolysaccharide (LPS), and has been shown to limit cell death. Another recently recognized rudimentary cellular response to injury is autophagy. The aim of these investigations was to test the hypothesis that HO-1 protects against hepatocyte cell death in experimental sepsis in vivo or LPS in vitro via induction of autophagy. These data demonstrate that both HO-1 and autophagy are up-regulated in the liver after cecal ligation and puncture (CLP) in C57BL/6 mice or in primary mouse hepatocytes after treatment with LPS (100 ng/mL). CLP or LPS results in minimal hepatocyte cell death. Pharmacological inhibition of HO-1 activity using tin protoporphyrin or knockdown of HO-1 prevents the induction of autophagic signaling in these models and results in increased hepatocellular injury, apoptosis, and death. Furthermore, inhibition of autophagy using 3-methyladenine or small interfering RNA specific to VPS34, a class III phosphoinositide 3-kinase that is an upstream regulator of autophagy, resulted in hepatocyte apoptosis in vivo or in vitro. LPS induced phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK), in part, via HO-dependent signaling. Moreover, inhibition of p38 MAPK prevented CLP- or LPS-induced autophagy. Conclusion: Sepsis or LPS-induced autophagy protects against hepatocellular death, in part via an HO-1 p38 MAPK-dependent signaling. Further investigations are needed to elucidate how autophagic signaling prevents apoptosis and cell death. (HEPATOLOGY 2011;53:2053-2062)
C1 [Carchman, Evie H.; Rao, Jayashree; Loughran, Patricia A.; Rosengart, Matthew R.; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA 15213 USA.
[Carchman, Evie H.; Rao, Jayashree; Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, Dept Surg, Sch Med, NW653 MUH,3459 5th Ave, Pittsburgh, PA 15213 USA.
EM zuckerbraunbs@upmc.edu
NR 23
TC 89
Z9 96
U1 2
U2 24
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD JUN
PY 2011
VL 53
IS 6
BP 2053
EP 2062
DI 10.1002/hep.24324
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 773KX
UT WOS:000291307300029
PM 21437926
ER
PT J
AU Singal, AK
Jampana, SC
Anand, BS
AF Singal, Ashwani K.
Jampana, Sarat C.
Anand, Bhupinderjit S.
TI Comment on a Systematic Review of Randomized Trials of Peginterferon
Alpha-2a Versus Peginterferon Alpha-2b in Chronic Hepatitis C
SO HEPATOLOGY
LA English
DT Letter
ID PEGYLATED INTERFERON ALPHA-2A; COINFECTED PATIENTS; PLUS RIBAVIRIN
C1 [Singal, Ashwani K.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA.
[Singal, Ashwani K.; Jampana, Sarat C.] Univ Texas Med Branch, Div Gastroenterol, Galveston, TX USA.
[Anand, Bhupinderjit S.] Baylor Coll Med, Dept Gastroenterol & Hepatol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
RP Singal, AK (reprint author), Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD JUN
PY 2011
VL 53
IS 6
BP 2151
EP 2151
DI 10.1002/hep.24165
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 773KX
UT WOS:000291307300056
PM 21538429
ER
PT J
AU Goetz, MB
Rimland, D
AF Goetz, Matthew Bidwell
Rimland, David
TI Effect of Expanded HIV Testing Programs on the Status of Newly Diagnosed
HIV-Infected Patients in Two Veterans Health Administration Facilities:
1999-2009
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID ANTIRETROVIRAL THERAPY; UNITED-STATES; TRANSMISSION; PREVALENCE
C1 [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Rimland, David] VA Med Ctr, Dept Med, Decatur, GA USA.
[Rimland, David] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA.
RP Goetz, MB (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
OI Goetz, Matthew/0000-0003-4542-992X
NR 12
TC 7
Z9 7
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2011
VL 57
IS 2
BP E23
EP E25
DI 10.1097/QAI.0b013e31821a0600
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 771MQ
UT WOS:000291163100003
PM 21709450
ER
PT J
AU Kwon, YM
Ostlere, SJ
McLardy-Smith, P
Athanasou, NA
Gill, HS
Murray, DW
AF Kwon, Young-Min
Ostlere, Simon J.
McLardy-Smith, Peter
Athanasou, Nicholas A.
Gill, Harinderjit S.
Murray, David W.
TI "Asymptomatic" Pseudotumors After Metal-on-Metal Hip Resurfacing
Arthroplasty
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article
DE pseudotumors; metal-on-metal; hip resurfacing; metal ions
ID INFLAMMATORY PSEUDOTUMOR; SURFACE REPLACEMENT; ION LEVELS; CHROMIUM;
COBALT; BEARINGS; DIAMETER; IMPLANTS; BLOOD; WEAR
AB Symptomatic abnormal periprosthetic soft-tissue reactions ("pseudotumors") have been reported after metal-on-metal hip resurfacing arthroplasty (MoMHRA). The aims of this study were (1) to determine the prevalence of asymptomatic pseudotumors after MoMHRA and (2) to measure metal ion levels in these patients. A total of 201 hips in 158 patients were evaluated at a mean follow-up of 61 months (range, 36-88) using ultrasound/magnetic resonance imaging and serum/hip aspirate cobalt and chromium measurements. Pseudotumors found in 7 patients (4%) were associated with significantly higher cobalt and chromium levels and inferior functional scores. Elevated levels of cobalt and chromium ions suggest that pseudotumors are associated with increased wear generated from metal-on-metal articulations. Clinicians need to be aware of pseudotumors as a differential diagnosis during clinical evaluation of MoMHRA patients, and further imaging such as ultrasound or magnetic resonance imaging is recommended to confirm the diagnosis.
C1 [Kwon, Young-Min] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Adult Reconstruct Surg Unit,Dept Orthopaed Surg, Boston, MA 02116 USA.
[Ostlere, Simon J.; McLardy-Smith, Peter; Athanasou, Nicholas A.; Gill, Harinderjit S.; Murray, David W.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Nuffield Orthopaed Ctr, Headington, England.
RP Kwon, YM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Adult Reconstruct Surg Unit,Dept Orthopaed Surg, 55 Fruit St,GRJ 1126, Boston, MA 02116 USA.
RI Murray, David/D-7117-2011; Gill, Richie/A-9808-2011
OI Gill, Richie/0000-0002-7740-2062
FU NIHR Biomedical Research Unit at the Nuffield Department of Orthopaedic
Surgery, Nuffield Orthopaedic Centre, Oxford, United Kingdom
FX This work was supported by the institutional funding, the NIHR
Biomedical Research Unit at the Nuffield Department of Orthopaedic
Surgery, Nuffield Orthopaedic Centre, Oxford, United Kingdom. None of
the authors have professional or financial affiliations that may be
perceived to have biased the presentation.
NR 37
TC 145
Z9 151
U1 0
U2 13
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD JUN
PY 2011
VL 26
IS 4
BP 511
EP 518
DI 10.1016/j.arth.2010.05.030
PG 8
WC Orthopedics
SC Orthopedics
GA 772NF
UT WOS:000291239900001
PM 20591612
ER
PT J
AU Talmo, CT
Kwon, YM
Freiberg, AA
Rubash, HE
Malchau, H
AF Talmo, Carl T.
Kwon, Young-Min
Freiberg, Andrew A.
Rubash, Harry E.
Malchau, Henrik
TI Management of Polyethylene Wear Associated With a Well-Fixed Modular
Cement less Shell During Revision Total Hip Arthroplasty
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article
DE total hip arthroplasty; revision; acetabular component; polyethylene;
treatment options
ID GALANTE ACETABULAR COMPONENTS; FOLLOW-UP; LINER; PROSTHESIS; 12-YEAR;
10-YEAR
AB We identified 128 revision total hip arthroplasties from 1993 to 2005 involving a well-fixed Harris-Galante Porous (HGP)-I or HGP-II acetabular component with minimum 2-year post-revision follow-up. Three treatment cohorts were identified. Of the hips that underwent modular liner exchange at revision, 14 hips (25%) required re-revision of the acetabular component, 8 for liner dislodgement, 3 for osteolysis and poly-wear, 2 for dislocation, and 1 for aseptic loosening. Of the hips that underwent revision of the well-fixed shell, 4 (15%) required subsequent re-revision of the acetabular component; 2 for dislocation and 2 for aseptic loosening. Six hips (27%) in the cemented liner group were re-revised; 4 for dislocation and 2 for loosening. Complete revision of a well-fixed HGP acetabular component is more reliable than liner exchange or liner cementation.
C1 [Kwon, Young-Min; Freiberg, Andrew A.; Rubash, Harry E.; Malchau, Henrik] Massachusetts Gen Hosp, Harris Orthopaed Biomech & Biomat Lab, Boston, MA 02114 USA.
[Kwon, Young-Min; Freiberg, Andrew A.; Rubash, Harry E.; Malchau, Henrik] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Talmo, Carl T.] New England Baptist Hosp, Boston, MA USA.
RP Malchau, H (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Biomech & Biomat Lab, 55 Fruit St,GRJ 1126, Boston, MA 02114 USA.
NR 17
TC 6
Z9 6
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD JUN
PY 2011
VL 26
IS 4
BP 576
EP 581
DI 10.1016/j.arth.2010.05.028
PG 6
WC Orthopedics
SC Orthopedics
GA 772NF
UT WOS:000291239900011
PM 20647163
ER
PT J
AU Srinivasan, VJ
Atochin, DN
Radhakrishnan, H
Jiang, JY
Ruvinskaya, S
Wu, WC
Barry, S
Cable, AE
Ayata, C
Huang, PL
Boas, DA
AF Srinivasan, Vivek J.
Atochin, Dmitriy N.
Radhakrishnan, Harsha
Jiang, James Y.
Ruvinskaya, Svetlana
Wu, Weicheng
Barry, Scott
Cable, Alex E.
Ayata, Cenk
Huang, Paul L.
Boas, David A.
TI Optical coherence tomography for the quantitative study of
cerebrovascular physiology
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE hydrogen clearance; optical coherence tomography; optical imaging;
vascular biology
ID CEREBRAL-BLOOD-FLOW; ANGIOGRAPHY; SCATTERING; OXYGEN; CELL
AB Doppler optical coherence tomography (DOCT) and OCT angiography are novel methods to investigate cerebrovascular physiology. In the rodent cortex, DOCT flow displays features characteristic of cerebral blood flow, including conservation along nonbranching vascular segments and at branch points. Moreover, DOCT flow values correlate with hydrogen clearance flow values when both are measured simultaneously. These data validate DOCT as a noninvasive quantitative method to measure tissue perfusion over a physiologic range. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1339-1345; doi:10.1038/jcbfm.2011.19; published online 2 March 2011
C1 [Srinivasan, Vivek J.; Radhakrishnan, Harsha; Ruvinskaya, Svetlana; Wu, Weicheng; Boas, David A.] Harvard Univ, Athinoula A Martinos Ctr Biomed Imaging, Sch Med, Massachusetts Gen Hosp,Dept Radiol,MGH MIT HMS, Charlestown, MA 02129 USA.
[Atochin, Dmitriy N.; Huang, Paul L.] Massachusetts Gen Hosp, Div Cardiol, Charlestown, MA USA.
[Atochin, Dmitriy N.; Huang, Paul L.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.
[Jiang, James Y.; Barry, Scott; Cable, Alex E.] Thorlabs Inc, Newton, NJ USA.
[Ayata, Cenk] Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab, Dept Radiol, Charlestown, MA USA.
[Ayata, Cenk] Massachusetts Gen Hosp, Dept Neurol, Stroke Serv & Neurosci Intens Care Unit, Boston, MA 02114 USA.
RP Srinivasan, VJ (reprint author), Harvard Univ, Athinoula A Martinos Ctr Biomed Imaging, Sch Med, Massachusetts Gen Hosp,Dept Radiol,MGH MIT HMS, Bldg 149,Room 2280,13th St, Charlestown, MA 02129 USA.
EM vjsriniv@nmr.mgh.harvard.edu
RI Radhakrishnan, Harsha/K-5557-2012; Atochin, Dmitriy/Q-3150-2016
FU NIH [R01-NS057476, R01-EB001954, R01-NS033335, R01-NS061505,
P01NS055104, P50NS010828, K99NS067050]; AHA [SDG 0835344N,
11IRG5440002]; AFOSR [MFEL FA9550-07-1-0101]
FX This study was supported by the NIH (R01-NS057476, R01-EB001954,
R01-NS033335, R01-NS061505, P01NS055104, P50NS010828, and K99NS067050),
the AHA (SDG 0835344N and 11IRG5440002), and the AFOSR (MFEL
FA9550-07-1-0101).
NR 22
TC 38
Z9 38
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD JUN
PY 2011
VL 31
IS 6
BP 1339
EP 1345
DI 10.1038/jcbfm.2011.19
PG 7
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 771HY
UT WOS:000291149000002
PM 21364599
ER
PT J
AU Tanaka, Y
Nagaoka, T
Nair, G
Ohno, K
Duong, TQ
AF Tanaka, Yoji
Nagaoka, Tsukasa
Nair, Govind
Ohno, Kikuo
Duong, Timothy Q.
TI Arterial spin labeling and dynamic susceptibility contrast CBF MRI in
postischemic hyperperfusion, hypercapnia, and after mannitol injection
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE arterial spin labeling; arterial transit time; cerebral blood flow;
dynamic susceptibility contrast; permeability; spin-lattice
relaxation-time constant
ID CEREBRAL-BLOOD-FLOW; CAPILLARY WATER PERMEABILITY; SINGULAR-VALUE
DECOMPOSITION; HIGH-RESOLUTION MEASUREMENT; TRACER BOLUS PASSAGES;
BRAIN-BARRIER; EMBOLIC STROKE; FUNCTIONAL MRI; TRANSIT-TIME; PERFUSION
AB Arterial spin labeling (ASL) and dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) are widely used to image cerebral blood flow (CBF) in stroke. This study examined how changes in tissue spin-lattice relaxation-time constant (T(1)), blood-brain barrier (BBB) permeability, and transit time affect CBF quantification by ASL and DSC in postischemic hyperperfusion in the same animals. In Group I (n = 6), embolic stroke rats imaged 48 hours after stroke showed regional hyperperfusion. In normal pixels, ASL- and DSC-CBF linearly correlated pixel-by-pixel. In hyperperfusion pixels, ASL-CBF was significantly higher than DSC-CBF pixel-by-pixel (by 25%). T1 increased from 1.76 +/- 0.14 seconds in normal pixels to 1.93 +/- 0.17 seconds in hyperperfusion pixels. Arterial transit time decreased from 300 milliseconds in normal pixels to 200 milliseconds in hyperperfusion pixels. Delta R(2)* profiles showed contrast-agent leakages in the hyperperfusion regions. In Group II (n = 3) in which hypercapnic inhalation was used to increase CBF without BBB disruption, CBF increased overall but ASL- and DSC-CBF remained linearly correlated. In Group III (n = 3) in which mannitol was used to break the BBB, ASL-CBF was significantly higher than DSC-CBF. We concluded that in normal tissue, ASL and DSC provide comparable quantitative CBF, whereas in postischemic hyperperfusion, ASL-CBF and DSC-CBF differed significantly because ischemia-induced changes in T1 and BBB permeability affected the two methods differently. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1403-1411; doi:10.1038/jcbfm.2010.228; published online 22 December 2010
C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA.
[Tanaka, Yoji; Nagaoka, Tsukasa; Nair, Govind] Emory Univ, Yerkes Imaging Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA.
[Tanaka, Yoji; Ohno, Kikuo] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU NINDS NIH HHS [R01 NS045879]
NR 43
TC 19
Z9 21
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0271-678X
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD JUN
PY 2011
VL 31
IS 6
BP 1403
EP 1411
DI 10.1038/jcbfm.2010.228
PG 9
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 771HY
UT WOS:000291149000010
PM 21179070
ER
PT J
AU Rose, AJ
Glickman, ME
D'Amore, MM
Orner, MB
Berlowitz, D
Kressin, NR
AF Rose, Adam J.
Glickman, Mark E.
D'Amore, Meredith M.
Orner, Michelle B.
Berlowitz, Dan
Kressin, Nancy R.
TI Effects of Daily Adherence to Antihypertensive Medication on Blood
Pressure Control
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID HYPERTENSIVE PATIENTS; PATIENT ADHERENCE; THERAPY; POPULATION;
INTENSIFICATION; NONCOMPLIANCE; DISEASE; PERIOD
AB Clinicians are often uncertain about how to manage elevated blood pressure (BP) when a patient reports that he/she has recently missed several doses of antihypertensive medications. While we know that better adherence can improve BP during several months, the magnitude of this relationship in the short term is poorly understood. The authors examined this issue using a group of patients who monitored adherence using a Medication Events Monitoring System (MEMS) cap and had BP measurements in the course of routine clinical practice. BP readings were compared following 7 days of excellent adherence (100%) or poor adherence (< 60%), omitting BP values following intermediate adherence. Using several different methods, BP following 7 days of excellent adherence was between 12/7 mm Hg and 15/8 mm Hg lower than after 7 days of poor adherence. Clinicians can use this effect size to calibrate their impressions of what the BP might have been with improved adherence. J Clin Hypertens (Greenwich). 2011;13:416-421. (C)2011 Wiley Periodicals, Inc.
C1 [Rose, Adam J.; Glickman, Mark E.; Orner, Michelle B.; Berlowitz, Dan; Kressin, Nancy R.] Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA.
[Rose, Adam J.; D'Amore, Meredith M.; Berlowitz, Dan; Kressin, Nancy R.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA.
[Glickman, Mark E.; Berlowitz, Dan] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02118 USA.
[Kressin, Nancy R.] VA Boston Hlth Care Syst, Boston, MA USA.
RP Glickman, ME (reprint author), Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, 200 Springs Rd 152, Bedford, MA 01730 USA.
EM mg@bu.edu
OI Kressin, Nancy/0000-0003-2767-4286; Glickman, Mark/0000-0003-3993-2801
FU National Institutes of Health [HL072814]; Department of Veterans
Affairs, Health Services Research and Development Service; Department of
Veterans Affairs, Health Services Research & Development Service [RCS
02-066-1]
FX Drs Rose and Glickman contributed equally to this manuscript. This
research was supported by a grant from the National Institutes of Health
(HL072814, NR Kressin, PI). Dr Rose is supported by a career development
award from the Department of Veterans Affairs, Health Services Research
and Development Service. Dr Kressin is supported in part by a Research
Career Scientist award from the Department of Veterans Affairs, Health
Services Research & Development Service (RCS 02-066-1). The views
expressed in this article are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs.
The authors have no conflicts of interest to disclose.
NR 25
TC 8
Z9 8
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1524-6175
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD JUN
PY 2011
VL 13
IS 6
BP 416
EP 421
DI 10.1111/j.1751-7176.2011.00427.x
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 774OB
UT WOS:000291394800005
PM 21649841
ER
PT J
AU Bloch, MJ
Basile, JN
AF Bloch, Michael J.
Basile, Jan N.
TI Analysis of Recent Papers in Hypertension
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
C1 [Bloch, Michael J.] Univ Nevada, St Marys Reg Med Ctr, Risk Reduct Ctr, Dept Internal Med,Sch Med, Reno, NV 89503 USA.
[Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA.
RP Bloch, MJ (reprint author), Univ Nevada, St Marys Reg Med Ctr, Risk Reduct Ctr, Dept Internal Med,Sch Med, 645 N Arlington St,Suite 460, Reno, NV 89503 USA.
EM mbloch@aol.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1524-6175
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD JUN
PY 2011
VL 13
IS 6
BP 455
EP 457
DI 10.1111/j.1751-7176.2011.00470.x
PG 3
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 774OB
UT WOS:000291394800010
PM 21649846
ER
PT J
AU Wheeler, LA
Trifonova, R
Vrbanac, V
Basar, E
McKernan, S
Xu, Z
Seung, E
Deruaz, M
Dudek, T
Einarsson, JI
Yang, L
Allen, TM
Luster, AD
Tager, AM
Dykxhoorn, DM
Lieberman, J
AF Wheeler, Lee Adam
Trifonova, Radiana
Vrbanac, Vladimir
Basar, Emre
McKernan, Shannon
Xu, Zhan
Seung, Edward
Deruaz, Maud
Dudek, Tim
Einarsson, Jon Ivar
Yang, Linda
Allen, Todd M.
Luster, Andrew D.
Tager, Andrew M.
Dykxhoorn, Derek M.
Lieberman, Judy
TI Inhibition of HIV transmission in human cervicovaginal explants and
humanized mice using CD4 aptamer-siRNA chimeras
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID SMALL INTERFERING RNAS; MUCOSAL TRANSMISSION; BLT MICE; INFECTION;
DELIVERY; GENE; REPLICATION; RESISTANCE; CELLS; CCR5
AB The continued spread of the HIV epidemic underscores the need to interrupt transmission. One attractive strategy is a topical vaginal microbicide. Sexual transmission of herpes simplex virus type 2 (HSV-2) in mice can be inhibited by intravaginal siRNA application. To overcome the challenges of knocking down gene expression in immune cells susceptible to HIV infection, we used chimeric RNAs composed of an aptamer fused to an siRNA for targeted gene knockdown in cells bearing an aptamer-binding receptor. Here, we showed that CD4 aptamer-siRNA chimeras (CD4-AsiCs) specifically suppress gene expression in CD4(+) T cells and macrophages in vitro, in polarized cervicovaginal tissue explants, and in the female genital tract of humanized mice. CD4-AsiCs do not activate lymphocytes or stimulate innate immunity. CD4-AsiCs that knock down HIV genes and/or CCR5 inhibited HIV infection in vitro and in tissue explants. When applied intravaginally to humanized mice, CD4-AsiCs protected against HIV vaginal transmission. Thus, CD4-AsiCs could be used as the active ingredient of a microbicide to prevent HIV sexual transmission.
C1 [Wheeler, Lee Adam; Trifonova, Radiana; Basar, Emre; McKernan, Shannon; Xu, Zhan; Dykxhoorn, Derek M.; Lieberman, Judy] Harvard Univ, Childrens Hosp Boston, Sch Med, Immune Dis Inst, Boston, MA USA.
[Wheeler, Lee Adam; Trifonova, Radiana; Basar, Emre; McKernan, Shannon; Xu, Zhan; Dykxhoorn, Derek M.; Lieberman, Judy] Harvard Univ, Childrens Hosp Boston, Sch Med, Program Cellular & Mol Med, Boston, MA USA.
[Wheeler, Lee Adam] Harvard Univ, Sch Med, MD PhD Program Immunol, Boston, MA USA.
[Vrbanac, Vladimir; Seung, Edward; Deruaz, Maud; Luster, Andrew D.; Tager, Andrew M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Dudek, Tim; Allen, Todd M.] Ragon Inst MGH MIT & Harvard, Boston, MA USA.
[Einarsson, Jon Ivar] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Yang, Linda] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Dykxhoorn, Derek M.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
RP Lieberman, J (reprint author), 200 Longwood Ave,WAB 255, Boston, MA 02115 USA.
EM lieberman@idi.harvard.edu
RI Lieberman, Judy/A-2717-2015; Dykxhoorn, Derek/D-1357-2015; Allen,
Todd/F-5473-2011
FU NIAID (NIH) [AI070302, AI090671]; Massachusetts Life Sciences Center;
Harvard CFAR; Ragon Institute; Cancer Research Institute; Ryan
Foundation; Point Foundation; Harvard CFAR Scholar award
FX This work was supported by the NIAID (NIH grants AI070302 and AI090671),
Massachusetts Life Sciences Center (to J. Lieberman), Harvard CFAR and
Ragon Institute (to J. Lieberman, A.D. Luster, and A.M. Tager),
predoctoral fellowships from the Cancer Research Institute and the Ryan
Foundation (to L.A. Wheeler), a Point Foundation scholarship (to L.A.
Wheeler), and a Harvard CFAR Scholar award (to R. Trifonova). We thank
members of the Lieberman laboratory, N. Barteneva, K. Ketman, M.
Manoharan, K. Charisse, C.M. Boutwell, S. Biswas, and P.T.N. Sarkis for
scientific advice; E. Oliva for providing human tissue samples; H.S.
Shin and S. Brooks for technical assistance; and the NIH AIDS Reagent
Program, A. Engelman, and B. Vogelstein for reagents.
NR 50
TC 113
Z9 117
U1 1
U2 17
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2011
VL 121
IS 6
BP 2401
EP 2412
DI 10.1172/JCI45876
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 772LB
UT WOS:000291234300038
PM 21576818
ER
PT J
AU Dougan, M
Li, DA
Neuberg, D
Mihm, M
Googe, P
Wong, KK
Dranoff, G
AF Dougan, Michael
Li, Danan
Neuberg, Donna
Mihm, Martin
Googe, Paul
Wong, Kwok-Kin
Dranoff, Glenn
TI A dual role for the immune response in a mouse model of
inflammation-associated lung cancer
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID NF-KAPPA-B; GM-CSF; LINKING INFLAMMATION; STAT3 ACTIVATION;
INTERFERON-GAMMA; EPITHELIAL-CELLS; IL-6 PRODUCTION; TUMOR-GROWTH;
TUMORIGENESIS; PROGRESSION
AB Lung cancer is the leading cause of cancer death worldwide. Both principal factors known to cause lung cancer, cigarette smoke and asbestos, induce pulmonary inflammation, and pulmonary inflammation has recently been implicated in several murine models of lung cancer. To further investigate the role of inflammation in the development of lung cancer, we generated mice with combined loss of IFN-gamma and the beta-common cytokines GM-CSF and IL-3. These immunodeficient mice develop chronic pulmonary inflammation and lung tumors at a high frequency. Examination of the relationship between these tumors and their inflammatory microenvironment revealed a dual role for the immune system in tumor development. The inflammatory cytokine IL-6 promoted optimal tumor growth, yet wild-type mice rejected transplanted tumors through the induction of adaptive immunity. These findings suggest a model whereby cytokine deficiency leads to oncogenic inflammation that combines with defective antitumor immunity to promote lung tumor formation, representing a unique system for studying the role of the immune system in lung tumor development.
C1 [Dougan, Michael; Li, Danan; Wong, Kwok-Kin; Dranoff, Glenn] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Dougan, Michael; Dranoff, Glenn] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Mihm, Martin] Harvard Univ, Sch Med, Boston, MA USA.
[Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Neuberg, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Mihm, Martin] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
[Googe, Paul] Knoxville Dermatopathol Lab, Knoxville, TN USA.
RP Dranoff, G (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Dana 520C,44 Binney St, Boston, MA 02115 USA.
EM glenn_dranoff@dfci.harvard.edu
OI Googe, Paul/0000-0002-9185-3548; wong, kwok kin/0000-0001-6323-235X
FU National Institute on Aging [F30AG030298]; Margaret A. Cunningham Immune
Mechanisms of Cancer Research Fellowship; American Lung Association,
United Against Lung Cancer; NIH [R01 CA122794, R01 CA140594, R01
CA143083]
FX We thank Stephen Conley of Massachusetts General Hospital for help with
photography. This work was supported by National Institute on Aging
grant F30AG030298 and the Margaret A. Cunningham Immune Mechanisms of
Cancer Research Fellowship (to M. Dougan); the American Lung
Association, United Against Lung Cancer, and NIH grants R01 CA122794 and
R01 CA140594 (to K.-K. Wong); and NIH grant R01 CA143083 (to G.
Dranoff).
NR 47
TC 45
Z9 46
U1 1
U2 8
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2011
VL 121
IS 6
BP 2436
EP 2446
DI 10.1172/JCI44796
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 772LB
UT WOS:000291234300042
PM 21537082
ER
PT J
AU Fujioka, M
Tokano, H
Fujioka, KS
Okano, H
Edge, ASB
AF Fujioka, Masato
Tokano, Hisashi
Fujioka, Keiko Shiina
Okano, Hideyuki
Edge, Albert S. B.
TI Generating mouse models of degenerative diseases using Ore/lox-mediated
in vivo mosaic cell ablation
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID DIPHTHERIA-TOXIN-A; TRANSGENIC MICE; STEM-CELLS; REGENERATION;
HOMEOSTASIS; EXPRESSION; PANCREAS; RECOVERY; HEARING; SYSTEM
AB Most degenerative diseases begin with a gradual loss of specific cell types before reaching a threshold for symptomatic onset. However, the endogenous regenerative capacities of different tissues are difficult to study, because of the limitations of models for early stages of cell loss. Therefore, we generated a transgenic mouse line (Mos-iCsp3) in which a lox-mismatched Cre/lox cassette can be activated to produce a drug-regulated dimerizable caspase-3. Tissue-restricted Cre expression yielded stochastic Casp3 expression, randomly ablating a subset of specific cell types in a defined domain. The limited and mosaic cell loss led to distinct responses in 3 different tissues targeted using respective Cre mice: reversible, impaired glucose tolerance with normoglycemia in pancreatic beta cells; wound healing and irreversible hair loss in the skin; and permanent moderate deafness due to the loss of auditory hair cells in the inner ear. These mice will be important for assessing the repair capacities of tissues and the potential effectiveness of new regenerative therapies.
C1 [Fujioka, Masato; Tokano, Hisashi; Fujioka, Keiko Shiina; Edge, Albert S. B.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Fujioka, Masato; Tokano, Hisashi; Fujioka, Keiko Shiina; Edge, Albert S. B.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Fujioka, Masato; Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Tokyo 160, Japan.
[Fujioka, Masato] Keio Univ, Sch Med, Dept Otolarnygol Head & Neck Surg, Tokyo 160, Japan.
[Edge, Albert S. B.] Harvard & Massachusetts Inst Technol, Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA USA.
RP Edge, ASB (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM albert_edge@meei.harvard.edu
RI Hidokano, Hideyuki/J-5973-2013
FU National Institute on Deafness and Other Communicative Disorders [RO1
DC007174, R21 DC010440-01, P30 DC05209]; Japanese Ministry of Education,
Culture, Sports, Science and Technology; Keio Gijuku Fukuzawa Memorial
Fund for the Advancement of Education and Research; Hamilton H. Kellogg
and Mildred H Kellogg Charitable Trust
FX We are grateful to K. Darrow for instruction on surgical methods, to K.
Takahashi for instruction on histopathology of the skin, to the
Dana-Farber Rodent Histopathology Core for assistance with
histopathology of skin and pancreas, and to J. Forrester, C. Miller, and
L. Liberman for technical assistance. We thank M.C. Liberman and A.
Brugeaud for critical discussions. This work was supported by grants RO1
DC007174, R21 DC010440-01, and P30 DC05209 from the National Institute
on Deafness and Other Communicative Disorders; by Grant-in-Aid for Young
Scientists (B) from the Japanese Ministry of Education, Culture, Sports,
Science and Technology to M. Fujioka; by Keio Gijuku Fukuzawa Memorial
Fund for the Advancement of Education and Research to M. Fujioka; and by
the Hamilton H. Kellogg and Mildred H Kellogg Charitable Trust.
NR 25
TC 9
Z9 9
U1 0
U2 3
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2011
VL 121
IS 6
BP 2462
EP 2469
DI 10.1172/JCI45081
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 772LB
UT WOS:000291234300045
PM 21576819
ER
PT J
AU Lazaro, E
Kadie, C
Stamegna, P
Zhang, SC
Gourdain, P
Lai, NY
Zhang, M
Martinez, SA
Heckerman, D
Le Gall, S
AF Lazaro, Estibaliz
Kadie, Carl
Stamegna, Pamela
Zhang, Shao Chong
Gourdain, Pauline
Lai, Nicole Y.
Zhang, Mei
Martinez, Sergio A.
Heckerman, David
Le Gall, Sylvie
TI Variable HIV peptide stability in human cytosol is critical to epitope
presentation and immune escape
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID T-LYMPHOCYTE ESCAPE; MHC CLASS-I; VIRUS TYPE-1 INFECTION; ANTIGEN
PRESENTATION; THIMET OLIGOPEPTIDASE; DEGRADATION; GAG; REPLICATION;
SELECTION; PATHWAY
AB Induction of virus-specific CD8(+) T cell responses is critical for the success of vaccines against chronic viral infections. Despite the large number of potential MHC-I-restricted epitopes located in viral proteins, MHC-I-restricted epitope generation is inefficient, and factors defining the production and presentation of MHC-I-restricted viral epitopes are poorly understood. Here, we have demonstrated that the half-lives of HIV-derived peptides in cytosol from primary human cells were highly variable and sequence dependent, and significantly affected the efficiency of cell recognition by CD8(+) T cells. Furthermore, multiple clinical isolates of HLA-associated HIV epitope variants displayed reduced half-lives relative to consensus sequence. This decreased cytosolic peptide stability diminished epitope presentation and CTL recognition, illustrating a mechanism of immune escape. Chaperone complexes including Hsp90 and histone deacetylase HDAC6 enhanced peptide stability by transient protection from peptidase degradation. Based on empirical results with 166 peptides, we developed a computational approach utilizing a sequence-based algorithm to estimate the cytosolic stability of antigenic peptides. Our results identify sequence motifs able to alter the amount of peptide available for loading onto MHC-I, suggesting potential new strategies to modulate epitope production from vaccine immunogens.
C1 [Lazaro, Estibaliz; Stamegna, Pamela; Zhang, Shao Chong; Gourdain, Pauline; Lai, Nicole Y.; Zhang, Mei; Martinez, Sergio A.; Le Gall, Sylvie] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Boston, MA 02129 USA.
[Kadie, Carl] Microsoft Res, eSci Res Grp, Redmond, WA USA.
[Heckerman, David] Microsoft Res, eSci Res Grp, Los Angeles, CA USA.
RP Le Gall, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, CNY Bldg 149,13th St, Boston, MA 02129 USA.
EM sylvie_legall@hms.harvard.edu
FU Bill and Melinda Gates Foundation; National Institute of Allergy and
Infectious Diseases [P01 AI074415-01A1, AI074415-02S1]
FX We would like to thank A. Brass, M. Brockman, D. Kaufman, D. Kavanagh,
and X. Yu for critical reading of the manuscript. This project was
funded by the Bill and Melinda Gates Foundation (Collaboration for AIDS
Vaccine Discovery) and, for the study on immune escape (Table 3 and
Figure 6), by the National Institute of Allergy and Infectious Diseases
(P01 AI074415-01A1 and AI074415-02S1 ARRA supplement; Special Emphasis
Panel Vaccine Design and Acute HIV Infection).
NR 34
TC 26
Z9 26
U1 0
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2011
VL 121
IS 6
BP 2480
EP 2492
DI 10.1172/JCI44932
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 772LB
UT WOS:000291234300047
PM 21555856
ER
PT J
AU Bezy, O
Tran, TT
Pihlajamaki, J
Suzuki, R
Emanuelli, B
Winnay, J
Mori, MA
Haas, J
Biddinger, SB
Leitges, M
Goldfine, AB
Patti, ME
King, GL
Kahn, CR
AF Bezy, Olivier
Tran, Thien T.
Pihlajamaki, Jussi
Suzuki, Ryo
Emanuelli, Brice
Winnay, Jonathan
Mori, Marcelo A.
Haas, Joel
Biddinger, Sudha B.
Leitges, Michael
Goldfine, Allison B.
Patti, Mary Elizabeth
King, George L.
Kahn, C. Ronald
TI PKC delta regulates hepatic insulin sensitivity and hepatosteatosis in
mice and humans
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID PROTEIN-KINASE-C; DIET-INDUCED OBESITY; RECEPTOR SUBSTRATE-1;
SKELETAL-MUSCLE; PHOSPHOINOSITIDE 3-KINASE; METABOLIC SYNDROME;
GLUCOSE-TRANSPORT; OXIDATIVE STRESS; RESISTANT MICE; FATTY LIVER
AB C57BL/6J and 129S6/Sv (B6 and 129) mice differ dramatically in their susceptibility to developing diabetes in response to diet- or genetically induced insulin resistance. A major locus contributing to this difference has been mapped to a region on mouse chromosome 14 that contains the gene encoding PKC delta. Here, we found that PKC delta expression in liver was 2-fold higher in B6 versus 129 mice from birth and was further increased in B6 but not 129 mice in response to a high-fat diet. PRKCD gene expression was also elevated in obese humans and was positively correlated with fasting glucose and circulating triglycerides. Mice with global or liver-specific inactivation of the Prkcd gene displayed increased hepatic insulin signaling and reduced expression of gluconeogenic and lipogenic enzymes. This resulted in increased insulin-induced suppression of hepatic gluconeogenesis, improved glucose tolerance, and reduced hepatosteatosis with aging. Conversely, mice with liver-specific overexpression of PKC delta developed hepatic insulin resistance characterized by decreased insulin signaling, enhanced lipogenic gene expression, and hepatosteatosis. Therefore, changes in the expression and regulation of PKC delta between strains of mice and in obese humans play an important role in the genetic risk of hepatic insulin resistance, glucose intolerance, and hepatosteatosis; and thus PKC delta may be a potential target in the treatment of metabolic syndrome.
C1 [Bezy, Olivier; Tran, Thien T.; Suzuki, Ryo; Emanuelli, Brice; Winnay, Jonathan; Mori, Marcelo A.; Haas, Joel; Biddinger, Sudha B.; Goldfine, Allison B.; Patti, Mary Elizabeth; King, George L.; Kahn, C. Ronald] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Bezy, Olivier; Tran, Thien T.; Suzuki, Ryo; Emanuelli, Brice; Winnay, Jonathan; Mori, Marcelo A.; Haas, Joel; Biddinger, Sudha B.; Goldfine, Allison B.; Patti, Mary Elizabeth; King, George L.; Kahn, C. Ronald] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Pihlajamaki, Jussi] Univ Eastern Finland, Dept Med, Kuopio, Finland.
[Pihlajamaki, Jussi] Univ Eastern Finland, Dept Clin Nutr, Kuopio, Finland.
[Pihlajamaki, Jussi] Kuopio Univ Hosp, SF-70210 Kuopio, Finland.
[Biddinger, Sudha B.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Endocrinol, Boston, MA USA.
[Leitges, Michael] Univ Oslo, Biotechnol Ctr Oslo, Oslo, Norway.
RP Kahn, CR (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.
EM c.ronald.kahn@joslin.harvard.edu
RI Emanuelli, Brice/M-2097-2016
FU NIH [DK31036, DK33201]; American Diabetes Association
FX The authors thank Michael Rourk and Graham Smith for animal technical
assistance. This work was supported by the NIH grants DK31036 and
DK33201, an American Diabetes Association mentor-based award, and the
Mary K. Iacocca Professorship to C.R. Kahn.
NR 54
TC 52
Z9 55
U1 1
U2 8
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2011
VL 121
IS 6
BP 2504
EP 2517
DI 10.1172/JCI46045
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 772LB
UT WOS:000291234300049
PM 21576825
ER
PT J
AU Hammond, SP
Bialek, R
Milner, DA
Petschnigg, EM
Baden, LR
Marty, FM
AF Hammond, Sarah P.
Bialek, Ralf
Milner, Danny A.
Petschnigg, Eva M.
Baden, Lindsey R.
Marty, Francisco M.
TI Molecular Methods To Improve Diagnosis and Identification of
Mucormycosis
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID FUNGAL-INFECTIONS; ZYGOMYCOSIS; TISSUE; ASPERGILLOSIS; AGENTS; ASSAYS;
MODEL
AB Mucormycosis is difficult to diagnose. Samples from suspected cases often fail to grow Mucorales in microbiologic cultures. We identified all hematologic malignancy and stem cell transplant patients diagnosed with proven mucormycosis between 2001 and 2009 at Brigham and Women's Hospital/Dana-Farber Cancer Institute. Seminested PCR targeting Mucorales 18S ribosomal DNA and sequencing were performed on formalin-fixed paraffin-embedded tissue samples. Of 29 cases of mucormycosis, 27 had tissue samples available for PCR and sequencing. Mucorales PCR was positive in 22. Among 12 culture-positive cases, 10 were PCR positive and sequencing was concordant with culture results to the genus level in 9. Among 15 culture-negative cases, PCR was positive and sequencing allowed genus identification in 12. Mucorales PCR is useful for confirmation of the diagnosis of mucormycosis and for further characterization of the infection in cases where cultures are negative.
C1 [Hammond, Sarah P.; Petschnigg, Eva M.; Baden, Lindsey R.; Marty, Francisco M.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Milner, Danny A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Hammond, Sarah P.; Baden, Lindsey R.; Marty, Francisco M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hammond, Sarah P.; Milner, Danny A.; Baden, Lindsey R.; Marty, Francisco M.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Bialek, Ralf] Labor Dr Krause & Kollegen MVZ, Kiel, Germany.
RP Hammond, SP (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St,PBB-A4, Boston, MA 02115 USA.
EM shammond2@partners.org
NR 12
TC 47
Z9 47
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2011
VL 49
IS 6
BP 2151
EP 2153
DI 10.1128/JCM.00256-11
PG 3
WC Microbiology
SC Microbiology
GA 769NZ
UT WOS:000291024500013
PM 21508149
ER
PT J
AU Hira, KG
Mackay, MR
Hempstead, AD
Ahmed, S
Karim, MM
O'Connor, RM
Hibberd, PL
Calderwood, SB
Ryan, ET
Khan, WA
Ward, HD
AF Hira, Kirthi G.
Mackay, Melanie R.
Hempstead, Andrew D.
Ahmed, Sabeena
Karim, Mohammad M.
O'Connor, Roberta M.
Hibberd, Patricia L.
Calderwood, Stephen B.
Ryan, Edward T.
Khan, Wasif A.
Ward, Honorine D.
TI Genetic Diversity of Cryptosporidium spp. from Bangladeshi Children
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID PHYLOGENETIC ANALYSIS; CHILDHOOD DIARRHEA; PARVUM; ASSOCIATION;
INFECTION; ANTIGEN; CLONING; EPIDEMIOLOGY; LIKELIHOOD; COMMUNITY
AB The genetic diversity of Cryptosporidium spp. from infected children was characterized for the first time in Bangladesh. Seven C. hominis and C. parvum subtype families (including a new family, IIm) and 15 subtypes (including 2 new subtypes) were identified. The dominance of specific families and subtypes was different from that in other countries.
C1 [Hira, Kirthi G.; Mackay, Melanie R.; O'Connor, Roberta M.; Hibberd, Patricia L.; Ward, Honorine D.] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA 02111 USA.
[Hempstead, Andrew D.; Ward, Honorine D.] Tufts Med Ctr, Sackler Sch Grad Med Sci, Program Mol Microbiol, Boston, MA 02111 USA.
[Ahmed, Sabeena; Karim, Mohammad M.; Khan, Wasif A.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
[Calderwood, Stephen B.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Ward, HD (reprint author), Tufts Med Ctr, Div Geog Med & Infect Dis, Box 041,800 Washington St, Boston, MA 02111 USA.
EM hward@tuftsmedicalcenter.org
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health (NIH) [UO1 AI45508, RO1 AI52786, U01 AI058935];
National Center for Complementary and Alternative Medicine, NIH
[K24AT003683]; Fogarty International Center, NIH [D43TW005571]; National
Institute of General Medical Sciences, NIH [T32 GM007310]
FX This study was supported by an opportunity pool grant and in part by
grants UO1 AI45508 (H. D. W.), RO1 AI52786 (H. D. W.), and U01 AI058935
(E. T. R. and S. B. C.), all from the National Institute of Allergy and
Infectious Diseases, National Institutes of Health (NIH), and
K24AT003683 (P. L. H.) from the National Center for Complementary and
Alternative Medicine, NIH. K. G. H. and M. R. M. were supported by grant
D43TW005571 from the Fogarty International Center, NIH. A. D. H. is
supported by grant T32 GM007310 from the National Institute of General
Medical Sciences, NIH.
NR 30
TC 7
Z9 7
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2011
VL 49
IS 6
BP 2307
EP 2310
DI 10.1128/JCM.00164-11
PG 4
WC Microbiology
SC Microbiology
GA 769NZ
UT WOS:000291024500043
PM 21471344
ER
PT J
AU Chen, YH
Chauhan, SK
Saban, DR
Sadrai, Z
Okanobo, A
Dana, R
AF Chen, Yihe
Chauhan, Sunil K.
Saban, Daniel R.
Sadrai, Zahra
Okanobo, Andre
Dana, Reza
TI Interferon-gamma-secreting NK cells promote induction of dry eye disease
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE immunopathogenesis; antigen-presenting cells; ocular surface
ID NATURAL-KILLER-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
T-CELLS; INFLAMMATORY CYTOKINES; DESICCATING STRESS; DENDRITIC CELLS;
PREVALENCE; SJOGRENS; FORMS; TH17
AB NK cells have been increasingly reported to be an important effector in autoimmune diseases. However, nothing is known in this regard in DED, the most common eye pathology, which is characterized by sustained inflammation on the ocular surface. In the present study, we have examined the profile of NK cells on the ocular surface as well as in the draining lymphoid tissues during the development of this disease. Our data demonstrate activated NK cells during the disease-induction phase. Moreover, in vivo depletion of NK cells in mice results in reduced disease severity and diminished proinflammatory cytokines. Furthermore, we show that NK cells are also able to modulate the maturation of APCs, which is correlated with IFN-gamma from NK cells. Together, our findings provide new in vivo evidence that IFN-gamma-secreting NK cells can promote induction of DED via direct target tissue damage and indirect influence on the priming phase of an adaptive immune response in secondary lymphoid tissue. J. Leukoc. Biol. 89: 965-972; 2011.
C1 [Chen, Yihe; Chauhan, Sunil K.; Saban, Daniel R.; Sadrai, Zahra; Okanobo, Andre; Dana, Reza] Harvard Univ, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Med Sch, Boston, MA 02114 USA.
RP Chen, YH (reprint author), Harvard Univ, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Med Sch, 20 Staniford St, Boston, MA 02114 USA.
EM yihe.chen@schepens.harvard.edu
FU National Institutes of Health [EY019098, EY20889]; Research to Prevent
Blindness Lew R. Wasserman Merit Award
FX This study was supported by National Institutes of Health EY019098 and
EY20889 and the Research to Prevent Blindness Lew R. Wasserman Merit
Award (R. D.).
NR 34
TC 25
Z9 27
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD JUN
PY 2011
VL 89
IS 6
BP 965
EP 972
DI 10.1189/jlb.1110611
PG 8
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 770SI
UT WOS:000291108400016
PM 21402771
ER
PT J
AU Sharman, MA
Cohen-Adad, J
Descoteaux, M
Messe, A
Benali, H
Lehericy, S
AF Sharman, Michael A.
Cohen-Adad, Julien
Descoteaux, Maxime
Messe, Arnaud
Benali, Habib
Lehericy, Stephane
TI Impact of Outliers on Diffusion Tensor and Q-Ball Imaging: Clinical
Implications and Correction Strategies
SO JOURNAL OF MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE diffusion; tensor; q-ball; imaging; magnetic resonance
ID SPHERICAL DECONVOLUTION; MRI; TRACTOGRAPHY; ANISOTROPY; RESOLUTION;
DISTORTION; GRADIENT; SCHEMES; MOTION
AB Purpose: To measure the impact of corrupted images often found to occur in diffusion-weighted magnetic resonance imaging (DW-MRI). To propose a robust method for the correction of outliers, applicable to diffusion tensor imaging (DTI) and q-ball imaging (QBI).
Materials and Methods: Monte Carlo simulations were carried out to measure the impact of outliers on DTI and QBI reconstruction in a single voxel. Methods to correct outliers based on q-space interpolation and direction removal were then implemented and validated in real image data.
Results: Corruption in a single voxel led to clear variations in DTI and QBI metrics. In real data, the method of q-space interpolation was successful in identifying corrupted voxels and restoring them to values consistent with those of uncorrupted images.
Conclusion: For images containing few gradient directions, where outlier removal was either impossible due to limited volumes or resulted in large changes in DTI/QBI metrics, q-space interpolation proved to be the method of choice for image restoration. A simple decision support system is proposed to assist clinicians in the correction of their corrupted DW data.
C1 [Sharman, Michael A.; Lehericy, Stephane] Hop La Pitie Salpetriere, Ctr Neuroimaging Res CENIR, F-75651 Paris, France.
[Sharman, Michael A.; Lehericy, Stephane] UPMC, INSERM, UMR S957, CRICM, Paris, Ile De France, France.
[Cohen-Adad, Julien] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Cohen-Adad, Julien; Messe, Arnaud; Benali, Habib] UPMC, INSERM, UMR S678, Paris, France.
[Descoteaux, Maxime] Univ Sherbrooke, Dept Comp Sci, Quebec City, PQ, Canada.
[Messe, Arnaud; Benali, Habib] IFR 49, Paris, France.
[Benali, Habib] Univ Montreal, CRIUGM, Unite Neuroimagerie Fonct, Montreal, PQ H3C 3J7, Canada.
RP Sharman, MA (reprint author), Hop La Pitie Salpetriere, Ctr Neuroimaging Res CENIR, Batiment Paul Castaigne,Niveau 1,47-83 Blvd Hop, F-75651 Paris, France.
EM michael.sharman@etu.upmc.fr
OI Messe, Arnaud/0000-0001-9081-3088
FU European Union (EU) [6]; GENEPARK [LSH-2005-1.2.2-2]
FX Contract grant sponsor: European Union (EU) Framework Project 6;
Contract grant sponsor: GENEPARK: Genomic Biomarkers for Parkinson's
Disease, Action Line: LIFESCIHEALTH Life sciences, genomics and
biotechnology for health; Contract grant number: LSH-2005-1.2.2-2
Development of innovative methods for diagnosis of nervous system
disorders.
NR 42
TC 3
Z9 3
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-1807
EI 1522-2586
J9 J MAGN RESON IMAGING
JI J. Magn. Reson. Imaging
PD JUN
PY 2011
VL 33
IS 6
BP 1491
EP 1502
DI 10.1002/jmri.22577
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 772WD
UT WOS:000291267700026
PM 21591020
ER
PT J
AU Cheung, JS
Au, WY
Ha, SY
Kim, D
Jensen, JH
Zhou, IY
Cheung, MM
Wu, Y
Guo, H
Khong, PL
Brown, TR
Brittenham, GM
Wu, EX
AF Cheung, Jerry S.
Au, Wing-Yan
Ha, Shau-Yin
Kim, Daniel
Jensen, Jens H.
Zhou, Iris Y.
Cheung, Matthew M.
Wu, Yin
Guo, Hua
Khong, Pek-Lan
Brown, Truman R.
Brittenham, Gary M.
Wu, Ed X.
TI Reduced Transverse Relaxation Rate (RR2) for Improved Sensitivity in
Monitoring Myocardial Iron in Thalassemia
SO JOURNAL OF MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE MRI; cardiac MR; heart; RR2; thalassemia; iron overload; chelation
therapy; ferritin; hemosiderin
ID T2-ASTERISK-CARDIOVASCULAR MAGNETIC-RESONANCE; LIVER-BIOPSY SPECIMENS;
NONINVASIVE MEASUREMENT; FERRITIN-LIKE; TISSUE-IRON; OVERLOAD;
HEMOSIDERIN; QUANTIFICATION; SUSCEPTIBILITY; COMPLICATIONS
AB Purpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short-term changes in myocardial storage iron produced by iron-chelating therapy in transfusion-dependent thalassemia patients.
Materials and Methods: A single-breathhold multi-echo fast spin-echo sequence was implemented at 3 Tesla (T) to estimate RR2 by acquiring signal decays with interecho times of 5, 9 and 13 ms. Transfusion-dependent thalassemia patients (N = 8) were examined immediately before suspending iron-chelating therapy for 1 week (Day 0), after a 1-week suspension of chelation (Day 7), and after a 1-week resumption of chelation (Day 14).
Results: The mean percent changes in RR2, R2, and R2* off chelation (between Day 0 and 7) were 11.9 +/- 8.9%, 5.4 +/- 7.7% and -4.4 +/- 25.0%; and, after resuming chelation (between Day 7 and 14), -10.6 +/- 13.9%, -8.9 +/- 8.0% and -8.5 +/- 24.3%, respectively. Significant differences in R2 and RR2 were observed between Day 0 and 7, and between Day 7 and 14, with the greatest proportional changes in RR2. No significant differences in R2* were found.
Conclusion: These initial results demonstrate that significant differences in RR2 are detectable after a single week of changes in iron-chelating therapy, likely as a result of superior sensitivity to soluble ferritin iron, which is in close equilibrium with the chelatable cytosolic iron pool. RR2 measurement may provide a new means of monitoring the short-term effectiveness of iron-chelating agents in patients with myocardial iron overload.
C1 [Cheung, Jerry S.; Zhou, Iris Y.; Cheung, Matthew M.; Wu, Yin; Guo, Hua; Wu, Ed X.] Univ Hong Kong, Lab Biomed Imaging & Signal Proc, Dept Elect & Elect Engn, Pokfulam, Hong Kong, Peoples R China.
[Cheung, Jerry S.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Cheung, Jerry S.] Harvard Univ, Sch Med, Charlestown, MA USA.
[Au, Wing-Yan] Univ Hong Kong, Dept Med, Pokfulam, Hong Kong, Peoples R China.
[Ha, Shau-Yin] Univ Hong Kong, Dept Pediat & Adolescent Med, Pokfulam, Hong Kong, Peoples R China.
[Kim, Daniel; Jensen, Jens H.] NYU, Sch Med, Dept Radiol, Ctr Biomed Imaging, New York, NY USA.
[Guo, Hua] Tsinghua Univ, Dept Biomed Engn, Beijing 100084, Peoples R China.
[Khong, Pek-Lan] Univ Hong Kong, Dept Diagnost Radiol, Pokfulam, Hong Kong, Peoples R China.
[Brown, Truman R.] Columbia Univ, Dept Radiol & Biomed Engn, New York, NY USA.
[Brittenham, Gary M.] Columbia Univ Coll Phys & Surg, Dept Pediat & Med, New York, NY 10032 USA.
RP Wu, EX (reprint author), Univ Hong Kong, Lab Biomed Imaging & Signal Proc, Dept Elect & Elect Engn, Pokfulam, Hong Kong, Peoples R China.
EM ewu@eee.hku.hk
RI Zhou, Yuwen/D-8009-2013; Zhou, Iris Yuwen/A-2089-2017
OI Zhou, Iris Yuwen/0000-0002-4351-7398
FU Hong Kong Research Grant Council [GRF7794/07M]; Hong Kong Children
Thalassaemia Foundation [2007/02]; National Institutes of Health
[R01-DK069373, R01-DK066251, R37-DK049108, R01-DK049108]; American Heart
Association [0730143N]
FX Contract grant sponsor: Hong Kong Research Grant Council; Contract grant
number: GRF7794/07M; Contract grant sponsor: Hong Kong Children
Thalassaemia Foundation; Contract grant number: 2007/02; Contract grant
sponsor: National Institutes of Health; Contract grant numbers:
R01-DK069373, R01-DK066251, R37-DK049108, R01-DK049108; Contract grant
sponsor: American Heart Association; Contract grant number: 0730143N.
NR 41
TC 5
Z9 5
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1053-1807
J9 J MAGN RESON IMAGING
JI J. Magn. Reson. Imaging
PD JUN
PY 2011
VL 33
IS 6
BP 1510
EP 1516
DI 10.1002/jmri.22553
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 772WD
UT WOS:000291267700028
PM 21591022
ER
PT J
AU Chan, CB
Liu, X
Pradoldej, S
Hao, CH
An, J
Yepes, M
Luo, HBR
Ye, KQ
AF Chan, Chi Bun
Liu, Xia
Pradoldej, Sompol
Hao, Chunhai
An, Jie
Yepes, Manuel
Luo, Hongbo R.
Ye, Keqiang
TI Phosphoinositide 3-Kinase Enhancer Regulates Neuronal Dendritogenesis
and Survival in Neocortex
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID MIDDLE CEREBRAL-ARTERY; LHERMITTE-DUCLOS-DISEASE; NEUROTROPHIC FACTOR;
CELL-DEATH; DENDRITIC ARBORIZATION; TARGETED DISRUPTION; NUCLEAR GTPASE;
NERVOUS-SYSTEM; SOMA SIZE; RAT-BRAIN
AB Phosphoinositide 3-kinase enhancer (PIKE) binds and enhances phosphatidylinositol 3-kinase (PI3K)/Akt activities. However, its physiological functions in brain have never been explored. Here we show that PIKE is important in regulating the neuronal survival and development of neocortex. During development, enhanced apoptosis is observed in the ventricular zone of PIKE knock-out (PIKE(-/-)) cortex. Moreover, PIKE(-/-) neurons show reduced dendritic complexity, dendritic branch length, and soma size. These defects are due to the reduced PI3K/Akt activities in PIKE(-/-) neurons, as the impaired dendritic arborization can be rescued when PI3K/Akt cascade is augmented in vitro or in PIKE(-/-) PTEN(-/-) double-knock-out mice. Interestingly, PIKE(-/-) mice display behavioral abnormality in locomotion and spatial navigation. Because of the diminished PI3K/Akt activities, PIKE(-/-) neurons are more vulnerable to glutamate- or stroke-induced neuronal cell death. Together, our data established the critical role of PIKE in regulating neuronal survival and development by substantiating the PI3K/Akt pathway.
C1 [Chan, Chi Bun; Liu, Xia; Pradoldej, Sompol; Hao, Chunhai; Ye, Keqiang] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
[An, Jie; Yepes, Manuel] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[An, Jie; Yepes, Manuel] Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA.
[Luo, Hongbo R.] Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr, Dept Pathol, Boston, MA 02215 USA.
[Luo, Hongbo R.] Childrens Hosp Boston, Dept Lab Med, Boston, MA 02215 USA.
RP Ye, KQ (reprint author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 615 Michael St, Atlanta, GA 30322 USA.
EM kye@emory.edu
RI Yepes, Manuel/C-3576-2011
FU NIH [R01 (NS45627), R01 (NS49478)]
FX This work is supported by NIH Grants R01 (NS45627) to K.Y. and R01
(NS49478) to M.Y. We thank the Rodent Behavioral Core Facility of Emory
University for performing the Morris water maze and Y-maze, and the
Histology and EM Laboratory of Yerkes National Primate Research Center,
Emory University for the preparation of the tissue sections.
NR 48
TC 33
Z9 33
U1 0
U2 2
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUN 1
PY 2011
VL 31
IS 22
BP 8083
EP 8092
DI 10.1523/JNEUROSCI.1129-11.2011
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 772CJ
UT WOS:000291208100015
PM 21632930
ER
PT J
AU Nelissen, K
Vanduffel, W
AF Nelissen, Koen
Vanduffel, Wim
TI Grasping-Related Functional Magnetic Resonance Imaging Brain Responses
in the Macaque Monkey
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID POSTERIOR PARIETAL CORTEX; VENTRAL PREMOTOR CORTEX; MEDIAL
PARIETOOCCIPITAL CORTEX; CORTICAL MOTOR SYSTEM; AREA V6A; VISUAL
GUIDANCE; SOMATOTOPIC ORGANIZATION; OBJECT RECOGNITION; ONLINE
ADJUSTMENTS; LATERAL SULCUS
AB Research in recent decades has suggested the existence of a dedicated brain network devoted to the organization and execution of grasping, one of the most important and skilled movements of primates. Grasping an object requires the transformation of intrinsic object properties such as size, orientation, and shape into an appropriate motor scheme shaping the hand. Although electrophysiological recordings in the monkey model have proven invaluable for gaining insights into the neuronal substrate underlying this complex behavior, knowledge concerning the existence and organization of a similar system in the human brain is derived mainly from imaging studies. Here, we present for the first time functional magnetic resonance imaging (fMRI) of brain activity while macaque monkeys performed reaching and grasping movements in a 3 tesla MR scanner. Grasping in the dark (compared with reaching) yielded significant activations in anterior intraparietal area and ventral premotor area F5, in addition to area PFG in the rostral inferior parietal lobule, somatosensory areas (SI, SII, area 5), and the hand field of F1. Whole-brain macaque fMRI motor studies will be instrumental in establishing possible homologies concerning grasping organization in the human and monkey brains, bridging the gap between human imaging and monkey electrophysiology.
C1 [Nelissen, Koen; Vanduffel, Wim] Katholieke Univ Leuven, Sch Med, Lab Neuro & Psychofysiol, B-3000 Louvain, Belgium.
[Nelissen, Koen; Vanduffel, Wim] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Nelissen, K (reprint author), Katholieke Univ Leuven, Sch Med, Lab Neuro & Psychofysiol, Herestr 49,Bus 1021,O&N2 Campus Gasthuisberg, B-3000 Louvain, Belgium.
EM koen.nelissen@med.kuleuven.be
FU Queen Elisabeth Foundation [10/008]; Interuniversity Attraction Pole
[6/29]; Geconcerteerde Onderzoeksactie [10/19]; Hercules II funds; Fonds
Wetenschappelijk Onderzoek (FWO) Vlaanderen [G.0.622.08, G.0.593.09];
National Institute of Neurological Disorders and Stroke [1R21 NS064432];
National Science Foundation [BCS-0745436]
FX This work was supported by the Queen Elisabeth Foundation, Program
Financing/10/008, Interuniversity Attraction Pole 6/29, Geconcerteerde
Onderzoeksactie/10/19, Hercules II funds, Fonds Wetenschappelijk
Onderzoek (FWO) Vlaanderen G.0.622.08 and G.0.593.09, National Institute
of Neurological Disorders and Stroke Grant 1R21 NS064432, and National
Science Foundation Grant BCS-0745436. K.N. is a postdoctoral research
fellow of the FWO. We thank A. Coeman, W. Depuydt, M. De Paep, M. Docx,
C. Fransen, P. Kayenbergh, Dr. H. Kolster, G. Meulemans, Dr. R. Peeters,
I. Puttemans, C. Van Eupen, and S. Verstraeten for technical assistance,
Dr. D. Stoianovici from Johns Hopkins Medicine for providing the
Pneustep MR-compatible motor, and Drs. G. Luppino and S. Raiguel for
valuable comments on this manuscript.
NR 90
TC 36
Z9 36
U1 0
U2 6
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUN 1
PY 2011
VL 31
IS 22
BP 8220
EP 8229
DI 10.1523/JNEUROSCI.0623-11.2011
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 772CJ
UT WOS:000291208100028
PM 21632943
ER
PT J
AU Spiliopoulos, K
Williams, Z
AF Spiliopoulos, Konstantinos
Williams, Ziv
TI Peripheral nerve injury Response
SO JOURNAL OF NEUROSURGERY
LA English
DT Editorial Material
ID BRACHIAL-PLEXUS
C1 [Spiliopoulos, Konstantinos; Williams, Ziv] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
RP Spiliopoulos, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD JUN
PY 2011
VL 114
IS 6
BP 1519
EP 1519
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 770YB
UT WOS:000291123300008
ER
PT J
AU Stufflebeam, SM
Liu, HS
Sepulcre, J
Tanaka, N
Buckner, RL
Madsen, JR
AF Stufflebeam, Steven M.
Liu, Hesheng
Sepulcre, Jorge
Tanaka, Naoaki
Buckner, Randy L.
Madsen, Joseph R.
TI Epileptic foci Response
SO JOURNAL OF NEUROSURGERY
LA English
DT Editorial Material
C1 [Stufflebeam, Steven M.; Liu, Hesheng; Sepulcre, Jorge; Tanaka, Naoaki; Buckner, Randy L.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Sepulcre, Jorge; Madsen, Joseph R.] Harvard Univ, Ctr Brain Sci, Dept Psychol, Cambridge, MA 02138 USA.
[Sepulcre, Jorge; Buckner, Randy L.] Howard Hughes Med Inst, Cambridge, MA USA.
[Madsen, Joseph R.] Childrens Hosp, Boston, MA 02115 USA.
[Stufflebeam, Steven M.; Buckner, Randy L.; Madsen, Joseph R.] Harvard Univ, Sch Med, Boston, MA USA.
RP Stufflebeam, SM (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD JUN
PY 2011
VL 114
IS 6
BP 1692
EP 1692
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 770YB
UT WOS:000291123300036
ER
PT J
AU Stufflebeam, SM
Liu, HS
Sepulcre, J
Tanaka, N
Buckner, RL
Madsen, JR
AF Stufflebeam, Steven M.
Liu, Hesheng
Sepulcre, Jorge
Tanaka, Naoaki
Buckner, Randy L.
Madsen, Joseph R.
TI Localization of focal epileptic discharges using functional connectivity
magnetic resonance imaging
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE functional MR imaging; epilepsy; interictal discharges; functional
connectivity MR imaging; localization; noninvasive localization
ID SPONTANEOUS FLUCTUATIONS; ALZHEIMERS-DISEASE; BRAIN ACTIVITY; EEG; MRI;
SEIZURES; NETWORKS; SURGERY; FMRI; HUBS
AB Object. In patients with medically refractory epilepsy the accurate localization of the seizure onset zone is critical for successful surgical treatment. The object of this study was to investigate whether the degree of coupling of spontaneous brain activity as measured with functional connectivity MR imaging (fcMR imaging) can accurately identify and localize epileptic discharges.
Methods. The authors studied 6 patients who underwent fcMR imaging presurgical mapping and subsequently underwent invasive electroencephalography.
Results. Focal regions of statistically significant increases in connectivity were identified in 5 patients when compared with an ad hoc normative sample of 300 controls. The foci identified by fcMR imaging overlapped the epileptogenic areas identified by in encephalography in all 5 patients.
Conclusions. These results suggest that fcMR imaging may provide an effective high spatial resolution and noninvasive method of localizing epileptic discharges in patients with refractory epilepsy. (DOI: 10.3171/2011.1.JNS10482)
C1 [Stufflebeam, Steven M.; Liu, Hesheng; Sepulcre, Jorge; Tanaka, Naoaki; Buckner, Randy L.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Stufflebeam, Steven M.; Buckner, Randy L.; Madsen, Joseph R.] Harvard Univ, Sch Med, Boston, MA USA.
[Sepulcre, Jorge; Buckner, Randy L.] Harvard Univ, Dept Psychol, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Madsen, Joseph R.] Childrens Hosp, Boston, MA 02115 USA.
RP Stufflebeam, SM (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St Mail Code 2301, Charlestown, MA USA.
EM sms@nmr.mgh.harvard.edu
FU National Institute on Aging [AG021910]; National Center for Research
Resources [P41RR14074]; National Institute of Mental Health
[K08MH067966]; Harvard Catalyst Pilot; Howard Hughes Medical Institute
FX This work was supported by National Institute on Aging Grant AG021910,
National Center for Research Resources Grant P41RR14074, National
Institute of Mental Health Grant K08MH067966, a Harvard Catalyst Pilot
Grant, and the Howard Hughes Medical Institute.
NR 29
TC 39
Z9 40
U1 1
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD JUN
PY 2011
VL 114
IS 6
BP 1693
EP 1697
DI 10.3171/2011.1.JNS10482
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 770YB
UT WOS:000291123300037
PM 21351832
ER
PT J
AU Natarajan, SK
Dandona, P
Karmon, Y
Yoo, AJ
Kalia, JS
Hao, Q
Hsu, DP
Hopkins, LN
Fiorella, DJ
Bendok, BR
Nguyen, TN
Rymer, MM
Nanda, A
Liebeskind, DS
Zaidat, OO
Nogueira, RG
Siddiqui, AH
Levy, EI
AF Natarajan, Sabareesh K.
Dandona, Paresh
Karmon, Yuval
Yoo, Albert J.
Kalia, Junaid S.
Hao, Qing
Hsu, Daniel P.
Hopkins, L. Nelson
Fiorella, David J.
Bendok, Bernard R.
Nguyen, Thanh N.
Rymer, Marilyn M.
Nanda, Ashish
Liebeskind, David S.
Zaidat, Osama O.
Nogueira, Raul G.
Siddiqui, Adnan H.
Levy, Elad I.
TI Prediction of adverse outcomes by blood glucose level after endovascular
therapy for acute ischemic stroke
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE admission blood glucose; acute ischemic stroke; change in blood glucose
at 48 hours; endovascular therapy; prognostic scale; vascular disorder
ID ACUTE MYOCARDIAL-INFARCTION; FOCAL CEREBRAL-ISCHEMIA; ADMISSION
HYPERGLYCEMIA; POSTSTROKE HYPERGLYCEMIA; BRAIN-DAMAGE; MERCI TRIAL;
INSULIN; MANAGEMENT; MORTALITY; REMOVAL
AB Object. The authors evaluated the prognostic significance of blood glucose level at admission (BOA) and change in blood glucose at 48 hours from the baseline value (CG48) in nondiabetic and diabetic patients before and after endovascular therapy for acute ischemie stroke (AIS).
Methods. The BOA and CG48 data were analyzed in 614 patients with AIS who received endovascular therapy at 7 US centers between 2006 and 2009. Data reviewed included demographics, stroke risk factors, diabetic status. National Institutes of Health Stroke Scale (NIHSS) score at presentation. recanalization grade. intracranial hemorrhage (ICH) rate, and 90-day outcomes (mortality rate and modified Rankin Scale score of 3-6 [defined as poor outcome]). Variables with p values < 0.2 in univariate analysis were included in a binary logistic regression model for independent predictors of 90-day outcomes.
Results. The mean patient age was 67.3 years. the median NIHSS score was 16, and 27% of patients had diabetes. In nondiabetic patients. BGA >= 116 mg/dl (>= 6.4 mmol/L) and failure of glucose level to drop > 30 mg/dl (> 1.7 mmol/L) from the admission value were both significant predictors of 90-day poor outcome and death (p < 0.001). In patients with diabetes. BGA >= 116 mg/dl (>= 6.4 mmol/L) was an independent predictor of poor outcome (p = 0.001). The CG48 was not a predictor of outcome in diabetic patients. A simplified 6-point scale including BGA. Thrombolysis in Myocardial Infarction (TIMI) Grade 2-3 Reperfusion. Age. presentation NIHSS score, CG48. and symptomatic ICH (BRANCH) corresponded with poor outcomes at 90 days: the area under the curve value was > 0.79.
Conclusions. Failure of blood glucose values to decrease in the first 48 hours after AIS intervention correlated with poor 90-day outcomes in nondiabetic patients. The BRANCH scale shows promise as a simple prognostication tool after endovascular therapy for AIS. and it merits prospective validation. (DOI: 10.3171/2011.LINS10884)
C1 [Natarajan, Sabareesh K.; Dandona, Paresh; Karmon, Yuval; Hopkins, L. Nelson; Siddiqui, Adnan H.; Levy, Elad I.] SUNY Buffalo, Buffalo, NY 14209 USA.
[Fiorella, David J.] SUNY Stony Brook, Med Ctr, Stony Brook, NY 11794 USA.
[Yoo, Albert J.; Nogueira, Raul G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nguyen, Thanh N.] Boston Univ, Boston, MA 02215 USA.
[Kalia, Junaid S.; Zaidat, Osama O.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Hao, Qing; Liebeskind, David S.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Hsu, Daniel P.; Nanda, Ashish] Univ Hosp Cleveland, Cleveland, OH 44106 USA.
[Bendok, Bernard R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Rymer, Marilyn M.] St Lukes Brain & Stroke Inst, Kansas City, MO USA.
RP Levy, EI (reprint author), SUNY Buffalo, 3 Gates Circle, Buffalo, NY 14209 USA.
EM elevy@ubns.com
OI Kalia, Junaid/0000-0001-7121-8638
NR 32
TC 10
Z9 11
U1 0
U2 2
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD JUN
PY 2011
VL 114
IS 6
BP 1785
EP 1799
DI 10.3171/2011.1.JNS10884
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 770YB
UT WOS:000291123300053
PM 21351835
ER
PT J
AU Ferreira, M
Walcott, BP
Nahed, BV
Sekhar, LN
AF Ferreira, Manuel, Jr.
Walcott, Brian P.
Nahed, Brian V.
Sekhar, Laligam N.
TI Vertebral artery pexy for microvascular decompression of the facial
nerve in the treatment of hemifacial spasm
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE hemifacial spasm; microvascular decompression; vertebral artery;
brainstem; facial nerve; cranial nerve VII; pledget
ID TRIGEMINAL NEURALGIA; TECHNICAL NOTE; COMPRESSION; PATTERNS
AB Object. Hemi facial spasm (HFS) is caused by arterial or venous compression of cranial nerve VII at its root exit zone. Traditionally, microvascular decompression of the facial nerve has been an effective treatment for posterior inferior and anterior inferior cerebellar artery as well as venous compression. The traditional technique involves Teflon felt or another construct to cushion the offending vessel from the facial nerve, or cautery and division of the offending vein. However, using this technique for severe vertebral artery (VA) compression can he ineffective and fraught with complications. The authors report the use of a new technique of VA pexy to the petrous or clival dura mater in patients with HFS attributed to a severely ectatic and tortuous VA. and detail the results in a series of patients.
Methods. Six patients with I-IFS due to VA compression underwent a retrosigmoid craniotomy. combined with a far-lateral approach in some patients. On identification of the site of VA compression. the vessel was mobilized adequately for the decompression. Great care was taken to avoid kinking the perforating vessels arising from the VA. Two 8-0 nylon sutures were passed through to the wall of the VA and then through the diva! or petrous dura, and then tied to alleviate compression on cranial nerve VII.
Results. Patients were followed for at least 1 year postoperatively (mean 2.7 years. range 1 4 years). All 6 patients had complete resolution of their HFS. Facial function was tested postoperatively. and was stable when compared with the preoperative baseline. Two of the 3 patients with preoperative Minims had resolution of this symptom after the procedure. Postoperative imaging demonstrated VA decompression of the facial nerve and no evidence of stroke in all patients. One patient suffered from hearing loss, another developed a postoperative transient unilateral vocal cord paralysis, and a third patient developed a pseudomeningocele that resolved with the placement of a lumbar drain.
Conclusions. Hemifacial spasm and other neurovascular syndromes are effectively treated by repositioning the compressing artery. Careful study of the preoperative MR images may identify a select group of patients with I-IFS due to an ectatic VA. Rather than traditional decompression with only pledget placement, these patients may be from a VA pexy to provide an effective. safe. and durable resolution of their symptoms while minimizing surgical complications. (DOI: 10.3171/2010.12.INS10891)
C1 [Sekhar, Laligam N.] Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurosurg, Seattle, WA 98104 USA.
[Walcott, Brian P.; Nahed, Brian V.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Walcott, Brian P.; Nahed, Brian V.] Harvard Univ, Sch Med, Boston, MA USA.
RP Sekhar, LN (reprint author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurosurg, Box 359924,325 9th Ave, Seattle, WA 98104 USA.
EM lsekhar@u.washington.edu
NR 24
TC 7
Z9 13
U1 0
U2 2
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD JUN
PY 2011
VL 114
IS 6
BP 1800
EP 1804
DI 10.3171/2010.12.JNS10891
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 770YB
UT WOS:000291123300054
PM 21275561
ER
PT J
AU Stepp, CE
Hillman, RE
Heaton, JT
AF Stepp, Cara E.
Hillman, Robert E.
Heaton, James T.
TI Modulation of Neck Intermuscular Beta Coherence During Voice and Speech
Production
SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH
LA English
DT Article
DE voice; speech disorders; electromyography
ID HIGH-FREQUENCY OSCILLATIONS; EEG-EMG; TENSION DYSPHONIA; MUSCLE;
FRAMEWORK; SPEAKING; HUMANS; FORCES; CORTEX; TASK
AB Purpose: The purpose of this study was to better understand neck intermuscular beta coherence (15-35 Hz; NIBcoh) in healthy individuals, with respect to modulation by behavioral tasks.
Method: Mean NIBcoh was measured using surface electromyography at 2 anterior neck locations in 10 individuals during normal speech, static nonspeech maneuvers, "clear" speech (intentionally produced to maximize intelligibility), divided-attention speech, singing, and mimicked hyperfunctional speech.
Results: An analysis of variance showed significant effects of both individual and condition (p = .001) on the mean beta-band intermuscular coherence. Dunnett's simultaneous paired t tests found decreased NIBcoh during low-attention speech, singing, and hyperfunctional speech (padj < .05), but no significant difference in NIBcoh during nonspeech tasks or clear speech production relative to normal speech.
Conclusions: Compared with normal speech, mean NIBcoh was decreased in a divided-attention speech task, but clear speech did not result in increased mean coherence relative to normal speech, possibly due to ceiling effects caused by heightened attention and precision during experimental recording. Mimicking a strained, hyperfunctional voice resulted in a reduction in mean beta intermuscular coherence quantitatively and qualitatively similar to the lowered values of mean beta coherence seen in individuals with vocal nodules relative to individuals with normal voice.
C1 [Stepp, Cara E.; Hillman, Robert E.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Stepp, Cara E.; Hillman, Robert E.; Heaton, James T.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA.
[Hillman, Robert E.; Heaton, James T.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
RP Stepp, CE (reprint author), MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
EM cstepp@alum.mit.edu
NR 31
TC 4
Z9 5
U1 2
U2 3
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1092-4388
J9 J SPEECH LANG HEAR R
JI J. Speech Lang. Hear. Res.
PD JUN 1
PY 2011
VL 54
IS 3
BP 836
EP 844
DI 10.1044/1092-4388(2010/10-0139)
PG 9
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA 771NM
UT WOS:000291166100009
PM 21106697
ER
PT J
AU Goodman, M
Siever, LJ
AF Goodman, Marianne
Siever, Larry J.
TI Hypermentalization in Adolescents With Borderline Personality Traits:
Extending the Conceptual Framework to Younger Ages
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Editorial Material
ID DISORDER
C1 [Goodman, Marianne; Siever, Larry J.] Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
RP Goodman, M (reprint author), Mt Sinai Sch Med, James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Marianne.Goodman@va.gov
NR 11
TC 2
Z9 2
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0890-8567
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD JUN
PY 2011
VL 50
IS 6
BP 536
EP 537
DI 10.1016/j.jaac.2011.02.013
PG 2
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 773DZ
UT WOS:000291288500002
PM 21621135
ER
PT J
AU Wilens, TE
Martelon, M
Joshi, G
Bateman, C
Fried, R
Petty, C
Biederman, J
AF Wilens, Timothy E.
Martelon, MaryKate
Joshi, Gagan
Bateman, Clancey
Fried, Ronna
Petty, Carter
Biederman, Joseph
TI Does ADHD Predict Substance-Use Disorders? A 10-Year Follow-up Study of
Young Adults With ADHD
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Article
DE ADHD; substance-use disorders; longitudinal follow-up; conduct disorder
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY
DISORDER; DSM-III-R; DRUG-USE; PSYCHIATRIC STATUS; ALCOHOL-ABUSE;
UNITED-STATES; CANNABIS USE; ADOLESCENT; RISK
AB Objective: High rates of substance-use disorders (SUD) have been found in samples of adolescents and adults with attention-deficit/hyperactivity disorder (ADHD). Predictors of SUD in children with ADHD who are at risk for the development of SUDs remain understudied. The main aims of this study were to identify clinically meaningful characteristics of children that predicted the future development of SUDs and to see whether the role of these characteristics varied by sex. Method: Subjects were children and adolescents with (n = 268; mean age +/- standard deviation = 10.9 +/- 3.2 years) and without (n = 229; mean age 11.9 +/- 3.3 years) DSM-III-R ADHD followed prospectively and blindly over a 10-year follow-up period onto young adult years. Subjects were assessed with structured diagnostic interviews for psychopathology and SUDs. Results: Over the 10-year follow-up period, ADHD was found to be a significant predictor of any SUD (hazards ratio 1.47; 95% confidence interval 1.07-2.02; p = .01) and cigarette smoking (2.38; 1.61-3.53; p < .01). Within ADHD, comorbid conduct disorder (2.74; 1.66-4.52; p < .01) and oppositional defiant disorder (2.21; 1.40-3.51; p < .01) at baseline were also found to be significant predictors of SUDs. Similar results were found for cigarette-, alcohol-, and drug-use disorders. There were few meaningful sex interaction effects. No clinically significant associations were found for any social or family environment factors or for cognitive functioning factors (p > .05 for all comparisons). Conclusions: These results indicate that ADHD is a significant risk factor for the development of SUDs and cigarette smoking in both sexes. J. Am. Acad. Child Adolesc. Psychiatry, 2011;50(6):543-553.
C1 [Wilens, Timothy E.] Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA.
RP Wilens, TE (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Clin & Res Program Pediat Psychopharmacol, 55 Parkman St,YAW 6A, Boston, MA 02114 USA.
EM twilens@partners.org
RI Reis, Aline/G-9573-2012
FU United States Public Health Service (National Institute on Child Health
and Human Development) [K24 DA016264]; Eli Lilly and Company Foundation
[5R01 HD-36317-07]; Pediatric Psychopharmacology Philanthropy Fund;
Abbott; McNeil; Eli Lilly and Co.; National Institutes of
Health-National Institute on Drug Abuse; Nextwave; Merck; Shire;
Guildford Press; Alza; AstraZeneca; Bristol Myers Squibb; Celltech;
Cephalon; Elminda; Esai; Forest; GlaxoSmithKline; Gliatech; Janssen;
Notional Alliance for Research on Schizophrenia and Depression; National
Institute on Drug Abuse; New River; National Institute of Child Health
and Human Development; National Institute of Mental Health; Novartis;
Noven; Neurosearch; Organon; Otsuka; Pfizer; Pharmacia; Prechter
Foundation; Stanley Foundation; UCB Pharma; Wyeth; Johnson and Johnson;
Takeda; Ethel DuPont Fellowship Award; American Academy of Child and
Adolescent Psychiatry
FX This study was funded by grant K24 DA016264 (T.W.) and in part by a
grant from the United States Public Health Service (National Institute
on Child Health and Human Development) and by grant 5R01 HD-36317-07
(J.B.) and in part by a grant from the Eli Lilly and Company Foundation
and the Pediatric Psychopharmacology Philanthropy Fund.; Dr. Wilens has
received grant support from Abbott, McNeil, Eli Lilly and Co., the
National Institutes of Health-National Institute on Drug Abuse,
Nextwave, Merck, and Shire. He has served on the speakers' bureau for
Eli Lilly and Co., McNeil, Novartis, and Shire. He has served as a
consultant to Abbott, AstraZeneca, McNeil, Eli Lilly and Co., the
National Institutes of Health, Nextwave, Novartis, Merck, and Shire. He
receives royalties from Guildford Press. Dr. Biederman has received
research support from Abbott, Alza, AstraZeneca, Bristol Myers Squibb,
Celltech, Cephalon, Eli Lilly and Co., Elminda, Esai, Forest,
GlaxoSmithKline, Gliatech, Janssen, McNeil, Merck, the Notional Alliance
for Research on Schizophrenia and Depression, the National Institute on
Drug Abuse, New River, the National Institute of Child Health and Human
Development, the National Institute of Mental Health, Novartis, Noven,
Neurosearch, Organon, Otsuka, Pfizer, Pharmacia, the Prechter
Foundation, Shire, the Stanley Foundation, UCB Pharma, and Wyeth. He has
served on the speakers' bureau for Fundacion Areces, Medice
Pharmaceuticals, and the Spanish Child Psychiatry Association. Dr. Joshi
has received research support from Abbott, Bristol Myers Squibb,
Cephalon, Eli Lilly and Co., GlaxoSmithKline, Johnson and Johnson,
McNeil, Merck, the National Institute of Mental Health, New River,
Novartis, Organon, Otsuka, Takeda, Pfizer, and Shire. He is a member of
the National Institute of Mental Health Editorial Board. He has received
the Ethel DuPont Fellowship Award. He has received the Pilot Research
Award from the American Academy of Child and Adolescent Psychiatry. Ms.
Marie Ion, Mr. Bateman, Ms. Fried, and Mr. Petty report no biomedical
financial interests or potential conflicts of interest.
NR 56
TC 82
Z9 83
U1 4
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0890-8567
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD JUN
PY 2011
VL 50
IS 6
BP 543
EP 553
DI 10.1016/j.jaac.2011.01.021
PG 11
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 773DZ
UT WOS:000291288500005
PM 21621138
ER
PT J
AU Lovas, D
AF Lovas, David
TI Room
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Book Review
C1 [Lovas, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Lovas, D (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM dlovas@partners.org
NR 1
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0890-8567
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD JUN
PY 2011
VL 50
IS 6
BP 624
EP 626
DI 10.1016/j.jaac.2011.04.006
PG 3
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 773DZ
UT WOS:000291288500015
ER
PT J
AU Farasat, S
Yu, SS
Neel, VA
Nehal, KS
Lardaro, T
Mihm, MC
Byrd, DR
Balch, CM
Califano, JA
Chuang, AY
Sharfman, WH
Shah, JP
Nghiem, P
Otley, CC
Thfaro, AP
Johnson, TM
Sober, AJ
Liegeois, NJ
AF Farasat, Sharifeh
Yu, Siegrid S.
Neel, Victor A.
Nehal, Kishwer S.
Lardaro, Thomas
Mihm, Martin C.
Byrd, David R.
Balch, Charles M.
Califano, Joseph A.
Chuang, Alice Y.
Sharfman, William H.
Shah, Jatin P.
Nghiem, Paul
Otley, Clark C.
Thfaro, Anthony P.
Johnson, Timothy M.
Sober, Arthur J.
Liegeois, Nanette J.
TI A new American Joint Committee on Cancer staging system for cutaneous
squamous cell carcinoma: Creation and rationale for inclusion of tumor
(T) characteristics
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
ID NONMELANOMA SKIN-CANCER; ORGAN TRANSPLANT RECIPIENTS; LYMPH-NODE
METASTASIS; PERINEURAL INVASION; PROGNOSTIC FACTORS; PAROTID-GLAND;
HEAD; NECK; RISK; LIP
AB Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is increasing. Although most patients achieve complete remission with surgical treatment, those with advanced disease have a poor prognosis. The American Joint Committee on Cancer (AJCC) is responsible for the staging criteria for all cancers. For the past 20 years, the AJCC cancer staging manual has grouped all nonmelanoma skin cancers, including cSCC, together for the purposes of staging. However, based on new evidence, the AJCC has determined that cSCC should have a separate staging system in the 7th edition AJCC staging manual.
Objective: We sought to present the rationale for and characteristics of the new AJCC staging system specific to cSCC tumor characteristics (T).
Methods: The Nonmelanoma Skin Cancer Task Force of AJCC reviewed relevant data and reached expert consensus in creating the 7th edition AJCC staging system for cSCC. Emphasis was placed on prospectively accumulated data and multivariate analyses. Concordance with head and neck cancer staging system was also achieved.
Results: A new AJCC cSCC T classification is presented. The T classification is determined by tumor diameter, invasion into cranial bone, and high-risk features, including anatomic location, tumor thickness and level, differentiation, and perineural invasion.
Limitations: The data available for analysis are still suboptimal, with limited prospective outcomes trials and few multivariate analyses.
Conclusions: The new AJCC staging system for cSCC incorporates tumor-specific (T) staging features and will encourage coordinated, consistent collection of data that will be the basis of improved prognostic systems in the future. (J Am Acad Dermatol 2011;64:1051-9.)
C1 [Farasat, Sharifeh; Lardaro, Thomas] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Balch, Charles M.] Johns Hopkins Univ, Dept Surg, Baltimore, MD USA.
[Balch, Charles M.; Sharfman, William H.; Liegeois, Nanette J.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA.
[Balch, Charles M.; Chuang, Alice Y.; Sharfman, William H.] Johns Hopkins Univ, Dept Dermatol, Baltimore, MD 21218 USA.
[Califano, Joseph A.; Liegeois, Nanette J.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21218 USA.
[Thfaro, Anthony P.; Liegeois, Nanette J.] Johns Hopkins Univ, Dept Plast Surg, Baltimore, MD 21218 USA.
[Yu, Siegrid S.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Neel, Victor A.; Sober, Arthur J.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Mihm, Martin C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Nehal, Kishwer S.] Mem Sloan Kettering Canc Ctr, Dermatol Serv, New York, NY 10021 USA.
[Shah, Jatin P.] Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10021 USA.
[Byrd, David R.] Univ Washington, Dept Surg, Div Plast Surg, Seattle, WA 98195 USA.
[Nghiem, Paul] Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98195 USA.
[Otley, Clark C.] Mayo Clin, Div Dermatol Surg, Rochester, MN USA.
[Johnson, Timothy M.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA.
RP Liegeois, NJ (reprint author), Univ Maryland, Dept Dermatol, 419 W Redwood St,Suite 240, Baltimore, MD 21201 USA.
EM NLiegeois@jhu.edu
RI Nghiem, Paul/A-9210-2011;
OI Nghiem, Paul/0000-0003-2784-963X; Shah, Jatin/0000-0002-6444-6592
FU Dermatology Foundation
FX Dr Liegeois is supported with a Career Development Award from the
Dermatology Foundation.
NR 56
TC 79
Z9 79
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUN
PY 2011
VL 64
IS 6
BP 1051
EP 1059
DI 10.1016/j.jaad.2010.08.033
PG 9
WC Dermatology
SC Dermatology
GA 770XD
UT WOS:000291120900004
PM 21255868
ER
PT J
AU Lipworth, AD
Park, JM
Trefrey, BL
Rubin, KM
Geller, AC
Sober, AJ
Tsao, H
AF Lipworth, Adam D.
Park, Jong Min
Trefrey, Brie L.
Rubin, Krista M.
Geller, Alan C.
Sober, Arthur J.
Tsao, Hensin
TI Urgent access to a specialty care melanoma clinic is associated with a
higher rate of melanoma detection
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE detection; melanoma; pigmented lesion; pigmented lesion clinic; routine
visit; urgent access; urgent access track
ID FOLLOW-UP GUIDELINES; LONG-TERM SURVIVAL; CUTANEOUS MELANOMA;
MALIGNANT-MELANOMA; DERMATOLOGY; DIAGNOSIS; STAGE; TELEDERMATOLOGY;
METASTASES; SYSTEM
AB Background: As melanoma rates increase, and the supply of dermatologists remains suboptimal to meet demand for services, detection of early melanoma has become an increasingly difficult challenge. Some authors advocate for shifting dermatologic resources from routine appointments to urgent visits for those With lesions concerning for melanoma.
Objective: We sought to investigate the potential of an urgent access track (UAT) embedded within a pigmented lesion clinic to improve early melanoma detection.
Methods: We conducted a retrospective review of patient records from a tertiary care hospital's pigmented lesion clinic and the associated UAT.
Results of procedures for all 4495 patient visits to the routine track and all 316 visits to the UAT during the 21-month study period were included, as were detailed chart reviews of all UAT patient visits. Results: UAT visits were more than 4 times as likely (4.1% vs 1.0%) to yield a diagnosis of melanoma as routine track visits (odds ratio 4.24; 95% confidence interval 2.28-7.88; P < .0001), and almost 25 times as likely (2.2% vs 0.1%) to yield a diagnosis of metastatic melanoma (odds ratio 25.4; 95% confidence interval 7.4-87.4; P < .0001).
Limitations: This was a preliminary analysis with only limited data extracted from the routine track pigmented lesion clinic patient visits.
Conclusion: This initial analysis of UAT strategy suggests that UATs have potential to detect patients with earlier melanomas; further research is needed to specifically delineate how resources should be best allocated between routine surveillance and urgent care to maximize melanoma early detection and survival. (J Am Acad Dermatol 2011;64: 1060-7.)
C1 [Lipworth, Adam D.; Trefrey, Brie L.; Sober, Arthur J.; Tsao, Hensin] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Park, Jong Min; Tsao, Hensin] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Trefrey, Brie L.; Rubin, Krista M.; Sober, Arthur J.; Tsao, Hensin] Massachusetts Gen Hosp, Melanoma & Pigmented Lesion Ctr, Ctr Canc, Boston, MA 02114 USA.
[Geller, Alan C.] Harvard Univ, Div Publ Hlth Practice, Sch Publ Hlth, Cambridge, MA 02138 USA.
RP Tsao, H (reprint author), Massachusetts Gen Hosp, Dept Dermatol, Bartlett 622,48 Blossom St, Boston, MA 02114 USA.
EM htsao@partners.org
NR 28
TC 4
Z9 4
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUN
PY 2011
VL 64
IS 6
BP 1060
EP 1067
DI 10.1016/j.jaad.2010.08.021
PG 8
WC Dermatology
SC Dermatology
GA 770XD
UT WOS:000291120900005
PM 21453985
ER
PT J
AU Ibrahimi, OA
Syed, Z
Sakamoto, FH
Avram, MM
Anderson, RR
AF Ibrahimi, Omar A.
Syed, Zain
Sakamoto, Fernanda H.
Avram, Mathew M.
Anderson, R. Rox
TI Treatment of tattoo allergy with ablative fractional resurfacing: A
novel paradigm for tattoo removal
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE laser therapy; Q-switchecl lasers; tattoo allergy
ID Q-SWITCHED RUBY; ND-YAG LASER; DOSE-RESPONSE; NM; PHOTOTHERMOLYSIS
AB Background: Q-switched lasers are the gold standard for tattoo treatment. Allergic tattoo reactions present a treatment dilemma. We present the application of ablative fractional resurfacing (AFR) as a novel method for tattoo removal.
Objective: We describe two patients with tattoo allergies, referred to us for treatment.
Methods: AFR was used in a series of treatments to remove the allergic-ink portion of a multicolored tattoo on the upper extremity of a 52-year-old man. In a 31-year-old woman with a red and black tattoo on her lower extremity, AFR was combined with a Q-switched neodymium:yttrium-aluminum-garnet laser.
Results: After a series of treatments, both patients experienced significant to complete removal of the offending tattoo inks with substantial or complete resolution of their symptoms.
Limitations: This uncontrolled observational series is based on two patients.
Conclusions: AFR appears to be safe and effective for removal of allergic tattoos. AFR can be combined with other treatments such as Q-switched lasers. The potential for a series of AFR treatments to remove tattoos, including allergic tattoos and inks of any color, merits further study. (J Am Acad Dermatol 201164:1111-4.)
C1 [Ibrahimi, Omar A.] Univ Connecticut, Dept Dermatol, Farmington, CT 06032 USA.
[Ibrahimi, Omar A.; Sakamoto, Fernanda H.; Avram, Mathew M.; Anderson, R. Rox] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Ibrahimi, Omar A.; Sakamoto, Fernanda H.; Avram, Mathew M.; Anderson, R. Rox] Harvard Univ, Sch Med, Wellman Ctr Photomed, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Syed, Zain] Univ Virginia, Charlottesville, VA 22903 USA.
RP Ibrahimi, OA (reprint author), Univ Connecticut, Dept Dermatol, 21 South Rd, Farmington, CT 06032 USA.
EM omar.ibrahimi@gmail.com
NR 14
TC 24
Z9 24
U1 2
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUN
PY 2011
VL 64
IS 6
BP 1111
EP 1114
DI 10.1016/j.jaad.2010.11.005
PG 4
WC Dermatology
SC Dermatology
GA 770XD
UT WOS:000291120900011
PM 21571169
ER
PT J
AU Kim, JM
Mudgal, CS
Konopka, JF
Jupiter, JB
AF Kim, Jaehon M.
Mudgal, Chaitanya S.
Konopka, Joseph F.
Jupiter, Jesse B.
TI Complications of Total Elbow Arthroplasty
SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
LA English
DT Review
ID RHEUMATOID-ARTHRITIS; MORREY PROSTHESIS; SURVIVAL ANALYSIS; REPLACEMENT;
REVISION; INFECTION; FRACTURES; COMPONENT; KINEMATICS; EXPERIENCE
AB Modifications in implant design and improvements in surgical technique have expanded the applications of total elbow arthroplasty. Complications associated with reconstructive elbow surgery persist, however, often leading to profound and sometimes nonsalvageable disability. The most recognized complications include implant loosening, periprosthetic fracture, implant failure, infection, triceps insufficiency, and nerve palsy. Although far fewer elbow arthroplasties than lower extremity arthroplasties are performed, the proportion of complications is greater with elbow arthroplasty, and the outcomes of secondary reconstruction are less favorable.
C1 [Kim, Jaehon M.; Konopka, Joseph F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Harvard Combined Orthopaed Residency Program, Boston, MA 02115 USA.
[Mudgal, Chaitanya S.; Jupiter, Jesse B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv, Boston, MA USA.
RP Kim, JM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Harvard Combined Orthopaed Residency Program, Boston, MA 02115 USA.
NR 52
TC 29
Z9 29
U1 1
U2 1
PU AMER ACAD ORTHOPAEDIC SURGEONS
PI ROSEMENT
PA 6300 N RIVER ROAD, ROSEMENT, IL 60018-4262 USA
SN 1067-151X
J9 J AM ACAD ORTHOP SUR
JI J. Am. Acad. Orthop. Surg.
PD JUN
PY 2011
VL 19
IS 6
BP 328
EP 339
PG 12
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 774FL
UT WOS:000291370400003
PM 21628644
ER
PT J
AU Pfister, DG
Ang, KK
Brizel, DM
Burtness, BA
Cmelak, AJ
Colevas, D
Dunphy, F
Eisele, DW
Gilbert, J
Gillison, ML
Haddad, RI
Haughey, BH
Hicks, WL
Hitchcock, YJ
Kies, MS
Lydiatt, WM
Maghami, E
Martins, R
McCaffrey, T
Mittal, BB
Pinto, HA
Ridge, JA
Samant, S
Sanguineti, G
Schuller, DE
Shah, JP
Spencer, S
Trotti, A
Weber, RS
Wolf, GT
Worden, F
AF Pfister, David G.
Ang, Kie-Kian
Brizel, David M.
Burtness, Barbara A.
Cmelak, Anthony J.
Colevas, Dimitrios
Dunphy, Frank
Eisele, David W.
Gilbert, Jill
Gillison, Maura L.
Haddad, Robert I.
Haughey, Bruce H.
Hicks, Wesley L., Jr.
Hitchcock, Ying J.
Kies, Merrill S.
Lydiatt, William M.
Maghami, Ellie
Martins, Renato
McCaffrey, Thomas
Mittal, Bharat B.
Pinto, Harlan A.
Ridge, John A.
Samant, Sandeep
Sanguineti, Giuseppe
Schuller, David E.
Shah, Jatin P.
Spencer, Sharon
Trotti, Andy, III
Weber, Randal S.
Wolf, Gregory T.
Worden, Frank
TI Head and Neck Cancers
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Review
DE NCCN Clinical Practice Guidelines; NCCN Guidelines; head and neck
cancer; chemotherapy; radiotherapy; surgery; oral cavity; oropharynx;
hypopharynx; nasopharynx; glottic; supraglottic; larynx
ID SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; INTENSITY-MODULATED
RADIOTHERAPY; COOPERATIVE-ONCOLOGY-GROUP; QUALITY-OF-LIFE; METASTATIC
NASOPHARYNGEAL CARCINOMA; PROSPECTIVE RANDOMIZED-TRIAL; CISPLATIN PLUS
FLUOROURACIL; ADVANCED LARYNGEAL-CANCER; PHASE-III TRIAL
C1 [Pfister, David G.; Shah, Jatin P.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Ang, Kie-Kian; Kies, Merrill S.; Weber, Randal S.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Cmelak, Anthony J.; Gilbert, Jill] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Colevas, Dimitrios; Pinto, Harlan A.] Stanford Comprehens Canc Ctr, Stanford, CA USA.
[Gillison, Maura L.; Schuller, David E.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Gillison, Maura L.; Schuller, David E.] Ohio State Univ, Ctr Comprehens Canc, Solove Res Inst, Columbus, OH 43210 USA.
[Haddad, Robert I.] Dana Farber Brigham & Womens Canc, Boston, MA USA.
[Haughey, Bruce H.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Haughey, Bruce H.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Hicks, Wesley L., Jr.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Hitchcock, Ying J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Lydiatt, William M.] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA.
[Maghami, Ellie] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[McCaffrey, Thomas; Trotti, Andy, III] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Mittal, Bharat B.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Samant, Sandeep] Univ Tennessee, St Jude Childrens Res Hosp, Inst Canc, Knoxville, TN 37996 USA.
[Sanguineti, Giuseppe] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Spencer, Sharon] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, W Midlands, England.
[Wolf, Gregory T.; Worden, Frank] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
RP Pfister, DG (reprint author), Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 205
TC 83
Z9 85
U1 0
U2 11
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2011
VL 9
IS 6
BP 596
EP 649
PG 54
WC Oncology
SC Oncology
GA 773BN
UT WOS:000291282100002
PM 21636536
ER
PT J
AU Macdonald, A
Monson, CM
Doron-Lamarca, S
Resick, PA
Palfai, TP
AF Macdonald, Alexandra
Monson, Candice M.
Doron-Lamarca, Susan
Resick, Patricia A.
Palfai, Tibor P.
TI Identifying Patterns of Symptom Change During a Randomized Controlled
Trial of Cognitive Processing Therapy for Military-Related Posttraumatic
Stress Disorder
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID CONFIRMATORY FACTOR-ANALYSIS; ADMINISTERED PTSD SCALE; SEXUAL ASSAULT
VICTIMS; MENTAL-HEALTH PROBLEMS; EXPOSURE THERAPY; BEHAVIOR THERAPY;
PSYCHOTHERAPY; CLINICIAN; DIMENSIONALITY; AFGHANISTAN
AB Cognitive processing therapy (CPT) for posttraumatic stress disorder (PTSD) has been shown to reduce symptoms of PTSD in a veteran population. This study explored patterns of self-reported symptom change during CPT. Veterans (N = 60) with PTSD were randomized to receive CPT immediately or after 10 weeks. We hypothesized that those treated immediately would evidence initial symptom stability followed by decline compared with those who waited, whose PTSD symptoms would remain stable. The best model fit based on deviance statistics and Bayesian information criteria comparisons was one in which participants treated immediately showed more rapid initial decline followed by a slower rate of PTSD symptom improvement relative to those who waited, who showed a stable level of symptomatology. Findings suggest that CPT produces quick and maintained improvements in veterans. The effect sizes for change between those who received CPT immediately and those who waited were approximately medium sized. Implications of findings are discussed.
C1 [Macdonald, Alexandra; Palfai, Tibor P.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Macdonald, Alexandra] VA Boston Healthcare Syst, Boston, MA USA.
RP Macdonald, A (reprint author), VA Boston Healthcare Syst 116B, 150 S Huntington Ave, Jamaica Plain, MA USA.
EM Alexandra.Macdonald@va.gov
RI Schueter, nicos/A-3625-2014
NR 40
TC 14
Z9 14
U1 4
U2 16
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2011
VL 24
IS 3
BP 268
EP 276
DI 10.1002/jts.20642
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 773ZF
UT WOS:000291350300004
PM 21626572
ER
PT J
AU Levy, HC
Conoscenti, LM
Tillery, JF
Dickstein, BD
Litz, BT
AF Levy, Hannah C.
Conoscenti, Lauren M.
Tillery, John F.
Dickstein, Benjamin D.
Litz, Brett T.
TI Deployment Stressors and Outcomes Among Air Force Chaplains
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID RESILIENCE; TRAUMA; CARE; RISK; IRAQ
AB Military chaplains are invaluable caregiver resources for service members. Little is known about how chaplains respond to the challenge of providing spiritual counsel in a warzone. In this exploratory study, 183 previously deployed Air Force chaplains completed an online survey assessing operational and counseling stress exposure, posttraumatic stress disorder (PTSD) symptoms, compassion fatigue, and posttraumatic growth. Despite reporting exposure to stressful counseling experiences, Air Force chaplains did not endorse high compassion fatigue. Rather, chaplains experienced positive psychological growth following exposure to stressful counseling experiences. However, 7.7% of Air Force chaplains reported clinically significant PTSD symptoms, suggesting that they are not immune to deployment-related mental health problems. Simultaneous regression analyses revealed that counseling stress exposure predicted compassion fatigue (beta = .20) and posttraumatic growth (beta = .24), suggesting that caretaking in theatre is stressful enough to spur positive psychological growth in chaplains. Consistent with findings from previous studies, hierarchical regression analyses revealed that operational stress exposure predicted PTSD symptom severity (beta = .33) while controlling for demographic variables.
C1 [Levy, Hannah C.; Conoscenti, Lauren M.; Dickstein, Benjamin D.; Litz, Brett T.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Tillery, John F.] AF Chaplains Corps Coll, Columbia, SC USA.
[Dickstein, Benjamin D.; Litz, Brett T.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
RP Levy, HC (reprint author), Concordia Univ, Dept Psychol, 7141 Sherbrooke St W,SP 244, Montreal, PQ H4B 1R6, Canada.
EM ha_levy@live.concordia.ca
NR 13
TC 3
Z9 3
U1 2
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2011
VL 24
IS 3
BP 342
EP 346
DI 10.1002/jts.20646
PG 5
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 773ZF
UT WOS:000291350300013
PM 21567477
ER
PT J
AU Simpson, TL
Comtois, KA
Moore, SA
Kaysen, D
AF Simpson, Tracy L.
Comtois, Katherine Anne
Moore, Sally A.
Kaysen, Debra
TI Comparing the Diagnosis of PTSD When Assessing Worst Versus Multiple
Traumatic Events in a Chronically Mentally Ill Sample
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; EFFECT SIZE; SCALE
AB Despite interest in the nature of the traumatic event required to meet Criterion A for posttraumatic stress disorder (PTSD) as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association, 1994), little attention has been paid to the diagnostic ramifications of linking PTSD symptoms to a single traumatic event in the context of multiple trauma exposures. In this study, 67 dually diagnosed clients with at least 2 potential Criterion A traumatic events completed the Posttraumatic Stress Diagnostic Scale twice, in counterbalanced order: once regarding their worst event and once regarding all events. When responding regarding their worst trauma, 53.7% met probable PTSD criteria. This rose to 67.2% when considering all traumas. Although preliminary, these results suggest that linking PTSD symptoms to a single traumatic event excludes a meaningful number of cases who are otherwise indistinguishable based on symptom profile.
C1 [Simpson, Tracy L.; Moore, Sally A.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA 98108 USA.
[Simpson, Tracy L.; Comtois, Katherine Anne; Moore, Sally A.; Kaysen, Debra] Univ Washington, Sch Med, Seattle, WA 98195 USA.
RP Simpson, TL (reprint author), VA Puget Sound Hlth Care Syst, Mental Hlth Serv, 1660 S Columbian Way,116 WTRC, Seattle, WA 98108 USA.
EM Tracy.Simpson@va.gov
NR 10
TC 4
Z9 4
U1 2
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2011
VL 24
IS 3
BP 361
EP 364
DI 10.1002/jts.20647
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 773ZF
UT WOS:000291350300017
PM 21594901
ER
PT J
AU Hajj-Ali, RA
Singhal, AB
Benseler, S
Molloy, E
Calabrese, LH
AF Hajj-Ali, Rula A.
Singhal, Aneesh B.
Benseler, Susanne
Molloy, Eamonn
Calabrese, Leonard H.
TI Primary angiitis of the CNS
SO LANCET NEUROLOGY
LA English
DT Review
ID CENTRAL-NERVOUS-SYSTEM; CEREBRAL AMYLOID ANGIOPATHY;
GRANULOMATOUS-ANGIITIS; VASOCONSTRICTION SYNDROMES; DIAGNOSTIC-CRITERIA;
ISCHEMIC-STROKE; BRAIN BIOPSY; MASS LESION; VASCULITIS; ANGIOGRAPHY
AB Meaningful progress in our understanding and clinical approach to primary angiitis of the CNS (PACNS) has been made in the past three decades. Increased recognition of PACNS and general advances in diagnosis of neurological disorders have led to an aggressive diagnostic approach and a proliferation of case reports providing enriched clinical and pathological descriptions. We have witnessed major advances not only in the diagnosis of PACNS but in the recognition of its mimics. Epidemiological, clinical, neuroradiagnostic, and laboratory findings have enhanced our diagnostic accuracy and recognition of PACNS mimics, however, many challenges to our understanding and management of the disease in children and adults remain.
C1 [Calabrese, Leonard H.] Cleveland Clin, Dept Rheumat & Immunol Dis, Orthopaed & Rheumatol Inst, Cleveland, OH 44195 USA.
[Singhal, Aneesh B.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Benseler, Susanne] Univ Toronto, Hosp Sick Children, Div Rheumatol, Dept Paediat, Toronto, ON M5G 1X8, Canada.
[Molloy, Eamonn] St Vincents Univ Hosp, Dublin 4, Ireland.
RP Calabrese, LH (reprint author), Cleveland Clin, Dept Rheumat & Immunol Dis, Orthopaed & Rheumatol Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM calabrl@ccf.org
FU RJ Fasenmyer educational Fund
FX LHC and RHA receive funding from The RJ Fasenmyer educational Fund. We
thank Elizabeth Kirchner for editing the manuscript.
NR 74
TC 96
Z9 103
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
J9 LANCET NEUROL
JI Lancet Neurol.
PD JUN
PY 2011
VL 10
IS 6
BP 561
EP 572
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA 774HK
UT WOS:000291376100015
PM 21601163
ER
PT J
AU Franco, RA
Dowdall, JR
Bujold, K
Amann, C
Faquin, W
Redmond, RW
Kochevar, IE
AF Franco, Ramon A.
Dowdall, Jayme R.
Bujold, Kenneth
Amann, Christopher
Faquin, William
Redmond, Robert W.
Kochevar, Irene E.
TI Photochemical Repair of Vocal Fold Microflap Defects
SO LARYNGOSCOPE
LA English
DT Article
DE Vocal folds; microflap; Rose Bengal; wound healing; photochemical tissue
bonding
ID CORNEAL INCISIONS; SKIN; KERATODESMOS; PRESSURE; COUGH; LASER; MODEL
AB Objectives: To bond vocal fold flaps using a sutureless, nonthermal laser-assisted method combining visible light and photosensitizing dyes to produce collagen crosslinks.
Study Design: In the ex vivo study, epithelial incisions were created in sheep vocal folds. The concentration of the Rose Bengal, and the laser fluence were varied and studied. The in vivo canine study evaluated the thickness of the basement membrane zone, density and distribution of collagen, elastin, and fibroblasts at time zero, 2 weeks, and 8 weeks.
Methods: Ex Vivo: Rose Bengal at concentrations between 0.5% and 1.0% was applied to the free margins of the incision and irradiated with an Nd:YAG laser at fluences varying from 150 to 600 J/cm(2). The bonding was considered positive when the incision could withstand air at 2 pounds per square inch (psi) from a distance of 3 cm. In Vivo: 0.75% Rose Bengal was applied to the microflap edges and irradiated with an Nd: YAG laser for 140 seconds (100 J/cm(2)). The control side was not irradiated.
Results: Ex Vivo: Bonding was achieved with a minimum of 0.75% Rose Bengal and 300 J/cm(2). In Vivo: There was no difference in the amount of subepithelial reaction between the experimental and control sides at 8 weeks.
Conclusions: Photochemical tissue bonding is effective at sealing vocal fold incisions and did not create long-term scarring of the vocal folds. Use of this technique may allow for more predictable healing after microflap resection and may reduce the need for postoperative voice rest.
C1 [Franco, Ramon A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Div Laryngol,Dept Otol & Laryngol, Boston, MA USA.
[Dowdall, Jayme R.] Wayne State Univ, Detroit, MI USA.
[Bujold, Kenneth; Amann, Christopher; Redmond, Robert W.; Kochevar, Irene E.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Faquin, William] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Massachusetts Eye & Ear Infirm,Dept Pathol, Boston, MA USA.
RP Franco, RA (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Laryngol, 243 Charles St, Boston, MA 02114 USA.
EM ramonfranco@meei.harvard.edu
FU Center for Integration of Medicine and Innovative Technology (CIMIT)
FX This work was supported with a Center for Integration of Medicine and
Innovative Technology (CIMIT) grant; no other financial disclosures for
R. Franco, J. Dowdall, K. Bujold, C. Amann, or W. Faquin.
NR 27
TC 11
Z9 12
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD JUN
PY 2011
VL 121
IS 6
BP 1244
EP 1251
DI 10.1002/lary.21797
PG 8
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 772TP
UT WOS:000291259900021
PM 21480282
ER
PT J
AU Wu, WE
Kirov, II
Zhang, K
Babb, JS
Joo, CG
Ratai, EM
Gonzalez, RG
Gonen, O
AF Wu, William E.
Kirov, Ivan I.
Zhang, Ke
Babb, James S.
Joo, Chan-Gyu
Ratai, Eva-Maria
Gonzalez, R. Gilberto
Gonen, Oded
TI Cross-Sectional and Longitudinal Reproducibility of Rhesus Macaque Brain
Metabolites: A Proton MR Spectroscopy Study at 3 T
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE animal models; brain; MR spectroscopy; longitudinal metabolites
concentration; rhesus macaque; reproducibility
ID MAGNETIC-RESONANCE-SPECTROSCOPY; IN-VIVO; NEURONAL INJURY; CYNOMOLGUS
MONKEYS; N-ACETYLASPARTATE; RELAXATION-TIMES; BASE-LINE; MODEL; REVEALS;
T-2
AB Non-human primates are often used as preclinical model systems for (mostly diffuse or multi-focal) neurological disorders and their experimental treatment. Due to cost considerations, such studies frequently utilize non-destructive imaging modalities, MRI and proton MR spectroscopy ((1)H MRS). Cost may explain why the inter-and intra-animal reproducibility of the (1)H MRS observed brain metabolites, are not reported. To this end, we performed test-retest three-dimensional brain (1)H MRS in five healthy rhesus macaques at 3 T. Spectra were acquired from 224 isotropic (0.5 cm)(3) 5 125 mu L voxels, over 28 cm(3) (similar to 35%) of the brain, then individually phased, frequency aligned and summed into a spectrum representative of the entire volume of interest. This dramatically increases the metabolites' signal-to-noise ratios, while maintaining the (narrow) voxel linewidth. The results show that the average N-acetylaspartate, creatine, choline, and myo-inositol concentrations in the macaque brain are: 7.7 +/- 0.5, 7.0 +/- 0.5, 1.2 +/- 0.1 and 4.0 +/- 0.6 mM/g wet weight (mean +/- standard deviation). Their inter-animal coefficients of variation (CV) are 4%, 4%, 6%, and 15%; and the longitudinal (intra-animal) CVs are lower still: 4%, 5%, 5%, and 4%, much better than the 22%, 33%, 36%, and 45% intra-voxel CVs, demonstrating the advantage of the approach and its utility for preclinical studies of diffuse neurological diseases in rhesus macaques. Magn Reson Med 65:1522-1531, 2011. (C)2011 Wiley-Liss, Inc.
C1 [Wu, William E.; Kirov, Ivan I.; Zhang, Ke; Babb, James S.; Gonen, Oded] NYU, Sch Med, Dept Radiol, New York, NY 10016 USA.
[Joo, Chan-Gyu; Ratai, Eva-Maria; Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Joo, Chan-Gyu; Ratai, Eva-Maria; Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Neuroradiol Div, Charlestown, MA USA.
RP Gonen, O (reprint author), NYU, Sch Med, Dept Radiol, 660 1st Ave,4th Floor, New York, NY 10016 USA.
EM oded.gonen@med.nyu.edu
OI Wu, William/0000-0003-0990-4164; Kirov, Ivan/0000-0001-5641-8578; Gonen,
Oded/0000-0002-3148-2028
FU NIH [EB01015, NS050520, NS050041, NS040237, NS059331]; National Center
for Research Resources [P41RR14075]
FX Grant sponsor: NIH; Grant numbers: EB01015, NS050520, NS050041,
NS040237, NS059331; Grant sponsor: National Center for Research
Resources; Grant number: P41RR14075.
NR 42
TC 5
Z9 5
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0740-3194
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD JUN
PY 2011
VL 65
IS 6
BP 1522
EP 1531
DI 10.1002/mrm.22867
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 770VB
UT WOS:000291115500003
PM 21337426
ER
PT J
AU Peng, Q
Zhang, Y
Nateras, OSE
van Osch, MJP
Duong, TQ
AF Peng, Qi
Zhang, Yi
Nateras, Oscar San Emeterio
van Osch, Matthias J. P.
Duong, Timothy Q.
TI MRI of Blood Flow of the Human Retina
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE ASL; retinal vessels; choroids; high-resolution MRI; hypercapnia
ID CARBON-DIOXIDE; FUNCTIONAL MRI; OXYGEN; INVERSION; BRAIN; RATS;
DEGENERATION; HYPERCAPNIA; RELAXATION; EFFICIENCY
AB This study reports a high-resolution MRI approach to image basal blood flow and hypercapnia-induced blood-flow changes in the unanesthetized human retina on a 3-T MRI scanner. Pseudo-continuous arterial spin labeling technique with static tissue suppression was implemented to minimize movement artifacts and improve blood-flow sensitivity. Turbo spin-echo acquisition was used to achieve high spatial resolution free of susceptibility artifacts. The size, shape, and position of a custom-made receive radiofrequency coil were optimized for sensitivity in the posterior retina. Synchronized eye blink and respiration to the end of each data readout minimized eye movement and physiological fluctuation. Robust high-contrast blood-flow MRI of the unanesthetized human retina was obtained at 500 X 800 mu m(2) in-plane resolution. Blood flow in the posterior retina was 93 +/- 31 mL/(100 mL min) (mean +/- standard deviation, N = 5). Hypercapnic inhalation (5% CO(2)) increased blood flow by 12 +/- 4% relative to air (P < 0.01, N = 5). This study demonstrates the feasibility of blood-flow MRI of the retina of unanesthetized human. Because blood flow is tightly coupled to metabolic function under normal conditions and it is often perturbed in diseases, this approach could provide unique insights into retinal physiology and serve as an objective imaging biomarker for disease staging and testing of novel therapeutic strategies. This approach could open up new avenue of retinal research. Magn Reson Med 65:1768-1775, 2011. (C)2011 Wiley-Liss, Inc.
C1 [Peng, Qi; Zhang, Yi; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Peng, Qi; Zhang, Yi; Nateras, Oscar San Emeterio; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[van Osch, Matthias J. P.] Leiden Univ, Med Ctr, Dept Radiol, CJ Gorter Ctr High Field MRI, Leiden, Netherlands.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU Clinical Translational Science Award Pilot Grant, Translational
Technology Resource Grant [UL1RR025767]; NIH/NEI [R01 EY014211,
EY018855]; Department of Veterans Affairs
FX Grant sponsors: Clinical Translational Science Award Pilot Grant,
Translational Technology Resource Grant to TQD (Parent; Grant number:
UL1RR025767); Grant sponsor: NIH/NEI; Grant numbers: R01 EY014211,
EY018855 to TQD; Grant sponsor: Department of Veterans Affairs (VISN7
Career Development Award and MERIT to TQD).
NR 45
TC 23
Z9 23
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0740-3194
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD JUN
PY 2011
VL 65
IS 6
BP 1768
EP 1775
DI 10.1002/mrm.22763
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 770VB
UT WOS:000291115500028
PM 21590806
ER
PT J
AU Vanti, C
Bonfiglioli, R
Calabrese, M
Marinelli, F
Guccione, A
Violante, FS
Pillastrini, P
AF Vanti, Carla
Bonfiglioli, Roberta
Calabrese, Monica
Marinelli, Francesco
Guccione, Andrew
Violante, Francesco Saverio
Pillastrini, Paolo
TI Upper limb neurodynamic test 1 and symptoms reproduction in carpal
tunnel syndrome. A validity study
SO MANUAL THERAPY
LA English
DT Article
DE Neurological examination; Reproducibility of the results; Carpal tunnel
syndrome
ID MEDIAN NERVE; PHYSICAL-EXAMINATION; PRACTICE PARAMETER; IN-VIVO;
COMPRESSION; DIAGNOSIS; CONDUCTION; TENSION; CLASSIFICATION;
LOCALIZATION
AB The aim of this study was to estimate the validity of the Upper Limb Neurodynamic Test 1 (ULNT1) for the diagnosis of Carpal Tunnel Syndrome (CTS) with blind comparison to a reference criterion of a compatible clinical presentation and abnormal nerve conduction. 47 subjects with suspected CTS were enrolled. All patients were tested with nerve conduction studies and ULNT1. Considering results as positive in the presence of reproduction of symptoms on affected upper limb, or side-to-side differences in elbow extension, or symptoms modified by lateral neck side-bending, we estimated sensitivity as 91.67%, specificity as 15%, positive likelihood ratio as 1.0784, negative likelihood ratio as 0.5556, and post-test probability for negative test as 40%. Using a new criterion, i.e. the reproduction of symptoms only in the first three digits of the affected hand, we estimated sensitivity as 54.17%, specificity as 70%, positive and negative likelihood ratios as 1.8056 and 0.6548, respectively, and post-test probability for positive test as 68%. Our investigation suggests that the reproduction of the typical current CTS symptoms in the affected hand during ULNT1 testing, improves estimation of the probability of the presence of this condition, even if this test alone cannot be used to diagnose CTS. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Bonfiglioli, Roberta; Calabrese, Monica; Marinelli, Francesco; Violante, Francesco Saverio; Pillastrini, Paolo] Alma Mater Studiorum Univ Bologna, Dept Internal Med Geriatr & Nephrol, Sect Occupat Med, I-40138 Bologna, Italy.
[Vanti, Carla] Univ Bologna, Sch Physiotherapy, I-40055 Bologna, Italy.
[Guccione, Andrew] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Off Res & Dev, Washington, DC 20420 USA.
RP Pillastrini, P (reprint author), Alma Mater Studiorum Univ Bologna, Dept Internal Med Geriatr & Nephrol, Sect Occupat Med, Via P Palagi 9, I-40138 Bologna, Italy.
EM cavanti@tin.it; roberta.bonfiglioli@unibo.it;
monica.calabrese5@unibo.it; francesco.marinelli5@unibo.it;
andrewguccione@cox.net; francesco.violante@unibo.it;
paolo.pillastrini@unibo.it
RI Pillastrini, Paolo/R-4901-2016;
OI VANTI, CARLA/0000-0002-7741-9200
NR 55
TC 9
Z9 9
U1 1
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1356-689X
J9 MANUAL THER
JI Man. Ther.
PD JUN
PY 2011
VL 16
IS 3
BP 258
EP 263
DI 10.1016/j.math.2010.11.003
PG 6
WC Rehabilitation
SC Rehabilitation
GA 772AH
UT WOS:000291201300008
PM 21185222
ER
PT J
AU Subramanian, S
Shahaf, G
Ozeri, E
Miller, LM
Vandenbark, AA
Lewis, EC
Offner, H
AF Subramanian, Sandhya
Shahaf, Galit
Ozeri, Eyal
Miller, Lisa M.
Vandenbark, Arthur A.
Lewis, Eli C.
Offner, Halina
TI Sustained expression of circulating human alpha-1 antitrypsin reduces
inflammation, increases CD4+FoxP3+Treg cell population and prevents
signs of experimental autoimmune encephalomyelitis in mice
SO METABOLIC BRAIN DISEASE
LA English
DT Article
DE hAAT; EAE; Tregs; Pro-inflammatory cytokines; CCR6
ID REGULATORY T-CELLS; OBSTRUCTIVE PULMONARY-DISEASE; ALPHA(1)-ANTITRYPSIN
DEFICIENCY; RHEUMATOID-ARTHRITIS; AUGMENTATION THERAPY;
MULTIPLE-SCLEROSIS; ULCERATIVE-COLITIS; DIABETES-MELLITUS; IMPAIRED
ACTIVITY; TH17 RESPONSES
AB Alpha-1-antitrypsin (AAT) is the primary circulating serine protease inhibitor, and is known to exert potent anti-inflammatory effects and to inhibit the progression of several autoimmune diseases. In this study, transgenic mice that over-express surfactant-driven human (h)AAT on the C57BL/6 background were evaluated for resistance to MOG-35-55 peptide-induced experimental autoimmune encephalomyelitis (EAE), compared to WT C57BL/6 control mice. According to the results, sustained levels of circulating hAAT profoundly inhibited induction of clinical signs, inflammatory lesions and demyelination observed in WT mice with EAE, concomitant with enhanced levels of CD4+FoxP3+ Treg cells, reduced secretion of MOG peptide-induced pro-inflammatory cytokines, IL-17, IL-1 beta & IL-6, diminished expression of caspase-1 and enhanced expression of CCR6. These results implicate hAAT as a potent immunoregulatory agent worthy of further investigation as a potential therapy in human autoimmune diseases including multiple sclerosis.
C1 [Subramanian, Sandhya; Miller, Lisa M.; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Neuroimmunol Res RD 31, Portland, OR 97239 USA.
[Shahaf, Galit; Ozeri, Eyal; Lewis, Eli C.] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
[Miller, Lisa M.; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
[Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
RP Offner, H (reprint author), Portland VA Med Ctr, Neuroimmunol Res RD 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
RI LEWIS, ELI/F-1552-2012
FU Biomedical Laboratory R&D Service, Department of Veterans' Affairs;
Israel Science Foundation [1027/07]
FX This work was supported by the Biomedical Laboratory R&D Service,
Department of Veterans' Affairs and the Israel Science Foundation
1027/07.
NR 52
TC 22
Z9 25
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7490
J9 METAB BRAIN DIS
JI Metab. Brain Dis.
PD JUN
PY 2011
VL 26
IS 2
BP 107
EP 113
DI 10.1007/s11011-011-9239-9
PG 7
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 774OT
UT WOS:000291396700002
PM 21437674
ER
PT J
AU Dziennis, S
Mader, S
Akiyoshi, K
Ren, XF
Ayala, P
Burrows, GG
Vandenbark, AA
Herson, PS
Hurn, PD
Offner, HA
AF Dziennis, Suzan
Mader, Sarah
Akiyoshi, Kozaburo
Ren, Xuefang
Ayala, Patricia
Burrows, Gregory G.
Vandenbark, Arthur A.
Herson, Paco S.
Hurn, Patricia D.
Offner, Halina A.
TI Therapy with recombinant T-cell receptor ligand reduces infarct size and
infiltrating inflammatory cells in brain after middle cerebral artery
occlusion in mice
SO METABOLIC BRAIN DISEASE
LA English
DT Article
DE Cerebral ischemia; T-cells; Inflammation; Neuroprotection; Therapeutic
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ISCHEMIC-STROKE; RAT-BRAIN;
MULTIPLE-SCLEROSIS; MESSENGER-RNA; ACTIVATION; CD44; LYMPHOCYTES;
MECHANISMS; EXPRESSION
AB Stroke induces a biphasic effect on the peripheral immune response that involves early activation of peripheral leukocytes followed by severe immunosuppression and atrophy of the spleen. Peripheral immune cells, including T lymphocytes, migrate to the brain and exacerbate the developing infarct. Recombinant T-cell receptor (TCR) Ligand (RTL)551 is designed as a partial TCR agonist for myelin oligodendrocyte glycoprotein (MOG)-reactive T cells and has demonstrated the capacity to limit infarct volume and inflammation in brain when administered to mice undergoing middle cerebral artery occlusion (MCAO). The goal of this study was to determine if RTL551 could retain protection when given within the therapeutically relevant 4 h time window currently in clinical practice for stroke patients. RTL551 was administered subcutaneously 4 h after MCAO, with repeated doses every 24 h until the time of euthanasia. Cell numbers were assessed in the brain, blood, spleen and lymph nodes and infarct size was measured after 24 and 96 h reperfusion. RTL551 reduced infarct size in both cortex and striatum at 24 h and in cortex at 96 h after MCAO and inhibited the accumulation of inflammatory cells in brain at both time points. At 24 h post-MCAO, RTL551 reduced the frequency of the activation marker, CD44, on T-cells in blood and in the ischemic hemisphere. Moreover, RTL551 reduced expression of the chemokine receptors, CCR5 in lymph nodes and spleen, and CCR7 in the blood and lymph nodes. These data demonstrate effective treatment of experimental stroke with RTL551 within a therapeutically relevant 4 h time window through immune regulation of myelin-reactive inflammatory T-cells.
C1 [Offner, Halina A.] Portland VA Med Ctr, Neuroimmunol Res R&D 31, Portland, OR 97239 USA.
[Vandenbark, Arthur A.; Offner, Halina A.] Vet Affairs Med Ctr, Portland, OR 97239 USA.
[Dziennis, Suzan; Mader, Sarah; Akiyoshi, Kozaburo; Ren, Xuefang; Ayala, Patricia; Herson, Paco S.; Hurn, Patricia D.; Offner, Halina A.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
[Burrows, Gregory G.; Vandenbark, Arthur A.; Offner, Halina A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
[Burrows, Gregory G.] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.
RP Offner, HA (reprint author), Portland VA Med Ctr, Neuroimmunol Res R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM offnerva@ohsu.edu
FU NIH [NR003521, NS047661]; Collins Medical Trust; AHA [09POST2190040];
Biomedical Laboratory R&D Service, Department of Veterans' Affairs
FX The authors wish to thank Dr. Sushmita Sinha and Ms. Sandhya Subramanian
for helpful discussions and Ms. Eva Niehaus for assistance in preparing
the manuscript. This work was supported by NIH Grant NR003521 (PDH), NIH
Grant NS047661 (AAV), the Collins Medical Trust (SD), AHA grant
09POST2190040 (SD), and the Biomedical Laboratory R&D Service,
Department of Veterans' Affairs.
NR 40
TC 19
Z9 19
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7490
J9 METAB BRAIN DIS
JI Metab. Brain Dis.
PD JUN
PY 2011
VL 26
IS 2
BP 123
EP 133
DI 10.1007/s11011-011-9241-2
PG 11
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 774OT
UT WOS:000291396700004
PM 21472429
ER
PT J
AU Niers, JM
Kerami, M
Pike, L
Lewandrowski, G
Tannous, BA
AF Niers, Johanna M.
Kerami, Mariam
Pike, Lisa
Lewandrowski, Grant
Tannous, Bakhos A.
TI Multimodal In Vivo Imaging and Blood Monitoring of Intrinsic and
Extrinsic Apoptosis
SO MOLECULAR THERAPY
LA English
DT Article
ID GAUSSIA LUCIFERASE; CASPASE-3 ACTIVATION; CANCER-THERAPY; PROTEASES;
NECROSIS; CULTURE; STRESS; CELLS; ASSAY
AB Noninvasive detection and in vivo imaging of apoptosis plays a critical role in the development of therapeutics in many different fields including cancer. We have developed an apoptosis biosensor by fusing green fluorescent protein (GFP) to the N-terminus of the naturally secreted Gaussia luciferase separated by a caspase-3 cleavage peptide consisting of aspartic acid (D), glutamic acid (E), valine (V), and aspartic acid (D) or DEVD. We showed that this fusion is retained in the cytoplasm of cells in an inactive form. Upon apoptosis, the DEVD peptide is cleaved in response to caspase-3 activation, freeing ssGluc, which can now enter the secretory pathway where it is folded properly and is released from the cells and can be detected in the conditioned medium in culture or in blood of live animals ex vivo over time. Because Gluc is secreted from cells via conventional pathway through the endoplasmic reticulum (ER), Golgi and vesicles, we showed that the presence of Gluc in these compartments in response to apoptosis can be visualized in vivo using bioluminescence imaging. This reporter provides a valuable tool for imaging and real-time monitoring of apoptosis and is compatible with high-throughput functional screening application in cultured cells and animal models.
C1 [Niers, Johanna M.; Kerami, Mariam; Pike, Lisa; Lewandrowski, Grant; Tannous, Bakhos A.] Massachusetts Gen Hosp, Ctr Neurosci, Dept Neurol, Charlestown, MA 02129 USA.
[Niers, Johanna M.; Kerami, Mariam] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Neurosurg, Neurooncol Res Grp, Amsterdam, Netherlands.
[Tannous, Bakhos A.] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Dept Radiol, Charlestown, MA 02129 USA.
[Tannous, Bakhos A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
RP Tannous, BA (reprint author), Massachusetts Gen Hosp, Ctr Neurosci, Dept Neurol, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM btannous@hms.harvard.edu
FU NIH/NCI [P50CA86355]; NIH/NINDS [1R21NS061051, 1R01NS064983,
P30NS045776]
FX This work was supported partly by grants from NIH/NCI P50CA86355,
NIH/NINDS 1R21NS061051, 1R01NS064983 and P30NS045776. We thank Dr Ralph
Weissleder, Director of the Center for Molecular Imaging Research-MGH
for the use of the CCD cameral; Dr Rampyari Walia (Targeting Systems)
for cloning the GFP-DEVD-Gluc fusion in pCMV plasmid; Dr Xandra
Breakefield for scientific discussions; Ms Lee-Ann Tjon-Kon-Fat for
technical assistance; and Dr Euiheon Chung for assistance with the
breast cancer metastasis model.
NR 24
TC 23
Z9 23
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD JUN
PY 2011
VL 19
IS 6
BP 1090
EP 1096
DI 10.1038/mt.2011.17
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 772PA
UT WOS:000291244900012
PM 21343914
ER
PT J
AU Pinto, D
Darvishi, K
Shi, XH
Rajan, D
Rigler, D
Fitzgerald, T
Lionel, AC
Thiruvahindrapuram, B
MacDonald, JR
Mills, R
Prasad, A
Noonan, K
Gribble, S
Prigmore, E
Donahoe, PK
Smith, RS
Park, JH
Hurles, ME
Carter, NP
Lee, C
Scherer, SW
Feuk, L
AF Pinto, Dalila
Darvishi, Katayoon
Shi, Xinghua
Rajan, Diana
Rigler, Diane
Fitzgerald, Tom
Lionel, Anath C.
Thiruvahindrapuram, Bhooma
MacDonald, Jeffrey R.
Mills, Ryan
Prasad, Aparna
Noonan, Kristin
Gribble, Susan
Prigmore, Elena
Donahoe, Patricia K.
Smith, Richard S.
Park, Ji Hyeon
Hurles, Matthew E.
Carter, Nigel P.
Lee, Charles
Scherer, Stephen W.
Feuk, Lars
TI Comprehensive assessment of array-based platforms and calling algorithms
for detection of copy number variants
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; STRUCTURAL VARIATION; MICROARRAY
PLATFORMS; RESOLUTION ANALYSIS; SPECTRUM; CGH; POLYMORPHISMS;
CHROMOSOMES; ASSOCIATION; DIAGNOSTICS
AB We have systematically compared copy number variant (CNV) detection on eleven microarrays to evaluate data quality and CNV calling, reproducibility, concordance across array platforms and laboratory sites, breakpoint accuracy and analysis tool variability. Different analytic tools applied to the same raw data typically yield CNV calls with <50% concordance. Moreover, reproducibility in replicate experiments is <70% for most platforms. Nevertheless, these findings should not preclude detection of large CNVs for clinical diagnostic purposes because large CNVs with poor reproducibility are found primarily in complex genomic regions and would typically be removed by standard clinical data curation. The striking differences between CNV calls from different platforms and analytic tools highlight the importance of careful assessment of experimental design in discovery and association studies and of strict data curation and filtering in diagnostics. The CNV resource presented here allows independent data evaluation and provides a means to benchmark new algorithms.
C1 [Feuk, Lars] Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, SciLifeLab Uppsala, Uppsala, Sweden.
[Pinto, Dalila; Lionel, Anath C.; Thiruvahindrapuram, Bhooma; MacDonald, Jeffrey R.; Prasad, Aparna; Scherer, Stephen W.] Hosp Sick Children, Ctr Appl Genom, Toronto, ON M5G 1X8, Canada.
[Darvishi, Katayoon; Shi, Xinghua; Mills, Ryan; Noonan, Kristin; Smith, Richard S.; Park, Ji Hyeon; Lee, Charles] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Rajan, Diana; Rigler, Diane; Fitzgerald, Tom; Gribble, Susan; Prigmore, Elena; Hurles, Matthew E.; Carter, Nigel P.] Sanger Inst, Cambridge, England.
[Noonan, Kristin; Donahoe, Patricia K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Scherer, Stephen W.] Univ Toronto, McLaughlin Ctr, Toronto, ON, Canada.
[Scherer, Stephen W.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
RP Feuk, L (reprint author), Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, SciLifeLab Uppsala, Uppsala, Sweden.
EM lars.feuk@igp.uu.se
RI Howe, Jennifer/I-9013-2012; Scherer, Stephen /B-3785-2013; Prasad,
Aparna/N-4253-2015; Mills, Ryan/A-1979-2011;
OI Scherer, Stephen /0000-0002-8326-1999; Prasad,
Aparna/0000-0002-6786-2313; Mills, Ryan/0000-0003-3425-6998; Fitzgerald,
Tomas/0000-0002-2370-8496
FU Genome Canada/Ontario Genomics Institute; Canadian Institutes of Health
Research (CIHR) [213997]; McLaughlin Centre; Canadian Institute of
Advanced Research; Hospital for Sick Children (SickKids) Foundation; US
National Institutes of Health (NIH) [HD055150]; Department of Pathology
at Brigham and Women's Hospital in Boston and NIH [HG005209, HG004221,
CA111560]; Wellcome Trust [WT077008]; Netherlands Organization for
Scientific Research [Rubicon 825.06.031]; Harvard Medical School; Goran
Gustafsson Foundation; Swedish Foundation for Strategic Research;
[HD007396]
FX We thank J. Rickaby and M. Lee for excellent technical assistance. We
thank colleagues at Affymetrix, Agilent, Illumina and NimbleGen, and
Biodiscovery for sharing data, sharing software and technical
assistance. The Toronto Centre for Applied Genomics at the Hospital for
Sick Children is acknowledged for database, technical assistance and
bioinformatics support. This work was supported by funding from the
Genome Canada/Ontario Genomics Institute, the Canadian Institutes of
Health Research (CIHR), the McLaughlin Centre, the Canadian Institute of
Advanced Research, the Hospital for Sick Children (SickKids) Foundation,
a Broad SPARC Project award to P.K.D. and C.L., US National Institutes
of Health (NIH) grant HD055150 to P.K.D., and the Department of
Pathology at Brigham and Women's Hospital in Boston and NIH grants
HG005209, HG004221 and CA111560 to C.L. N.P.C., D. Rajan, D. Rigler,
T.F., S.G. and E.P. are supported by the Wellcome Trust (grant no.
WT077008). D.P. is supported by fellowships from the Canadian Institutes
of Health Research (no. 213997) and the Netherlands Organization for
Scientific Research (Rubicon 825.06.031). X.S. is supported by a T32
Harvard Medical School training grant, and K.N. is supported by a T32
institutional training grant (HD007396). S.W.S. holds the
GlaxoSmithKline-CIHR Pathfinder Chair in Genetics and Genomics at the
University of Toronto and the Hospital for Sick Children (Canada). L.F.
is supported by the Goran Gustafsson Foundation and the Swedish
Foundation for Strategic Research.
NR 49
TC 186
Z9 193
U1 2
U2 27
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD JUN
PY 2011
VL 29
IS 6
BP 512
EP U76
DI 10.1038/nbt.1852
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 773WL
UT WOS:000291342100017
PM 21552272
ER
PT J
AU Baba, A
Ohtake, F
Okuno, Y
Yokota, K
Okada, M
Imai, Y
Ni, M
Meyer, CA
Igarashi, K
Kanno, J
Brown, M
Kato, S
AF Baba, Atsushi
Ohtake, Fumiaki
Okuno, Yosuke
Yokota, Kenichi
Okada, Maiko
Imai, Yuuki
Ni, Min
Meyer, Clifford A.
Igarashi, Katsuhide
Kanno, Jun
Brown, Myles
Kato, Shigeaki
TI PKA-dependent regulation of the histone lysine demethylase complex
PHF2-ARID5B
SO NATURE CELL BIOLOGY
LA English
DT Article
ID DOMAIN-CONTAINING PROTEINS; HEPATIC GLUCONEOGENESIS; CHROMATIN
MODIFICATIONS; GLUCOSE-METABOLISM; NUCLEAR RECEPTORS; DIOXIN RECEPTOR;
TRANSCRIPTION; COACTIVATOR; FAMILY; PGC-1
AB Reversible histone methylation and demethylation are highly regulated processes that are crucial for chromatin reorganization and regulation of gene transcription in response to extracellular conditions. However, the mechanisms that regulate histone-modifying enzymes are largely unknown. Here, we characterized a protein kinase A (PKA)-dependent histone lysine demethylase complex, PHF2-ARID5B. PHF2, a jmjC demethylase, is enzymatically inactive by itself, but becomes an active H3K9Me2 demethylase through PKA-mediated phosphorylation. We found that phosphorylated PHF2 then associates with ARID5B, a DNA-binding protein, and induce demethylation of methylated ARID5B. This modification leads to targeting of the PHF2 ARID5B complex to its target promoters, where it removes the repressive H3K9Me2 mark. These findings suggest that the PHF2 ARID5B complex is a signal-sensing modulator of histone methylation and gene transcription, in which phosphorylation of PHF2 enables subsequent formation of a competent and specific histone demethylase complex.
C1 [Baba, Atsushi; Ohtake, Fumiaki; Okuno, Yosuke; Yokota, Kenichi; Okada, Maiko; Imai, Yuuki; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
[Ohtake, Fumiaki; Okuno, Yosuke; Okada, Maiko; Kato, Shigeaki] Japan Sci & Technol Agcy, ERATO, Kawaguchishi, Saitama 3320012, Japan.
[Imai, Yuuki; Ni, Min; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Imai, Yuuki; Ni, Min; Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Meyer, Clifford A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Meyer, Clifford A.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Igarashi, Katsuhide; Kanno, Jun] Natl Inst Hlth Sci, Div Cellular & Mol Toxicol, Setagaya Ku, Tokyo 1588501, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
OI Brown, Myles/0000-0002-8213-1658
FU Ministry of Education, Culture, Sports, Science and Technology, MEXT,
Japan; JSPS; Naito Foundation
FX We thank D. D. Moore for critical discussion, R. Sato and J. Inoue for
providing materials, N. Moriyama and S. Fujiyama for technical
assistance and M. Yamaki for manuscript preparation. This work was
supported in part by Priority Areas from the Ministry of Education,
Culture, Sports, Science and Technology, MEXT, Japan, JSPS, and The
Naito Foundation (to F.O. and S.K.).
NR 37
TC 61
Z9 66
U1 6
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD JUN
PY 2011
VL 13
IS 6
BP 668
EP U101
DI 10.1038/ncb2228
PG 23
WC Cell Biology
SC Cell Biology
GA 771HI
UT WOS:000291147400007
PM 21532585
ER
PT J
AU Saylor, PJ
AF Saylor, Philip J.
TI Denosumab-a new option for solid tumors metastatic to bone
SO NATURE REVIEWS CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID MULTIPLE-MYELOMA; ZOLEDRONIC ACID; BREAST-CANCER; LIGAND
AB Zoledronic acid is a potent bisphosphonate used as the standard therapy for the prevention of skeletal-related events in patients with solid tumors metastatic to bone. Three phase III studies have reported head-to-head comparisons of zoledronic acid with denosumab, an inhibitor of the RANK signaling pathway.
C1 Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, Boston, MA 02114 USA.
RP Saylor, PJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, 55 Fruit St,Yawkey 7E Boston, Boston, MA 02114 USA.
EM psaylor@partners.org
NR 10
TC 1
Z9 1
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4774
J9 NAT REV CLIN ONCOL
JI Nat. Rev. Clin. Oncol.
PD JUN
PY 2011
VL 8
IS 6
BP 322
EP 324
DI 10.1038/nrclinonc.2011.70
PG 4
WC Oncology
SC Oncology
GA 771ZM
UT WOS:000291199200004
PM 21556026
ER
PT J
AU Eichler, AF
Chung, E
Kodack, DP
Loeffler, JS
Fukumura, D
Jain, RK
AF Eichler, April F.
Chung, Euiheon
Kodack, David P.
Loeffler, Jay S.
Fukumura, Dai
Jain, Rakesh K.
TI The biology of brain metastases-translation to new therapies
SO NATURE REVIEWS CLINICAL ONCOLOGY
LA English
DT Review
ID CELL LUNG-CANCER; HUMAN BREAST-CANCER; ENDOTHELIAL GROWTH-FACTOR;
P-GLYCOPROTEIN INHIBITOR; II RANDOMIZED-TRIAL; ATHYMIC NUDE-MICE;
STEM-LIKE CELLS; RADIATION-THERAPY; PHASE-III; IN-VIVO
AB Brain metastases are a serious obstacle in the treatment of patients with solid tumors and contribute to the morbidity and mortality of these cancers. It is speculated that the frequency of brain metastasis is increasing for several reasons, including improved systemic therapy and survival, and detection of metastases in asymptomatic patients. The lack of preclinical models that recapitulate the clinical setting and the exclusion of patients with brain metastases from most clinical trials have slowed progress. Molecular factors contributing to brain metastases are being elucidated, such as genes involved in cell adhesion, extravasation, metabolism, and cellular signaling. Furthermore, the role of the unique brain microenvironment is beginning to be explored. Although the presence and function of the blood-brain barrier in metastatic tumors is still poorly understood, it is likely that some tumor cells are protected from therapeutics by the blood-tumor barrier, creating a sanctuary site. This Review discusses what is known about the biology of brain metastases, what preclinical models are available to study the disease, and which novel therapeutic strategies are being studied in patients.
C1 [Eichler, April F.; Jain, Rakesh K.] Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
OI Chung, Euiheon/0000-0002-3326-6927
FU National Institutes of Health [P01-CA080124, R01-CA085140, R01-CA115767,
R01-CA126642, R01-CA096915, R21-CA135605, U01-CA062490]; Federal Share
Income Grant [T32-CA073479]; Department of Defense Breast Cancer
Research [W81XWH-10-1-0016]; Massachusetts Biomedical Research
Corporation; Gwangju Institute of Science and Technology, Gwangju,
Republic of Korea
FX We thank J. Engelman, S. Goel, L. Xu, I. J. Fidler, R. S. Kerbel, W.
Cruz-Munoz and S. Mohla for their helpful comments on the manuscript.
This work was supported by the National Institutes of Health grants
P01-CA080124 (R. K. Jain and D. Fukumura), R01-CA085140, R01-CA115767
and R01-CA126642 (R. K. Jain), R01-CA096915 (D. Fukumura), R21-CA135605
and U01-CA062490 (A. F. Eichler), a Federal Share Income Grant (R. K.
Jain and D. Fukumura), T32-CA073479 (D. P. Kodak) and Department of
Defense Breast Cancer Research Innovator Award W81XWH-10-1-0016 (R. K.
Jain). E. Chung was supported by a Tosteson postdoctoral fellowship
award from the Massachusetts Biomedical Research Corporation. E. Chung
also acknowledges support from his current institute: Gwangju Institute
of Science and Technology, Gwangju, Republic of Korea.
NR 156
TC 139
Z9 141
U1 4
U2 32
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4774
EI 1759-4782
J9 NAT REV CLIN ONCOL
JI Nat. Rev. Clin. Oncol.
PD JUN
PY 2011
VL 8
IS 6
BP 344
EP 356
DI 10.1038/nrclinonc.2011.58
PG 13
WC Oncology
SC Oncology
GA 771ZM
UT WOS:000291199200007
PM 21487419
ER
PT J
AU Carmeliet, P
Jain, RK
AF Carmeliet, Peter
Jain, Rakesh K.
TI Principles and mechanisms of vessel normalization for cancer and other
angiogenic diseases
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR VASCULATURE; BLOOD-VESSELS;
ANTIANGIOGENIC THERAPY; RECTAL-CANCER; SOLID TUMORS; SHORT-TERM;
INTERSTITIAL HYPERTENSION; GLIOBLASTOMA PATIENTS; IONIZING-RADIATION
C1 [Carmeliet, Peter] Katholieke Univ Leuven VIB, Vesalius Res Ctr, B-3000 Louvain, Belgium.
[Jain, Rakesh K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Edwin L Steele Lab Tumour Biol,Dept Radiat Oncol, Boston, MA 02114 USA.
RP Carmeliet, P (reprint author), Katholieke Univ Leuven VIB, Vesalius Res Ctr, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.
EM peter.carmeliet@vib-kuleuven.be; jain@steele.mgh.harvard.edu
FU NCI NIH HHS [R01-CA115767, P01-CA80124, R01-CA126642, R01-CA85140]
NR 126
TC 473
Z9 483
U1 8
U2 103
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
EI 1474-1784
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD JUN
PY 2011
VL 10
IS 6
BP 417
EP 427
DI 10.1038/nrd3455
PG 11
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 771NE
UT WOS:000291165000019
PM 21629292
ER
PT J
AU Byers, AL
Yaffe, K
AF Byers, Amy L.
Yaffe, Kristine
TI Depression and risk of developing dementia
SO NATURE REVIEWS NEUROLOGY
LA English
DT Review
ID MILD COGNITIVE IMPAIRMENT; LATE-LIFE DEPRESSION; WHITE-MATTER
HYPERINTENSITIES; ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME; MAJOR
DEPRESSION; GERIATRIC DEPRESSION; NEUROTROPHIC FACTOR;
CEREBROVASCULAR-DISEASE; VASCULAR DEPRESSION
AB Depression is highly common throughout the life course and dementia is common in late life. Depression has been linked with dementia, and growing evidence implies that the timing of depression may be important in defining the nature of this association. In particular, earlier-life depression (or depressive symptoms) has consistently been associated with a more than twofold increase in dementia risk. By contrast, studies of late-life depression and dementia risk have been conflicting; most support an association, yet the nature of this association (for example, if depression is a prodrome or consequence of, or risk factor for dementia) remains unclear. The likely biological mechanisms linking depression to dementia include vascular disease, alterations in glucocorticoid steroid levels and hippocampal atrophy, increased deposition of amyloid-beta plaques, inflammatory changes, and deficits of nerve growth factors. Treatment strategies for depression could interfere with these pathways and alter the risk of dementia. Given the projected increase in dementia incidence in the coming decades, understanding whether treatment for depression alone, or combined with other regimens, improves cognition is of critical importance. In this Review, we summarize and analyze current evidence linking late-life and earlier-life depression and dementia, and discuss the primary underlying mechanisms and implications for treatment.
C1 [Byers, Amy L.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Byers, Amy L.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Byers, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,116H, San Francisco, CA 94121 USA.
EM amy.byers@ucsf.edu
FU National Institute of Mental Health [K01 MH079093, R01 MH086498];
National Institute on Aging [K24 AG031155]
FX This work was supported by the National Institute of Mental Health
(grant K01 MH079093 to A. L. Byers and R01 MH086498 to K. Yaffe) and the
National Institute on Aging (grant K24 AG031155 to K. Yaffe).
NR 128
TC 168
Z9 177
U1 5
U2 46
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD JUN
PY 2011
VL 7
IS 6
BP 323
EP 331
DI 10.1038/nrneurol.2011.60
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 774LM
UT WOS:000291387500008
PM 21537355
ER
PT J
AU Waubant, E
Mowry, EM
Krupp, L
Chitnis, T
Yeh, EA
Kuntz, N
Ness, J
Chabas, D
Strober, J
McDonald, J
Belman, A
Milazzo, M
Gorman, M
Weinstock-Guttman, B
Rodriguez, M
Oksenberg, JR
James, JA
AF Waubant, E.
Mowry, E. M.
Krupp, L.
Chitnis, T.
Yeh, E. A.
Kuntz, N.
Ness, J.
Chabas, D.
Strober, J.
McDonald, J.
Belman, A.
Milazzo, M.
Gorman, M.
Weinstock-Guttman, B.
Rodriguez, M.
Oksenberg, J. R.
James, J. A.
CA US Pediat MS Network
TI Common viruses associated with lower pediatric multiple sclerosis risk
SO NEUROLOGY
LA English
DT Article
ID EPSTEIN-BARR-VIRUS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ENVIRONMENTAL SUN
EXPOSURE; INFECTION; HLA-DRB1-ASTERISK-1501; ANTIBODIES; RECEPTOR;
CHILDREN; LOCUS
AB Background: Because common viruses are encountered during childhood, pediatric multiple sclerosis (MS) offers a unique opportunity to investigate the influence of these viruses on disease susceptibility and the interactions between seroprevalence and select HLA genotypes. We studied seroprevalence for Epstein-Barr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus (HSV) type 1 and HLA-DRB1*1501/1503 status as predictors of pediatric MS.
Methods: This was a retrospective analysis of prospectively collected demographic, clinical, and biologic data in subjects up to 18 years of age with early MS, control subjects seen at the same regional referral pediatric MS clinics, and additional healthy pediatric control subjects.
Results: Patients with early pediatric MS (n = 189) and pediatric control subjects (n = 66) were tested. Epstein-Barr nuclear antigen-1 seropositivity was associated with an increased odds of MS (odds ratio [OR] 3.78, 95% confidence interval [CI] 1.52-9.38, p = 0.004) in analyses adjusted for age, sex, race, ethnicity, and HLA-DRB1*1501/1503 status. In multivariate analyses including EBV status, a remote infection with CMV (OR 0.27,95% CI 0.11-0.67, p = 0.004) was associated with a lower risk of developing MS. Although a remote infection with HSV-1 was not associated with an increased odds of MS, a strong interaction was found between HSV-1 status and HLA-DRB1 in predicting MS (p < 0.001). HSV-1 was associated with an increased risk of MS in those without a DRB1*15 allele (OR 4.11, 95% CI 1.17-14.37, p = 0.03), whereas the effect was reversed in those who were DRB1*15-positive (OR 0.07, 95% CI 0.02-0.32, p = 0.001).
Conclusions: These findings suggest that some infections with common viruses may in fact lower MS susceptibility. If this is confirmed, the pathways for risk modification remain to be elucidated. Neurology (R) 2011;76:1989-1995
C1 [Waubant, E.; Chabas, D.; Strober, J.; McDonald, J.] Univ Calif San Francisco, UCSF Reg Pediat MS Ctr, San Francisco, CA 94143 USA.
[Waubant, E.; Mowry, E. M.; Oksenberg, J. R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Krupp, L.; Belman, A.; Milazzo, M.] Natl Pediat MS Ctr, Stony Brook, NY USA.
[Chitnis, T.; Gorman, M.] Massachusetts Gen Hosp, Partners Pediat MS Ctr, Boston, MA 02114 USA.
[Yeh, E. A.; Weinstock-Guttman, B.] Buffalo Pediat MS Ctr, Buffalo, NY USA.
[Kuntz, N.; Rodriguez, M.] Mayo Clin, Pediat MS Ctr, Rochester, MN USA.
[Ness, J.] Alabama Pediat MS Ctr, Birmingham, AL USA.
[James, J. A.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
[James, J. A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
RP Waubant, E (reprint author), UCSF Reg Pediat Multiple Sclerosis Ctr, 350 Parnassus Ave,Suite 908, San Francisco, CA 94117 USA.
EM emmanuelle.waubant@ucsf.edu
OI Rodriguez, Moses/0000-0001-6328-6497
FU National Multiple Sclerosis Society; University of California; San
Francisco; Stony Brook; Buffalo; University of Alabama Birmingham;
Harvard University; Mayo Clinic; NIH [K23NS067055, RR015577, AI082714,
U19AI082714, AR053483]; Nancy Davis Foundation; NMSS [RG2901D9/1];
National MS Society; National NS Society; Partners MS Center; Acorda
Therapeutics Inc.; Bayer Schering Pharma; Biogen Idec; EMD Serono, Inc.;
Genentech, Inc.; Teva Pharmaceutical Industries Ltd.; Novartis;
sanofi-aventis; GlaxoSmithKline; MS Association of America; France
Foundation; Eli Lilly and Company; MedImmune; Vertex Pharmaceuticals;
Wyeth; ZymoGenetics; EPI-Q; Genzyme Corporation; Tibotec Therapeutics;
Roche; Johnson Johnson; Janssen; ER Squibb Sons; NIH/NINDS; NIH; Jake
Foundation; Children's Guild Foundation; Spinal Muscular Atrophy
Foundation; Cooperative International Neuromuscular Research Group/U. S.
Department of Education; Pfizer Inc; Mayo Rehabilitation Research
Training Center; Conrad Hilton Foundation; Donald and Frances Herdrich
Foundation; Canadian MS Society; Morphotek
FX The Pediatric MS Network, initiated and sponsored by the National
Multiple Sclerosis Society, includes the following centers: University
of California, San Francisco, Stony Brook, Buffalo, University of
Alabama Birmingham, Harvard University, and the Mayo Clinic. Dr. Mowry
has a National MS Society Sylvia Lawry Fellowship Award and an NIH
K23NS067055. Dr. Waubant is also supported by the Nancy Davis
Foundation. Dr. James is supported by NIH RR015577, AI082714,
U19AI082714, and AR053483. Dr. Oksenberg is supported by NMSS
RG2901D9/1.; Dr. Waubant serves on scientific advisory boards for the
NIH and Actelion Pharmaceuticals Ltd; has received speaker honoraria
from Teva Pharmaceutical Industries Ltd.; has served as a consultant for
Actelion Pharmaceuticals Ltd., Roche, and sanofi-aventis; has received
free drugs for ongoing trials from sanofi-aventis and Biogen Idec; and
receives research support from the NIH, the National MS Society, and the
Nancy Davis Foundation. Dr. Mowry receives research support from the
NIH, the National NS Society, and Partners MS Center. Dr. Krupp has
served on scientific advisory boards for Acorda Therapeutics Inc.,
Genentech, Inc., Pfizer Inc, Novartis, and sanofi-aventis; has received
funding for travel from Acorda Therapeutics Inc., Bayer Schering Pharma,
Biogen Idec, EMD Serono, Inc., Genentech, Inc., Teva Pharmaceutical
Industries Ltd., Novartis, and sanofi-aventis; has received honoraria
from Acorda Therapeutics Inc., Bayer Schering Pharma, EMD Serono, Inc.,
Biogen Idec, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, the
MS Association of America, and the France Foundation; has received
royalties for publication of Fatigue in Multiple Sclerosis (Demos,
2005); serves as consultant for Leerink Swan, Gerson Lehrman Group, and
Guidepoint Global; serves on speakers' bureaus for Bayer Schering
Pharma, Biogen Idec, Teva Pharmaceutical Industries Ltd., and EMD
Serono, Inc.; receives research support from Biogen Idec, EMD Serono,
Inc., Teva Pharmaceutical Industries Ltd., Novartis, Genentech, Inc.,
Acorda Therapeutics Inc., BioMS Medical, the NIH (HD38107-02 [PI]), the
National MS Society, the Lourie Foundation, and the Slomo and Cindy
Silvian Foundation; has received license fee payments for a
questionnaire she developed from the following companies: Eli Lilly and
Company, MedImmune, Vertex Pharmaceuticals, Wyeth, ZymoGenetics, EPI-Q,
Novartis, Genzyme Corporation, Tibotec Therapeutics, Genentech, Inc.,
Roche, sanofi-aventis, Johnson & Johnson, Janssen, and ER Squibb & Sons;
and has served as an expert witness in medico-legal cases. Dr. Chitnis
has served as a consultant for Biogen Idec, Teva Pharmaceutical
Industries Ltd., and EMD Serono, Inc.; and receives research support
from EMD Serono, Inc., the NIH/NINDS, and the National MS Society; and
her spouse is employed by Novartis. Dr. Yeh has received research
support from the NIH, the Jog for the Jake Foundation, the Children's
Guild Foundation, and the National MS Society. Dr. Kuntz has received
research support from the National MS Society, the Spinal Muscular
Atrophy Foundation, Cooperative International Neuromuscular Research
Group/U. S. Department of Education, and the NIH. Dr. Ness has served as
a consultant for Merck Serono and receives research support from the
NIH/NINDS, EMD Serono, Inc., and the National MS Society. Dr. Chabas has
received honoraria from Teva Pharmaceutical Industries Ltd., EMD Serono,
Inc., and Pfizer Inc; has received license fee payments and may accrue
revenue on office of technology licensing Stanford Docket 501-085
(issued 5/6/2003): Osteopontin Related Compositions and Methods; and
receives research support from the National MS Society and the Nancy
Davis Foundation. Dr. Strober, J. McDonald, and Dr. Belman report no
disclosures. M. Milazzo has received honoraria from Teva Pharmaceutical
Industries Ltd. Dr. Gorman receives research support from the National
MS Society. Dr.; Weinstock-Guttman serves on a medical advisory board
for the National MS Society; has received funding for travel, serves on
a speakers' bureau, and/or serves as a consultant to Bioge Idec, Teva
Pharmaceutical Industries Ltd., EMD Serono, Inc., Pfizer Inc, Novartis,
and Acorda Therapeutics Inc.; serves on the editorial boards of aan.com
and Multiple Sclerosis International; and receives research support from
Biogen Idec, EMD Serono, Inc., Teva Pharmaceutical Industries Ltd.,
Cyberonics, Inc., Novartis, Acorda Therapeutics Inc., the NIH, the
National Science Foundation, the Jog for the Jake Foundation, and the
National MS Society. Dr. Rodriguez serves on scientific advisory boards
for the NIH/NINDS and Fast Forward LLC; serves on editorial advisory
boards of the Annals of Neurology, Brain Pathology, the Journal of
Neurovirology, and VerusMed; receives royalties from publication of
Advances in Multiple Sclerosis (Current Topics in Microbiology and
Immunology, vol. 318) (Springer-Verlag, 2008); may accrue revenue on
patents re: Monoclonal Antibodies Which Promote Central Nervous System
Remyelination and Method of Treating Autoimmune and/or Viral Induced
Diseases That Are Mediated by CD8 Phenotype T Cells; and receives
research support from Acorda Therapeutics, Inc., Mayo Rehabilitation
Research Training Center, the NIH, the National MS Society, the Conrad
Hilton Foundation, the Donald and Frances Herdrich Foundation, and the
Canadian MS Society. Dr. Oksenberg serves as an Associate Editor for
Annals of Neurology and receives research support from the NIH and the
National MS Society. Dr. James serves on a scientific advisory board for
InNexus Biotechnology, Inc.; serves as a consultant and on the speakers'
bureaus for and has received speaker honoraria from Pfizer Inc and
Novartis; and receives research support from Morphotek and the NIH.
NR 28
TC 40
Z9 42
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUN
PY 2011
VL 76
IS 23
BP 1989
EP 1995
DI 10.1212/WNL.0b013e31821e552a
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 773WZ
UT WOS:000291343500011
PM 21646624
ER
PT J
AU Walcott, BP
Nahed, BV
Kahle, KT
Redjal, N
Coumans, JV
AF Walcott, Brian P.
Nahed, Brian V.
Kahle, Kristopher T.
Redjal, Navid
Coumans, Jean-Valery
TI Determination of geographic variance in stroke prevalence using Internet
search engine analytics
SO NEUROSURGICAL FOCUS
LA English
DT Article
DE search engine; stroke; epidemiology; prevalence; public health
AB Object. Previous methods to determine stroke prevalence, such as nationwide surveys, are labor-intensive endeavors. Recent advances in search engine query analytics have led to a new metric for disease surveillance to evaluate symptomatic phenomenon, such as influenza. The authors hypothesized that the use of search engine query data can determine the prevalence of stroke.
Methods. The Google Insights for Search database was accessed to analyze anonymized search engine query data. The authors' search strategy utilized common search queries used when attempting either to identify the signs and symptoms of a stroke or to perform stroke education. The search logic was as follows: (stroke signs + stroke symptoms + mini stroke - heat) from January 1, 2005, to December 31, 2010.
The relative number of searches performed (the interest level) for this search logic was established for all 50 states and the District of Columbia. A Pearson product-moment correlation coefficient was calculated from the state-specific stroke prevalence data previously reported.
Results. Web search engine interest level was available for all 50 states and the District of Columbia over the time period for January 1, 2005-December 31, 2010. The interest level was highest in Alabama and Tennessee (100 and 96, respectively) and lowest in California and Virginia (58 and 53, respectively). The Pearson correlation coefficient (r) was calculated to be 0.47 (p = 0.0005, 2-tailed).
Conclusions. Search engine query data analysis allows for the determination of relative stroke prevalence. Further investigation will reveal the reliability of this metric to determine temporal pattern analysis and prevalence in this and other symptomatic diseases. (DOI: 10.3171/2011.2.FOCUS1124)
C1 [Walcott, Brian P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Walcott, BP (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg,Room 502, Boston, MA 02114 USA.
EM walcott.brian@mgh.harvard.edu
NR 10
TC 6
Z9 6
U1 1
U2 6
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 1092-0684
J9 NEUROSURG FOCUS
JI Neurosurg. Focus
PD JUN
PY 2011
VL 30
IS 6
AR E19
DI 10.3171/2011.2.FOCUS1124
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 771NF
UT WOS:000291165100020
PM 21631220
ER
PT J
AU Foster, MC
Hwang, SJ
Massaro, JM
Hoffmann, U
DeBoer, IH
Robins, SJ
Vasan, RS
Fox, CS
AF Foster, Meredith C.
Hwang, Shih-Jen
Massaro, Joseph M.
Hoffmann, Udo
DeBoer, Ian H.
Robins, Sander J.
Vasan, Ramachandran S.
Fox, Caroline S.
TI Association of Subcutaneous and Visceral Adiposity With Albuminuria: The
Framingham Heart Study
SO OBESITY
LA English
DT Article
ID BODY-FAT DISTRIBUTION; CHRONIC KIDNEY-DISEASE; METABOLIC RISK-FACTORS;
INSULIN SENSITIVITY; DIABETES-MELLITUS; CENTRAL OBESITY;
SEX-DIFFERENCES; TISSUE VOLUMES; RENAL-DISEASE; ALL-CAUSE
AB Microalbuminuria is a common condition associated with increased incidence of cardiovascular events and mortality. Abdominal obesity is associated with microalbuminuria, but studies linking visceral adipose tissue (VAT) and microalbuminuria are limited. Our objective was to determine the associations of albuminuria with VAT and subcutaneous adipose tissue (SAT). We performed a cross-sectional study in the Framingham Multi-Detector Computed Tomography (MDCT) cohort (n = 3,099, 48.2% women, mean age 53 years). VAT and SAT volumes were measured using computed tomography. Urinary albumin-to-creatinine ratio (UACR) was calculated from spot urine samples. Microalbuminuria was defined as a UACR >25 mg/g in women or >17 mg/g in men. Overall, 7.9% (n = 244) of the sample had microalbuminuria. Among men, VAT (odds ratio (OR) 1.48 per s.d., P < 0.0001) and SAT (OR 1.37 per s.d., P = 0.0002) were associated with microalbuminuria in minimally adjusted models, which remained significant after multivariable adjustment (VAT OR 1.34 per s.d., P = 0.001; SAT OR 1.28 per s.d., P = 0.005). Additionally, when considered jointly, VAT (P = 0.002) but not SAT (P = 0.2) was associated with microalbuminuria. In women, VAT was associated with microalbuminuria after minimal adjustment (OR 1.28, P = 0.01), but not after multivariable adjustment (OR 1.03, P = 0.8). In multivariable models in women, SAT was associated with a decreased odds of having microalbuminuria (OR 0.75 per s.d., P = 0.03). In conclusion, VAT is associated with microalbuminuria in men but not women. Albuminuria may be a manifestation of visceral adiposity.
C1 [Foster, Meredith C.; Hwang, Shih-Jen; Robins, Sander J.; Vasan, Ramachandran S.; Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Foster, Meredith C.; Hwang, Shih-Jen; Fox, Caroline S.] NHLBI, Ctr Populat Studies, NIH, Bethesda, MD 20892 USA.
[Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[DeBoer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA.
[Robins, Sander J.; Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Prevent Med & Epidemiol Sect, Boston, MA 02118 USA.
[Robins, Sander J.; Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Cardiol Sect, Boston, MA 02118 USA.
[Fox, Caroline S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrinol & Metab, Boston, MA 02115 USA.
RP Fox, CS (reprint author), NHLBI, Framingham Heart Study, Framingham, MA USA.
EM foxca@nhlbi.nih.gov
OI Massaro, Joseph/0000-0002-2682-4812; Ramachandran,
Vasan/0000-0001-7357-5970
FU National Heart, Lung, and Blood Institute [N01-HC-25195]
FX The Framingham Heart Study is supported by the National Heart, Lung, and
Blood Institute (N01-HC-25195).
NR 40
TC 30
Z9 32
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD JUN
PY 2011
VL 19
IS 6
BP 1284
EP 1289
DI 10.1038/oby.2010.308
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 769NG
UT WOS:000291021600026
PM 21183930
ER
PT J
AU Santos, JLF
Salemi, VMC
Picard, MH
Mady, C
Coelho, OR
AF Santos, Jose L. F.
Salemi, Vera M. C.
Picard, Michael H.
Mady, Charles
Coelho, Otavio R.
TI Subclinical Regional Left Ventricular Dysfunction in Obese Patients With
and Without Hypertension or Hypertrophy
SO OBESITY
LA English
DT Article
ID BODY-MASS INDEX; CONGESTIVE-HEART-FAILURE; WEIGHT-LOSS; STANDARDS
COMMITTEE; OF-ECHOCARDIOGRAPHY; FOLLOW-UP; RECOMMENDATIONS; OVERWEIGHT;
DISEASE; IMPACT
AB We investigated the impact of obesity on the abnormalities of systolic and diastolic regional left ventricular (LV) function in patients with or without hypertension or hypertrophy, and without heart failure. We studied 120 individuals divided into 6 groups of 20 patients (42 +/- 6 years, 60 females) using standard and pulsed-wave tissue Doppler imaging (TDI) echocardiography, and heterogeneity index (HI): nonobese (I: no hypertension, no hypertrophy, control group; II: hypertension, no hypertrophy; III: hypertension and hypertrophy) and obese (IV: no hypertension, no hypertrophy; V: hypertension, no hypertrophy; VI: hypertension and hypertrophy). The criterion for obesity was BMI >= 30 kg/m(2), for hypertension was blood pressure >= 140/90 mm Hg, for hypertrophy in nonobese was LV mass/body surface area (BSA) >134 g/m(2) (men) and >110 mg/m(2) (women), and in obese was LV mass/height((2.7)) >50 (men) and >40 (women). Obese groups had normal LV ejection fraction compared with nonobese groups, but decreased longitudinal and radial systolic myocardial peak velocities (S'), and early diastolic myocardial peak velocity (E'). Also, a great variability of E' and late diastolic myocardial peak velocity (A') from the longitudinal basal region was observed in obese groups (E' basal nonobese: 11 +/- 7 vs. obese 19 +/- 11, P < 0.001, A' basal nonobese: 7 +/- 4 vs. obese 11 +/- 7, P < 0.001). Our findings were more evident when comparing groups IV with V and VI, with the latter having concentric hypertrophy and obvious segmental systolic and diastolic dysfunctions. Subclinical myocardial alterations and increased variability of the velocities were observed in obese groups, especially with hypertension and hypertrophy, reflecting impaired regional LV relaxation, segmental atrial, and systolic dysfunctions.
C1 [Salemi, Vera M. C.; Mady, Charles] Univ Sao Paulo, Fac Med, Cardiomyopathy Unit, Heart Inst InCor,Hosp Clin, Sao Paulo, Brazil.
[Santos, Jose L. F.; Coelho, Otavio R.] Univ Estadual Campinas, UNICAMP, Fac Ciencias Med, Sao Paulo, Brazil.
[Picard, Michael H.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Picard, Michael H.] Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
[Picard, Michael H.] Harvard Univ, Sch Med, Boston, MA USA.
RP Salemi, VMC (reprint author), Univ Sao Paulo, Fac Med, Cardiomyopathy Unit, Heart Inst InCor,Hosp Clin, Sao Paulo, Brazil.
EM verasalemi@uol.com.br
RI Mady, Charles/C-8870-2012; Salemi, Vera/C-9104-2013;
OI Mady, Charles/0000-0002-8838-199X; Salemi, Vera/0000-0002-7152-1810;
Picard, Michael/0000-0002-9264-3243
NR 34
TC 6
Z9 6
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD JUN
PY 2011
VL 19
IS 6
BP 1296
EP 1303
DI 10.1038/oby.2010.253
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 769NG
UT WOS:000291021600028
PM 20966911
ER
PT J
AU Serra, V
Scaltriti, M
Prudkin, L
Eichhorn, PJA
Ibrahim, YH
Chandarlapaty, S
Markman, B
Rodriguez, O
Guzman, M
Rodriguez, S
Gili, M
Russillo, M
Parra, JL
Singh, S
Arribas, J
Rosen, N
Baselga, J
AF Serra, V.
Scaltriti, M.
Prudkin, L.
Eichhorn, P. J. A.
Ibrahim, Y. H.
Chandarlapaty, S.
Markman, B.
Rodriguez, O.
Guzman, M.
Rodriguez, S.
Gili, M.
Russillo, M.
Parra, J. L.
Singh, S.
Arribas, J.
Rosen, N.
Baselga, J.
TI PI3K inhibition results in enhanced HER signaling and acquired ERK
dependency in HER2-overexpressing breast cancer
SO ONCOGENE
LA English
DT Article
DE PI3K/mTOR; HER2; feedback; ERK; BEZ235
ID VIVO ANTITUMOR-ACTIVITY; PHASE-II; TRASTUZUMAB RESISTANCE; PATHWAY
ACTIVATION; MEK INHIBITION; CELL-SURVIVAL; PTEN; MUTATIONS; RECEPTOR;
PIK3CA
AB There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease and it also mediates resistance to anti-HER2 therapies. However, initial studies with rapalogs, allosteric inhibitors of mTORC1, have resulted in limited clinical efficacy probably due to the release of a negative regulatory feedback loop that triggers AKT and ERK signaling. Since activation of AKT occurs via PI3K, we decided to explore whether PI3K inhibitors prevent the activation of these compensatory pathways. Using HER2-overexpressing breast cancer cells as a model, we observed that PI3K inhibitors abolished AKT activation. However, PI3K inhibition resulted in a compensatory activation of the ERK signaling pathway. This enhanced ERK signaling occurred as a result of activation of HER family receptors as evidenced by induction of HER receptors dimerization and phosphorylation, increased expression of HER3 and binding of adaptor molecules to HER2 and HER3. The activation of ERK was prevented with either MEK inhibitors or anti-HER2 monoclonal antibodies and tyrosine kinase inhibitors. Combined administration of PI3K inhibitors with either HER2 or MEK inhibitors resulted in decreased proliferation, enhanced cell death and superior anti-tumor activity compared with single agent PI3K inhibitors. Our findings indicate that PI3K inhibition in HER2-overexpressing breast cancer activates a new compensatory pathway that results in ERK dependency. Combined anti-MEK or anti-HER2 therapy with PI3K inhibitors may be required in order to achieve optimal efficacy in HER2-overexpressing breast cancer. This approach warrants clinical evaluation. Oncogene (2011) 30, 2547-2557; doi:10.1038/onc.2010.626; published online 31 January 2011
C1 [Baselga, J.] Vall Hebron Univ Hosp, VHIO, Expt Therapeut Program, E-08035 Barcelona, Spain.
[Scaltriti, M.; Baselga, J.] Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Res, Boston, MA USA.
[Prudkin, L.; Rodriguez, S.] Vall Hebron Inst Oncol, Mol Pathol Program, Barcelona, Spain.
[Chandarlapaty, S.; Rosen, N.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Chandarlapaty, S.; Rosen, N.] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA.
[Markman, B.; Baselga, J.] Vall Hebron Univ Hosp, Dept Med Oncol, E-08035 Barcelona, Spain.
[Parra, J. L.; Arribas, J.] Vall Hebron Inst Oncol, Growth Factors Lab, Barcelona, Spain.
[Singh, S.] Prometheus Therapeut & Diagnost, San Diego, CA USA.
[Arribas, J.; Baselga, J.] Univ Autonoma Barcelona, E-08193 Barcelona, Spain.
[Arribas, J.] Inst Catalana Recerca & Estudis Acancats, Barcelona, Spain.
[Baselga, J.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.
RP Baselga, J (reprint author), Vall Hebron Univ Hosp, VHIO, Expt Therapeut Program, Passeig Vall Hebron 119-129, E-08035 Barcelona, Spain.
EM jbaselga@vhio.net
RI Arribas, Joaquin/M-4482-2014
OI Arribas, Joaquin/0000-0002-0504-0664
FU Instituto de Salud Carlos III [PSO9/00623]; Breast Cancer Research
Foundation; ERC [AdG09 250244]
FX This research was supported by grants from the Instituto de Salud Carlos
III (Intrasalud PSO9/00623), from the Breast Cancer Research Foundation
and from the ERC (AdG09 250244). BEZ235 and NVP-AEW541 were kindly
provided by C Garcia-Echeverria from Novartis, Basel, Switzerland. The
AKT1/2/3 inhibitor was provided by Pradip Majumder at Merck Research
Laboratories, Boston. Lapatinib was kindly provided by GlaxoSmithKline,
Research Triangle Park, NJ. Torin1 was obtained from Whitehead/DFCI.
Trastuzumab was kindly provided by F Hoffmann-La Roche, Basel,
Switzerland.
NR 54
TC 222
Z9 226
U1 4
U2 32
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUN
PY 2011
VL 30
IS 22
BP 2547
EP 2557
DI 10.1038/onc.2010.626
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 771ZE
UT WOS:000291198400006
PM 21278786
ER
PT J
AU Mohan, N
Vakoc, B
AF Mohan, Nishant
Vakoc, Benjamin
TI Principal-component-analysis-based estimation of blood flow velocities
using optical coherence tomography intensity signals
SO OPTICS LETTERS
LA English
DT Article
ID ANGIOGRAPHY; MICROVASCULATURE
AB The intensity signal in optical coherence tomography contains information about the translational velocity of scatterers, and can be used to quantify blood flow. We apply principal component analysis to efficiently extract this information. We also study use of nonuniform temporal sampling of the intensity signal to increase the range of quantifiable flow velocities. We demonstrate this technique in simulation, phantom and in vivo blood flow measurements, and highlight its potential to enable three-dimensional wide-field mapping of blood flow using OCT. (C) 2011 Optical Society of America
C1 [Vakoc, Benjamin] Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Vakoc, B (reprint author), Harvard Univ, Sch Med, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.
EM bvakoc@partners.org
FU NCI NIH HHS [K25 CA127465]
NR 17
TC 8
Z9 9
U1 0
U2 1
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
J9 OPT LETT
JI Opt. Lett.
PD JUN 1
PY 2011
VL 36
IS 11
BP 2068
EP 2070
PG 3
WC Optics
SC Optics
GA 771HZ
UT WOS:000291149100040
PM 21633451
ER
PT J
AU Feudtner, C
Kang, TI
Hexem, KR
Friedrichsdorf, SJ
Osenga, K
Siden, H
Friebert, SE
Hays, RM
Dussel, V
Wolfe, J
AF Feudtner, Chris
Kang, Tammy I.
Hexem, Kari R.
Friedrichsdorf, Stefan J.
Osenga, Kaci
Siden, Harold
Friebert, Sarah E.
Hays, Ross M.
Dussel, Veronica
Wolfe, Joanne
TI Pediatric Palliative Care Patients: A Prospective Multicenter Cohort
Study
SO PEDIATRICS
LA English
DT Article
DE pediatric care; palliative care; hospice care; chronic illness;
technology dependence; polypharmacy
ID SURVIVAL; TEAM
AB OBJECTIVE: To describe demographic and clinical characteristics and outcomes of patients who received hospital-based pediatric palliative care (PPC) consultations.
DESIGN, SETTING, AND PATIENTS: Prospective observational cohort study of all patients served by 6 hospital-based PPC teams in the United States and Canada from January to March 2008.
RESULTS: There were 515 new (35.7%) or established (64.3%) patients who received care from the 6 programs during the 3-month enrollment interval. Of these, 54.0% were male, and 69.5% were identified as white and 8.1% as Hispanic. Patient age ranged from less than one month (4.7%) to 19 years or older (15.5%). Of the patients, 60.4% lived with both parents, and 72.6% had siblings. The predominant primary clinical conditions were genetic/congenital (40.8%), neuromuscular (39.2%), cancer (19.8%), respiratory (12.8%), and gastrointestinal (10.7%). Most patients had chronic use of some form of medical technology, with gastrostomy tubes (48.5%) being the most common. At the time of consultation, 47.2% of the patients had cognitive impairment; 30.9% of the cohort experienced pain. Patients were receiving many medications (mean: 9.1). During the 12-month follow-up, 30.3% of the cohort died; the median time from consult to death was 107 days. Patients who died within 30 days of cohort entry were more likely to be infants and have cancer or cardiovascular conditions.
CONCLUSIONS: PPC teams currently serve a diverse cohort of children and young adults with life-threatening conditions.In contrast to the reported experience of adult-oriented palliative care teams, most PPC patients are alive for more than a year after initiating PPC. Pediatrics 2011;127:1094-1101
C1 [Feudtner, Chris; Kang, Tammy I.; Hexem, Kari R.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Friedrichsdorf, Stefan J.; Osenga, Kaci] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA.
[Siden, Harold] Child & Family Res Inst, Vancouver, BC, Canada.
[Friebert, Sarah E.] Akron Childrens Hosp, Akron, OH USA.
[Hays, Ross M.] Seattle Childrens Hosp, Seattle, WA USA.
[Dussel, Veronica; Wolfe, Joanne] Childrens Hosp Boston, Boston, MA USA.
[Dussel, Veronica; Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Feudtner, C (reprint author), Childrens Hosp Philadelphia, 3535 Market St,Room 1523,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM feudtner@email.chop.edu
FU Children's Hospital of Philadelphia
FX Core funding for this project was provided by the Research Institute of
The Children's Hospital of Philadelphia.
NR 16
TC 91
Z9 95
U1 2
U2 10
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2011
VL 127
IS 6
BP 1094
EP 1101
DI 10.1542/peds.2010-3225
PG 8
WC Pediatrics
SC Pediatrics
GA 771GV
UT WOS:000291146100051
PM 21555495
ER
PT J
AU Kleinman, RE
Brown, RT
Cutter, GR
DuPaul, GJ
Clydesdale, FM
AF Kleinman, Ronald E.
Brown, Ronald T.
Cutter, Gary R.
DuPaul, George J.
Clydesdale, Fergus M.
TI A Research Model for Investigating the Effects of Artificial Food
Colorings on Children With ADHD
SO PEDIATRICS
LA English
DT Article
DE children; attention-deficit/hyperactivity disorder; artificial food
colorings; elimination diet; food safety
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY
DISORDER; GENETICALLY-MODIFIED FOODS; DOUBLE-BLIND CROSSOVER; FOLLOW-UP;
FEINGOLD HYPOTHESIS; PRESCHOOL-CHILDREN; CLINICAL-TRIAL; DIET; BEHAVIOR
AB The United Kingdom and European Union recently restricted the use of artificial food colorings (AFCs) to improve the health of children. These decisions provide an interesting case study of the role of scientific evidence in the assessment of food additives and risk to children's health and formulation of food policy. Although there continues to be uncertainty concerning the link between AFCs and attention-deficit/hyperactivity disorder (ADHD), policy decisions have been made that have far-reaching implications. In addition, publicity surrounding the policy changes may shape public perceptions concerning effective management of ADHD. We believe that the balance of existing evidence neither refutes nor supports the link between AFCs and ADHD, which highlights the need for carefully designed studies to further investigate the link between AFCs and ADHD. In this article we describe a model for such studies. In developing our model, we drew from current investigative standards in ADHD research, such as those used in the landmark Multimodal Treatment Study of Children With ADHD. These standards encompass methodologic considerations including sample selection, outcome assessment, and data analyses. It is our hope that this model research methodology may prove valuable in addressing design considerations in future studies of AFCs and ADHD with the goal of producing reliable data that will enable policy-makers to better formulate effective, evidence-based food-policy decisions. Pediatrics 2011; 127:e1575-e1584
C1 [Kleinman, Ronald E.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Kleinman, Ronald E.] Harvard Univ, Sch Med, Boston, MA USA.
[Brown, Ronald T.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA.
[Cutter, Gary R.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[DuPaul, George J.] Lehigh Univ, Dept Educ & Human Serv, Bethlehem, PA 18015 USA.
[Clydesdale, Fergus M.] Univ Massachusetts, Dept Food Sci, Amherst, MA 01003 USA.
RP Kleinman, RE (reprint author), Massachusetts Gen Hosp, Dept Pediat, CPZS 578,175 Cambridge St, Boston, MA 02114 USA.
EM rkleinman@partners.org
FU Cargill, Inc.; Coca-Cola Company; ConAgra Foods, Inc.; Kraft; Mars,
Inc.; Nestle RD Center, Inc.; Pepsi Cola, Inc.; Tate and Lyle North
America, Unilever NA; Massachusetts Department of Agricultural
Resources; University of Massachusetts Amherst; Eli Lilly; Shire
Pharmaceuticals; UMass Amherst Food Science Strategic Policy Alliance
FX With reference to this article, only Dr Clydesdale has a working
relationship with a company involved in the manufacture of food
colorings. The UMass Amherst Food Science Strategic Policy Alliance
receives funding from Cargill, Inc, Coca-Cola Company, ConAgra Foods,
Inc, Kraft, Mars, Inc, Nestle R&D Center, Inc, Pepsi Cola, Inc, Tate and
Lyle North America, Unilever NA, Massachusetts Department of
Agricultural Resources (grant), and University of Massachusetts Amherst.
Dr Kleinman has served on the scientific advisory boards of General
Mills, Beechnut, Hero Foods, the Grain Foods Foundation, and Burger King
and consulted for Elanco, Mead Johnson, and Cantox; Dr Brown has served
on a scientific advisory board for Shire Pharmaceuticals and has
received grant support from Eli Lilly; Dr Cutter has served on data and
safety monitoring committees for AntiSense Pharmaceuticals,
Sanofi-Aventis, Bayhill Pharmaceuticals Inc, Bayer Pharmaceuticals,
BioMS Pharmaceuticals, Daichi-Sankyo Pharmaceuticals, Enzo
Pharmaceuticals, Esai Pharmaceuticals, GlaxoSmithKline Pharmaceuticals,
Genentech Pharmaceuticals, Genmab Biopharmaceuticals, Incyte
Pharmaceuticals, Medivation Pharmaceuticals, Millennium Pharmaceuticals,
Novartis Pharmaceuticals, Peptimmune Pharmaceuticals, PTC Therapeutics,
Teva Pharmaceuticals, Vivus Pharmaceuticals, the National Heart, Lung,
and Blood Institute, the National Institute of Neurological Disorders
and Stroke, and the [National Multiple Sclerosis Society] NMSS and has
served as a consultant to Alexion Pharmaceuticals, Accentia
Pharmaceuticals, Bayer Pharmaceuticals, Barofold Pharmaceuticals, Biogen
Idec Pharmaceuticals, CibaVision, Millenium Pharmaceuticals, Consortium
of MS Centers, an MS-CORE-and NMSS-funded research group, Novartis
Pharmaceuticals, Klein-Buendel Incorporated, and Somnus Pharmaceuticals;
Dr DuPaul receives research grant support from Shire Pharmaceuticals;
and Dr Clydesdale has served on the scientific advisory boards of
General Mills, Mars Snackfood US, McCain Foods, Tate and Lyle, ConAgra,
Unilever, and the Coca-Cola Company, has consulted with Cantox, and
serves on the board of directors of Sensient Technologies, Inc (a
manufacturer of both artificial and natural food colorings).; This
article was prepared at a meeting convened by the University of
Massachusetts (UMass) Amherst Food Science Strategic Policy Alliance on
April 1-3, 2009, to address the issue of the current state of research
in food policy and ADHD and was supported by the UMass Amherst Food
Science Strategic Policy Alliance and its members, including the
Massachusetts Department of Agricultural Resources (grant) and UMass
Amherst. The meeting gathered thought leaders in the areas of food
science and policy and clinical psychology with emphasis on the design
and conduct of clinical trials that assess the effects of
pharmacotherapeutic and behavioral interventions for ADHD, pediatric
nutrition with emphasis on assessing the bioavailability and metabolism
of nutritional exposures, and biostatistics and the design and conduct
of clinical trials and research projects. Participants were selected on
the basis of large-scale screening and in-depth personal interviews.
Moderators were selected to facilitate discussion, and a writer with
expertise in medical publications was chosen to work with panel members
to develop a consensus report based on expert panel recommendations. The
UMass Amherst Food Science Strategic Policy Alliance is a policy program
based at UMass Amherst with members from industry, government (
including the US Food and Drug Administration and US Department of
Agriculture), and university faculty and students. The opinions and
positions taken in this consensus report are scientifically based and
not influenced by the UMass Amherst Food Science Strategic Policy
Alliance or its members. Editorial assistance for this project was
provided by BioScience Communications with financial support from the
UMass Amherst Food Science Strategic Policy Alliance.
NR 84
TC 2
Z9 2
U1 2
U2 38
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2011
VL 127
IS 6
BP E1575
EP E1584
DI 10.1542/peds.2009-2206
PG 10
WC Pediatrics
SC Pediatrics
GA 771GV
UT WOS:000291146100027
PM 21576306
ER
PT J
AU Kosten, TA
AF Kosten, Therese A.
TI Pharmacologically targeting the P2rx4 gene on maintenance and
reinstatement of alcohol self-administration in rats
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Article
DE Ivermectin; Purinergic system; P2X(4) receptors; Relapse; Operant
conditioning
ID P2X(4) RECEPTOR CHANNELS; ETHANOL-SEEKING BEHAVIOR; DRUG-ADDICTION; ION
CHANNELS; IVERMECTIN; RELAPSE; NEURONS; NEUROBIOLOGY; POTENTIATION;
CONSUMPTION
AB Genetic studies indicate that alcohol consumption associates with expression of the P2rx4 gene, a gene that codes for the P2X(4) receptor. This receptor is a subtype in the purinergic system of ligand-gated ion channels that when activated exerts excitatory effects in CNS. P2X(4) function is inhibited by alcohol and P2X(4) receptors are modulated positively by the antiparasitic agent, ivermectin. Two experiments were performed to test the ability of ivermectin to alter the behavioral effects of alcohol in rats. After alcohol exposure was achieved via the "drinking in the dark" procedure, separate groups of Sprague-Dawley rats were trained to lever press for either alcohol (10% ethanol/2% sucrose) or sucrose (3%) solutions in operant chambers. Rats were tested for maintenance of operant self-administration under a progressive ratio condition (Experiment 1) and for reinstatement of extinguished responding induced by solution presentation (Experiment 2) after ivermectin (0; 1-10 mg/kg; IP) administration. Ivermectin decreased the amount of work that the animal performed to obtain reinforcers in the maintenance study, particularly in the group reinforced with alcohol, and tended to decrease reinstated lever press responding. Conditioned approach behavior (head entries) was significantly reduced by ivermectin in both experiments. Reduction in motor activity was seen during the longer maintenance sessions but not in the shorter reinstatement sessions. Results suggest some support for ivermectin-like drugs as potential treatment agents for alcohol dependence. Caution is warranted due to modest specificity on behavior reinforced by alcohol, some reduction in general activity levels, and the lack of dose-response effects. (C) 2011 Elsevier Inc. All rights reserved.
C1 Baylor Coll Med, Dept Psychiat & Behav Sci, Michael E Debakey Vet Adm Med Ctr, Houston, TX 77030 USA.
RP Kosten, TA (reprint author), Baylor Coll Med, Dept Psychiat & Behav Sci, Michael E Debakey Vet Adm Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM tkosten@bcm.edu
FU [U01-AA013476]
FX This research was supported by grant U01-AA013476. We greatly
acknowledge the technical assistance provided by A. Aruffo, W. Huang, M.
Kosten, P. O'Malley, M. Rengasamy, J. Taylor, W. Webb, and X. Xiang.
NR 51
TC 13
Z9 13
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD JUN
PY 2011
VL 98
IS 4
BP 533
EP 538
DI 10.1016/j.pbb.2011.02.026
PG 6
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 773GP
UT WOS:000291295300006
PM 21402096
ER
PT J
AU Chen, ACH
Huang, YY
Sharma, SK
Hamblin, MR
AF Chen, Aaron C. -H.
Huang, Ying-Ying
Sharma, Sulbha K.
Hamblin, Michael R.
TI Effects of 810-nm Laser on Murine Bone-Marrow-Derived Dendritic Cells
SO PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
ID NF-KAPPA-B; CYTOCHROME-C-OXIDASE; INFLAMMATORY CYTOKINES;
IMMUNE-RESPONSE; NITRIC-OXIDE; LEVEL; THERAPY; IRRADIATION; ACTIVATION;
LIGHT
AB Objective: The purpose of this study was to Investigate the effect of 810-nm low level laser therapy (LLLT) on dendritic cells (DC) in vitro. Background data: LLLT can enhance wound healing and increase cell proliferation and survival, and is used to treat inflammatory conditions. However there are reports that LLLT can stimulate leukocytes and could therefore be pro-inflammatory. Recently, DC have been found to play an important role in inflammation and immune response. Methods: Murine bone-marrow-derived DC were isolated, stimulated with lipopolysaccharide (LPS) or CpG oligodeoxynucleotide and treated with 810-nm laser, using fluences of 0.3, 3, and 30 J/cm(2) delivered at irradiances of 1, 10, and 100mW/cm(2) respectively. Confocal microscopy, flow cytometry for DC markers, viability using propidium iodide, enzyme-linked immunosorbent assays (ELISA) for secreted interleukin-12 (IL-12), and bioluminescence measurements in cells transduced with a reporter for toll-like receptor (TLR)-9/nuclear factor kappa B (NF-kappa B) activation, were performed. Results: LLLT changed the morphology of LPS-stimulated DC, increased their viability, and altered the balance of DC activation markers (major histocompatibility complex [MHC] class 2 up and CD86 down). LLLT reduced IL-12 secretion from DC stimulated by either LPS or CpG. LLLT reduced NF-kappa B activation in reporter cells stimulated with CpG. There was no obvious light dose response observed. Conclusions: Taken together, these data suggest that 810-nm LLLT has an anti-inflammatory effect on activated DC, possibly mediated by cyclic adenosine monophosphate (cAMP) and reduced NF-kappa B signaling.
C1 [Chen, Aaron C. -H.; Huang, Ying-Ying; Sharma, Sulbha K.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.
EM Hamblin@helix.mgh.harvard.edu
RI Huang, Ying-ying/G-3153-2011;
OI Huang, Ying-ying/0000-0003-3066-6981; Hamblin,
Michael/0000-0001-6431-4605
FU NIH [R01AI050875]; Center for Integration of Medicine and Innovative
Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514];
Air Force Office of Scientific Research [FA9950-04-1-0079]
FX This work was supported by NIH grant R01AI050875, Center for Integration
of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program
in TBI (W81XWH-09-1-0514), and Air Force Office of Scientific Research
(FA9950-04-1-0079).
NR 40
TC 16
Z9 17
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-5418
J9 PHOTOMED LASER SURG
JI Photomed. Laser Surg.
PD JUN
PY 2011
VL 29
IS 6
BP 383
EP 389
DI 10.1089/pho.2010.2837
PG 7
WC Surgery
SC Surgery
GA 771ZT
UT WOS:000291199900003
PM 21214383
ER
PT J
AU Curtin, SJ
Zhang, F
Sander, JD
Haun, WJ
Starker, C
Baltes, NJ
Reyon, D
Dahlborg, EJ
Goodwin, MJ
Coffman, AP
Dobbs, D
Joung, JK
Voytas, DF
Stupar, RM
AF Curtin, Shaun J.
Zhang, Feng
Sander, Jeffry D.
Haun, William J.
Starker, Colby
Baltes, Nicholas J.
Reyon, Deepak
Dahlborg, Elizabeth J.
Goodwin, Mathew J.
Coffman, Andrew P.
Dobbs, Drena
Joung, J. Keith
Voytas, Daniel F.
Stupar, Robert M.
TI Targeted Mutagenesis of Duplicated Genes in Soybean with Zinc-Finger
Nucleases
SO PLANT PHYSIOLOGY
LA English
DT Article
ID PLANTS; RESISTANCE; EXPRESSION; PROTEINS; DATABASE; PATHWAY; ARRAYS;
DOMAIN; SEED; TOOL
AB We performed targeted mutagenesis of a transgene and nine endogenous soybean (Glycine max) genes using zinc-finger nucleases (ZFNs). A suite of ZFNs were engineered by the recently described context-dependent assembly platform-a rapid, open-source method for generating zinc-finger arrays. Specific ZFNs targeting DICER-LIKE (DCL) genes and other genes involved in RNA silencing were cloned into a vector under an estrogen-inducible promoter. A hairy-root transformation system was employed to investigate the efficiency of ZFN mutagenesis at each target locus. Transgenic roots exhibited somatic mutations localized at the ZFN target sites for seven out of nine targeted genes. We next introduced a ZFN into soybean via whole-plant transformation and generated independent mutations in the paralogous genes DCL4a and DCL4b. The dcl4b mutation showed efficient heritable transmission of the ZFN-induced mutation in the subsequent generation. These findings indicate that ZFN-based mutagenesis provides an efficient method for making mutations in duplicate genes that are otherwise difficult to study due to redundancy. We also developed a publicly accessible Web-based tool to identify sites suitable for engineering context-dependent assembly ZFNs in the soybean genome.
C1 [Curtin, Shaun J.; Haun, William J.; Coffman, Andrew P.; Stupar, Robert M.] Univ Minnesota, Dept Agron & Plant Genet, St Paul, MN 55108 USA.
[Zhang, Feng; Starker, Colby; Baltes, Nicholas J.; Voytas, Daniel F.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
[Zhang, Feng; Starker, Colby; Baltes, Nicholas J.; Voytas, Daniel F.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA.
[Sander, Jeffry D.; Dahlborg, Elizabeth J.; Goodwin, Mathew J.; Joung, J. Keith] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA.
[Sander, Jeffry D.; Dahlborg, Elizabeth J.; Goodwin, Mathew J.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.
[Sander, Jeffry D.; Dahlborg, Elizabeth J.; Goodwin, Mathew J.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA.
[Sander, Jeffry D.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Joung, J. Keith] Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02115 USA.
[Reyon, Deepak; Dobbs, Drena] Iowa State Univ, Dept Genet Dev & Cell Biol, Bioinformat & Computat Biol Program, Ames, IA 50011 USA.
RP Stupar, RM (reprint author), Univ Minnesota, Dept Agron & Plant Genet, St Paul, MN 55108 USA.
EM rstupar@umn.edu
OI Stupar, Robert/0000-0002-8836-2924
FU Minnesota Soybean Research and Promotion Council [667234-13-10CN]; U.S.
Department of Agriculture-Agricultural Research Service [58-3640-0-626];
National Science Foundation [DBI 0923827]; National Institutes of Health
[R01 GM088040, R01 GM069906, R24 GM078369, T32 CA009216]
FX This work was supported by the Minnesota Soybean Research and Promotion
Council (award no. 667234-13-10CN), the U.S. Department of
Agriculture-Agricultural Research Service (agreement 58-3640-0-626), the
National Science Foundation (award no. DBI 0923827), and the National
Institutes of Health (award nos. R01 GM088040, R01 GM069906, R24
GM078369, and T32 CA009216).
NR 38
TC 86
Z9 94
U1 5
U2 37
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 0032-0889
J9 PLANT PHYSIOL
JI Plant Physiol.
PD JUN
PY 2011
VL 156
IS 2
BP 466
EP 473
DI 10.1104/pp.111.172981
PG 8
WC Plant Sciences
SC Plant Sciences
GA 771HC
UT WOS:000291146800003
PM 21464476
ER
PT J
AU Craft, RO
May, JW
AF Craft, Randall O.
May, James W., Jr.
TI Staged Nipple Reconstruction with Vascularized SurgiMend Acellular
Dermal Matrix
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Letter
ID ALLODERM
C1 [Craft, Randall O.; May, James W., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA USA.
RP Craft, RO (reprint author), Harvard Plast Surg, Boston, MA 02115 USA.
EM rcraft@partners.org
NR 4
TC 10
Z9 10
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD JUN
PY 2011
VL 127
IS 6
BP 148E
EP 149E
DI 10.1097/PRS.0b013e3182131e74
PG 2
WC Surgery
SC Surgery
GA 772DP
UT WOS:000291212700011
PM 21617431
ER
PT J
AU Hartzell, TL
Medina, M
Hornicek, FJ
Austen, WG
AF Hartzell, Tristan L.
Medina, Miguel
Hornicek, Francis J.
Austen, William G., Jr.
TI Extended Dermal Apposition: A Simple Technique for the Closure of
Irradiated Perineal and Sacral Wounds
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Letter
C1 [Hartzell, Tristan L.; Medina, Miguel; Austen, William G., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Boston, MA 02114 USA.
[Hornicek, Francis J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA.
RP Hartzell, TL (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, 55 Fruit St, Boston, MA 02114 USA.
EM thartzell@partners.org
NR 5
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD JUN
PY 2011
VL 127
IS 6
BP 170E
EP 173E
DI 10.1097/PRS.0b013e318213a3e2
PG 4
WC Surgery
SC Surgery
GA 772DP
UT WOS:000291212700025
PM 21617445
ER
PT J
AU Medina, MA
Nguyen, JT
Kirkham, JC
Lee, JH
McCormack, MC
Randolph, MA
Austen, WG
AF Medina, Miguel A., III
Nguyen, John T.
Kirkham, John C.
Lee, Jeffery H.
McCormack, Michael C.
Randolph, Mark A.
Austen, William G., Jr.
TI Polymer Therapy: A Novel Treatment to Improve Fat Graft Viability
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID RHEOTHRX INJECTION; MAMMALIAN-CELLS; POLOXAMER-188; LIPOSUCTION; INJURY;
RECOVERY; CENTRIFUGATION; SURVIVAL; NECROSIS; HARVEST
AB Background: Autologous fat grafting is currently undergoing a renaissance. However, fat grafts are limited by unpredictable survival. Poloxamers can act as tissue surfactants. These nonionic surfactants have been shown to stabilize the membranes of damaged cells and to protect against injury and apoptosis in numerous models. This study was designed to investigate the ability of poloxamers to protect harvested adipocytes and to increase fat graft survival.
Methods: Lipoaspirate was obtained from surgical patients. Samples were washed in normal saline, centrifuged at 200 g, treated with various poloxamers or poloxamer components for 30 minutes, centrifuged at 200 g, and implanted into the flanks of nude mice in 1.0-cc, 1.0-g lobules. The grafts were explanted serially for 10 days and at 6 weeks. Endpoints were weight, apoptosis, cell viability, DNA content, and histology.
Results: Grafts treated with poloxamers P188, F108, and F127 demonstrated increased graft survival by weight. Fat grafts treated with poloxamers L64 and P188 demonstrated improvement in cell viability, and those treated with poloxamers L64, P188, and F38 demonstrated improved histology. P188-treated grafts demonstrated a 50 percent reduction in apoptosis compared with saline-treated controls (p < 0.05) and an overall 72 percent survival by weight at 6 weeks. P188 demonstrated statistically significant improvement by weight, DNA content, histology, and cell viability (89 percent versus 33 percent).
Conclusions: The authors demonstrate that poloxamers, with membrane-sealing capability, can increase graft survival. Among these poloxamers, P188 demonstrated statistically significant improvement in apoptosis, graft survival by weight, cell viability, DNA content, and histology. (Plast. Reconstr. Surg. 127: 2270, 2011.)
C1 [Medina, Miguel A., III; Nguyen, John T.; Kirkham, John C.; Lee, Jeffery H.; McCormack, Michael C.; Randolph, Mark A.; Austen, William G., Jr.] Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Dept Surg, Boston, MA 02114 USA.
RP Medina, MA (reprint author), Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Dept Surg, 55 Fruit St,Wang 435, Boston, MA 02114 USA.
EM mamedina@partners.org
FU Aesthetec Corporation
FX This study was funded in part by a grant from Aesthetec Corporation (to
W.G.A.).
NR 46
TC 10
Z9 10
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD JUN
PY 2011
VL 127
IS 6
BP 2270
EP 2282
DI 10.1097/PRS.0b013e3182139fc1
PG 13
WC Surgery
SC Surgery
GA 772DP
UT WOS:000291212700044
PM 21617461
ER
PT J
AU Kruger, EA
Im, DD
Bischoff, DS
Pereira, CT
Huang, WB
Rudkin, GH
Yamaguchi, DT
Miller, TA
AF Kruger, Erwin A.
Im, Daniel D.
Bischoff, David S.
Pereira, Clifford T.
Huang, Weibiao
Rudkin, George H.
Yamaguchi, Dean T.
Miller, Timothy A.
TI In Vitro Mineralization of Human Mesenchymal Stem Cells on
Three-Dimensional Type I Collagen versus PLGA Scaffolds: A Comparative
Analysis
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID CYCLIC TENSILE STRAIN; OSTEOGENIC DIFFERENTIATION; CHEMOKINE RECEPTORS;
EXPRESSION; PROLIFERATION; HYPOXIA; STIMULATION; MATRICES; MIGRATE;
CULTURE
AB Background: Development of a tissue engineered bone graft requires efficient bioactivity screening of biomaterials in clinically relevant three-dimensional systems. The authors analyzed the relative osteogenic potential of two three-dimensional biomaterials-type I collagen and poly(L-lactide-co-glycolide) (PLGA)-to support in vitro mineralization of human mesenchymal stem cells.
Methods: Human mesenchymal stem cells were seeded onto three-dimensional PLGA or type I collagen scaffolds; incubated in osteogenic media; and harvested at 1, 4, and 7 days. Messenger RNA expression was analyzed using quantitative real-time reverse-transcriptase polymerase chain reaction for osteogenic (i.e., alkaline phosphatase, osteocalcin, bone sialoprotein, Runx2/core binding factor alpha-1) and angiogenic (i.e., vascular endothelial growth factor and interleukin-8) markers. Alkaline phosphatase enzyme activity was measured at 4 and 7 days. Mineralization was detected by alizarin red staining and micro-computed tomographic imaging at 8 and 12 weeks. Mineral composition was analyzed by solid-phase nuclear magnetic resonance spectroscopy.
Results: Early osteogenic and angiogenic markers, and alkaline phosphatase enzyme activity, were up-regulated on PLGA versus collagen scaffolds. However, long-term mineralization endpoints favored type I collagen. By 8 weeks, human mesenchymal stem cells on collagen exhibited significantly higher mineral density by micro-computed tomographic and alizarin red staining than PLGA scaffolds. Both biomaterials deposited calcium hydroxyapatite as determined by nuclear magnetic resonance spectroscopy.
Conclusions: The authors' findings suggest that despite early PLGA induction of osteogenic gene expression, long-term mineralization occurs earlier and to a greater extent on type I collagen, highlighting collagen as a potential bone tissue engineering scaffold in the human mesenchymal stem cell niche. When screening the relative osteoinductive profiles of three-dimensional bone tissue engineering scaffolds in vitro, the authors recommend including long-term endpoints of osteogenesis. (Plast. Reconstr. Surg. 127: 2301, 2011.)
C1 [Miller, Timothy A.] Vet Affairs Greater Los Angeles Healthcare Syst, Plast Surg Lab, Los Angeles, CA 90073 USA.
Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, Dept Surg, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
Albert Einstein Coll Med, Bronx, NY USA.
Harbor UCLA Med Ctr, Dept Surg, Torrance, CA USA.
RP Miller, TA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Plast Surg Lab, Room 221,Bldg 114,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM tmiller@mednet.ucla.edu
FU Veterans Affairs National Merit Review Grant
FX This work was supported by a Veterans Affairs National Merit Review
Grant awarded to Dr. Timothy Miller. The authors thank Nalini Makhijani
of the Veterans Affairs Research Service for assistance in cell culture
and Dr. Robert Taylor of the University of California, Los Angeles
Department of Chemistry for assistance with nuclear magnetic resonance
spectroscopy.
NR 35
TC 14
Z9 14
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD JUN
PY 2011
VL 127
IS 6
BP 2301
EP 2311
DI 10.1097/PRS.0b013e318213a004
PG 11
WC Surgery
SC Surgery
GA 772DP
UT WOS:000291212700047
PM 21617464
ER
PT J
AU Singh, JA
Sarkin, A
Shieh, M
Khanna, D
Terkeltaub, R
Lee, SJ
Kavanaugh, A
Hirsch, JD
AF Singh, Jasvinder A.
Sarkin, A.
Shieh, M.
Khanna, D.
Terkeltaub, R.
Lee, S. J.
Kavanaugh, A.
Hirsch, J. D.
TI Health Care Utilization in Patients with Gout
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Review
DE health care utilization; gout; predictors; resource utilization; gout
severity
ID QUALITY-OF-LIFE; MEDICAL-RECORD; MYOCARDIAL-INFARCTION; SELF-REPORTS;
SERUM URATE; ARTHRITIS; VALIDITY; COSTS; POPULATION; DISEASE
AB Objective: To study health care utilization patterns in patients with gout.
Methods: In a gout population from primary care and rheumatology clinics in 3 U.S. metropolitan cities, we collected data on gout-related utilization (primary care, rheumatology, urgent care, emergency room, and other) in the past year. We evaluated the association of comorbidities, age, gender, gout characteristics (time since last gout attack and tophi), and gout severity ratings (mean of serum uric acid, patient-rated, and physician-rated gout severity) and with emergency/urgent care and primary care utilization using regression and correlation analyses.
Results: Of the 296 patients who reported visiting at least 1 type of health practitioner for gout in the past year, the percentage of patients utilizing the service at least once and annual utilization rates among utilizers were as follows: primary care physician, 60%, 3.0 +/- 3.4; nurse practitioner/physician assistant, 26%, 2.7 +/- 2.5; rheumatologist, 51%, 3.7 +/- 5.7; urgent care, 23%, 2.1 +/- 2.2; emergency room, 20%, 2.0 +/- 1.7; and hospitalization, 7%, 2.1 +/- 1.4. Higher overall gout severity was associated with greater use of each resource type and with overall gout-related utilization. Nonemergency/nonurgent care utilization (primary care physician, nurse practitioner, physician's assistant, and rheumatologist for gout) was the strongest predictor of gout-related emergency/urgent care utilization. Patients with more comorbidities had greater gout-related primary care utilization.
Conclusions: Overall gout severity was associated with all types of gout-related utilization. This may help to screen high utilizers for targeted behavioral and therapeutic interventions. Having a higher number of comorbid conditions was a risk factor for higher gout-related primary care utilization. Published by Elsevier Inc. Semin Arthritis Rheum 40:501-511
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama, Birmingham, AL USA.
[Sarkin, A.; Shieh, M.] Univ Calif San Diego, Hlth Serv Res Ctr, San Diego, CA 92103 USA.
[Khanna, D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Terkeltaub, R.; Lee, S. J.; Kavanaugh, A.; Hirsch, J. D.] VA San Diego Healthcare Syst, San Diego, CA USA.
[Hirsch, J. D.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Takeda Pharmaceutical Products, Inc; San Diego General Clinical Research
Center [M01 RR00827]; National Center for Research Resources, National
Institutes of Health; National Institutes of Health [NIAMS K23
AR053858-01A1, 1 KL2 RR024151-01]; VA Research Service; University of
California; Department of Veterans Affairs; Arthritis Foundation;
University of Minnesota; Cochrane centers; Minnesota Medical Foundation;
Allergan; Takeda; Savient; Wyeth; Amgen; URL Pharmaceuticals; Novartis;
TAP; Takeda pharmaceuticals; Regeneron; Research Service of the
Department of Veterans Affairs
FX This work was supported by the Takeda Pharmaceutical Products, Inc, VA
Research Service and the University of California, San Diego General
Clinical Research Center Program, M01 RR00827, National Center for
Research Resources, National Institutes of Health. D.K. was also
supported by a National Institutes of Health Award (NIAMS K23
AR053858-01A1) during this period. J.A.S. was supported by a National
Institutes of Health CTSA Award 1 KL2 RR024151-01 (Mayo Clinic Center
for Clinical and Translational Research). R.T. was supported by the VA
Research Service.; Disclosure Statement: J.A.S. has received speaker
honoraria from Abbott, research grants from Department of Veterans
Affairs, National Institutes of Health, Arthritis Foundation, University
of Minnesota, Cochrane centers, Minnesota Medical Foundation, research
and travel grants from Allergan, Takeda, Savient, Wyeth, and Amgen and
consultant fees from Savient, URL Pharmaceuticals, and Novartis. J.D.H.
has received a research grant from TAP and Takeda pharmaceuticals and
consultant fees from Regeneron. R.T. is a consultant for Takeda,
Savient, EnzymeRx, Altus, BioCryst, Regeneron, Novartis, Pfizer, URL
Pharma, and Proctor & Gamble and has received grants from the Research
Service of the Department of Veterans Affairs and Takeda
Pharmaceuticals. D.K. has received consultant fees and research grants
from Takeda Pharmaceuticals. A.K. has received consultant fees from URL
pharmaceuticals. All other authors have no conflicts of interest to
disclose.
NR 29
TC 21
Z9 21
U1 1
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0049-0172
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD JUN
PY 2011
VL 40
IS 6
BP 501
EP 511
DI 10.1016/j.semarthrit.2010.07.001
PG 11
WC Rheumatology
SC Rheumatology
GA 772ZZ
UT WOS:000291278100002
PM 20828793
ER
PT J
AU Burstein, HJ
AF Burstein, Harold J.
TI Introduction: Current and Future Approaches to Chemotherapy in Patients
With Resistant Breast Cancer
SO SEMINARS IN ONCOLOGY
LA English
DT Editorial Material
ID PHASE-II; RANDOMIZED-TRIAL; PACLITAXEL; CAPECITABINE; DOXORUBICIN; PLUS;
ANTHRACYCLINE; COMBINATION; CONCOMITANT; DOCETAXEL
C1 Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA 02115 USA.
RP Burstein, HJ (reprint author), Dana Farber Canc Inst, Breast Oncol Ctr, 44 Binney St,Mayer 2, Boston, MA 02115 USA.
EM hal_burstein@dfci.harvard.edu
NR 13
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
J9 SEMIN ONCOL
JI Semin. Oncol.
PD JUN
PY 2011
VL 38
IS 3
SU 2
BP S1
EP S2
DI 10.1053/j.seminoncol.2011.04.001
PG 2
WC Oncology
SC Oncology
GA 771PU
UT WOS:000291174000001
PM 21600379
ER
PT J
AU Burstein, HJ
AF Burstein, Harold J.
TI Novel Agents and Future Directions for Refractory Breast Cancer
SO SEMINARS IN ONCOLOGY
LA English
DT Review
ID CELLS; SRC; INHIBITION; DASATINIB; PATHWAYS; THERAPY; GROWTH
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA 02215 USA.
RP Burstein, HJ (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Breast Oncol Ctr, 450 Brookline Ave, Boston, MA 02215 USA.
EM hal_burstein@dfci.harvard.edu
FU Eisai, Inc.
FX Publication of this article was supported by Eisai, Inc.
NR 30
TC 21
Z9 23
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0093-7754
J9 SEMIN ONCOL
JI Semin. Oncol.
PD JUN
PY 2011
VL 38
IS 3
SU 2
BP S17
EP S24
DI 10.1053/j.seminoncol.2011.04.002
PG 8
WC Oncology
SC Oncology
GA 771PU
UT WOS:000291174000004
PM 21600381
ER
PT J
AU Xie, AL
Bedekar, A
Skatrud, JB
Teodorescu, M
Gong, YS
Dempsey, JA
AF Xie, Ailiang
Bedekar, Ajay
Skatrud, James B.
Teodorescu, Mihaela
Gong, Yuansheng
Dempsey, Jerome A.
TI The Heterogeneity of Obstructive Sleep Apnea (Predominant Obstructive vs
Pure Obstructive Apnea)
SO SLEEP
LA English
DT Article
DE CO(2) reserve; Pcrit; OSA
ID UPPER AIRWAY COLLAPSIBILITY; CONTROL MECHANISMS; RESPIRATORY DRIVE;
NEGATIVE-PRESSURE; MUSCLE-ACTIVITY; PATHOGENESIS; RESISTANCE; STABILITY;
INSTABILITY; THRESHOLD
AB Study Objectives: To compare the breathing instability and upper airway collapsibility between patients with pure OSA (i.e. 100% of apneas are obstructive) and patients with predominant OSA (i.e., coexisting obstructive and central apneas).
Design: A cross-sectional study with data scored by a fellow being blinded to the subjects' classification. The results were compared between the 2 groups with unpaired student t-test.
Setting and interventions: Standard polysomnography technique was used to document sleep-wake state. Ventilator in pressure support mode was used to introduce hypocapnic apnea during CO(2) reserve measurement. CPAP with both positive and negative pressures was used to produce obstructive apnea during upper airway collapsibility measurement.
Participants: 21 patients with OSA: 12 with coexisting central/mixed apneas and hypopneas (28% +/- 6% of total), and 9 had pure OSA.
Measurements: The upper airway collapsibility was measured by assessing the critical closing pressure (Pcrit). Breathing stability was assessed by measuring CO(2) reserve (i.e.,Delta PCO(2) [eupnea-apnea threshold]) during NREM sleep.
Results: There was no difference in Pcrit between the 2 groups (pure OSA vs. predominant OSA: 2.0 +/- 0.4 vs. 2.7 +/- 0.4 cm H(2)O, P = 0.27); but the CO(2) reserve was significantly smaller in predominant OSA group (1.6 +/- 0.7 mm Hg) than the pure OSA group (3.8 +/- 0.6 mm Hg) (P = 0.02).
Conclusions: The present data indicate that breathing stability rather than upper airway collapsibility distinguishes OSA patients with a combination of obstructive and central events from those with pure OSA.
C1 [Bedekar, Ajay; Skatrud, James B.; Teodorescu, Mihaela; Gong, Yuansheng] Univ Wisconsin, Dept Med, Madison, WI USA.
[Xie, Ailiang; Skatrud, James B.; Teodorescu, Mihaela] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Xie, AL (reprint author), VA Hosp, Pulm Physiol Lab, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM axie@wisc.edu
FU VA Medical Research Service; American Lung Association of Wisconsin;
NIH-NHLB1 [1RC1HL099724-01]
FX We would like to thanks Dominic S. Puleo for technique assistance.
Research work performed at Pulmonary Physiology Laboratory, VA Hospital,
Madison, WI. This work was supported by the VA Medical Research Service;
American Lung Association of Wisconsin; and NIH-NHLB1 (Grant
1RC1HL099724-01).
NR 35
TC 15
Z9 15
U1 0
U2 1
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2011
VL 34
IS 6
BP 745
EP 750
DI 10.5665/SLEEP.1040
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 771LE
UT WOS:000291158000010
PM 21629362
ER
PT J
AU Siegel, JM
AF Siegel, Jerome M.
TI REM sleep: A biological and psychological paradox
SO SLEEP MEDICINE REVIEWS
LA English
DT Editorial Material
ID EYE-MOVEMENT SLEEP; IN-VIVO MICRODIALYSIS; LOCUS-COERULEUS; MEDIAL
MEDULLA; BLOOD-PRESSURE; GABA RELEASE; CATAPLEXY; NEURONS; NARCOLEPSY;
PONTINE
C1 [Siegel, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, Neurobiol Res 151A3, North Hills, CA 91343 USA.
[Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA.
RP Siegel, JM (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Neurobiol Res 151A3, 16111 Plummer St, North Hills, CA 91343 USA.
EM JSiegel@ucla.edu
FU BLRD VA [I01 BX001753]; NIDA NIH HHS [R01 DA034748]; NIMH NIH HHS [R01
MH064109, R01 MH064109-09]; NINDS NIH HHS [R01 NS014610-30, R01
NS014610, R01 NS069640, R01 NS069640-01]
NR 58
TC 25
Z9 25
U1 3
U2 26
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1087-0792
J9 SLEEP MED REV
JI Sleep Med. Rev.
PD JUN
PY 2011
VL 15
IS 3
BP 139
EP 142
DI 10.1016/j.smrv.2011.01.001
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 771QE
UT WOS:000291175000001
PM 21482156
ER
PT J
AU Patel, VI
Mukhopadhyay, S
Aranson, NJ
Ergul, E
Schainfeld, R
Conrad, MF
Cambria, RP
AF Patel, Virendra I.
Mukhopadhyay, Shankha
Aranson, Nathan J.
Ergul, Emel
Schainfeld, Robert
Conrad, Mark F.
Cambria, Richard P.
TI Clinical outcomes of aortic reconstruction for vasculitis in the
Medicare population (2004-2007)
SO VASCULAR MEDICINE
LA English
DT Meeting Abstract
C1 [Patel, Virendra I.; Mukhopadhyay, Shankha; Aranson, Nathan J.; Ergul, Emel; Schainfeld, Robert; Conrad, Mark F.; Cambria, Richard P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1358-863X
J9 VASC MED
JI Vasc. Med.
PD JUN
PY 2011
VL 16
IS 3
MA 35
BP 235
EP 235
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 772FB
UT WOS:000291218600043
ER
PT J
AU Campbell, J
Prochazka, A
Gopal, R
AF Campbell, Jessica
Prochazka, Allan
Gopal, Ravi
TI The Need for a Uniform Use of the Construct of Burnout Reply
SO ACADEMIC MEDICINE
LA English
DT Letter
ID PERCEIVED MEDICAL ERRORS; ASSOCIATION; DISTRESS
C1 [Campbell, Jessica; Prochazka, Allan; Gopal, Ravi] Univ Colorado, Denver Sch Med, Aurora, CO USA.
[Campbell, Jessica] Denver Hlth Med Ctr, Div Hosp Med, Denver, CO USA.
[Prochazka, Allan; Gopal, Ravi] Denver VA Med Ctr, Dept Ambulatory Care, Denver, CO USA.
RP Campbell, J (reprint author), Univ Colorado, Denver Sch Med, Aurora, CO USA.
EM jessica.campbell@dhha.org
NR 7
TC 0
Z9 0
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD JUN
PY 2011
VL 86
IS 6
BP 661
EP 661
DI 10.1097/ACM.0b013e318218858f
PG 1
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 769IM
UT WOS:000291006100003
ER
PT J
AU Scott, DR
Weimer, M
English, C
Shaker, L
Ward, W
Choi, D
Cedfeldt, A
Girard, D
AF Scott, David R.
Weimer, Melissa
English, Clea
Shaker, Lynn
Ward, William
Choi, Dongseok
Cedfeldt, Andrea
Girard, Donald
TI A Novel Approach to Increase Residents' Involvement in Reporting Adverse
Events
SO ACADEMIC MEDICINE
LA English
DT Article
ID IMPROVE PATIENT SAFETY; QUALITY IMPROVEMENT; MEDICAL ERRORS; TEACHING
HOSPITALS; PHYSICIANS; EDUCATION
AB Purpose
In the wake of the Patient Safety and Quality Improvement Act of 2005, national attention has increasingly focused on adverse-event reporting as a means of identifying systems changes to improve patient safety. However, physicians and residents have demonstrated meager involvement in this effort.
Method
In 2008-2009, the authors measured participation in adverse-event reporting by 680 residents at Oregon Health & Science University before and after implementing a quality improvement initiative, which consisted of a financial incentive and multifaceted educational campaign. The primary measure of success was an increase in the average monthly adverse-event reports submitted by residents to greater than 5% of the institution's overall report submissions.
Results
The average number of adverse events reported by residents increased from 1.6% to 9.0% of the institution's overall event reports, representing a 5.6-fold increase during the initiative (P < .001). The relative percentage of resident-submitted reports defined as "near-misses" increased from 6% to 27% during the initiative (P < .001).
Conclusions
The novel approach of integrating a retirement benefit and educational campaign to increase residents' involvement in adverse-event reporting was successful. In addition to increasing residents' contributions to adverse-event reporting to levels higher than any documented in the current literature, there was also a remarkable increase in the relative frequency of near-miss reporting by residents.
C1 [Scott, David R.; Weimer, Melissa] Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med & Geriatr, Portland, OR 97239 USA.
[Scott, David R.] Portland VA Med Ctr, Dept Med, Portland, OR USA.
[Ward, William] Mayo Clin, Dept Primary Care Internal Med, Rochester, MN USA.
[Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
[Girard, Donald] Oregon Hlth & Sci Univ, Dept Grad & Continuing Med Educ, Portland, OR 97239 USA.
RP Scott, DR (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Gen Internal Med & Geriatr, 3181 SW Sam Jackson Pk Rd,OP-30, Portland, OR 97239 USA.
EM scottdav@ohsu.edu
RI Ward, William/C-7052-2013
FU Oregon Health & Science University
FX Salary support was obtained from Oregon Health & Science University.
NR 16
TC 11
Z9 11
U1 9
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD JUN
PY 2011
VL 86
IS 6
BP 742
EP 746
DI 10.1097/ACM.0b013e318217e12a
PG 5
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 769IM
UT WOS:000291006100026
PM 21512369
ER
PT J
AU Mimiaga, MJ
Landers, SJ
Conron, KJ
AF Mimiaga, Matthew J.
Landers, Stewart J.
Conron, Kerith J.
TI Prevalence and Correlates of Lifetime HIV Testing in a Population-Based
Sample of Men Who Have Sex with Men in Massachusetts
SO AIDS PATIENT CARE AND STDS
LA English
DT Letter
ID RISK; BEHAVIORS; VIRUS
C1 [Mimiaga, Matthew J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Sch Publ Hlth,Dept Epidemiol, Boston, MA 02114 USA.
[Mimiaga, Matthew J.] Fenway Inst, Boston, MA USA.
[Landers, Stewart J.] John Snow Inc, Boston, MA USA.
[Conron, Kerith J.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Conron, Kerith J.] Northeastern Univ, Inst Urban Hlth Res, Boston, MA 02115 USA.
RP Mimiaga, MJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Sch Publ Hlth,Dept Epidemiol, 1 Bowdoin Sq 7th Floor, Boston, MA 02114 USA.
EM mmimiaga@partners.org
NR 11
TC 4
Z9 4
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD JUN
PY 2011
VL 25
IS 6
BP 323
EP 326
DI 10.1089/apc.2011.0078
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 769LM
UT WOS:000291015000001
PM 21612544
ER
PT J
AU Merkulova, M
Hurtado-Lorenzo, A
Hosokawa, H
Zhuang, ZJ
Brown, D
Ausiello, DA
Marshansky, V
AF Merkulova, Maria
Hurtado-Lorenzo, Andres
Hosokawa, Hiroyuki
Zhuang, Zhenjie
Brown, Dennis
Ausiello, Dennis A.
Marshansky, Vladimir
TI Aldolase directly interacts with ARNO and modulates cell morphology and
acidic vesicle distribution
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE ADP-ribosylation factor nucleotide site opener; vacuolar H(+)-ATPase;
a-subunit isoforms; actin cytoskeleton; gelsolin; surface plasmon
resonance; endosomal/lysosomal compartments
ID VACUOLAR H+-ATPASE; NUCLEOTIDE-EXCHANGE FACTORS; YEAST V-ATPASE; PH
DOMAIN; FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; ACTIN CYTOSKELETON;
EPITHELIAL-CELLS; PROXIMAL TUBULE; EARLY ENDOSOMES; SUBUNIT GENES
AB Merkulova M, Hurtado-Lorenzo A, Hosokawa H, Zhuang Z, Brown D, Ausiello DA, Marshansky V. Aldolase directly interacts with ARNO and modulates cell morphology and acidic vesicle distribution. Am J Physiol Cell Physiol 300: C1442-C1455, 2011. First published February 9, 2011; doi: 10.1152/ajpcell.00076.2010.-Previously, we demonstrated that the vacuolar-type H(+)-ATPase (V-ATPase) a2-subunit functions as an endosomal pH sensor that interacts with the ADP-ribosylation factor (Arf) guanine nucleotide exchange factor, ARNO. In the present study, we showed that ARNO directly interacts not only with the a2-subunit but with all a-isoforms (a1-a4) of the V-ATPase, indicating a widespread regulatory interaction between V-ATPase and Arf GTPases. We then extended our search for other ARNO effectors that may modulate V-ATPase-dependent vesicular trafficking events and actin cytoskeleton remodeling. Pull-down experiments using cytosol of mouse proximal tubule cells (MTCs) showed that ARNO interacts with aldolase, but not with other enzymes of the glycolytic pathway. Direct interaction of aldolase with the pleckstrin homology domain of ARNO was revealed by pull-down assays using recombinant proteins, and surface plasmon resonance revealed their high avidity interaction with a dissociation constant: K(D) = 2.84 x 10(-10) M. MTC cell fractionation revealed that aldolase is also associated with membranes of early endosomes. Functionally, aldolase knockdown in HeLa cells produced striking morphological changes accompanied by long filamentous cell protrusions and acidic vesicle redistribution. However, the 50% knockdown we achieved did not modulate the acidification capacity of endosomal/lysosomal compartments. Finally, a combination of small interfering RNA knockdown and overexpression revealed that the expression of aldolase is inversely correlated with gelsolin levels in HeLa cells. In summary, we have shown that aldolase forms a complex with ARNO/Arf6 and the V-ATPase and that it may contribute to remodeling of the actin cytoskeleton and/or the trafficking and redistribution of V-ATPase-dependent acidic compartments via a combination of protein-protein interaction and gene expression mechanisms.
C1 [Marshansky, Vladimir] Massachusetts Gen Hosp, Program Membrane Biol, Ctr Syst Biol, Simches Res Ctr, Boston, MA 02114 USA.
[Marshansky, Vladimir] Massachusetts Gen Hosp, Div Nephrol, Ctr Syst Biol, Simches Res Ctr, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Marshansky, V (reprint author), Massachusetts Gen Hosp, Program Membrane Biol, Ctr Syst Biol, Simches Res Ctr, 185 Cambridge St,CPZN,Suite 8212, Boston, MA 02114 USA.
EM Vladimir_Marshansky@hms.harvard.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[DK038452]; Boston Area Diabetes Research Center NIDDK [DK057521-08]
FX This work was supported by National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) Grant DK038452 (to V. Marshansky, D. Brown,
and D. A. Ausiello) and a pilot and feasibility study supported by a
Boston Area Diabetes Research Center NIDDK Grant DK057521-08 (to V.
Marshansky).
NR 75
TC 25
Z9 25
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD JUN
PY 2011
VL 300
IS 6
BP C1442
EP C1455
DI 10.1152/ajpcell.00076.2010
PG 14
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 769LY
UT WOS:000291016400026
PM 21307348
ER
PT J
AU Wang, XR
Zhang, MW
Chen, DD
Zhang, Y
Chen, AF
AF Wang, Xiao-Rong
Zhang, Ming-Wei
Chen, Dan-Dan
Zhang, Yun
Chen, Alex F.
TI AMP-activated protein kinase rescues the angiogenic functions of
endothelial progenitor cells via manganese superoxide dismutase
induction in type 1 diabetes
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE protein phosphatase 2A; angiogenesis; oxidase stress
ID SUPPRESSING OXIDATIVE STRESS; NITRIC-OXIDE SYNTHASE; VASCULAR
COMPLICATIONS; SKELETAL-MUSCLE; UP-REGULATION; HYPERTENSION; EXPRESSION;
MICE; DIFFERENTIATION; VASCULOPATHY
AB Endothelial progenitor cells (EPCs) play an essential role in angiogenesis but are functionally impaired in diabetes. We recently reported that decreased expression of manganese superoxide dismutase (MnSOD) critically contributes to diabetic EPC dysfunction. AMP-activated protein kinase (AMPK) activation has been shown to induce MnSOD and suppress hyperglycemia-induced mitochondrial ROS production in endothelial cells. However, whether AMPK protects EPCs from oxidative stress in diabetes is unknown. We tested the hypothesis that AMPK activation rescues impaired EPC functions through MnSOD induction in type 1 diabetes. Bone marrow-derived EPCs from adult male streptozotocin-induced diabetic mice and normal controls were used. AMPK activity was decreased in diabetic EPCs, indicated by reduced AMPK and acetyl-CoA carboxylase phosphorylation. AMPK activation by treating diabetic EPCs with its selective agonist AICAR rescued their in vitro functions, including Matrigel tube formation, adhesion, and migration. Furthermore, AICAR restored the decreased MnSOD protein and enzymatic activity and suppressed the mitochondrial superoxide level in diabetic EPCs, indicated by MitoSOX flow cytometry. These beneficial effects of AICAR on MnSOD and EPC functions were significantly attenuated by silencing MnSOD or AMPK antagonist compound C pretreatment. Finally, the expression of protein phosphatase 2A, a key enzyme for AMPK dephosphorylation and inactivation, was increased in diabetic EPCs, and its inhibition by siRNA or okadaic acid reversed the deficient AMPK activation and MnSOD level in diabetic EPCs. These findings demonstrate for the first time that AMPK activation rescues impaired EPC functions and suppresses mitochondrial superoxide by inducing MnSOD in type 1 diabetes.
C1 [Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Vasc Med Inst,McGowan Inst Regenerat Med, Pittsburgh, PA 15213 USA.
[Wang, Xiao-Rong; Zhang, Ming-Wei; Zhang, Yun] Shandong Univ, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, Dept Cardiol,Qilu Hosp, Jinan 250100, Peoples R China.
[Wang, Xiao-Rong; Zhang, Ming-Wei; Zhang, Yun] Shandong Univ, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Publ Hlth, Dept Cardiol,Qilu Hosp, Jinan 250100, Peoples R China.
[Wang, Xiao-Rong; Zhang, Ming-Wei; Chen, Dan-Dan; Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Vasc Surg Res, Pittsburgh, PA USA.
RP Chen, AF (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, Vasc Med Inst,McGowan Inst Regenerat Med, W1148 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM chena5@upmc.edu
FU National Institute of General Medical Science [R01 GM-077352]; American
Diabetes Association [7-08-RA-23]; American Heart Association
[09POST2370060]
FX This work was funded by Grant R01 GM-077352 from the National Institute
of General Medical Science; Grant 7-08-RA-23 from the American Diabetes
Association (to A. F. Chen). X. R. Wang is the recipient of an American
Heart Association postdoctoral fellowship award (09POST2370060).
NR 42
TC 31
Z9 33
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JUN
PY 2011
VL 300
IS 6
BP E1135
EP E1145
DI 10.1152/ajpendo.00001.2011
PG 11
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 768SP
UT WOS:000290959000021
PM 21427411
ER
PT J
AU Haastrup, AA
Mendez, P
Cote, CJ
AF Haastrup, Adeniran A.
Mendez, Pedro
Cote, Charles J.
TI Suction the Tongue: A New Adjunct for Improving the Laryngeal View for
Fiberoptic Intubation
SO ANESTHESIA AND ANALGESIA
LA English
DT Letter
C1 [Haastrup, Adeniran A.; Mendez, Pedro; Cote, Charles J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol,Shriners Hosp Children, Boston, MA 02115 USA.
RP Haastrup, AA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol,Shriners Hosp Children, Boston, MA 02115 USA.
EM ahaastrup@partners.org
NR 4
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JUN
PY 2011
VL 112
IS 6
BP 1512
EP 1513
DI 10.1213/ANE.0b013e318215c905
PG 4
WC Anesthesiology
SC Anesthesiology
GA 768TL
UT WOS:000290961200049
PM 21613205
ER
PT J
AU Crosby, G
Culley, DJ
Hyman, BT
AF Crosby, Gregory
Culley, Deborah J.
Hyman, Bradley T.
TI Preoperative Cognitive Assessment of the Elderly Surgical Patient A Call
for Action
SO ANESTHESIOLOGY
LA English
DT Editorial Material
ID NONCARDIAC SURGERY; CARDIAC-SURGERY; DYSFUNCTION; IMPAIRMENT; DELIRIUM;
DISEASE; ILLNESS
C1 [Crosby, Gregory; Culley, Deborah J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
[Hyman, Bradley T.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Charlestown, MA USA.
[Hyman, Bradley T.] Alzheimer Dis Res Ctr, Charlestown, MA USA.
RP Crosby, G (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
EM gcrosby@zeus.bwh.harvard.edu
FU NIA NIH HHS [P50 AG005134, P50 AG005134-29]; NIGMS NIH HHS [GM088817,
K08 GM077057, K08 GM077057-05, R01 GM088817, R01 GM088817-08]
NR 17
TC 20
Z9 20
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD JUN
PY 2011
VL 114
IS 6
BP 1265
EP 1268
DI 10.1097/ALN.0b013e31821b1bc8
PG 4
WC Anesthesiology
SC Anesthesiology
GA 768PM
UT WOS:000290947500003
PM 21490501
ER
PT J
AU Gadikota, HR
Seon, JK
Chen, CH
Wu, JL
Gill, TJ
Li, GA
AF Gadikota, Hemanth R.
Seon, Jong Keun
Chen, Chih-Hui
Wu, Jia-Lin
Gill, Thomas J.
Li, Guoan
TI In Vitro and Intraoperative Laxities After Single-Bundle and
Double-Bundle Anterior Cruciate Ligament Reconstructions
SO ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY
LA English
DT Article
ID PATELLAR TENDON-BONE; NAVIGATED ACL RECONSTRUCTION; PIVOT-SHIFT;
BIOMECHANICAL ANALYSIS; HAMSTRING TENDON; JOINT KINEMATICS; TIBIAL
ROTATION; STABILITY; KNEE; GRAFT
AB Purpose: The purpose of this study was to objectively evaluate whether double-bundle anterior cruciate ligament (ACL) reconstruction can better restore the normal translational and rotational laxities than the conventional single-bundle ACL reconstruction among the reported biomechanical studies. Methods: A systematic literature search was conducted to identify in vitro and in vivo (intraoperative) biomechanical studies that compared the laxities (anterior or anteroposterior or rotational) between single-and double-bundle ACL reconstructions. Because of large variability among the loading conditions and testing methods used to determine the rotational laxities among the studies, a meta-analysis of rotational laxities was not feasible. Results: Seven in vitro and three in vivo studies were included in this analysis based on the predefined inclusion criteria. The overall mean differences calculated by the random effects model in anteroposterior laxity between the single-bundle and double-bundle ACL reconstruction techniques at 0 degrees, 30 degrees, 60 degrees, and 90 degrees of flexion were 0.99 mm, 0.38 mm, 0.34 mm, and 0.07 mm, respectively. No statistically significant difference was noted between the 2 treatments at all flexion angles. Among the 9 studies that compared the rotational laxity of single-bundle and double-bundle ACL reconstructions, 4 reported that double-bundle reconstruction can provide better rotational control than single-bundle reconstruction. The other 5 studies could not identify any significant difference between the 2 reconstructions in terms of rotational laxity. Conclusions: Both single-and double-bundle treatment options for ACL injury result in similar anteroposterior knee joint laxity at time 0. No conclusive evidence on the superiority of 1 reconstruction technique over the other in terms of rotation laxity can be obtained because of several variations in the experimental protocol and the kinematics used to measure the rotational laxity among the studies. Level of Evidence: Level III, meta-analysis.
C1 [Gadikota, Hemanth R.; Seon, Jong Keun; Chen, Chih-Hui; Wu, Jia-Lin; Gill, Thomas J.; Li, Guoan] Massachusetts Gen Hosp, Bioengn Lab, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Gadikota, Hemanth R.; Seon, Jong Keun; Chen, Chih-Hui; Wu, Jia-Lin; Gill, Thomas J.; Li, Guoan] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Seon, Jong Keun] Chonnam Natl Univ, Dept Orthopaed, Hwasun Hosp, Jeonnam, South Korea.
[Chen, Chih-Hui] Taichung Vet Gen Hosp, Dept Orthopaed Surg, Taichung, Taiwan.
[Wu, Jia-Lin] Natl Def Med Ctr, Dept Orthopaed Surg, Tri Serv Gen Hosp, Taipei, Taiwan.
RP Li, GA (reprint author), Massachusetts Gen Hosp, Bioengn Lab, Dept Orthopaed Surg, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
EM gli1@partners.org
FU National Institutes of Health [R01AR055612]
FX Supported by National Institutes of Health Grant No. R01AR055612. The
authors report no conflict of interest.
NR 46
TC 13
Z9 18
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-8063
J9 ARTHROSCOPY
JI Arthroscopy
PD JUN
PY 2011
VL 27
IS 6
BP 849
EP 860
DI 10.1016/j.arthro.2010.12.003
PG 12
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 769WB
UT WOS:000291047900019
PM 21624681
ER
PT J
AU Badr, CE
Wurdinger, T
Tannous, BA
AF Badr, Christian E.
Wurdinger, Thomas
Tannous, Bakhos A.
TI Functional Drug Screening Assay Reveals Potential Glioma Therapeutics
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
ID TRAIL-INDUCED APOPTOSIS; STEM-CELLS; IN-VIVO; LUCIFERASE; CANCER;
EXPRESSION; RESISTANCE; INHIBITOR; VARIANT; MODELS
AB Here we describe a novel functional screening assay based on bioluminescence monitoring of the naturally secreted Gaussia luciferase (Gluc) in the conditioned medium of cultured cells. Using this assay, we identified small-molecule drugs that sensitized brain tumor cells to the tumor necrosis factor-related apoptosis-inducing ligand-induced cell death. Human glioblastoma multiforme cells were engineered by gene transfer to express Gluc as a reporter for cell viability, which can be monitored over time by bioluminescence measurements using a plate luminometer. We have optimized the Gluc assay for screening and validated it using the National Institute of Neurological Disorders and Stroke (NINDS) custom collection II library consisting of 1,040 drugs and bioactive compounds, most of which are Food and Drug Administration-approved and are able to cross the blood-brain barrier. We found that the cardiac glycosides family sensitized glioblastoma multiforme cells to the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. In conclusion, the Gluc secretion assay is a robust tool for functional drug screening and can be applied to many different fields including cancer.
C1 [Badr, Christian E.; Wurdinger, Thomas; Tannous, Bakhos A.] Massachusetts Gen Hosp, Ctr Neurosci, Dept Neurol, Boston, MA 02129 USA.
[Badr, Christian E.; Wurdinger, Thomas; Tannous, Bakhos A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
[Badr, Christian E.; Wurdinger, Thomas] Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, Neurooncol Res Grp, Amsterdam, Netherlands.
[Wurdinger, Thomas; Tannous, Bakhos A.] Massachusetts Gen Hosp, Dept Radiol, Ctr Mol Imaging Res, Boston, MA 02114 USA.
RP Tannous, BA (reprint author), Massachusetts Gen Hosp E, Ctr Neurosci, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM btannous@hms.harvard.edu
FU National Institutes of Health/National Cancer Institute [4R00CA126839];
National Institutes of Health/National Institute of Neurological
Disorders and Stroke [1R21NS061051, NS045776, 1R01NS064983]; American
Brain Tumor Association; Executive Committee on Research at
Massachusetts General Hospital
FX The authors thank Dr. Robert Carter for providing the tumor tissue
sections from GBM patients, Dr. Johan Skog for dissociation of these
cells, and Mrs. Jorien Koelen for technical help. The authors are
grateful to Dr. Xandra Breakefield for her significant input on this
work and Drs. Hang Lee and Patrick Sluss for statistical analysis
guidance. This work was supported by grants from the National Institutes
of Health/National Cancer Institute (4R00CA126839), National Institutes
of Health/National Institute of Neurological Disorders and Stroke
(1R21NS061051, NS045776, and 1R01NS064983 to B. A. T.), the American
Brain Tumor Association (to T. W.), Executive Committee on Research at
Massachusetts General Hospital (to C.B.).
NR 26
TC 13
Z9 13
U1 2
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD JUN
PY 2011
VL 9
IS 3
BP 281
EP 289
DI 10.1089/adt.2010.0324
PG 9
WC Biochemical Research Methods; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 769LD
UT WOS:000291014100006
PM 21184646
ER
PT J
AU Richardson, PG
Chanan-Khan, AA
Lonial, S
Krishnan, AY
Carroll, MP
Alsina, M
Albitar, M
Berman, D
Messina, M
Anderson, KC
AF Richardson, Paul G.
Chanan-Khan, Asher A.
Lonial, Sagar
Krishnan, Amrita Y.
Carroll, Michael P.
Alsina, Melissa
Albitar, Maher
Berman, David
Messina, Marianne
Anderson, Kenneth C.
TI Tanespimycin and bortezomib combination treatment in patients with
relapsed or relapsed and refractory multiple myeloma: results of a phase
1/2 study
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE tanespimycin; bortezomib; myeloma; heat shock protein 90; proteasome
ID CANCER STATISTICS; DOSE-ESCALATION; ADULT PATIENTS; SOLID TUMORS; I
TRIAL; INHIBITION; HSP90; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN;
KOS-953; THERAPY
AB P>This open-label, dose escalation, multicentre phase 1/2 trial was undertaken to determine the safety and tolerability of the heat shock protein 90 (HSP90) inhibitor tanespimycin (100-340 mg/m2) + bortezomib (0 center dot 7-1 center dot 3 mg/m2) given on days 1, 4, 8 and 11 in each 21-d cycle. Phase 2 expansion occurred at the highest tested dose of tanespimycin at 340 mg/m2 and bortezomib at 1 center dot 3 mg/m2. Seventy-two patients (median age, 60 years) with relapsed or relapsed and refractory multiple myeloma (MM) were enrolled; 63 patients (89%) completed the study. Tanespimycin in combination with bortezomib was well tolerated; few patients experienced significant neutropenia, constipation and anorexia (< 10%), and no patients developed severe peripheral neuropathy. Among 67 efficacy-evaluable patients, there were 2 (3%) complete responses and 8 (12%) partial responses, for an objective response rate (ORR) of 27%, including 8 (12%) minimal responses. Response rates were highest among bortezomib-naive patients and proved durable in all patient subgroups, including those with bortezomib-refractory disease. Pharmacodynamic analyses indicated that tanespimycin plus bortezomib effectively inhibited the proteasome, as evidenced by decreased 20S proteasome activity, and inhibited HSP90, as reflected by increased HSP70 expression. The results of this study support additional studies of this combination approach in MM.
C1 [Richardson, Paul G.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chanan-Khan, Asher A.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Krishnan, Amrita Y.] City Hope Natl Med Ctr, Duarte, CA USA.
[Carroll, Michael P.] Sutter Reg Canc Inst, Sacramento, CA USA.
[Alsina, Melissa] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Albitar, Maher] Quest Diagnost Nichols Inst, San Juan Capistrano, CA USA.
[Berman, David] Bristol Myers Squibb Co, Princeton, NJ USA.
[Messina, Marianne] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA.
RP Richardson, PG (reprint author), Dana Farber Canc Inst, 44 Binney St,Dana 1B02, Boston, MA 02115 USA.
EM paul_richardson@dfci.harvard.edu
FU Bristol-Myers Squibb (Kosan Biosciences); Millennium Pharmaceuticals;
Celgene Corporation; Novartis; Bristol-Myers Squibb; Gloucester
Pharmaceuticals; Facet Biotech; Centocor Ortho Biotech Inc.
FX The authors would like to thank the research nurses, physicians,
coordinators, and other staff at the Dana-Farber Cancer Institute;
Roswell Park Cancer Institute; Emory University, The Winship Cancer
Institute; City of Hope; Sutter Regional Cancer Institute; H. Lee
Moffitt Cancer Center; and Quest Diagnostics Nichols Institute. The
authors would also like to thank Alison L. Hannah, MD, consultant, for
her contributions to the study and study design, as well as Bindu
Murthy, PharmD. The authors are most grateful to Monica Nicosia, PhD,
Mary Dominiecki, PhD, Anne Lambert, MS, Robert O'Beirne, Andrew Graham,
Katie Rogers, and Ted Everson, PhD for graphics and editorial
assistance, and Katie Redman for administrative assistance in the
preparation of this manuscript. Finally, we would especially like to
thank the patients and their families for their participation. This
study was sponsored by Bristol-Myers Squibb (and previously Kosan
Biosciences).; Dr. Richardson serves on advisory boards to Millennium
Pharmaceuticals, Inc., Celgene Corporation, Johnson & Johnson, Novartis,
and Bristol-Myers Squibb. Dr. Chanan-Khan is on the speakers' bureaus
and receives honoraria from Celgene Corporation, ImmunoGen, Inc., and
Millennium Pharmaceuticals. Dr. Lonial is a consultant for Millennium
Pharmaceuticals, Celgene Corporation, Novartis, Bristol-Myers Squibb,
and Facet Biotech.* He has received research funding from Millennium
Pharmaceuticals, Celgene Corporation, Novartis, Bristol-Myers Squibb,
Gloucester Pharmaceuticals, and Facet Biotech.* Dr. Krishnan is on the
speakers bureaus for Millennium Pharmaceuticals and Celgene Corporation,
and is a consultant for Celgene Corporation. Dr. Alsina has received
commercial research grants from Millennium Pharmaceuticals and Centocor
Ortho Biotech Inc., and is a consultant for Millennium Pharmaceuticals
and Celgene Corporation. Drs. Carroll and Albitar have no relevant
conflicts of interest to disclose. Dr. Berman and Ms. Messina are
employees of Bristol-Myers Squibb and have no relevant conflicts of
interest to disclose. Dr. Anderson is a consultant for Celgene
Corporation, Novartis, Millennium Pharmaceuticals, and Bristol-Myers
Squibb. He receives research funding from Celgene Corporation, Novartis,
Millennium Pharmaceuticals, and Bristol-Myers Squibb, and he has
received honoraria from Celgene Corporation, Novartis, Millennium
Pharmaceuticals, and Bristol-Myers Squibb. *Facet Biotech is now Abbott
Biotherapeutics Corp.
NR 31
TC 61
Z9 66
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JUN
PY 2011
VL 153
IS 6
BP 729
EP 740
DI 10.1111/j.1365-2141.2011.08664.x
PG 12
WC Hematology
SC Hematology
GA 769UR
UT WOS:000291044300005
PM 21534941
ER
PT J
AU Sacks, DB
Arnold, M
Bakris, GL
Bruns, DE
Horvath, AR
Kirkman, MS
Lernmark, A
Metzger, BE
Nathan, DM
AF Sacks, David B.
Arnold, Mark
Bakris, George L.
Bruns, David E.
Horvath, Andrea Rita
Kirkman, M. Sue
Lernmark, Ake
Metzger, Boyd E.
Nathan, David M.
TI Executive Summary: Guidelines and Recommendations for Laboratory
Analysis in the Diagnosis and Management of Diabetes Mellitus
SO CLINICAL CHEMISTRY
LA English
DT Editorial Material
ID US
AB BACKGROUND: Multiple laboratory tests are used in the diagnosis and management of patients with diabetes mellitus. The quality of the scientific evidence supporting the use of these assays varies substantially.
APPROACH: An expert committee compiled evidence-based recommendations for the use of laboratory analysis in patients with diabetes. A new system was developed to grade the overall quality of the evidence and the strength of the recommendations. A draft of the guidelines was posted on the Internet, and the document was modified in response to comments. The guidelines were reviewed by the joint Evidence-Based Laboratory Medicine Committee of the AACC and the National Academy of Clinical Biochemistry and were accepted after revisions by the Professional Practice Committee and subsequent approval by the Executive Committee of the American Diabetes Association.
CONTENT: In addition to the long-standing criteria based on measurement of venous plasma glucose, diabetes can be diagnosed by demonstrating increased hemoglobin A(1c) (Hb A(1c)) concentrations in the blood. Monitoring of glycemic control is performed by the patients measuring their own plasma or blood glucose with meters and by laboratory analysis of Hb A(1c). The potential roles of noninvasive glucose monitoring, genetic testing, and measurement of autoantibodies, urine albumin, insulin, proinsulin, C-peptide, and other analytes are addressed.
SUMMARY: The guidelines provide specific recommendations based on published data or derived from expert consensus. Several analytes are found to have minimal clinical value at the present time, and measurement of them is not recommended. (C) 2011 American Association for Clinical Chemistry and American Diabetes Association
C1 [Sacks, David B.] NIH, Dept Lab Med, Bethesda, MD 20892 USA.
[Arnold, Mark] Univ Iowa, Dept Chem, Iowa City, IA 52242 USA.
[Bakris, George L.] Univ Chicago, Dept Med, Hypertens Dis Unit, Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA.
[Bruns, David E.] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.
[Horvath, Andrea Rita] Univ Sydney, Screening & Test Evaluat Program, Sch Publ Hlth, SEALS Dept Clin Chem,Prince Wales Hosp, Sydney, NSW 2006, Australia.
[Kirkman, M. Sue] Amer Diabet Assoc, Alexandria, VA USA.
[Lernmark, Ake] Lund Univ, Dept Clin Sci, CRC, Skane Univ Hosp Malmo, Malmo, Sweden.
[Metzger, Boyd E.] Northwestern Univ, Div Endocrinol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Nathan, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nathan, David M.] Harvard Univ, Sch Med, Ctr Diabet, Boston, MA USA.
RP Sacks, DB (reprint author), NIH, Dept Lab Med, 10 Ctr Dr,Bldg 10,Rm 2C306, Bethesda, MD 20892 USA.
EM sacksdb@mail.nih.gov
OI Sacks, David/0000-0003-3100-0735
NR 8
TC 43
Z9 44
U1 1
U2 6
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2011
VL 57
IS 6
BP 793
EP 798
DI 10.1373/clinchem.2011.163634
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 769PF
UT WOS:000291028600002
PM 21617153
ER
PT J
AU Sacks, DB
Arnold, M
Bakris, GL
Bruns, DE
Horvath, AR
Kirkman, MS
Lernmark, A
Metzger, BE
Nathan, DM
AF Sacks, David B.
Arnold, Mark
Bakris, George L.
Bruns, David E.
Horvath, Andrea Rita
Kirkman, M. Sue
Lernmark, Ake
Metzger, Boyd E.
Nathan, David M.
TI Guidelines and Recommendations for Laboratory Analysis in the Diagnosis
and Management of Diabetes Mellitus
SO CLINICAL CHEMISTRY
LA English
DT Article
ID GLUTAMIC-ACID DECARBOXYLASE; POINT-OF-CARE; NUTRITION EXAMINATION
SURVEY; RANDOMIZED CONTROLLED-TRIAL; IMPAIRED FASTING GLUCOSE;
GENOME-WIDE ASSOCIATION; ANTIBODY STANDARDIZATION PROGRAM;
PROTEIN-TYROSINE-PHOSPHATASE; HEMOGLOBIN A(1C) MEASUREMENT;
COST-EFFECTIVENESS ANALYSIS
AB BACKGROUND: Multiple laboratory tests are used to diagnose and manage patients with diabetes mellitus. The quality of the scientific evidence supporting the use of these tests varies substantially.
APPROACH: An expert committee compiled evidence-based recommendations for the use of laboratory testing for patients with diabetes. A new system was developed to grade the overall quality of the evidence and the strength of the recommendations. Draft guidelines were posted on the Internet and presented at the 2007 Arnold O. Beckman Conference. The document was modified in response to oral and written comments, and a revised draft was posted in 2010 and again modified in response to written comments. The National Academy of Clinical Biochemistry and the Evidence Based Laboratory Medicine Committee of the AACC jointly reviewed the guidelines, which were accepted after revisions by the Professional Practice Committee and subsequently approved by the Executive Committee of the American Diabetes Association.
CONTENT: In addition to long-standing criteria based on measurement of plasma glucose, diabetes can be diagnosed by demonstrating increased blood hemoglobin A(1c) (Hb A(1c)) concentrations. Monitoring of glycemic control is performed by self-monitoring of plasma or blood glucose with meters and by laboratory analysis of Hb A(1c). The potential roles of noninvasive glucose monitoring, genetic testing, and measurement of autoantibodies, urine albumin, insulin, proinsulin, C-peptide, and other analytes are addressed.
SUMMARY: The guidelines provide specific recommendations that are based on published data or derived from expert consensus. Several analytes have minimal clinical value at present, and their measurement is not recommended. (C) 2011 American Association for Clinical Chemistry and American Diabetes Association
C1 [Sacks, David B.] NIH, Dept Lab Med, Bethesda, MD 20892 USA.
[Arnold, Mark] Univ Iowa, Dept Chem, Iowa City, IA 52242 USA.
[Bakris, George L.] Univ Chicago, Dept Med, Hypertens Dis Unit, Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA.
[Bruns, David E.] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.
[Horvath, Andrea Rita] Univ Sydney, Sch Publ Hlth, Screening & Test Evaluat Program, SEALS Dept Clin Chem,Prince Wales Hosp, Sydney, NSW 2006, Australia.
[Kirkman, M. Sue] Amer Diabet Assoc, Alexandria, VA USA.
[Lernmark, Ake] Lund Univ, CRC, Skane Univ Hosp Malmo, Dept Clin Sci, Malmo, Sweden.
[Metzger, Boyd E.] Northwestern Univ, Feinberg Sch Med, Div Endocrinol, Chicago, IL 60611 USA.
[Nathan, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nathan, David M.] Harvard Univ, Sch Med, Ctr Diabet, Boston, MA USA.
RP Sacks, DB (reprint author), NIH, Dept Lab Med, 10 Ctr Dr,Bldg 10,Rm 2C306, Bethesda, MD 20892 USA.
EM sacksdb@mail.nih.gov
OI Sacks, David/0000-0003-3100-0735
FU GlaxoSmithKline; Forest Laboratories; Novartis; PepsiCo; Abbott
Diagnostics; Siemens; NIH; Partnership for Clean Competition
FX G.L. Bakris, GlaxoSmithKline, Forest Laboratories, Novartis, and
PepsiCo; D.E. Bruns, Abbott Diagnostics, Siemens, NIH, and Partnership
for Clean Competition.
NR 381
TC 140
Z9 148
U1 2
U2 35
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2011
VL 57
IS 6
BP E1
EP E47
DI 10.1373/clinchem.2010.161596
PG 47
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 769PF
UT WOS:000291028600001
PM 21617152
ER
PT J
AU Zheng, H
Nathan, DM
Schoenfeld, DA
AF Zheng, Hui
Nathan, David M.
Schoenfeld, David A.
TI Using A Multi-Level B-Spline Model to Analyze and Compare Patient
Glucose Profiles Based on Continuous Monitoring Data
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID REAL-TIME; PENALTIES
AB Objective: We show how continuous glucose monitoring (CGM) data can be analyzed using a three-level B-spline model, facilitating the estimation of inter-patient variability, within-patient inter-day variability, and measurement error. We propose methods for statistical comparison of glucose profiles among patient groups.
Methods: We applied a three-level random effects model using quadratic B-spline functions to analyze inter-patient and within-patient inter-day variations of the glucose trend. The estimated SD values of the glucose curves are time-dependent and were averaged over a 24-h period. We analyzed CGM data from 322 patients with type 1 diabetes, 223 patients with type 2 diabetes, and 86 subjects without diabetes using interstitial glucose levels measured every 5 min, for approximately 8 days per patient. We compared group-wide glucose profiles from the insulin pump-treated (n = 124) and multiple daily injection (MDI)-treated (n = 144) patients with type 1 diabetes.
Results: The average inter-patient SD values were 49 mg/dL, 43 mg/dL, and 15 mg/dL for type 1 diabetes patients, type 2 diabetes patients, and subjects without diabetes, respectively. The average within-patient, inter-day SD values were 67 mg/dL, 41 mg/dL, and 18 mg/dL, respectively. The residual SD values were 19 mg/dL, 14 mg/dL, and 8 mg/dL, respectively. We identified a statistically significant difference in glucose profiles during the morning between insulin pump-treated and MDI-treated type 1 diabetes patients.
Conclusions: B-spline models facilitate the analysis of CGM data and show that type 1 diabetes is associated with higher inter-day glucose variation than type 2 diabetes or being without diabetes. Pump therapy and MDI have different effects on glucose control during specific time periods.
C1 [Zheng, Hui; Schoenfeld, David A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02446 USA.
[Zheng, Hui; Nathan, David M.; Schoenfeld, David A.] Harvard Univ, Sch Med, Boston, MA USA.
[Nathan, David M.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02446 USA.
RP Zheng, H (reprint author), Massachusetts Gen Hosp, Ctr Biostat, 5th Floor,Suite 560,50 Staniford St, Boston, MA 02446 USA.
EM hzheng1@partners.org
FU Massachusetts General Hospital; Harvard Catalyst; Harvard Clinical and
Translational Science Center (National Institutes of Health) [UL1 RR
025758]; Harvard University; American Diabetes Association
[7-06-A1C-11]; European Association for the Study of Diabetes; Abbott
Diabetes Care; Bayer Healthcare; GlaxoSmithKline; Sanofi-Aventis
Netherlands; Merck Company; Lifescan, Inc.; Medtronic MiniMed
FX Support for the current analyses was provided by the Charlton Fund for
Innovative Diabetes Research at Massachusetts General Hospital and from
Harvard Catalyst, The Harvard Clinical and Translational Science Center
(National Institutes of Health Award number UL1 RR 025758 and financial
contributions from Harvard University and its affiliated academic health
care centers). ADAG was supported by research grants from the American
Diabetes Association (7-06-A1C-11) and the European Association for the
Study of Diabetes. Financial support for ADAG was provided by Abbott
Diabetes Care, Bayer Healthcare, GlaxoSmithKline, Sanofi-Aventis
Netherlands, Merck & Company, Lifescan, Inc., and Medtronic MiniMed, and
supplies and equipment were provided by Medtronic MiniMed, Lifescan,
Inc., and Hemocue. A complete listing of the ADAG Research Group can be
found in Nathan et al.9 The content is solely the
responsibility of the authors and does not necessarily represent the
official views of Harvard Catalyst, Harvard University and its
affiliated academic health care centers, the National Center for
Research Resources, the National Institutes of Health, or the ADAG
Research Group.
NR 19
TC 1
Z9 1
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
EI 1557-8593
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD JUN
PY 2011
VL 13
IS 6
BP 675
EP 682
DI 10.1089/dia.2010.0199
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 769JP
UT WOS:000291009000012
PM 21488799
ER
PT J
AU Kim, Y
Mylonakis, E
AF Kim, Younghoon
Mylonakis, Eleftherios
TI Killing of Candida albicans Filaments by Salmonella enterica Serovar
Typhimurium Is Mediated by sopB Effectors, Parts of a Type III Secretion
System
SO EUKARYOTIC CELL
LA English
DT Article
ID BIOFILM FORMATION; CAENORHABDITIS-ELEGANS; ESCHERICHIA-COLI;
STREPTOCOCCUS-GORDONII; QUANTITATIVE PCR; EPITHELIAL-CELLS;
GENE-EXPRESSION; HYPHAL GROWTH; HOST-CELLS; PROTEIN
AB Although bacterial-fungal interactions shape microbial virulence during polymicrobial infections, only a limited number of studies have evaluated this interaction on a genetic level. We report here that one interaction is mediated by sopB, an effector of a type III secretion system (TTSS) of Salmonella enterica serovar Typhimurium. In these studies, we screened 10 TTSS effector-related mutants and determined their role in the killing of C. albicans filaments in vitro during coinfection in planktonic environments. We found that deleting the sopB gene (which encodes inositol phosphatase) was associated with a significant decrease in C. albicans killing at 25 degrees C after 5 days, similar to that caused by the deletion of sipB (which encodes TTSS translocation machinery components). The sopB deletion dramatically influenced the killing of C. albicans filaments. It was associated with repressed filamentation in the Caenorhabditis elegans model of C. albicans-S. Typhimurium coinfection, as well as with biofilm formation by C. albicans. We confirmed that SopB translocated to fungal filaments through SipB during coinfection. Using quantitative real-time PCR assays, we found that the Candida supernatant upregulated the S. Typhimurium genes associated with C. albicans killing (sopB and sipB). Interestingly, the sopB effector negatively regulated the transcription of CDC42, which is involved in fungal viability. Taken together, these results indicate that specific TTSS effectors, including SopB, play a critical role in bacterial-fungal interactions and are important to S. Typhimurium in order to selectively compete with fungal pathogens. These findings highlight a new role for TTSS of S. Typhimurium in the intestinal tract and may further explain the evolution and maintenance of these traits.
C1 [Kim, Younghoon; Mylonakis, Eleftherios] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA.
RP Mylonakis, E (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA.
EM emylonakis@partners.org
FU National Institutes of Health [P01 AI083214, R01 AI075286, R21 AI079569]
FX This study was supported by grants from the National Institutes of
Health (P01 AI083214, R01 AI075286, and R21 AI079569) to E.M.
NR 74
TC 15
Z9 20
U1 2
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1535-9778
J9 EUKARYOT CELL
JI Eukaryot. Cell
PD JUN
PY 2011
VL 10
IS 6
BP 782
EP 790
DI 10.1128/EC.00014-11
PG 9
WC Microbiology; Mycology
SC Microbiology; Mycology
GA 770MP
UT WOS:000291091100009
PM 21498643
ER
PT J
AU Chen, YL
Brand, A
Morrison, EL
Silao, FGS
Bigol, UG
Malbas, FF
Nett, JE
Andes, DR
Solis, NV
Filler, SG
Averette, A
Heitman, J
AF Chen, Ying-Lien
Brand, Alexandra
Morrison, Emma L.
Silao, Fitz Gerald S.
Bigol, Ursela G.
Malbas, Fedelino F., Jr.
Nett, Jeniel E.
Andes, David R.
Solis, Norma V.
Filler, Scott G.
Averette, Anna
Heitman, Joseph
TI Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in
Candida dubliniensis
SO EUKARYOTIC CELL
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CRYPTOCOCCUS-NEOFORMANS;
ASPERGILLUS-FUMIGATUS; OROPHARYNGEAL CANDIDIASIS; ANTIFUNGAL
SUSCEPTIBILITY; TRANSCRIPTION FACTOR; DENTURE STOMATITIS; INFECTED
PATIENTS; CALCOFLUOR WHITE; GENE-EXPRESSION
AB Candida dubliniensis is an emerging pathogenic yeast species closely related to Candida albicans and frequently found colonizing or infecting the oral cavities of HIV/AIDS patients. Drug resistance during C. dubliniensis infection is common and constitutes a significant therapeutic challenge. The calcineurin inhibitor FK506 exhibits synergistic fungicidal activity with azoles or echinocandins in the fungal pathogens C. albicans, Cryptococcus neoformans, and Aspergillus fumigatus. In this study, we show that calcineurin is required for cell wall integrity and wild-type tolerance of C. dubliniensis to azoles and echinocandins; hence, these drugs are candidates for combination therapy with calcineurin inhibitors. In contrast to C. albicans, in which the roles of calcineurin and Crz1 in hyphal growth are unclear, here we show that calcineurin and Crz1 play a clearly demonstrable role in hyphal growth in response to nutrient limitation in C. dubliniensis. We further demonstrate that thigmotropism is controlled by Crz1, but not calcineurin, in C. dubliniensis. Similar to C. albicans, C. dubliniensis calcineurin enhances survival in serum. C. dubliniensis calcineurin and crz1/crz1 mutants exhibit attenuated virulence in a murine systemic infection model, likely attributable to defects in cell wall integrity, hyphal growth, and serum survival. Furthermore, we show that C. dubliniensis calcineurin mutants are unable to establish murine ocular infection or form biofilms in a rat denture model. That calcineurin is required for drug tolerance and virulence makes fungus-specific calcineurin inhibitors attractive candidates for combination therapy with azoles or echinocandins against emerging C. dubliniensis infections.
C1 [Chen, Ying-Lien; Averette, Anna; Heitman, Joseph] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.
[Brand, Alexandra; Morrison, Emma L.] Univ Aberdeen, Inst Med Sci, Sch Med Sci, Aberdeen Fungal Grp, Aberdeen, Scotland.
[Silao, Fitz Gerald S.] Dr Jose G Tamayo Med Univ, Univ Perpetual Help, Dept Microbiol & Parasitol, Binan, Laguna, Philippines.
[Bigol, Ursela G.] Dept Sci & Technol, Environm & Biotechnol Div, Bicutan, Philippines.
[Malbas, Fedelino F., Jr.] Res Inst Trop Med, Alabang, Philippines.
[Nett, Jeniel E.; Andes, David R.] Univ Wisconsin, Dept Med, Madison, WI USA.
[Nett, Jeniel E.; Andes, David R.] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA.
[Nett, Jeniel E.; Andes, David R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Solis, Norma V.; Filler, Scott G.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA.
[Filler, Scott G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Heitman, J (reprint author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.
EM heitm001@duke.edu
OI Brand, Alexandra/0000-0002-7381-131X; Chen,
Ying-Lien/0000-0002-1966-470X
FU Duke University Center for AIDS Research (CFAR) [2P30 AI064518-06]; NIH
[P30 AI64518, R01DE017088]; NIH/NIAID [AI42159, AI50438]
FX This research was supported by the Duke University Center for AIDS
Research (CFAR grant 2P30 AI064518-06 to Y.-L. Chen), NIH-funded program
P30 AI64518 to Duke University, and NIH/NIAID R01 grants AI42159 and
AI50438 (to J. Heitman). S. G. Filler and N. V. Solis were supported in
part by NIH grant R01DE017088.
NR 91
TC 41
Z9 43
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1535-9778
J9 EUKARYOT CELL
JI Eukaryot. Cell
PD JUN
PY 2011
VL 10
IS 6
BP 803
EP 819
DI 10.1128/EC.00310-10
PG 17
WC Microbiology; Mycology
SC Microbiology; Mycology
GA 770MP
UT WOS:000291091100011
PM 21531874
ER
PT J
AU Kang, ES
Magkos, F
Sienkiewicz, E
Mantzoros, CS
AF Kang, Eun Seok
Magkos, Faidon
Sienkiewicz, Elizabeth
Mantzoros, Christos S.
TI Circulating vaspin and visfatin are not affected by acute or chronic
energy deficiency or leptin administration in humans
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID SERINE-PROTEASE INHIBITOR; METHIONYL HUMAN LEPTIN; ADIPOSE-TISSUE;
INSULIN-RESISTANCE; WEIGHT-LOSS; BARIATRIC SURGERY; SERUM VISFATIN;
OBESE WOMEN; HEALTHY-MEN; IN-VIVO
AB Objective: Animal and in vitro studies indicate that leptin alleviates starvation-induced reduction in circulating vaspin and stimulates the production of visfatin. We thus examined whether vaspin and visfatin are affected by short-and long-term energy deprivation and leptin administration in human subjects in vivo.
Design and methods: We measured circulating levels of vaspin and visfatin i) before and after 72 h of starvation (leading to severe hypoleptinemia) with or without leptin administration in replacement doses in 13 normal-weight subjects, ii) before and after 72 h of starvation with leptin administration in pharmacological doses in 13 lean and obese subjects, iii) during chronic energy deficiency in eight women with hypothalamic amenorrhea on leptin replacement for 3 months, and iv) during chronic energy deficiency in 18 women with hypothalamic amenorrhea on leptin replacement or placebo for 3 months.
Results: Acute starvation decreased serum leptin to 21% of baseline values, (P=0.002) but had no significant effect on vaspin and visfatin concentrations (P > 0.05). Nor did normalization of leptin levels affect the concentrations of these two adipokines (P > 0.9). Leptin replacement in women with hypothalamic amenorrhea did not significantly alter vaspin and visfatin concentrations, whether relative to baseline or placebo administration (P > 0.25). Pharmacological doses of leptin did not affect circulating vaspin and visfatin concentrations (P > 0.9).
Conclusions: Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency leading to hypoleptinemia and are not regulated by leptin in human subjects, indicating that these adipocyte-secreted hormonal regulators of metabolism are independently regulated in humans.
C1 [Kang, Eun Seok; Magkos, Faidon; Sienkiewicz, Elizabeth; Mantzoros, Christos S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab,Dept Med, Boston, MA 02215 USA.
[Kang, Eun Seok] Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab,Severance Hosp Diabet Ctr, Seoul, South Korea.
[Mantzoros, Christos S.] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Endocrinol Sect, Boston, MA 02130 USA.
[Mantzoros, Christos S.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
RP Kang, ES (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab,Dept Med, 330 Brookline Ave,SL Room 412, Boston, MA 02215 USA.
EM ekang@bidmc.harvard.edu
FU Harvard Clinical and Translational Science Center, from the National
Center for Research Resources [UL1 RR025758, M01-RR-01032-]; National
Institute of Diabetes and Digestive and Kidney Diseases [DK58785,
DK79929, DK81913, AG032030]; Yonsei University College of Medicine
[6-2011-0000]; Korean Government MEST [NRF-2010-013-E0008]; Beth Israel
Deaconess Medical Center
FX This work was supported by Grant Number UL1 RR025758 and M01-RR-01032-
Harvard Clinical and Translational Science Center, from the National
Center for Research Resources. The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the National Center for Research Resources or the National Institutes of
Health. Funding was received from the National Institute of Diabetes and
Digestive and Kidney Diseases grants DK58785, DK79929, and DK81913,
AG032030; a faculty research grant from Yonsei University College of
Medicine (6-2011-0000); and the National Research Foundation of Korea
(Grant funded by the Korean Government MEST, Basic Research Promotion
Fund, NRF-2010-013-E0008). The Mantzoros Laboratory is also supported by
a discretionary grant from Beth Israel Deaconess Medical Center. Amgen,
Inc., and Amylin Pharmaceuticals, Inc., supplied metreleptin for this
study and approved the design of the study but had no role in the study
design; conduct of the study; collection, management, analysis, and
interpretation of the data; or the preparation, review, or approval of
the manuscript.
NR 43
TC 11
Z9 14
U1 0
U2 3
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 0804-4643
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD JUN
PY 2011
VL 164
IS 6
BP 911
EP 917
DI 10.1530/EJE-11-0052
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 769MZ
UT WOS:000291020500008
PM 21422197
ER
PT J
AU Desalermos, A
Muhammed, M
Glavis-Bloom, J
Mylonakis, E
AF Desalermos, Athanasios
Muhammed, Maged
Glavis-Bloom, Justin
Mylonakis, Eleftherios
TI Using Caenorhabditis elegans for antimicrobial drug discovery
SO EXPERT OPINION ON DRUG DISCOVERY
LA English
DT Review
DE Caenorhabditis elegans; Candida albicans; drug discovery; high
throughput; model host
ID THROUGHPUT SCREENING ASSAYS; HOST-PATHOGEN INTERACTIONS; ANIMAL
INFECTION MODEL; CRYPTOCOCCUS-NEOFORMANS; C-ELEGANS; CANDIDA-ALBICANS;
INNATE IMMUNITY; ACINETOBACTER-BAUMANNII; ANTIFUNGAL COMPOUNDS;
ALZHEIMERS-DISEASE
AB Introduction: The number of microorganism strains with resistance to known antimicrobials is increasing. Therefore, there is a high demand for new, nontoxic and efficient antimicrobial agents. Research with the microscopic nematode Caenorhabditis elegans can address this high demand for the discovery of new antimicrobial compounds. In particular, C. elegans can be used as a model host for in vivo drug discovery through high-throughput screens of chemical libraries.
Areas covered: This review introduces the use of substitute model hosts and especially C. elegans in the study of microbial pathogenesis. The authors also highlight recently published literature on the role of C. elegans in drug discovery and outline its use as a promising host with unique advantages in the discovery of new antimicrobial drugs.
Expert opinion: Caenorhabditis elegans can be used, as a model host, to research many diseases, including fungal infections and Alzheimer's disease. In addition, high-throughput techniques for screening chemical libraries can also be facilitated. Nevertheless, C. elegans and mammals have significant differences that both limit the use of the nematode in research and the degree by which results can be interpreted. That being said, the use of C. elegans in drug discovery still holds promise and the field continues to grow, with attempts to improve the methodology already underway.
C1 [Desalermos, Athanasios; Muhammed, Maged; Glavis-Bloom, Justin; Mylonakis, Eleftherios] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA.
RP Mylonakis, E (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, 55 Fruit St,Gray Jackson 5,Room GRJ 504, Boston, MA 02114 USA.
EM emylonakis@partners.org
FU NIH [P01 AI 083214, R01 AI075286, R21 AI079569]; Astellas Pharma, Inc.
FX The authors work has been supported by NIH grants P01 AI 083214, R01
AI075286 and R21 AI079569. E Mylonakis has served on an Advisory Board
and received research support from Astellas Pharma, Inc. The authors
declare no other conflict of interest.
NR 93
TC 12
Z9 13
U1 3
U2 19
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1746-0441
EI 1746-045X
J9 EXPERT OPIN DRUG DIS
JI Expert. Opin. Drug Discov.
PD JUN
PY 2011
VL 6
IS 6
BP 645
EP 652
DI 10.1517/17460441.2011.573781
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 768VJ
UT WOS:000290966200005
PM 21686092
ER
PT J
AU Hofstatter, EW
Domchek, SM
Miron, A
Garber, J
Wang, M
Componeschi, K
Boghossian, L
Miron, PL
Nathanson, KL
Tung, N
AF Hofstatter, Erin W.
Domchek, Susan M.
Miron, Alexander
Garber, Judy
Wang, Molin
Componeschi, Kathryn
Boghossian, Leigh
Miron, Penelope L.
Nathanson, Katherine L.
Tung, Nadine
TI PALB2 mutations in familial breast and pancreatic cancer
SO FAMILIAL CANCER
LA English
DT Article
DE BRCA2; Breast cancer; PALB2; Pancreatic cancer
ID BRCA2-INTERACTING PROTEIN; SUSCEPTIBILITY GENE; FANCONI-ANEMIA; BRCA2;
ELECTROPHORESIS
AB PALB2 (Partner And Localizer of BRCA2) binds to and co-localizes with BRCA2 in DNA repair. Germline mutations in PALB2 have been identified in approximately 1-2% of familial breast cancer and 3-4% of familial pancreatic cancer cases. The goal of this study was to evaluate the prevalence of PALB2 mutations in women with breast cancer without BRCA1/2 mutations who also had a personal or family history of pancreatic cancer. PALB2 mutation analysis was performed in 94 non-BRCA1/2 breast cancer patients with a personal or family history of pancreatic cancer. Two truncating PALB2 mutations, c.3549C > CA and c.2962C > CT, were identified resulting in a mutation prevalence of 2.1%. The proband found to carry the c.3549C > CA PALB2 mutation had a mother diagnosed with both breast and pancreatic cancer; this relative was subsequently confirmed to carry the identical mutation. The proband with the c.2962C > CT mutation had a father and paternal aunt diagnosed with pancreatic cancer; neither relative was available for testing. Two novel PALB2 missense variants were also found, one of which was deemed potentially deleterious. The prevalence rate of PALB2 mutations in a non-BRCA1/2 breast cancer population specifically selected for a family history of pancreatic cancer does not appear to be significantly increased compared to that observed in other breast cancer populations studied thus far. Further evaluation is needed to determine the prevalence of PALB2 mutations and the clinical utility of such testing in those individuals affected with both breast and pancreatic cancers.
C1 [Hofstatter, Erin W.] Yale Univ, Sch Med, Yale Canc Ctr, Sect Med Oncol, New Haven, CT 06520 USA.
[Domchek, Susan M.; Boghossian, Leigh; Nathanson, Katherine L.] Univ Penn, Div Med Oncol, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Miron, Alexander; Miron, Penelope L.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Wang, Molin] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Componeschi, Kathryn; Tung, Nadine] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA.
RP Hofstatter, EW (reprint author), Yale Univ, Sch Med, Yale Canc Ctr, Sect Med Oncol, 333 Cedar St,POB 208032, New Haven, CT 06520 USA.
EM erin.hofstatter@yale.edu
OI Nathanson, Katherine/0000-0002-6740-0901
FU Breast Cancer Research Foundation; Dana Farber/Harvard Cancer Center [CA
006516]; Dana Farber/Harvard Cancer Center Breast SPORE [CA 089393];
Mac-Donald Family Foundation
FX This work was supported by grants from the Breast Cancer Research
Foundation (to KLN, NT, and JG); the Dana Farber/Harvard Cancer Center
(CA 006516); the Dana Farber/Harvard Cancer Center Breast SPORE (CA
089393); and the Mac-Donald Family Foundation (to SMD).
NR 27
TC 36
Z9 36
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1389-9600
J9 FAM CANCER
JI Fam. Cancer
PD JUN
PY 2011
VL 10
IS 2
BP 225
EP 231
DI 10.1007/s10689-011-9426-1
PG 7
WC Oncology; Genetics & Heredity
SC Oncology; Genetics & Heredity
GA 768LZ
UT WOS:000290937500007
PM 21365267
ER
PT J
AU Inman, AG
Altman, A
Kaduvettoor-Davidson, A
Carr, A
Walker, JA
AF Inman, Arpana G.
Altman, Abby
Kaduvettoor-Davidson, Anju
Carr, Amanda
Walker, Jessica A.
TI Cultural Intersections: A Qualitative Inquiry into the Experience of
Asian Indian-White Interracial Couples
SO FAMILY PROCESS
LA English
DT Article
DE Asian Indian-White Couples; Interracial Marriages; Qualitative Study
ID COUNSELING PSYCHOLOGY; CONFLICT; THERAPY
AB The purpose of this study was to examine the "lived experience" of Asian Indian (AI)-White couples in interracial marriages. Ten highly educated AI-White professional couples were individually interviewed about their subjective experience of being in an interracial marriage, the challenges and strengths of this marriage, and the potential role of culture in their marriages. Data were analyzed using the Consensual Qualitative Research methodology. Results indicated that the couples' marital experiences were influenced by a complex intersection of ecosystemic factors with significant psychological impacts. These findings highlight shortcomings in drawing simplistic conclusions regarding the success or failure of an interracial marriage and have important implications for theory, research, and clinical practice.
C1 [Inman, Arpana G.; Carr, Amanda] Lehigh Univ, Bethlehem, PA 18015 USA.
[Altman, Abby] VA Boston Healthcare Syst, Boston, MA USA.
[Kaduvettoor-Davidson, Anju] Univ Delaware, Ctr Counseling & Student Dev, Newark, DE 19716 USA.
[Walker, Jessica A.] WG Bill Hefner VA Med Ctr, Salisbury, NC USA.
RP Inman, AG (reprint author), Lehigh Univ, 111 Res Dr, Bethlehem, PA 18015 USA.
EM agi2@lehigh.edu
NR 47
TC 4
Z9 4
U1 2
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0014-7370
J9 FAM PROCESS
JI Fam. Process
PD JUN
PY 2011
VL 50
IS 2
BP 248
EP 266
DI 10.1111/j.1545-5300.2011.01358.x
PG 19
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA 763FP
UT WOS:000290541000009
PM 21564064
ER
PT J
AU Crawford, JM
Hoffman, RD
Black-Schaffer, WS
AF Crawford, James M.
Hoffman, Robert D.
Black-Schaffer, W. Stephen
TI Pathology subspecialty fellowship application reform 2007 to 2010
SO HUMAN PATHOLOGY
LA English
DT Article
DE Subspecialty fellowship; Pathology; Anatomic pathology; Clinical
pathology; Exploding market; NRMP; Match
ID GASTROENTEROLOGY MATCH; RADIOLOGY FELLOWSHIP; SUCCEED; MARKET
AB The specialty of Pathology and Laboratory Medicine has entered into a phase when the 4-year sequence of Anatomic Pathology and/or Clinical Pathology Residency Training is almost universally followed by 1 or more years of Subspecialty Fellowship Training. Such training may occur in one of the American Board of Pathology-recognized subspecialties or any number of "subspecialty fellowships" that, although not leading to subspecialty board certification, may nevertheless fall under the oversight of the local institutional Graduate Medical Education Committee and the Accreditation Council for Graduate Medical Education Review Committee for Pathology. Unlike the application process for first-year Pathology Residency, which is run through the National Resident Matching Program, applications for Subspecialty Pathology Fellowships are not coordinated by any consistent schedule. Competition for Subspecialty Pathology Fellowships has consistently resulted in undesirable drift of the fellowship application process to dates that are unacceptably early for many fellowship applicants. Responding to widespread dissatisfaction voiced by national pathology resident organizations, in 2007, the Association of Pathology Chairs began evaluation and potential intervention in the fellowship application process. Three years of intermittently intense discussion, surveys, and market analysis, have led the Council of the Association of Pathology Chairs to recommend implementation of a Pathology Subspecialty Fellowship Matching program starting in the 2011 to 2012 recruiting year, for those Applicants matriculating in fellowship programs July 2013. We report on the data that informed this decision and discuss the pros and cons that are so keenly felt by the stakeholders in this as-yet-incomplete reform process. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Crawford, James M.] N Shore Long Isl Jewish Hlth Syst, Dept Pathol & Lab Med, Manhasset, NY 11042 USA.
[Crawford, James M.] Hofstra N Shore LIJ Sch Med, Manhasset, NY 11042 USA.
[Hoffman, Robert D.] Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA.
[Black-Schaffer, W. Stephen] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Black-Schaffer, W. Stephen] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Crawford, JM (reprint author), N Shore LIJ Labs, Lake Success, NY 11042 USA.
EM jcrawford1@nshs.edu
NR 30
TC 3
Z9 3
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD JUN
PY 2011
VL 42
IS 6
SI SI
BP 774
EP 794
DI 10.1016/j.humpath.2010.08.002
PG 21
WC Pathology
SC Pathology
GA 770GY
UT WOS:000291076200004
PM 21035167
ER
PT J
AU Weingart, SN
Zhu, JY
Chiappetta, L
Stuver, SO
Schneider, EC
Epstein, AM
David-Kasdan, JA
Annas, CL
Fowler, FJ
Weissman, JS
AF Weingart, Saul N.
Zhu, Junya
Chiappetta, Laurel
Stuver, Sherri O.
Schneider, Eric C.
Epstein, Arnold M.
David-Kasdan, Jo Ann
Annas, Catherine L.
Fowler, Floyd J., Jr.
Weissman, Joel S.
TI Hospitalized patients' participation and its impact on quality of care
and patient safety
SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE
LA English
DT Article
DE medical error; adverse events; patient participation
ID ADVERSE DRUG EVENTS; PATIENTS TELL US; HEALTH-CARE; MEDICAL ERRORS;
INVOLVEMENT; INTERNET; INTERVENTION; EXPERIENCE; DISCHARGE; SYMPTOMS
AB To understand the extent to which hospitalized patients participate in their care, and the association of patient participation with quality of care and patient safety.
Random sample telephone survey and medical record review.
US acute care hospitals in 2003.
A total of 2025 recently hospitalized adults.
Hospitalized patients reported participation in their own care, assessments of overall quality of care and the presence of adverse events (AEs) in telephone interviews. Physician reviewers rated the severity and preventability of AEs identified by interview and chart review among 788 surveyed patients who also consented to medical record review.
Of the 2025 patients surveyed, 99.9 of patients reported positive responses to at least one of seven measures of participation. High participation (use of 4 activities) was strongly associated with patients' favorable ratings of the hospital quality of care (adjusted OR: 5.46, 95 CI: 4.157.19). Among the 788 patients with both patient survey and chart review data, there was an inverse relationship between participation and adverse events. In multivariable logistic regression analyses, patients with high participation were half as likely to have at least one adverse event during the admission (adjusted OR 0.49, 0.310.78).
Most hospitalized patients participated in some aspects of their care. Participation was strongly associated with favorable judgments about hospital quality and reduced the risk of experiencing an adverse event.
C1 [Weingart, Saul N.; Zhu, Junya; Chiappetta, Laurel; Stuver, Sherri O.] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA.
[Zhu, Junya] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USA.
[Schneider, Eric C.; Epstein, Arnold M.; Weissman, Joel S.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Schneider, Eric C.; Epstein, Arnold M.] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA.
[David-Kasdan, Jo Ann; Weissman, Joel S.] Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA.
[Annas, Catherine L.] Eastern Massachusetts Healthcare Initiat, Cambridge, MA USA.
[Fowler, Floyd J., Jr.] Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA.
[Weissman, Joel S.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Weissman, Joel S.] Commonwealth Massachusetts, Execut Off Hlth & Human Serv, Boston, MA USA.
RP Weingart, SN (reprint author), Dana Farber Canc Inst, Ctr Patient Safety, 44 Binney St, Boston, MA 02115 USA.
EM saul_weingart@dfci.harvard.edu
OI Stuver, Sherri/0000-0002-4027-2663; Schneider, Eric/0000-0002-1132-5084
FU US Agency for Healthcare Research and Quality [U18 HS11928]; Center for
Patient Safety, Dana-Farber Cancer Institute
FX This work was supported by a Cooperative Agreement from the US Agency
for Healthcare Research and Quality to the Massachusetts Department of
Public Health [U18 HS11928]; and the Center for Patient Safety,
Dana-Farber Cancer Institute.
NR 42
TC 36
Z9 40
U1 3
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1353-4505
J9 INT J QUAL HEALTH C
JI Int. J. Qual. Health Care
PD JUN
PY 2011
VL 23
IS 3
BP 269
EP 277
DI 10.1093/intqhc/mzr002
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 763VI
UT WOS:000290587400008
PM 21307118
ER
PT J
AU Pessach, IM
Ordovas-Montanes, J
Zhang, SY
Casanova, JL
Giliani, S
Gennery, AR
Al-Herz, W
Manos, PD
Schlaeger, TM
Park, IH
Rucci, F
Agarwal, S
Mostoslavsky, G
Daley, GQ
Notarangelo, LD
AF Pessach, Itai M.
Ordovas-Montanes, Jose
Zhang, Shen-Ying
Casanova, Jean-Laurent
Giliani, Silvia
Gennery, Andrew R.
Al-Herz, Waleed
Manos, Philip D.
Schlaeger, Thorsten M.
Park, In-Hyun
Rucci, Francesca
Agarwal, Suneet
Mostoslavsky, Gustavo
Daley, George Q.
Notarangelo, Luigi D.
TI Induced pluripotent stem cells: A novel frontier in the study of human
primary immunodeficiencies
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Primary immunodeficiency; induced pluripotent stem cells; reprogramming
ID HERPES-SIMPLEX ENCEPHALITIS; HYPER-IGE SYNDROME; IPS CELLS; EFFICIENT
GENERATION; DOPAMINERGIC-NEURONS; IN-VITRO; HUMAN ES; DIFFERENTIATION;
DEFICIENCY; DERIVATION
AB Background: The novel ability to epigenetically reprogram somatic cells into induced pluripotent stem cells (iPSCs) through the exogenous expression of transcription promises to revolutionize the study of human diseases.
Objective: Here we report on the generation of 25 iPSC lines from 6 patients with various forms of primary immunodeficiencies (PIDs) affecting adaptive immunity, innate immunity, or both.
Methods: Patients' dermal fibroblasts were reprogrammed by expression of 4 transcription factors, octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2), Krueppel-like factor 4 (KLF4), and cellular myelomonocytosis proto-oncogene (cMYC), by using a single excisable polycistronic lentiviral vector.
Results: iPSCs derived from patients with PIDs show a stemness profile that is comparable with that observed in human embryonic stem cells. After in vitro differentiation into embryoid bodies, pluripotency of the patient-derived iPSC lines was demonstrated by expression of genes characteristic of each of the 3 embryonic layers. We have confirmed the patient-specific origin of the iPSC lines and ascertained maintenance of karyotypic integrity.
Conclusion: By providing a limitless source of diseased stem cells that can be differentiated into various cell types in vitro, the repository of iPSC lines from patients with PIDs represents a unique resource to investigate the pathophysiology of hematopoietic and extrahematopoietic manifestations of these diseases and might assist in the development of novel therapeutic approaches based on gene correction. (J Allergy Clin Immunol 2011;127:1400-7.)
C1 [Pessach, Itai M.; Ordovas-Montanes, Jose; Rucci, Francesca; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Div Immunol, Childrens Hosp Boston, Boston, MA 02115 USA.
[Pessach, Itai M.] Safra Childrens Hosp, Talpiot Med Leadership Program, Sheba Med Ctr, Tel Hashomer, Israel.
[Ordovas-Montanes, Jose] Tufts Univ, Dept Biol, Medford, MA 02155 USA.
[Zhang, Shen-Ying; Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, New York, NY 10021 USA.
[Casanova, Jean-Laurent] Univ Paris 05, Lab Human Genet Infect Dis, Necker Branch, Paris, France.
[Casanova, Jean-Laurent] Necker Med Sch, INSERM U980, Paris, France.
[Giliani, Silvia] Univ Brescia, Dept Pediat, Angelo Nocivelli Inst Mol Med, Brescia, Italy.
[Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.
[Al-Herz, Waleed] Al Sabah Hosp, Dept Pediat, Allergy & Clin Immunol Unit, Kuwait, Kuwait.
[Manos, Philip D.; Schlaeger, Thorsten M.; Park, In-Hyun; Agarwal, Suneet; Daley, George Q.] Childrens Hosp Boston, Div Pediat Hematol Oncol, Boston, MA USA.
[Manos, Philip D.; Schlaeger, Thorsten M.; Park, In-Hyun; Agarwal, Suneet; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Manos, Philip D.; Schlaeger, Thorsten M.; Park, In-Hyun; Daley, George Q.] Childrens Hosp Boston, Stem Cell Program, Boston, MA USA.
[Schlaeger, Thorsten M.; Agarwal, Suneet; Daley, George Q.] Harvard Stem Cell Inst, Cambridge, England.
[Park, In-Hyun] Yale Univ, Sch Med, Yale Stem Cell Ctr, Dept Genet, New Haven, CT 06520 USA.
[Agarwal, Suneet; Daley, George Q.; Notarangelo, Luigi D.] Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA.
[Mostoslavsky, Gustavo] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Mostoslavsky, Gustavo] Boston Univ, Sch Med, Ctr Regenerat Med CReM, Boston, MA 02118 USA.
RP Notarangelo, LD (reprint author), Harvard Univ, Sch Med, Div Immunol, Childrens Hosp Boston, Karp Bldg,Rm 9210,1 Blackfan Circle, Boston, MA 02115 USA.
EM luigi.notarangelo@childrens.harvard.edu
RI Notarangelo, Luigi/F-9718-2016
OI Notarangelo, Luigi/0000-0002-8335-0262
FU National Institutes of Health [1R03AI088352-01, 1R21AI0898-10-01]; March
of Dimes [6-FY10-282]; Translation Research Program; Harvard Catalyst
Grant; Manton Foundation; Fondazione "Angelo Nocivelli"
FX Supported by National Institutes of Health grants 1R03AI088352-01 and
1R21AI0898-10-01, March of Dimes grant 6-FY10-282, the Translation
Research Program (all to L.D.N.), and a Harvard Catalyst Grant (to
G.Q.D.). Also supported by the Manton Foundation (to L.D.N. and G.Q.D.)
and by Fondazione "Angelo Nocivelli" (to S.G.).
NR 61
TC 28
Z9 28
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUN
PY 2011
VL 127
IS 6
BP 1400
EP U140
DI 10.1016/j.jaci.2010.11.008
PG 12
WC Allergy; Immunology
SC Allergy; Immunology
GA 769WH
UT WOS:000291048500011
PM 21185069
ER
PT J
AU Biagtan, MJ
Viswanathan, RK
Evans, MD
Mathur, SK
AF Biagtan, Mark J.
Viswanathan, Ravi K.
Evans, Michael D.
Mathur, Sameer K.
TI Clinical utility of the Chronic Urticaria Index
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Letter
ID CHRONIC IDIOPATHIC URTICARIA; CHRONIC AUTOIMMUNE URTICARIA
C1 [Biagtan, Mark J.; Viswanathan, Ravi K.; Mathur, Sameer K.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Viswanathan, Ravi K.; Mathur, Sameer K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA.
RP Biagtan, MJ (reprint author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA.
EM sm4@medicine.wisc.edu
OI Evans, Michael/0000-0001-7449-3993
FU NIAID NIH HHS [T32 AI007635, AI007635, T32 AI007635-12]
NR 10
TC 9
Z9 9
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUN
PY 2011
VL 127
IS 6
BP 1626
EP 1627
DI 10.1016/j.jaci.2011.01.045
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA 769WH
UT WOS:000291048500047
PM 21376378
ER
PT J
AU Waldman, AT
Gorman, MP
Rensel, MR
Austin, TE
Hertz, DP
Kuntz, NL
AF Waldman, Amy T.
Gorman, Mark P.
Rensel, Mary R.
Austin, Tracy E.
Hertz, Deborah P.
Kuntz, Nancy L.
CA Network Pediat Multiple Sclerosis
TI Management of Pediatric Central Nervous System Demyelinating Disorders:
Consensus of United States Neurologists
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE multiple sclerosis; acute disseminated encephalomyelitis; optic neuritis
ID ACUTE DISSEMINATED ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; OPTIC
NEURITIS; CHILDREN
AB Demyelinating diseases are a group of autoimmune inflammatory disorders affecting the central nervous system in adults and children; however, the diagnosis, evaluation, and treatment of these disorders are primarily based on adult data. The purpose of this study was to assess the practice patterns of US physicians who specialize in treating acquired central nervous system demyelinating diseases in children and adolescents. The Delphi technique was used to identify areas of consensus in management and treatment. Forty-two experts in the field participated in the process. Intravenous methylprednisolone was the first-line treatment of choice for acute episodes of all forms of demyelinating disease; however, consensus was lacking regarding specific dose, treatment duration, and use of an oral taper. First-line disease-modifying therapies for pediatric multiple sclerosis were interferons and glatiramer acetate, chosen based on perceived efficacy and tolerability, respectively. Areas lacking agreement among the expert panel and requiring further research are identified.
C1 [Kuntz, Nancy L.] Childrens Mem Hosp, Dept Pediat, Chicago, IL 60614 USA.
[Waldman, Amy T.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA.
[Waldman, Amy T.] Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA.
[Waldman, Amy T.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Gorman, Mark P.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Gorman, Mark P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rensel, Mary R.] Cleveland Clin, Dept Neurol, Cleveland, OH 44106 USA.
[Austin, Tracy E.; Hertz, Deborah P.] Natl Multiple Sclerosis Soc, New York, NY USA.
RP Kuntz, NL (reprint author), Childrens Mem Hosp, Dept Pediat, 2300 Childrens Plaza,Box 51, Chicago, IL 60614 USA.
EM nkuntz@childrensmemorial.org
FU NINDS NIH HHS [K08 NS060695]
NR 14
TC 32
Z9 37
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
J9 J CHILD NEUROL
JI J. Child Neurol.
PD JUN
PY 2011
VL 26
IS 6
BP 675
EP 682
DI 10.1177/0883073810395141
PG 8
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 768TJ
UT WOS:000290961000002
PM 21518802
ER
PT J
AU Nahed, BV
Ferreira, M
Babu, MA
Terry, AR
Walcott, BP
Kahle, KT
Smith, ER
AF Nahed, Brian V.
Ferreira, Manuel, Jr.
Babu, Maya A.
Terry, Anna R.
Walcott, Brian P.
Kahle, Kristopher T.
Smith, Edward R.
TI Dural Scalp and Intracranial Hemangiomas Causing Hydrocephalus and
Venous Sinus Thrombosis in an Infant
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE hemangioma; hydrocephalus; thrombosis; venous; dural
ID CEREBRAL SINOVENOUS THROMBOSIS; ARTERIAL ISCHEMIC-STROKE;
IRON-DEFICIENCY ANEMIA; CAPILLARY HEMANGIOMA; CHILDREN; HOMOCYSTINURIA;
PROPRANOLOL; CAVERNOMAS; DISORDERS; NEONATE
AB Cutaneous scalp hemangiomas may herald the presence of occult intracranial hemangiomas. A previously healthy 4-month-old girl presented with a bleeding scalp hemangioma, a bulging fontanel, and anemia. Magnetic resonance imaging (MRI) of the brain revealed hydrocephalus along with multiple intracranial hemangiomas. These lesions compressed the jugular foramina, resulting in venous sinus thrombosis involving the right transverse sinus, the left sigmoid sinus, and the torcular herophili. The patient had no family history of phakomatoses or other genetic abnormalities. A thrombophilia work-up result was unremarkable. The patient was treated with prednisolone (10 mg twice daily) and low molecular weight heparin (1 mg/kg/dose) twice daily. This treatment decreased the size of her cutaneous and intracranial hemangiomas and led to the resolution of her venous sinus thromboses and hydrocephalus. Innocuous scalp hemangioma in an infant may herald more concerning intracranial pathology, which can be treated effectively if diagnosed with appropriate imaging studies.
C1 [Smith, Edward R.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Neurosurg, Boston, MA 02115 USA.
[Nahed, Brian V.; Ferreira, Manuel, Jr.; Babu, Maya A.; Terry, Anna R.; Walcott, Brian P.; Kahle, Kristopher T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA.
RP Smith, ER (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Neurosurg, 300 Longwood Ave, Boston, MA 02115 USA.
EM Edward.smith@childrens.harvard.edu
NR 39
TC 2
Z9 2
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
J9 J CHILD NEUROL
JI J. Child Neurol.
PD JUN
PY 2011
VL 26
IS 6
BP 777
EP 781
DI 10.1177/0883073810390694
PG 5
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 768TJ
UT WOS:000290961000019
PM 21325128
ER
PT J
AU Molitch, ME
Clemmons, DR
Malozowski, S
Merriam, GR
Vance, ML
AF Molitch, Mark E.
Clemmons, David R.
Malozowski, Saul
Merriam, George R.
Vance, Mary Lee
TI Evaluation and Treatment of Adult Growth Hormone Deficiency: An
Endocrine Society Clinical Practice Guideline
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID GH-REPLACEMENT THERAPY; BONE-MINERAL DENSITY; QUALITY-OF-LIFE;
INTIMA-MEDIA THICKNESS; TRAUMATIC BRAIN-INJURY; CARDIOVASCULAR
RISK-FACTORS; BASE-LINE CHARACTERISTICS; RECOMBINANT HUMAN GH; BODY-MASS
INDEX; BENIGN INTRACRANIAL HYPERTENSION
AB Objective: The aim was to update The Endocrine Society Clinical Practice Guideline on Evaluation and Treatment of Adult Growth Hormone Deficiency (GHD) previously published in 2006.
Consensus Process: Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails. An initial draft was prepared by the Task Force, with the help of a medical writer, and reviewed and commented on by members of The Endocrine Society. A second draft was reviewed and approved by The Endocrine Society Council. At each stage of review, the Task Force received written comments and incorporated substantive changes.
Conclusions: GHD can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood. GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD. The risks associated with GH treatment are low. GH dosing regimens should be individualized. The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual. (J Clin Endocrinol Metab 96: 1587-1609, 2011)
C1 [Molitch, Mark E.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Clemmons, David R.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA.
[Malozowski, Saul] Natl Inst Diabet Digest & Kidney Dis, NIH, Bethesda, MD 20892 USA.
[Merriam, George R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98493 USA.
[Merriam, George R.] Univ Washington, Sch Med, Tacoma, WA USA.
[Vance, Mary Lee] Univ Virginia, Hlth Sci Ctr, Charlottesville, VA 22908 USA.
RP Molitch, ME (reprint author), Endocrine Soc, 8401 Connecticut Ave,Suite 900, Chevy Chase, MD 20815 USA.
EM govt-prof@endo-society.org
FU Eli Lilly, Co.; American Diabetes Association; American College of
Physicians; Pituitary Society; Sanofi Aventis; Ipsen; Corcept; Pfizer,
Inc.; Genentech, Inc.; Lilly Inc.; Ipsen Inc.; America Neuroendocrine
Society; National Institutes of Health; Washington State Health
Department; Novo Nordisk, Inc.; Novartis Pharmaceuticals
FX Financial Disclosures of the Task Force: Mark E. Molitch, M. D.
(chair)-Financial or Business/Organizational Interests: Eli Lilly, Co.,
American Diabetes Association, American College of Physicians, Pituitary
Society, Sanofi Aventis, Ipsen, Corcept; Significant Financial Interest
or Leadership Position: none declared. David R. Clemmons, M.
D.-Financial or Business/Organizational Interests: Pfizer, Inc.,
Genentech, Inc., Lilly Inc., Ipsen Inc.; Significant Financial Interest
or Leadership Position: none declared. Saul Malozowski, M. D.-Financial
or Business/Organizational Interests: none declared; Significant
Financial Interest or Leadership Position: none declared. George R.
Merriam, M. D.-Financial or Business/Organizational Interests: America
Neuroendocrine Society, National Institutes of Health, Washington State
Health Department; Significant Financial Interest or Leadership
Position: Novo Nordisk, Inc., Eli Lilly, Co., American Neuroendocrine
Society. Mary Lee Vance, M. D.-Financial or Business/Organizational
Interests: Novartis Pharmaceuticals, Ipsen; Significant Financial
Interest or Leadership Position: none declared.
NR 215
TC 198
Z9 211
U1 1
U2 15
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2011
VL 96
IS 6
BP 1587
EP 1609
DI 10.1210/jc.2011-0179
PG 23
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 766TU
UT WOS:000290810200029
PM 21602453
ER
PT J
AU Eckel, RH
Kahn, SE
Ferrannini, E
Goldfine, AB
Nathan, DM
Schwartz, MW
Smith, RJ
Smith, SR
AF Eckel, Robert H.
Kahn, Steven E.
Ferrannini, Ele
Goldfine, Allison B.
Nathan, David M.
Schwartz, Michael W.
Smith, Robert J.
Smith, Steven R.
TI Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be
Individualized?
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID CARDIOVASCULAR RISK-FACTORS; GENOME-WIDE ASSOCIATION; LIFE-STYLE
INTERVENTION; Y GASTRIC BYPASS; BARIATRIC SURGERY; ADIPOSE-TISSUE;
GLYCEMIC INDEX; WEIGHT-LOSS; MELLITUS; IDENTIFICATION
AB Objective: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care.
Research Design and Methods: An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data.
Results: The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions.
Conclusions: The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to beta-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on beta-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management. ( J Clin Endocrinol Metab 96: 1654-1663, 2011)
C1 [Eckel, Robert H.] Univ Colorado, Div Endocrinol Metab & Diabet, Dept Med, Aurora, CO 80045 USA.
Univ Washington, Seattle, WA 98108 USA.
[Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA.
[Ferrannini, Ele] Univ Pisa, Dept Internal Med, I-56100 Pisa, Italy.
[Goldfine, Allison B.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Goldfine, Allison B.] Harvard Univ, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Nathan, David M.] Massachusetts Gen Hosp, Clin Res Ctr, Boston, MA 02114 USA.
[Nathan, David M.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Schwartz, Michael W.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98109 USA.
[Smith, Robert J.] Brown Univ, Alpert Med Sch, Div Endocrinol, Providence, RI 02914 USA.
[Smith, Robert J.] Brown Univ, Alpert Med Sch, Hallett Ctr Diabet & Endocrinol, Providence, RI 02914 USA.
[Smith, Steven R.] Florida Hosp Sanford, Burnham Res Inst, Orlando, FL 32827 USA.
RP Eckel, RH (reprint author), Univ Colorado, Div Endocrinol Metab & Diabet, Dept Med, Anschutz Med Campus,12801 E 17th Ave,Box 8106,RC-, Aurora, CO 80045 USA.
EM robert.eckel@ucdenver.edu; skahn@u.washington.edu
OI Kahn, Steven/0000-0001-7307-9002
FU Endocrine Society; American Diabetes Association; European Association
for the Study of Diabetes; Novo Nordisk; Sanofi Research Grant;
dia-Dexus; GlaxoSmithKline; Cardiometabolic Health Congress and
Metabolic Syndrome Institute; Eli Lilly; Intarcia Therapeutics;
Boehringer Ingelheim; Merck; Daiichi Sankyo; Bristol-Myers
Squibb/AstraZeneca; sanofi-aventis; Novartis; Pfizer; Orexigen; GI
Dynamics; Amylin
FX This article is based on a conference jointly sponsored by The Endocrine
Society, the American Diabetes Association, and the European Association
for the Study of Diabetes, with the financial support of an unrestricted
educational grant from Novo Nordisk.; R.H.E. received grant/research
support from Sanofi Research Grant (fellowship educational grant),
dia-Dexus, and GlaxoSmithKline; compensation for working as a consultant
for Amylin, GTC Nutrition, Genfit, Eli Lilly, Pfizer, Johnson&Johnson,
and Esperion; financial or material support from Cardiometabolic Health
Congress and Metabolic Syndrome Institute; and honoraria from Vindico,
CME Incite, and Voxmedia. S. E. K. received consulting fees from Eli
Lilly, GlaxoSmithKline, Intarcia Therapeutics, and Novo Nordisk for
acting as an advisory board member; consulting fees and honoraria from
Boehringer Ingelheim and Merck for acting as an advisory board member
and speaker; and grant support from Daiichi Sankyo. E. F. received
consulting fees from Merck, Boehringer Ingelheim, Bristol-Myers
Squibb/AstraZeneca, sanofi-aventis, Novartis, GlaxoSmithKline, and
Daiichi Sankyo and grant support from Merck and Eli Lilly. A. B. G.
acted as Site Principal Investigator for a clinical trial funded by Eli
Lilly that is now complete with results published. M. W. S. received
consulting fees from Merck, Pfizer, and Orexigen. R.J.S. received
consulting fees from GI Dynamics and royalties from Baxter and Fresenius
Kabi. S. R. S. received consulting fees from Amylin, Bristol-Myers
Squibb, Eli Lilly, and Novartis and consulting fees as an advisory board
member for Arena. No other potential conflicts of interest relevant to
this article were reported.
NR 50
TC 69
Z9 70
U1 1
U2 10
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2011
VL 96
IS 6
BP 1654
EP 1663
DI 10.1210/jc.2011-0585
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 766TU
UT WOS:000290810200036
PM 21602457
ER
PT J
AU Biller, BMK
Ji, HJ
Ahn, H
Savoy, C
Siepl, EC
Popovic, V
Coculescu, M
Roemmler, J
Gavrila, C
Cook, DM
Strasburger, CJ
AF Biller, Beverly M. K.
Ji, Hyi-Jeong
Ahn, Hyunji
Savoy, Conrad
Siepl, E. Christine
Popovic, Vera
Coculescu, Mihail
Roemmler, Josefine
Gavrila, Catalin
Cook, David M.
Strasburger, Christian J.
TI Effects of Once-Weekly Sustained-Release Growth Hormone: A Double-Blind,
Placebo-Controlled Study in Adult Growth Hormone Deficiency
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID GH DEFICIENCY; HYPOPITUITARY ADULTS; DOSE TITRATION;
SACCHAROMYCES-CEREVISIAE; REPLACEMENT; EFFICACY; ANTIBODIES; CHILDREN;
THERAPY; LB03002
AB Background: A sustained-release recombinant human GH formulation, LB03002, has been recently developed, with pharmacokinetics and pharmacodynamic activity appropriate for once-weekly administration. LB03002 is a long-acting GH that is administered once a week by sc injection.
Objective: This study evaluated efficacy and safety of LB03002 in adult patients with GH deficiency.
Patients and Methods: A total of 152 patients were randomized to receive LB03002 or placebo once weekly for 26 wk. Changes in body composition were evaluated from DXA (dual-energy x-ray absorptiometry). IGF-I was assessed at each study visit. Safety was assessed from adverse events, glucose homeostasis, and antibody development.
Results: IGF-I increased significantly (P < 0.001) with LB03002 and remained unchanged with placebo. Mean fat mass (FM) decreased by 1.052 kg [95% confidence interval (CI) = -1.614 to -0.491] in the LB03002 group vs. an increase of 0.570 kg (95% CI = -0.205-1.345) in the placebo group; treatment difference was 1.622 kg (95% CI = -2.527 to -0.717; P < 0.001). FM change was mainly due to decreased trunk fat. Least square mean treatment difference was 1.032 kg (95% CI = -1.560 to -0.515; P < 0.001). LBM (lean body mass) was significantly increased with LB03002 vs. placebo (least square mean difference was 1.393 kg; 95% CI = 0.614-2.171; P < 0.001). No concerning safety issues arose during the study.
Conclusions: Weekly GH replacement with the sustained-release preparation LB03002 in adults significantly reduced FM over 6 months and was well tolerated. (J Clin Endocrinol Metab 96: 1718-1726, 2011)
C1 [Biller, Beverly M. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ji, Hyi-Jeong; Ahn, Hyunji] LG Life Sci Ltd, Seoul 150721, South Korea.
[Savoy, Conrad; Siepl, E. Christine] Biopartners GmbH, CH-6340 Baar, Switzerland.
[Popovic, Vera] Inst Endocrinol, Belgrade 11000, Serbia.
[Coculescu, Mihail] CI Parhon, Inst Endocrinol, Bucharest 011863, Romania.
[Roemmler, Josefine] Univ Munich, D-80336 Munich, Germany.
[Gavrila, Catalin] SANA Med Ctr, Bucharest 011025, Romania.
[Cook, David M.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Strasburger, Christian J.] Campus Charite, Dept Med, Div Clin Endocrinol, D-10117 Berlin, Germany.
RP Biller, BMK (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM bbiller@partners.org
RI Coculescu, Mihail/D-7162-2011
OI Coculescu, Mihail/0000-0003-1468-9446
FU LG Life Sciences, Ltd., Korea; Biopartners, GmbH, Switzerland
FX H.J.J. and H. A. are employees of LG Life Sciences, Ltd.; C. S. and E.
C. S. are employees of Biopartners, GmbH. B. M. K. B. and C.J.S.
received consulting fees from LG Life Sciences, Ltd., Korea, and
Biopartners, GmbH, Switzerland. V. P., M. C., J.R., C. G., and D. M. C.
have nothing to declare.
NR 21
TC 26
Z9 26
U1 0
U2 9
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2011
VL 96
IS 6
BP 1718
EP 1726
DI 10.1210/jc.2010-2819
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 766TU
UT WOS:000290810200046
PM 21411551
ER
PT J
AU Chan, YM
Butler, JP
Pinnell, NE
Pralong, FP
Crowley, WF
Ren, C
Chan, KK
Seminara, SB
AF Chan, Yee-Ming
Butler, James P.
Pinnell, Nancy E.
Pralong, Francois P.
Crowley, William F., Jr.
Ren, Chen
Chan, Kenneth K.
Seminara, Stephanie B.
TI Kisspeptin Resets the Hypothalamic GnRH Clock in Men
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID GONADOTROPIN-RELEASING-HORMONE; HYPOGONADOTROPIC HYPOGONADISM;
NEUROENDOCRINE CONTROL; OLFACTORY PLACODE; RECEPTOR GPR54; IN-VIVO;
SECRETION; NEURONS; PUBERTY; INCREASE
AB Context: Reproduction in all mammals is controlled by a hypothalamic clock that produces periodic secretory pulses of GnRH, but how the timing of these pulses is determined is poorly understood. The neuropeptide kisspeptin potently and selectively stimulates the secretion of GnRH. Although this property of kisspeptin is well described, the effects of kisspeptin on endogenous GnRH pulse generation remain largely unexplored.
Objective: The objective of the study was to detail the effects of kisspeptin on GnRH secretion, as reflected by LH secretion, in men.
Participants: Thirteen healthy adult men participated in the study.
Intervention: The intervention was the administration of a single iv bolus of the C-terminal decapeptide of kisspeptin (amino acids 112-121 of the parent protein).
Results: Kisspeptin induced an immediate LH pulse, regardless of the timing of the previous endogenous pulse. The kisspeptin-induced pulses were on average larger than endogenous pulses (amplitude 5.0 +/- 1.0 vs. 2.1 +/- 0.3 mIU/ml, P = 0.02). Comparison of the morphology of kisspeptin-induced LH pulses in healthy men with that of GnRH-induced LH pulses in men with isolated GnRH deficiency suggests that a single iv bolus of kisspeptin triggered sustained GnRH release lasting approximately 17 min. Furthermore, kisspeptin reset the GnRH pulse generator, as it not only induced an immediate LH pulse but also delayed the next endogenous pulse by an interval approximating the normal interpulse interval.
Conclusions: As the first known agent capable of resetting the hypothalamic GnRH pulse generator, kisspeptin can be used as a physiological tool for studying GnRH pulse generation and opens a door to understanding the mechanisms of biological clocks in general. (J Clin Endocrinol Metab 96: E908-E915, 2011)
C1 [Chan, Yee-Ming; Pinnell, Nancy E.; Pralong, Francois P.; Crowley, William F., Jr.; Seminara, Stephanie B.] Massachusetts Gen Hosp, Dept Med, Harvard Reprod Sci Ctr, Boston, MA 02114 USA.
[Chan, Yee-Ming; Pinnell, Nancy E.; Pralong, Francois P.; Crowley, William F., Jr.; Seminara, Stephanie B.] Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA.
[Chan, Yee-Ming] Childrens Hosp Boston, Dept Med, Div Endocrinol, Boston, MA 02115 USA.
[Butler, James P.] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA.
[Ren, Chen; Chan, Kenneth K.] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA.
RP Chan, YM (reprint author), Massachusetts Gen Hosp, Dept Med, Harvard Reprod Sci Ctr, 55 Fruit St,BHX 5, Boston, MA 02114 USA.
EM ymchan@partners.org
FU Eunice Kennedy Shriver National Institute for Child Health and Human
Development [R01 HD43341]; National Center for Research Resources
(Harvard Clinical and Translational Science Center) [UL1 RR025758];
Charles A. King Trust; Children's Hospital Boston
FX This work was supported by Grant R01 HD43341 from the Eunice Kennedy
Shriver National Institute for Child Health and Human Development and
Grant UL1 RR025758 (Harvard Clinical and Translational Science Center)
from the National Center for Research Resources. Y.-M.C. was supported
by a Charles A. King Trust postdoctoral fellowship and a Career
Development Award from Children's Hospital Boston.
NR 39
TC 44
Z9 44
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2011
VL 96
IS 6
BP E908
EP E915
DI 10.1210/jc.2010-3046
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 766TU
UT WOS:000290810200005
PM 21470997
ER
PT J
AU Chadwick, EK
Blana, D
Simeral, JD
Lambrecht, J
Kim, SP
Cornwell, AS
Taylor, DM
Hochberg, LR
Donoghue, JP
Kirsch, RF
AF Chadwick, E. K.
Blana, D.
Simeral, J. D.
Lambrecht, J.
Kim, S. P.
Cornwell, A. S.
Taylor, D. M.
Hochberg, L. R.
Donoghue, J. P.
Kirsch, R. F.
TI Continuous neuronal ensemble control of simulated arm reaching by a
human with tetraplegia
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
ID SPINAL-CORD-INJURY; FUNCTIONAL ELECTRICAL-STIMULATION; NEUROMUSCULAR
STIMULATION; CORTICAL CONTROL; NEURAL-CONTROL; HAND; RESTORATION;
COMPUTER; SYSTEM; MOVEMENT
AB Functional electrical stimulation (FES), the coordinated electrical activation of multiple muscles, has been used to restore arm and hand function in people with paralysis. User interfaces for such systems typically derive commands from mechanically unrelated parts of the body with retained volitional control, and are unnatural and unable to simultaneously command the various joints of the arm. Neural interface systems, based on spiking intracortical signals recorded from the arm area of motor cortex, have shown the ability to control computer cursors, robotic arms and individual muscles in intact non-human primates. Such neural interface systems may thus offer a more natural source of commands for restoring dexterous movements via FES. However, the ability to use decoded neural signals to control the complex mechanical dynamics of a reanimated human limb, rather than the kinematics of a computer mouse, has not been demonstrated. This study demonstrates the ability of an individual with long-standing tetraplegia to use cortical neuron recordings to command the real-time movements of a simulated dynamic arm. This virtual arm replicates the dynamics associated with arm mass and muscle contractile properties, as well as those of an FES feedback controller that converts user commands into the required muscle activation patterns. An individual with long-standing tetraplegia was thus able to control a virtual, two-joint, dynamic arm in real time using commands derived from an existing human intracortical interface technology. These results show the feasibility of combining such an intracortical interface with existing FES systems to provide a high-performance, natural system for restoring arm and hand function in individuals with extensive paralysis.
C1 [Chadwick, E. K.; Blana, D.; Lambrecht, J.; Cornwell, A. S.; Taylor, D. M.; Kirsch, R. F.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
[Simeral, J. D.; Hochberg, L. R.; Donoghue, J. P.] Rehabil R&D Serv, Ctr Restorat & Regenerat Med, Dept Vet Affairs, Providence, RI USA.
[Kim, S. P.; Donoghue, J. P.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA.
[Taylor, D. M.; Kirsch, R. F.] Louis Stokes VA Med Ctr, Cleveland, OH USA.
[Simeral, J. D.; Hochberg, L. R.] Brown Univ, Sch Engn, Providence, RI 02912 USA.
[Hochberg, L. R.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Hochberg, L. R.] Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Hochberg, L. R.] Harvard Univ, Sch Med, Dept Neurol, Spaulding Rehabil Hosp, Boston, MA 02115 USA.
RP Chadwick, EK (reprint author), Aberystwyth Univ, Dept Sport & Exercise Sci, Aberystwyth, Dyfed, Wales.
EM robert.kirsch@case.edu
OI Chadwick, Edward/0000-0003-0877-5110; Blana, Dimitra/0000-0003-0488-6120
FU NICHD NIH HHS [N01 HD053403]; NIDCD NIH HHS [R01 DC009899, R01
DC009899-01, R01 DC009899-02]
NR 27
TC 43
Z9 43
U1 2
U2 15
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
J9 J NEURAL ENG
JI J. Neural Eng.
PD JUN
PY 2011
VL 8
IS 3
AR 034003
DI 10.1088/1741-2560/8/3/034003
PG 7
WC Engineering, Biomedical; Neurosciences
SC Engineering; Neurosciences & Neurology
GA 769RE
UT WOS:000291035100005
PM 21543840
ER
PT J
AU Freeman, DK
Rizzo, JF
Fried, SI
AF Freeman, Daniel K.
Rizzo, Joseph F., III
Fried, Shelley I.
TI Encoding visual information in retinal ganglion cells with prosthetic
stimulation
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article; Proceedings Paper
CT 6th Biennial Research Congress of the Eye and the Chip
CY SEP, 2010
CL Detroit, MI
ID TEMPORAL RESPONSE PROPERTIES; ISOLATED CHICKEN RETINA;
ELECTRICAL-STIMULATION; PRIMATE RETINA; SACCADIC SUPPRESSION; IN-VITRO;
RECEPTIVE-FIELDS; RABBIT RETINA; SPIKE TRAINS; RD1 MICE
AB Retinal prostheses aim to restore functional vision to those blinded by outer retinal diseases using electric stimulation of surviving retinal neurons. The ability to replicate the spatiotemporal pattern of ganglion cell spike trains present under normal viewing conditions is presumably an important factor for restoring high-quality vision. In order to replicate such activity with a retinal prosthesis, it is important to consider both how visual information is encoded in ganglion cell spike trains, and how retinal neurons respond to electric stimulation. The goal of the current review is to bring together these two concepts in order to guide the development of more effective stimulation strategies. We review the experiments to date that have studied how retinal neurons respond to electric stimulation and discuss these findings in the context of known retinal signaling strategies. The results from such in vitro studies reveal the advantages and disadvantages of activating the ganglion cell directly with the electric stimulus (direct activation) as compared to activation of neurons that are presynaptic to the ganglion cell (indirect activation). While direct activation allows high temporal but low spatial resolution, indirect activation yields improved spatial resolution but poor temporal resolution. Finally, we use knowledge gained from in vitro experiments to infer the patterns of elicited activity in ongoing human trials, providing insights into some of the factors limiting the quality of prosthetic vision.
C1 [Freeman, Daniel K.; Rizzo, Joseph F., III; Fried, Shelley I.] Boston VA Healthcare Syst, Ctr Innovat Visual Rehabil, Boston, MA 02130 USA.
[Freeman, Daniel K.; Fried, Shelley I.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Freeman, Daniel K.; Rizzo, Joseph F., III; Fried, Shelley I.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Rizzo, Joseph F., III] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
RP Freeman, DK (reprint author), Boston VA Healthcare Syst, Ctr Innovat Visual Rehabil, 150 S Huntington Ave, Boston, MA 02130 USA.
EM dfreeman@mit.edu; Fried.Shelley@mgh.harvard.edu
FU NEI NIH HHS [R01 EY019967-01, R01 EY019967, R01 EY-019967-01]
NR 150
TC 17
Z9 18
U1 5
U2 15
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
J9 J NEURAL ENG
JI J. Neural Eng.
PD JUN
PY 2011
VL 8
IS 3
AR 035005
DI 10.1088/1741-2560/8/3/035005
PG 18
WC Engineering, Biomedical; Neurosciences
SC Engineering; Neurosciences & Neurology
GA 769RE
UT WOS:000291035100012
PM 21593546
ER
PT J
AU Jeng, J
Tang, S
Molnar, A
Desai, NJ
Fried, SI
AF Jeng, J.
Tang, S.
Molnar, A.
Desai, N. J.
Fried, S. I.
TI The sodium channel band shapes the response to electric stimulation in
retinal ganglion cells
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
ID AXON INITIAL SEGMENT; MORPHOMETRIC-ANALYSIS; RETINITIS-PIGMENTOSA;
ACTIVATION; NEURONS; MICROELECTRODE; DEGENERATION; PRESERVATION;
PROSTHESIS; MOUSE
AB To improve the quality of prosthetic vision, it is desirable to understand how targeted retinal neurons respond to stimulation. Unfortunately, the factors that shape the response of a single neuron to stimulation are not well understood. A dense band of voltage-gated sodium channels within the proximal axon of retinal ganglion cells is the site most sensitive to electric stimulation, suggesting that band properties are likely to influence the response to stimulation. Here, we examined how three band properties influence sensitivity using a morphologically realistic ganglion cell model in NEURON. Longer bands were more sensitive to short-duration pulses than shorter bands and increasing the distance between band and soma also increased sensitivity. Simulations using the known limits of band length and location resulted in a sensitivity difference of approximately 2. Additional simulations tested how changes to sodium channel conductance within the band influenced threshold and found that the sensitivity difference increased to a factor of nearly 3. This is close to the factor of 5 difference measured in physiological studies suggesting that band properties contribute significantly to the sensitivity differences found between different types of retinal neurons.
C1 [Jeng, J.; Desai, N. J.; Fried, S. I.] Boston VA Healthcare Syst, Ctr Innovat Visual Rehabil, Boston, MA 02130 USA.
[Jeng, J.; Desai, N. J.; Fried, S. I.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Jeng, J.; Desai, N. J.; Fried, S. I.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Tang, S.] Univ Calif, Dept Nat Sci, Merced, CA 95348 USA.
[Tang, S.; Molnar, A.] Cornell Univ, Sch Elect & Comp Engn, Ithaca, NY 14853 USA.
RP Jeng, J (reprint author), Boston VA Healthcare Syst, Ctr Innovat Visual Rehabil, 150 S Huntington Ave, Boston, MA 02130 USA.
EM fried.shelley@mgh.harvard.edu
FU NEI NIH HHS [1 R01 EY019967-01, R01 EY019967, R01 EY019967-01]
NR 35
TC 15
Z9 16
U1 1
U2 3
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
J9 J NEURAL ENG
JI J. Neural Eng.
PD JUN
PY 2011
VL 8
IS 3
AR 036022
DI 10.1088/1741-2560/8/3/036022
PG 12
WC Engineering, Biomedical; Neurosciences
SC Engineering; Neurosciences & Neurology
GA 769RE
UT WOS:000291035100034
PM 21558602
ER
PT J
AU Jensen, RJ
Rizzo, JF
AF Jensen, Ralph J.
Rizzo, Joseph F., III
TI Effects of GABA receptor antagonists on thresholds of P23H rat retinal
ganglion cells to electrical stimulation of the retina
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article; Proceedings Paper
CT 6th Biennial Research Congress of the Eye and the Chip
CY SEP, 2010
CL Detroit, MI
ID ROD BIPOLAR CELLS; PHOTORECEPTOR DEGENERATION; MOUSE RETINA; SLICE
PREPARATION; MAMMALIAN RETINA; TRANSGENIC RAT; AMACRINE CELLS;
RHO-SUBUNITS; RD10 MOUSE; RCS RATS
AB An electronic retinal prosthesis may provide useful vision for patients suffering from retinitis pigmentosa (RP). In animal models of RP, the amount of current needed to activate retinal ganglion cells (RGCs) is higher than in normal, healthy retinas. In this study, we sought to reduce the stimulation thresholds of RGCs in a degenerate rat model (P23H-line 1) by blocking GABA receptor mediated inhibition in the retina. We examined the effects of TPMPA, a GABA(C) receptor antagonist, and SR95531, a GABA(A) receptor antagonist, on the electrically evoked responses of RGCs to biphasic current pulses delivered to the subretinal surface through a 400 mu m diameter electrode. Both TPMPA and SR95531 reduced the stimulation thresholds of ON-center RGCs on average by 15% and 20% respectively. Co-application of the two GABA receptor antagonists had the greatest effect, on average reducing stimulation thresholds by 32%. In addition, co-application of the two GABA receptor antagonists increased the magnitude of the electrically evoked responses on average three-fold. Neither TPMPA nor SR95531, applied alone or in combination, had consistent effects on the stimulation thresholds of OFF-center RGCs. We suggest that the effects of the GABA receptor antagonists on ON-center RGCs may be attributable to blockage of GABA receptors on the axon terminals of ON bipolar cells.
C1 [Jensen, Ralph J.; Rizzo, Joseph F., III] VA Boston Healthcare Syst, Ctr Innovat Visual Rehabil, Boston, MA 02130 USA.
[Rizzo, Joseph F., III] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Jensen, RJ (reprint author), VA Boston Healthcare Syst, Ctr Innovat Visual Rehabil, Mail Stop 151E,150 S Huntington Ave, Boston, MA 02130 USA.
EM Ralph.jensen@va.gov
NR 45
TC 4
Z9 4
U1 1
U2 2
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
J9 J NEURAL ENG
JI J. Neural Eng.
PD JUN
PY 2011
VL 8
IS 3
AR 035002
DI 10.1088/1741-2560/8/3/035002
PG 8
WC Engineering, Biomedical; Neurosciences
SC Engineering; Neurosciences & Neurology
GA 769RE
UT WOS:000291035100009
PM 21593547
ER
PT J
AU Suva, M
Chi, A
Rheinbay, E
Wakimoto, H
Rivera, M
Oksuz, O
Rabkin, S
Martuza, R
Louis, D
Bernstein, B
AF Suva, Mario
Chi, Andrew
Rheinbay, Esther
Wakimoto, Hiro
Rivera, Miguel
Oksuz, Ozgur
Rabkin, Samuel
Martuza, Robert
Louis, David
Bernstein, Bradley
TI Genome-Wide Chromatin Landscape of Glioblastoma Cancer Stem Cells
Highlights an Aberrant Network of Transcription Factors
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 87th Annual Meeting of the American-Association-of-Neuropathologists
CY JUN 23-26, 2011
CL Seattle, WA
SP Amer Assoc Neuropathologists
C1 [Suva, Mario; Rheinbay, Esther; Rivera, Miguel; Oksuz, Ozgur; Louis, David; Bernstein, Bradley] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Chi, Andrew] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Wakimoto, Hiro; Rabkin, Samuel; Martuza, Robert] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RI rabkin, samuel/C-2443-2012
OI rabkin, samuel/0000-0003-2344-2795
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2011
VL 70
IS 6
MA 2
BP 498
EP 498
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 766AV
UT WOS:000290751700011
ER
PT J
AU William, C
Shatz, C
Frosch, M
Hyman, B
AF William, Christopher
Shatz, Carla
Frosch, Matthew
Hyman, Bradley
TI Ocular Dominance Plasticity Defect in Alzheimer Disease Model Mice
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 87th Annual Meeting of the American-Association-of-Neuropathologists
CY JUN 23-26, 2011
CL Seattle, WA
SP Amer Assoc Neuropathologists
C1 [William, Christopher; Frosch, Matthew] Massachusetts Gen Hosp, Neuropathol Serv, Boston, MA 02114 USA.
[Shatz, Carla] Stanford Univ, Stanford, CA 94305 USA.
[Hyman, Bradley] MGH, MassGen Inst Neurodegenerat Dis, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2011
VL 70
IS 6
MA 12
BP 501
EP 501
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 766AV
UT WOS:000290751700021
ER
PT J
AU Stein, T
Dols, O
Scotton, T
Da Rocha-Souto, B
Alberto, SP
Matthew, F
John, G
Bradley, H
Teresa, GI
AF Stein, Thor
Dols, Oriol
Scotton, Thomas
Da Rocha-Souto, Bibiana
Alberto, Serrano-Pozo
Matthew, Frosch
John, Growdon
Bradley, Hyman
Teresa, Gomez-Isla
TI Characterization of Human Brains Resilient to beta-amyloid and Tau
Pathologies
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 87th Annual Meeting of the American-Association-of-Neuropathologists
CY JUN 23-26, 2011
CL Seattle, WA
SP Amer Assoc Neuropathologists
C1 [Stein, Thor; Dols, Oriol; Scotton, Thomas; Da Rocha-Souto, Bibiana; Alberto, Serrano-Pozo; Matthew, Frosch; John, Growdon; Bradley, Hyman; Teresa, Gomez-Isla] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2011
VL 70
IS 6
MA 15
BP 502
EP 502
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 766AV
UT WOS:000290751700024
ER
PT J
AU Auluck, P
Lindquist, S
AF Auluck, Pavan
Lindquist, Susan
TI The Relationship Between Mitochondrial Dysfunction and Alpha-Synuclein
in a Yeast Model of Alpha-Synucleinopathies
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 87th Annual Meeting of the American-Association-of-Neuropathologists
CY JUN 23-26, 2011
CL Seattle, WA
SP Amer Assoc Neuropathologists
C1 [Auluck, Pavan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lindquist, Susan] HHMI, Whitehead Inst Biomed Res, Chevy Chase, MD USA.
[Lindquist, Susan] MIT, Cambridge, MA 02139 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2011
VL 70
IS 6
MA 32
BP 506
EP 507
PG 2
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 766AV
UT WOS:000290751700041
ER
PT J
AU Stemmer-Rachamimov, A
Camelo-Piragua, S
Plotkin, S
AF Stemmer-Rachamimov, Anat
Camelo-Piragua, Sandra
Plotkin, Scott
TI Mutant Isocitrate Dehydrogenase 1 Immunohistochemistry: Not Useful in
the Diagnosis of Low Grade Diffuse Astrocytomas in NF1
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 87th Annual Meeting of the American-Association-of-Neuropathologists
CY JUN 23-26, 2011
CL Seattle, WA
SP Amer Assoc Neuropathologists
C1 [Stemmer-Rachamimov, Anat; Camelo-Piragua, Sandra; Plotkin, Scott] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Stemmer-Rachamimov, Anat] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2011
VL 70
IS 6
MA 51
BP 511
EP 511
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 766AV
UT WOS:000290751700060
ER
PT J
AU Snuderl, M
Sheth, S
Wirth, D
Ogas, P
Kwon, CS
Curry, W
Frosch, M
Yaroslavsky, A
AF Snuderl, Matija
Sheth, Sameer
Wirth, Dennis
Ogas, Polina
Kwon, Churl-Su
Curry, William
Frosch, Matthew
Yaroslavsky, Anna
TI Dye-Enhanced Multimodal Confocal Imaging as a Novel Approach to
Intraoperative Diagnosis of Brain Tumors
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 87th Annual Meeting of the American-Association-of-Neuropathologists
CY JUN 23-26, 2011
CL Seattle, WA
SP Amer Assoc Neuropathologists
C1 [Snuderl, Matija; Frosch, Matthew] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Sheth, Sameer; Ogas, Polina; Kwon, Churl-Su; Curry, William] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Wirth, Dennis] Univ Massachusetts, Dept Phys & Appl Phys, Amherst, MA 01003 USA.
[Yaroslavsky, Anna] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2011
VL 70
IS 6
MA 110
BP 527
EP 527
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 766AV
UT WOS:000290751700119
ER
PT J
AU Davidson, C
Plotkin, S
Stemmer-Rachamimov, A
AF Davidson, Christian
Plotkin, Scott
Stemmer-Rachamimov, Anat
TI Diffusely Infiltrative Plexiform Schwannoma in Two Patients With
Neurofibromatosis Type 2
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 87th Annual Meeting of the American-Association-of-Neuropathologists
CY JUN 23-26, 2011
CL Seattle, WA
SP Amer Assoc Neuropathologists
C1 [Davidson, Christian; Plotkin, Scott; Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2011
VL 70
IS 6
MA 159
BP 540
EP 540
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 766AV
UT WOS:000290751700168
ER
PT J
AU Heras, FL
Stemmer-Rachamimov, A
AF Heras, Facundo Las
Stemmer-Rachamimov, Anat
TI Hybrid Schwannoma/Perineurioma of the VIII Cranial Nerve: Case Report
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Meeting Abstract
CT 87th Annual Meeting of the American-Association-of-Neuropathologists
CY JUN 23-26, 2011
CL Seattle, WA
SP Amer Assoc Neuropathol
C1 [Heras, Facundo Las] Univ Chile, Clin Hosp, Santiago, Chile.
[Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD JUN
PY 2011
VL 70
IS 6
BP 541
EP +
PG 2
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 766AV
UT WOS:000290751700172
ER
PT J
AU Courtwright, AM
Laughon, MM
Doron, MW
AF Courtwright, A. M.
Laughon, M. M.
Doron, M. W.
TI Length of life and treatment intensity in infants diagnosed prenatally
or postnatally with congenital anomalies considered to be lethal
SO JOURNAL OF PERINATOLOGY
LA English
DT Article
DE congenital malformation; pregnancy termination; intensive care; decision
making; ethics; lethal
ID TRISOMY-18; MANAGEMENT; MALFORMATIONS; MORTALITY; FETAL
AB Objectives: The objectives of this study were (1) to compare age at death and the intensity and cost of medical treatment for infants diagnosed prenatally or postnatally with congenital anomalies considered to be lethal. (2) To determine whether greater treatment intensity is associated with longer life.
Study Design: This is a retrospective cohort study of all fetuses and neonates with congenital anomalies classified as lethal who were diagnosed or treated at the University of North Carolina Hospitals from January 1998 to December 2003.
Result: The cohort consisted of 192 fetuses and infants: 160 were diagnosed prenatally, 2 were diagnosed perinatally, and 30 were diagnosed postnatally. In all, 115 (72%) pregnancies were terminated. Of the liveborn infants, 75% died before 10 days of age and 90% before 4 months of age. Compared with postnatally diagnosed infants, prenatally diagnosed infants received less intense treatment (median average daily Neonatal Therapeutic Intervention Scoring System score 8.3 versus 14.0; P = 0.02), at less cost (median direct cost of hospitalization $1550 versus $8474; P = 0.03) and died sooner (median age at death <1 day versus 4 days; P = 0.01). Greater treatment intensity did not correlate with longer survival (r = -0.04; P = 0.66).
Conclusion: Although some kinds of medical therapy may be appropriate for newborns with lethal congenital anomalies, highly aggressive interventions did not prolong survival and should not be offered. Even when pregnancy termination is not elected, infants diagnosed prenatally receive less intense care. Journal of Perinatology (2011) 31, 387-391; doi:10.1038/jp.2010.124; published online 16 December 2010
C1 [Courtwright, A. M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Laughon, M. M.; Doron, M. W.] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC USA.
RP Doron, MW (reprint author), UNC Hosp, Dept Pediat, CB 7596, Chapel Hill, NC 27599 USA.
EM mia_doron@med.unc.edu
FU Howard Holderness Medical Fellowship Grant
FX We thank Carl Bose, Cynthia Cassell, Michael McDade, Robert Meyer, Kelly
Gilmore, Emily Hardisty, Anthony Johnson, Kenneth Moise, Cynthia Powell,
Ben Saville, Kathleen Veness-Meehan and Honor Wolfe for their help with
this project. Salary support for Andrew Courtwright was provided by a
Howard Holderness Medical Fellowship Grant.
NR 28
TC 16
Z9 16
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0743-8346
J9 J PERINATOL
JI J. Perinatol.
PD JUN
PY 2011
VL 31
IS 6
BP 387
EP 391
DI 10.1038/jp.2010.124
PG 5
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA 769NX
UT WOS:000291024300002
PM 21164425
ER
PT J
AU Cadge, W
Calle, K
Dillinger, J
AF Cadge, Wendy
Calle, Katherine
Dillinger, Jennifer
TI What Do Chaplains Contribute to Large Academic Hospitals? The
Perspectives of Pediatric Physicians and Chaplains
SO JOURNAL OF RELIGION & HEALTH
LA English
DT Article
DE Chaplains; Chaplaincy; Pediatric physicians; Spiritual care
ID UNITED-STATES; HEALTH-CARE; SPIRITUALITY; RELIGION; PROVISION; MEDICINE;
BELIEFS
AB This article analyzes interviews with pediatric physicians (N = 30) and chaplains (N = 22) who work at the same large academic medical centers (N = 13). We ask how pediatric physicians understand and work with chaplains and how chaplains describe their own work. We find that physicians see chaplains as part of interdisciplinary medical teams where they perform rituals and support patients and families, especially around death. Chaplains agree but frame their contributions in terms of the perspectives related to wholeness, presence, and healing they bring. Chaplains have a broader sense of what they contribute to patient care than do physicians.
C1 [Cadge, Wendy] Brandeis Univ, Dept Sociol, Waltham, MA 02454 USA.
[Calle, Katherine] Harvard Univ, Cambridge, MA 02138 USA.
[Dillinger, Jennifer] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Cadge, W (reprint author), Brandeis Univ, Dept Sociol, MS 071, Waltham, MA 02454 USA.
EM wcadge@brandeis.edu
NR 53
TC 7
Z9 7
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0022-4197
J9 J RELIG HEALTH
JI J. Relig. Health
PD JUN
PY 2011
VL 50
IS 2
BP 300
EP 312
DI 10.1007/s10943-011-9474-8
PG 13
WC Public, Environmental & Occupational Health; Religion
SC Public, Environmental & Occupational Health; Religion
GA 763RV
UT WOS:000290578300010
PM 21409483
ER
PT J
AU Yared, K
Noseworthy, P
Weyman, AE
McCabe, E
Picard, MH
Baggish, AL
AF Yared, Kibar
Noseworthy, Peter
Weyman, Arthur E.
McCabe, Elizabeth
Picard, Michael H.
Baggish, Aaron L.
TI Pulmonary Artery Acceleration Time Provides an Accurate Estimate of
Systolic Pulmonary Arterial Pressure during Transthoracic
Echocardiography
SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
LA English
DT Article
DE Pulmonary artery acceleration time; Right ventricular systolic pressure;
Pulmonary artery pressure; Transthoracic echocardiography
ID SALINE CONTRAST ENHANCEMENT; TRICUSPID REGURGITATION; NONINVASIVE
ESTIMATION; DOPPLER ULTRASOUND; CATHETERIZATION; HYPERTENSION; VELOCITY
AB Background: Transthoracic echocardiographic estimates of peak systolic pulmonary artery pressure are conventionally calculated from the maximal velocity of the tricuspid regurgitation (TR) jet. Unfortunately, there is insufficient TR to determine estimated peak systolic pulmonary artery pressure (EPSPAP) in a significant number of patients. To date, in the absence of TR, no noninvasive method of deriving EPSPAP has been developed.
Methods: Five hundred clinically indicated transthoracic echocardiograms were reviewed over a period of 6 months. Patients with pulmonic stenosis were excluded. Pulsed-wave Doppler was used to measure pulmonary artery acceleration time (PAAT) and right ventricular ejection time. Continuous-wave Doppler was used to measure the peak velocity of TR (TR(Vmax)), and EPSPAP was calculated as 4 -TR(Vmax)2 + 10mmHg (to account for right atrial pressure). The relationship between PAAT and EPSPAP was then assessed.
Results: Adequate imaging to measure PAAT was available in 99.6% of patients (498 of 500), but 25.3% (126 of 498) had insufficient TR to determine EPSPAP, and 1 patient had significant pulmonic stenosis. Therefore, 371 were included in the final analysis. Interobserver variability for PAAT was 0.97. There were strong inverse correlations between PAAT and TRVmax (r = -0.96), the right atrial/right ventricular pressure gradient (r = -0.95), and EPSPAP (r = -0.95). The regression equation describing the relationship between PAAT and EPSPAP was log(10)(EPSPAP) = -0.004 (PAAT) + 2.1 (P <.001).
Conclusions: PAAT is routinely obtainable and correlates strongly with both TRVmax and EPSPAP in a large population of randomly selected patients undergoing transthoracic echocardiography. Characterization of the relationship between PAAT and EPSPAP permits PAAT to be used to estimate peak systolic pulmonary artery pressure independent of TR, thereby increasing the percentage of patients in whom transthoracic echocardiography can be used to quantify pulmonary artery pressure. (J Am Soc Echocardiogr 2011; 24:687-92.)
C1 [Yared, Kibar] Univ Toronto, Sch Med, Div Cardiol, Scarborough Hosp, Toronto, ON M1P 2V5, Canada.
[Yared, Kibar; Noseworthy, Peter; Weyman, Arthur E.; McCabe, Elizabeth; Picard, Michael H.; Baggish, Aaron L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP Yared, K (reprint author), Univ Toronto, Sch Med, Div Cardiol, Scarborough Hosp, Gen Campus,3050 Lawrence Ave W, Toronto, ON M1P 2V5, Canada.
EM kibaryared@yahoo.com
OI Picard, Michael/0000-0002-9264-3243
NR 27
TC 50
Z9 53
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0894-7317
J9 J AM SOC ECHOCARDIOG
JI J. Am. Soc. Echocardiogr.
PD JUN
PY 2011
VL 24
IS 6
BP 687
EP 692
DI 10.1016/j.echo.2011.03.008
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 768OI
UT WOS:000290944100012
PM 21511434
ER
PT J
AU Yeramian, A
Santacana, M
Sorolla, A
Llobet, D
Encinas, M
Velasco, A
Bahi, N
Eritja, N
Domingo, M
Oliva, E
Dolcet, X
Matias-Guiu, X
AF Yeramian, Andree
Santacana, Maria
Sorolla, Anabel
Llobet, David
Encinas, Mario
Velasco, Ana
Bahi, Nuria
Eritja, Nuria
Domingo, Monica
Oliva, Esther
Dolcet, Xavier
Matias-Guiu, Xavier
TI Nuclear factor-kappa B2/p100 promotes endometrial carcinoma cell
survival under hypoxia in a HIF-1 alpha independent manner
SO LABORATORY INVESTIGATION
LA English
DT Article
DE apoptosis; hypoxia; IKK alpha; IKK beta; NF-kappa B
ID NF-KAPPA-B; IKK-ALPHA; NF-KAPPA-B2 P100; GENE-EXPRESSION; INDUCIBLE
FACTOR-1-ALPHA; PROTEASOME INHIBITORS; IMMUNE-RESPONSES; KINASE-ALPHA;
CANCER CELLS; ACTIVATION
AB Endometrial carcinoma (EC) is a common female cancer, treated mainly by surgery and adjuvant radiotherapy. Relapse following treatment is associated with increased risk of metastases. Hypoxia, a common microenvironment in solid tumors, correlates with malignant progression, rendering tumors resistant to ionizing therapy. Hence, we assessed here the immunohistochemical expression of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and members of the NF-kappa B family in 82 primary EC and 10 post-radiation recurrences of EC. Post-radiation recurrences were highly hypoxic, with a higher expression of HIF-1 alpha and also RelA (p65) and p52 when compared with primary EC. We next investigated the effects of hypoxia on EC cell lines. We found that EC cell lines are highly resistant to hypoxia-induced apoptosis. We thus focused on the molecular mechanisms involved in conferring hypoxic cell death resistance. We show that in addition to the classical NF-kappa B, hypoxia activates the alternative NF-kappa B pathway. To characterize the upstream kinases involved in the activation of these pathways, we used lentiviral-mediated knockdown and mouse embryonic fibroblasts lacking IKK alpha and IKK beta kinases. Both IKK alpha and IKK beta kinases are required for RelA (p65) and p100 accumulation, whereas p52 processing under hypoxia is IKK alpha dependent. Furthermore, Ishikawa endometrial cell line harboring either RelA (p65) or p52 short-hairpin RNA was sensitive to hypoxia-induced cell death, indicating that, in addition to the known prosurvival role of RelA (p65) under hypoxia, alternative NF-kappa B pathway also enhances hypoxic survival of EC cells. Interestingly, although HIF-1 alpha controlled classical NF-kappa B activation pathway and survival under hypoxia through RelA (p65) nuclear accumulation, the alternative pathway was HIF-1 alpha independent. These findings have important clinical implications for the improvement of EC prognosis before radiotherapy. Laboratory Investigation (2011) 91, 859-871; doi:10.1038/labinvest.2011.58; published online 2 May 2011
C1 [Yeramian, Andree; Santacana, Maria; Sorolla, Anabel; Llobet, David; Velasco, Ana; Bahi, Nuria; Eritja, Nuria; Domingo, Monica; Dolcet, Xavier; Matias-Guiu, Xavier] Univ Lleida, Hosp Univ Arnau Vilanova, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet,Lab Recerca Biomed, Ileida, Spain.
[Encinas, Mario] IRBLleida, Dept Expt Med, Ileida, Spain.
[Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Yeramian, A (reprint author), Univ Lleida, Hosp Univ Arnau Vilanova, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet,Lab Recerca Biomed, Av Rovira Roure 80, Lleida 25198, Spain.
EM andree.yeramian@cmb.udl.es
RI Llobet-Navas, David/B-5660-2009; Bahi Pla, Nuria/B-8022-2009; Eritja
Sanchez, Nuria/C-4465-2011; Encinas, Mario/B-5600-2009; matias-guiu,
xavier/C-3039-2009; Dolcet, Xavi/B-5665-2009; Sorolla,
Anabel/E-2546-2012; eritja, Nuria/M-1347-2015
OI Llobet-Navas, David/0000-0003-1443-7003; Bahi Pla,
Nuria/0000-0003-2845-0313; Encinas, Mario/0000-0003-3509-7431;
matias-guiu, xavier/0000-0002-7201-6605; eritja,
Nuria/0000-0003-1018-6649
FU Ministerio de Educacion y Ciencia (Juan de la Cierva) [RD 06/00/20/134,
2009 SGR 174, Fis PI070276]; Fondo de Investigaciones Sanitarias,
Ministerio de Sanidad y Consumo [CP05/00028, FI05/00191, FI08/0012];
Fundacion Cientifica AECC, Catalunya contra el Cancer, Lleida
FX We thank Concepcio Soler and Jordi Torres for critical reading of the
manuscript. We thank Dr Michael Karin for providing IKK alpha-/- and IKK
beta-/- MEFs. This work was supported by grants from RD 06/00/20/134,
2009 SGR 174, Fis PI070276, Ministerio de Educacion y Ciencia (Juan de
la Cierva Postdoctoral fellowship to AY), the Fondo de Investigaciones
Sanitarias, Ministerio de Sanidad y Consumo (Postdoctoral fellowship
CP05/00028 to XD and Predoctoral fellowships FI05/00191 to DL and
FI08/0012 to NE), Fundacion Cientifica AECC, Catalunya contra el Cancer,
Lleida (fellowship to AS). Tumor samples were obtained with the support
of Xarxa Catalana de Bancs de Tumors, The Tumor Banc Platform of RTICC
and RD09/0076/000S9. This work is dedicated to Daniel, Alfonso and
Irene.
NR 44
TC 17
Z9 18
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD JUN
PY 2011
VL 91
IS 6
BP 859
EP 871
DI 10.1038/labinvest.2011.58
PG 13
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 769OO
UT WOS:000291026300006
PM 21537326
ER
PT J
AU Hughes, KS
Roche, CA
AF Hughes, Kevin S.
Roche, Constance A.
TI The complexity of breast cancer risk needs to be embraced, not
oversimplified
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Editorial Material
ID TAMOXIFEN
C1 [Hughes, Kevin S.; Roche, Constance A.] Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA.
RP Hughes, KS (reprint author), Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA.
OI Hughes, Kevin/0000-0003-4084-6484
NR 5
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD JUN
PY 2011
VL 18
IS 6
BP 599
EP 600
DI 10.1097/gme.0b013e31821bbd55
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 769HV
UT WOS:000291004400003
PM 21587090
ER
PT J
AU Seldin, E
AF Seldin, Edward
TI The interconnectedness of medical and dental health
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Seldin, E (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD JUN
PY 2011
VL 18
IS 6
BP 601
EP 602
DI 10.1097/gme.0b013e3182113bff
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 769HV
UT WOS:000291004400004
PM 21403581
ER
PT J
AU Jessup, JA
Zhang, LL
Chen, AF
Presley, TD
Kim-Shapiro, DB
Chappell, MC
Wang, H
Groban, L
AF Jessup, Jewell A.
Zhang, Lili
Chen, Alex F.
Presley, Tennille D.
Kim-Shapiro, Daniel B.
Chappell, Mark C.
Wang, Hao
Groban, Leanne
TI Neuronal nitric oxide synthase inhibition improves diastolic function
and reduces oxidative stress in ovariectomized mRen2.Lewis rats
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Diastolic function; Fibrosis; Left ventricular modeling; Myocardial
relaxation; Nitric oxide; Postmenopausal
ID LEFT-VENTRICULAR HYPERTROPHY; HEART-FAILURE; POSTMENOPAUSAL WOMEN;
VASCULAR TETRAHYDROBIOPTERIN; PRESSURE-OVERLOAD; SYSTOLIC FUNCTION;
RECEPTOR BLOCKER; BLOOD-PRESSURE; ADVANCED-STAGE; ESTROGEN
AB Objective: The loss of estrogen in mRen2.Lewis rats leads to an exacerbation of diastolic dysfunction. Because specific neuronal nitric oxide synthase (nNOS) inhibition reverses renal damage in the same model, we assessed the effects of inhibiting neuronal nitric oxide on diastolic function, left ventricular remodeling, and the components of the cardiac nitric oxide system in ovariectomized (OVX) and sham-operated mRen2.Lewis rats treated with N(5)-(1-imino-3-butenyl)-L-ornithine (L-VNIO; 0.5 mg/kg per day for 28 d) or vehicle (saline).
Methods: Female mRen2.Lewis rats underwent either bilateral oophorectomy (OVX; n = 15) or sham operation (or surgical procedure) (sham; n = 19) at 4 weeks of age. Beginning at 11 weeks of age, the rats were randomized to receive either L-VNIO or vehicle.
Results: The surgical loss of ovarian hormones, particularly estrogen, led to exacerbated hypertension, impaired myocardial relaxation, diminished diastolic compliance, increased perivascular fibrosis, and increased relative wall thickness. The cardiac tetrahydrobiopterin-to-dihydrobiopterin levels were lower among OVX rats compared with sham-operated rats, and this altered cardiac biopterin profile was associated with enhanced myocardial superoxide production and decreased nitric oxide release. L-VNIO decreased myocardial reactive oxygen species production, increased nitrite concentrations, attenuated cardiac remodeling, and improved diastolic function.
Conclusions: Impaired relaxation, diastolic stiffness, and cardiac remodeling were found among OVX mRen2.Lewis rats. A possible mechanism for this unfavorable cardiac phenotype may have resulted from a deficiency in available tetrahydrobiopterin and subsequent increase in nNOS-derived superoxide and reduction in nitric oxide synthase metabolites within the heart. Selective nNOS inhibition with L-VNIO attenuated cardiac superoxide production and limited remodeling, leading to improved diastolic function in OVX mRen2.Lewis rats.
C1 [Wang, Hao; Groban, Leanne] Wake Forest Univ, Dept Anesthesiol, Sch Med, Winston Salem, NC 27157 USA.
[Jessup, Jewell A.; Groban, Leanne] Wake Forest Univ, Dept Physiol & Pharmacol, Sch Med, Winston Salem, NC 27157 USA.
[Zhang, Lili; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA.
[Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Vasc Surg Res, Pittsburgh, PA USA.
[Presley, Tennille D.; Kim-Shapiro, Daniel B.] Winston Salem State Univ, Dept Chem, Winston Salem, NC USA.
[Kim-Shapiro, Daniel B.] Wake Forest Univ, Translat Sci Ctr, Winston Salem, NC 27157 USA.
[Chappell, Mark C.] Wake Forest Univ, Hypertens & Vasc Res Ctr, Sch Med, Winston Salem, NC 27157 USA.
RP Groban, L (reprint author), Wake Forest Univ, Dept Anesthesiol, Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM lgroban@wfubmc.edu
FU National Institutes of Health [R01-AG033727-01, K08-AG026764-05,
HL058091, R01 GM077352, HL-56973]; American Heart Association
[0855601GH]
FX The work described here was supported in part by grants from the
National Institutes of Health R01-AG033727-01 (L.G.), K08-AG026764-05
Paul Beeson Award (L.G.), National Institutes of Health HL058091
(D.B.K.-S.), R01 GM077352 (A.F.C.), HL-56973 (M.C.C.), and American
Heart Association Grant-in-Aid 0855601GH (A.F.C.).
NR 53
TC 13
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD JUN
PY 2011
VL 18
IS 6
BP 698
EP 708
DI 10.1097/gme.0b013e31820390a2
PG 11
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 769HV
UT WOS:000291004400018
PM 21293310
ER
PT J
AU Aronis, KN
Kim, YB
Mantzoros, CS
AF Aronis, Konstantinos N.
Kim, Young-Bum
Mantzoros, Christos S.
TI Clusterin (apolipoprotein J): wither link with diabetes and
cardiometabolic risk?
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Editorial Material
ID CORONARY-HEART-DISEASE; RETE TESTIS FLUID; PROSTATE-CANCER; EXPRESSION;
DENSITY; OVEREXPRESSION; PURIFICATION; PROGRESSION; BIOMARKER; SURVIVAL
C1 [Aronis, Konstantinos N.; Kim, Young-Bum; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab,Dept Internal Med, Boston, MA 02215 USA.
[Mantzoros, Christos S.] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA.
[Mantzoros, Christos S.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Dept Internal Med,Sect Endocrinol, Boston, MA 02215 USA.
RP Aronis, KN (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab,Dept Internal Med, Boston, MA 02215 USA.
EM cmantzor@bidmc.harvard.edu
RI Aronis, Konstantinos/F-3586-2012
OI Aronis, Konstantinos/0000-0001-7189-8434
NR 21
TC 5
Z9 5
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
J9 METABOLISM
JI Metab.-Clin. Exp.
PD JUN
PY 2011
VL 60
IS 6
BP 747
EP 748
DI 10.1016/j.metabol.2010.12.013
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 770GX
UT WOS:000291076100001
PM 21333309
ER
PT J
AU Magkos, F
Mantzoros, CS
AF Magkos, Faidon
Mantzoros, Christos S.
TI Body fat redistribution and metabolic abnormalities in HIV-infected
patients on highly active antiretroviral therapy: novel insights into
pathophysiology and emerging opportunities for treatment
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Editorial Material
ID RECOMBINANT HUMAN LEPTIN; INSULIN-RESISTANCE; ADIPOSE-TISSUE;
LIPODYSTROPHY SYNDROME; CARDIOVASCULAR RISK; LIPOPROTEIN-LIPASE;
LIPOATROPHY; DYSLIPIDEMIA; MEN; LIPOLYSIS
C1 [Magkos, Faidon; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
[Mantzoros, Christos S.] Harvard Univ, Boston VA Healthcare Syst, Sch Med, Endocrinol Sect, Boston, MA 02215 USA.
RP Magkos, F (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
EM cmantzor@bidmc.harvard.edu
FU NIA NIH HHS [AG032030, R01 AG032030, R01 AG032030-01A1]; NIDDK NIH HHS
[R56 DK058785, DK79929, DK81913, K24 DK081913-02, R01 DK058785, R01
DK079929-02, DK58785, K24 DK081913, R01 DK058785-02, R01 DK079929]
NR 45
TC 20
Z9 21
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
J9 METABOLISM
JI Metab.-Clin. Exp.
PD JUN
PY 2011
VL 60
IS 6
BP 749
EP 753
DI 10.1016/j.metabol.2010.09.011
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 770GX
UT WOS:000291076100002
PM 20965525
ER
PT J
AU Murai, J
Yang, KL
Dejsuphong, D
Hirota, K
Takeda, S
D'Andrea, AD
AF Murai, Junko
Yang, Kailin
Dejsuphong, Donniphat
Hirota, Kouji
Takeda, Shunichi
D'Andrea, Alan D.
TI The USP1/UAF1 Complex Promotes Double-Strand Break Repair through
Homologous Recombination
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID FANCONI-ANEMIA PATHWAY; CROSS-LINK REPAIR; DNA-DAMAGE RESPONSE;
POLY(ADP-RIBOSE) POLYMERASE; VERTEBRATE CELLS; GENOMIC INSTABILITY;
BRCA1 DEFICIENCY; UBIQUITIN; INHIBITION; PROTEIN
AB Protein ubiquitination plays a key role in the regulation of a variety of DNA repair mechanisms. Protein ubiquitination is controlled by the coordinate activity of ubiquitin ligases and deubiquitinating enzymes (DUBs). The deubiquitinating enzyme USP1 regulates DNA repair and the Fanconi anemia pathway through its association with its WD40 binding partner, UAF1, and through its deubiquitination of two critical DNA repair proteins, FANCD2-Ub and PCNA-Ub. To investigate the function of USP1 and UAF1, we generated USP1(-/-), UAF1(-/-/-), and USP1(-/-) UAF1(-/-/-) chicken DT40 cell clones. These three clones showed similar sensitivities to chemical cross-linking agents, to a topoisomerase poison, camptothecin, and to an inhibitor of poly(ADP-ribose) polymerase (PARP), indicating that the USP1/UAF1 complex is a regulator of the cellular response to DNA damage. The hypersensitivity to both camptothecin and a PARP inhibitor suggests that the USP1/UAF1 complex promotes homologous recombination (HR)-mediated double-strand break (DSB) repair. To gain insight into the mechanism of the USP1/UAF1 complex in HR, we inactivated the nonhomologous end-joining (NHEJ) pathway in UAF1-deficient cells. Disruption of NHEJ in UAF1-deficient cells restored cellular resistance to camptothecin and the PARP inhibitor. Our results indicate that the USP1/UAF1 complex promotes HR, at least in part by suppressing NHEJ.
C1 [Murai, Junko; Yang, Kailin; Dejsuphong, Donniphat; D'Andrea, Alan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Murai, Junko; Hirota, Kouji; Takeda, Shunichi] Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan.
RP D'Andrea, AD (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St, Boston, MA 02115 USA.
EM alan_dandrea@dfci.harvard.edu
RI Yang, Kailin/D-7966-2013; Yang, Kailin/L-2205-2013
OI Yang, Kailin/0000-0001-5968-6738
FU TOYOBO Biotechnology Foundation; NIH [P01CA092584, R01DK43889,
R01HL52725]
FX J.M. was funded by long-term research grants from the TOYOBO
Biotechnology Foundation. K.Y. is a Harvard University Presidential
Scholar. This work was supported by NIH grants P01CA092584, R01DK43889,
and R01HL52725 to A.D.D.
NR 45
TC 51
Z9 56
U1 2
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUN
PY 2011
VL 31
IS 12
BP 2462
EP 2469
DI 10.1128/MCB.05058-11
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 769KA
UT WOS:000291010100010
PM 21482670
ER
PT J
AU Freedman, ML
Monteiro, ANA
Gayther, SA
Coetzee, GA
Risch, A
Plass, C
Casey, G
De Biasi, M
Carlson, C
Duggan, D
James, M
Liu, PY
Tichelaar, JW
Vikis, HG
You, M
Mills, IG
AF Freedman, Matthew L.
Monteiro, Alvaro N. A.
Gayther, Simon A.
Coetzee, Gerhard A.
Risch, Angela
Plass, Christoph
Casey, Graham
De Biasi, Mariella
Carlson, Chris
Duggan, David
James, Michael
Liu, Pengyuan
Tichelaar, Jay W.
Vikis, Haris G.
You, Ming
Mills, Ian G.
TI Principles for the post-GWAS functional characterization of cancer risk
loci
SO NATURE GENETICS
LA English
DT Article
ID HUMAN GENE-EXPRESSION; GENOME-WIDE ASSOCIATION; LONG-RANGE INTERACTION;
GERMLINE EPIMUTATION; COLORECTAL-CANCER; ENHANCERS; VARIANTS; BREAST;
TRAITS; MYC
C1 [Mills, Ian G.] Univ Oslo, Nord European Mol Biol Lab EMBL Partnership, Norwegian Ctr Mol Med, Oslo, Norway.
[Freedman, Matthew L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Freedman, Matthew L.] Eli & Edythe L Broad Inst MIT & Harvard, Cambridge, MA USA.
[Monteiro, Alvaro N. A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Canc Epidemiol Program, Tampa, FL 33612 USA.
[Gayther, Simon A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Gayther, Simon A.] UCL, Elizabeth Garrett Anderson Inst Womens Hlth EGA, Translat Res Lab, London, England.
[Coetzee, Gerhard A.] Univ So Calif, Dept Urol, Norris Canc Ctr, Los Angeles, CA USA.
[Risch, Angela; Plass, Christoph] German Canc Res Ctr, Div Epigenom & Canc Risk Factors, D-6900 Heidelberg, Germany.
[Casey, Graham] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
[De Biasi, Mariella] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.
[Carlson, Chris] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Duggan, David] Translat Genom Res Inst TGen, Phoenix, AZ USA.
[James, Michael; Liu, Pengyuan; Tichelaar, Jay W.; Vikis, Haris G.; You, Ming] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Mills, Ian G.] Canc Res UK Cambridge Res Inst, Urooncol Res Grp, Cambridge, England.
RP Mills, IG (reprint author), Univ Oslo, Nord European Mol Biol Lab EMBL Partnership, Norwegian Ctr Mol Med, Oslo, Norway.
EM ian.mills@ncmm.uio.no
RI Plass, Christoph/H-7192-2014; Risch, Angela/H-2669-2013;
OI Risch, Angela/0000-0002-8026-5505; Monteiro, Alvaro/0000-0002-8448-4801
FU NIH Post-Genome Wide Association Initiative [1U19CA148537-01,
1U19CA148065-01, 1U19CA148112-01, 1U19CA148107-01, 1U19CA148127-01]
FX We would like to thank F. Bunz and all the members of the NIH
Post-Genome Wide Association Initiative for helpful discussions and, in
particular, I. Tomlinson (Wellcome Trust Centre for Human Genetics,
Oxford). The contributing groups are supported by funding made available
through the NIH Post-Genome Wide Association Initiative in response to
Call (http://grants.nih.gov./grants/oer.htm). This Call sustains
research across five cancer organ sites (prostate: 1U19CA148537-01;
breast: 1U19CA148065-01; ovarian: 1U19CA148112-01; colorectal:
1U19CA148107-01; and lung: 1U19CA148127-01). For further information on
this Initiative, please refer to the website:
(http://epi.grants.cancer.gov/). In addition, this article is the
product of the first attempt to engage the entire scientific community
in the drafting of a scientific paper through open-access websites. We
would like to thank R. Hoffmann at WikiGenes for hosting the
pre-submission version of this submission
(http://www.wikigenes.org/e/pub/e/84.html) and his unstinting energy and
enthusiasm for this project and also Nature Precedings for hosting the
same version (http://precedings.nature.com/documents/5162/version/1).
NR 57
TC 182
Z9 187
U1 3
U2 27
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2011
VL 43
IS 6
BP 513
EP 518
DI 10.1038/ng.840
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 769ME
UT WOS:000291017000006
PM 21614091
ER
PT J
AU Yang, J
Manolio, TA
Pasquale, LR
Boerwinkle, E
Caporaso, N
Cunningham, JM
de Andrade, M
Feenstra, B
Feingold, E
Hayes, MG
Hill, WG
Landi, MT
Alonso, A
Lettre, G
Lin, P
Ling, H
Lowe, W
Mathias, RA
Melbye, M
Pugh, E
Cornelis, MC
Weir, BS
Goddard, ME
Visscher, PM
AF Yang, Jian
Manolio, Teri A.
Pasquale, Louis R.
Boerwinkle, Eric
Caporaso, Neil
Cunningham, Julie M.
de Andrade, Mariza
Feenstra, Bjarke
Feingold, Eleanor
Hayes, M. Geoffrey
Hill, William G.
Landi, Maria Teresa
Alonso, Alvaro
Lettre, Guillaume
Lin, Peng
Ling, Hua
Lowe, William
Mathias, Rasika A.
Melbye, Mads
Pugh, Elizabeth
Cornelis, Marilyn C.
Weir, Bruce S.
Goddard, Michael E.
Visscher, Peter M.
TI Genome partitioning of genetic variation for complex traits using common
SNPs
SO NATURE GENETICS
LA English
DT Article
ID BODY-MASS INDEX; VON-WILLEBRAND-FACTOR; WIDE ASSOCIATION; HUMAN HEIGHT;
LARGE PROPORTION; AGING RESEARCH; BLOOD-GROUP; FACTOR-VIII;
HERITABILITY; POPULATION
AB We estimate and partition genetic variation for height, body mass index (BMI), von Willebrand factor and QT interval (QTi) using 586,898 SNPs genotyped on 11,586 unrelated individuals. We estimate that similar to 45%, similar to 17%, similar to 25% and similar to 21% of the variance in height, BMI, von Willebrand factor and QTi, respectively, can be explained by all autosomal SNPs and a further similar to 0.5-1% can be explained by X chromosome SNPs. We show that the variance explained by each chromosome is proportional to its length, and that SNPs in or near genes explain more variation than SNPs between genes. We propose a new approach to estimate variation due to cryptic relatedness and population stratification. Our results provide further evidence that a substantial proportion of heritability is captured by common SNPs, that height, BMI and QTi are highly polygenic traits, and that the additive variation explained by a part of the genome is approximately proportional to the total length of DNA contained within genes therein.
C1 [Yang, Jian; Visscher, Peter M.] Queensland Inst Med Res, Queensland Stat Genet Lab, Brisbane, Qld 4006, Australia.
[Manolio, Teri A.] NHGRI, Off Populat Genom, Bethesda, MD 20892 USA.
[Pasquale, Louis R.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr, Div Epidemiol, Houston, TX USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA.
[Caporaso, Neil; Landi, Maria Teresa] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Cunningham, Julie M.] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN USA.
[de Andrade, Mariza] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA.
[Feenstra, Bjarke; Melbye, Mads] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.
[Feingold, Eleanor] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA.
[Hayes, M. Geoffrey] Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA.
[Hill, William G.] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland.
[Alonso, Alvaro] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Lettre, Guillaume] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada.
[Lin, Peng] Washington Univ, Sch Med, Human & Stat Genet Program, St Louis, MO USA.
[Ling, Hua; Pugh, Elizabeth] Johns Hopkins Univ, Sch Med, Ctr Inherited Dis Res, Baltimore, MD USA.
[Mathias, Rasika A.] Johns Hopkins Univ, Sch Med, Dept Gen Internal Med, Baltimore, MD USA.
[Cornelis, Marilyn C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Weir, Bruce S.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Goddard, Michael E.] Univ Melbourne, Dept Food & Agr Syst, Melbourne, Vic 3010, Australia.
[Goddard, Michael E.] Dept Primary Ind, Biosci Res Div, Bundoora, Vic, Australia.
RP Visscher, PM (reprint author), Queensland Inst Med Res, Queensland Stat Genet Lab, Brisbane, Qld 4006, Australia.
EM peter.visscher@qimr.edu.au
RI Alonso, Alvaro/A-4917-2010; Hill, William/B-3198-2012; Weir,
Bruce/A-2894-2013; Lin, P/G-7702-2014; Yang, Jian/A-5852-2010;
OI Alonso, Alvaro/0000-0002-2225-8323; Yang, Jian/0000-0003-2001-2474;
Feenstra, Bjarke/0000-0003-1478-649X; Goddard,
Michael/0000-0001-9917-7946; Feingold, Eleanor/0000-0003-2898-6484;
Visscher, Peter/0000-0002-2143-8760; de Andrade,
Mariza/0000-0003-2329-2686
FU US National Institutes of Health Genes, Environment and Health
Initiative; Research to Prevent Blindness in New York City; Canadian
Institutes of Health Research; Australian National Health and Medical
Research Council (NHMRC) [389892, 613672]; Australian Research Council
(ARC) [DP0770096, DP1093900]; [U01 HG 004402]; [U01 HG 004399]; [U01
HG 004728]; [U01 HG04424]; [U01 HG 004446]
FX Funding support for the Gene, Environment Association Studies (GENEVA)
project has been provided through the US National Institutes of Health
Genes, Environment and Health Initiative. For the ARIC project, support
was from U01 HG 004402 (PI: E. A. Boerwinkle). For the NHS and HPFS
support is from U01 HG 004399 and U01 HG 004728 (PIs: F. B. Hu and L. R.
Pasquale). The genotyping for the ARIC, NHS and HPFS studies was
performed at the Broad Institute of MIT and Harvard with funding support
from U01 HG04424 (PI: S. Gabriel). The GENEVA Coordinating Center
receives support from U01 HG 004446 (PI: B. S. Weir). Assistance with
GENEVA data cleaning was provided by the National Center for
Biotechnology Information. D. Crosslin and C. Laurie of the GENEVA
project assisted in making the data available for analysis. A Physician
Scientist Award from Research to Prevent Blindness in New York City also
supports L. R. P. M. C. C. is a recipient of a Canadian Institutes of
Health Research Fellowship. We acknowledge funding from the Australian
National Health and Medical Research Council (NHMRC grants 389892 and
613672) and the Australian Research Council (ARC grants DP0770096 and
DP1093900). We thank D. Posthuma for discussions and the referees for
constructive comments.
NR 43
TC 341
Z9 345
U1 9
U2 73
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2011
VL 43
IS 6
BP 519
EP U44
DI 10.1038/ng.823
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 769ME
UT WOS:000291017000007
PM 21552263
ER
PT J
AU Yu, HY
Tardivo, L
Tam, S
Weiner, E
Gebreab, F
Fan, CY
Svrzikapa, N
Hirozane-Kishikawa, T
Rietman, E
Yang, XP
Sahalie, J
Salehi-Ashtiani, K
Hao, T
Cusick, ME
Hill, DE
Roth, FP
Braun, P
Vidal, M
AF Yu, Haiyuan
Tardivo, Leah
Tam, Stanley
Weiner, Evan
Gebreab, Fana
Fan, Changyu
Svrzikapa, Nenad
Hirozane-Kishikawa, Tomoko
Rietman, Edward
Yang, Xinping
Sahalie, Julie
Salehi-Ashtiani, Kourosh
Hao, Tong
Cusick, Michael E.
Hill, David E.
Roth, Frederick P.
Braun, Pascal
Vidal, Marc
TI Next-generation sequencing to generate interactome datasets
SO NATURE METHODS
LA English
DT Article
ID OPEN READING FRAMES; PROTEIN INTERACTIONS; GENOME; NETWORK; SYSTEM; MAP
AB Next-generation sequencing has not been applied to protein-protein interactome network mapping so far because the association between the members of each interacting pair would not be maintained in en masse sequencing. We describe a massively parallel interactome-mapping pipeline, Stitch-seq, that combines PCRCR stitching with next-generation sequencing and used it to generate a new human interactome dataset. Stitch-seq is applicable to various interaction assays and should help expand interactome network mapping.
C1 [Yu, Haiyuan; Tardivo, Leah; Tam, Stanley; Weiner, Evan; Gebreab, Fana; Fan, Changyu; Svrzikapa, Nenad; Hirozane-Kishikawa, Tomoko; Rietman, Edward; Yang, Xinping; Sahalie, Julie; Salehi-Ashtiani, Kourosh; Hao, Tong; Cusick, Michael E.; Hill, David E.; Roth, Frederick P.; Braun, Pascal; Vidal, Marc] Dana Farber Canc Inst, Dept Canc Biol, Ctr Canc Syst Biol CCSB, Boston, MA 02115 USA.
[Yu, Haiyuan; Tardivo, Leah; Tam, Stanley; Weiner, Evan; Gebreab, Fana; Fan, Changyu; Svrzikapa, Nenad; Hirozane-Kishikawa, Tomoko; Rietman, Edward; Yang, Xinping; Sahalie, Julie; Salehi-Ashtiani, Kourosh; Hao, Tong; Cusick, Michael E.; Hill, David E.; Braun, Pascal; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Yu, Haiyuan] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY USA.
[Yu, Haiyuan] Cornell Univ, Weill Inst Cell & Mol Biol, Ithaca, NY USA.
[Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA USA.
RP Braun, P (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Ctr Canc Syst Biol CCSB, Boston, MA 02115 USA.
EM pascal_braun@dfci.harvard.edu; marc_vidal@dfci.harvard.edu
RI Hill, David/B-6617-2011; Roth, Frederick/H-6308-2011; Braun,
Pascal/B-9669-2013;
OI Salehi-Ashtiani, Kourosh/0000-0002-6521-5243; Braun,
Pascal/0000-0003-2012-6746; Roth, Frederick/0000-0002-6628-649X
FU US National Human Genome Research Institute of the National Institutes
of Health [R01 HG001715, R21 HG004756]; Ellison Foundation; Canadian
Institute for Advanced Research Fellowship and Canada Excellence
Research Chair; Dana-Farber Cancer Institute Strategic Initiative in
support of Center for Cancer Systems Biology; Fonds de la Recherche
Scientifique (French Community of Belgium)
FX We thank members of the Dana-Farber Cancer Institute Center for Cancer
Systems Biology and the Roth Laboratory for helpful discussions, and
members of the University of Pennsylvania DNA Sequencing Facility in the
Department of Genetics for the 454 FLX sequencing. This work was funded
in part by grants R01 HG001715 (to D. E. H., F. P. R. and M. V.) and R21
HG004756 (to F. P. R.) from the US National Human Genome Research
Institute of the National Institutes of Health, a grant from the Ellison
Foundation (to M. V.), a Canadian Institute for Advanced Research
Fellowship and Canada Excellence Research Chair (to F. P. R.) and in
part by Institute Sponsored Research funds from the Dana-Farber Cancer
Institute Strategic Initiative in support of Center for Cancer Systems
Biology. M. V. is supported as a Chercheur Qualifie Honoraire from the
Fonds de la Recherche Scientifique (French Community of Belgium).
NR 20
TC 86
Z9 87
U1 1
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1548-7091
J9 NAT METHODS
JI Nat. Methods
PD JUN
PY 2011
VL 8
IS 6
BP 478
EP U2257
DI 10.1038/NMETH.1597
PG 5
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 769QB
UT WOS:000291031800016
PM 21516116
ER
PT J
AU Makimura, H
AF Makimura, Hideo
TI OBESITY Cure obesity: sleep more, eat out less and turn down the heat?
SO NATURE REVIEWS ENDOCRINOLOGY
LA English
DT Editorial Material
ID BROWN ADIPOSE-TISSUE
AB Optimal strategies to treat patients with obesity have remained elusive. Now, Bo et al. demonstrate the contribution of a set of easily changeable lifestyle factors-sleep restriction, high consumption of restaurant meals and increased room temperature-to the incidence of obesity and hyperglycemia in an Italian population-based cohort.
C1 [Makimura, Hideo] Harvard Univ, Sch Med, Program Nutr Metab, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Makimura, Hideo] Harvard Univ, Sch Med, Neuroendocrine Unit, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Makimura, H (reprint author), Harvard Univ, Sch Med, Program Nutr Metab, Massachusetts Gen Hosp, 55 Fruit St,LON 207, Boston, MA 02114 USA.
EM hmakimura@partners.org
FU NIDDK NIH HHS [K23 DK087857]
NR 10
TC 2
Z9 2
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5029
J9 NAT REV ENDOCRINOL
JI Nat. Rev. Endocrinol.
PD JUN
PY 2011
VL 7
IS 6
BP 318
EP 319
DI 10.1038/nrendo.2011.55
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 769JH
UT WOS:000291008200002
PM 21448142
ER
PT J
AU Cheung, OS
Richler, JJ
Phillips, WS
Gauthier, I
AF Cheung, Olivia S.
Richler, Jennifer J.
Phillips, W. Stewart
Gauthier, Isabel
TI Does temporal integration of face parts reflect holistic processing?
SO PSYCHONOMIC BULLETIN & REVIEW
LA English
DT Article
DE Oscillator strength; face perception; holistic perception; response
conflict; composite paradigm, temporal information processing
ID TIME-COURSE ANALYSIS; RECOGNITION; PERCEPTION; INTERFERENCE
AB We examined whether temporal integration of face parts reflects holistic processing or response interference. Participants learned to name two faces "Fred" and two "Bob." At test, the top and bottom halves of different faces formed composites and were presented briefly separated in time. Replicating prior findings (Singer & Sheinberg, Vision Research, 46, 1838-1847, 2006), naming of the target half for aligned composites was slowed when the irrelevant half was from a face with a different name rather than from the original face. However, no interference was observed when the irrelevant half had a name identical to the name of the target half but came from a different learned face, arguing against a true holistic effect. Instead, response interference was obtained when the target half briefly preceded the irrelevant half. Experiment 2 confirmed a double dissociation of holistic processing versus response interference for intact faces versus temporally separated face halves, suggesting that simultaneous presentation of facial information is critical for holistic processing.
C1 [Cheung, Olivia S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging,Dept Radiol, Charlestown, MA 02129 USA.
[Cheung, Olivia S.; Richler, Jennifer J.; Phillips, W. Stewart; Gauthier, Isabel] Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA.
RP Cheung, OS (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging,Dept Radiol, 149 13th St,Room 2301, Charlestown, MA 02129 USA.
EM olivia@nmr.mgh.harvard.edu
OI Gauthier, Isabel/0000-0002-6249-4769
FU NEI NIH HHS [P30-EY008126, R01 EY013441, R01 EY013441-06A2, P30
EY008126]
NR 19
TC 7
Z9 7
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1069-9384
J9 PSYCHON B REV
JI Psychon. Bull. Rev.
PD JUN
PY 2011
VL 18
IS 3
BP 476
EP 483
DI 10.3758/s13423-011-0051-7
PG 8
WC Psychology, Mathematical; Psychology, Experimental
SC Psychology
GA 766TP
UT WOS:000290809700004
PM 21327378
ER
PT J
AU Googe, J
Brucker, AJ
Bressler, NM
Qin, HJ
Aiello, LP
Antoszyk, A
Beck, RW
Bressler, SB
Ferris, FL
Glassman, AR
Marcus, D
Stockdale, CR
AF Googe, Joseph
Brucker, Alexander J.
Bressler, Neil M.
Qin, Haijing
Aiello, Lloyd P.
Antoszyk, Andrew
Beck, Roy W.
Bressler, Susan B.
Ferris, Frederick L., III
Glassman, Adam R.
Marcus, Dennis
Stockdale, Cynthia R.
CA Diabetic Retinopathy
Writing Comm
TI RANDOMIZEDTRIAL EVALUATING SHORT-TERM EFFECTS OF INTRAVITREAL
RANIBIZUMAB OR TRIAMCINOLONE ACETONIDE ON MACULAR EDEMA AFTER FOCAL/GRID
LASER FOR DIABETIC MACULAR EDEMA IN EYES ALSO RECEIVING PANRETINAL
PHOTOCOAGULATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE proliferative diabetic retinopathy; diabetic macular edema; panretinal
photocoagulation; ranibizumab; triamcinolone; randomized clinical trial;
Diabetic Retinopathy Clinical Research Network
ID ENDOTHELIAL GROWTH-FACTOR; CLINICAL-TRIAL; RETINOPATHY
AB Purpose: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation.
Methods: Three hundred and forty-five eyes with a visual acuity of 20/320 or better, center-involved diabetic macular edema receiving focal/grid laser, and diabetic retinopathy receiving prompt panretinal photocoagulation were randomly assigned to sham (n = 123), 0.5-mg ranibizumab (n = 113) at baseline and 4 weeks, and 4-mg triamcinolone at baseline and sham at 4 weeks (n = 109). Treatment was at investigator discretion from 14 weeks to 56 weeks.
Results: Mean changes (+/-SD) in visual acuity letter score from baseline were significantly better in the ranibizumab (+1 +/- 11; P < 0.001) and triamcinolone (+2 +/- 11; P, 0.001) groups compared with those in the sham group (24 +/- 14) at the 14-week visit, mirroring retinal thickening results. These differences were not maintained when study participants were followed for 56 weeks for safety outcomes. One eye (0.9%; 95% confidence interval, 0.02%-4.7%) developed endophthalmitis after receiving ranibizumab. Cerebrovascular/cardiovascular events occurred in 4%, 7%, and 3% of the sham, ranibizumab, and triamcinolone groups, respectively.
Conclusion: The addition of 1 intravitreal triamcinolone injection or 2 intravitreal ranibizumab injections in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation is associated with better visual acuity and decreased macular edema by 14 weeks. Whether continued long-term intravitreal treatment is beneficial cannot be determined from this study. RETINA 31: 1009-1027, 2011
C1 [Googe, Joseph; Diabetic Retinopathy] SE Retina Associates PC, Knoxville, TN USA.
[Brucker, Alexander J.] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
[Bressler, Neil M.; Bressler, Susan B.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
[Qin, Haijing; Beck, Roy W.; Glassman, Adam R.; Stockdale, Cynthia R.] Jaeb Ctr Hlth Res, Tampa, FL USA.
[Aiello, Lloyd P.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02115 USA.
[Antoszyk, Andrew] Charlotte Eye Ear Nose & Throat Assoc PA, Charlotte, NC USA.
[Ferris, Frederick L., III] NEI, NIH, Bethesda, MD 20892 USA.
[Marcus, Dennis] SE Retina Ctr PC, Augusta, GA USA.
RP Googe, J (reprint author), SE Retina Associates PC, Knoxville, TN USA.
FU National Eye Institute and the National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health; Department
of Health and Human Services [EY14231, EY14229, EY018817]; Genentech;
Allergan, Inc; Office of Research Administration; Allergan; Bausch Lomb;
Carl Zeiss Meditec; EMMES Corporation; Lumenis; Notal Vision; Novartis;
QLT; Regeneron; Steba Biotech; Abbott Medical Optics; ForSight Labs,
LLC; Genzyme Corporation
FX A complete list of the DRCR. net can be found at www.drcr.net. Supported
through a cooperative agreement from the National Eye Institute and the
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health, and Department of Health and Human
Services (EY14231, EY14229, and EY018817).; Genentech provided
ranibizumab for the study, and Allergan, Inc, provided triamcinolone for
the study. In addition, Genentech and Allergan, Inc, provided funds to
DRCR. net to defray the study's clinical site costs.; A. J. Brucker:
Genentech (C, G); L. P. Aiello: Genentech (O); A. Antoszyk: Genentech
(C, G) and Allergan (G); S. S. Bressler: Genentech (G) and Allergan (G);
D. Marcus: Genentech (C, G, T, B); N. Bressler: Grants to investigator
at the Johns Hopkins University are negotiated and administered by the
institution (such as the School of Medicine) that receives the grants,
typically through the Office of Research Administration.; Dr. Neil
Bressler is the principal investigator of grants at the Johns Hopkins
University sponsored by the following entities (not including the
National Institutes of Health): Allergan, Bausch & Lomb, Carl Zeiss
Meditec, EMMES Corporation, Genentech, Lumenis, Notal Vision, Novartis,
QLT, Regeneron, Steba Biotech, Abbott Medical Optics, ForSight Labs,
LLC, and Genzyme Corporation.
NR 28
TC 48
Z9 51
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2011
VL 31
IS 6
BP 1009
EP 1027
DI 10.1097/IAE.0b013e318217d739
PG 19
WC Ophthalmology
SC Ophthalmology
GA 769JT
UT WOS:000291009400002
ER
PT J
AU Sheetz, MJ
Aiello, LP
Shahri, N
Davis, MD
Kles, KA
Danis, RP
AF Sheetz, Matthew J.
Aiello, Lloyd Paul
Shahri, Nazila
Davis, Matthew D.
Kles, Keri A.
Danis, Ronald P.
CA Mbdv Study Grp
TI EFFECT OF RUBOXISTAURIN (RBX) ON VISUAL ACUITY DECLINE OVER A 6-YEAR
PERIOD WITH CESSATION AND REINSTITUTION OF THERAPY Results of an
Open-Label Extension of the Protein Kinase C Diabetic Retinopathy Study
2 (PKC-DRS2)
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ruboxistaurin; sustained moderate visual loss; open-label extension;
diabetes; diabetic retinopathy
ID PKC-BETA; COMPLICATIONS; GROWTH; NEOVASCULARIZATION; INHIBITION;
ACTIVATION; MELLITUS; ISOFORMS
AB Purpose: The PKC-DRS2 was a Phase 3, randomized, double-masked, placebo (PBO)controlled, 3-year study of the effect of 32 mg/day of ruboxistaurin (RBX), an orally administered protein kinase C inhibitor, on vision loss in patients with moderate to severe nonproliferative diabetic retinopathy. Ruboxistaurin reduced the occurrence of sustained moderate visual loss (SMVL; >15-letter decline in visual acuity sustained for the last 6 months of study participation) from 9.1% in the PBO group (N = 340) to 5.5% in the RBX group (N = 345, P = 0.034). This study evaluates the primary end point of SMVL in a 2-year open-label extension (OLE) of the PKC-DRS2, which began a median of 466 days (range, 263-1,296 days) after the conclusion of PKC-DRS2.
Methods: Visual acuity was measured by certified examiners using the Early Treatment Diabetic Retinopathy Study chart.
Results: Of the 514 patients who completed PKC-DRS2, 366 did so in the 32 study centers participating in the OLE, and of these, 203 (55%) enrolled in the OLE for treatment with 32 mg/day of RBX for 2 years. Of the 203 enrolled in the OLE, 100 had previously been treated with PBO (prior PBO subgroup) and 103 had been treated with RBX (prior RBX subgroup). PKC-DRS2 baseline patient and ocular characteristics were well matched between these two subgroups and were similar to the PKC-DRS2 patient population as a whole. Using the PKC-DRS2 baseline as the starting point, SMVL occurred in 6% of the prior PBO subgroup during the PKC-DRS2, increasing to 26% by the end of the OLE. However, in the prior RBX subgroup, SMVL occurred in only 4% and 8% during the PKC-DRS2 and by the end of the OLE, respectively (P < 0.001 for difference at the end of the OLE). In the prior PBO subgroup, mean visual acuity declined from 79.6 letters at PKC-DRS2 baseline to 73.1 letters at OLE end point (26.5 letters). In the prior RBX subgroup, this loss was 2.7 letters (79.8 to 77.1) over the same period (P = 0.02).
Conclusion: Over a 6-year study period incorporating 3 years of a rigorously placebo-controlled trial, approximately 1 year off treatment and 2-year OLE where all groups received therapy, those patients with greatest RBX exposure (similar to 5 years) experienced less SMVL compared with those in the original PBO group (similar to 2-year RBX exposure). RETINA 31: 1053-1059, 2011
C1 [Sheetz, Matthew J.; Kles, Keri A.] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA.
[Aiello, Lloyd Paul] Harvard Univ, Sch Med, Joslin Diabet Ctr, Beetham Eye Inst,Dept Ophthalmol, Boston, MA 02115 USA.
[Shahri, Nazila] I3 Statprobe, San Diego, CA USA.
[Davis, Matthew D.; Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
RP Sheetz, MJ (reprint author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA.
EM msheetz@lilly.com
FU Eli Lilly and Company
FX Supported by Eli Lilly and Company.
NR 19
TC 14
Z9 15
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2011
VL 31
IS 6
BP 1053
EP 1059
DI 10.1097/IAE.0b013e3181fe545f
PG 7
WC Ophthalmology
SC Ophthalmology
GA 769JT
UT WOS:000291009400006
PM 21386766
ER
PT J
AU Budd, MA
AF Budd, Maggi A.
TI Sex & Disability: Politics, Identity and Access
SO SEXUALITY AND DISABILITY
LA English
DT Book Review
C1 [Budd, Maggi A.] Harvard Univ, Sch Med, VA Boston Healthcare, Brockton, MA 02301 USA.
RP Budd, MA (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare, 940 Belmont St, Brockton, MA 02301 USA.
EM Margaret.budd@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0146-1044
J9 SEX DISABIL
JI Sex. Disabil.
PD JUN
PY 2011
VL 29
IS 2
BP 187
EP 189
DI 10.1007/s11195-011-9214-8
PG 3
WC Rehabilitation
SC Rehabilitation
GA 763QJ
UT WOS:000290574500012
ER
PT J
AU Dosa, E
Tuladhar, S
Muldoon, LL
Hamilton, BE
Rooney, WD
Neuwelt, EA
AF Dosa, Edit
Tuladhar, Suchita
Muldoon, Leslie L.
Hamilton, Bronwyn E.
Rooney, William D.
Neuwelt, Edward A.
TI MRI Using Ferumoxytol Improves the Visualization of Central Nervous
System Vascular Malformations
SO STROKE
LA English
DT Article
DE central nervous system; ferumoxytol; magnetic resonance imaging;
ultrasmall superparamagnetic iron oxide nanoparticles; vascular
malformations
ID IRON-OXIDE; CONTRAST AGENT; PARTICLES; VENOGRAPHY; MECHANISMS; BRAIN
AB Background and Purpose-Central nervous system vascular malformations (VMs) result from abnormal vasculo-and/or angiogenesis. Cavernomas and arteriovenous malformations are also sites of active inflammation. The aim of this study was to determine whether MRI detection of VMs can be improved by administration of ferumoxytol iron oxide nanoparticle, which acts as a blood pool agent at early time points and an inflammatory marker when taken up by tissue macrophages.
Methods-Nineteen patients (11 men, 8 women; mean age, 47.5 years) with central nervous system VMs underwent 3-T MRI both with gadoteridol and ferumoxytol. The ferumoxytol-induced signal changes on the T1-, T2-, and susceptibility-weighted images were analyzed at 25 minutes (range, 21 to 30 minutes) and 24 hours (range, 22 to 27 hours).
Results-Thirty-five lesions (capillary telangiectasia, n = 6; cavernoma, n = 21; developmental venous anomaly, n = 7; arteriovenous malformation, n = 1) were seen on the pre- and postgadoteridol images. The postferumoxytol susceptibility-weighted sequences revealed 5 additional VMs (3 capillary telangiectasias, 2 cavernomas) and demonstrated further tributary veins in all patients with developmental venous anomalies. The 24-hour T1 and T2 ferumoxytol-related signal abnormalities were inconsistent among patients and within VM types. No additional area of T1 or T2 enhancement was noted with ferumoxytol compared with gadoteridol in any lesion.
Conclusions-Our findings indicate that the blood pool agent ferumoxytol provides important information about the number and true extent of VMs on the susceptibility-weighted MRI. The use of ferumoxytol as a macrophage imaging agent in the visualization of inflammatory cells within and around the lesions warrants further investigation. (Stroke. 2011;42:1581-1588.)
C1 [Dosa, Edit; Tuladhar, Suchita; Muldoon, Leslie L.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Hamilton, Bronwyn E.] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97239 USA.
[Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97239 USA.
[Rooney, William D.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA.
RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA.
EM neuwelte@ohsu.edu
FU National Institutes of Health, National Cancer Institute [CA137488];
National Institute of Neurological Disorders and Stroke [NS53468];
American Recovery and Reinvestment Ac [CA137488-15S1]; National Cancer
Institute-Fredrick Cancer Research and Development Center; AMAG
FX This work was supported by National Institutes of Health grants National
Cancer Institute CA137488, National Institute of Neurological Disorders
and Stroke NS53468, American Recovery and Reinvestment Act
CA137488-15S1, and an National Cancer Institute-Fredrick Cancer Research
and Development Center Contract to E.A.N.; AMAG Pharmaceuticals, Inc
provided the study drug ferumoxytol free of charge. Oregon Health and
Science University has received a sponsored research agreement from AMAG
to conduct clinical trials of MRI with ferumoxytol. None of the authors
has financial interest in this agent or in its developer, AMAG.
NR 20
TC 27
Z9 28
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2011
VL 42
IS 6
BP 1581
EP 1588
DI 10.1161/STROKEAHA.110.607994
PG 8
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 769QH
UT WOS:000291032700034
PM 21493906
ER
PT J
AU Furie, KL
AF Furie, Karen L.
TI Response to Letter by Naylor Regarding Article, "Guidelines for the
Prevention of Stroke in Patients With Stroke or Transient Ischemic
Attack: A Guideline for Healthcare Professionals From the American Heart
Association/American Stroke Association"
SO STROKE
LA English
DT Letter
C1 Massachusetts Gen Hosp, Dept Neurol, J Philip Kistler MGH Stroke Res Ctr, Boston, MA 02114 USA.
RP Furie, KL (reprint author), Massachusetts Gen Hosp, Dept Neurol, J Philip Kistler MGH Stroke Res Ctr, Boston, MA 02114 USA.
NR 0
TC 2
Z9 2
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD JUN
PY 2011
VL 42
IS 6
BP E386
EP E386
DI 10.1161/STROKEAHA.111.614933
PG 1
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 769QH
UT WOS:000291032700003
ER
PT J
AU Krieger, JN
Dobrindt, U
Riley, DE
Oswald, E
AF Krieger, John N.
Dobrindt, Ulrich
Riley, Donald E.
Oswald, Eric
TI Acute Escherichia coli Prostatitis in Previously Health Young Men:
Bacterial Virulence Factors, Antimicrobial Resistance, and Clinical
Outcomes
SO UROLOGY
LA English
DT Article
ID URINARY-TRACT-INFECTION; MOLECULAR EPIDEMIOLOGY; PHYLOGENETIC GROUP;
STRAINS; PYELONEPHRITIS; COMMENSALISM; GENOTYPES; ADHESINS; CYSTITIS;
ISLAND
AB OBJECTIVES To investigate clinical outomes, bacterial virulence factors, and antimicrobial resistance in E. coli from young men presenting with acute bacterial prostatitis.
METHODS Initial E. coli isolates from previously healthy young men with no factors compromising urinary tract anatomy or function were tested for virulence-associated genes by polymerase chain reaction (PCR) assays, phylogenetic grouping by triplex polymerase PCR, and antibiotic resistance.
RESULTS All 18 patients responded to treatment, including 2 who required long-term therapy. E. coli were allocated to phylogenetic groups B2 (13 strains) and D (5 strains). Prostatitis isolates belonged to clones mainly represented by extraintestinal pathogenic E. coli (ExPEC) and preferentially uropathogenic E. coli and displayed marked accumulation of virulence genes (hly, cdt1, clb, pap, sfa/foc, fyuA, iroN, kpsMT(II), and traT) characteristic of highly virulent ExPEC. All phylogenetic group B2 strains coded for at least 1 toxin with carcinogenic potential (Colibactin, cytolethal distending toxins, or cytotoxic necrotizing factor). In contrast to their accumulation of virulence-associated traits, prostatitis strains were sensitive to standard antibiotics.
CONCLUSIONS The phylogenetic background and accumulation of an exceptional repertoire of extraintestinal pathogenic virulence-associated genes indicate that these E. coli strains belong to a highly virulent subset of uropathogenic variants. In contrast, antibiotic resistance was minimal in these E. coli strains from previously healthy, young outpatients. UROLOGY 77: 1420-1425, 2011. Published by Elsevier Inc.
C1 [Krieger, John N.] Univ Washington, Sch Med, Dept Urol Surg, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
Univ Munster, Inst Hyg, Munster, Germany.
CHU Toulouse, Lab Bacteriol Hyg, Toulouse, France.
Univ Toulouse, Fac Med Purpan, Toulouse, France.
RP Krieger, JN (reprint author), Univ Washington, Sch Med, Dept Urol Surg, VA Puget Sound Hlth Care Syst, UW Campus Mail Box 358280, Seattle, WA 98108 USA.
EM jkrieger@uw.edu
FU ERA-NET project; German Research Foundation [DO 789/4-1]
FX This study was supported in part by the ERA-NET project, "Deciphering
the intersection of extraintestinal pathogenic and commensal Escherichia
coli." The authors would like to thank Michele Boury (Toulouse) and
Barbara Plaschke (Wurzburg) for their excellent technical support. D was
supported by the German Research Foundation (DO 789/4-1).
NR 30
TC 11
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
J9 UROLOGY
JI Urology
PD JUN
PY 2011
VL 77
IS 6
BP 1420
EP 1425
DI 10.1016/j.urology.2010.12.059
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 769VX
UT WOS:000291047500049
PM 21459419
ER
PT J
AU Durazzo, TC
Tosun, D
Buckley, S
Gazdzinski, S
Mon, A
Fryer, SL
Meyerhoff, DJ
AF Durazzo, Timothy C.
Tosun, Duygu
Buckley, Shannon
Gazdzinski, Stefan
Mon, Anderson
Fryer, Susanna L.
Meyerhoff, Dieter J.
TI Cortical Thickness, Surface Area, and Volume of the Brain Reward System
in Alcohol Dependence: Relationships to Relapse and Extended Abstinence
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Alcohol Dependence; Neuroimaging; Brain Volume; Cortical Thickness;
Surface Area; Relapse
ID MAGNETIC-RESONANCE SPECTROSCOPY; CONSUMPTION FOLLOWING TREATMENT;
NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; HUMAN
CEREBRAL-CORTEX; ADDICTED HUMAN BRAIN; DSM-IV ALCOHOL; ORBITOFRONTAL
CORTEX; UNITED-STATES; DRUG-USE
AB Background:
At least 60% of those treated for an alcohol use disorder will relapse. Empirical study of the integrity of the brain reward system (BRS) is critical to understanding the mechanisms of relapse as this collection of circuits is implicated in the development and maintenance of all forms of addictive disorders. This study compared thickness, surface area, and volume in neocortical components of the BRS among nonsmoking light-drinking controls (controls), individuals who remained abstinent and those who relapsed after treatment.
Methods:
Seventy-five treatment-seeking alcohol-dependent individuals (abstinent for 7 +/- 3 days) and 43 controls completed 1.5T proton magnetic resonance imaging studies. Parcellated morphological data were obtained for following bilateral components of the BRS: rostral and caudal anterior cingulate cortex, insula, medial and lateral orbitofrontal cortex (OFC), rostral and caudal middle and superior frontal gyri, amygdala and hippocampus as well as for 26 other bilateral neocortical regions. Alcohol-dependent participants were followed over 12-months after baseline study and were classified as abstainers (no alcohol consumption; n = 24) and relapsers (any alcohol consumption; n = 51) at follow-up.
Results:
Relapsers and abstainers demonstrated lower cortical thickness in the vast majority of BRS regions as well as lower global thickness compared to controls. Relapsers had lower total BRS surface area than both controls and abstainers, but abstainers were not significantly different from controls on any surface area measure. Relapsers demonstrated lower volumes than controls in the majority of regions, while abstainers showed lower volumes than controls in the superior frontal gyrus, insula, amygdala, and hippocampus, bilaterally. Relapsers exhibited smaller volumes than abstainers in the right rostral middle and caudal middle frontal gyri and the lateral OFC, bilaterally. In relapsers, lower baseline volumes and surface areas in multiple regions were associated with a greater magnitude of post-treatment alcohol consumption.
Conclusions:
Results suggest relapsers demonstrated morphological abnormalities in regions involved in the "top down" regulation/modulation of internal drive states, emotions, reward processing, and behavior, which may impart increased risk for the relapse/remit cycle that afflicts many with an alcohol use disorder. Results also highlight the importance of examining both cortical thickness and surface area to better understand the nature of regional volume loss frequently observed in alcohol use disorders. Results from this report are consistent with previous research implicating plastic neurobiological changes in the BRS in the maintenance of addictive disorders.
C1 [Durazzo, Timothy C.; Mon, Anderson; Fryer, Susanna L.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Durazzo, Timothy C.; Tosun, Duygu; Buckley, Shannon; Gazdzinski, Stefan; Mon, Anderson; Fryer, Susanna L.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
RP Durazzo, TC (reprint author), San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St,114M, San Francisco, CA 94121 USA.
EM timothy.durazzo@ucsf.edu
FU National Institutes of Health [AA10788, DA24136]
FX This material is the result of work supported by National Institutes of
Health (AA10788 to D.J.M. and DA24136 to T.C.D.) and with resources and
the use of facilities at the San Francisco Veterans Administration
Medical Center, San Francisco CA. We thank Mary Rebecca Young, Bill
Clift, Jeanne Eichenbaum and Drs. Peter Banys and Ellen Herbst of the
Veterans Administration Substance Abuse Day Hospital and Dr. David
Pating, Karen Moise and their colleagues at the Kaiser Permanente
Chemical Dependency Recovery Program in San Francisco for their valuable
assistance in recruiting participants. We also extend our gratitude to
the study participants, who made this research possible.
NR 93
TC 77
Z9 77
U1 2
U2 16
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2011
VL 35
IS 6
BP 1187
EP 1200
DI 10.1111/j.1530-0277.2011.01452.x
PG 14
WC Substance Abuse
SC Substance Abuse
GA 765FG
UT WOS:000290688200021
PM 21410483
ER
PT J
AU Tschanz, JT
Corcoran, CD
Schwartz, S
Treiber, K
Green, RC
Norton, MC
Mielke, MM
Piercy, K
Steinberg, M
Rabins, PV
Leoutsakos, JM
Welsh-Bohmer, KA
Breitner, JCS
Lyketsos, CG
AF Tschanz, JoAnn T.
Corcoran, Chris D.
Schwartz, Sarah
Treiber, Katherine
Green, Robert C.
Norton, Maria C.
Mielke, Michelle M.
Piercy, Kathleen
Steinberg, Martin
Rabins, Peter V.
Leoutsakos, Jeanne-Marie
Welsh-Bohmer, Kathleen A.
Breitner, John C. S.
Lyketsos, Constantine G.
TI Progression of Cognitive, Functional, and Neuropsychiatric Symptom
Domains in a Population Cohort With Alzheimer Dementia: The Cache County
Dementia Progression Study
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Alzheimer disease; Alzheimer dementia; cognition; decline; dementia;
neuropsychiatric symptoms; progression
ID MINI-MENTAL-STATE; VASCULAR FACTORS; DISEASE; DECLINE; PROGNOSIS; AD;
PREDICTORS; EPSILON-4; EDUCATION; SEVERITY
AB Objectives: Progression of Alzheimer dementia (AD) is highly variable. Most estimates derive from convenience samples from dementia clinics or research centers where there is substantial potential for survival bias and other distortions. In a population-based sample of incident AD cases, we examined progression of impairment in cognition, function, and neuropsychiatric symptoms, and the influence of selected variables on these domains. Design: Longitudinal, prospective cohort study. Setting: Cache County (Utah). Participants: Three hundred twenty-eight persons with a diagnosis of possible/probable AD. Measurements: Mini-Mental State Exam (MMSE), Clinical Dementia Rating sum-of-boxes (CDR-sb), and Neuropsychiatric Inventory (NPI). Results: Over a mean follow-up of 3.80 (range: 0.07-12.90) years, the mean (SD) annual rates of change were -1.53 (2.69) scale points on the MMSE, 1.44 (1.82) on the CDR-sb, and 2.55 (5.37) on the NPI. Among surviving participants, 30% to 58% progressed less than 1 point per year on these measures, even 5 to 7 years after dementia onset. Rates of change were correlated between MMSE and CDR-sb (r = -0.62, df = 201, p < 0.001) and between the CDR-sb and NPI (r = 0.20, df = 206, p < 0.004). Female subjects (LR chi(2) = 8.7, df = 2, p = 0.013) and those with younger onset (likelihood ratio [LR] chi(2) = 5.7, df = 2, p = 0.058) declined faster on the MMSE. Although one or more apolipoprotein E epsilon 4 alleles and ever use of FDA-approved antidementia medications were associated with initial MMSE scores, neither was related to the rate of progression in any domain. Conclusions: A significant proportion of persons with AD progresses slowly. The results underscore differences between population-based versus clinic-based samples and suggest ongoing need to identify factors that may slow the progression of AD. (Am J Geriatr Psychiatry 2011; 19:532-542)
C1 [Tschanz, JoAnn T.; Corcoran, Chris D.; Schwartz, Sarah; Norton, Maria C.; Piercy, Kathleen] Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA.
[Tschanz, JoAnn T.; Treiber, Katherine; Norton, Maria C.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA.
[Corcoran, Chris D.] Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA.
[Norton, Maria C.; Piercy, Kathleen] Utah State Univ, Dept Family Consumer & Human Dev, Logan, UT 84322 USA.
[Green, Robert C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA.
[Green, Robert C.] Boston Univ, Sch Med, Dept Med Genet, Boston, MA 02215 USA.
[Mielke, Michelle M.; Steinberg, Martin; Rabins, Peter V.; Leoutsakos, Jeanne-Marie; Lyketsos, Constantine G.] Johns Hopkins Univ, Dept Psychiat, Johns Hopkins Bayview & Sch Med, Baltimore, MD USA.
[Welsh-Bohmer, Kathleen A.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA.
[Welsh-Bohmer, Kathleen A.] Duke Univ, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA.
[Breitner, John C. S.] Univ Washington, Sch Med, Seattle, WA USA.
[Breitner, John C. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Tschanz, JT (reprint author), Utah State Univ, Ctr Epidemiol Studies, 4440 Old Main Hill, Logan, UT 84322 USA.
EM joann.tschanz@usu.edu
RI Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Schwartz,
Sarah/E-2050-2016;
OI Schwartz, Sarah/0000-0001-9980-7493; Steinberg,
Martin/0000-0001-8800-8020
FU NIH [R01AG-21136, R01AG11380, R01AG18712, R01HG02213, P30AG028377,
K24AG027841, P30AG13846, NIA AG11380, NIA AG028377]; DPS; NIMH; NIA;
Associated Jewish Federation of Baltimore; Weinberg Foundation; Forest;
Glaxo-Smith-Kline; Eisai; Pfizer; Astra-Zeneca; Lilly; Ortho-McNeil;
Bristol-Myers; Novartis
FX This study is supported by NIH grants: R01AG-21136, R01AG11380,
R01AG18712, R01HG02213, P30AG028377, K24AG027841, and P30AG13846.; The
authors thank Dr Ronald Munger for his unqualified support of the DPS.
They also thank the following individuals whose activities have helped
to ensure the success of the project: Cara Brewer, B. A., Tony Calvert,
B. A., R.N., Michelle Carlson, Ph.D., Elizabeth Fauth, Ph.D., Kimberly
Graham, B. A., Kyle Hess, M. S., Hochang Ben Lee, M. D., Carol Leslie,
M. S., Lawrence S. Mayer, Ph.D., Chiadi U. Onyike, M. D., Roxane
Pfister, M. S., Georgiann Sanborn, M. S., Nancy Sassano, Ph.D., Ingmar
Skoog, M. D., Heidi Wengreen, Ph. D., RD, James Wyatt, and Peter P.
Zandi, Ph. D., M. P. H. Finally, they thank the participants and their
families for their participation and support.; Authors disclosure: Peter
V. Rabins: Legal testimony for Janssen Pharmaceutical; Martin Steinberg:
Grant support from NIA and Elan Pharmaceuticals; Kathleen A.
Welsh-Bohmer: 1) Scientific advisory board for Medivation, Inc. 2)
Received funding for travel and speaker honoraria from Medivation, Inc.,
and Elan Corporation/Wyeth. 3) Has served/serves as an associate editor
of Neuropsychology Review, on the editorial boards of Alzheimer's &
Dementia, the Journal International Neuropsychological Society, and the
Journal of Experimental and Clinical Neuropsychology, and as a
consulting editor for Aging, Neuropsychology, and Cognition and
Neuropsychology. 4) Holds US Patent #6867236 (issued 2005): Nonsteroidal
Anti-inflammatory drugs for the treatment of Alzheimer's disease. 5)
Receives royalties from the publication of Geriatric Neuropsychology:
Assessment and Intervention (Guildford Publications, 2006). 6) Receives
research support from the NIH (NIA AG11380 [PI] and NIA AG028377 [PI]);
Constantine Lyketsos: 1) Grant support (research or CME)-NIMH, NIA,
Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest,
Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil,
Bristol-Myers, Novartis. 2) Consultant/Advisor-Astra-Zeneca, Glaxo-Smith
Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth,
Lundbeck, Merz, Lilly, Genentech. 3) Honorarium or travel
support-Pfizer, Forest, Glaxo-Smith Kline, Health Monitor; JoAnn
Tschanz, Chris Corcoran, Sarah Schwartz, Katherine Treiber, Robert
Green, Maria Norton, Michelle Mielke, Kathleen Piercy, Jeanne-Marie
Leoutsakos, and John C. S. Breitner have no disclosures.
NR 44
TC 59
Z9 61
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2011
VL 19
IS 6
BP 532
EP 542
DI 10.1097/JGP.0b013e3181faec23
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 766MP
UT WOS:000290787300005
PM 21606896
ER
PT J
AU Givens, JL
Prigerson, HG
Kiely, DK
Shaffer, ML
Mitchell, SL
AF Givens, Jane L.
Prigerson, Holly G.
Kiely, Dan K.
Shaffer, Michele L.
Mitchell, Susan L.
TI Grief Among Family Members of Nursing Home Residents With Advanced
Dementia
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Dementia; grief; nursing homes
ID STAGE ALZHEIMERS-DISEASE; MENTAL-HEALTH; COMPLICATED GRIEF; TRAUMATIC
GRIEF; BEREAVED CAREGIVERS; PHYSICAL MORBIDITY; OF-LIFE; DEATH;
SYMPTOMS; CARE
AB Objectives: To describe preloss and postloss grief symptoms among family members of nursing home (NH) residents with advanced dementia, and to identify predictors of greater postloss grief symptoms. Design: Prospective cohort study. Setting: 22 NHs in the greater Boston area. Participants: 123 family members of NH residents who died with advanced dementia. Measurements: Preloss grief was measured at baseline, and postloss grief was measured 2 and 7 months postloss using the Prolonged Grief Disorder Scale. Independent variables included resident and family member sociodemographic characteristics, resident comfort, acute illness, acute care prior to death, family member depression, and family member understanding of dementia and of resident's prognosis. Results: Levels of preloss and postloss grief were relatively stable from baseline to 7 months postloss. Feelings of separation and yearning were the most prominent grief symptoms. After multivariable adjustment, greater preloss grief and the family member having lived with the resident prior to NH admission were the only factors independently associated with greater postloss grief 7 months after resident death. Conclusions: The pattern of grieving for some family members of NH residents with advanced dementia is prolonged and begins before resident death. Identification of family members at risk for postloss grief during the preloss period may help guide interventions aimed at lessening postloss grief. (Am J Geriatr Psychiatry 2011; 19:543-550)
C1 [Givens, Jane L.; Kiely, Dan K.; Mitchell, Susan L.] Hebrew SeniorLife Inst Aging Res, Boston, MA 02131 USA.
[Givens, Jane L.; Mitchell, Susan L.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA.
[Prigerson, Holly G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Shaffer, Michele L.] Penn State Coll Med, Hershey, PA USA.
RP Givens, JL (reprint author), Hebrew SeniorLife Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.
EM JaneGivens@hrca.harvard.edu
FU NIH-NIA [R01 AG024091, K24AG033640]; Hartford Geriatrics Health Outcomes
Research Scholars Award
FX This work was supported by 1) NIH-NIA R01 AG024091, 2) Hartford
Geriatrics Health Outcomes Research Scholars Award (JLG), and 3) NIH-NIA
K24AG033640 (SLM).
NR 36
TC 13
Z9 14
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2011
VL 19
IS 6
BP 543
EP 550
DI 10.1097/JGP.0b013e31820dcbe0
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 766MP
UT WOS:000290787300006
PM 21606897
ER
PT J
AU Motyckova, G
Murali, M
AF Motyckova, Gabriela
Murali, Mandakolathur
TI Laboratory testing for cryoglobulins
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID HEPATITIS-C VIRUS; MIXED CRYOGLOBULINEMIA; RITUXIMAB; EFFICACY; DISEASE;
SAFETY
AB Cryoglobulins are immunoglobulins that precipitate below 37 degrees C and can cause multiorgan damage. There are three types of cryoglobulins: Type I (also called simple), which is mostly associated with monoclonal gammopathy and/or other hematologic disorders and Type II and Type III (known as mixed cryoglobulins), which are associated with infectious and systemic diseases. Testing for cryoglobulins is complicated by lack of reference range, standards, and stringency in maintaining testing temperature conditions. Identification of cryoprecipitate can be critical for patient care; therefore, correct testing conditions are crucial for reliable cryoglobulin testing. The patient's blood sample should be kept at 37 degrees C initially to avoid premature precipitation of cryoglobulins and thereby decreasing the yield for subsequent identification. This could cause a false negative result. After warm centrifugation or warm cell precipitation, the clear serum is observed at 4 degrees C for formation of cryoprecipitate. The cryoprecipitate is then washed in cold buffer, and the resulting precipitate is warmed to 37 degrees C and subjected to further analysis by immunodiffusion and immunofixation. In addition to Meltzer's triad of purpura, weakness and arthralgias, cryoglobulinemias have protean manifestations involving skin, joints, kidney, nervous system, as well as the hematopoietic system. The management of cryoglobulinemia especially in patients with organ damage remains difficult. Treatment of cryoglobulinemia focuses on management of the underlying lymphoproliferative disorder or infectious or systemic causes. Medical management may also include corticosteroids and other immunosuppressive agents and plasmapheresis. Rituximab therapy seems to abrogate the aberrant B cell response. Am. J. Hematol. 86:500-502, 2011. (C) 2011 Wiley-Liss, Inc.
C1 [Murali, Mandakolathur] Massachusetts Gen Hosp, Clin Immunol Lab, Ctr Canc, Boston, MA 02114 USA.
[Motyckova, Gabriela; Murali, Mandakolathur] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Murali, Mandakolathur] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Murali, M (reprint author), Massachusetts Gen Hosp, Clin Immunol Lab, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.
EM mmurali@partners.org
NR 17
TC 23
Z9 23
U1 1
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD JUN
PY 2011
VL 86
IS 6
BP 500
EP 502
DI 10.1002/ajh.22023
PG 3
WC Hematology
SC Hematology
GA 766CI
UT WOS:000290757400008
PM 21594887
ER
PT J
AU Sobota, A
Neufeld, EJ
Sprinz, P
Heeney, MM
AF Sobota, Amy
Neufeld, Ellis J.
Sprinz, Philippa
Heeney, Matthew M.
TI Transition from pediatric to adult care for sickle cell disease: Results
of a survey of pediatric providers
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID HEALTH-CARE; CYSTIC-FIBROSIS; RISK-FACTORS; ADOLESCENTS; PERSPECTIVES;
CHILDREN; SERVICES; PEOPLE
AB As recently as the 1970s, children born with sickle cell disease (SCD) were unlikely to survive into adulthood. With advances in medical care, most patients now survive childhood and live into their forties or beyond [1,2]. A better transition from pediatric- to adult-focused care is therefore increasingly important [3]. Despite recent awareness of the importance of transition by the SCD community, little is known about existing transition programs. We conducted a survey of pediatric sickle cell clinics to describe current transition practices and identify areas for improvement. Survey topics included program demographics, transition logistics, assessment of patient transition readiness and independence, transition preparation, and program evaluation. Twenty-three clinics (77%) report having a transition program, although half have been in place for under 2 years. There is wide variation in specific transition practices. Most centers (97%) have an identified accepting adult provider, however, only 60% routinely transfer their patients to an adult hematologist specializing in SCD. Although there has been a recent effort to establish transition programs in pediatric sickle cell clinics, specific practices vary widely. As anticipated, lack of an accepting adult hematologist with an interest in SCD emerged as a common barrier to transition.
C1 [Sobota, Amy; Sprinz, Philippa] Boston Med Ctr, Div Pediat Hematol Oncol, Boston, MA 02118 USA.
[Sobota, Amy; Neufeld, Ellis J.; Heeney, Matthew M.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Sobota, Amy; Neufeld, Ellis J.; Heeney, Matthew M.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Sobota, Amy; Sprinz, Philippa] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA.
[Neufeld, Ellis J.; Heeney, Matthew M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Sobota, A (reprint author), Boston Med Ctr, Div Pediat Hematol Oncol, Yawkey Bldg 4S-11,850 Harrison Ave, Boston, MA 02118 USA.
EM amy.sobota@bmc.org
RI Neufeld, Ellis/F-9331-2011; Heeney, Matthew/J-6838-2015
OI Sobota, Amy/0000-0003-3979-7435; Heeney, Matthew/0000-0002-1104-6843
FU AHRQ HHS [T32 HS000063]; NHLBI NIH HHS [K24 HL004184]
NR 27
TC 14
Z9 14
U1 0
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD JUN
PY 2011
VL 86
IS 6
BP 512
EP 515
DI 10.1002/ajh.22016
PG 5
WC Hematology
SC Hematology
GA 766CI
UT WOS:000290757400015
PM 21594889
ER
PT J
AU O'Seaghdha, CM
Hwang, SJ
Bhavsar, NA
Kottgen, A
Coresh, J
Astor, BC
Fox, CS
AF O'Seaghdha, Conall M.
Hwang, Shih-Jen
Bhavsar, Nrupen A.
Koettgen, Anna
Coresh, Josef
Astor, Brad C.
Fox, Caroline S.
TI Lower Urinary Connective Tissue Growth Factor Levels and Incident CKD
Stage 3 in the General Population
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Chronic kidney disease; connective tissue growth factor; epidemiology
ID CHRONIC KIDNEY-DISEASE; TGF-BETA; DIABETIC-NEPHROPATHY;
TUBULOINTERSTITIAL FIBROSIS; ATHEROSCLEROSIS RISK; RENAL-INSUFFICIENCY;
FACTOR EXCRETION; UNITED-STATES; EXPRESSION; PREVALENCE
AB Background: Connective tissue growth factor (CTGF) is involved in the development and progression of kidney diseases, including diabetic nephropathy and kidney fibrosis, but also may have a role in mesangial repair after injury. It is unknown whether, in the general population, urinary CTGF levels are associated with a decrease in estimated glomerular filtration rate (eGFR) to <60 mL/min/1.73 m(2) (ie, development of chronic kidney disease [CKD] stage 3).
Study Design: Nested case-control.
Setting & Participants: 100 cases of incident CKD stage 3 and 100 age-and sex-matched controls in the Framingham Heart Study; 141 cases and 135 age-, sex-, and race-matched controls in the Atherosclerosis Risk in Communities (ARIC) Study. Controls had eGFR >= 60 mL/min/1.73 m(2) at follow-up in both studies.
Predictors: Urinary CTGF concentrations.
Outcomes: Incident CKD stage 3, defined as eGFR <60 mL/min/1.73 m(2).
Measurements: Stored urine samples from Framingham Heart Study and ARIC were measured for CTGF. Covariates were obtained from Framingham Heart Study and ARIC participant examinations.
Results: In the Framingham Heart Study, the median baseline urinary CTGF concentration was lower in cases (1.35 ng/mL) than controls (2.35 ng/mL; paired t test, P < 0.0001). The multivariable-adjusted OR for incident CKD stage 3 was 0.33 (95% CI, 0.17-0.64; P < 0.001) per 1-standard deviation in log urinary CTGF level after adjustment for CKD risk factors, baseline eGFR, and baseline log urinary albumin-creatinine ratio, with similar results in participants without diabetes (n = 184). Results were not materially different when urinary CTGF level was indexed to urinary creatinine level (multivariable-adjusted OR, 0.34; 95% CI, 0.21-0.56; P < 0.001). A similar, but nonsignificant, trend of risk of incident CKD stage 3 with lower baseline urinary CTGF concentration was observed in an independent case-control study conducted in the ARIC Study, with the strongest results observed in participants free of diabetes. This inverse relationship was robust in meta-analysis of both the overall and diabetes-free groups.
Limitations: Observational study; causality cannot be inferred.
Conclusions: Lower urinary CTGF concentrations precede the onset of CKD stage 3 in the general population. Further work is required to fully characterize how CTGF level influences risk of CKD. Am J Kidney Dis. 57(6): 841-849. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [O'Seaghdha, Conall M.; Hwang, Shih-Jen; Fox, Caroline S.] NHLBI, Div Intramural Res, Framingham Heart Study, Framingham, MA 01702 USA.
[O'Seaghdha, Conall M.; Hwang, Shih-Jen; Fox, Caroline S.] Ctr Populat Studies, Framingham, MA USA.
[O'Seaghdha, Conall M.; Hwang, Shih-Jen; Fox, Caroline S.] NHLBI, Div Intramural Res, Framingham Heart Study, Bethesda, MD 20892 USA.
[O'Seaghdha, Conall M.; Hwang, Shih-Jen; Fox, Caroline S.] Ctr Populat Studies, Bethesda, MD USA.
[O'Seaghdha, Conall M.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Div Renal, Boston, MA 02114 USA.
[Bhavsar, Nrupen A.; Koettgen, Anna; Coresh, Josef; Astor, Brad C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Bhavsar, Nrupen A.; Coresh, Josef; Astor, Brad C.] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
[Koettgen, Anna] Univ Hosp Freiburg, Div Renal, Freiburg, Germany.
[Coresh, Josef; Astor, Brad C.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
[Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA.
[Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[O'Seaghdha, Conall M.; Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Fox, CS (reprint author), NHLBI, Div Intramural Res, Framingham Heart Study, 73 Mt Wayte Ave,Ste 2, Framingham, MA 01702 USA.
EM foxca@nhlbi.nih.gov
RI Kottgen, Anna/D-2920-2012
FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-25195,
N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020,
N01-HC-55021, N01-HC-55022]; American Diabetes Association; National
Institute of Diabetes and Digestive and Kidney Diseases [1 R01
DK076770-01]; [U01HL075572-01]
FX The Framingham Heart Study is supported by grant N01-HC-25195 from the
National Heart, Lung, and Blood Institute (NHLBI); Framingham Heart
Study UACR measurements were supported by an American Diabetes
Association Research Grant. ARIC sample assays were supported by the
National Institute of Diabetes and Digestive and Kidney Diseases (1 R01
DK076770-01). ARIC is carried out as a collaborative study supported by
NHLBI contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019,
N01-HC-55020, N01-HC-55021, and N01-HC-55022, with the ARIC carotid MRI
examination funded by U01HL075572-01.
NR 53
TC 13
Z9 14
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JUN
PY 2011
VL 57
IS 6
BP 841
EP 849
DI 10.1053/j.ajkd.2010.11.022
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 766MX
UT WOS:000290788400008
PM 21292366
ER
PT J
AU Howrigan, DP
Laird, NM
Smoller, JW
Devlin, B
McQueen, MB
AF Howrigan, D. P.
Laird, N. M.
Smoller, J. W.
Devlin, B.
McQueen, M. B.
TI Using Linkage Information to Weight a Genome-Wide Association of Bipolar
Disorder
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE biploar disorder; genome-wide association; weighted false discovery
approach
ID SEROTONIN TRANSPORTER GENE; GIRDLE MUSCULAR-DYSTROPHY; FAMILY-BASED
ASSOCIATION; MYOSIN VB; INCLUSION DISEASE; I DISORDER; POLYMORPHISMS;
SUSCEPTIBILITY; METAANALYSIS; COMORBIDITY
AB Issues of multiple-testing and statistical significance in genome-wide association studies (GWAS) have prompted statistical methods utilizing prior data to increase the power of association results. Using prior findings from genome-wide linkage studies on bipolar disorder (BPD), we employed a weighted false discovery approach (wFDR; [Roeder et al. 2006. Am J Hum Genet 78(2): 243-252]) to previously reported GWAS data drawn from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Using this method, association signals are up or down-weighted given the linkage score in that genomic region. Although no SNPs in our sample reached genome-wide significance through the wFDR approach, the strongest single SNP result from the original GWAS results (rs4939921 in myosin VB) is strongly up-weighted as it occurs on a linkage peak of chromosome 18. We also identify regions on chromosome 9, 17, and 18 where modestly associated SNP clusters coincide with strong linkage scores, implicating them as possible candidate regions for further analysis. Moving forward, we believe the application of prior linkage information will be increasingly useful to future GWAS studies that incorporate rarer variants into their analysis. (C) 2011 Wiley-Liss, Inc.
C1 [Howrigan, D. P.] Univ Colorado, Dept Psychol, Boulder, CO 80309 USA.
[Howrigan, D. P.; McQueen, M. B.] Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA.
[Laird, N. M.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Smoller, J. W.] Massachusetts Gen Hosp, Dept Psychiat, Psychiat Genet Program Mood & Anxiety Disorders, Boston, MA 02114 USA.
[Devlin, B.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[McQueen, M. B.] Univ Colorado, Dept Integrat Physiol, Boulder, CO 80309 USA.
RP Howrigan, DP (reprint author), Univ Colorado, Dept Psychol, Campus Box 345, Boulder, CO 80309 USA.
EM daniel.howrigan@gmail.com
FU National Institute of Child Health and Human Development [T32 HD007289];
National Institute of Mental Health [T32 MH016880, MH063445]; National
Institute on Drug Abuse [DA011015]
FX Grant sponsor: National Institute of Child Health and Human Development;
Grant Number: T32 HD007289; Grant sponsor: National Institute of Mental
Health; Grant Number: T32MH016880; Grant sponsor: National Institute on
Drug Abuse; Grant Number: DA011015; Grant sponsor: National Institute of
Mental Health; Grant Number: MH063445.
NR 39
TC 6
Z9 6
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1552-4841
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUN
PY 2011
VL 156B
IS 4
BP 462
EP 471
DI 10.1002/ajmg.b.31183
PG 10
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 766FA
UT WOS:000290765200011
PM 21480485
ER
PT J
AU Samuels, J
Wang, Y
Riddle, MA
Greenberg, BD
Fyer, AJ
McCracken, JT
Rauch, SL
Murphy, DL
Grados, MA
Knowles, JA
Piacentini, J
Cullen, B
Bienvenu, OJ
Rasmussen, SA
Geller, D
Pauls, DL
Liang, KY
Shugart, YY
Nestadt, G
AF Samuels, Jack
Wang, Ying
Riddle, Mark A.
Greenberg, Benjamin D.
Fyer, Abby J.
McCracken, James T.
Rauch, Scott L.
Murphy, Dennis L.
Grados, Marco A.
Knowles, James A.
Piacentini, John
Cullen, Bernadette
Bienvenu, O. Joseph, III
Rasmussen, Steven A.
Geller, Daniel
Pauls, David L.
Liang, Kung-Yee
Shugart, Yin Y.
Nestadt, Gerald
TI Comprehensive Family-Based Association Study of the Glutamate
Transporter Gene SLC1A1 in Obsessive-Compulsive Disorder
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE obsessive-compulsive disorder; glutamate transporter; candidate gene
ID OCD COLLABORATIVE GENETICS; O-METHYLTRANSFERASE COMT; LINKAGE ANALYSIS;
SEX; SCHIZOPHRENIA; SUPPORTS; AUTISM; SAMPLE
AB SLC1A1 encodes a neuronal glutamate transporter and is a promising candidate gene for obsessive-compulsive disorder (OCD). Several independent research groups have reported significant associations between OCD and single nucleotide polymorphisms (SNPs) in this gene. Previously, we evaluated 13 SNPs in, or near, SLC1A1 and reported a strong association signal with rs301443, a SNP 7.5 kb downstream of the gene [Shugart et al. (2009); Am J Med Genet Part B 150B:886-892]. Theaims of the current study were first, to further investigate this finding by saturating the region around rs301443; and second, to explore the entire gene more thoroughly with a dense panel of SNP markers. We genotyped an additional 111 SNPs in or near SLC1A1, covering from 9 kb upstream to 84 kb downstream of the gene at average spacing of 1.7 kb per SNP, and conducted family-based association analyses in 1,576 participants in 377 families. We found that none of the surrounding markers were in linkage disequilibrium with rs301443, nor were any associated with OCD. We also found that SNP rs4740788, located about 8.8 kb upstream of the gene, was associated with OCD in all families (P = 0.003) and in families with male affecteds (P = 0.002). A three-SNP haplotype (rs4740788-rs10491734-rs10491733) was associated with OCD in the total sample (P = 0.00015) and in families with male affecteds (P = 0.0007). Although of nominal statistical significance considering the number of comparisons, these findings provide further support for the involvement of SLC1A1 in the pathogenesis of OCD. (C) 2011 Wiley-Liss, Inc.
C1 [Samuels, Jack; Wang, Ying; Riddle, Mark A.; Grados, Marco A.; Cullen, Bernadette; Bienvenu, O. Joseph, III; Nestadt, Gerald] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21231 USA.
[Greenberg, Benjamin D.; Rasmussen, Steven A.] Butler Hosp, Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI 02906 USA.
[Fyer, Abby J.] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, Coll Phys & Surg, New York, NY USA.
[McCracken, James T.; Piacentini, John] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Rauch, Scott L.; Geller, Daniel] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Murphy, Dennis L.] NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA.
[Knowles, James A.] Univ So Calif, Sch Med, Dept Psychiat, Los Angeles, CA USA.
[Pauls, David L.] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Liang, Kung-Yee] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
[Shugart, Yin Y.] NIMH, Genom Res Branch, Div Neurosci & Basic Behav Sci, Bethesda, MD 20892 USA.
RP Samuels, J (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, 1629 Thames St,Suite 401, Baltimore, MD 21231 USA.
EM jacks@jhmi.edu
RI Liang, Kung-Yee/F-8299-2011;
OI Samuels, Jack/0000-0002-6715-7905
FU National Institute of Mental Health [RO1MH50214, R01MH071507,
NIH/NCRR/OPD-GCRC RR00052]
FX Grant sponsor: National Institute of Mental Health; Grant numbers:
RO1MH50214, R01MH071507, NIH/NCRR/OPD-GCRC RR00052.
NR 40
TC 32
Z9 34
U1 1
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1552-4841
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUN
PY 2011
VL 156B
IS 4
BP 472
EP 477
DI 10.1002/ajmg.b.31184
PG 6
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 766FA
UT WOS:000290765200012
PM 21445956
ER
PT J
AU Yu, EW
Bauer, SR
Bain, PA
Bauer, DC
AF Yu, Elaine W.
Bauer, Scott R.
Bain, Paul A.
Bauer, Douglas C.
TI Proton Pump Inhibitors and Risk of Fractures: A Meta-Analysis of 11
International Studies
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Bone mineral density; Calcium absorption; Fracture; H2-receptor
antagonists; Osteoporosis; Proton pump inhibitor
ID BONE-MINERAL DENSITY; HIP FRACTURE; CALCIUM-ABSORPTION; ACQUIRED
PNEUMONIA; ACID SUPPRESSION; OLDER-ADULTS; K+-ATPASE; OMEPRAZOLE; WOMEN;
THERAPY
AB BACKGROUND: Concerns have been raised about the risk of fractures with acid-suppressive medications, such as proton pump inhibitors and histamine(2)-receptor antagonists.
METHODS: This meta-analysis evaluated the association between proton pump inhibitor or histamine(2)-receptor antagonist use and fractures. We performed a systematic search of published literature (1970 to October 10, 2010) in MEDLINE, EMBASE, and other sources. Ten publications reporting 11 studies were considered eligible for analysis.
RESULTS: All studies were observational case-control or cohort studies and primarily evaluated older adults. The summary effect estimate for risk of hip fracture increased modestly among individuals taking proton pump inhibitors (relative risk [RR] 1.30, 95% confidence interval [CI], 1.19-1.43). There also was an increase in spine (RR 1.56, 95% CI, 1.31-1.85) and any-site fractures (RR 1.16, 95% CI, 1.04-1.30) among proton pump inhibitor users. These findings were similar in both men and women and after stratification by duration of use. In contrast, histamine(2)-receptor antagonist use was not significantly associated with increased risk of hip fracture (RR 1.12, 95% CI, 0.97-1.30).
CONCLUSION: In this meta-analysis of observational studies, proton pump inhibitors modestly increased the risk of hip, spine, and any-site fractures, whereas histamine(2)-receptor antagonists were not associated with fracture risk. The possibility of residual confounding cannot be excluded. Further skeletal evaluation should be considered for patients who are taking proton pump inhibitors and also at risk for osteoporotic fracture. (C) 2011 Elsevier Inc. All rights reserved. The American Journal of Medicine (2011) 124, 519-526
C1 [Yu, Elaine W.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Bauer, Scott R.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Bain, Paul A.] Harvard Univ, Sch Med, Countway Lib Med, Boston, MA 02115 USA.
[Bauer, Douglas C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Bauer, Douglas C.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA.
[Bauer, Douglas C.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA USA.
RP Yu, EW (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,Thier 1051, Boston, MA 02114 USA.
EM ewyu@partners.org
FU National Institutes of Health [K24 ARO51895]
FX Dr Bauer is supported by National Institutes of Health Grant K24
ARO51895.
NR 45
TC 105
Z9 112
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
J9 AM J MED
JI Am. J. Med.
PD JUN
PY 2011
VL 124
IS 6
BP 519
EP 526
DI 10.1016/j.amjmed.2011.01.007
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 768BD
UT WOS:000290905400015
PM 21605729
ER
PT J
AU Tabatabaei, S
Saylor, PJ
Coen, J
Dahl, DM
AF Tabatabaei, Shahin
Saylor, Philip J.
Coen, John
Dahl, Douglas M.
TI Prostate Cancer Imaging: What Surgeons, Radiation Oncologists, and
Medical Oncologists Want to Know
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Review
DE cancer staging; CT; MRI; prostate neoplasms; transrectal ultrasound
ID BONE; METASTASES; CARCINOMA
AB OBJECTIVE. The purpose of this article is to discuss the information that is important to note in imaging reports of patients with prostate cancer.
CONCLUSION. Accurate staging through imaging is an integral part of prostate cancer management. Ultrasound, CT, bone scanning, and MRI are used for prostate cancer patients to assess the primary tumor, lymph node status, and bone metastasis. Accurate reporting of images is crucial for effective cancer treatment.
C1 [Tabatabaei, Shahin; Dahl, Douglas M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Urol, Boston, MA 02114 USA.
[Saylor, Philip J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Canc Ctr, Boston, MA 02114 USA.
[Coen, John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Tabatabaei, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Urol, GRB 1102,55 Fruit St, Boston, MA 02114 USA.
EM stabatabaei@partners.org
NR 15
TC 8
Z9 8
U1 0
U2 4
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUN
PY 2011
VL 196
IS 6
BP 1263
EP 1266
DI 10.2214/AJR.10.6263
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767JX
UT WOS:000290854000038
PM 21606287
ER
PT J
AU Eisner, BH
McQuaid, JW
Hyams, E
Matlaga, BR
AF Eisner, Brian H.
McQuaid, Joseph W.
Hyams, Elias
Matlaga, Brian R.
TI Nephrolithiasis: What Surgeons Need to Know
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Review
DE imaging; kidney; nephrolithiasis; ureter
ID UNENHANCED HELICAL CT; SHOCK-WAVE LITHOTRIPSY; ACUTE FLANK PAIN;
COMPUTED-TOMOGRAPHY; MULTIDETECTOR CT; URINARY CALCULI; STONE
COMPOSITION; URETERAL CALCULI; RENAL-CALCULI; MR UROGRAPHY
AB OBJECTIVE. In this article, we review the standard of care for imaging of nephrolithiasis as well as new technology and radiation concerns from the perspective of the urologic surgeon.
CONCLUSION. Nephrolithiasis is a common cause of morbidity with a lifetime prevalence of 5-10% worldwide. Increasingly, diagnostic evaluation and planning for medical or surgical intervention have become reliant on imaging.
C1 [Eisner, Brian H.; McQuaid, Joseph W.] Harvard Univ, Massachusetts Gen Hosp, Dept Urol, Kidney Stone Ctr,Med Sch, Boston, MA 02114 USA.
[Hyams, Elias; Matlaga, Brian R.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA.
RP Eisner, BH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Urol, Kidney Stone Ctr,Med Sch, GRB 1102,55 Fruit St, Boston, MA 02114 USA.
EM beisner@partners.org
NR 60
TC 12
Z9 12
U1 0
U2 3
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUN
PY 2011
VL 196
IS 6
BP 1274
EP 1278
DI 10.2214/AJR.11.6434
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767JX
UT WOS:000290854000040
PM 21606289
ER
PT J
AU Seaman, DM
Meyer, CA
Gilman, MD
McCormack, FX
AF Seaman, Danielle M.
Meyer, Cristopher A.
Gilman, Matthew D.
McCormack, Francis X.
TI Diffuse Cystic Lung Disease at High-Resolution CT
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE cystic lung disease; high-resolution CT; interstitial lung disease;
Langerhans cell histiocytosis; lymphangioleiomyomatosis
ID THIN-SECTION CT; LYMPHANGIOLEIOMYOMATOSIS; AMYLOIDOSIS; SARCOMA
AB OBJECTIVE. This article will illustrate and describe the spectrum of diseases associated with air cysts at high-resolution CT (HRCT).
CONCLUSION. HRCT is an important modality in the evaluation of interstitial lung disease to include cystic lung disease. Although most commonly associated with lymphangioleiomyomatosis or Langerhans cell histiocytosis, cystic lung disease is increasingly being recognized as a feature of other entities. Awareness of the spectrum of HRCT findings associated with these diseases may help the trained observer narrow the differential diagnosis.
C1 [Seaman, Danielle M.] Duke Univ, Dept Radiol, Med Ctr, Durham, NC 27710 USA.
[Meyer, Cristopher A.] Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA.
[Gilman, Matthew D.] Massachusetts Gen Hosp, Dept Radiol, Div Thorac Radiol, Boston, MA 02114 USA.
[McCormack, Francis X.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Cincinnati, OH USA.
RP Seaman, DM (reprint author), Duke Univ, Dept Radiol, Med Ctr, Box 3808 DUMC, Durham, NC 27710 USA.
EM seaman.danielle@gmail.com
OI McCormack, Francis/0000-0001-7168-9464
NR 16
TC 40
Z9 42
U1 0
U2 2
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUN
PY 2011
VL 196
IS 6
BP 1305
EP 1311
DI 10.2214/AJR.10.4420
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767JX
UT WOS:000290854000044
PM 21606293
ER
PT J
AU Asrani, A
Kaewlai, R
Digumarthy, S
Gilman, M
Shepard, JAO
AF Asrani, Ashwin
Kaewlai, Rathachai
Digumarthy, Subba
Gilman, Matthew
Shepard, Jo-Anne O.
TI Urgent Findings on Portable Chest Radiography: What the Radiologist
Should Know-Review
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Review
DE chest imaging; emergency radiology; hemothorax; lobar collapse;
mediastinal hematoma; pneumomediastinum; pneumothorax; pulmonary edema;
pulmonary embolism; pulmonary hemorrhage; pulmonary infarct
ID ACUTE PULMONARY-EMBOLISM; THIN-SECTION CT; PNEUMOMEDIASTINUM; DIAGNOSIS;
DISEASE; EDEMA; LUNG; SIGN; PNEUMOTHORAX; ANGIOGRAPHY
C1 [Asrani, Ashwin] Weill Cornell Med Coll, Dept Radiol, New York, NY 10065 USA.
[Kaewlai, Rathachai; Digumarthy, Subba; Gilman, Matthew; Shepard, Jo-Anne O.] Massachusetts Gen Hosp, Dept Thorac Radiol, Boston, MA 02114 USA.
RP Asrani, A (reprint author), Weill Cornell Med Coll, Dept Radiol, 525 E 68th St, New York, NY 10065 USA.
EM ashwinasrani@yahoo.com
OI Kaewlai, Rathachai/0000-0002-0650-9380
NR 41
TC 1
Z9 1
U1 0
U2 4
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUN
PY 2011
VL 196
IS 6
SU S
BP S45
EP S61
DI 10.2214/AJR.09.7170
PG 17
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767JK
UT WOS:000290852500001
PM 21606235
ER
PT J
AU Asrani, A
Kaewlai, R
Digumarthy, S
Gilman, M
Shepard, JA
AF Asrani, Ashwin
Kaewlai, Rathachai
Digumarthy, Subba
Gilman, Matthew
Shepard, Jo-Anne
TI Urgent Findings on Portable Chest Radiography: What the Radiologist
Should Know-Self-Assessment Module
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE chest imaging; emergency radiology; hemothorax; lobar collapse;
mediastinal hematoma; pneumomediastinum; pneumothorax; pulmonary edema;
pulmonary embolism; pulmonary hemorrhage; pulmonary infarct
AB The educational objectives for this self-assessment module are for the participant to exercise, self-assess, and improve his or her understanding of the spectrum of urgent findings on portable chest radiography.
C1 [Asrani, Ashwin] Weill Cornell Med Coll, Dept Radiol, New York, NY 10065 USA.
[Kaewlai, Rathachai; Digumarthy, Subba; Gilman, Matthew; Shepard, Jo-Anne] Massachusetts Gen Hosp, Dept Thorac Radiol, Boston, MA 02114 USA.
RP Asrani, A (reprint author), Weill Cornell Med Coll, Dept Radiol, 525 E 68th St, New York, NY 10065 USA.
EM ashwinasrani@yahoo.com
OI Kaewlai, Rathachai/0000-0002-0650-9380
NR 4
TC 0
Z9 0
U1 0
U2 2
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUN
PY 2011
VL 196
IS 6
SU S
BP WS37
EP WS46
DI 10.2214/AJR.10.7308
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767JK
UT WOS:000290852500005
PM 21606239
ER
PT J
AU Kambadakone, AR
Chaudhary, NA
Desai, GS
Nguyen, DD
Kulkarni, NM
Sahani, DV
AF Kambadakone, Avinash R.
Chaudhary, Naueen A.
Desai, Gaurav S.
Nguyen, Deanna D.
Kulkarni, Naveen M.
Sahani, Dushyant V.
TI Low-Dose MDCT and CT Enterography of Patients With Crohn Disease:
Feasibility of Adaptive Statistical Iterative Reconstruction
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE adaptive statistical iterative reconstruction; Crohn disease; CT
enterography; radiation dose
ID INFLAMMATORY-BOWEL-DISEASE; IONIZING-RADIATION EXPOSURE; FOLLOW-THROUGH;
COMPUTED-TOMOGRAPHY; MR ENTEROGRAPHY; REDUCTION; CHILDREN; EPIDEMIOLOGY;
MODULATION; STRATEGIES
AB OBJECTIVE. The purpose of this study was to evaluate the image quality and diagnostic performance of low-dose MDCT and CT enterography with adaptive statistical iterative reconstruction (ASIR) in the evaluation of Crohn disease.
SUBJECTS AND METHODS. Forty-eight patients (20 men, 28 women; mean age, 33.3 years; range, 17-83 years) with known or suspected Crohn disease who underwent low-dose MDCT and CT enterography with ASIR between December 2008 and December 2009 were included in the study. Twenty-seven patients had previously undergone standard-dose 64-MDCT and CT enterography with filtered back projection (FBP), and those images were used for comparison. The weight-based IV contrast protocol and scan parameters (120 kVp, 5-mm section thickness, 0.5-second rotation, pitch of 1.375, 64 x 0.625 mm detector configuration) were constant for the two techniques except for a higher noise index (x1.3) in the ASIR group. Two blinded readers reviewed 75 randomized MDCT-CT enterographic scans of 48 patients to assess image quality and diagnostic performance in the evaluation of Crohn disease, and the radiation dose for the studies was estimated.
RESULTS. All 75 MDCT and CT enterographic scans had acceptable quality for diagnostic interpretation. Findings of Crohn disease were seen on 63 of 75 scans (84%). Low-dose scans in the ASIR group had optimal image quality and were rated comparable to or better than standard-dose FBP images (mean score, 4.2 vs 3.87; p = 0.007). The subjective image noise score (mean, 1.43 vs 1.58; p = 0.2) and objective image noise measurements were lower for ASIR images (p < 0.001). Low-dose studies with ASIR allowed average dose reduction of 34.5% compared with standard-dose scans with FBP (volume CT dose index for ASIR, 7.7 +/- 2.1 mGy; for FBP, 12 +/- 5.5 mGy; p < 0.01).
CONCLUSION. Low-dose MDCT and CT enterographic studies reconstructed with ASIR were of appropriate quality for confident evaluation of the manifestations of Crohn disease while allowing approximately 34% dose reduction in comparison with FBP technique.
C1 [Kambadakone, Avinash R.; Chaudhary, Naueen A.; Desai, Gaurav S.; Kulkarni, Naveen M.; Sahani, Dushyant V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Nguyen, Deanna D.] Massachusetts Gen Hosp, Dept Med, Gastroenterol Unit, Boston, MA 02114 USA.
RP Sahani, DV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, White 270,55 Fruit St, Boston, MA 02114 USA.
EM dsahani@partners.org
NR 38
TC 64
Z9 65
U1 0
U2 14
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUN
PY 2011
VL 196
IS 6
BP W743
EP W752
DI 10.2214/AJR.10.5303
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767JX
UT WOS:000290854000012
PM 21606263
ER
PT J
AU Li, XH
Zhang, D
Liu, B
AF Li, Xinhua
Zhang, Da
Liu, Bob
TI Automated Extraction of Radiation Dose Information From CT Dose Report
Images
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE CT dose image; optical character recognition; text extraction
ID COMPUTED-TOMOGRAPHY
AB OBJECTIVE. The purpose of this article is to describe the development of an automated tool for retrieving texts from CT dose report images.
CONCLUSION. Optical character recognition was adopted to perform text recognitions of CT dose report images. The developed tool is able to automate the process of analyzing multiple CT examinations, including text recognition, parsing, error correction, and exporting data to spreadsheets. The results were precise for total dose-length product (DLP) and were about 95% accurate for CT dose index and DLP of scanned series.
C1 [Li, Xinhua; Zhang, Da; Liu, Bob] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Diagnost Imaging Phys,Dept Radiol, Boston, MA 02114 USA.
RP Liu, B (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Diagnost Imaging Phys,Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM bliu7@bics.bwh.harvard.edu
NR 4
TC 12
Z9 12
U1 0
U2 4
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUN
PY 2011
VL 196
IS 6
BP W781
EP W783
DI 10.2214/AJR.10.5718
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767JX
UT WOS:000290854000018
PM 21606269
ER
PT J
AU Wu, CC
Maher, MM
Shepard, JAO
AF Wu, Carol C.
Maher, Michael M.
Shepard, Jo-Anne O.
TI Complications of CT-Guided Percutaneous Needle Biopsy of the Chest:
Prevention and Management
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Editorial Material
DE complications; CT-guided biopsy; diagnosis of lung cancer; lung biopsy;
lung cancer
ID ASPIRATION LUNG-BIOPSY; PULMONARY-LESIONS; PNEUMOTHORAX; RISK;
HEMORRHAGE
AB OBJECTIVE. The objective of this article is to describe potential complications of percutaneous needle biopsy of the chest, discuss the risk factors associated with the development of complications, and explain how to prevent complications and manage complications when they occur.
CONCLUSION. Pneumothorax and pulmonary hemorrhage are the most common complications of percutaneous needle biopsy of the chest, whereas air embolism and tumor seeding are extremely rare. Attention to biopsy planning and technique and postprocedural care help to prevent or minimize most potential complications.
C1 [Wu, Carol C.; Shepard, Jo-Anne O.] Massachusetts Gen Hosp, Dept Radiol, Div Thorac Imaging & Intervent, Boston, MA 02114 USA.
[Maher, Michael M.] Cork Univ, Dept Radiol, Cork, Ireland.
[Maher, Michael M.] Mercy Univ Hosp, Cork, Ireland.
[Maher, Michael M.] Univ Coll Cork, Cork, Ireland.
RP Wu, CC (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Thorac Imaging & Intervent, 55 Fruit St,Founders 202, Boston, MA 02114 USA.
EM cwu8@partners.org
NR 16
TC 58
Z9 61
U1 0
U2 5
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUN
PY 2011
VL 196
IS 6
BP W678
EP W682
DI 10.2214/AJR.10.4659
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767JX
UT WOS:000290854000002
PM 21606253
ER
PT J
AU Ferrone, CR
Konstantinidis, IT
Sahani, DV
Wargo, JA
Castillo, CFD
Warshaw, AL
AF Ferrone, Cristina R.
Konstantinidis, Ioannis T.
Sahani, Dushyant V.
Wargo, Jennifer A.
Castillo, Carlos Fernandez-del
Warshaw, Andrew L.
TI Twenty-Three Years of the Warshaw Operation for Distal Pancreatectomy
With Preservation of the Spleen
SO ANNALS OF SURGERY
LA English
DT Article; Proceedings Paper
CT 40th Anniversary Meeting of the
American-Pancreatic-Association-and-Japan-Pancreas-Society
CY NOV 04-07, 2009
CL Honolulu, HI
SP Amer Pancreat Assoc & Japan Pancreas Soc
ID CURATIVE LAPAROSCOPIC RESECTION; SPLENIC ARTERY; POSTSPLENECTOMY SEPSIS;
SINGLE INSTITUTION; VEIN; SPLENECTOMY; NEOPLASMS; CONSERVATION;
CIRCULATION; MORTALITY
AB Objective: To describe our series of distal pancreatectomies with preservation of the spleen utilizing the Warshaw operation with a focus on possible long-term complications due to the development of gastric varices.
Background: The Warshaw operation was first described in 1988. The splenic vessels are resected and the spleen survives via the short gastric and left gastroepiploic vessels.
Methods: Retrospective review of 721 patients who underwent a distal pancreatectomy between February 1986 and February 2009.
Results: The spleen was preserved via the Warshaw operation in 158 patients (22%). Median age was 55 years (range 10-85) and 72% were females. Pathologies included: 35 mucinous cystic neoplasms (adenoma 28, borderline 7), 22 intraductal papillary mucinous neoplasms (adenoma 9, borderline 9, cancer 4), 23 serous cystadenomas, 13 other pancreatic cysts, 27 pancreatic endocrine tumors, 16 chronic pancreatitis, 9 ductal adenocarcinomas, and 13 other pathologies. Only 3 (1.9%) patients required a reoperation because of splenic infarction at 3 to 100 days postoperatively because of abdominal pain and/or fever. Median follow-up was 2.7 years (mean 4.5 years, range 0-21 years). There was evidence of perigastric varices in 16 of 65 (25%) patients who had follow-up imaging at a median of 3.4 years, but none of the 158 patients developed gastrointestinal bleeding or hypersplenism.
Conclusions: Spleen preservation with the Warshaw operation has a low postoperative failure rate of 1.9%. Radiologic evidence of asymptomatic perigastric varices was identified in 25% of patients. There were no clinical consequences of perigastric varices in any patient during a follow-up period of up to 21 years.
C1 [Ferrone, Cristina R.; Konstantinidis, Ioannis T.; Wargo, Jennifer A.; Castillo, Carlos Fernandez-del] Dept Surg, Boston, MA USA.
[Warshaw, Andrew L.] Inst Pancreat Canc Res, Boston, MA USA.
[Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Ferrone, CR (reprint author), Wang Ambulatory Care Ctr 460, 15 Parkman St, Boston, MA 02114 USA.
EM cferrone@partners.org
NR 22
TC 48
Z9 49
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD JUN
PY 2011
VL 253
IS 6
BP 1136
EP 1139
DI 10.1097/SLA.0b013e318212c1e2
PG 4
WC Surgery
SC Surgery
GA 764WB
UT WOS:000290664100014
PM 21394008
ER
PT J
AU Barker, RH
Urgaonkar, S
Mazitschek, R
Celatka, C
Skerlj, R
Cortese, JF
Tyndall, E
Liu, HL
Cromwell, M
Sidhu, AB
Guerrero-Bravo, JE
Crespo-Llado, KN
Serrano, AE
Lin, JW
Janse, CJ
Khan, SM
Duraisingh, M
Coleman, BI
Angulo-Barturen, I
Jimenez-Diaz, MB
Magan, N
Gomez, V
Ferrer, S
Martinez, MS
Wittlin, S
Papastogiannidis, P
O'Shea, T
Klinger, JD
Bree, M
Lee, E
Levine, M
Wiegand, RC
Munoz, B
Wirth, DF
Clardy, J
Bathurst, I
Sybertz, E
AF Barker, Robert H., Jr.
Urgaonkar, Sameer
Mazitschek, Ralph
Celatka, Cassandra
Skerlj, Renato
Cortese, Joseph F.
Tyndall, Erin
Liu, Hanlan
Cromwell, Mandy
Sidhu, Amar Bir
Guerrero-Bravo, Jose E.
Crespo-Llado, Keila N.
Serrano, Adelfa E.
Lin, Jing-wen
Janse, Chris J.
Khan, Shahid M.
Duraisingh, Manoj
Coleman, Bradley I.
Angulo-Barturen, Inigo
Belen Jimenez-Diaz, Maria
Magan, Noemi
Gomez, Vanesa
Ferrer, Santiago
Santos Martinez, Maria
Wittlin, Sergio
Papastogiannidis, Petros
O'Shea, Thomas
Klinger, Jeffrey D.
Bree, Mark
Lee, Edward
Levine, Mikaela
Wiegand, Roger C.
Munoz, Benito
Wirth, Dyann F.
Clardy, Jon
Bathurst, Ian
Sybertz, Edmund
TI Aminoindoles, a Novel Scaffold with Potent Activity against Plasmodium
falciparum
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN LIVER-MICROSOMES; IN-VITRO; MALARIA PARASITES; RODENT MALARIA;
BERGHEI; RESISTANCE; IDENTIFICATION; ERYTHROCYTES; ARTEMISININ;
INFECTION
AB This study characterizes aminoindole molecules that are analogs of Genz-644442. Genz-644442 was identified as a hit in a screen of similar to 70,000 compounds in the Broad Institute's small-molecule library and the ICCB-L compound collection at Harvard Medical School. Genz-644442 is a potent inhibitor of Plasmodium falciparum in vitro (50% inhibitory concentrations [IC(50)s], 200 to 285 nM) and inhibits P. berghei in vivo with an efficacy of > 99% in an adapted version of Peters' 4-day suppressive test (W. Peters, Ann. Trop. Med. Parasitol. 69: 155-171, 1975). Genz-644442 became the focus of medicinal chemistry optimization; 321 analogs were synthesized and were tested for in vitro potency against P. falciparum and for in vitro absorption, distribution, metabolism, and excretion (ADME) properties. This yielded compounds with IC(50)s of approximately 30 nM. The lead compound, Genz-668764, has been characterized in more detail. It is a single enantiomer with IC(50)s of 28 to 65 nM against P. falciparum in vitro. In the 4-day P. berghei model, when it was dosed at 100 mg/kg of body weight/day, no parasites were detected on day 4 postinfection. However, parasites recrudesced by day 9. Dosing at 200 mg/kg/day twice a day resulted in cures of 3/5 animals. The compound had comparable activity against P. falciparum blood stages in a humanengrafted NOD-scid mouse model. Genz-668764 had a terminal half-life of 2.8 h and plasma trough levels of 41 ng/ml when it was dosed twice a day orally at 55 mg/kg/day. Seven-day rat safety studies showed a no-observableadverse- effect level (NOAEL) at 200 mg/kg/day; the compound was not mutagenic in Ames tests, did not inhibit the hERG channel, and did not have potent activity against a broad panel of receptors and enzymes. Employing allometric scaling and using in vitro ADME data, the predicted human minimum efficacious dose of Genz-668764 in a 3-day once-daily dosing regimen was 421 mg/day/70 kg, which would maintain plasma trough levels above the IC(90) against P. falciparum for at least 96 h after the last dose. The predicted human therapeutic index was approximately 3, on the basis of the exposure in rats at the NOAEL. We were unable to select for parasites with > 2-fold decreased sensitivity to the parent compound, Genz-644442, over 270 days of in vitro culture under drug pressure. These characteristics make Genz-668764 a good candidate for preclinical development.
C1 [Barker, Robert H., Jr.; Celatka, Cassandra; Skerlj, Renato; Liu, Hanlan; Cromwell, Mandy; O'Shea, Thomas; Klinger, Jeffrey D.; Bree, Mark; Lee, Edward; Levine, Mikaela; Sybertz, Edmund] Genzyme Corp, Waltham, MA 02451 USA.
[Urgaonkar, Sameer; Mazitschek, Ralph; Cortese, Joseph F.; Tyndall, Erin; Wiegand, Roger C.; Munoz, Benito] 7 Cambridge Ctr, Infect Dis Initiat Program, Broad Inst, Cambridge, MA 02142 USA.
[Guerrero-Bravo, Jose E.; Crespo-Llado, Keila N.; Serrano, Adelfa E.] Univ Puerto Rico, Sch Med, Dept Microbiol & Med Zool, San Juan, PR 00936 USA.
[Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Lin, Jing-wen; Janse, Chris J.; Khan, Shahid M.] Leiden Univ Med Ctr LUMC, Leiden Malaria Res Grp, Ctr Infect Dis, NL-2333 ZA Leiden, Netherlands.
[Sidhu, Amar Bir; Duraisingh, Manoj; Coleman, Bradley I.; Wirth, Dyann F.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Angulo-Barturen, Inigo; Belen Jimenez-Diaz, Maria; Magan, Noemi; Gomez, Vanesa; Ferrer, Santiago; Santos Martinez, Maria] GlaxoSmithKline Inc, Dis Dev World, Madrid 28760, Spain.
[Wittlin, Sergio; Papastogiannidis, Petros] Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland.
[Wittlin, Sergio; Papastogiannidis, Petros] Univ Basel, CH-4056 Basel, Switzerland.
[Clardy, Jon] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Bathurst, Ian] Med Malaria Venture, CH-1215 Geneva, Switzerland.
RP Barker, RH (reprint author), Genzyme Corp, 153 2nd Ave, Waltham, MA 02451 USA.
EM Robert.barker@genzyme.com
RI Mazitschek, Ralph/E-3741-2013
OI Mazitschek, Ralph/0000-0002-1105-689X
FU Broad Institute; Medicines for Malaria Venture; Humanitarian Assistance
for Neglected Diseases Initiative at Genzyme Corporation; China
Scholarship Council; [NIH-RCMI-NCRR-G12RR030-51]
FX This work was supported by SPARC funds from the Broad Institute, with
funds from Medicines for Malaria Venture, and with support from the
Humanitarian Assistance for Neglected Diseases Initiative at Genzyme
Corporation. Partial support for infrastructure to A.E.S. was provided
by NIH-RCMI-NCRR-G12RR030-51. J.-W. Lin is supported by a grant from the
China Scholarship Council.
NR 41
TC 17
Z9 17
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2011
VL 55
IS 6
BP 2612
EP 2622
DI 10.1128/AAC.01714-10
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 765NA
UT WOS:000290713400018
PM 21422215
ER
PT J
AU Ikuta, T
Thatte, HS
Tang, JX
Mukerji, I
Knee, K
Bridges, KR
Wang, S
Montero-Huerta, P
Joshi, RM
Head, CA
AF Ikuta, Tohru
Thatte, Hemant S.
Tang, Jay X.
Mukerji, Ishita
Knee, Kelly
Bridges, Kenneth R.
Wang, Sabina
Montero-Huerta, Pedro
Joshi, Ratan Mani
Head, C. Alvin
TI Nitric oxide reduces sickle hemoglobin polymerization: Potential role of
nitric oxide-induced charge alteration in depolymerization
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Sickle cell disease; Nitric oxide; Oxygen affinity; Anti-sickling;
Polymer formation
ID ACUTE CHEST SYNDROME; CELL-DISEASE; OXYGEN-AFFINITY; CARBON-MONOXIDE;
BLOOD; NUCLEATION; GELATION; METHEMOGLOBIN; MECHANISM; TRANSPORT
AB We previously demonstrated that inhaling nitric oxide (NO) increases the oxygen affinity of sickle red blood cells (RBCs) in patients with sickle cell disease (SCD). Our recent studies found that NO lowered the P(50) values of sickle hemoglobin (HbS) hemolysates but did not increase methemoglobin (metHb) levels, supporting the role of NO, but not metHb, in the oxygen affinity of HbS. Here we examine the mechanism by which NO increases HbS oxygen affinity. Because anti-sickling agents increase sickle RBC oxygen affinity, we first determined whether NO exhibits anti-sickling properties. The viscosity of HbS hemolysates, measured by falling ball assays, increased upon deoxygenation: NO treatment reduced the increment. Multiphoton microscopic analyses showed smaller HbS polymers in deoxygenated sickle RBCs and HbS hemolysates exposed to NO. These results suggest that NO inhibits HbS polymer formation and has anti-sickling properties. Furthermore, we found that HbS treated with NO exhibits an isoelectric point similar to that of HbA, suggesting that NO alters the electric charge of HbS. NO HbS adducts had the same elution time as HbA upon high performance liquid chromatography analysis. This study demonstrates that NO may disrupt HbS polymers by abolishing the excess positive charge of HbS, resulting in increased oxygen affinity. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Ikuta, Tohru; Wang, Sabina; Montero-Huerta, Pedro; Joshi, Ratan Mani; Head, C. Alvin] Georgia Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Augusta, GA 30912 USA.
[Thatte, Hemant S.] Harvard Univ, Sch Med, VA Boston Hlth Care Syst, Dept Surg, Boston, MA 02301 USA.
[Tang, Jay X.] Brown Univ, Dept Phys, Providence, RI 02912 USA.
[Mukerji, Ishita] Wesleyan Univ, Mol Biol & Biochem Dept, Middletown, CT 06459 USA.
[Knee, Kelly] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Bridges, Kenneth R.] Amgen Inc, Hematol Oncol, Thousand Oaks, CA 91320 USA.
RP Head, CA (reprint author), Georgia Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, 1120 15th St,BIW-2144, Augusta, GA 30912 USA.
EM ahead@georgiahealth.edu
FU Southeastern Clinical and Translational Research Institute; National
Institutes of Health [P20 MD003383]; Department of Defense/Office of
Naval Research
FX We thank Dr. Keith Miller for the use of his laboratory and suggestions
regarding ESR, Drs. Celia Bonaventura and Carl Rosow for their helpful
comments, and Nadine Odo for editing. We are grateful to Yuchiao Chang
for statistical analysis. We also thank INO-Therapeutics for providing
the NO gas. This study was supported in part by a Southeastern Clinical
and Translational Research Institute grant (T.I.) and P20 MD003383
(T.I.) from the National Institutes of Health, and a grant from the
Department of Defense/Office of Naval Research (H.S.T.).
NR 55
TC 7
Z9 7
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JUN 1
PY 2011
VL 510
IS 1
BP 53
EP 61
DI 10.1016/j.abb.2011.03.013
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 768JJ
UT WOS:000290929900007
PM 21457702
ER
PT J
AU Iverson, KM
Resick, PA
Suvak, MK
Walling, S
Taft, CT
AF Iverson, Katherine M.
Resick, Patricia A.
Suvak, Michael K.
Walling, Sherry
Taft, Casey T.
TI Intimate Partner Violence Exposure Predicts PTSD Treatment Engagement
and Outcome in Cognitive Processing Therapy
SO BEHAVIOR THERAPY
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; SEXUAL ASSAULT VICTIMS; BATTERED WOMEN;
PROLONGED EXPOSURE; TRAUMA THERAPY; RISK-FACTORS; LONGITUDINAL DATA;
CLINICAL-TRIAL; FEMALE VICTIMS; ABUSE
AB Intimate partner violence (IPV) exposure was examined as a predictor of treatment engagement (i.e., starting and completing therapy) and treatment outcome in 150 women taking part in a dismantling study of cognitive processing therapy (CPT) for posttraumatic stress disorder (PTSD; Resick et al., 2008). Results indicate that women in a current intimate relationship with recent IPV (i.e., past year) were less likely to begin treatment relative to women who reported past IPV only or no history of IPV. For women who began treatment, IPV exposure was not predictive of whether or not they completed treatment. Among women who began treatment, the frequency of IPV was associated with treatment outcome such that women who experienced more frequent IPV exhibited larger reductions in PTSD and depression symptoms over the course of treatment, but experienced similar levels of PTSD and depression severity at the 6-month follow-up. Findings highlight the importance of targeting treatment engagement among women who report recent IPV and suggest that women who have experienced frequent IPV respond well to CPT treatment in spite of their IPV experiences.
C1 [Iverson, Katherine M.; Resick, Patricia A.; Suvak, Michael K.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA.
[Iverson, Katherine M.; Resick, Patricia A.; Suvak, Michael K.; Taft, Casey T.] Boston Univ, Boston, MA 02215 USA.
[Walling, Sherry] Fresno Pacific Univ, Fresno, CA USA.
[Taft, Casey T.] VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA 02130 USA.
RP Iverson, KM (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, 150 S Huntington Ave,116B-3, Boston, MA 02130 USA.
EM Katherine.Iverson@va.gov
FU NIMH NIH HHS [R01 MH051509, R01 MH051509-05, R01-MH51509, T32 MH019836,
T32MH019836]
NR 58
TC 11
Z9 12
U1 4
U2 17
PU ASSOC ADV BEHAVIOR THERAPY
PI NEW YORK
PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA
SN 0005-7894
J9 BEHAV THER
JI Behav. Therapy
PD JUN
PY 2011
VL 42
IS 2
BP 236
EP 248
DI 10.1016/j.beth.2010.06.003
PG 13
WC Psychology, Clinical
SC Psychology
GA 763XT
UT WOS:000290593700007
PM 21496509
ER
PT J
AU Gros, DF
Yoder, M
Tuerk, PW
Lozano, BE
Acierno, R
AF Gros, Daniel F.
Yoder, Matthew
Tuerk, Peter W.
Lozano, Brian E.
Acierno, Ron
TI Exposure Therapy for PTSD Delivered to Veterans via Telehealth:
Predictors of Treatment Completion and Outcome and Comparison to
Treatment Delivered in Person
SO BEHAVIOR THERAPY
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY;
PSYCHOMETRIC PROPERTIES; PROLONGED EXPOSURE; TELEPSYCHIATRY;
VIDEOCONFERENCE; TELEMEDICINE; SERVICES; SCALES; SAMPLE
AB Recent research has focused on the effectiveness of evidence-based psychotherapy delivered via telehealth services. Unfortunately to date, the majority of studies employ very small samples and limited predictor and moderator variables. To address these concerns and further replicate and extend the literature on telehealth, the present study investigated the effectiveness of 12-session exposure therapy delivered either via telehealth (n=62) or in person (n=27) in veterans with posttraumatic stress disorder (PTSD). Findings demonstrated that although older veterans and Vietnam veterans were more likely to complete the telehealth treatment, telehealth findings were not influenced by patient age, sex, race, combat theater, or disability status. Exposure therapy delivered via telehealth was effective in reducing the symptoms of PTSD, anxiety, depression, stress, and general impairment with large effect sizes. Interestingly, exposure therapy via telehealth was less effective than exposure therapy delivered in person; however, lack of random assignment to condition limits conclusions of differential effectiveness. Overall, these findings support the utility of telehealth services to provide effective, evidence-based psychotherapies.
C1 [Gros, Daniel F.] Ralph H Johnson Vet Adm Med Ctr, Mental Hlth Serv 116, Charleston, SC 29401 USA.
Med Univ S Carolina, Charleston, SC USA.
RP Gros, DF (reprint author), Ralph H Johnson Vet Adm Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM grosd@musc.edu
RI Schueter, nicos/A-3625-2014
NR 34
TC 69
Z9 70
U1 3
U2 11
PU ASSOC ADV BEHAVIOR THERAPY
PI NEW YORK
PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA
SN 0005-7894
J9 BEHAV THER
JI Behav. Therapy
PD JUN
PY 2011
VL 42
IS 2
BP 276
EP 283
DI 10.1016/j.beth.2010.07.005
PG 8
WC Psychology, Clinical
SC Psychology
GA 763XT
UT WOS:000290593700010
PM 21496512
ER
PT J
AU Williams, SB
D'Amico, AV
Weinberg, AC
Gu, XM
Lipsitz, SR
Hu, JC
AF Williams, Stephen B.
D'Amico, Anthony V.
Weinberg, Aaron C.
Gu, Xiangmei
Lipsitz, Stuart R.
Hu, Jim C.
TI Population-based determinants of radical prostatectomy surgical margin
positivity
SO BJU INTERNATIONAL
LA English
DT Article
DE positive margins; prostatectomy; minimally invasive; surgeon volume;
outcomes
ID LEARNING-CURVE; CANCER; OUTCOMES; TRENDS; RISK; RADIOTHERAPY; SPECIMENS;
LOCATION; SURGEONS; VOLUME
AB OBJECTIVE
To characterize factors associated with positive surgical margins (PSMs) and derive population-based PSM cutoffs to evaluate surgeon performance in radical prostatectomy (RP).
PATIENTS AND METHODS
SEER-Medicare data were used to identify 4247 men diagnosed with prostate cancer during 2004-2005 who underwent RP up to 2006.
We performed logistic regression to assess the impact of tumour characteristics, surgeon volume and surgical approach on the likelihood of PSMs for pT2 and PT3a disease.
Moreover, we derived 25th and 10th percentile cutoffs from binomial distribution equations.
RESULTS
Overall, 19.4% of men experienced PSMs with a pT2 vs pT3a PSM rate of 14.9% vs 42% (P < 0.001). Extrapolating from our population-based results, a surgeon incurring more than three PSMs in 10 cases of pT2 disease performed below the 25th percentile.
There was a trend for fewer PSMs with minimally invasive vs open RP (17.4% vs 20.1%, P = 0.086), and the PSM rate also decreased over the study period from 21.3% in 2004 to 16.6% in 2006 (P = 0.028) with significant geographic variation (P < 0.001).
In adjusted analyses, temporal and geographic variation in PSM persisted, and men with high (odds ratio 3.68, 95% CI 2.82-4.81) and intermediate (odds ratio 2.52, 95% CI 2.03-3.13) vs low-risk disease were at greater odds to experience PSMs. Notably, neither surgical approach nor surgeon volume was significantly associated with PSMs.
CONCLUSION
Our population-based PSM benchmarks allow identification of under-performing outliers who may seek courses or video self-study to improve outcomes. There was significant temporal and geographic variation in PSMs but neither surgeon volume nor surgical approach was associated with PSMs.
C1 [Williams, Stephen B.; Weinberg, Aaron C.; Hu, Jim C.] Brigham & Womens Hosp, Div Urol Surg, Boston, MA 02115 USA.
[Gu, Xiangmei; Lipsitz, Stuart R.; Hu, Jim C.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Hu, Jim C.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
[D'Amico, Anthony V.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Hu, JC (reprint author), Brigham & Womens Hosp, Div Neurol, ASBII-3,45 Francis St, Boston, MA 02115 USA.
EM jhu2@partners.org
OI weinberg, aaron/0000-0002-0957-5703
FU Department of Defense [PC073261]
FX This work was supported by a Department of Defense Prostate Cancer
Physician Training Award (PC073261) presented to Dr Hu. This study used
the linked SEER-Medicare database. The interpretation and reporting of
these data are the sole responsibility of the authors. The authors
acknowledge the efforts of the Applied Research Program, National Cancer
Institute; the Office of Research, Development and Information, Centers
for Medicare and Medicaid Services; Information Management Services
Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program
tumour registries in the creation of the SEER-Medicare database.
NR 34
TC 12
Z9 12
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1464-4096
J9 BJU INT
JI BJU Int.
PD JUN
PY 2011
VL 107
IS 11
BP 1734
EP 1740
DI 10.1111/j.1464-410X.2010.09662.x
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 766GW
UT WOS:000290770000005
PM 20942827
ER
PT J
AU Roland, M
Rao, SR
Sibbald, B
Hann, M
Harrison, S
Walter, A
Guthrie, B
Desroches, C
Ferris, TG
Campbell, EG
AF Roland, Martin
Rao, Sowmya R.
Sibbald, Bonnie
Hann, Mark
Harrison, Stephen
Walter, Alex
Guthrie, Bruce
Desroches, Catherine
Ferris, Timothy G.
Campbell, Eric G.
TI Professional values and reported behaviours of doctors in the USA and
UK: quantitative survey
SO BMJ QUALITY & SAFETY
LA English
DT Article
ID MEDICAL PROFESSIONALISM; MILLENNIUM; PHYSICIANS; CHARTER; CARE; FACE
AB Background: The authors aimed to determine US and UK doctors' professional values and reported behaviours, and the extent to which these vary with the context of care.
Method: 1891 US and 1078 UK doctors completed the survey (64.4% and 40.3% response rate respectively). Multivariate logistic regression was used to compare responses to identical questions in the two surveys.
Results: UK doctors were more likely to have developed practice guidelines (82.8% UK vs 49.6% US, p<0.001) and to have taken part in a formal medical error-reduction programme (70.9% UK vs 55.7% US, p<0.001). US doctors were more likely to agree about the need for periodic recertification (completely agree 23.4% UK vs 53.9% US, p<0.001). Nearly a fifth of doctors had direct experience of an impaired or incompetent colleague in the previous 3 years. Where the doctor had not reported the colleague to relevant authorities, reasons included thinking that someone else was taking care of the problem, believing that nothing would happen as a result, or fear of retribution. UK doctors were more likely than US doctors to agree that significant medical errors should always be disclosed to patients. More US doctors reported that they had not disclosed an error to a patient because they were afraid of being sued.
Discussion: The context of care may influence both how professional values are expressed and the extent to which behaviours are in line with stated values. Doctors have an important responsibility to develop their healthcare systems in ways which will support good professional behaviour.
C1 [Roland, Martin] Univ Cambridge, Cambridge Ctr Hlth Serv Res, Inst Publ Hlth, Cambridge CB2 0SR, England.
[Rao, Sowmya R.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Sibbald, Bonnie; Hann, Mark; Harrison, Stephen; Walter, Alex] Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England.
[Guthrie, Bruce] Univ Dundee, Ctr Primary Care & Populat Res, Dundee, Scotland.
[Desroches, Catherine; Ferris, Timothy G.; Campbell, Eric G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mongan Inst Hlth Policy, Boston, MA USA.
RP Roland, M (reprint author), Univ Cambridge, Cambridge Ctr Hlth Serv Res, Inst Publ Hlth, Robinson Way, Cambridge CB2 0SR, England.
EM mr108@cam.ac.uk
OI Roland, Martin/0000-0002-8533-3060; Guthrie, Bruce/0000-0003-4191-4880
FU Nuffield Trust; ABIM Foundation; Institute on Medicine
FX We are grateful to the Nuffield Trust who funded the UK survey, to the
ABIM Foundation who part-funded the US survey and to the Institute on
Medicine as a Profession who funded the US survey and provided financial
support for focus groups held in the UK during the development of the
questionnaire.
NR 21
TC 19
Z9 19
U1 1
U2 9
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD JUN
PY 2011
VL 20
IS 6
BP 515
EP 521
DI 10.1136/bmjqs.2010.048173
PG 7
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 768DB
UT WOS:000290910600007
PM 21383386
ER
PT J
AU Swensen, SJ
Kaplan, GS
Meyer, GS
Nelson, EC
Hunt, GC
Pryor, DB
Weissberg, JI
Daley, J
Yates, GR
Chassin, MR
AF Swensen, Stephen J.
Kaplan, Gary S.
Meyer, Gregg S.
Nelson, Eugene C.
Hunt, Gordon C.
Pryor, David B.
Weissberg, Jed I.
Daley, Jennifer
Yates, Gary R.
Chassin, Mark R.
TI Controlling healthcare costs by removing waste: what American doctors
can do now
SO BMJ QUALITY & SAFETY
LA English
DT Article
ID CONCEPTUAL-FRAMEWORK; RANDOMIZED-TRIAL; ANTIBIOTIC USE; VERTEBROPLASTY;
FRACTURES; QUALITY; IMPACT
AB Healthcare costs are unsustainable. The authors propose a solution to control costs without rationing (deliberate withholding of effective care) or payment reductions to doctors and hospitals. Three physician-led strategies comprise this solution: reduce (1) overuse of health services, (2) preventable complications and (3) waste within healthcare processes. These challenges know no borders.
C1 [Swensen, Stephen J.] Mayo Clin, Rochester, MN 55905 USA.
[Kaplan, Gary S.] Virginia Mason Hlth Syst, Seattle, WA USA.
[Meyer, Gregg S.] Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA.
[Meyer, Gregg S.] Massachusetts Gen Phys Org, Boston, MA USA.
[Nelson, Eugene C.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Hunt, Gordon C.] Sutter Hlth, Sacramento, CA USA.
[Pryor, David B.] Ascens Hlth, St Louis, MO USA.
[Weissberg, Jed I.] Kaiser Permanente, Qual & Care Delivery Excellence, Oakland, CA USA.
[Daley, Jennifer] Univ Massachusetts, Mem Med Ctr, Worcester, MA 01605 USA.
[Daley, Jennifer] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Yates, Gary R.] Sentara Healthcare, Norfolk, VA USA.
[Chassin, Mark R.] Int Joint Commiss, Oak Brook Terrace, IL USA.
RP Swensen, SJ (reprint author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.
EM swensen.stephen@mayo.edu
NR 39
TC 14
Z9 14
U1 1
U2 9
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD JUN
PY 2011
VL 20
IS 6
BP 534
EP 537
DI 10.1136/bmjqs.2010.049213
PG 4
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 768DB
UT WOS:000290910600010
PM 21339313
ER
PT J
AU Ramsey, B
Bai, T
Newell, AH
Troxell, M
Park, B
Olson, S
Keenan, E
Luoh, SW
AF Ramsey, Betsy
Bai, Tao
Newell, Amy Hanlon
Troxell, Megan
Park, Byung
Olson, Susan
Keenan, Edward
Luoh, Shiuh-Wen
TI GRB7 protein over-expression and clinical outcome in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Biomarker; Prognostic marker; Signal transduction; Gene
amplification; Oncogenes; HER-2 gene; GRB7 gene
ID IN-SITU HYBRIDIZATION; RECEPTOR-BOUND PROTEIN-7; HER-2 NEU ONCOGENE;
AMERICAN-SOCIETY; ERBB2 AMPLICON; AMPLIFICATION; GENES; RECOMMENDATIONS;
TUMORIGENESIS; ACTIVATION
AB The growth factor receptor-bound protein-7 gene (GRB7) encodes a multi-domain signal transduction molecule. The purpose of this study was to examine the clinical significance of GRB7 protein expression in human breast cancer. Western blotting analysis of protein extracts from 563 annotated frozen breast tumors was performed. Expression status of GRB7 and HER-2 was correlated with clinical covariates and outcomes. Cox proportional hazards were used to identify factors associated with breast cancer-free interval. The median follow-up was 71 months. P values < 0.05 were considered statistically significant (two-sided). A discrepancy between HER-2 and GRB7 protein over-expression was observed. GRB7 protein over-expression was associated with negative estrogen and progesterone receptor status, higher tumor grade, larger primary tumor size, (more) axillary lymph node involvement, higher clinical stage, and shortened breast cancer-free interval. HER-2 protein over-expression was associated only with higher tumor grade. Multi-variate analysis revealed that GRB7 protein over-expression was an independent adverse prognostic factor for breast cancer-free interval (hazard ratio 1.69, 95% confidence interval 1.07-2.67; P = 0.024). The same was true of the subset of patients who did not receive any adjuvant systemic therapy (hazard ratio 1.68, 95% confidence interval 1.16-2.31; P = 0.0055). Using FISH analysis, 32/32 (100%; 95% CI 89-100%) tumors which over-expressed both HER-2 and GRB7 proteins and 1/35 (3%; 95% CI 0-15%) tumors with HER-2 but no GRB7 protein over-expression with Western blotting analysis demonstrated HER-2 gene amplification. GRB7 protein over-expression is an independent adverse prognostic factor in human breast cancer.
C1 [Bai, Tao; Luoh, Shiuh-Wen] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA.
[Ramsey, Betsy; Keenan, Edward] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA.
[Bai, Tao; Luoh, Shiuh-Wen] Portland VA Med Ctr, Portland, OR 97239 USA.
[Newell, Amy Hanlon; Olson, Susan] Oregon Hlth & Sci Univ, Dept Med & Mol Genet, Portland, OR 97239 USA.
[Troxell, Megan] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA.
[Park, Byung] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
[Ramsey, Betsy; Bai, Tao; Newell, Amy Hanlon; Troxell, Megan; Park, Byung; Olson, Susan; Keenan, Edward; Luoh, Shiuh-Wen] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.
RP Luoh, SW (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, 3181 SW Sam Jackson Pk Rd,MC L586, Portland, OR 97239 USA.
EM luohs@ohsu.edu
OI /0000-0003-3516-7516
FU Department of Veterans Affairs; Portland VA Research Foundation; OHSU;
OHSU Foundation
FX The work is supported by Department of Veterans Affairs, Portland VA
Research Foundation, OHSU Presidential Bridge Award, and OHSU
Foundation. We are grateful to the technical assistance provided by the
Histology Shared Resources at the Knight Cancer Institute, OHSU.
NR 31
TC 19
Z9 20
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUN
PY 2011
VL 127
IS 3
BP 659
EP 669
DI 10.1007/s10549-010-1010-0
PG 11
WC Oncology
SC Oncology
GA 766UH
UT WOS:000290811500008
PM 20635137
ER
PT J
AU Bortfeld, T
Jeraj, R
AF Bortfeld, T.
Jeraj, R.
TI The physical basis and future of radiation therapy
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Review
ID POSITRON-EMISSION-TOMOGRAPHY; TARGET VOLUME DELINEATION; SQUAMOUS-CELL
CARCINOMA; MULTICRITERIA OPTIMIZATION; LUNG-CANCER; ADAPTIVE
RADIOTHERAPY; DOSE DISTRIBUTIONS; NORMAL TISSUE; NECK-CANCER;
PROTON-BEAM
AB The remarkable progress in radiation therapy over the last century has been largely due to our ability to more effectively focus and deliver radiation to the tumour target volume. Physics discoveries and technology inventions have been an important driving force behind this progress. However, there is still plenty of room left for future improvements through physics, for example image guidance and four-dimensional motion management and particle therapy, as well as increased efficiency of more compact and cheaper technologies. Bigger challenges lie ahead of physicists in radiation therapy beyond the dose localisation problem, for example in the areas of biological target definition, improved modelling for normal tissues and tumours, advanced multicriteria and robust optimisation, and continuous incorporation of advanced technologies such as molecular imaging. The success of physics in radiation therapy has been based on the continued "fuelling" of the field with new discoveries and inventions from physics research. A key to the success has been the application of the rigorous scientific method. In spite of the importance of physics research for radiation therapy, too few physicists are currently involved in cutting-edge research. The increased emphasis on more "professionalism" in medical physics will tip the situation even more off balance. To prevent this from happening, we argue that medical physics needs more research positions, and more and better academic programmes. Only with more emphasis on medical physics research will the future of radiation therapy and other physics-related medical specialties look as bright as the past, and medical physics will maintain a status as one of the most exciting fields of applied physics.
C1 [Bortfeld, T.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Bortfeld, T.] Harvard Univ, Sch Med, Boston, MA USA.
[Jeraj, R.] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA.
RP Bortfeld, T (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA.
EM tbortfeld@partners.org
NR 71
TC 28
Z9 28
U1 0
U2 10
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD JUN
PY 2011
VL 84
IS 1002
BP 485
EP 498
DI 10.1259/bjr/86221320
PG 14
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767HU
UT WOS:000290847100007
PM 21606068
ER
PT J
AU Carabe-Fernandez, A
Dale, RG
Paganetti, H
AF Carabe-Fernandez, A.
Dale, R. G.
Paganetti, H.
TI Repair kinetic considerations in particle beam radiotherapy
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Article
ID DOUBLE-STRAND BREAKS; REJOINING DNA BREAKS; IONIZING-RADIATION;
MAMMALIAN-CELLS; ALPHA-PARTICLES; CARBON-IONS; DAMAGE; IRRADIATION;
INACTIVATION; MECHANISMS
AB Objectives: A second-order repair kinetics model is developed to predict damage repair rates following low or high linear energy transfer (LET) irradiations and to assess the amount of unrepairable damage produced by such radiations. The model is a further development of an earlier version designed to test if low-LET radiation repair processes could be quantified in terms of second-order kinetics. The newer version allows calculation of both the repair rate of the proportion of DNA damages that repair according to second-order kinetics and the proportion of DNA damages that do not repair.
Methods: The original and present models are intercompared in terms of their goodness-of-fit to a number of data sets obtained from different ion beams. The analysis demonstrates that the present model provides a better fit to the data in all cases studied.
Results: The proportions of unrepairable damage created by radiations of different LET predicted by the new model correspond well with previous studies on the increased effectiveness of high-LET radiations in inducing reproductive cell death. The results show that the original model may underestimate the proportion of unrepaired damage at any given time after its creation as well as failing to predict very slow or unrepairable damage components, which may result from high-LET irradiation.
Conclusion: It is suggested that the second-order model presented here offers a more realistic view of the patterns of repair in cell lines or tissues exposed to high-LET radiation.
C1 [Carabe-Fernandez, A.; Paganetti, H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Carabe-Fernandez, A.; Paganetti, H.] Harvard Univ, Sch Med, Boston, MA USA.
[Dale, R. G.] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Dept Radiat Phys & Radiobiol, London, England.
[Dale, R. G.] Univ Oxford, Gray Inst Radiat Oncol & Biol, Oxford, England.
RP Carabe-Fernandez, A (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA.
EM acarabe@partners.org
FU Cyclotron Trust, UK
FX This study was funded in full by the Cyclotron Trust, UK
(www.neutrontherapy.co.uk). The authors want to thank Professor Bleddyn
Jones for his comments and suggestions about the manuscript.
NR 37
TC 4
Z9 4
U1 0
U2 2
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD JUN
PY 2011
VL 84
IS 1002
BP 546
EP 555
DI 10.1259/19934996
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767HU
UT WOS:000290847100013
PM 21266398
ER
PT J
AU Harzstark, AL
Rosenberg, JE
Weinberg, VK
Sharib, J
Ryan, CJ
Smith, DC
Pagliaro, LC
Beer, TM
Liu, G
Small, EJ
AF Harzstark, Andrea L.
Rosenberg, Jonathan E.
Weinberg, Vivian K.
Sharib, Jeremy
Ryan, Charles J.
Smith, David C.
Pagliaro, Lance C.
Beer, Tomasz M.
Liu, Glenn
Small, Eric J.
TI Ixabepilone, Mitoxantrone, and Prednisone for Metastatic
Castration-Resistant Prostate Cancer After Docetaxel-Based Therapy A
Phase 2 Study of the Department of Defense Prostate Cancer Clinical
Trials Consortium
SO CANCER
LA English
DT Article
DE prostate cancer; chemotherapy; metastatic; mitoxantrone; ixabepilone;
docetaxel
ID EPOTHILONE-B ANALOG; ADVANCED BREAST-CANCER; WORKING GROUP; BMS-247550;
RECOMMENDATIONS; ANTHRACYCLINE; CHEMOTHERAPY; ANTIGEN; TAXANE
AB BACKGROUND: Mitoxantrone plus prednisone and ixabepilone each have modest activity as monotherapy for second-line chemotherapy in patients with docetaxel-refractory castration-resistant prostate cancer. Clinical noncross-resistance was previously observed. Phase 1 testing determined the maximum tolerated dose and dose-limiting toxicities with the combination regimen; a phase 2 study was conducted to evaluate the activity of the combination. METHODS: Patients with metastatic progressive castration-resistant prostate cancer during or after 3 or more cycles of taxane-based chemotherapy enrolled in a phase 2 multicenter study of ixabepilone 35 mg/m(2) and mitoxantrone 12 mg/m(2) administered on Day 1 every 21 days with pegfilgrastim support, along with prednisone 5 mg twice daily. Patients were evaluated for disease response and toxicity. RESULTS: Results are reported for the 56 evaluable patients. Twenty-five (45%; 95% confidence interval [CI], 31%-59%) experienced confirmed >= 50% prostate-specific antigen (PSA) declines, 33 (59%; 95% CI, 45%-72%) experienced confirmed >= 30% PSA declines, and 8 of 36 patients (22%; 95% CI, 10%-39%) with measurable disease experienced objective responses. Median time to PSA or objective progression was 4.4 months (95% CI, 3.5-5.6), and median progression-free survival was also 4.4 months (95% CI, 3.0-6.0). Median overall survival was 12.5 months (95% CI, 10.2-15.9). Thirty-two percent of patients experienced grade 3 of 4 neutropenia, and 11% experienced grade 3 or higher neutropenic infections, including 1 treatment-related death. Grade 2 and 3 neuropathy occurred in 11% and 12.5% of patients, respectively. CONCLUSIONS: These results suggest that the combination of ixabepilone and mitoxantrone is both feasible and active in castration-resistant prostate cancer and requires dosing with pegfilgrastim. Cancer 2011; 117: 2419-25. (C) 2010 American Cancer Society.
C1 [Harzstark, Andrea L.] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Rosenberg, Jonathan E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Smith, David C.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Pagliaro, Lance C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Beer, Tomasz M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Liu, Glenn] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
RP Harzstark, AL (reprint author), Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, 1600 Divisadero St,Box 1711, San Francisco, CA 94143 USA.
EM andrea.harzstark@ucsf.edu
FU National Cancer Institute, Department of Defense Prostate Cancer
Clinical Trials Consortium [W81XWH-05-1-175, W81XWH-06-01-0256];
Prostate Cancer Foundation
FX This study was supported in part by: Department of Defense Physicians
Research Training Grant No. W81XWH-05-1-175 from the Cancer Therapy
Evaluation Program of the National Cancer Institute, Department of
Defense Prostate Cancer Clinical Trials Consortium Grant No.
W81XWH-06-01-0256, and the Prostate Cancer Foundation.
NR 13
TC 5
Z9 6
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUN 1
PY 2011
VL 117
IS 11
BP 2419
EP 2425
DI 10.1002/cncr.25810
PG 7
WC Oncology
SC Oncology
GA 767ME
UT WOS:000290859900013
PM 24048789
ER
PT J
AU Tan, ASL
Bourgoin, A
Gray, SW
Armstrong, K
Hornik, RC
AF Tan, Andy S. L.
Bourgoin, Angel
Gray, Stacy W.
Armstrong, Katrina
Hornik, Robert C.
TI How Does Patient-Clinician Information Engagement Influence
Self-Reported Cancer-Related Problems? Findings From a Longitudinal
Analysis
SO CANCER
LA English
DT Article
DE patient-clinician communication; self-reported outcomes; cancer;
survivor
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CENTERED CARE;
COMMUNICATION; OUTCOMES; IMPROVE; IMPACT; NEEDS
AB BACKGROUND: Past research has linked patient-physician communication with improved emotional, physical, and social health. One component of communication, patient-clinician information engagement (PCIE), predicts improved short-term patient-reported outcomes, such as treatment satisfaction, through perceptions of feeling informed. However, to the authors' knowledge, the relation between PCIE and longer term cancer-related problems has not been examined previously. The authors examined the influence of PCIE on self-reported problems associated with cancer diagnosis and treatment based on a longitudinal survey among a randomly selected sample from the 2005 Pennsylvania Cancer Registry. METHODS: In total, 1293 respondents were surveyed who were diagnosed with colorectal, breast, or prostate cancers during 2006 and 2007. The baseline response rate was 64%, and the retention rate was 65%. The authors predicted an index of cancer-related problems at 1-year follow-up with the baseline cancer-related problem index and PCIE, controlling for demographic and clinical factors using regression analyses. The mean age of participants was 65 years, approximately 50% were women, and 86% were white. RESULTS: Having more cancer-related problems and PCIE at baseline significantly predicted more cancer-related problems at follow-up. In addition, baseline cancer-related problems and PCIE interacted significantly (P=.01): PCIE was associated with more cancer-related problems at follow-up among participants who reported more symptoms rather than fewer symptoms at baseline. CONCLUSIONS: If respondents reported engaging more with their physicians at baseline, then they reported experiencing more cancer-related issues at follow-up; this pattern was stronger among those who reported more baseline problems. The current results indicated that increased discussion of cancer information with physicians may maintain the salience of these problems in cancer survivors' minds over time. Cancer 2011; 117: 256-976. (C) 2011 American Cancer Society.
C1 [Tan, Andy S. L.; Bourgoin, Angel; Armstrong, Katrina; Hornik, Robert C.] Univ Penn, Annenberg Sch Commun, Ctr Excellence Canc Commun Res, Philadelphia, PA 19146 USA.
[Gray, Stacy W.] Dana Farber Canc Inst, Ctr Community Based Res, Dept Med Oncol, Boston, MA 02115 USA.
[Armstrong, Katrina] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19146 USA.
[Armstrong, Katrina] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19146 USA.
[Armstrong, Katrina] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19146 USA.
RP Tan, ASL (reprint author), Univ Penn, Annenberg Sch Commun, Ctr Excellence Canc Commun Res, 3620 Walnut St, Philadelphia, PA 19146 USA.
EM atan@asc.upenn.edu
RI Tan, Andy/H-1102-2012;
OI Hornik, Robert/0000-0002-2148-8805
FU National Cancer Institute [5P50CA095856-05]
FX Research support was received thorough Grant 5P50CA095856-05 from the
National Cancer Institute.
NR 28
TC 9
Z9 9
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUN 1
PY 2011
VL 117
IS 11
BP 2569
EP 2576
DI 10.1002/cncr.25804
PG 8
WC Oncology
SC Oncology
GA 767ME
UT WOS:000290859900030
PM 24048804
ER
PT J
AU Abramson, JS
Hochberg, EP
AF Abramson, Jeremy S.
Hochberg, Ephraim P.
TI Reply to Intravenous Methotrexate as Central Nervous System (CNS)
Prophylaxis Is Associated With a Low Risk of CNS Recurrence in High-Risk
Patients With Diffuse Large B-Cell Lymphoma
SO CANCER
LA English
DT Letter
ID NON-HODGKIN-LYMPHOMA
C1 [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Abramson, JS (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA.
OI Abramson, Jeremy/0000-0001-8467-9257
NR 4
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUN 1
PY 2011
VL 117
IS 11
BP 2580
EP 2581
DI 10.1002/cncr.25788
PG 2
WC Oncology
SC Oncology
GA 767ME
UT WOS:000290859900036
ER
PT J
AU Anderson, KS
Zeng, WY
Sasada, T
Choi, J
Riemer, AB
Su, M
Drakoulakos, D
Kang, YJ
Brusic, V
Wu, C
Reinherz, EL
AF Anderson, Karen S.
Zeng, Wanyong
Sasada, Tetsuro
Choi, Jaewon
Riemer, Angelika B.
Su, Mei
Drakoulakos, Donna
Kang, Yoon-Joong
Brusic, Vladimir
Wu, Catherine
Reinherz, Ellis L.
TI Impaired tumor antigen processing by immunoproteasome-expressing
CD40-activated B cells and dendritic cells
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE Vaccination; Tumor immunity; Antigen processing; Dendritic cells
ID CYTOTOXIC T-CELLS; PRESENTING CELLS; STANDARD PROTEASOME;
CANCER-IMMUNOTHERAPY; LYMPHOCYTES; GENERATION; RESPONSES; PEPTIDES;
CLEAVAGE; DISTINCT
AB Professional APCs, such as dendritic cells, are routinely used in vitro for the generation of cytotoxic T lymphocytes specific for tumor antigens. In addition to dendritic cells, CD40-activated B cells and variant K562 leukemic cells can be readily transfected with nucleic acids for in vitro and in vivo antigen presentation. However, the expression of immunoproteasome components in dendritic cells may preclude display of tumor antigens such as Mart1/MelanA. Here, we use three target epitopes, two derived from tumor antigens [Mart1(26-34) (M26) and Cyp1B1(239-247) (Cyp239)] and one derived from the influenza A viral antigen [FluM1(58-66) (FluM58)], to demonstrate that CD40-activated B cells, like dendritic cells, have a limited capability to process certain tumor antigens. In contrast, the K562 HLA-A*0201 transfectant efficiently processes and presents M26 and Cyp239 as well as the influenza FluM58 epitopes to T cells. These results demonstrate that the choice of target APC for gene transfer of tumor antigens may be limited by the relative efficacy of proteasome components to process certain tumor epitopes. Importantly, K562 can be exploited as an artificial APC, efficient in processing both M26 and Cyp239 epitopes and presumably, by extension, other relevant tumor antigens.
C1 [Anderson, Karen S.; Zeng, Wanyong; Sasada, Tetsuro; Choi, Jaewon; Riemer, Angelika B.; Su, Mei; Drakoulakos, Donna; Kang, Yoon-Joong; Brusic, Vladimir; Wu, Catherine; Reinherz, Ellis L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
RP Anderson, KS (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr, Room HIM416,77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM kanderson@partners.org
FU deBeaumont Foundation; National Cancer Institute/Avon Foundation [5 P30
CA006516-44, R21 CA115043-2]; Cancer Vaccine Center at the Dana-Farber
Cancer Institute
FX We thank Dr. Lee Nadler for providing valuable scientific reagents. This
study was supported by a research grant from the deBeaumont Foundation
and the National Cancer Institute/Avon Foundation (5 P30 CA006516-44,
KSA), R21 CA115043-2 (CW) and the Cancer Vaccine Center at the
Dana-Farber Cancer Institute.
NR 42
TC 4
Z9 4
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD JUN
PY 2011
VL 60
IS 6
BP 857
EP 867
DI 10.1007/s00262-011-0995-5
PG 11
WC Oncology; Immunology
SC Oncology; Immunology
GA 766QS
UT WOS:000290802200010
PM 21400024
ER
PT J
AU Gaur, SK
Friese, JL
Sadow, CA
Ayyagari, R
Binkert, CA
Schenker, MP
Kulke, M
Baum, R
AF Gaur, Shantanu K.
Friese, Jeremy L.
Sadow, Cheryl A.
Ayyagari, Rajasekhara
Binkert, Christoph A.
Schenker, Matthew P.
Kulke, Matthew
Baum, Richard
TI Hepatic Arterial Chemoembolization Using Drug-Eluting Beads in
Gastrointestinal Neuroendocrine Tumor Metastatic to the Liver
SO CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Article
DE Embolization; Chemoembolization; Carcinoid; Liver; Neuroendocrine tumor
ID DIGESTIVE ENDOCRINE TUMORS; ISLET-CELL CARCINOMA; INTRAARTERIAL
CHEMOTHERAPY; OCTREOTIDE ACETATE; EMBOLIZATION; DOXORUBICIN; MANAGEMENT;
COMPLICATIONS; FLUOROURACIL; EXPERIENCE
AB Purpose This study was designed to evaluate short (<3 months) and intermediate-term (>3 months) follow-up in patients with metastatic neuroendocrine tumor to the liver who underwent hepatic arterial chemoembolization with drug-eluting beads at a single institution.
Methods Institutional review board approval was obtained for this retrospective review. All patients who were treated with 100-300 or 300-500 mu m drug-eluting LC Beads (Biocompatibles, UK) preloaded with doxorubicin (range, 50-100 mg) for GI neuroendocrine tumor metastatic to the liver from June 2004 to June 2009 were included. CT and MRI were evaluated for progression using Response Evaluation Criteria In Solid Tumors (RE-CIST) or European Association for the Study of the Liver (EASL) criteria. Short-term (<3 months) and intermediateterm (>3 months) imaging response was determined and Kaplan-Meier survival curves were plotted.
Results Thirty-eight drug-eluting bead chemoembolization procedures were performed on 32 hepatic lobes, comprising 21 treatment cycles in 18 patients. All procedures were technically successful with two major complications (biliary injuries). At short-term follow-up (<3 months), 22 of 38 (58%) procedures and 10 of 21 (48%) treatment cycles produced an objective response (OR) with the remainder having stable disease (SD). At intermediate-term follow-up (mean, 445 days; range, 163-1247), 17 of 26 (65%) procedures and 8 of 14 (57%) treatment cycles produced an OR. Probability of progressing was approximately 52% at 1 year with a median time to progression of 419 days.
Conclusions Drug-eluting bead chemoembolization is a reasonable alternative to hepatic arterial embolization and chemoembolization for the treatment of metastatic neuroendocrine tumor to the liver.
C1 [Binkert, Christoph A.; Baum, Richard] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Binkert, Christoph A.] Kantonsspital Winterthur, Dept Radiol, CH-8401 Winterthur, Switzerland.
[Kulke, Matthew] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.
RP Baum, R (reprint author), Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
EM rbaum@partners.org
OI Gaur, Shantanu/0000-0003-0876-0517
FU Society for Interventional Radiology Foundation; Paul & Daisy Soros
Fellowship
FX SKG was supported by the Society for Interventional Radiology Foundation
Student Research Grant and the Paul & Daisy Soros Fellowship.
NR 42
TC 23
Z9 23
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0174-1551
J9 CARDIOVASC INTER RAD
JI Cardiovasc. Interv. Radiol.
PD JUN
PY 2011
VL 34
IS 3
BP 566
EP 572
DI 10.1007/s00270-011-0122-1
PG 7
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 765TA
UT WOS:000290730300018
PM 21431978
ER
PT J
AU Bande, D
Abbara, S
Kalva, SP
AF Bande, Dinesh
Abbara, Suhny
Kalva, Sanjeeva P.
TI Acute Renal Infarction Secondary to Calcific Embolus from Mitral Annular
Calcification
SO CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Article
DE Imaging; Intraarterial; Kidney/Renal
ID EMBOLIZATION; ARTERY
AB We report a case of a 62-year-old man who presented with right groin pain who subsequently was found to have a renal infarct secondary to calcific embolus from mitral annular calcification on CT and angiography. We briefly review the literature and discuss the importance of this entity in clinical practice.
C1 [Abbara, Suhny; Kalva, Sanjeeva P.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Bande, Dinesh] Univ N Dakota, Sch Med & Hlth Sci, Dept Med, Grand Forks, ND 58201 USA.
RP Kalva, SP (reprint author), Massachusetts Gen Hosp, Dept Radiol, GRB-270,55 Fruit St, Boston, MA 02114 USA.
EM skalva@partners.org
FU Amirsys Inc.; Elsevier
FX Dr. Bande declares no conflict of interest. Dr. Abbara declares the
following conflicts of interest: Board membership in SCCT and CBCCT,
Consultancy at Partners Imaging, Magellan Healthcare and Perceptive
Informatics, Honoraria from Siemens, and Royalties from Amirsys Inc. and
Elsevier. Dr. Kalva declares the following conflicts of interest:
Consultancy and Honoraria from Cordis Endovascular, Research Grant from
Angiodynamics and Cook, and Royalties from Amirsys Inc. and Elsevier.
NR 6
TC 2
Z9 3
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0174-1551
J9 CARDIOVASC INTER RAD
JI Cardiovasc. Interv. Radiol.
PD JUN
PY 2011
VL 34
IS 3
BP 647
EP 649
DI 10.1007/s00270-010-9944-5
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 765TA
UT WOS:000290730300031
PM 20661568
ER
PT J
AU Connors, G
Todoran, TM
Engelson, BA
Sobieszczyk, PS
Eisenhauer, AC
Kinlay, S
AF Connors, Gerard
Todoran, Thomas M.
Engelson, Brian A.
Sobieszczyk, Piotr S.
Eisenhauer, Andrew C.
Kinlay, Scott
TI Percutaneous Revascularization of Long Femoral Artery Lesions for
Claudication: Patency Over 2.5 Years and Impact of Systematic
Surveillance
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE peripheral artery disease; percutaneous peripheral interventions;
stents; long-term outcomes; PVD-peripheral vascular disease
ID NITINOL STENT IMPLANTATION; MAJOR VASCULAR-SURGERY; ENDOVASCULAR
TREATMENT; BALLOON ANGIOPLASTY; POPLITEAL ARTERIES; RANDOMIZED-TRIAL;
LOWER-EXTREMITY; SAPHENOUS-VEIN; FOLLOW-UP; TASC-II
AB Background: Angioplasty and stenting are preferred treatments for revascularizing femoral artery lesions up to 100 mm, but surgical bypass is recommended for longer lesions. We assessed long-term patency after percutaneous revascularization of long femoral artery lesions for claudication with intensive out-patient surveillance. Methods: We followed a cohort of 111 consecutive patients receiving angioplasty or stenting in 142 limbs in two institutions. Patients were followed for 2.5 years, and event curves and multivariable survival analysis used to compare outcomes in three groups according to lesion length (< 100 mm, 100-200 mm, and greater than 200 mm). Failed patency was defined as recurrence of symptoms with a decline in ankle brachial index, or stenosis identified by duplex ultrasound, or reintervention. Results: Compared to lesions less than 100 mm, longer lesions had higher failed primary patency (100-200 mm: HR = 2.0, P = 0.16, >200 mm: HR = 2.6, P = 0.03). Failed secondary patency was similar for short and intermediate lesions (< 5% incidence), but trended higher for lesions >200 mm (HR = 4.2, P = 0.06). An initial procedure residual stenosis greater than 20% was the only significant multivariable factor related to poorer long-term patency (HR = 15.8, P = 0.003). Compared to short lesions, the gain in long-term patency with out-patient surveillance and reintervention was higher for longer lesions and significantly so for intermediate lesions (100-200 mm = 23% versus <100 mm = 8%, P = 0.041). Conclusion: Percutaneous treatment of long femoral artery lesions can provide acceptable long-term patency for patients with claudication when out-patient surveillance is used to identify patients who require repeat interventions. Future long-term studies should consider overall patency encompassing more than one percutaneous reintervention. (C) 2011 Wiley-Liss, Inc.
C1 [Connors, Gerard; Todoran, Thomas M.; Kinlay, Scott] VA Boston Healthcare Syst, Div Cardiovasc, W Roxbury, MA 02132 USA.
[Connors, Gerard; Todoran, Thomas M.; Engelson, Brian A.; Sobieszczyk, Piotr S.; Eisenhauer, Andrew C.; Kinlay, Scott] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Connors, Gerard; Todoran, Thomas M.; Sobieszczyk, Piotr S.; Eisenhauer, Andrew C.; Kinlay, Scott] Harvard Univ, Sch Med, Boston, MA USA.
RP Kinlay, S (reprint author), VA Boston Healthcare Syst, Div Cardiovasc, W Roxbury, MA 02132 USA.
EM scott.kinlay@va.gov
NR 33
TC 13
Z9 14
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD JUN 1
PY 2011
VL 77
IS 7
BP 1055
EP 1062
DI 10.1002/ccd.22802
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 767MT
UT WOS:000290861400027
PM 20853355
ER
PT J
AU Mohamed, JA
DuPont, HL
Flores, J
Palur, H
Nair, P
Jiang, ZD
Guo, DC
Belkind-Gerson, J
Okhuysen, PC
AF Mohamed, Jamal A.
DuPont, Herbert L.
Flores, Jose
Palur, Himaja
Nair, Parvathy
Jiang, Zhi-Dong
Guo, Dongchuan
Belkind-Gerson, Jaime
Okhuysen, Pablo C.
TI Single Nucleotide Polymorphisms in the Promoter of the Gene Encoding the
Lipopolysaccharide Receptor CD14 Are Associated With Bacterial Diarrhea
in US and Canadian Travelers to Mexico
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID PATTERN-RECOGNITION RECEPTOR; ENTEROTOXIGENIC ESCHERICHIA-COLI;
NORTH-AMERICAN TRAVELERS; SOLUBLE CD14; DEVELOPING-COUNTRIES;
HELICOBACTER-PYLORI; INFECTION; ENDOTOXIN; ANTIBODY; DISEASE
AB Background. Under normal conditions, the expression of CD14, which is the principal receptor for bacterial lipopolysaccharide, is down-regulated in the intestinal mucosa but increases in response to inflammatory stimuli. The aim of the present study was to investigate whether fecal CD14 levels increased in response to infection with diarrheagenic Escherichia coli and whether single nucleotide polymorphisms (SNPs) in the CD14 gene were associated with an increased susceptibility to traveler's diarrhea (TD) in US visitors to Mexico.
Methods. Six SNPs located at the promoter, exon, and untranslated regions of CD14 were typed in a prospective cohort study of 1360 visitors to Mexico at risk for TD. Stools from visitors with TD were studied for enteric pathogens by culture, colony hybridization, and polymerase chain reaction. Fecal soluble CD14 (sCD14) was measured in a subgroup of 203 adults with diarrhea and 66 healthy controls by enzyme-linked immunosorbent assay.
Results. The minor allele frequencies for CD14 SNPs were significantly different among the various racial and ethnic groups studied. Two SNPs in the promoter region of CD14 (-159 C > T; rs2569190 and -4191 C > T; rs5744441) were found to be associated with TD in White visitors. The -159 TT genotype was associated with a higher risk for TD (Relative risk [RR], 1.21; 95% confidence interval [CI], 1.05-1.38; P = .008), whereas individuals with the -4191 TT genotype were protected from infection (RR, 0.82; 95% CI, 0.71-0.92; P = .006). Subjects with TD excreted higher levels of fecal CD14 than did healthy controls (33,480 pg/mL vs 6178 pg/mL; P < .02). Fecal sCD14 levels were higher in stool samples from visitors with TD and the -159 TT genotype than they were in visitors with the CC/CT genotypes (P = .02), and stool samples from subjects with the -4191 CC genotype had higher fecal sCD14 levels than did stool samples from visitors with the CT/TT (P = .005) genotype. In a multivariate analysis with haplotypes constructed with the 6 SNPs studied, subjects with the haplotype containing the -159 C and the -4191 T allele were less likely to acquire TD (P = .015).
Conclusions. Our study suggests that CD14 levels increase in response to bacterial diarrhea and that polymorphisms in the CD14 gene influence susceptibility to TD. Intestinal CD14 plays an important role in the innate immune response to enteric pathogens.
C1 [Mohamed, Jamal A.; DuPont, Herbert L.; Flores, Jose; Palur, Himaja; Nair, Parvathy; Okhuysen, Pablo C.] Univ Texas Med Sch Houston, Div Infect Dis, Dept Internal Med, Houston, TX 77030 USA.
[DuPont, Herbert L.; Jiang, Zhi-Dong; Okhuysen, Pablo C.] Univ Texas Sch Publ Hlth Houston, Ctr Infect Dis, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA.
[DuPont, Herbert L.; Okhuysen, Pablo C.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
[DuPont, Herbert L.] St Lukes Episcopal Hosp, Houston, TX 77030 USA.
[Guo, Dongchuan] Div Med Genet UT Hlth, Dept Internal Med, Houston, TX USA.
[Belkind-Gerson, Jaime] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
RP Okhuysen, PC (reprint author), Univ Texas Med Sch Houston, Div Infect Dis, Dept Internal Med, 6431 Fannin St,MSB 2-112, Houston, TX 77030 USA.
EM pablo.c.okhuysen@uth.tmc.edu
OI Okhuysen, Pablo/0000-0002-1596-3411
FU National Institutes of Health [R01 AI54948-01]; University of Texas
Center for Clinical and Translational Sciences of the University of
Texas Medical School at Houston [UL1RR024148]; Salix Pharmaceuticals;
Pfizer; Cubist; Theravance; [DK56338]
FX This work was supported by the National Institutes of Health (R01
AI54948-01 to P. C. O.), the University of Texas Center for Clinical and
Translational Sciences (UL1RR024148) of the University of Texas Medical
School at Houston, and DK56338, which funds the Texas Gulf Coast
Digestive Diseases Center.; P. C. O. has received payments for lectures
and speakers' bureau from Salix Pharmaceuticals, Pfizer, Cubist, and
Theravance and has received payment through his institution for
consultation work with Intercell unrelated to this article. All other
authors: no conflicts.
NR 47
TC 14
Z9 14
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2011
VL 52
IS 11
BP 1332
EP 1341
DI 10.1093/cid/cir228
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 767JZ
UT WOS:000290854200008
PM 21596674
ER
PT J
AU Mayer, KH
Mimiaga, MJ
AF Mayer, Kenneth H.
Mimiaga, Matthew J.
TI Past as Prologue: The Refractory and Evolving HIV Epidemic Among Men Who
Have Sex With Men
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
ID ACTIVE ANTIRETROVIRAL THERAPY; VIRUS TYPE-III; HOMOSEXUAL-MEN; RISK
BEHAVIOR; BISEXUAL MEN; SAN-FRANCISCO; UNITED-STATES; HTLV-III;
INFECTION; GAY
C1 [Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA 02215 USA.
[Mayer, Kenneth H.; Mimiaga, Matthew J.] Brown Univ, Miriam Hosp, Warren Alpert Med Sch, Providence, RI USA.
[Mimiaga, Matthew J.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Mimiaga, Matthew J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Mayer, KH (reprint author), Fenway Hlth, Fenway Inst, 1340 Boylston St, Boston, MA 02215 USA.
EM kenneth_mayer@brown.edu
NR 38
TC 5
Z9 5
U1 2
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2011
VL 52
IS 11
BP 1371
EP 1373
DI 10.1093/cid/cir206
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 767JZ
UT WOS:000290854200014
PM 21596679
ER
PT J
AU McDonald, J
Goldman, RE
O'Brien, A
Ayash, C
Mitchell, K
Marshall, R
Simon, SR
Taveras, EM
AF McDonald, Julia
Goldman, Roberta E.
O'Brien, Ashley
Ayash, Christine
Mitchell, Kathy
Marshall, Richard
Simon, Steven R.
Taveras, Elsie M.
TI Health Information Technology to Guide Pediatric Obesity Management
SO CLINICAL PEDIATRICS
LA English
DT Article
DE obesity treatment; pediatric; guidelines; electronic records; decision
support system
ID ELECTRONIC MEDICAL-RECORD; CHILDHOOD OBESITY; CARE; RECOMMENDATIONS;
TRIAL
AB The purpose of this study was to examine pediatricians' familiarity with expert committee recommendations on the management of childhood obesity and their use of health information technology for obesity-related care. The authors interviewed 35 pediatricians from 17 primary care practices using an electronic health record; immersion crystallization facilitated analysis of the qualitative data. Nearly all pediatricians were unfamiliar with expert recommendations; however, all participants reported using growth charts and providing nutrition and physical activity counseling. Most participants wanted easy access to educational materials they could print for patients. The majority of participants were in favor of an electronic alert to identify obese patients, remind clinicians of current guidelines, and facilitate ordering, believing it would help standardize care. Concerns included "alert fatigue," distraction, and disruption of workflow. Suggestions for future electronic functions included tailored educational materials and physical activity resources customized by patient address.
C1 [McDonald, Julia] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA.
[McDonald, Julia; O'Brien, Ashley; Ayash, Christine; Taveras, Elsie M.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA.
[Goldman, Roberta E.] Brown Univ, Providence, RI 02912 USA.
[Goldman, Roberta E.] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA.
[Mitchell, Kathy; Marshall, Richard] Harvard Vanguard Med Associates, Boston, MA USA.
[Simon, Steven R.] VA Boston Healthcare Syst, Boston, MA USA.
[Simon, Steven R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP McDonald, J (reprint author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,3rd Floor, Boston, MA 02215 USA.
EM Julia_mcdonald@hphc.org
FU American Diabetes Association; Robert Wood Johnson Foundation; U.S.
Department of Health and Human Services, Office of the Assistant
Secretary for Planning and Evaluation
FX The author(s) disclosed receipt of the following financial support for
the research and/or authorship of this article:; This study was
supported in part by grants from the American Diabetes Association, the
Robert Wood Johnson Foundation, and the U.S. Department of Health and
Human Services, Office of the Assistant Secretary for Planning and
Evaluation. The opinions and conclusions expressed herein are solely
those of the author(s) and should not be constructed as representing the
opinions or policy of any agency of the Federal Government.
NR 17
TC 8
Z9 8
U1 2
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0009-9228
J9 CLIN PEDIATR
JI Clin. Pediatr.
PD JUN
PY 2011
VL 50
IS 6
BP 543
EP 549
DI 10.1177/0009922810395131
PG 7
WC Pediatrics
SC Pediatrics
GA 763US
UT WOS:000290585800011
PM 21565885
ER
PT J
AU Pelosi, P
Ferguson, ND
Frutos-Vivar, F
Anzueto, A
Putensen, C
Raymondos, K
Apezteguia, C
Desmery, P
Hurtado, J
Abroug, F
Elizalde, J
Tomicic, V
Cakar, N
Gonzalez, M
Arabi, Y
Moreno, R
Esteban, A
AF Pelosi, Paolo
Ferguson, Niall D.
Frutos-Vivar, Fernando
Anzueto, Antonio
Putensen, Christian
Raymondos, Konstantinos
Apezteguia, Carlos
Desmery, Pablo
Hurtado, Javier
Abroug, Fekri
Elizalde, Jose
Tomicic, Vinko
Cakar, Nahit
Gonzalez, Marco
Arabi, Yaseen
Moreno, Rui
Esteban, Andres
CA Ventila Study Grp
TI Management and outcome of mechanically ventilated neurologic patients
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE mechanical ventilation; stroke; brain trauma; outcome; mortality;
epidemiology
ID TRAUMATIC BRAIN-INJURY; ACUTE LUNG INJURY; ANEURYSMAL SUBARACHNOID
HEMORRHAGE; RESPIRATORY-DISTRESS-SYNDROME; INTENSIVE-CARE-UNIT; SEVERE
HEAD-INJURY; EXTRACRANIAL COMPLICATIONS; INTRACEREBRAL HEMORRHAGE;
MEDICAL COMPLICATIONS; ORGAN DYSFUNCTION
AB Objective: To describe and compare characteristics, ventilatory practices, and associated outcomes among mechanically ventilated patients with different types of brain injury and between neurologic and nonneurologic patients.
Design: Secondary analysis of a prospective, observational, and multicenter study on mechanical ventilation.
Setting: Three hundred forty-nine intensive care units from 23 countries.
Patients: We included 552 mechanically ventilated neurologic patients (362 patients with stroke and 190 patients with brain trauma). For comparison we used a control group of 4,030 mixed patients who were ventilated for nonneurologic reasons.
Interventions: None.
Measurements and Main Results: We collected demographics, ventilatory settings, organ failures, and complications arising during ventilation and outcomes. Multivariate logistic regression analysis was performed with intensive care unit mortality as the dependent variable. At admission, a Glasgow Coma Scale score <= 8 was observed in 68% of the stroke, 77% of the brain trauma, and 29% of the nonneurologic patients. Modes of ventilation and use of a lung-protective strategy within the first week of mechanical ventilation were similar between groups. In comparison with nonneurologic patients, patients with neurologic disease developed fewer complications over the course of mechanical ventilation with the exception of a higher rate of ventilator-associated pneumonia in the brain trauma cohort. Neurologic patients showed higher rates of tracheotomy and longer duration of mechanical ventilation. Mortality in the intensive care unit was significantly (p <.001) higher in patients with stroke (45%) than in brain trauma (29%) and nonneurologic disease (30%). Factors associated with mortality were: stroke (in comparison to brain trauma), Glasgow Coma Scale score on day 1, and severity at admission in the intensive care unit.
Conclusions: In our study, one of every five mechanically ventilated patients received this therapy as a result of a neurologic disease. This cohort of patients showed a higher mortality rate than nonneurologic patients despite a lower incidence of extracerebral organ dysfunction. (Crit Care Med 2011; 39: 1482-1492)
C1 [Pelosi, Paolo] Univ Genoa, Dipartimento Sci Chirurg Diagnost Integrate, Genoa, Italy.
[Ferguson, Niall D.] Univ Hlth Network, Interdept Div Crit Care Med, Toronto, ON, Canada.
[Ferguson, Niall D.] Univ Hlth Network, Dept Med, Div Respirol, Toronto, ON, Canada.
[Ferguson, Niall D.] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Frutos-Vivar, Fernando; Esteban, Andres] Hosp Univ Getafe, Madrid, Spain.
[Frutos-Vivar, Fernando; Esteban, Andres] CIBER Enfermedades Resp, Madrid, Spain.
[Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Putensen, Christian] Univ Bonn, Dept Anesthesiol & Intens Care Med, D-5300 Bonn, Germany.
[Raymondos, Konstantinos] Hannover Med Sch, D-30623 Hannover, Germany.
[Apezteguia, Carlos] Hosp Prof A Posadas, Buenos Aires, DF, Argentina.
[Desmery, Pablo] Sanat Mitre, Buenos Aires, DF, Argentina.
[Hurtado, Javier] Hosp Clin Montevideo, Montevideo, Uruguay.
[Elizalde, Jose] Hosp ABC, Mexico City, DF, Mexico.
[Tomicic, Vinko] Clin Las Lilas, Santiago, Chile.
[Cakar, Nahit] Istanbul Fac Med, Istanbul, Turkey.
[Gonzalez, Marco] Clin Medellin, Medellin, Colombia.
[Gonzalez, Marco] Univ Pontificia Bolivariana, Medellin, Colombia.
[Arabi, Yaseen] King Abdul Aziz Med City, Riyadh, Saudi Arabia.
[Moreno, Rui] Hosp Santo Antonio Capuchos, Lisbon, Portugal.
RP Pelosi, P (reprint author), Univ Genoa, Dipartimento Sci Chirurg Diagnost Integrate, Genoa, Italy.
EM aesteban@ucigetafe.com
RI Pesenti, Antonio/H-7483-2012; koca, ugur/F-1265-2016; Malbrain,
Manu/B-3680-2017;
OI koca, ugur/0000-0002-2949-4265; Malbrain, Manu/0000-0002-1816-5255;
Severgnini, Paolo/0000-0001-8027-0059; Frutos-Vivar,
Fernando/0000-0002-4648-9636; Ost, David/0000-0001-6351-5552; Ferguson,
Niall/0000-0002-6213-5264; CHIUMELLO, DAVIDE ALBERTO/0000-0001-9260-3930
FU CIBER; Instituto de Salud Carlos III, Spain; Canadian Institutes of
Health Research New Investigator Award (Ottawa, Canada)
FX Funded by CIBER Enfermedades Respiratorias from Instituto de Salud
Carlos III, Spain.; N.D.F. is supported by a Canadian Institutes of
Health Research New Investigator Award (Ottawa, Canada). The remaining
authors have not disclosed any potential conflicts of interest.
NR 43
TC 34
Z9 38
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD JUN
PY 2011
VL 39
IS 6
BP 1482
EP 1492
DI 10.1097/CCM.0b013e31821209a8
PG 11
WC Critical Care Medicine
SC General & Internal Medicine
GA 765NM
UT WOS:000290715000036
PM 21378554
ER
PT J
AU Telander, DG
Morales, SA
Mareninov, S
Forward, K
Gordon, LK
AF Telander, David G.
Morales, Shawn A.
Mareninov, Sergey
Forward, Krisztina
Gordon, Lynn K.
TI Epithelial Membrane Protein-2 (EMP2) and Experimental Proliferative
Vitreoretinopathy (PVR)
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Epithelial membrane protein 2; Fibrosis; Integrin regulation;
Proliferative vitreoretinopathy; Retina; Rhegmatogenous retinal
detachment; Retinal pigment epithelium; Therapy; Vitreous membranes
ID EXPERIMENTAL RETINAL-DETACHMENT; COLLAGEN GEL CONTRACTION; MESENCHYMAL
TRANSITION; SURFACE EXPRESSION; EXPERIMENTAL-MODEL; CELL-DEATH; PATHWAY;
ALKYLPHOSPHOCHOLINES; ACTIVATION; SILICONE
AB Purpose: Proliferative vitreoretinopathy (PVR) is believed to result in part from de-differentiation of retinal pigment epithelium (RPE) with cellular migration in the vitreous cavity, membrane formation, and contraction in an aberrant wound-healing strategy. In an in vitro collagen-gel contraction assay, epithelial membrane protein 2 (EMP2) controls contraction through activation of focal adhesion kinase (FAK) in a RPE cell line (ARPE-19). The purpose of this study was to investigate how blocking or altering the level of EMP2 expression changed clinical PVR in an in vivo model.
Methods: Using the ARPE-19 cell line, the levels of EMP2 modulated through stable transfections of an EMP2 overexpressing construct, EMP2 ribozyme, or vector alone. These transfected cell lines were used in a rabbit model of PVR. The severity of PVR was classified by two masked observers. An EMP2 blocking antibody was also used to decrease functional EMP2 in the PVR model. Immunohistochemistry was used to evaluate EMP2 expression in vivo.
Results: The transfectants with lower levels of EMP2 had significantly less PVR severity than the degree of PVR induced by wild-type cells (p = 0.05). Also, the transfectants with a low-level of EMP2 expression showed a strong trend of less PVR severity than the high-levels EMP2 transfectants (p = 0.06). Blocking EMP2 with a specific polyclonal antibody significantly decreased the level of PVR severity (p = 0.02). PVR membranes were found to be positive for EMP2 expression.
Conclusions: These in vivo studies support a direct correlation between EMP2 expression and severity of PVR. These results validate the potential for controlling RPE biology through a change in EMP2 expression, and provide a potential therapeutic target for this disease.
C1 [Telander, David G.; Forward, Krisztina] Univ Calif Davis, Dept Ophthalmol, Sacramento, CA 95817 USA.
[Morales, Shawn A.; Gordon, Lynn K.] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Mareninov, Sergey] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Gordon, Lynn K.] Greater Los Angeles VA Healthcare syst, Los Angeles, CA USA.
RP Telander, DG (reprint author), UC Davis, Retina Div, Dept Ophthalmol & Visual Sci, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM dgtelander@ucdavis.edu
FU Research to Prevent Blindness; Foundation Fighting Blindness; Veterans
Administration; NIH NEI [1R01EY019909-01A1]
FX The authors acknowledge support via unrestricted departmental funds from
Research to Prevent Blindness, Foundation Fighting Blindness (DGT), and
a Veterans Administration Merit Grant (LKG). NIH NEI R01 Grant Number:
1R01EY019909-01A1.
NR 34
TC 8
Z9 8
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUN
PY 2011
VL 36
IS 6
BP 546
EP 552
DI 10.3109/02713683.2011.561468
PG 7
WC Ophthalmology
SC Ophthalmology
GA 765SE
UT WOS:000290728100008
PM 21591864
ER
PT J
AU Signorovitch, JE
Wu, EQ
Betts, KA
Parikh, K
Kantor, E
Guo, A
Bollu, VK
Williams, D
Wei, LJ
DeAngelo, DJ
AF Signorovitch, James E.
Wu, Eric Q.
Betts, Keith A.
Parikh, Kejal
Kantor, Evan
Guo, Amy
Bollu, Vamsi K.
Williams, Denise
Wei, L. J.
DeAngelo, Daniel J.
TI Comparative efficacy of nilotinib and dasatinib in newly diagnosed
chronic myeloid leukemia: a matching-adjusted indirect comparison of
randomized trials
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE CML; Nilotinib; Dasatinib; Efficacy; Matching-adjusted indirect
comparison
ID CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITOR; LOW-DOSE
CYTARABINE; MOLECULAR RESPONSES; IMATINIB MESYLATE; INTERFERON
AB Objective:
Nilotinib and dasatinib have not been directly compared in a randomized trial for the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase (CML-CP). The purpose of this study was to indirectly compare rates of major molecular response (MMR), progression-free survival (PFS) and overall survival by month 12 with nilotinib and dasatinib treatment of newly diagnosed CML-CP.
Methods:
Individual patient data from a randomized trial of nilotinib vs. imatinib (ENESTnd) and published summary data from a separate randomized trial of dasatinib vs. imatinib (DASISION) were utilized. A matching-adjusted indirect comparison was conducted by weighting individual patients treated with nilotinib to match baseline characteristics reported for dasatinib-treated patients, including age, gender, ECOG performance status and hematology lab values. After matching, efficacy outcomes were compared for patients treated with nilotinib 300 mg twice daily vs. dasatinib 100 mg once daily. Patients randomized to imatinib 400 mg once daily in each trial were used to assess the adequacy of the matching.
Results:
Before matching, patients randomized to nilotinib in ENESTnd (n = 273) were older, with a lower median platelet count and more favorable performance status compared to patients randomized to dasatinib in DASISION (n = 259). After matching, all baseline characteristics were balanced across treatment groups. Matched patients treated with nilotinib vs. dasatinib experienced significantly higher rates of MMR (56.8 vs. 45.9%, p = 0.014) and overall survival (99.5 vs. 97.3%, p = 0.046) and numerically higher rates of PFS (98.8 vs. 96.5%). Matched imatinib arms showed no statistically significant or clinically meaningful differences in these outcomes.
Limitations:
Baseline measures unavailable in one or both trials could not be matched. Adverse event rates were not formally compared across trials due to differences in reporting.
Conclusion:
Nilotinib was associated with significantly higher rates of MMR and overall survival compared with dasatinib by month 12 in the treatment of newly diagnosed CML-CP.
C1 [Signorovitch, James E.; Wu, Eric Q.; Betts, Keith A.; Parikh, Kejal; Kantor, Evan] Anal Grp Inc, Boston, MA 02199 USA.
[Guo, Amy; Bollu, Vamsi K.; Williams, Denise] Novartis Pharmaceut, E Hanover, NJ USA.
[Wei, L. J.] Harvard Univ, Boston, MA 02115 USA.
[DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Signorovitch, JE (reprint author), Anal Grp Inc, 111 Huntington Ave,10th Floor, Boston, MA 02199 USA.
EM jsignorovitch@analysisgroup.com
OI Betts, Keith/0000-0002-3088-7453
FU Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Novartis
Pharmaceuticals Corporation
FX Research was funded by Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA.; J.E.S., E. Q. W., K. A. B., K. P. and E. K. have
disclosed that they are employees of Analysis Group, Inc., a company
that received funding from Novartis Pharmaceuticals Corporation to
conduct this study. A. G., V. K. B. and D. W. have disclosed that they
are employees of Novartis Pharmaceuticals Corporation. D.J.D. is a
member of a scientific advisory board with Novartis. L.J.W. is on
various Data Monitoring Boards for Novartis clinical studies and is a
statistical consultant for Novartis. He is also a consultant for Merck,
J&J, GSK, Amgen, Roche, Pfizer, Alkermes and Genzyme.
NR 18
TC 20
Z9 22
U1 2
U2 9
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0300-7995
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JUN
PY 2011
VL 27
IS 6
BP 1263
EP 1271
DI 10.1185/03007995.2011.576238
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 764YY
UT WOS:000290671800019
PM 21524239
ER
PT J
AU Song, C
Milbury, CA
Li, J
Liu, PF
Zhao, MP
Makrigiorgos, GM
AF Song, Chen
Milbury, Coren A.
Li, Jin
Liu, Pingfang
Zhao, Meiping
Makrigiorgos, Gerasimos Mike
TI Rapid and Sensitive Detection of KRAS Mutation After fast-COLD-PCR
Enrichment and High-resolution Melting Analysis
SO DIAGNOSTIC MOLECULAR PATHOLOGY
LA English
DT Article
DE COLD-PCR; HRM; KRAS; lung adenocarcinoma; mutation detection
ID CELL LUNG-CANCER; COLORECTAL-CANCER; SIGNAL GENERATION; SOMATIC
MUTATION; RAS MUTATIONS; DNA; HETEROGENEITY; EGFR; IDENTIFICATION;
METASTASES
AB KRAS mutations exhibit significant predictive and prognostic value in cancer. Efficient, sensitive, and accurate molecular approaches are required to evaluate KRAS mutation status, even when mutant alleles are restricted to a small portion of a clinical sample, which otherwise contains wild-type alleles. We describe a highly sensitive method to detect KRAS mutations by high-resolution melting (HRM) analysis after mutation enrichment by fast-COLDpolymerase chain reaction (PCR). Using 10 ng of starting DNA and after fast-COLD-PCR of a 76-bp region containing KRAS codons 12 and 13; the amplicons undergo a nested conventional PCR reaction followed by HRM analysis. Samples exhibiting aberrant melting profiles are sequenced to identify mutation type and position. Serial dilution experiments indicate a sensitivity of approximately 0.3% mutant-to-wild type for HRM-based mutation detection and the ability to directly sequence mutation-containing samples. A number of lung adenocarcinoma specimens earlier characterized were screened. Fast-COLD-PCR-HRM analysis correctly identified KRAS mutations and also showed a previously undetected, low-level missense GGT > TTT complex mutation. On account of the short target regions and low requirement of starting DNA, this rapid, cost-effective, and sensitive fast-COLD-PCR-HRM approach is expected to find broad application for detecting low-abundance KRAS mutations in a wide range of clinical specimens.
C1 [Song, Chen; Milbury, Coren A.; Li, Jin; Liu, Pingfang; Makrigiorgos, Gerasimos Mike] Harvard Univ, Brigham & Womens Hosp, WDivis Genome Stabil & DNA Repair, Dana Farber Brigham & Womens Canc Ctr,Sch Med, Boston, MA 02115 USA.
[Song, Chen; Milbury, Coren A.; Li, Jin; Liu, Pingfang; Makrigiorgos, Gerasimos Mike] Harvard Univ, Sch Med, Dept Radiat Oncol, Div Med Phys & Biophys, Boston, MA 02115 USA.
[Song, Chen; Zhao, Meiping] Peking Univ, Coll Chem & Mol Engn, Minist Educ, BNLMS,Key Lab Bioorgan Chem & Mol Engn, Beijing 100871, Peoples R China.
RP Makrigiorgos, GM (reprint author), Harvard Univ, Brigham & Womens Hosp, WDivis Genome Stabil & DNA Repair, Dana Farber Brigham & Womens Canc Ctr,Sch Med, Level L2,75 Francis St, Boston, MA 02115 USA.
EM mmakrigiorgos@partners.org
RI Song, Chen/H-6615-2015
OI Song, Chen/0000-0002-4439-4377
FU NCI [T32-CA009078]; China Scholarship Council CSC [2009601213]; JCRT
Foundation; NIH [CA-138280, CA-111994]
FX Supported by T32-CA009078 from the NCI (C. M.), by a student grant from
the China Scholarship Council CSC 2009601213 (C. S.), by the JCRT
Foundation (J.L.), and by NIH grants CA-138280 and CA-111994. The
contents of this study are the responsibility of the authors and do not
necessarily represent the official views of the NIH.
NR 44
TC 14
Z9 17
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1052-9551
J9 DIAGN MOL PATHOL
JI Diagn. Mol. Pathol.
PD JUN
PY 2011
VL 20
IS 2
BP 81
EP 89
DI 10.1097/PDM.0b013e3181fde92f
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Pathology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Pathology
GA 764VI
UT WOS:000290662100003
PM 21532494
ER
PT J
AU Jacobson, BC
Giovannucci, EL
Fuchs, CS
AF Jacobson, Brian C.
Giovannucci, Edward L.
Fuchs, Charles S.
TI Smoking and Barrett's Esophagus in Women Who Undergo Upper Endoscopy
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Barrett's esophagus; Smoking; Cigarettes; Gastroesophageal reflux; GERD
ID GASTROESOPHAGEAL-REFLUX DISEASE; BODY-MASS INDEX; RISK-FACTORS; GASTRIC
CARDIA; CIGARETTE-SMOKING; UNITED-STATES; ESOPHAGOGASTRIC JUNCTION;
INCREASING INCIDENCE; GENERAL-POPULATION; CANCER-RISK
AB Background Cigarette use is associated with esophageal adenocarcinoma, and cross-sectional studies suggest an association between smoking and Barrett's esophagus.
Aims We sought to examine prospectively the effect of smoking on the risk for Barrett's esophagus.
Methods This was a prospective cohort study among 20,863 women within the Nurses' Health Study who underwent upper gastrointestinal endoscopy for any reason between 1980 and 2006. We assessed the association between smoking and pathologically-confirmed Barrett's esophagus (n = 377). Self-reported data on smoking and potential confounding variables were collected from biennial questionnaires.
Results Compared with women who never smoked, former smokers of 1-24 cigarettes/day had a multivariate odds ratio for Barrett's esophagus of 1.25 (95% CI 0.99-1.59), former smokers of a parts per thousand yen25 cigarettes/day had a multivariate odds ratio of 1.52 (95% CI 1.04-2.22), current smokers of 1-24 cigarettes/day had a multivariate odds ratio of 0.89 (95% CI 0.54-1.45), and current smokers of a parts per thousand yen25 cigarettes/day had a multivariate odds ratio of 0.92 (95% CI 0.34-2.54). The risk for Barrett's esophagus increased significantly with increasing pack-years smoked among former (P = 0.008) but not current smokers (P = 0.99), especially when considering exposure a parts per thousand yen25 years before index endoscopy. Results were similar among women reporting regular heartburn/acid-reflux one or more times a week, and were not accounted for by changes in weight.
Conclusions Heavy, remote smoking is associated with an increased risk for Barrett's esophagus. This finding suggests a long latency period between exposure and development of the disease, even after discontinuation of smoking.
C1 [Jacobson, Brian C.] Boston Univ, Med Ctr, Dept Med, Gastroenterol Sect, Boston, MA 02118 USA.
[Jacobson, Brian C.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Fuchs, Charles S.] Dana Farber & Harvard Canc Ctr, Canc Epidemiol Program, Boston, MA USA.
[Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Giovannucci, Edward L.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Giovannucci, Edward L.; Fuchs, Charles S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Jacobson, BC (reprint author), Boston Univ, Med Ctr, Dept Med, Gastroenterol Sect, 85 E Concord St,Room 7721, Boston, MA 02118 USA.
EM brian.jacobson@bmc.org
OI Jacobson, Brian/0000-0001-7064-2357
FU National Cancer Institute [CA087969]; National Institutes of Diabetes
and Digestive and Kidney Diseases [RO1DK088782]
FX The Nurses' Health Study is funded by the National Cancer Institute
program project grant CA087969. Dr Jacobson was funded by a grant from
the National Institutes of Diabetes and Digestive and Kidney Diseases
(RO1DK088782). None of the authors has any other financial disclosures.
NR 73
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD JUN
PY 2011
VL 56
IS 6
BP 1707
EP 1717
DI 10.1007/s10620-011-1672-4
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 766HF
UT WOS:000290770900017
PM 21448698
ER
PT J
AU Michalek, W
Semler, JR
Kuo, B
AF Michalek, Whitney
Semler, John R.
Kuo, Braden
TI Impact of Acid Suppression on Upper Gastrointestinal pH and Motility
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Stomach and duodenum; Gastric emptying; Motility; Acidity (intragastric)
ID GASTROESOPHAGEAL-REFLUX DISEASE; HEIDELBERG CAPSULE; SCINTIGRAPHY;
PANTOPRAZOLE; OMEPRAZOLE; THERAPY; TRANSIT; HEALTHY
AB Background Proton pump inhibitors (PPIs), widely prescribed to patients with upper gastrointestinal symptoms, alter intragastric pH, and may affect upper gastrointestinal transit and motility parameters in addition to affecting the ability to determine Wireless Motility Capsule (WMC) gastric emptying time.
Aim To assess PPI effect on motility parameters of the upper gastrointestinal tract and to determine if PPIs confound ability of WMC to measure gastric emptying time.
Methods Twenty healthy subjects were treated with esomeprazole 40 mg bid for 1 week. Another 50 healthy subjects underwent evaluation in absence of PPIs. All subjects underwent WMC test after meal ingestion. After a rapid, sustained luminal pH rise a parts per thousand yen 0.5 pH units, marking potential gastric emptying time of WMC, an abdominal X-ray (KUB) was taken for gastric emptying time confirmation. Mean pH, pressure and transit time were compared between PPI-treated and untreated groups.
Results There was no difference in gastric emptying time, small bowel transit time (SBTT), or pressure profiles between the groups. The pH in all cases rose a parts per thousand yen 0.5 pH units. Distal small bowel pH was significantly lower in subjects on PPIs. Gastric emptying time was identified in all subjects treated with PPIs. Pressure and slope criteria were developed to confirm the time of emptying.
Conclusion PPI therapy does not have a significant impact on upper gastrointestinal transit and motility but it does decrease distal small bowel pH. The medication reduced the magnitude of pH change at gastric emptying time but using additional criteria based on slope and contraction frequency, WMC was able to measure gastric emptying time in all patients treated with PPIs.
C1 [Michalek, Whitney; Kuo, Braden] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Semler, John R.] SmartPill Corp, Buffalo, NY 14203 USA.
RP Kuo, B (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRJ 274, Boston, MA 02114 USA.
EM wmichalek@partners.org; jrsemeler@smartpillcorp.com; bkuo@partners.org
FU The Smart Pill Corporation [208598]; National Institute of Health
[218969]; International Foundation for Functional Gastrointestinal
Disorders
FX This study was funded in part by The Smart Pill Corporation, grant
number 208598, also in part by the National Institute of Health, grant
number 218969, and International Foundation for Functional
Gastrointestinal Disorders.
NR 22
TC 16
Z9 17
U1 1
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD JUN
PY 2011
VL 56
IS 6
BP 1735
EP 1742
DI 10.1007/s10620-010-1479-8
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 766HF
UT WOS:000290770900021
PM 21086166
ER
PT J
AU Jessup, JA
Zhang, LL
Presley, TD
Kim-Shapiro, DB
Wang, H
Chen, AF
Groban, L
AF Jessup, Jewell A.
Zhang, Lili
Presley, Tennille D.
Kim-Shapiro, Daniel B.
Wang, Hao
Chen, Alex F.
Groban, Leanne
TI Tetrahydrobiopterin Restores Diastolic Function and Attenuates
Superoxide Production in Ovariectomized mRen2.Lewis Rats
SO ENDOCRINOLOGY
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; PREVENTS ENDOTHELIAL DYSFUNCTION; MYOCARDIAL
REPERFUSION INJURY; LEFT-VENTRICULAR HYPERTROPHY; ESTROGEN-RECEPTOR
SUBTYPES; HEART-FAILURE; OXIDATIVE STRESS; 17-BETA-ESTRADIOL
ANTAGONIZES; VASCULAR TETRAHYDROBIOPTERIN; POSTMENOPAUSAL WOMEN
AB After oophorectomy, mRen2.Lewis rats exhibit diastolic dysfunction associated with elevated superoxide, increased cardiac neuronal nitric oxide synthase (nNOS) expression, and diminished myocardial tetrahydrobiopterin (BH4) content, effects that are attenuated with selective nNOS inhibition. BH4 is an essential cofactor of nNOS catalytic activity leading to nitric oxide production. Therefore, we assessed the effect of 4wk BH4 supplementation on diastolic function and left ventricular (LV) remodeling in oophorectomized mRen2.Lewis rats compared with sham-operated controls. Female mRen2.Lewis rats underwent either bilateral ovariectomy (OVX) (n = 19) or sham operation (n = 13) at 4wk of age. Beginning at 11 wk of age, OVX rats were randomized to receive either BH4 (10 mg/kg.d) or saline, whereas the sham rats received saline via sc mini-pumps. Loss of ovarian hormones reduced cardiac BH4 when compared with control hearts; this was associated with impaired myocardial relaxation, augmented filling pressures, increased collagen deposition, and thickened LV walls. Additionally, superoxide production increased and nitric oxide decreased in hearts from OVX compared with sham rats. Chronic BH4 supplementation after OVX improved diastolic function and attenuated LV remodeling while restoring myocardial nitric oxide release and preventing reactive oxygen species generation. These data indicate that BH4 supplementation protects against the adverse effects of ovarian hormonal loss on diastolic function and cardiac structure in mRen2.Lewis rats by restoring myocardial NO release and mitigating myocardial O-2(-) generation. Whether BH4 supplementation is a therapeutic option for the management of diastolic dysfunction in postmenopausal women will require direct testing in humans. (Endocrinology 152: 2428-2436, 2011)
C1 [Wang, Hao; Groban, Leanne] Wake Forest Univ, Dept Anesthesiol, Sch Med, Winston Salem, NC 27157 USA.
[Jessup, Jewell A.; Groban, Leanne] Wake Forest Univ, Dept Physiol, Sch Med, Winston Salem, NC 27157 USA.
[Jessup, Jewell A.; Groban, Leanne] Wake Forest Univ, Dept Pharmacol, Sch Med, Winston Salem, NC 27157 USA.
[Zhang, Lili; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15206 USA.
Vet Affairs Pittsburgh Healthcare Syst, Vasc Surg Res, Pittsburgh, PA 15206 USA.
[Presley, Tennille D.; Kim-Shapiro, Daniel B.] Wake Forest Univ, Dept Phys, Winston Salem, NC 27106 USA.
[Presley, Tennille D.; Kim-Shapiro, Daniel B.] Wake Forest Univ, Translat Sci Ctr, Winston Salem, NC 27106 USA.
RP Groban, L (reprint author), Wake Forest Univ, Dept Anesthesiol, Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM lgroban@wfubmc.edu
FU National Institutes of Health [R01-AG033727-01, KO8-AG026764-05,
HL-058091, R01 GM077352, 2PO1 HL-051952]; American Heart Association
[0855601GH]
FX This work was supported by grants from the National Institutes of Health
R01-AG033727-01 (to L.G.), KO8-AG026764-05 Paul Beeson award (to L.G.),
HL-058091 (to D.B.K.-S.), R01 GM077352 (to A.F.C.), 2PO1 HL-051952 (to
C.M. Ferrario), and American Heart Association Grant-in-Aid 0855601GH
(to A.F.C.). Support was limited to funding.
NR 58
TC 11
Z9 12
U1 0
U2 3
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD JUN
PY 2011
VL 152
IS 6
BP 2428
EP 2436
DI 10.1210/en.2011-0061
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 766MY
UT WOS:000290788500029
PM 21427216
ER
PT J
AU Kreuziger, LMB
Wolanskyj, AP
Hanson, CA
Steensma, DP
AF Kreuziger, Lisa M. Baumann
Wolanskyj, Alexandra P.
Hanson, Curtis A.
Steensma, David P.
TI Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired
idiopathic sideroblastic anaemia, including refractory anaemia with ring
sideroblasts
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE pyridoxine; vitamin B6; sideroblastic anaemia; myelodysplastic syndrome;
refractory anaemia with ring sideroblasts
ID WORLD-HEALTH-ORGANIZATION; MYELODYSPLASTIC SYNDROMES; CLASSIFICATION;
ANAEMIA; MUTATION
AB Pyridoxine, or vitamin B6, is commonly used to treat acquired idiopathic sideroblastic anaemia (AISA, including refractory anaemia with ring sideroblasts), but the efficacy of this therapy in an unselected AISA population (i.e. patients without confirmed ALAS2 or other pyridoxine-responsive germline mutations) has not been established. We reviewed clinical data from 231 patients with AISA and found that 42% of 203 evaluable patients had been treated with pyridoxine. Only 6.8% of pyridoxine-treated patients experienced a haemoglobin improvement (>= 1.5 g/dL) meeting 2006 International Working Group for Myelodysplastic Syndromes standardised response criteria. As some patients received combination therapy with erythropoietin or other agents, improvement could be attributed to pyridoxine monotherapy in only one patient (1.4%). Smaller, less meaningful increments in haemoglobin levels of 0.5 g/dL were observed in 13.5% of patients. Response to therapy did not correlate with International Prognostic Scoring System (IPSS) risk group or multilineage vs unilineage dysplasia. New symptomatic peripheral neuropathy was noted in 2.3% of patients treated with pyridoxine. In this large series of unselected patients with sideroblastic anaemia, pyridoxine therapy was ineffective and was associated with a risk of adverse effects. Pyridoxine therapy should be reserved for patients with known or suspected pyridoxine-responsive mutations.
C1 [Steensma, David P.] Harvard Univ, Dana Farber Canc Inst, Div Hematol Oncol, Sch Med, Boston, MA 02115 USA.
[Kreuziger, Lisa M. Baumann; Wolanskyj, Alexandra P.; Hanson, Curtis A.] Mayo Clin, Rochester, MN USA.
[Kreuziger, Lisa M. Baumann] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
RP Steensma, DP (reprint author), Harvard Univ, Dana Farber Canc Inst, Div Hematol Oncol, Sch Med, 44 Binney St,Suite D1B30, Boston, MA 02115 USA.
EM David_Steensma@dfci.harvard.edu
OI Steensma, David/0000-0001-5130-9284; Baumann Kreuziger,
Lisa/0000-0002-1171-0548
FU Robert A. Kyle Hematologic Malignancies Fund
FX We thank Darrell Schroeder for advice regarding statistical analysis.
This study was funded by a grant from the Robert A. Kyle Hematologic
Malignancies Fund.
NR 20
TC 2
Z9 2
U1 2
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0902-4441
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD JUN
PY 2011
VL 86
IS 6
BP 512
EP 516
DI 10.1111/j.1600-0609.2011.01604.x
PG 5
WC Hematology
SC Hematology
GA 765TH
UT WOS:000290731000009
ER
PT J
AU Benzer, JK
Young, G
Stolzmann, K
Osatuke, K
Meterko, M
Caso, A
White, B
Mohr, DC
AF Benzer, Justin K.
Young, Gary
Stolzmann, Kelly
Osatuke, Katerine
Meterko, Mark
Caso, Allison
White, Bert
Mohr, David C.
TI The Relationship between Organizational Climate and Quality of Chronic
Disease Management
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Organizational climate; primary care; diabetes; organizational context
ID PRIMARY-CARE; HEALTH-CARE; CHRONIC ILLNESS; PSYCHOLOGICAL CLIMATE;
GROUP-PERFORMANCE; OUTCOMES; IMPROVE; PERCEPTIONS; BEHAVIOR;
INTERDEPENDENCE
AB Objective
To test the utility of a two-dimensional model of organizational climate for explaining variation in diabetes care between primary care clinics.
Data Sources/Study Setting
Secondary data were obtained from 223 primary care clinics in the Department of Veterans Affairs health care system.
Study Design
Organizational climate was defined using the dimensions of task and relational climate. The association between primary care organizational climate and diabetes processes and intermediate outcomes were estimated for 4,539 patients in a cross-sectional study.
Data Collection/Extraction Methods
All data were collected from administrative datasets. The climate data were drawn from the 2007 VA All Employee Survey, and the outcomes data were collected as part of the VA External Peer Review Program. Climate data were aggregated to the facility level of analysis and merged with patient-level data.
Principal Findings
Relational climate was related to an increased likelihood of diabetes care process adherence, with significant but small effects for adherence to intermediate outcomes. Task climate was generally not shown to be related to adherence.
Conclusions
The role of relational climate in predicting the quality of chronic care was supported. Future research should examine the mediators and moderators of relational climate and further investigate task climate.
C1 [Benzer, Justin K.] VA Boston Healthcare Syst 152M, Ctr Org Leadership & Management Res COLMR, Boston, MA 02130 USA.
[Young, Gary; Stolzmann, Kelly; Meterko, Mark; White, Bert; Mohr, David C.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res COLMR, Boston, MA 02130 USA.
[Young, Gary] Northeastern Univ, Ctr Hlth Policy & Healthcare Res, Boston, MA 02115 USA.
[Meterko, Mark; Mohr, David C.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Osatuke, Katerine] Natl Ctr Org Dev, Vet Hlth Adm, Cincinnati, OH USA.
RP Benzer, JK (reprint author), VA Boston Healthcare Syst 152M, Ctr Org Leadership & Management Res COLMR, 150 S Huntington Ave, Boston, MA 02130 USA.
EM justin.benzer@va.gov
OI Benzer, Justin/0000-0001-5151-2127
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development [IIR 05-221]; VA Office of Academic
Affiliations HSRD; Robert Wood Johnson Foundation
FX This material is based upon work supported by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development (IIR 05-221). The views expressed in this article are those
of the authors and do not necessarily reflect the position or policy of
the Department of Veterans Affairs or the United States Government.
Financial support was provided in part from a VA Office of Academic
Affiliations HSR&D postdoctoral fellowship and a Robert Wood Johnson
Foundation Investigator Award in Health Policy Research. An earlier
version of this manuscript was presented at the 2010 Academy of
Management Annual Meeting. The authors acknowledge the intellectual and
editorial contributions of James Burgess and Mark Bauer. No conflicts of
interest influenced this manuscript. Disclosures: None. Disclaimers:
None.
NR 60
TC 12
Z9 13
U1 4
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD JUN
PY 2011
VL 46
IS 3
BP 691
EP 711
DI 10.1111/j.1475-6773.2010.01227.x
PG 21
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 758NN
UT WOS:000290171600002
PM 21210799
ER
PT J
AU Zheng, H
Zhang, W
Ayanian, JZ
Zaborski, LB
Zaslavsky, AM
AF Zheng, Hui
Zhang, Wei
Ayanian, John Z.
Zaborski, Lawrence B.
Zaslavsky, Alan M.
TI Profiling Hospitals by Survival of Patients with Colorectal Cancer
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Cancer care; colorectal cancer; provider profiling; quality measurement;
Bayesian inference
ID SHORT-TERM MORTALITY; RECTAL-CANCER; COLON-CANCER; QUALITY; CARE;
SURGERY; PERFORMANCE; VOLUME; RATES; INFORMATION
AB Objective
To profile hospitals by survival rates of colorectal cancer patients in multiple periods after initial treatment.
Data Sources
California Cancer Registry data from 50,544 patients receiving primary surgery with curative intent for stage I-III colorectal cancer in 1994-1998, supplemented with hospital discharge abstracts.
Study Design
We estimated a single Bayesian hierarchical model to quantify associations of survival to 30 days, 30 days to 1 year, and 1-5 years by hospital, adjusted for patient age, sex, race, stage, tumor site, and comorbidities. We compared two profiling methods for 30-day survival and four longer-term profiling methods by the fractions of hospitals with demonstrably superior survival profiles and of hospital pairs whose relative standings could be established confidently.
Principal Findings
Interperiod correlation coefficients of the random effects are (95 percent credible interval 0.27, 0.85), (0.20, 0.76), and (0.19, 0.82). The three-period model ranks 5.4 percent of pairwise comparisons by 30-day survival with at least 95 percent confidence, versus 3.3 percent of pairs using a single-period model, and 15-20 percent by weighted multiperiod methods.
Conclusions
The quality of care for colorectal cancer provided by a hospital system is somewhat consistent across the immediate postoperative and long-term follow-up periods. Combining mortality profiles across longer periods may improve the statistical reliability of outcome comparisons.
C1 [Ayanian, John Z.; Zaborski, Lawrence B.; Zaslavsky, Alan M.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Zheng, Hui] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Zhang, Wei] China Europe Int Business Sch, Beijing, Peoples R China.
RP Zaslavsky, AM (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM zaslavsk@hcp.med.harvard.edu
FU Agency for Healthcare Research and Quality [R01 HS09869, U01 CA93324];
National Cancer Institute
FX This study was supported by grants R01 HS09869 and U01 CA93324 from the
Agency for Healthcare Research and Quality and the National Cancer
Institute. The authors are grateful to William E. Wright, Ph.D., and
Mark E. Allen, M.S., for facilitating access to California Cancer
Registry data; to Craig Earle, M.D., for insightful comments; and to
Robert Wolf, M.S., for data preparation.
NR 34
TC 6
Z9 7
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD JUN
PY 2011
VL 46
IS 3
BP 729
EP 746
DI 10.1111/j.1475-6773.2010.01222.x
PG 18
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 758NN
UT WOS:000290171600004
PM 21210794
ER
PT J
AU Boscoe, FP
Schrag, D
Chen, K
Roohan, PJ
Schymura, MJ
AF Boscoe, Francis P.
Schrag, Deborah
Chen, Kun
Roohan, Patrick J.
Schymura, Maria J.
TI Building Capacity to Assess Cancer Care in the Medicaid Population in
New York State
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Data linkage; cancer registration; Medicaid; economically disadvantaged
populations
ID SOCIOECONOMIC-STATUS; ELDERLY POPULATION; COLORECTAL-CANCER;
TUMOR-REGISTRY; DISPARITIES; DIAGNOSIS; SURVIVAL; STAGE; MORTALITY
AB Objective
To link data from a central cancer registry with Medicaid enrollment and claims files in order to assess cancer care in an economically disadvantaged population.
Data Sources
Over 500,000 cancer patients diagnosed between 2002 and 2006 reported to the New York State Cancer Registry were linked with New York State Medicaid enrollment and claims records.
Study Design
A probabilistic linkage was performed between the two data sources. The resulting Medicaid and non-Medicaid populations were compared in terms of demographics and stage at diagnosis.
Data Collection Methods
Existing databases were used.
Principal Findings
One-quarter of cancer patients were enrolled in Medicaid at or near the time of cancer diagnosis. The Medicaid cohort was younger, more likely to be an ethnic minority, foreign born, never married, live in either an inner-city or remote rural area, and have a higher stage at diagnosis.
Conclusions
The linked dataset will permit detailed analysis of cancer treatment and cancer treatment disparities among historically understudied groups. The linkage has also resulted in improvements in Cancer Registry quality through the identification of errors and missing values. The linkage did present technical challenges in the form of immense file sizes not easily adaptable to desktop computers.
C1 [Boscoe, Francis P.; Schymura, Maria J.] New York State Canc Registry, Menands, NY 12204 USA.
[Schrag, Deborah] Dana Farber Canc Inst, Gastrointestinal Canc Ctr, Boston, MA 02115 USA.
[Chen, Kun] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA.
[Roohan, Patrick J.] New York State Dept Hlth, Off Hlth Insurance Programs, Albany, NY USA.
RP Boscoe, FP (reprint author), New York State Canc Registry, 150 Broadway,Suite 361, Menands, NY 12204 USA.
EM fpb01@health.state.ny.us
FU American Schools of Public Health/Centers for Disease Control and
Prevention [S3888]; National Cancer Institute [R01-CA131847-01A1]
FX This work was supported by Cooperative Agreement S3888 from the American
Schools of Public Health/Centers for Disease Control and Prevention and
National Cancer Institute R01-CA131847-01A1.
NR 28
TC 11
Z9 12
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD JUN
PY 2011
VL 46
IS 3
BP 805
EP 820
DI 10.1111/j.1475-6773.2010.01221.x
PG 16
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 758NN
UT WOS:000290171600008
PM 21158856
ER
PT J
AU Chirinos, JA
Kips, JG
Roman, MJ
Medina-Lezama, J
Li, Y
Woodiwiss, AJ
Norton, GR
Yasmin
Van Bortel, L
Wang, JG
Cockcroft, JR
Devereux, RB
Wilkinson, IB
Segers, P
McEniery, CM
AF Chirinos, Julio A.
Kips, Jan G.
Roman, Mary J.
Medina-Lezama, Josefina
Li, Yan
Woodiwiss, Angela J.
Norton, Gavin R.
Yasmin
Van Bortel, Luc
Wang, Ji-Guang
Cockcroft, John R.
Devereux, Richard B.
Wilkinson, Ian B.
Segers, Patrick
McEniery, Carmel M.
TI Ethnic Differences in Arterial Wave Reflections and Normative Equations
for Augmentation Index
SO HYPERTENSION
LA English
DT Article
DE wave reflections; augmentation index; ethnicity
ID LEFT-VENTRICULAR HYPERTROPHY; REFERENCE VALUES; BLOOD-PRESSURE;
PULSE-WAVE; CARDIOVASCULAR-DISEASE; VASCULAR-DISEASE; POPULATION;
STIFFNESS; MEN; HEMODYNAMICS
AB Data regarding ethnic differences in wave reflections, which markedly affect the central pressure profile, are very limited. Furthermore, because age, heart rate, and body height are strong determinants of augmentation index, relating single measurements to normative data (in which augmentation index values correspond with average population values of its determinants) is challenging. We studied subject-level data from 10 550 adults enrolled in large population-based studies. In a healthy reference sample (n = 3497), we assessed ethnic differences in augmentation index (ratio of second/first systolic peaks) and generated equations for adjusted z scores, allowing for a standardized comparison between individual augmentation index measurements and the normative population mean from subjects of the same age, sex, ethnic population, body height, and heart rate. After adjustment for age, body height, heart rate, and mean arterial pressure, African blacks (women: 154%; men: 138%) and Andean Hispanics (women: 152%; men: 133%) demonstrated higher central (aortic) augmentation index values than British whites (women: 140%; men: 128%), whereas American Indians (women: 133%; men: 122%) demonstrated lower augmentation index (all P < 0.0001), without significant differences between Chinese and British whites. Similar results were found for radial augmentation index. Nonlinear ethnic/sex-specific equations for z scores were successfully generated to adjust individual augmentation index values for age, body height, and heart rate. Marked ethnic differences in augmentation index exist, which may contribute to ethnic differences in hypertensive organ damage. Our study provides normative data that can be used to complement the interpretation of individual hemodynamic assessments among men and women of various ethnic populations, after removing the effect of various physiological determinants. (Hypertension. 2011;57:1108-1116.). Online Data Supplement
C1 [Chirinos, Julio A.] Univ Penn, Div Cardiol, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Kips, Jan G.; Van Bortel, Luc; Segers, Patrick] Univ Ghent, IBiTech, B-9000 Ghent, Belgium.
Univ Ghent, Heymans Inst Pharmacol, B-9000 Ghent, Belgium.
[Roman, Mary J.; Devereux, Richard B.] Weill Cornell Med Coll, Div Cardiol, New York, NY USA.
[Medina-Lezama, Josefina] Santa Maria Catholic Univ, Santa Maria Res Inst, Arequipa, Peru.
[Li, Yan; Wang, Ji-Guang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hypertens, Ctr Epidemiol Studies & Clin Trials,Ruijin Hosp, Shanghai 200030, Peoples R China.
[Woodiwiss, Angela J.] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Cardiovasc Pathophysiol & Genom Res Unit, Johannesburg, South Africa.
[Yasmin; Wilkinson, Ian B.; McEniery, Carmel M.] Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England.
[Cockcroft, John R.] Univ Cardiff, Dept Cardiol, Cardiff, S Glam, Wales.
RP Chirinos, JA (reprint author), Rm 8B111,Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM julio.chirinos@uphs.upenn.edu
FU National Heart, Lung, and Blood Institute [U01-HL65521]; South African
Medical Research Council; National Research Foundation of South Africa;
University Research Council of the University of the Witwatersrand;
Santa Maria Research Institute (AQP/Peru); National Natural Science
Foundation of China [30871360, 30871081]; Ministry of Science and
Technology, Beijing, China [2006BAI01A03]; Shanghai Commissions of
Science and Technology [07JC14047, 06QA14043, 07ZZ32, 08SG20]; Shanghai
Shenkang Hospital Development Centre [SHDC12007318]; Shanghai Jiaotong
University School of Medicine; European Union [LSHM-CT-2006-037093,
HEALTH-F4-2007-201550]
FX This study was supported by National Heart, Lung, and Blood Institute
grant U01-HL65521; the South African Medical Research Council; the
National Research Foundation of South Africa; the University Research
Council of the University of the Witwatersrand; the Santa Maria Research
Institute (AQP/Peru); the National Natural Science Foundation of China
(grants 30871360 and 30871081); the Ministry of Science and Technology
(grant 2006BAI01A03), Beijing, China; the Shanghai Commissions of
Science and Technology (grant 07JC14047 and the "Rising Star" program
06QA14043) and Education (grant 07ZZ32 and the "Dawn" project 08SG20);
the Shanghai Shenkang Hospital Development Centre (grant SHDC12007318);
Shanghai Jiaotong University School of Medicine (a grant of
Distinguished Young Investigators to Y.L.); and the European Union
(grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550).
NR 27
TC 48
Z9 48
U1 4
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD JUN
PY 2011
VL 57
IS 6
BP 1108
EP U153
DI 10.1161/HYPERTENSIONAHA.110.166348
PG 13
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 765MI
UT WOS:000290710800023
PM 21536986
ER
PT J
AU Plourde, E
Delgutte, B
Brown, EN
AF Plourde, Eric
Delgutte, Bertrand
Brown, Emery N.
TI A Point Process Model for Auditory Neurons Considering Both Their
Intrinsic Dynamics and the Spectrotemporal Properties of an Extrinsic
Signal
SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING
LA English
DT Article
DE Auditory system; generalized linear model; point process;
spectrotemporal receptive field; spike train model
ID NEURAL SPIKING
AB We propose a point process model of spiking activity from auditory neurons. The model takes account of the neuron's intrinsic dynamics as well as the spectrotemporal properties of an input stimulus. A discrete Volterra expansion is used to derive the form of the conditional intensity function. The Volterra expansion models the neuron's baseline spike rate, its intrinsic dynamics-spiking history-and the stimulus effect which in this case is the analog of the spectrotemporal receptive field (STRF). We performed the model fitting efficiently in a generalized linear model framework using ridge regression to address properly this ill-posed maximum likelihood estimation problem. The model provides an excellent fit to spiking activity from 55 auditory nerve neurons. The STRF-like representation estimated jointly with the neuron's intrinsic dynamics may offer more accurate characterizations of neural activity in the auditory system than current ones based solely on the STRF.
C1 [Plourde, Eric; Brown, Emery N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurosci Stat Res Lab, Boston, MA 02114 USA.
[Plourde, Eric; Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Delgutte, Bertrand] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Delgutte, Bertrand; Brown, Emery N.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Delgutte, Bertrand] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
RP Plourde, E (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurosci Stat Res Lab, Boston, MA 02114 USA.
EM eplourde@mit.edu; Bertrand_Delgutte@meei.harvard.edu;
enb@neurostat.mit.edu
OI , /0000-0003-1349-9608
FU Fonds quebecois de la recherche sur la nature et les technologies;
National Institutes of Health [DP1-OD003646]
FX Manuscript received October 18, 2010; revised December 28, 2010;
accepted January 5, 2011. Date of publication February 10, 2011; date of
current version May 18, 2011. This work was supported in part by the
Fonds quebecois de la recherche sur la nature et les technologies, and
in part by the National Institutes of Health under Grant DP1-OD003646.
Asterisk indicates corresponding author.
NR 12
TC 7
Z9 7
U1 0
U2 0
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9294
J9 IEEE T BIO-MED ENG
JI IEEE Trans. Biomed. Eng.
PD JUN
PY 2011
VL 58
IS 6
BP 1507
EP 1510
DI 10.1109/TBME.2011.2113349
PG 4
WC Engineering, Biomedical
SC Engineering
GA 765UA
UT WOS:000290732900001
PM 21317068
ER
PT J
AU Su, CW
Cao, Y
Kaplan, J
Zhang, M
Li, WL
Conroy, M
Walker, WA
Shi, HN
AF Su, Chien-Wen
Cao, Yue
Kaplan, Jess
Zhang, Mei
Li, Wanglin
Conroy, Michelle
Walker, W. Allan
Shi, Hai Ning
TI Duodenal Helminth Infection Alters Barrier Function of the Colonic
Epithelium via Adaptive Immune Activation
SO INFECTION AND IMMUNITY
LA English
DT Article
ID HELIGMOSOMOIDES-POLYGYRUS; E-CADHERIN; RECIPROCAL REGULATION; NEMATODE
INFECTION; ENTERIC NEMATODE; DENDRITIC CELLS; INDUCED COLITIS; TIGHT
JUNCTION; MAST-CELLS; INTESTINE
AB Chronic infection with intestinal helminth parasites is a major public health problem, particularly in the developing world, and can have significant effects on host physiology and the immune response to other enteric infections and antigens. The mechanisms underlying these effects are not well understood. In the current study, we investigated the impact of infection with the murine nematode parasite Heligmosomoides polygyrus, which resides in the duodenum, on epithelial barrier function in the colon. We found that H. polygyrus infection produced a significant increase in colonic epithelial permeability, as evidenced by detection of elevated serum levels of the tracer horseradish peroxidase following rectal administration. This loss of normal barrier function was associated with clear ultrastructural changes in the tight junctions of colonic epithelial cells and an alteration in the expression and distribution of the junctional protein E-cadherin. These parasite-induced abnormalities were not observed in SCID mice but did occur in SCID mice that were adoptively transferred with wild-type T cells, indicating a requirement for adaptive immunity. Furthermore, the helminth-induced increase in gut permeability was not seen in STAT6 knockout (KO) mice. Taken together, the results demonstrate that one of the mechanisms by which helminths exert their effects involves the lymphocyte-and STAT6-dependent breakdown of the intestinal epithelial barrier. This increase in epithelial permeability may facilitate the movement of lumenal contents across the mucosa, thus helping to explain how helminth infection can alter the immune response to enteric antigens.
C1 [Shi, Hai Ning] Massachusetts Gen Hosp, Mucosal Immunol Lab, Charlestown, MA 02129 USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
RP Shi, HN (reprint author), Massachusetts Gen Hosp, Mucosal Immunol Lab, Bldg 114,16th St,Room 3504, Charlestown, MA 02129 USA.
EM shiha@helix.mgh.harvard.edu
FU Clinical Nutrition Research Center at Harvard [P30 DK040561];
[R21DK074727]; [R01DK082427]
FX This work was supported by R21DK074727 and R01DK082427 (to H.N.S.) and
the Clinical Nutrition Research Center at Harvard (P30 DK040561).
NR 40
TC 18
Z9 18
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JUN
PY 2011
VL 79
IS 6
BP 2285
EP 2294
DI 10.1128/IAI.01123-10
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 765LJ
UT WOS:000290707200016
PM 21444669
ER
PT J
AU Karlsson, P
Cole, BF
Colleoni, M
Roncadin, M
Chua, BH
Murray, E
Price, KN
Castiglione-Gertsch, M
Goldhirsch, A
Gruber, G
AF Karlsson, Per
Cole, Bernard F.
Colleoni, Marco
Roncadin, Mario
Chua, Boon H.
Murray, Elizabeth
Price, Karen N.
Castiglione-Gertsch, Monica
Goldhirsch, Aron
Gruber, Guenther
CA Int Breast Canc Study Grp
TI TIMING OF RADIOTHERAPY AND OUTCOME IN PATIENTS RECEIVING ADJUVANT
ENDOCRINE THERAPY
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE Breast cancer; Radiotherapy; Radiotherapy timing; Breast-conserving
surgery; Endocrine therapy
ID BREAST-CONSERVING SURGERY; RADIATION-THERAPY; RANDOMIZED-TRIAL; CANCER
PATIENTS; CHEMOTHERAPY; DELAY; RECURRENCE; EXPERIENCE; TIME
AB Purpose: To evaluate the association between the interval from breast-conserving surgery (BCS) to radiotherapy (RT) and the clinical outcome among patients treated with adjuvant endocrine therapy.
Patients and Methods: Patient information was obtained from three International Breast Cancer Study Group trials. The analysis was restricted to 964 patients treated with BCS and adjuvant endocrine therapy. The patients were divided into two groups according to the median number of days between BCS and RT and into four groups according to the quartile of time between BCS and RT. The endpoints were the interval to local recurrence, disease-free survival, and overall survival. Proportional hazards regression analysis was used to perform comparisons after adjustment for baseline factors.
Results: The median interval between BCS and RT was 77 days. RT timing was significantly associated with age, menopausal status, and estrogen receptor status. After adjustment for these factors, no significant effect of a RT delay weeks was found. The adjusted hazard ratio for RT within 77 days vs. after 77 days was 0.94(95% confidence interval [CI], 0.47-1.87) for the interval to local recurrence, 1.05 (95% CI, 0.82-1.34) for disease-free survival, and 1.07 (95% CI, 0.77-1.49) for overall survival. For the interval to local recurrence the adjusted hazard ratio for <= 48, 49-77, and 78-112 days was 0.90(95% CI, 0.34-2.37), 0.86 (95% CI, 0.33-2.25), and 0.89 (95% CI, 0.33-2.41), respectively, relative to >= 113 days.
Conclusion: A RT delay of <= 20 weeks was significantly associated with baseline factors such as age, menopausal status, and estrogen-receptor status. After adjustment for these factors, the timing of RT was not significantly associated with the interval to local recurrence, disease-free survival, or overall survival. (C) 2011 Elsevier Inc.
C1 [Karlsson, Per] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Oncol, S-41345 Gothenburg, Sweden.
[Cole, Bernard F.] Univ Vermont, Dept Math & Stat, Coll Engn & Math Sci, Burlington, VT 05405 USA.
[Cole, Bernard F.] Dana Farber Canc Inst, Int Breast Canc Study Grp, Ctr Stat, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Colleoni, Marco] European Inst Oncol, Res Unit Med Senol, Dept Med, Milan, Italy.
[Roncadin, Mario] Ctr Riferimento Oncol, Dept Radiotherapy, I-33081 Aviano, Italy.
[Chua, Boon H.] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia.
[Murray, Elizabeth] Univ Cape Town, ZA-7925 Cape Town, South Africa.
[Murray, Elizabeth] Groote Shuur Hosp, Dept Radiat Oncol, Cape Town, South Africa.
[Price, Karen N.] Frontier Sci & Technol Res Fdn Inc, Int Breast Canc Study Grp Stat Ctr, Boston, MA USA.
[Castiglione-Gertsch, Monica] Int Breast Canc Study Grp Coordinating Ctr, Bern, Switzerland.
[Goldhirsch, Aron] European Inst Oncol, Milan, Italy.
[Goldhirsch, Aron] Oncol Inst So Switzerland, Bellinzona, Switzerland.
[Gruber, Guenther] Klin Hirslanden, Inst Radiotherapie, Zurich, Switzerland.
RP Karlsson, P (reprint author), Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Oncol, S-41345 Gothenburg, Sweden.
EM per.karlsson@oncology.gu.se
FU Swiss Group for Clinical Cancer Research; Frontier Science and
Technology Research Foundation; Cancer Council Australia; Australian New
Zealand Breast Cancer Trials Group (National Health Medical Research
Council); National Cancer Institute [CA-75362]; Swedish Cancer Society;
Cancer Association of South Africa; Foundation for Clinical Cancer
Research of Eastern Switzerland (OSKK)
FX The International Breast Cancer Study Group was funded in part by the
Swiss Group for Clinical Cancer Research, the Frontier Science and
Technology Research Foundation, the Cancer Council Australia, the
Australian New Zealand Breast Cancer Trials Group (National Health
Medical Research Council), the National Cancer Institute (Grant
CA-75362), the Swedish Cancer Society, the Cancer Association of South
Africa, and the Foundation for Clinical Cancer Research of Eastern
Switzerland (OSKK).
NR 16
TC 10
Z9 10
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2011
VL 80
IS 2
BP 398
EP 402
DI 10.1016/j.ijrobp.2010.02.042
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 767EC
UT WOS:000290837100012
PM 20729007
ER
PT J
AU Mori, S
Kanematsu, N
Asakura, H
Sharp, GC
Kumagai, M
Dobashi, S
Nakajima, M
Yamamoto, N
Kandatsu, S
Baba, M
AF Mori, Shinichiro
Kanematsu, Nobuyuki
Asakura, Hiroshi
Sharp, Gregory C.
Kumagai, Motoki
Dobashi, Sugltru
Nakajima, Mio
Yamamoto, Naoyoshi
Kandatsu, Susumu
Baba, Masayuki
TI FOUR-DIMENSIONAL LUNG TREATMENT PLANNING IN LAYER-STACKING CARBON ION
BEAM TREATMENT: COMPARISON OF LAYER-STACKING AND CONVENTIONAL
UNGATED/GATED IRRADIATION
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE Carbon ion beam; CT; Four-dimensional; Layer-stacking; Lung; Treatment
planning
ID GATED RADIOTHERAPY; 3-DIMENSIONAL IRRADIATION; AUDIOVISUAL BIOFEEDBACK;
PROTON RADIOTHERAPY; RADIATION-THERAPY; SCANNING SYSTEM; TUMOR MOTION;
WAVE-FORM; CANCER; TRACKING
AB Purpose: We compared four-dimensional (4D) layer-stacking and conventional carbon ion beam distribution in the treatment of lung cancer between ungated and gated respiratory strategies using 4DCT data sets.
Methods and Materials: Twenty lung patients underwent 4DCT imaging under free-breathing conditions. Using planning target volumes (PTVs) at respective respiratory phases, two types of compensating bolus were designed, a full single respiratory cycle for the ungated strategy and an approximately 30% duty cycle for the exhalationgated strategy. Beams were delivered to the PTVs for the ungated and gated strategies, PTV(ungated) and PTV(gated), respectively, which were calculated by combining the respective PTV(Tn)s by layer-stacking and conventional irradiation. Carbon ion beam dose distribution was calculated as a function of respiratory phase by applying a compensating bolus to 4DCT. Accumulated dose distributions were calculated by applying deformable registration.
Results: With the ungated strategy, accumulated dose distributions were satisfactorily provided to the PTV, with 1195 values for layer-stacking and conventional irradiation of 94.0% and 96.2%, respectively. V20 for the lung and Dmax for the spinal cord were lower with layer-stacking than with conventional irradiation, whereas Dmax for the skin (14.1 GyE) was significantly lower (21.9 GyE). In addition, dose conformation to the GTV/PTV with layer-stacking irradiation was better with the gated than with the ungated strategy.
Conclusions: Gated layer-stacking irradiation allows the delivery of a carbon ion beam to a moving target without significant degradation of dose conformity or the development of hot spots. (C) 2011 Elsevier Inc.
C1 [Mori, Shinichiro] Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Inage Ku, Chiba 2638555, Japan.
[Sharp, Gregory C.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Sharp, Gregory C.] Harvard Univ, Sch Med, Boston, MA USA.
RP Mori, S (reprint author), Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Inage Ku, Chiba 2638555, Japan.
EM shinshin@nirs.go.jp
RI Kanematsu, Nobuyuki/B-9130-2008;
OI Kanematsu, Nobuyuki/0000-0002-2534-9933; Mori,
Shinichiro/0000-0002-0412-4399
NR 42
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUN 1
PY 2011
VL 80
IS 2
BP 597
EP 607
DI 10.1016/j.ijrobp.2010.07.1982
PG 11
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 767EC
UT WOS:000290837100038
PM 20971576
ER
PT J
AU Zhao, H
Goetz, MB
AF Zhao, Hui
Goetz, Matthew Bidwell
TI Complications of HIV infection in an ageing population: challenges in
managing older patients on long-term combination antiretroviral therapy
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Review
DE immunocompromised host; epidemiology; age
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MYOCARDIAL-INFARCTION RATES; BONE-MINERAL
DENSITY; HEALTH-CARE-SYSTEM; D-A-D; DIABETES-MELLITUS; NAIVE PATIENTS;
RISK-FACTORS; CELL COUNT; RANDOMIZED-TRIAL
AB With the use of combination antiretroviral therapy, the proportion of HIV-infected patients over age 50 has greatly increased. The rate of progression of untreated HIV disease, response to therapy and complicating effects of co-morbidities differ in older versus younger patients. Compared with younger individuals, older untreated HIV patients demonstrate faster rates of CD4+ cell loss and more rapid progression to AIDS and death. With treatment, older patients have a better virological response, but a less robust immunological response. The treatment of older HIV-infected patients is further complicated by pre-existing co-morbid conditions including cardiovascular, hepatic and metabolic complications that may be exacerbated by the effects of HIV infection per se, modest immunodeficiency (i.e. at CD4+ counts >350 cells/mm(3)), and the metabolic and other adverse effects of combination antiretroviral therapy. Based on these considerations guidelines for the treatment of HIV-infected patients state that increased age is a consideration in initiating antiretroviral therapy in persons with >350-500 CD4+ cells/mm(3).
C1 [Zhao, Hui; Goetz, Matthew Bidwell] VA Greater Angeles Healthcare Syst, Infect Dis Sect, Dept Med, Los Angeles, CA 90073 USA.
[Zhao, Hui] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Goetz, MB (reprint author), VA Greater Angeles Healthcare Syst, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM matthew.goetz@va.gov
OI Goetz, Matthew/0000-0003-4542-992X
NR 67
TC 8
Z9 8
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUN
PY 2011
VL 66
IS 6
BP 1210
EP 1214
DI 10.1093/jac/dkr058
PG 5
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 763VM
UT WOS:000290587800003
PM 21421583
ER
PT J
AU Harker, N
Garefalaki, A
Menzel, U
Ktistaki, E
Naito, T
Georgopoulos, K
Kioussis, D
AF Harker, Nicola
Garefalaki, Anna
Menzel, Ursula
Ktistaki, Eleni
Naito, Taku
Georgopoulos, Katia
Kioussis, Dimitris
TI Pre-TCR Signaling and CD8 Gene Bivalent Chromatin Resolution during
Thymocyte Development
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID T-CELL DEVELOPMENT; HISTONE H3; REMODELING COMPLEXES; TRANSGENIC MICE;
EXPRESSION; LINEAGE; LOCUS; IKAROS; DIFFERENTIATION; METHYLATION
AB The CD8 gene is silent in CD4(-)CD8(-) double-negative thymocytes, expressed in CD4(+)CD8(+) double-positive cells, and silenced in cells committing to the CD4(+) single-positive (SP) lineage, remaining active in the CD8(+) SP lineage. In this study, we show that the chromatin of the CD8 locus is remodeled in C57BL/6 and B6/J Rag1(-/-) MOM double-negative thymocytes as indicated by DNaseI hypersensitivity and widespread bivalent chromatin marks. Pre-TCR signaling coincides with chromatin bivalency resolution into monovalent activating modifications in double-positive and CD8 SP cells. Shortly after commitment to CD4 SP cell lineage, monovalent repressive characteristics and chromatin inaccessibility are established. Differential binding of Ikaros, NuRD, and heterochromatin protein 1 alpha on the locus during these processes may participate in the complex regulation of CD8. The Journal of Immunology, 2011, 186: 6368-6377.
C1 [Harker, Nicola; Garefalaki, Anna; Menzel, Ursula; Ktistaki, Eleni; Kioussis, Dimitris] Natl Inst Med Res, MRC, Div Mol Immunol, London NW7 1AA, England.
[Naito, Taku] RIKEN, Res Ctr Allergy & Immunol, Transcript Regulat Lab, Yokohama, Kanagawa 2300045, Japan.
[Georgopoulos, Katia] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
RP Harker, N (reprint author), Natl Inst Med Res, MRC, Div Mol Immunol, Ridgeway,Mill Hill, London NW7 1AA, England.
EM nharker@nimr.mrc.ac.uk
FU Medical Research Council UK [U117512796]
FX This work was supported by the Medical Research Council UK (U117512796).
NR 61
TC 12
Z9 12
U1 1
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUN 1
PY 2011
VL 186
IS 11
BP 6368
EP 6377
DI 10.4049/jimmunol.1003567
PG 10
WC Immunology
SC Immunology
GA 766BX
UT WOS:000290755700036
PM 21515796
ER
PT J
AU Rosenblatt, J
Glotzbecker, B
Mills, H
Vasir, B
Tzachanis, D
Levine, JD
Joyce, RM
Wellenstein, K
Keefe, W
Schickler, M
Rotem-Yehudar, R
Kufe, D
Avigan, D
AF Rosenblatt, Jacalyn
Glotzbecker, Brett
Mills, Heidi
Vasir, Baldev
Tzachanis, Dimitrios
Levine, James D.
Joyce, Robin M.
Wellenstein, Kerry
Keefe, Whitney
Schickler, Michael
Rotem-Yehudar, Rinat
Kufe, Donald
Avigan, David
TI PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell
Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
SO JOURNAL OF IMMUNOTHERAPY
LA English
DT Article
DE PD-1 blockade; DC/tumor fusion cell; tumor vaccine; cancer vaccines;
immunotherapy
ID PROGRAMMED DEATH-1 LIGAND-1; MULTIPLE-MYELOMA; CLINICAL-SIGNIFICANCE;
CARCINOMA-CELLS; DISEASE PROGRESSION; THERAPEUTIC TARGET; ANTITUMOR
IMMUNITY; PROGNOSTIC-FACTORS; PANCREATIC-CANCER; PERIPHERAL-BLOOD
AB We have developed a cancer vaccine in which autologous tumor is fused with dendritic cells (DCs) resulting in the presentation of tumor antigens in the context of DC-mediated costimulation. In clinical trials, immunologic responses have been observed, however responses may be muted by inhibitory pathways. The PD1/PDL1 pathway is an important element contributing to tumor-mediated immune suppression. In this study, we demonstrate that myeloma cells and DC/tumor fusions strongly express PD-L1. Compared with a control population of normal volunteers, increased PD-1 expression was observed on T cells isolated from patients with myeloma. It is interesting to note that after autologous transplantation, T-cell expression of PD-1 returned to levels seen in normal controls. We examined the effect of PD-1 blockade on T-cell response to DC/tumor fusions ex vivo. Presence of CT-011, an anti-PD1 antibody, promoted the vaccine-induced T-cell polarization towards an activated phenotype expressing Th1 compared with Th2 cytokines. A concomitant decrease in regulatory T cells and enhanced killing in a cytotoxicity assay was observed. In summary, we demonstrate that PD-1 expression is increased in T cells of patients with active myeloma, and that CT-011 enhances activated T-cell responses after DC/tumor fusion stimulation.
C1 [Rosenblatt, Jacalyn; Glotzbecker, Brett; Mills, Heidi; Tzachanis, Dimitrios; Levine, James D.; Joyce, Robin M.; Wellenstein, Kerry; Keefe, Whitney; Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Vasir, Baldev; Kufe, Donald] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schickler, Michael; Rotem-Yehudar, Rinat] CureTech Ltd, Yavne, Israel.
RP Rosenblatt, J (reprint author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave,KS-121, Boston, MA 02215 USA.
EM jrosenb1@bidmc.harvard.edu
FU DOD [W81XWH-09-1-0296]; NIH [5 K12 CA087723]; CureTech, Ltd.
FX Funding to conduct the study was obtained from the DOD (grant #
W81XWH-09-1-0296 to David Avigan, MD), the NIH (K12 Clinical Research
Career Development Program Award grant # 5 K12 CA087723 to Jacalyn
Rosenblatt, MD), and by research funding obtained from CureTech, Ltd. to
David Avigan, MD and Jacalyn Rosenblatt, MD.
NR 51
TC 110
Z9 113
U1 2
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1524-9557
J9 J IMMUNOTHER
JI J. Immunother.
PD JUN
PY 2011
VL 34
IS 5
BP 409
EP 418
DI 10.1097/CJI.0b013e31821ca6ce
PG 10
WC Oncology; Immunology; Medicine, Research & Experimental
SC Oncology; Immunology; Research & Experimental Medicine
GA 766BD
UT WOS:000290752500001
PM 21577144
ER
PT J
AU Brooks-Pollock, E
Becerra, MC
Goldstein, E
Cohen, T
Murray, MB
AF Brooks-Pollock, Ellen
Becerra, Mercedes C.
Goldstein, Edward
Cohen, Ted
Murray, Megan B.
TI Epidemiologic Inference From the Distribution of Tuberculosis Cases in
Households in Lima, Peru
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID MULTIDRUG-RESISTANT TUBERCULOSIS; COMMUNITY TRANSMISSION PARAMETERS;
MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; INFECTION; CONTACTS;
DISEASE; RISK; REACTIVATION; METAANALYSIS
AB Background. Tuberculosis (TB) often occurs among household contacts of people with active TB. It is unclear whether clustering of cases represents household transmission or shared household risk factors for TB.
Methods. We used cross-sectional data from 764 households in Lima, Peru, to estimate the relative contributions of household and community transmission, the average time between cases, and the immunity afforded by a previous TB infection.
Results. The distribution of cases per household suggests that almost 7 of 10 nonindex household cases were infected in the community rather than in the household. The average interval between household cases was 3.5 years. We observed a saturation effect in the number of cases per household and estimated that protective immunity conferred up to 35% reduction in the risk of disease.
Conclusions. Cross-sectional household data can elucidate the natural history and transmission dynamics of TB. In this high-incidence setting, we found that the majority of cases were attributable to community transmission and that household contacts of case patients derive some immunity from household exposures. Screening of household contacts may be an effective method of detecting new TB cases if carried out over several years.
C1 [Brooks-Pollock, Ellen; Goldstein, Edward; Cohen, Ted; Murray, Megan B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Becerra, Mercedes C.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA.
[Becerra, Mercedes C.; Cohen, Ted; Murray, Megan B.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA.
[Murray, Megan B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Brooks-Pollock, E (reprint author), Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge CB3 0ES, England.
EM ellen.brooks.pollock@gmail.com
RI Cohen, Ted/G-8101-2011
FU National Institutes of Health [U19 AI0176217]; Charles H. Hood
Foundation
FX This work was supported by the National Institutes of Health (grant U19
AI0176217 [PI: MBM] to E. B. P., T. C. and M. B. M.) and the Charles H.
Hood Foundation (M. B.).
NR 40
TC 20
Z9 20
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2011
VL 203
IS 11
BP 1582
EP 1589
DI 10.1093/infdis/jir162
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 767LT
UT WOS:000290858800012
PM 21592987
ER
PT J
AU Mamtani, M
Mummidi, S
Ramsuran, V
Pham, MH
Maldonado, R
Begum, K
Valera, MS
Sanchez, R
Castiblanco, J
Kulkarni, H
Ndung'u, T
He, WJ
Anaya, JM
Ahuja, SK
AF Mamtani, Manju
Mummidi, Srinivas
Ramsuran, Veron
Pham, Minh-Hieu
Maldonado, Robert
Begum, Kazi
Valera, Maria Soledad
Sanchez, Racquel
Castiblanco, John
Kulkarni, Hemant
Ndung'u, Thumbi
He, Weijing
Anaya, Juan Manuel
Ahuja, Sunil K.
TI Influence of Variations in CCL3L1 and CCR5 on Tuberculosis in a
Northwestern Colombian Population
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RECEPTOR 5 GENE; HIV-1; EXPRESSION;
SUSCEPTIBILITY; POLYMORPHISM; ASSOCIATION; HAPLOTYPES; CHEMOKINES;
GENOTYPES
AB We investigated the association of polymorphisms in CCR5, the major human immunodeficiency virus (HIV)-1 coreceptor, and copy number of its potent ligand CCL3L1 with tuberculosis in 298 individuals from Colombia. The CCR5-HHD haplotype, a known genetic determinant of increased susceptibility to HIV-AIDS, and a high copy number of CCL3L1, a known genetic determinant of enhanced CCL3/CCL3L1 chemokine expression, each associated with presence of tuberculosis. Furthermore, CCR5-HHD was associated with higher CCR5 gene and surface expression. These results substantiate the strong link between the pro-inflammatory effects of CCR5 and its ligands with active tuberculosis and suggest that chemokine-chemokine receptor genetic determinants may influence tuberculosis in addition to HIV/AIDS.
C1 [Mamtani, Manju; Mummidi, Srinivas; Pham, Minh-Hieu; Maldonado, Robert; Begum, Kazi; Valera, Maria Soledad; Sanchez, Racquel; Castiblanco, John; Kulkarni, Hemant; He, Weijing; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Ctr AIDS & HIV Infect 1, San Antonio, TX USA.
[Mamtani, Manju; Mummidi, Srinivas; Pham, Minh-Hieu; Maldonado, Robert; Begum, Kazi; Valera, Maria Soledad; Sanchez, Racquel; Castiblanco, John; Kulkarni, Hemant; He, Weijing; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX USA.
[Mamtani, Manju; Mummidi, Srinivas; Pham, Minh-Hieu; Maldonado, Robert; Begum, Kazi; Valera, Maria Soledad; Sanchez, Racquel; Castiblanco, John; Kulkarni, Hemant; He, Weijing; Ahuja, Sunil K.] Univ Texas San Antonio, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Ramsuran, Veron; Ndung'u, Thumbi] Univ KwaZulu Natal, CAPRISA, Nelson R Mandela Sch Med, Durban, South Africa.
[Ramsuran, Veron; Ndung'u, Thumbi] Univ KwaZulu Natal, HIV Pathogenesis Programme, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, Durban, South Africa.
[Anaya, Juan Manuel] Corp Invest Biol, Cellular Biol & Immunogenet Unit, Medellin, Colombia.
[Anaya, Juan Manuel] Univ Rosario, Sch Med, Bogota, Colombia.
RP Ahuja, SK (reprint author), VA Ctr Personalized Med, San Antonio, TX 78229 USA.
EM ahujas@uthscsa.edu
RI CASTIBLANCO, JOHN/B-6599-2009; Mummidi, Srinivas/C-1004-2008; Anaya,
Juan-Manuel/J-1960-2016;
OI CASTIBLANCO, JOHN/0000-0002-7965-9822; Ndung'u,
Thumbi/0000-0003-2962-3992; Mummidi, Srinivas/0000-0002-4068-6380;
Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario,
Biblioteca/0000-0003-3491-9392; CASTIBLANCO, JOHN/0000-0003-2556-3697
FU Veterans Administration Center on AIDS and HIV infection of the South
Texas Veterans Health Care System; NIH [R37046326]; VA MERIT award;
Elizabeth Glaser Scientist Award; Burroughs Wellcome Clinical Scientist
Award in Translational Research; Doris Duke Distinguished Clinical
Scientist Award
FX This work was supported by the Veterans Administration Center on AIDS
and HIV infection of the South Texas Veterans Health Care System, and
the NIH (R37046326), a VA MERIT award, the Elizabeth Glaser Scientist
Award, the Burroughs Wellcome Clinical Scientist Award in Translational
Research, and the Doris Duke Distinguished Clinical Scientist Award to
S. K. A. The work was also supported by a VA MERIT award to S. M.
NR 16
TC 13
Z9 15
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2011
VL 203
IS 11
BP 1590
EP 1594
DI 10.1093/infdis/jir145
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 767LT
UT WOS:000290858800013
PM 21592988
ER
PT J
AU Gerstner, ER
Eichler, AF
Plotkin, SR
Drappatz, J
Doyle, CL
Xu, L
Duda, DG
Wen, PY
Jain, RK
Batchelor, TT
AF Gerstner, Elizabeth R.
Eichler, April F.
Plotkin, Scott R.
Drappatz, Jan
Doyle, Colin L.
Xu, Lei
Duda, Dan G.
Wen, Patrick Y.
Jain, Rakesh K.
Batchelor, Tracy T.
TI Phase I trial with biomarker studies of vatalanib (PTK787) in patients
with newly diagnosed glioblastoma treated with enzyme inducing
anti-epileptic drugs and standard radiation and temozolomide
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Angiogenesis; Biomarkers; Clinical trial; Glioblastoma; Treatment
ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; VASCULAR
NORMALIZATION; MALIGNANT GLIOMA; TUMOR; CANCER; IMATINIB; SU11248; BLOOD
AB Targeting angiogenesis in glioblastoma (GBM) may improve patient outcome by normalizing tumor vasculature and improving delivery of chemotherapeutics and oxygen. Consequently, concomitant administration of small molecule inhibitors of the VEGF pathway will likely have a positive impact on chemoradiation treatment outcome. We conducted a Phase I study of vatalanib, a small molecule inhibitor of VEGFR, PDGFR, and c-kit in patients with newly diagnosed GBM receiving radiation, temozolomide, and an enzyme-inducing anti-epileptic drug in order to determine the MTD of vatalanib in this patient population. We incorporated circulating biomarker and SNP analyses and pharmacokinetic studies. Nineteen patients were enrolled and the MTD was not reached at the time of study termination. Vatalanib was well tolerated with only 2 DLTs (thrombocytopenia and elevated transaminases). Other grade 3/4 toxicities included leukopenia, lymphopenia, neutropenia, and hand-foot syndrome. There were no wound-healing complications. Of the 13 patients evaluable for a radiographic response, 2 had a partial response and 9 had stable disease. Vatalanib significantly increased PlGF and sVEGFR1 in plasma circulation and decreased sVEGFR2 and sTie2. Plasma collagen IV increased significantly by day 50 of treatment. Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies.
C1 [Gerstner, Elizabeth R.; Eichler, April F.; Plotkin, Scott R.; Doyle, Colin L.; Batchelor, Tracy T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA.
[Drappatz, Jan; Wen, Patrick Y.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.
[Xu, Lei; Duda, Dan G.; Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Steele Lab, Boston, MA 02114 USA.
RP Gerstner, ER (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Stephen E & Catherine Pappas Ctr Neurooncol, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM egerstner@partners.org
FU NCI NIH HHS [K24 CA125440]
NR 19
TC 36
Z9 36
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD JUN
PY 2011
VL 103
IS 2
BP 325
EP 332
DI 10.1007/s11060-010-0390-7
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 766IB
UT WOS:000290773100016
PM 20821342
ER
PT J
AU Thompson, EM
Dosa, E
Kraemer, DF
Neuwelt, EA
AF Thompson, Eric M.
Dosa, Edit
Kraemer, Dale F.
Neuwelt, Edward A.
TI Correlation of MRI sequences to assess progressive glioblastoma
multiforme treated with bevacizumab
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Bevacizumab; Macdonald criteria; FLAIR; Progressive malignant glioma
ID RECURRENT MALIGNANT GLIOMA; GRADE GLIAL TUMORS; PHASE-II; IRINOTECAN;
EFFICACY; MODEL; CARBOPLATIN; SURVIVAL; CRITERIA; VOLUME
AB In the context of bevacizumab therapy for the treatment of progressive malignant gliomas, it is currently unclear how different magnetic resonance imaging (MRI) sequences correlate with each other over time. The objective of this study was to determine if a reliable and predictable relationship over time exists between post-gadolinium based contrast agent T1-weighted (T1 + GBCA), T2-weighted, and FLAIR MRI in patients with progressive glioblastoma multiforme (GBM) receiving bevacizumab and chemotherapy. The MRI lesion volumes of 10 patients with progressive GBM that received bevacizumab plus chemotherapy were manually calculated by two independent reviewers. T2 and FLAIR volumes were analyzed by analysis of covariance (ANCOVA) as a function of T1 + GBCA lesion enhancement volume, reviewer, and time interval between MRI acquisitions. Pearson product moment correlation (r) was used to compare pre and post treatment volumes for the group of 10 patients and for each individual patient over their treatment course. ANCOVA demonstrated a significant association between T1 + GBCA and T2-weighted volumes (P = 0.0006) and between T1 + GBCA and FLAIR volumes (P < 0.0001). These associations remained constant over time. The correlation between T1 + GBCA and both T2-weighted and FLAIR volumes improved after bevacizumab treatment. Individual correlations between T1 + GBCA and FLAIR were strong (r a parts per thousand yen 0.63) with one exception, while correlations between T1 + GBCA and T2 were more variable (r = 0.18-0.99). These findings suggest that FLAIR MRI should be evaluated in addition to T1 + GBCA MRI when evaluating GBM responses.
C1 [Thompson, Eric M.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA.
[Dosa, Edit; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
[Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
[Kraemer, Dale F.] Oregon Hlth & Sci Univ, Dept Pharm Practice, Oregon State Univ, Coll Pharm, Portland, OR 97239 USA.
[Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA.
EM neuwelte@ohsu.edu
NR 22
TC 6
Z9 6
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD JUN
PY 2011
VL 103
IS 2
BP 353
EP 360
DI 10.1007/s11060-010-0397-0
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 766IB
UT WOS:000290773100019
PM 20848300
ER
PT J
AU Lessell, S
AF Lessell, Simmons
TI Pitfalls in Imaging
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Editorial Material
ID INTRACRANIAL ANEURYSMS
C1 [Lessell, Simmons] Massachusetts Eye & Ear Infirm, Neuroophthalmol Unit, Boston, MA 02114 USA.
[Lessell, Simmons] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Lessell, S (reprint author), Massachusetts Eye & Ear Infirm, Neuroophthalmol Unit, 243 Charles St, Boston, MA 02114 USA.
EM simmons_lessell@meei.harvard.edu
NR 9
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1070-8022
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD JUN
PY 2011
VL 31
IS 2
BP 101
EP 102
DI 10.1097/WNO.0b013e318219c906
PG 2
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA 766LO
UT WOS:000290784000002
PM 21593626
ER
PT J
AU Rizzo, JF
AF Rizzo, Joseph F., III
TI Update on Retinal Prosthetic Research: The Boston Retinal Implant
Project
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Review
ID GANGLION-CELLS; ELECTRICAL-STIMULATION; ARTIFICIAL VISION; SUBRETINAL
IMPLANTATION; PERCEPTUAL THRESHOLDS; RETINITIS-PIGMENTOSA; DEGENERATION;
ACTIVATION; RESPONSES; PERFORMANCE
AB The field of retinal prosthetic research, now more than 20 years old, has producedmany high-quality technical options that have the potential to restore vision to patients with acquired disease of the outer retina. Five companies have performed Phase I clinical trials demonstrating that blind patients can reliably report basic elements of visual percepts induced by electrical stimulation. However, at present patients and observers generally do not consider the results to be useful enough in the performance of tasks of daily living to justify the risks of surgery and chronic implantation or the costs. Having developed a wireless device implanted in the subretinal space, the Boston Retinal Implant Project has focused its efforts on developing scalable technologies to create a hermetic device that can deliver individually controlled pulses of electrical stimulation to each of hundreds of electrodes. An advanced device with such attributes will be needed to justify the risks of implantation. An assessment of long-term biocompatibility for all devices remains to be done.
C1 [Rizzo, Joseph F., III] Harvard Univ, Sch Med, Dept Vet Adm, Boston, MA USA.
[Rizzo, Joseph F., III] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Rizzo, Joseph F., III] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02458 USA.
RP Rizzo, JF (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02458 USA.
EM joseph_rizzo@meei.harvard.edu
NR 64
TC 42
Z9 42
U1 0
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-8022
EI 1536-5166
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD JUN
PY 2011
VL 31
IS 2
BP 160
EP 168
DI 10.1097/WNO.0b013e31821eb79e
PG 9
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA 766LO
UT WOS:000290784000015
PM 21593628
ER
PT J
AU Ruchelsman, DE
Ramos, LE
Price, AE
Grossman, LA
Valencia, H
Grossman, JAI
AF Ruchelsman, David E.
Ramos, Lorna E.
Price, Andrew E.
Grossman, Leslie Agatha
Valencia, Herbert
Grossman, John A. I.
TI Outcome After Tendon Transfers to Restore Wrist Extension in Children
With Brachial Plexus Birth Injuries
SO JOURNAL OF PEDIATRIC ORTHOPAEDICS
LA English
DT Article
DE tendon transfer; brachial plexus; extensor paralysis
ID HAND
AB Children with brachial plexus birth injuries often require tendon transfer to restore active wrist extension and maximize hand function. The purpose of this study is to assess the clinical results in children with brachial plexus birth injuries after tendon transfer to reconstruct active wrist extension. Over a 10-year period, 21 children (11 male, 10 female) underwent tendon transfer to reconstruct active wrist extension by a single surgeon. Eight patients had C5/C6/C7 injury and 13 patients had global palsy (C5-T1). The average age at surgery was 5.5 years (range, 3 to 8 y). Restoration of wrist extension was measured according to the functional scale of Duclos and Gilbert. The mean duration of follow-up was 36 months (minimum follow-up of 1 y). At latest follow-up, 14 (66%) children (C5/C6/C7, n = 8; global, n = 6) demonstrated active wrist extension >= 30 degrees. Within the global injury subcohort, 3 patients demonstrated static extension of the wrist. Four failures occurred in the global palsy group. Children with absent active wrist extension after a brachial plexus birth injury can benefit from a tendon transfer. The more severe global palsy cases have a worse outcome.
C1 [Ramos, Lorna E.; Price, Andrew E.; Grossman, Leslie Agatha; Valencia, Herbert; Grossman, John A. I.] Miami Childrens Hosp, Brachial Plexus Program, Miami, FL 33243 USA.
[Ruchelsman, David E.; Grossman, Leslie Agatha] Harvard Univ, Sch Med, Dept Orthopaed Surg, Boston, MA USA.
[Ruchelsman, David E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Boston, MA USA.
[Ramos, Lorna E.; Price, Andrew E.; Grossman, Leslie Agatha; Valencia, Herbert; Grossman, John A. I.] NYU Hosp Joint Dis, Dept Orthoped Surg, New York, NY USA.
RP Grossman, JAI (reprint author), Miami Childrens Hosp, Brachial Plexus Program, POB 430942, Miami, FL 33243 USA.
EM drg@handandnervespecialist.com
NR 6
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0271-6798
J9 J PEDIATR ORTHOPED
JI J. Pediatr. Orthop.
PD JUN
PY 2011
VL 31
IS 4
BP 455
EP 457
DI 10.1097/BPO.0b013e31821adcc0
PG 3
WC Orthopedics; Pediatrics
SC Orthopedics; Pediatrics
GA 763MN
UT WOS:000290562300019
PM 21572285
ER
PT J
AU Nadazdin, O
Abrahamian, G
Boskovic, S
Smith, RN
Schoenfeld, DA
Madsen, JC
Colvin, RB
Sachs, DH
Cosimi, AB
Kawai, T
AF Nadazdin, Ognjenka
Abrahamian, Gregory
Boskovic, Svjetlan
Smith, Rex-Neal
Schoenfeld, David A.
Madsen, Joren C.
Colvin, Robert B.
Sachs, David H.
Cosimi, A. Benedict
Kawai, Tatsuo
TI Stem Cell Mobilization and Collection for Induction of Mixed Chimerism
and Renal Allograft Tolerance in Cynomolgus Monkeys
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE kidney transplantation; nonhuman primates; tolerance; mixed chimerism;
peripheral blood stem cell transplantation; leukapheresis
ID BONE-MARROW-TRANSPLANTATION; COLONY-STIMULATING FACTOR;
NONHUMAN-PRIMATES; PROGENITOR CELLS; IMMUNOSUPPRESSION; IRRADIATION;
BLOCKADE; SURVIVAL; REGIMEN; TRIAL
AB Background. We have previously observed that donor bone marrow hematopoietic stem cells successfully induce transient mixed chimerism and renal allograft tolerance following non-myeloablative conditioning of the recipient. Stem cells isolated from the peripheral blood (PBSC) may provide similar benefits. We sought to determine the most effective method of mobilizing PBSC for this approach and the effects of differing conditioning regimens on their engraftment.
Methods. A standard dose (10 mu g/kg) or high dose (100 mu g/kg) of granulocyte colony-stimulating factor (GCSF) with or without stem cell factor (SCF) was administered to the donor, and PBSC were collected by leukapheresis. Cynomolgus monkey recipients underwent a nonmyeloablative conditioning regimen (total body irradiation, thymic irradiation, and ATG) with splenectomy (splenectomy group) or a short course of anti-CD154 antibody (aCD154) (aCD154 group). Recipients then received combined kidney and PBSC transplantation and a 1-mo post-transplant course of cyclosporine.
Results. Treatments with either two cytokines (GCSF + SCF) or high dose GCSF provided significantly more hematopoietic progenitor cells than standard dose GCSF alone. Recipients in the aCD154 group developed significantly higher myeloid and lymphoid chimerism (P < 0.0001 and P = 0.0002, respectively) than those in the splenectomy group. Longer term renal allograft survival without immunosuppression was also observed in the aCD154 group, while two of three recipients in the splenectomy group rejected their allografts soon after discontinuation of immunosuppression.
Conclusions. Protocols including administration of two cytokines (GCSF + SCF) or high dose GCSF alone significantly mobilized more PBSC than standard dose GCSF alone. The recipients of PBSC consistently developed excellent chimerism and survived long-term without immunosuppression, when treated with CD154 blockade. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Nadazdin, Ognjenka; Abrahamian, Gregory; Boskovic, Svjetlan; Schoenfeld, David A.; Madsen, Joren C.; Cosimi, A. Benedict; Kawai, Tatsuo] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
[Smith, Rex-Neal; Colvin, Robert B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Schoenfeld, David A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Sachs, David H.] Massachusetts Gen Hosp E, Transplantat Biol Res Ctr, Charlestown, MA USA.
RP Kawai, T (reprint author), Massachusetts Gen Hosp, Transplant Ctr, White 521,55 Fruit St, Boston, MA 02114 USA.
EM tkawai@partners.org
FU NHL-BI [5U19DK080652-02]; NIH-NIAID; NIH/NIAID [5R01 AI50987-03];
[POI-HL18646]; [ROIA137692]
FX The authors acknowledge support in part for this study by
5U19DK080652-02 NHL-BI, POI-HL18646, NIH-NIAID, ROIA137692, and
NIH/NIAID 5R01 AI50987-03. The authors thank Dr. Elizabeth Smoot for
statistical analysis, Patricia Della Pelle for pathologic analysis, and
Drs. Michael Duggan and Elisabeth Moeller for anesthesia and
postoperative care.
NR 19
TC 4
Z9 5
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD JUN
PY 2011
VL 168
IS 2
BP 294
EP 300
DI 10.1016/j.jss.2010.02.027
PG 7
WC Surgery
SC Surgery
GA 768BZ
UT WOS:000290907800021
PM 20605588
ER
PT J
AU de Prost, N
El-Karak, C
Avila, M
Ichinose, F
Melo, MFV
AF de Prost, Nicolas
El-Karak, Claudine
Avila, Maria
Ichinose, Fumito
Melo, Marcos F. Vidal
TI Changes in cysteinyl leukotrienes during and after cardiac surgery with
cardiopulmonary bypass in patients with and without chronic obstructive
pulmonary disease
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; EXHALED BREATH CONDENSATE;
HEALTHY-SUBJECTS; LUNG INJURY; METABOLISM; COPD; MONTELUKAST; MEDIATORS;
OUTCOMES; ASPIRIN
AB Objective: Pulmonary function frequently deteriorates after cardiopulmonary bypass (CPB). Chronic obstructive pulmonary disease (COPD) increases risk of respiratory complications after CPB. Cysteinyl leukotrienes are important mediators of respiratory dysfunction. Their role during cardiac surgery and its lung complications is incompletely understood. We studied whether production of cysteinyl leukotrienes changes during and after cardiac surgery with CPB and differs between patients with and without COPD.
Methods: Patients with (n = 9) and without (n = 10) moderate-to-severe COPD undergoing cardiac surgery with CPB were prospectively included. Plasma and urinary cysteinyl leukotriene and leukotriene B(4) concentrations were measured by enzyme-linked immunosorbent assay after anesthesia induction, at end of CPB, after CPB, and 2 hours after intensive care unit admission. Gas exchange and respiratory mechanics were also assessed.
Results: Patients with COPD had larger airway resistances after CPB and chest closure (P <. 001), lower ratio of arterial Po(2) to inspired oxygen fraction at intensive care unit admission (215 +/- 37 vs 328 +/- 30 mm Hg, P <. 05), and longer postoperative mechanical ventilation (13.7 +/- 5.8 vs 6.8 +/- 3.4 hours, P <. 01). Urinary cysteinyl leukotriene concentrations increased with time in both groups (P <. 01), but more in patients with than without COPD (P <. 05). Plasma cysteinyl leukotriene concentrations increased significantly between baseline and intensive care unit admission in patients with but not without COPD (P <. 01). Concentrations of leukotriene B(4) in plasma and urine did not increase significantly with time and were not different between groups.
Conclusions: Release of cysteinyl leukotrienes increases during cardiac surgery with CPB and is larger in patients with than without COPD. This may be related to higher lung and airway production of cysteinyl leukotrienes and neutrophil activation in patients with COPD. (J Thorac Cardiovasc Surg 2011;141:1496-502)
C1 [Melo, Marcos F. Vidal] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Melo, MFV (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM mvidalmelo@partners.org
OI de Prost, Nicolas/0000-0002-4833-4320
FU La Societe de Pneumologie de Langue Francaise; National Institutes of
Health [R01HL101930]; Merck Co.
FX Supported by an investigator-initiated grant from Merck & Co. Nicolas de
Prost was supported by a scholarship from La Societe de Pneumologie de
Langue Francaise, and Fumito Ichinose was supported by the National
Institutes of Health R01HL101930.
NR 34
TC 3
Z9 3
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD JUN
PY 2011
VL 141
IS 6
BP 1496
EP U208
DI 10.1016/j.jtcvs.2011.01.035
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 765MJ
UT WOS:000290710900029
PM 21377695
ER
PT J
AU Park, ER
Japuntich, S
Temel, J
Lanuti, M
Pandiscio, J
Hilgenberg, J
Davies, D
Dresler, C
Rigotti, NA
AF Park, Elyse R.
Japuntich, Sandra
Temel, Jennifer
Lanuti, Michael
Pandiscio, Jennifer
Hilgenberg, Joanna
Davies, Diane
Dresler, Carolyn
Rigotti, Nancy A.
TI A Smoking Cessation Intervention for Thoracic Surgery and Oncology
Clinics A Pilot Trial
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Lung cancer; Smoking; Cessation; Pharmacotherapy; Counseling
ID CELL LUNG-CANCER; QUALITY-OF-LIFE; TOBACCO USE OUTCOMES; 2ND PRIMARY
CANCERS; NECK-CANCER; NICOTINE DEPENDENCE; CIGARETTE-SMOKING;
CHILDHOOD-CANCER; DEPRESSION SCALE; HOSPITAL ANXIETY
AB Introduction: Although most smokers diagnosed with lung cancer report that they want to quit smoking, many do not succeed. Smokers who quit when lung cancer is diagnosed have improved treatment efficacy, quality of life, and survival. Effective smoking cessation interventions targeted to thoracic oncology patients are needed.
Methods: This pilot study examined the feasibility and potential efficacy of a 12-week program that combined smoking cessation counseling with varenicline. Seven-day point prevalence tobacco abstinence rates at the end of treatment were compared with a usual care control group. From January 2008 to August 2009, patients with a diagnosed or suspected thoracic malignancy were recruited at their initial visit to a thoracic surgeon or thoracic oncologist at Massachusetts General Hospital.
Results: Of 1130 patients screened, 187 (17%) were current smokers, and an additional 66 (6%) reported quitting within the past 6 months. One hundred sixteen (67%) of smokers were eligible, and 49 (42%) of eligible smokers enrolled (control group n = 17, intervention group n = 32). Intervention participants completed a median of nine counseling sessions; 50% of intervention participants completed the full varenicline course. At 12-week follow-up, biochemically validated 7-day point prevalence tobacco abstinence rates were 34.4% in the intervention group versus 14.3% in the control group (odds ratio = 3.14, 95% confidence interval = 0.59-16.62, p = 0.18).
Conclusion: Our findings support the feasibility and acceptability of this program. At the end of treatment, quit rates were higher in the control group. Further testing is indicated to establish the efficacy of this treatment package in a randomized clinical trial.
C1 [Park, Elyse R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
[Park, Elyse R.; Japuntich, Sandra; Pandiscio, Jennifer; Hilgenberg, Joanna; Rigotti, Nancy A.] Harvard Univ, Sch Med, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Park, Elyse R.; Japuntich, Sandra; Rigotti, Nancy A.] Massachusetts Gen Hosp, Dept Med, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA.
[Lanuti, Michael; Davies, Diane] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA.
[Dresler, Carolyn] Arkansas Dept Hlth, Tobacco Prevent & Cessat Program, Little Rock, AR 72205 USA.
RP Park, ER (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM epark@partners.org
FU Nabi Biopharmaceuticals
FX Nancy A. Regotti, MD, is an unpaid consultant to Pfizer and Free &
Clear, Inc. Her institution also received a research grant from Nabi
Biopharmaceuticals. Elyse R. Park, PhD, MPH, received a grant for
research. Pfizer provided the medication for this pilot trial.
NR 49
TC 26
Z9 26
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
BP 1059
EP 1065
DI 10.1097/JTO.0b013e318215a4dc
PG 7
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 766FM
UT WOS:000290766400012
PM 21512406
ER
PT J
AU Fadda, L
O'Connor, GM
Kumar, S
Piechocka-Trocha, A
Gardiner, CM
Carrington, M
McVicar, DW
Altfeld, M
AF Fadda, Lena
O'Connor, Geraldine M.
Kumar, Swati
Piechocka-Trocha, Alicja
Gardiner, Clair M.
Carrington, Mary
McVicar, Daniel W.
Altfeld, Marcus
TI Common HIV-1 Peptide Variants Mediate Differential Binding of KIR3DL1 to
HLA-Bw4 Molecules
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HLA-B; NK CELLS; INFECTION; MUTATION; RECEPTOR; AIDS; SUBTYPES; ESCAPE;
GAG
AB Epidemiological studies have shown the protective effect of KIR3DL1/HLA-Bw4 genotypes in human immunodeficiency virus type 1 (HIV-1) infection; however, the functional correlates for the protective effect remain unknown. We investigated whether human leukocyte antigen (HLA)-Bw4-presented HIV-1 peptides could affect the interaction between the inhibitory natural killer (NK) cell receptor KIR3DL1 and its ligand HLA-Bw4. Distinct HIV-1 epitopes differentially modulated the binding of KIR3DL1 to HLA-Bw4. Furthermore, cytotoxic T lymphocyte (CTL) escape mutations within the immunodominant HLA-B57 (Bw4)-restricted Gag epitope TSTLQEQIGW abrogated KIR3DL1 binding to HLA-B57, suggesting that sensing of CTL escape variants by NK cells can contribute to the protective effect of the KIR3DL1/HLA-Bw4 compound genotype.
C1 [Fadda, Lena; Kumar, Swati; Piechocka-Trocha, Alicja; Carrington, Mary; Altfeld, Marcus] Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Charlestown, MA 02129 USA.
[O'Connor, Geraldine M.; McVicar, Daniel W.] NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21702 USA.
[Gardiner, Clair M.] Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland.
[Carrington, Mary] NCI, Canc & Inflammat Program, Expt Immunol Lab, SAIC Frederick Inc, Frederick, MD 21701 USA.
RP Altfeld, M (reprint author), Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM maltfeld@partners.org
RI McVicar, Daniel/G-1970-2015
FU NIH [RO1AI067031]; Doris Duke Charitable Foundation; Bill and Melinda
Gates Foundation; Susan and Philip T. Ragon Foundation; Ragon Institute
of MGH, MIT, and Harvard; National Cancer Institute, National Institutes
of Health [HHSN261200800001E]; NIH, National Cancer Institute, Center
for Cancer Research
FX These studies were supported by the NIH (RO1AI067031), the Doris Duke
Charitable Foundation, the Bill and Melinda Gates Foundation, and the
Susan and Philip T. Ragon Foundation. L. F. is supported by a Ragon
Fellowship of the Ragon Institute of MGH, MIT, and Harvard. This project
has been funded in whole or in part with federal funds from the National
Cancer Institute, National Institutes of Health, under contract no.
HHSN261200800001E. This research was supported in part by the Intramural
Research Program of the NIH, National Cancer Institute, Center for
Cancer Research.
NR 17
TC 37
Z9 40
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN
PY 2011
VL 85
IS 12
BP 5970
EP 5974
DI 10.1128/JVI.00412-11
PG 5
WC Virology
SC Virology
GA 766CD
UT WOS:000290756600025
PM 21471246
ER
PT J
AU Woodard, LD
Urech, T
Landrum, CR
Wang, D
Petersen, LA
AF Woodard, LeChauncy D.
Urech, Tracy
Landrum, Cassie R.
Wang, Degang
Petersen, Laura A.
TI Impact of Comorbidity Type on Measures of Quality for Diabetes Care
SO MEDICAL CARE
LA English
DT Article
DE diabetes mellitus; quality of health care; comorbidity
ID UNITED-STATES; PERFORMANCE-MEASURES; HYPERTENSION; MEDICATION;
IMPROVEMENT; DEPRESSION; PREVALENCE; ADHERENCE; OUTCOMES; DISEASE
AB Objective: Studies provide conflicting results about the impact of comorbid conditions on the quality of chronic illness care. We assessed the effect of comorbidity type (concordant, discordant, or both) on the receipt of guideline-recommended care among patients with diabetes.
Research Design: Patients were assigned to 1 of 4 condition groups: diabetes-concordant (hypertension, ischemic heart disease, hyperlipidemia), and/or diabetes-discordant (arthritis, depression, chronic obstructive pulmonary disease) conditions, or neither. We evaluated hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol readings at index and measured overall good quality of diabetes care, including a 6-month follow-up interval. We assessed the effect of condition group on overall good quality of care with logistic regression and generalized ordered logistic regression.
Results: We assigned 35,872 patients to the diabetes comorbid condition groups, ranging from 2.0% in the discordant-only group to 58.0% in the concordant-only group. Patients with both types of conditions were more likely than those with no comorbidities to receive overall good quality for glycemic [odds ratio (OR), 2.13; 95% confidence interval (CI), 1.86-2.41], blood pressure (OR, 1.62; 95% CI, 1.40-1.84), and low-density lipoprotein cholesterol (OR, 3.57; 95% CI, 3.08-4.05) control within 6 months of an index visit. They were also more likely to receive overall good quality for all 3 quality measures combined (OR, 2.17; 95% CI, 1.96-2.39).
Conclusions: Patients with the greatest clinical complexity were more likely than less complex patients to receive high quality diabetes care, suggesting that increased complexity does not necessarily predispose chronically ill patients to receiving poorer care. However, caution should be used in treating certain patient groups, such as the elderly, for whom adherence to multiple condition-specific guidelines may lack benefit or cause harm.
C1 [Woodard, LeChauncy D.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Hlth Policy & Qual Program, Houston, TX 77030 USA.
Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
RP Woodard, LD (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Hlth Policy & Qual Program, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM woodard.lechauncy@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service [PPO 09-316, IIR 04-349];
National Institutes of Health [R01 HL079173-01]; Houston VA HSR&D Center
of Excellence [HFP90-020]; Dr Petersen was a Robert Wood Johnson
Foundation [045444]; American Heart Association [0540043N]
FX Supported by the Department of Veterans Affairs, Veterans Health
Administration, Health Services Research and Development Service, (PPO
09-316, PI LeChauncy D. Woodard, MD, MPH), (IIR 04-349, PI Laura A.
Petersen, MD, MPH), National Institutes of Health (R01 HL079173-01, PI
Laura A. Petersen, MD, MPH), and Houston VA HSR&D Center of Excellence
HFP90-020 (PI Laura A. Petersen, MD, MPH). Dr Petersen was a Robert Wood
Johnson Foundation Generalist Physician Faculty Scholar (grant number
045444) and an American Heart Association Established Investigator
Awardee (grant number 0540043N) at the time this work was conducted. Dr
Woodard is an assistant professor at the Michael E. DeBakey VA Medical
Center Health Services Research and Development Center of Excellence,
Houston, Texas. The funding sources played no role in the design and
conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the
manuscript.
NR 25
TC 30
Z9 30
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JUN
PY 2011
VL 49
IS 6
BP 605
EP 610
DI 10.1097/MLR.0b013e31820f0ed0
PG 6
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 763MS
UT WOS:000290563600013
PM 21422952
ER
PT J
AU Shwartz, M
Cohen, AB
Restuccia, JD
Ren, ZJ
Labonte, A
Theokary, C
Kang, R
Horwitt, J
AF Shwartz, Michael
Cohen, Alan B.
Restuccia, Joseph D.
Ren, Z. Justin
Labonte, Alan
Theokary, Carol
Kang, Raymond
Horwitt, Jedediah
TI How Well Can We Identify the High-Performing Hospital?
SO MEDICAL CARE RESEARCH AND REVIEW
LA English
DT Article
DE high-performing hospital; performance measures; quality; composite
measures
ID ACUTE MYOCARDIAL-INFARCTION; REGIONAL-VARIATIONS; MORTALITY-RATES;
QUALITY; CARE; ASSOCIATION; OUTCOMES; COSTS; SATISFACTION; ADJUSTMENT
AB Sharing lessons from high-performing hospitals facilitates quality improvement. High-performing hospitals have usually been identified using a small number of performance measures. The objective was to analyze how well 1,006 hospitals performed across a broader range of measures. Five measures were developed from publicly available data: adherence to processes of care, 30-day readmission rates, in-hospital mortality, efficiency, and patient satisfaction. For a subset of hospitals, the authors included two survey-based assessments of patient care quality, one by chief quality officers and one by frontline clinicians. In general, there was little correlation among the publicly available measures (r <= .10), though there was notable correlation between objective measures and survey-based measures (r = .23). Hospitals that performed well on a composite measure calculated from the publicly available measures were often not in the top quintile on most individual measures. This highlights the challenge in identifying high-performing hospitals to learn organizational-level best practices.
C1 [Shwartz, Michael] Boston Univ, Sch Management, Boston, MA 02215 USA.
[Shwartz, Michael; Cohen, Alan B.; Restuccia, Joseph D.; Labonte, Alan] VA Boston Healthcare Syst, Boston, MA USA.
[Kang, Raymond] Northwestern Univ, Chicago, IL 60611 USA.
RP Shwartz, M (reprint author), Boston Univ, Sch Management, 595 Commonwealth Ave, Boston, MA 02215 USA.
EM mshwartz@bu.edu
FU Commonwealth Fund
FX This study was supported by a grant from the Commonwealth Fund.
NR 38
TC 11
Z9 11
U1 3
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-5587
J9 MED CARE RES REV
JI Med. Care Res. Rev.
PD JUN
PY 2011
VL 68
IS 3
BP 290
EP 310
DI 10.1177/1077558710386115
PG 21
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 758ZX
UT WOS:000290209600002
PM 21156708
ER
PT J
AU Newcomb, LW
Koltyn, KF
Morgan, WP
Cook, DB
AF Newcomb, Lauren W.
Koltyn, Kelli F.
Morgan, William P.
Cook, Dane B.
TI Influence of Preferred versus Prescribed Exercise on Pain in
Fibromyalgia
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE PHYSICAL ACTIVITY; CHRONIC PAIN; RPE; EXERCISE PRESCRIPTION
ID STRESS-INDUCED ANALGESIA; CHRONIC-FATIGUE-SYNDROME; PHYSICAL-ACTIVITY;
AEROBIC EXERCISE; IMPACT QUESTIONNAIRE; MECHANISMS; CONTRACTION;
THRESHOLDS; PERCEPTION; RESPONSES
AB NEWCOMB, L. W., K. F. KOLTYN, W. P. MORGAN, and D. B. COOK. Influence of Preferred versus Prescribed Exercise on Pain in Fibromyalgia. Med. Sci. Sports Exerc., Vol. 43, No. 6, pp. 1106-1113, 2011. Purpose: The purpose of this study was to examine the influence of a preferred-versus a prescribed-intensity exercise session on pain in women with fibromyalgia (FM). Methods: Twenty-one women with FM (mean age = 44 yr) completed two randomly assigned exercise sessions consisting of 20 min of cycle ergometry at a self-selected intensity and a prescribed intensity. Experimental pain perception was assessed before and after aerobic exercise. During exercise, HR, watts, RPE, and muscle pain were assessed every 5 min. Clinical pain was assessed with the Short-Form McGill Pain Questionnaire (SF-MPQ) immediately and 24, 48, 72, and 96 h after exercise. Data were analyzed with repeated-measures ANOVA. Results: Women with FM preferred a lower intensity of exercise than what was prescribed as indicated by significantly lower HR, watts, and RPE responses (P < 0.05). Muscle pain in the legs, however, was similar in the two conditions and significantly increased during exercise (P < 0.05). Pain thresholds and pain tolerances increased significantly after exercise, whereas peak pain ratings decreased after exercise (P < 0.05). Furthermore, pain (SF-MPQ) in the follow-up period was found to be lower than baseline (P < 0.05). Conclusions: It is concluded that the women with FM who participated in this study experienced significant improvements in pain after exercise. The results from this study are novel and indicate that recommendations for exercise prescription for individuals with FM should consider the preferred-intensity exercise model as a strategy to reduce pain.
C1 [Newcomb, Lauren W.; Koltyn, Kelli F.; Morgan, William P.; Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA.
[Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI USA.
RP Cook, DB (reprint author), Univ Wisconsin, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA.
EM dcook@education.wisc.edu
FU Diane and Donald Masterson Gift Fund
FX This study was supported by the Diane and Donald Masterson Gift Fund.
NR 47
TC 15
Z9 15
U1 3
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD JUN
PY 2011
VL 43
IS 6
BP 1106
EP 1113
DI 10.1249/MSS.0b013e3182061b49
PG 8
WC Sport Sciences
SC Sport Sciences
GA 764TW
UT WOS:000290657300025
PM 21085031
ER
PT J
AU Paust, S
von Andrian, UH
AF Paust, Silke
von Andrian, Ulrich H.
TI Natural killer cell memory
SO NATURE IMMUNOLOGY
LA English
DT Review
ID CHEMOKINE RECEPTOR EXPRESSION; IMMUNOGLOBULIN-LIKE RECEPTORS; MOUSE
LYMPHOID-CELLS; COMPLEX CLASS-I; T-CELLS; NK CELLS;
RHEUMATOID-ARTHRITIS; DENDRITIC CELLS; IFN-GAMMA; CYTOTOXIC REACTIVITY
AB Natural killer (NK) cells are bone marrow-derived granular lymphocytes that have a key role in immune defense against viral and bacterial infections and malignancies. NK cells are traditionally defined as cells of the innate immune response because they lack RAG recombinase-dependent clonal antigen receptors. However, evidence suggests that specific subsets of mouse NK cells can nevertheless develop long-lived and highly specific memory to a variety of antigens. Here we review published evidence of NK cell-mediated, RAG-independent adaptive immunity. We also compare and contrast candidate mechanisms for mammalian NK cell memory and antigen recognition with other examples of RAG-independent pathways that generate antigen receptor diversity in non-mammalian species and discuss NK cell memory in the context of lymphocyte evolution.
C1 [Paust, Silke; von Andrian, Ulrich H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Paust, Silke] MGH, Ragon Inst, MIT, Charlestown, MA USA.
[von Andrian, Ulrich H.] Immune Dis Inst, Boston, MA USA.
RP von Andrian, UH (reprint author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
EM uva@hms.harvard.edu
RI von Andrian, Ulrich/A-5775-2008
FU Cancer Research Institute; Ragon Institute of MGH, MIT and Harvard; US
National Institutes of Health [AI069259, AI072252, AI1078897]
FX Supported by the Cancer Research Institute (S.P.), the Ragon Institute
of MGH, MIT and Harvard (S.P. and U.H.v.A.) and the US National
Institutes of Health (AI069259, AI072252 and AI1078897 to U.H.v.A.).
NR 106
TC 102
Z9 106
U1 2
U2 25
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JUN
PY 2011
VL 12
IS 6
BP 500
EP 508
DI 10.1038/ni.2032
PG 9
WC Immunology
SC Immunology
GA 765LI
UT WOS:000290707100008
PM 21739673
ER
PT J
AU Ise, W
Kohyama, M
Schraml, BU
Zhang, TT
Schwer, B
Basu, U
Alt, FW
Tang, J
Oltz, EM
Murphy, TL
Murphy, KM
AF Ise, Wataru
Kohyama, Masako
Schraml, Barbara U.
Zhang, Tingting
Schwer, Bjoern
Basu, Uttiya
Alt, Frederick W.
Tang, Jun
Oltz, Eugene M.
Murphy, Theresa L.
Murphy, Kenneth M.
TI The transcription factor BATF controls the global regulators of
class-switch recombination in both B cells and T cells
SO NATURE IMMUNOLOGY
LA English
DT Article
ID FOLLICULAR-HELPER-CELLS; NEGATIVE REGULATOR; DENDRITIC CELLS;
GENE-REGULATION; C-MAF; DIFFERENTIATION; EXPRESSION; PROMOTER; DIVISION;
IL-21
AB The transcription factor BATF controls the differentiation of interleukin 17 (IL-17)-producing helper T cells (T(H)17 cells) by regulating expression of the transcription factor ROR gamma t itself and ROR gamma t target genes such as Il17. Here we report the mechanism by which BATF controls in vivo class-switch recombination (CSR). In T cells, BATF directly controlled expression of the transcription factors Bcl-6 and c-Maf, both of which are needed for development of follicular helper T cells (T(FH) cells). Restoring T(FH) cell activity to Batf(-/-) T cells in vivo required coexpression of Bcl-6 and c-Maf. In B cells, BATF directly controlled the expression of both activation-induced cytidine deaminase (AID) and of germline transcripts of the intervening heavy-chain region and constant heavy-chain region (I(H)-C(H)). Thus, BATF functions at multiple hierarchical levels in two cell types to globally regulate switched antibody responses in vivo.
C1 [Ise, Wataru; Kohyama, Masako; Schraml, Barbara U.; Tang, Jun; Oltz, Eugene M.; Murphy, Theresa L.; Murphy, Kenneth M.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA.
[Ise, Wataru; Kohyama, Masako; Zhang, Tingting; Schwer, Bjoern; Basu, Uttiya; Alt, Frederick W.; Murphy, Kenneth M.] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.
[Zhang, Tingting; Schwer, Bjoern; Basu, Uttiya; Alt, Frederick W.] Childrens Hosp, Immune Dis Inst, Boston, MA 02115 USA.
[Zhang, Tingting; Schwer, Bjoern; Basu, Uttiya; Alt, Frederick W.] Harvard Univ, Sch Med, Boston, MA USA.
RP Murphy, KM (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA.
EM kmurphy@wustl.edu
FU Howard Hughes Medical Institute
FX We thank T. Honjo (Kyoto University) for Aicda-/- mice; and
D. Bhattacharya (Washington University) for retroviruses Bcl-6-GFP RV
and CD40L-GFP RV. Supported by the Howard Hughes Medical Institute
(K.M.M.).
NR 41
TC 136
Z9 139
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JUN
PY 2011
VL 12
IS 6
BP 536
EP U245
DI 10.1038/ni.2037
PG 10
WC Immunology
SC Immunology
GA 765LI
UT WOS:000290707100014
PM 21572431
ER
PT J
AU Tambe, DT
Hardin, CC
Angelini, TE
Rajendran, K
Park, CY
Serra-Picamal, X
Zhou, EHH
Zaman, MH
Butler, JP
Weitz, DA
Fredberg, JJ
Trepat, X
AF Tambe, Dhananjay T.
Hardin, C. Corey
Angelini, Thomas E.
Rajendran, Kavitha
Park, Chan Young
Serra-Picamal, Xavier
Zhou, Enhua H.
Zaman, Muhammad H.
Butler, James P.
Weitz, David A.
Fredberg, Jeffrey J.
Trepat, Xavier
TI Collective cell guidance by cooperative intercellular forces
SO NATURE MATERIALS
LA English
DT Article
ID GLASS-TRANSITION; FOCAL ADHESIONS; SHEET MIGRATION; DYNAMICS; TENSION;
MORPHOGENESIS; MALIGNANCY; MECHANICS; JUNCTIONS; CANCER
AB Cells comprising a tissue migrate as part of a collective. How collective processes are coordinated over large multi-cellular assemblies has remained unclear, however, because mechanical stresses exerted at cell-cell junctions have not been accessible experimentally. We report here maps of these stresses within and between cells comprising a monolayer. Within the cell sheet there arise unanticipated fluctuations of mechanical stress that are severe, emerge spontaneously, and ripple across the monolayer. Within that stress landscape, local cellular migrations follow local orientations of maximal principal stress. Migrations of both endothelial and epithelial monolayers conform to this behaviour, as do breast cancer cell lines before but not after the epithelial-mesenchymal transition. Collective migration in these diverse systems is seen to be governed by a simple but unifying physiological principle: neighbouring cells join forces to transmit appreciable normal stress across the cell-cell junction, but migrate along orientations of minimal intercellular shear stress.
C1 [Tambe, Dhananjay T.; Rajendran, Kavitha; Park, Chan Young; Zhou, Enhua H.; Butler, James P.; Fredberg, Jeffrey J.] Harvard Univ, Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Boston, MA 02115 USA.
[Hardin, C. Corey] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA.
[Angelini, Thomas E.; Weitz, David A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
[Serra-Picamal, Xavier; Trepat, Xavier] Univ Barcelona, Inst Bioengn Catalonia, Barcelona 08036, Spain.
[Serra-Picamal, Xavier; Trepat, Xavier] Inst Catalana Recerca & Estudis Avancats, Catalana 08036, Spain.
[Zaman, Muhammad H.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
RP Fredberg, JJ (reprint author), Harvard Univ, Sch Publ Hlth, Program Mol & Integrat Physiol Sci, 665 Huntington Ave, Boston, MA 02115 USA.
EM jfredber@hsph.harvard.edu; xtrepat@ub.edu
RI Tambe, Dhananjay/E-3511-2010; Trepat, Xavier/I-3912-2015
OI Trepat, Xavier/0000-0002-7621-5214
FU European Research Council [FP7/ERC-242993]; Spanish Ministry of Science
and Innovation [BFU2009-07595]; National Institutes of Health
[R01HL102373, R01HL107561, R01CA132633]
FX For their critical comments, we thank R. Hubmayr (Mayo Clinic), R.
Phillips (CalTech), D. Navajas (University of Barcelona), L. B. Freund
(Brown University), D. Tschumperlin (Harvard University), C. Forbes
Dewey, Jr (MIT) and V. B. Shenoy (Brown University). We acknowledge the
support of the European Research Council (Starting Grant
FP7/ERC-242993), the Spanish Ministry of Science and Innovation
(BFU2009-07595) and the National Institutes of Health (R01HL102373,
R01HL107561, R01CA132633). We thank D. Yu (MDACC) for the kind gift of
MCF-10A cell lines.
NR 43
TC 252
Z9 252
U1 16
U2 134
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-1122
EI 1476-4660
J9 NAT MATER
JI Nat. Mater.
PD JUN
PY 2011
VL 10
IS 6
BP 469
EP 475
DI 10.1038/NMAT3025
PG 7
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 767KI
UT WOS:000290855100023
PM 21602808
ER
PT J
AU Gagnon, L
Perdue, K
Greve, DN
Goldenholz, D
Kaskhedikar, G
Boas, DA
AF Gagnon, Louis
Perdue, Katherine
Greve, Douglas N.
Goldenholz, Daniel
Kaskhedikar, Gayatri
Boas, David A.
TI Improved recovery of the hemodynamic response in diffuse optical imaging
using short optode separations and state-space modeling
SO NEUROIMAGE
LA English
DT Article
DE Diffuse optical imaging; Hemodynamic response; Multidistance
measurements; Adaptive filtering; Kalman filtering
ID NEAR-INFRARED SPECTROSCOPY; CEREBRAL OXYGEN-METABOLISM; BRAIN
ACTIVATION; HUMAN ADULTS; TOMOGRAPHY; NIRS; MOTOR; BOLD; FMRI
AB Diffuse optical imaging (DOI) allows the recovery of the hemodynamic response associated with evoked brain activity. The signal is contaminated with systemic physiological interference which occurs in the superficial layers of the head as well as in the brain tissue. The back-reflection geometry of the measurement makes the DOI signal strongly contaminated by systemic interference occurring in the superficial layers. A recent development has been the use of signals from small source-detector separation (1 cm) optodes as regressors. Since those additional measurements are mainly sensitive to superficial layers in adult humans, they help in removing the systemic interference present in longer separation measurements (3 cm). Encouraged by those findings, we developed a dynamic estimation procedure to remove global interference using small optode separations and to estimate simultaneously the hemodynamic response. The algorithm was tested by recovering a simulated synthetic hemodynamic response added over baseline DOI data acquired from 6 human subjects at rest. The performance of the algorithm was quantified by the Pearson R-2 coefficient and the mean square error (MSE) between the recovered and the simulated hemodynamic responses. Our dynamic estimator was also compared with a static estimator and the traditional adaptive filtering method. We observed a significant improvement (two-tailed paired t-test, p < 0.05) in both HbO and HbR recovery using our Kalman filter dynamic estimator compared to the traditional adaptive filter, the static estimator and the standard GLM technique. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Gagnon, Louis; Perdue, Katherine; Greve, Douglas N.; Goldenholz, Daniel; Kaskhedikar, Gayatri; Boas, David A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA USA.
[Gagnon, Louis; Boas, David A.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Gagnon, Louis] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
[Perdue, Katherine] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
RP Gagnon, L (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA USA.
EM lgagnon@nmr.mgh.harvard.edu
RI Perdue, Katherine/D-4306-2013;
OI Perdue, Katherine/0000-0003-2846-3149; Goldenholz,
Daniel/0000-0002-8370-2758
FU NIH [P41-RR14075, R01-EB006385]; Fonds Quebecois sur la Nature et les
Technologies; IDEA at MIT
FX This work was supported by NIH grants P41-RR14075 and R01-EB006385. L.
Gagnon was supported by the Fonds Quebecois sur la Nature et les
Technologies and by the IDEA-squared program at MIT. We acknowledge
fruitful discussions with Sol Diamond, Emery Brown, Patrick Purdon, Lino
Becerra and Dana Brooks. We would also like to thank Michele Desjardins
for critical reading of the manuscript.
NR 46
TC 70
Z9 70
U1 2
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JUN 1
PY 2011
VL 56
IS 3
BP 1362
EP 1371
DI 10.1016/j.neuroimage.2011.03.001
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 764RF
UT WOS:000290649300049
PM 21385616
ER
PT J
AU Lord, LD
Allen, P
Expert, P
Howes, O
Lambiotte, R
McGuire, P
Bose, SK
Hyde, S
Turkheimer, FE
AF Lord, Louis-David
Allen, Paul
Expert, Paul
Howes, Oliver
Lambiotte, Renaud
McGuire, Philip
Bose, Subrata K.
Hyde, Samuel
Turkheimer, Federico E.
TI Characterization of the anterior cingulate's role in the at-risk mental
state using graph theory
SO NEUROIMAGE
LA English
DT Article
ID SMALL-WORLD NETWORKS; FUNCTIONAL CONNECTIVITY; VERBAL FLUENCY;
1ST-EPISODE SCHIZOPHRENIA; BRAIN CONNECTIVITY; PREFRONTAL CORTEX;
WORKING-MEMORY; 1ST EPISODE; PSYCHOSIS; ABNORMALITIES
AB The onset of positive symptoms in schizophrenia is often preceded by a prodromal phase characterized by neurocognitive abnormalities as well as changes in brain structure and function. Increasing efforts have been made to identify individuals at elevated risk of developing schizophrenia, as early intervention may help prevent progression towards psychosis. The present study uses functional MRI and graph theoretical analysis to characterize the organization of a functional brain network in at-risk mental state patients with varying symptoms assessed with the PANSS and healthy volunteers during performance of a verbal fluency task known to recruit frontal lobe networks and to be impaired in psychosis. We first examined between-groups differences in total network connectivity and global network compactness/efficiency. We then addressed the role of specific brain regions in the network organization by calculating the node-specific "betweeness centrality", "degree centrality" and "local average path length" metrics: different ways of assessing a region's importance in a network. We focused our analysis on the anterior cingulate cortex (ACC): a region known to support executive function that is structurally and functionally impaired in at-risk mental state patients. Although global network connectivity and efficiency were maintained in at-risk patients relative to the controls, we report a significant decrease in the contribution of the ACC to task-relevant network organization in at risk subjects with elevated symptoms (PANSS 45) relative to both the controls and the less symptomatic at-risk subjects, as reflected by a reduction in the topological centrality of the ACC. These findings provide evidence of network abnormalities and anterior cingulate cortex dysfunction in people with prodromal signs of schizophrenia. (C) 2011 Elsevier Inc. Alrrights reserved.
C1 [Lord, Louis-David; Howes, Oliver; Turkheimer, Federico E.] Univ London Imperial Coll Sci Technol & Med, Dept Expt Med, London, England.
[Allen, Paul; Howes, Oliver; McGuire, Philip] Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
[Expert, Paul; Lambiotte, Renaud] Univ London Imperial Coll Sci Technol & Med, Inst Math Sci, London, England.
[Howes, Oliver; Bose, Subrata K.; Turkheimer, Federico E.] Hammersmith Hosp, MRC, Ctr Clin Sci, London, England.
[Lord, Louis-David; Hyde, Samuel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula Martinos Ctr Biomed Imaging, Boston, MA USA.
RP Lord, LD (reprint author), 2 Hawthorne Pl,Suite 5B, Boston, MA 02114 USA.
EM LDL@nmr.mgh.harvard.edu
RI Lambiotte, Renaud/C-1085-2009; Turkheimer, Federico/B-9485-2012; Expert,
Paul/E-7697-2012; Howes, Oliver/E-7156-2010;
OI Lambiotte, Renaud/0000-0002-0583-4595; Turkheimer,
Federico/0000-0002-3766-3815; Howes, Oliver/0000-0002-2928-1972; Allen,
Paul/0000-0001-8510-878X
FU EPSRC [EP/E049451/1]; MRC [U.1200.04.007.00001.01]
FX the project has been funded in part by the EPSRC grant EP/E049451/1 and
MRC grant U.1200.04.007.00001.01.
NR 55
TC 30
Z9 31
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JUN 1
PY 2011
VL 56
IS 3
BP 1531
EP 1539
DI 10.1016/j.neuroimage.2011.02.012
PG 9
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 764RF
UT WOS:000290649300066
PM 21316462
ER
PT J
AU Celone, KA
Thompson-Brenner, H
Ross, RS
Pratt, EM
Stern, CE
AF Celone, Kim A.
Thompson-Brenner, Heather
Ross, Robert S.
Pratt, Elizabeth M.
Stern, Chantal E.
TI An fMRI investigation of the fronto-striatal learning system in women
who exhibit eating disorder behaviors
SO NEUROIMAGE
LA English
DT Article
DE Eating disorders; fMRI; Fronto-striatal system; Weather prediction task;
Bulimia nervosa; Memory system interactions
ID MEDIAL TEMPORAL-LOBE; BULIMIA-NERVOSA; MEMORY-SYSTEMS;
PARKINSONS-DISEASE; NEURONAL-ACTIVITY; ANOREXIA-NERVOSA; COGNITIVE
SKILL; FUNCTIONAL MRI; BASAL GANGLIA; HUMAN BRAIN
AB In the present study, we sought to examine whether the fronto-striatal learning system, which has been implicated in bulimia nervosa, would demonstrate altered BOLD activity during probabilistic category learning in women who met subthreshold criteria for bulimia nervosa (Sub-BN). Sub-BN, which falls within the clinical category of Eating Disorder Not Otherwise Specified (EDNOS). is comprised of individuals who demonstrate recurrent binge eating, efforts to minimize their caloric intake and caloric retention, and elevated levels of concern about shape, weight, and/or eating, but just fail to meet the diagnostic threshold for bulimia nervosa (BN). fMRI data were collected from eighteen women with subthreshold-BN (Sub-BN) and nineteen healthy control women group-matched for age, education and body mass index (MC) during the weather prediction task. Sub-BN participants demonstrated increased caudate nucleus and dorsolateral prefrontal cortex (DLPFC) activation during the learning of probabilistic categories. Though the two subject groups did not differ in behavioral performance, over the course of learning, Sub-BN participants showed a dynamic pattern of brain activity differences when compared to matched control participants. Regions implicated in episodic memory, including the medial temporal lobe (MTL), retrosplenial cortex, middle frontal gyrus, and anterior and posterior cingulate cortex showed decreased activity in the Sub-BN participants compared to MCs during early learning which was followed by increased involvement of the DLPFC during later learning. These findings demonstrate that women with Sub-BN demonstrate differences in fronto-striatal learning system activity, as well as a distinct functional pattern between fronto-striatal and MTL learning systems during the course of implicit probabilistic category learning. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Celone, Kim A.; Thompson-Brenner, Heather; Ross, Robert S.; Pratt, Elizabeth M.; Stern, Chantal E.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Celone, Kim A.; Ross, Robert S.; Stern, Chantal E.] Boston Univ, Silvio O Conte Ctr Memory & Brain, Boston, MA 02215 USA.
[Celone, Kim A.; Ross, Robert S.; Stern, Chantal E.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Thompson-Brenner, Heather; Pratt, Elizabeth M.] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA.
[Stern, Chantal E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Celone, KA (reprint author), Boston Univ, Ctr Memory & Brain, 2 Cummington St,Rm 109, Boston, MA 02143 USA.
EM kcelone@bu.edu
OI Ross, Robert/0000-0002-3987-881X
FU Boston University Department of Psychology; National Center for Research
Resources [P41RR14075]
FX This research was supported by the Boston University Department of
Psychology, and National Center for Research Resources (P41RR14075). We
thank Dr. Russell Poldrack and Dr. Karin Foerde for providing their
weather prediction task experimental design, as well as Jessica Saurman
for her help with participant recruitment. We also thank Mary Foley,
Larry White, and the Martinos Center staff for assistance with magnetic
resonance imaging data collection.
NR 51
TC 11
Z9 12
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JUN 1
PY 2011
VL 56
IS 3
BP 1749
EP 1757
DI 10.1016/j.neuroimage.2011.03.026
PG 9
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 764RF
UT WOS:000290649300089
PM 21419229
ER
PT J
AU Geser, F
Malunda, JA
Hurtig, HI
Duda, JE
Wenning, GK
Gilman, S
Low, PA
Lee, VMY
Trojanowski, JQ
AF Geser, F.
Malunda, J. A.
Hurtig, H. I.
Duda, J. E.
Wenning, G. K.
Gilman, S.
Low, P. A.
Lee, V. M. -Y.
Trojanowski, J. Q.
TI TDP-43 pathology occurs infrequently in multiple system atrophy
SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
LA English
DT Article
DE 43-kDa transactive response DNA-binding protein; multiple system atrophy
ID AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION;
MOTOR-NEURON DISEASE; GROUP EMSA-SG; ALZHEIMERS-DISEASE; CYTOPLASMIC
INCLUSIONS; ALPHA-SYNUCLEIN; WHITE-MATTER; DNA-BINDING; DEMENTIA
AB Aims and Methods: The alpha-synucleinopathy multiple system atrophy (MSA) and diseases defined by pathological 43-kDa transactive response DNA-binding protein (TDP-43) or fused in sarcoma (FUS) aggregates such as amyotrophic lateral sclerosis and frontotemporal lobar degeneration show overlapping clinico-pathological features. Consequently, we examined MSA for evidence of TDP-43 or FUS pathology utilizing immunohistochemical studies in autopsy material from 29 MSA patients. Results: TDP-43 pathology was generally rare, and there were no FUS lesions. The TDP-43 lesions were located predominantly in medio-temporal lobe and subcortical brain areas and were comprised mainly of dystrophic processes and perivascular (and subpial) lesions. Conclusions: The multisystem clinical symptoms and signs of MSA, and in particular the neurobehavioural/cognitive and pyramidal features, appear not to result from concomitant TDP-43 or FUS pathology, but rather from widespread white matter alpha-synuclein positive glial cytoplasmic inclusions and neurodegeneration in keeping with a primary alpha-synuclein-mediated oligodendrogliopathy. The gliodegenerative disease MSA evidently results from different pathogenetic mechanisms than neurodegenerative diseases linked to pathological TDP-43.
C1 [Geser, F.; Malunda, J. A.; Lee, V. M. -Y.; Trojanowski, J. Q.] Univ Penn, Sch Med, HUP, Ctr Neurodegenerat Dis Res,Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Hurtig, H. I.; Duda, J. E.] Univ Penn, Sch Med, Penn Hosp, Dept Neurol, Philadelphia, PA 19104 USA.
[Duda, J. E.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA.
[Gilman, S.] Univ Michigan, Dept Neurol, Michigan Alzheimers Dis Res Ctr, Ann Arbor, MI USA.
[Low, P. A.] Mayo Clin, Dept Neurol, Rochester, MN USA.
[Wenning, G. K.] Innsbruck Med Univ, Neurodegenerat Res Lab, Div Clin Neurobiol, Innsbruck, Austria.
RP Trojanowski, JQ (reprint author), Univ Penn, Sch Med, HUP, Ctr Neurodegenerat Dis Res,Dept Pathol & Lab Med, Maloney 3rd Floor,36th & Spruce St, Philadelphia, PA 19104 USA.
EM trojanow@mail.med.upenn.edu
FU National Institutes of Health [AG-10124, AG-17586, NS044233, NS 32352,
NS 44233, NS 22352, NS 43364]; Mayo CTSA [UL1 RR24150]; Mayo Funds;
Federal Ministry of Education and Science, Vienna, Austria
FX This work was funded by grants from the National Institutes of Health
(AG-10124, AG-17586 and NS044233, NS 32352, NS 44233, NS 22352, NS
43364), Mayo CTSA (UL1 RR24150) and Mayo Funds. Dr Virginia M.-Y. Lee is
the John H. Ware III Chair of Alzheimer's Research and Dr John Q.
Trojanowski is the William Maul Measey-Truman G. Schnabel, Jr., MD
Professor of Geriatric Medicine and Gerontology. Dr Sid Gilman is the
William J. Herdman Distinguished University Professor of Neurology. Dr
Gregor K. Wenning is Professor of Neurology and Clinical Neurobiology
and he has received a Neuroscience Centre Grant by the Federal Ministry
of Education and Science, Vienna, Austria. We thank the families of
patients whose generosity made this research possible. We also thank Dr
Manuela Neumann for providing us with the anti-phosporylated TDP-43
antibody (S409/410), John Robinson, BS, for the comments on the
manuscript, and our colleagues at the Center for Neurodegenerative
Disease Research and Department of Psychiatry, University of
Pennsylvania School of Medicine, for their technical support and advice,
particularly Theresa Schuck, BA, Lauren Stutzbach, BA, Michael Partain,
BA and Mfon Umoh.
NR 50
TC 5
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0305-1846
J9 NEUROPATH APPL NEURO
JI Neuropathol. Appl. Neurobiol.
PD JUN
PY 2011
VL 37
IS 4
BP 358
EP 365
DI 10.1111/j.1365-2990.2010.01136.x
PG 8
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 763WA
UT WOS:000290589200003
PM 20942898
ER
PT J
AU Cohen, AW
Copel, JA
Macones, GA
Menard, MK
Riley, L
Saade, GR
AF Cohen, Arnold W.
Copel, Joshua A.
Macones, George A.
Menard, M. Kathryn
Riley, Laura
Saade, George R.
TI Unjustified Increase in Cost of Care Resulting From US Food and Drug
Administration Approval of Makena (17 alpha-Hydroxyprogesterone
Caproate)
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID PRETERM DELIVERY; PREVENTION
AB U.S. Food and Drug Administration (FDA) approval of 17 alpha-hydroxyprogesterone caproate for the indication of decreasing the risk of preterm delivery in those high-risk patients who previously had spontaneous preterm birth has come at considerable cost to the health care system. Weekly injections provided by compounding pharmacies starting at 16-20 weeks of gestation and continuing until 36 weeks currently cost the health care system $200 to $300 per pregnancy. This cost is significantly less than the costs associated with delivering and caring for preterm children. Makena, by KV Pharmaceutical, the same 17 alpha-hydroxyprogesterone caproate product, is priced at $1,500 per injection, or a projected cost of $30,000 per pregnancy. With approximately 132,000 pregnancies being eligible for treatment annually, this increase in cost of 75-150 times what previously had been paid far exceeds the benefits derived from the FDA-approved Makena when compared with previously available compounded versions of 17 alpha-hydroxyprogesterone caproate. This increased health care cost is not justified at this time. The price barrier to access imposed by KV Pharmaceutical actually could result in an increase in preterm deliveries over current rates. Actions are needed by the FDA, national societies, and the manufacturer to ensure that all high-risk patients continue to get the needed therapy to reduce the number of preterm births. (Obstet Gynecol 2011;117:1408-12) DOI: 10.1097/AOG.0b013e31821c2d75
C1 Albert Einstein Med Ctr, Philadelphia, PA 19141 USA.
Yale Univ, Sch Med, New Haven, CT USA.
Washington Univ, Sch Med, St Louis, MO USA.
Univ N Carolina, Sch Med, Chapel Hill, NC USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Texas Med Branch, Galveston, TX USA.
RP Menard, MK (reprint author), CB 7516,3010 Old Clin Bldg, Chapel Hill, NC 27599 USA.
EM kmenard@med.unc.edu
NR 6
TC 11
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD JUN
PY 2011
VL 117
IS 6
BP 1408
EP 1410
DI 10.1097/AOG.0b013e31821c2d75
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 768AT
UT WOS:000290904200023
PM 21471853
ER
PT J
AU Lobo, AM
Stacy, R
Cestari, D
Stone, JH
Jakobiec, FA
Sobrin, L
AF Lobo, Ann-Marie
Stacy, Rebecca
Cestari, Dean
Stone, John H.
Jakobiec, Frederick A.
Sobrin, Lucia
TI Optic Nerve Involvement with Panuveitis in Sweet Syndrome
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE infliximab; neuro-Sweet; optic nerve; sweet syndrome
ID FEBRILE NEUTROPHILIC DERMATOSIS; DISEASE; MANIFESTATIONS
AB Purpose: To report a case of a patient with optic nerve involvement in neuro-Sweet syndrome and review the literature on this systemic disease.
Methods: Interventional case report and review of the literature.
Results: A 49-year-old man developed an acute exacerbation of bilateral panuveitis and optic disc edema together with symptoms of a papular rash on his forearms, fevers, malaise, and arthalgias. Laboratory findings revealed an aseptic meningitis and neutrophilic leukocytosis. Biopsy of the skin rash demonstrated an intense neutrophilic infiltrate in the dermis consistent with the diagnosis of neuro-Sweet syndrome. The patient continued to require corticosteroids for inflammation control in spite of immunomodulatory therapies, including tumor necrosis factor-alpha inhibitor infliximab.
Conclusions: Sweet syndrome can present with optic nerve involvement. Screening for underlying etiologies, including autoimmune disease, malignancy, and offending drugs, is important for targeted therapy.
C1 [Lobo, Ann-Marie; Stacy, Rebecca; Cestari, Dean; Jakobiec, Frederick A.; Sobrin, Lucia] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Stone, John H.] Massachusetts Gen Hosp, Dept Rheumatol, Boston, MA 02114 USA.
RP Lobo, AM (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM Ann-Marie_Lobo@meei.harvard.edu
FU NIH [EY16335-02]
FX Supported by a Research to Prevent Blindness Career Development Award
(L.S.), NIH EY16335-02 (L.S.), and a Harvard Catalyst Program for
Faculty Development and Diversity Faculty Fellowship
NR 19
TC 5
Z9 6
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0927-3948
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD JUN
PY 2011
VL 19
IS 3
BP 167
EP 170
DI 10.3109/09273948.2011.560411
PG 4
WC Ophthalmology
SC Ophthalmology
GA 766DH
UT WOS:000290760700004
PM 21595532
ER
PT J
AU Kolesar, JM
Dahlberg, SE
Marsh, S
McLeod, HL
Johnson, DH
Keller, SM
Schiller, JH
AF Kolesar, Jill M.
Dahlberg, Suzanne E.
Marsh, Sharon
McLeod, Howard L.
Johnson, David H.
Keller, Steven M.
Schiller, Joan H.
TI The NQO1*2/*2 polymorphism is associated with poor overall survival in
patients following resection of stages II and IIIa non-small cell lung
cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE lung cancer; NAD(P)H:quinone oxidoreductase 1; polymorphism; p53
ID POSTOPERATIVE ADJUVANT THERAPY; PROTEASOMAL DEGRADATION;
PROGNOSTIC-SIGNIFICANCE; RANDOMIZED-TRIAL; ONCOLOGY-GROUP;
DT-DIAPHORASE; P53; NQO1; CHEMOSENSITIVITY; CHEMOTHERAPY
AB NAD(P)H:quinone oxidoreductase 1 (NQO1), is a cytosolic flavoenzyme that catalyzes the two-electron reduction of quinones into hydroquinones. A polymorphism (NQO1*2) alters enzymatic activity of NQO1 resulting in diminished NQO1 activity. Malignancies with NQO1*2 may be resistant to radiation and chemotherapy with resulting poorer survival. NQO1 allele was evaluated in subjects enrolled in ECOG 3590, a randomized comparison of radiation (RT) vs radiation and chemotherapy with cisplatin/etoposide (RCT) in patients with completely resected stages II and IIIa NSCLC. Overall survival was estimated using the Kaplan-Meier method and compared via the log-rank test. Cox models were used to assess the impact of covariates on outcomes. Among 152 patients with assessable samples, 24 (16%) had NQO1*2. Median follow-up was 139 months. The presence of NQO1*2/*2 was associated with decreased overall survival (OS) (median in the heterozygote/wild-type group 42.3 vs. 33.5 months in the variant group, p=0.04). In a multivariable Cox model, variant NQO1 (HR=1.58, p=0.05), age < 60 (HR=0.67, p=0.04), PS 1 (HR=1.47, p=0.05), cardiovascular disease (HR=1.93, p=0.003) and alkaline phosphatase < 100 mg/ml (HR=0.59, p=0.005) were all significant predictors of OS. NQO1*2/*2 may be an independent predictor of poor overall survival in individuals with resected stages II and IIIa NSCLC. Although the basis for the NQO1 association with decreased survival requires additional evaluation, NQO1 may represent a biomarker for guiding individualized therapy.
C1 [Kolesar, Jill M.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53792 USA.
[Kolesar, Jill M.] Univ Wisconsin, Sch Pharm, Madison, WI 53792 USA.
[Dahlberg, Suzanne E.] Univ Alberta, Eastern Cooperat Oncol Grp, Edmonton, AB, Canada.
[Marsh, Sharon] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
[Dahlberg, Suzanne E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[McLeod, Howard L.] Univ N Carolina, Chapel Hill, NC USA.
[Johnson, David H.] Vanderbilt Univ, Nashville, TN USA.
[Keller, Steven M.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Schiller, Joan H.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Kolesar, JM (reprint author), Univ Wisconsin, Ctr Comprehens Canc K4 554, 600 Highland Ave, Madison, WI 53792 USA.
EM jmkolesar@pharmacy.wisc.edu
FU NIH Pharmacogenetics Research Network [GM63340]; ACCP; American Cancer
Society
FX This study was supported by the ACCP Oncology Research Award, the NIH
Pharmacogenetics Research Network (GM63340), and the American Cancer
Society.
NR 26
TC 10
Z9 10
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD JUN
PY 2011
VL 25
IS 6
BP 1765
EP 1772
DI 10.3892/or.2011.1249
PG 8
WC Oncology
SC Oncology
GA 764RI
UT WOS:000290649600037
PM 21479364
ER
PT J
AU Tian, YH
Wang, SX
Ma, YX
Lim, G
Kim, H
Mao, JR
AF Tian, Yinghong
Wang, Shuxing
Ma, Yuxin
Lim, Grewo
Kim, Hyangin
Mao, Jianren
TI Leptin enhances NMDA-induced spinal excitation in rats: A functional
link between adipocytokine and neuropathic pain
SO PAIN
LA English
DT Article
DE Leptin; NMDA receptor; Neuropathic pain; JAK2/STAT3; Patch-clamp
recording; Hyperalgesia; Allodynia
ID DORSAL-HORN NEURONS; CENTRAL-NERVOUS-SYSTEM; HIPPOCAMPAL SYNAPTIC
PLASTICITY; SUBSTANTIA GELATINOSA NEURONS; LONG-TERM POTENTIATION;
GENE-EXPRESSION; RECEPTOR EXPRESSION; PITUITARY-GLAND; SERUM LEPTIN;
DB/DB MICE
AB Recent studies have shown that leptin (an adipocytokine) played an important role in nociceptive behavior induced by nerve injury, but the cellular mechanism of this action remains unclear. Using the whole-cell patch-clamp recording from rat's spinal cord slices, we showed that superfusion of leptin onto spinal cord slices dose-dependently enhanced N-methyl-D-aspartate (NMDA) receptor-mediated currents in spinal cord lamina II neurons. At the cellular level, the effect of leptin on spinal NMDA-induced currents was mediated through the leptin receptor and the JAK2/STAT3 (but not PI3K or MAPK) pathway, as the leptin effect was abolished in leptin receptor-deficient (db/db) mice and inhibited by a JAK/STAT inhibitor. Moreover, we demonstrated in naive rats that a single intrathecal administration of leptin enhanced spontaneous biting, scratching, and licking behavior induced by intrathecal NMDA and that repeated intrathecal administration of leptin elicited thermal hyperalgesia and mechanical allodynia, which was attenuated by the noncompetitive NMDA receptor antagonist MK-801. Intrathecal leptin also upregulated the expression of NMDA receptors and pSTAT3 within the rat's spinal cord dorsal horn, and intrathecal MK-801 attenuated this leptin effect as well. Our data demonstrate a relationship between leptin and NMDA receptor-mediated spinal neuronal excitation and its functional role in nociceptive behavior. Since leptin contributes to nociceptive behavior induced by nerve injury, the present findings suggest an important cellular link between the leptin's spinal effect and the NMDA receptor-mediated cellular mechanism of neuropathic pain. (C) 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
C1 [Tian, Yinghong; Wang, Shuxing; Ma, Yuxin; Lim, Grewo; Kim, Hyangin; Mao, Jianren] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, Boston, MA 02114 USA.
[Tian, Yinghong] So Med Univ, Dept Physiol, Guangzhou 510515, Guangdong, Peoples R China.
RP Mao, JR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, Boston, MA 02114 USA.
EM jmao@partners.org
FU National Institutes of Health [P20DA26002, RO1DE18214, RO1DE18538]
FX This study was supported by National Institutes of Health Grants
P20DA26002, RO1DE18214, and RO1DE18538.
NR 68
TC 29
Z9 31
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3959
J9 PAIN
JI Pain
PD JUN
PY 2011
VL 152
IS 6
BP 1263
EP 1271
DI 10.1016/j.pain.2011.01.054
PG 9
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA 765MD
UT WOS:000290710100012
PM 21376468
ER
PT J
AU Kaplan, JL
Shi, HN
Walker, WA
AF Kaplan, Jess L.
Shi, Hai Ning
Walker, W. Allan
TI The Role of Microbes in Developmental Immunologic Programming
SO PEDIATRIC RESEARCH
LA English
DT Review
ID PLACEBO-CONTROLLED TRIAL; FORMULA-FED INFANTS; DUST-MITE ALLERGEN;
IMMUNE-RESPONSES; CORD BLOOD; IN-UTERO; NECROTIZING ENTEROCOLITIS;
INTESTINAL MICROBIOTA; FOLLOW-UP; ATOPIC-DERMATITIS
AB The role of microorganisms in the gastrointestinal tract has undergone significant modification in the past few decades with new observations from clinical, epidemiologic, and basic science research. We now know that the perception of these gut microbes as pathogens or even as commensals is somewhat outdated. It is becoming increasingly clear that the gut microbiome plays an important role in a host of activities including digestion, protection from potentially pathogenic organisms, and the regulation and development of the host immune system. The complex interactions between microbes and host combined with recent clinical observations and epidemiologic trends may point to the convergence of two well-supported (though imperfect) hypotheses: the "hygiene hypothesis" and the "fetal programming hypothesis." We are beginning to understand that exposure to microbes before conception, during gestation, and in the neonatal period have profound effects on the developing immune system. Recent observations from a variety of fields help support the expansion of the "fetal programming hypothesis" to a host-microbe corollary that microbe-host interactions at critical windows influence the future immune phenotype, the maintenance of immune health, and the development of immune-mediated disease. (Pediatr Res 69: 465-472, 2011)
C1 Harvard Univ, MassGen Hosp Children, Sch Med, Dept Pediat, Boston, MA 02114 USA.
Harvard Univ, MassGen Hosp Children, Sch Med, Mucosal Immunol Lab, Boston, MA 02114 USA.
RP Walker, WA (reprint author), MassGen Hosp Children, Mucosal Immunol Lab, 114 16th St 114-3503, Charlestown, MA 02129 USA.
EM wwalker@partners.org
FU NIDDK NIH HHS [R01 DK082427]
NR 108
TC 69
Z9 72
U1 3
U2 34
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 W CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD JUN
PY 2011
VL 69
IS 6
BP 465
EP 472
DI 10.1203/PDR.0b013e318217638a
PG 8
WC Pediatrics
SC Pediatrics
GA 767CA
UT WOS:000290831700001
PM 21364495
ER
PT J
AU Hwang, NS
Im, SG
Wu, PB
Bichara, DA
Zhao, X
Randolph, MA
Langer, R
Anderson, DG
AF Hwang, Nathaniel S.
Im, Sung Gap
Wu, Patrick B.
Bichara, David A.
Zhao, Xing
Randolph, Mark A.
Langer, Robert
Anderson, Daniel G.
TI Chondrogenic Priming Adipose-Mesenchymal Stem Cells for Cartilage Tissue
Regeneration
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE auricular chondrocytes; cartilage; co-culture; human adipose derived
mesenchymal stem cells; tissue engineering
ID IN-VIVO; OSTEOGENIC DIFFERENTIATION; MATURE CHONDROCYTES; REPAIR;
MONOLAYER; SIGNALS; PROTEIN
AB Purpose Chondrocytes lose their ability to produce cartilaginous matrix during multiplication in culture through repeated passages, resulting in inferior tissue phenotype. To overcome the limited amount of primary chondrocytes, we aimed to determine the optimal culture condition for in vitro/in vivo cartilage regeneration using human adipose-derived mesenchymal stem cells (AMSCs).
Methods To evaluate the effects exerted by the chondrocytic culture condition on AMSC, we utilized chondrocyte conditioned medium (CM) and/or co-culture methods to prime and differentiate AMSCs. We evaluated ultimate in vivo engineered cartilage with primed AMSCs with that of chondrocytes. To examine the link between conditioned factors and proliferation/differentiation, cell cycle progression of AMSCs were examined using 5-ethynyl-2'-deoxyuridine (EdU), and gene expression was monitored.
Results We report that AMSCs can be stimulated to become chondrogenic cells when expanded with chondrocyte CM. Polymeric scaffolds co-seeded with CM-expanded AMSCs and primary chondrocytes resulted in in vivo cartilaginous tissues with similar biochemical content to constructs seeded with chondrocytes alone.
Conclusion These results indicate that chondrocyte CM consists of suitable morphogenetic factors that induce the chondrogenic priming of AMSCs for cartilage tissue engineering.
C1 [Im, Sung Gap; Langer, Robert; Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Hwang, Nathaniel S.; Wu, Patrick B.; Langer, Robert; Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Im, Sung Gap] Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Taejon 305701, South Korea.
[Bichara, David A.; Zhao, Xing; Randolph, Mark A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Plast Surg Res Lab, Boston, MA 02114 USA.
RP Anderson, DG (reprint author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
EM dgander@mit.edu
RI Im, Sung Gap/C-1823-2011
OI Im, Sung Gap/0000-0002-2802-6398
FU Armed Forces Institute of Regenerative Medicine [W81XWH-08-2-0034]
FX This research was sponsored by the Armed Forces Institute of
Regenerative Medicine award number W81XWH-08-2-0034. The U.S. Army
Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick
MD 21702-5014 is the awarding and administering acquisition office. The
content of the study does not necessarily reflect the position or the
policy of the Government, and no official endorsement should be
inferred.
NR 39
TC 24
Z9 29
U1 1
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUN
PY 2011
VL 28
IS 6
BP 1395
EP 1405
DI 10.1007/s11095-011-0445-2
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 766RK
UT WOS:000290804000015
PM 21494923
ER
PT J
AU Woodby, LL
Williams, BR
Wittich, AR
Burgio, KL
AF Woodby, Lesa L.
Williams, Beverly Rosa
Wittich, Angelina R.
Burgio, Kathryn L.
TI Expanding the Notion of Researcher Distress: The Cumulative Effects of
Coding
SO QUALITATIVE HEALTH RESEARCH
LA English
DT Article
DE coding; data collection and management; emotions / emotion work;
end-of-life issues; research, qualitative; risk; stress / distress
ID QUALITATIVE HEALTH RESEARCH; METHODOLOGICAL ISSUES; SENSITIVE TOPICS;
LAST HOURS; LIFE; INTERVIEW; CANCER; CARE; REFLECTIONS; EXPLORATION
AB Qualitative researchers who explore the individual's experience of health, illness, death, and dying often experience emotional stress in their work. In this article, we describe the emotional stress we experienced while coding semistructured, after-death interviews conducted with 38 next of kin of deceased veterans. Coding sensitive topic data required an unexpected level of emotional labor, the impact of which has not been addressed in the literature. In writing this discussion article, we stepped back from our roles as interviewers/coders and reflected on how our work affected us individually and as a team, and how a sequence of exposures could exert a cumulative effect for researchers in such a dual role. Through this article, we hope to generate an expanded discourse on how qualitative inquiry impacts the emotional well-being of researchers.
C1 [Woodby, Lesa L.] Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA.
RP Woodby, LL (reprint author), Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, GRECC 11G,700 S 19th St, Birmingham, AL 35233 USA.
EM Lesa.Woodby@va.gov
NR 72
TC 18
Z9 19
U1 2
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-7323
J9 QUAL HEALTH RES
JI Qual. Health Res.
PD JUN
PY 2011
VL 21
IS 6
BP 830
EP 838
DI 10.1177/1049732311402095
PG 9
WC Information Science & Library Science; Social Sciences,
Interdisciplinary; Social Sciences, Biomedical
SC Information Science & Library Science; Social Sciences - Other Topics;
Biomedical Social Sciences
GA 759BH
UT WOS:000290214400009
PM 21393618
ER
PT J
AU Fennessy, FM
Kong, CY
Tempany, CM
Swan, JS
AF Fennessy, Fiona M.
Kong, Chung Yin
Tempany, Clare M.
Swan, J. Shannon
TI Quality-of-Life Assessment of Fibroid Treatment Options and Outcomes
SO RADIOLOGY
LA English
DT Article
ID FOCUSED ULTRASOUND SURGERY; UTERINE ARTERY EMBOLIZATION;
COST-EFFECTIVENESS; RHEUMATOID-ARTHRITIS; PROCESS UTILITY; HEALTH;
LEIOMYOMAS; DISEASE; HYSTERECTOMY; INSTRUMENTS
AB Purpose: To obtain utilities (a unit of measure of a person's relative preferences for different health states compared with death or worst possible outcome) for uterine fibroids before and after treatment and to measure short-term utilities for the following uterine fibroid treatments: abdominal hysterectomy, magnetic resonance (MR) imaging-guided focused ultrasound surgery, and uterine artery embolization (UAE).
Materials and Methods: This retrospective study was approved by the institutional review board and was HIPAA compliant. The waiting trade-off (WTO) method, a variation on the time trade-off (TTO) method, is used to obtain utilities for diagnostic procedures on the basis of the fact that people wait longer to avoid noxious tests and/or procedures. The WTO method provides short-term quality of life tolls in terms of quality-adjusted life-weeks by scaling wait times with pre-and posttreatment utilities. Utilities for uterine fibroids before and after treatment were obtained with the TTO method and a visual analog scale (VAS) by using a questionnaire administered by means of a phone interview. WTO wait times were adjusted for quality of life with VAS and TTO utilities and a transformation of VAS. Wait times were compared by using nonparametric tests. The study participants included 62 patients who had undergone abdominal hysterectomy, 74 who had undergone UAE, and 61 who had undergone MR imaging-guided focused ultrasound surgery.
Results: Quality of life increased with all treatments. The median WTO wait time was higher for hysterectomy (21.6 weeks) than for UAE or MR imaging-guided focused ultrasound surgery (14.1 weeks for both) (P < .05). Quality-adjusted life-week tolls were smaller when scaled according to TTO than when scaled according to VAS or transformation of VAS.
Conclusion: Quality of life increased after all fibroid treatments. WTO is feasible for assessing the quality-adjusted morbidity of treatment procedures. (C) RSNA, 2011
C1 [Fennessy, Fiona M.; Tempany, Clare M.] Harvard Univ, Sch Med, Dept Radiol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Kong, Chung Yin; Swan, J. Shannon] Harvard Univ, Sch Med, Inst Technol Assessment, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Fennessy, FM (reprint author), Harvard Univ, Sch Med, Dept Radiol, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM ffennessy@partners.org
FU General Electric AUR Radiology Research Academic Fellowship (GERRAF);
National Institutes of Health [U41-RR019703]; InSightec
FX F.M.F. supported by General Electric AUR Radiology Research Academic
Fellowship (GERRAF).; This research was supported in part by the
National Institutes of Health (grant U41-RR019703).; F.M.F. Financial
activities related to the present article: none to disclose. Financial
activities not related to the present article: none to disclose. Other
relationships: none to disclose. C. H. K. Financial activities related
to the present article: none to disclose. Financial activities not
related to the present article: none to disclose. Other relationships:
none to disclose. C. M. T. Financial activities related to the present
article: receives a consulting fee or honorarium from InSightec;
institution received money from InSightec for clinical trial support.
Financial activities not related to the present article: none to
disclose. Other relationships: none to disclose. J.S.S. Financial
activities related to the present article: none to disclose. Financial
activities not related to the present article: none to disclose. Other
relationships: none to disclose.
NR 40
TC 12
Z9 13
U1 0
U2 3
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUN
PY 2011
VL 259
IS 3
BP 785
EP 792
DI 10.1148/radiol.11100704
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767ZB
UT WOS:000290898100018
PM 21364084
ER
PT J
AU Deatrick, JA
Given, B
AF Deatrick, Janet A.
Given, Barbara
TI Creating a Pipeline for Tomorrow's Nurse Researchers
SO RESEARCH IN NURSING & HEALTH
LA English
DT Editorial Material
ID HIGH-SCHOOL-STUDENTS; EDUCATION; RETENTION; PROGRAM
C1 [Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA.
[Given, Barbara] Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA.
RP Deatrick, JA (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Room 223,Claire M Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA.
NR 23
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0160-6891
J9 RES NURS HEALTH
JI Res. Nurs. Health
PD JUN
PY 2011
VL 34
IS 3
BP 171
EP 175
DI 10.1002/nur.20436
PG 5
WC Nursing
SC Nursing
GA 762EG
UT WOS:000290455000002
PM 21520145
ER
PT J
AU Gould, J
Ellsmere, J
Fanelli, R
Hutter, M
Jones, S
Pratt, J
Schauer, P
Schirmer, B
Schwaitzberg, S
Jones, DB
AF Gould, J.
Ellsmere, J.
Fanelli, R.
Hutter, M.
Jones, S.
Pratt, J.
Schauer, P.
Schirmer, B.
Schwaitzberg, S.
Jones, D. B.
TI Panel report: best practices for the surgical treatment of obesity
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article
DE Bariatric surgery; Weight loss surgery; Patient safety
ID WEIGHT-LOSS SURGERY; LAPAROSCOPIC GASTRIC BYPASS; BARIATRIC SURGERY;
SLEEP-APNEA; INFORMED-CONSENT; MORBID-OBESITY; RECOMMENDATIONS;
ADOLESCENTS; EDUCATION; CHILDREN
AB Background Bariatric surgery is a rapidly growing field. Advances in surgical technologies and techniques have raised concerns about patient safety. Bariatric surgeons and programs are under increased scrutiny from regulatory agencies, insurers, and public health officials to provide high quality and safe care for bariatric patients at all phases of care.
Methods During the 2009 annual meeting of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), a panel of experts convened to provide updated information on patient safety and best practices in bariatric surgery. The following article is a summary of this panel presentation.
Results and Conclusions Weight loss surgery is a field that is evolving and adapting to multiple external pressures. Safety concerns along with increasing public scrutiny have led to a systematic approach to defining best practices, creating standards of care, and identifying mechanisms to ensure that patients consistently receive the best and most effective care possible. In many ways, bariatric surgery and multidisciplinary bariatric surgery programs may serve as a model for other programs and surgical specialties in the near future.
C1 [Gould, J.] Univ Wisconsin, Sch Med, Clin Sci Ctr H4 726, Madison, WI 53792 USA.
[Ellsmere, J.] Dalhousie Univ, Div Gen Surg, Halifax, NS, Canada.
[Fanelli, R.] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA USA.
[Hutter, M.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Jones, S.] Beth Israel Deaconess Med Ctr, Dept Anesthesia, Boston, MA 02215 USA.
[Pratt, J.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Schauer, P.] Cleveland Clin, Dept Surg, Cleveland, OH 44106 USA.
[Schirmer, B.] Univ Virginia, Dept Surg, Charlottesville, VA USA.
[Schwaitzberg, S.] Cambridge Hlth Alliance, Dept Surg, Cambridge, MA USA.
[Jones, D. B.] Beth Israel Deaconess Med Ctr, Sect Minimally Invas Surg, Boston, MA 02215 USA.
RP Gould, J (reprint author), Univ Wisconsin, Sch Med, Clin Sci Ctr H4 726, 600 Highland Ave, Madison, WI 53792 USA.
EM gould@surgery.wisc.edu
OI Jones, Stephanie/0000-0001-8342-0374
FU Gore; Baxter; Covidien; Allergan; Ethicon; Cinemed
FX Dr. Gould serves as a speaker for Covidien. Dr. Ellsmere serves as a
consultant for Ethicon. Dr. Fanelli is a consultant and a speaker for
Ethicon, is on the surgeon advisory board and provides research support
for RTI Biologics, serves on the medical advisory board for Polytouch
Medical, is a consultant and provides research support for Bracco
Diagnostics, and serves as a consultant and receives a royalty stream
from Cook Medical. For New Wave Surgical he is an owner, serves on the
Board of Directors, and the Medical Advisory Board. Dr. Pratt serves as
a consultant for Covidien and as a Scientific Advisor for Boston
Scientific. Dr. Schauer is a consultant, a research grant recipient, and
serves on the Scientific Advisory Board for Ethicon. He serves on the
Board of Directors for Remedy MD. He has received an Educational Grant
and serves on the Scientific Advisory Board for Stryker. He is a
consultant, a research grant recipient, and serves on the Scientific
Advisory Board for Bard-Davol. He is a consultant and the recipient of a
research grant from Gore. He has received an educational grant from
Baxter. He serves on the Scientific Advisory Board for Barosense,
Surgiquest, and Cardinal/Snowden Pencer. He has received educational
grants from Covidien and Allergan. He is also on the Board of Directors
for Surgical Excellence LLC. Dr. Schwaitzberg serves as a consultant for
Olympus, Stryker, Surgiquest, Cambridge Endoscopy, Endocore, and Acuity
Bio. Dr. Daniel Jones serves as a consultant for Olympus, Allergan,
Stryker, and Surgiquest; he is the recipient of training grants from
Ethicon and Covidien, and he receives book royalties from Cinemed. Drs.
Hutter, Stephanie Jones, and Schirmer have no conflicts of interest or
financial ties to disclose.
NR 41
TC 12
Z9 12
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
J9 SURG ENDOSC
JI Surg. Endosc.
PD JUN
PY 2011
VL 25
IS 6
BP 1730
EP 1740
DI 10.1007/s00464-010-1487-y
PG 11
WC Surgery
SC Surgery
GA 766SG
UT WOS:000290806200004
PM 21136099
ER
PT J
AU Batista, LM
Carvalho, CH
Acioly, MA
Gharabaghi, A
Ramina, KF
Schittenhelm, J
Tatagiba, M
AF Batista, Leonardo Moura
Carvalho, Carlos Henrique
Acioly, Marcus Andre
Gharabaghi, Alireza
Ramina, Kristofer Fingerle
Schittenhelm, Jens
Tatagiba, Marcos
TI Spinal metastasis of endometrial stromal sarcoma: Clinicopathological
features and management
SO SURGICAL ONCOLOGY-OXFORD
LA English
DT Review
DE Endometrial stromal sarcoma; Metastasis; Thoracic spine; Spinal tumor;
Immunohistochemical
ID SMOOTH-MUSCLE TUMORS; EXPRESSION; NEOPLASMS; THERAPY; CORD; CD10
AB Background: Endometrial Stromal Sarcoma(ESS) is a rare uterine malignancy which often metastasizes several years after initial diagnosis. Thoracic spine is a rare ESS metastatic site and its proper management is still not a consensus. We discuss the histopathological features and the management strategies through an illustrative case of a 77 year-old woman with metastasis to the thoracic spine 13 years after total hysterectomy for ESS.
Methods: Review of the literature and identification of 5 patients, including our present case, with ESS involving the spinal cord. We discuss the outcomes achieved after each therapy. In our case, the patient presented a mass involving the thoracic spinal canal constricting the spinal cord at T7 level. A two-level decompression laminectomy was performed and the lesion was partially excised.
Results: The histopathological along with the immunohistochemical profile mitotic rate indicated the endometrial stromal cells origin of the tumor, confirming the diagnosis of a low-grade ESS metastasis. The patient was managed with surgery in combination with postoperative radiation therapy.
Conclusions: The small number of published cases precludes definitive conclusions regarding standard management. However, it seems that treatment of metastatic ESS to the spine matches the same general concepts of spine metastasis, namely surgery followed by radiation therapy, due to clinical improvement and long-term disease control of the reported cases. Hormonal therapy may be considered in recurrent disease with strong expression of estrogen and progesterone receptors. However, these findings need confirmation in larger studies. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Batista, Leonardo Moura; Carvalho, Carlos Henrique; Acioly, Marcus Andre; Gharabaghi, Alireza; Ramina, Kristofer Fingerle; Tatagiba, Marcos] Univ Tubingen, Dept Neurosurg, Eberhard Karls Univ Hosp, D-72076 Tubingen, Germany.
[Batista, Leonardo Moura] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Sch Med, Boston, MA 02114 USA.
[Schittenhelm, Jens] Univ Tubingen, Inst Brain Res, Eberhard Karls Univ Hosp, D-72076 Tubingen, Germany.
RP Batista, LM (reprint author), Univ Tubingen, Dept Neurosurg, Eberhard Karls Univ Hosp, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.
EM lbatista@nmr.mgh.harvard.edu
RI Acioly, Marcus /G-2724-2012
NR 26
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-7404
J9 SURG ONCOL
JI Surg. Oncol.-Oxf.
PD JUN
PY 2011
VL 20
IS 2
BP E78
EP E83
DI 10.1016/j.suronc.2010.10.006
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA 766BZ
UT WOS:000290756000003
PM 21071207
ER
PT J
AU Ozhathil, DK
Abar, B
Baumann, BM
Camargo, CA
Ziedonis, D
Boudreaux, ED
AF Ozhathil, Deepak K.
Abar, Beau
Baumann, Brigitte M.
Camargo, Carlos A., Jr.
Ziedonis, Douglas
Boudreaux, Edwin D.
TI The Effect of Removing Cost as a Barrier to Treatment Initiation With
Outpatient Tobacco Dependence Clinics Among Emergency Department
Patients
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID SMOKING; INTERVENTION
AB Objectives: The campaign against tobacco addiction and smoking continues to play an important role in public health. However, referrals to outpatient tobacco cessation programs by emergency physicians are rarely pursued by patients following discharge. This study explored cost as a barrier to follow-up.
Methods: The study was performed at a large urban hospital emergency department (ED) in Camden, New Jersey. Enrollment included adults who reported tobacco use in the past 30 days. Study participants were informed about a "Stop Smoking Clinic" affiliated with the hospital and, depending on enrollment date, cost of treatment was advertised as $150 (standard fee), $20 (reduced fee), or $0 (no fee). Monitoring of patient inquiries and visits to the clinic was performed for 6 months following enrollment of the last study subject.
Results: The analyzed sample consisted of 577 tobacco users. There were no statistically significant demographic differences between treatment groups (p > 0.05). Two-hundred forty-seven (43%) participants reported "very much" interest in smoking cessation. However, there was no significant difference in initiating treatment with the Stop Smoking Clinic across experimental condition. Only a single subject, enrolled in the no-fee phase, initiated treatment with the clinic.
Conclusions: Cost is unlikely to be the only barrier to pursing outpatient tobacco treatment after an ED visit. Further research is needed to determine the critical components of counseling and referral that maximize postdischarge treatment initiation. ACADEMIC EMERGENCY MEDICINE 2011; 18:662-664 (C) 2011 by the Society for Academic Emergency Medicine
C1 [Ozhathil, Deepak K.; Abar, Beau; Ziedonis, Douglas; Boudreaux, Edwin D.] Univ Massachusetts, Sch Med, Worcester, MA 01610 USA.
[Baumann, Brigitte M.] Cooper Univ Hosp, Camden, NJ USA.
[Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Boston, MA USA.
RP Boudreaux, ED (reprint author), Univ Massachusetts, Sch Med, Worcester, MA 01610 USA.
EM edwin.boudreaux@umassmed.edu
OI Boudreaux, Edwin/0000-0002-3223-6371
FU NIH/NIDA [K23DA16698]
FX This study was supported by a NIH/NIDA K23 Research Career Award (EDB)
(K23DA16698).
NR 10
TC 4
Z9 4
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD JUN
PY 2011
VL 18
IS 6
BP 662
EP 664
DI 10.1111/j.1553-2712.2011.01048.x
PG 3
WC Emergency Medicine
SC Emergency Medicine
GA 781BP
UT WOS:000291905900014
PM 21518096
ER
PT J
AU Taylor, DM
Balabadra, U
Xiang, ZM
Woodman, B
Meade, S
Amore, A
Maxwell, MM
Reeves, S
Bates, GP
Luthi-Carter, R
Lowden, PAS
Kazantsev, AG
AF Taylor, David M.
Balabadra, Uma
Xiang, Zhongmin
Woodman, Ben
Meade, Sarah
Amore, Allison
Maxwell, Michele M.
Reeves, Steven
Bates, Gillian P.
Luthi-Carter, Ruth
Lowden, Philip A. S.
Kazantsev, Aleksey G.
TI A Brain-Permeable Small Molecule Reduces Neuronal Cholesterol by
Inhibiting Activity of Sirtuin 2 Deacetylase
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID HUNTINGTONS-DISEASE; MODELS
AB Sirtuin 2 (SIRT2) deacetylase-dependent inhibition mediates neuroprotective reduction of cholesterol biosynthesis in an in vitro Huntington's disease model. This study sought to identify the first brain permeable SIRT2 inhibitor and to characterize its cholesterol-reducing properties in neuronal models. Using biochemical sirtuin deacetylation assays, we screened a brain-permeable in silico compound library, yielding 3-(1-azepanyl-sulfonyl)-N-(3-bromphenyl)benzamide as the most potent and selective SIRT2 inhibitor. Pharmacokinetic studies demonstrated brain-permeability but limited metabolic stability of the selected candidate. In accordance with previous observations, this SIRT2 inhibitor stimulated cytoplasmic retention of sterol regulatory element binding protein-2 and subsequent transcriptional down-regulation of cholesterol biosynthesis genes, resulting in reduced total cholesterol in primary striatal neurons. Furthermore, the identified inhibitor reduced cholesterol in cultured naive neuronal cells and brain slices from wild-type mice. The outcome of this study provides a clear opportunity for lead optimization and drug development, targeting metabolic dysfunctions in CNS disorders where abnormal cholesterol homeostasis is implicated.
C1 [Xiang, Zhongmin; Meade, Sarah; Amore, Allison; Maxwell, Michele M.; Reeves, Steven; Kazantsev, Aleksey G.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA.
[Taylor, David M.; Luthi-Carter, Ruth] Ecole Polytech Fed Lausanne, Brain Mind Inst, CH-1015 Lausanne, Switzerland.
[Balabadra, Uma; Lowden, Philip A. S.] Univ London, Dept Biol Sci, London WC1E 7HX, England.
[Woodman, Ben; Bates, Gillian P.] Guys Hosp, Kings Coll London, Dept Med & Mol Genet, London SE1 9RT, England.
[Maxwell, Michele M.; Kazantsev, Aleksey G.] Harvard Univ, Sch Med, Boston, MA 02129 USA.
RP Kazantsev, AG (reprint author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA.
EM akazantsev@partners.org
RI Bates, Gillian/E-1146-2012
OI Bates, Gillian/0000-0002-4041-6305
FU Carmen Foundation; RJG Foundation; Michael J. Fox Foundation for
Parkinson's Research; CHDI Foundation; Ecole Polytechnique Federale de
Lausanne; Swiss National Science Foundation
FX We thank M. Forrest and L. Feletti for help with culture preparation.
This work was supported by the Carmen Foundation, the RJG Foundation,
the Michael J. Fox Foundation for Parkinson's Research, the CHDI
Foundation, the Ecole Polytechnique Federale de Lausanne, and the Swiss
National Science Foundation.
NR 18
TC 50
Z9 51
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD JUN
PY 2011
VL 6
IS 6
BP 540
EP 546
DI 10.1021/cb100376q
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 780YD
UT WOS:000291896400003
PM 21370928
ER
PT J
AU Campbell, GR
Watkins, JD
Loret, EP
Spector, SA
AF Campbell, Grant R.
Watkins, Jennifer D.
Loret, Erwann P.
Spector, Stephen A.
TI Differential Induction of Rat Neuronal Excitotoxic Cell Death by Human
Immunodeficiency Virus Type 1 Clade B and C Tat Proteins
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HIV-1 TAT; STRUCTURAL-CHARACTERIZATION; HOMONUCLEAR H-1-NMR;
CEREBROSPINAL-FLUID; RICH REGION; T-CELLS; ZINC; APOPTOSIS; BRAIN;
INFECTION
AB In the absence of effective antiretroviral therapy, infection with clade B human immunodeficiency virus (HIV-1) infection commonly progresses to AIDS dementia. However, in India, where clade C infection is most prevalent, severe cognitive impairment due to HIV-1 is reported to be less prevalent. The Tat protein of HIV-1, which is released from HIV-1-infected macrophages, is thought to play a major role in the disruption of neuronal function as well as in the infiltration of macrophages associated with advanced neuropathogenesis. Clade B Tat is excitotoxic to hippocampal neurons by potentiating N-methyl-D-aspartate-induced currents of the zinc-sensitive NR1/NR2A N-methyl-D-aspartate receptor in a zinc-binding-dependent mechanism. This study characterizes the zinc-binding properties of clade C Tat protein. Using ultraviolet spectroscopy and the Ellman reaction, we show that clade C Tat protein binds just one zinc ion per monomer. We then investigated the ability of clade C Tat to block the inhibition of N-methyl-D-aspartate receptors from zinc antagonism through ion chelation. Although clade C Tat enhanced N-methyl-D-aspartate-mediated rat hippocampus neuronal toxicity in the presence of zinc, the increase was significantly less than that observed with clade B Tat. These findings suggest that the observed differences in neuropathogenesis found with HIV-1 clade C infection compared to clade B may, in part, be due to a decrease in Tat-mediated neurotoxicity.
C1 [Campbell, Grant R.; Spector, Stephen A.] Univ Calif San Diego, Div Infect Dis, Dept Pediat, La Jolla, CA 92093 USA.
[Watkins, Jennifer D.; Loret, Erwann P.] Univ Aix Marseille 2, Fac Pharm, Equipe Technol Rech Appl VIH 1 2011, Marseille, France.
[Watkins, Jennifer D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Spector, Stephen A.] Rady Childrens Hosp, San Diego, CA USA.
RP Spector, SA (reprint author), Univ Calif San Diego, Div Infect Dis, Dept Pediat, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM saspector@ucsd.edu
OI Campbell, Grant/0000-0003-3927-1994
FU National Institute of Allergy and Infectious Diseases (NIAID) of the
United States National Institutes of Health (NIH) [U01 AI068632]
FX This work was supported by the National Institute of Allergy and
Infectious Diseases (NIAID) of the United States National Institutes of
Health (NIH) Grant U01 AI068632 to the International Maternal Pediatric
Adolescent AIDS Clinical Trials Group (IMPAACT).
NR 52
TC 11
Z9 11
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUN
PY 2011
VL 27
IS 6
BP 647
EP 654
DI 10.1089/aid.2010.0192
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 769LJ
UT WOS:000291014700009
PM 20977378
ER
PT J
AU Simpson, T
Rosenthal, C
Gurrad, B
Luterek, J
Kaysen, D
AF Simpson, Tracy
Rosenthal, Christina
Gurrad, Bethann
Luterek, Jane
Kaysen, Debra
TI A PILOT STUDY EVALUATING MECHANISMS OF CHANGE AMONG PATIENTS WITH
COMORBID PTSD AND ALCOHOL DEPENDENCE: METHODS AND FEASIBILITY
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 34th Annual Scientific Meeting of the Research-Society-on-Alcoholism
CY JUN 25-29, 2011
CL Atlanta, GA
SP Res Soc Alcoholism
C1 [Simpson, Tracy; Rosenthal, Christina; Gurrad, Bethann; Luterek, Jane; Kaysen, Debra] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2011
VL 35
IS 6
SU S
BP 142A
EP 142A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 766RN
UT WOS:000290804301023
ER
PT J
AU van Doorn, H
van Hoffen, E
Jager, SH
Knulst, A
Shreffler, W
Knol, K
AF van Doorn, H.
van Hoffen, E.
Jager, Hartog S.
Knulst, A.
Shreffler, W.
Knol, K.
TI Peanut allergen Ara h 6 is the most potent peanut allergen in basophil
activation
SO ALLERGY
LA English
DT Meeting Abstract
CT 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
(EAACI)
CY JUN 11-15, 2011
CL Istanbul, TURKEY
SP European Acad Allergy & Clin Immunol (EAACI)
C1 [van Doorn, H.; van Hoffen, E.; Jager, Hartog S.; Knulst, A.; Knol, K.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[Shreffler, W.] Massachusetts Gen Hosp, Food Allergy Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD JUN
PY 2011
VL 66
SU 94
SI SI
MA 203
BP 98
EP 98
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 286IS
UT WOS:000329462200204
ER
PT J
AU Cernadas, J
Santos, N
Pinto, C
Castells, M
AF Cernadas, J.
Santos, N.
Pinto, C.
Castells, M.
TI Hypersensitivity reaction and tolerance induction to ethambutol
SO ALLERGY
LA English
DT Meeting Abstract
CT 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
(EAACI)
CY JUN 11-15, 2011
CL Istanbul, TURKEY
SP European Acad Allergy & Clin Immunol (EAACI)
C1 [Cernadas, J.; Santos, N.] Hosp Sao Joao, EPE, Serv Imunoalergol, Oporto, Portugal.
[Castells, M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD JUN
PY 2011
VL 66
SU 94
SI SI
MA 985
BP 381
EP 381
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 286IS
UT WOS:000329462202168
ER
PT J
AU Craig, T
Riedl, M
Riedl, M
Baker, J
Banerji, A
Hurewitz, D
Kalfus, I
Tillotson, G
AF Craig, T.
Riedl, M.
Riedl, M.
Baker, J.
Banerji, A.
Hurewitz, D.
Kalfus, I
Tillotson, G.
TI Open-label use of nanofiltered C1 esterase inhibitor (human) for
treatment or prophylaxis of acute attacks of hereditary angioedema in
pregnant subjects
SO ALLERGY
LA English
DT Meeting Abstract
CT 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology
(EAACI)
CY JUN 11-15, 2011
CL Istanbul, TURKEY
SP European Acad Allergy & Clin Immunol (EAACI)
C1 [Craig, T.] Penn State Univ, Hershey, PA USA.
[Riedl, M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Baker, J.] Allergy Asthma & Dermatol Res Ctr, Lake Oswego, OR USA.
[Banerji, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hurewitz, D.] Allergy Clin Tulsa, Tulsa, OK USA.
[Kalfus, I; Tillotson, G.] Viropharma Inc, Exton, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
PD JUN
PY 2011
VL 66
SU 94
SI SI
MA 1089
BP 419
EP 419
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 286IS
UT WOS:000329462202272
ER
PT J
AU Gold, NB
Westgate, MN
Holmes, LB
AF Gold, Nina B.
Westgate, Marie-Noel
Holmes, Lewis B.
TI Anatomic and Etiological Classification of Congenital Limb Deficiencies
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE classification; congenital anomalies; limb reduction defect
ID HOLT-ORAM-SYNDROME; FANCONI-ANEMIA; 1ST TRIMESTER; DEFECTS;
MALFORMATIONS; MUTATIONS; DAUGHTER; HYPOPLASIA; DIAGNOSIS; EXPOSURE
AB Limb deficiencies, the congenital absence or hypoplasia of a long bone and/or digits, vary greatly in their anatomy and etiology. Previous attempts to classify the range of possible phenotypes have not included all types of deficiencies. We present a new classification system, which includes all potential phenotypes. Infants with limb deficiencies were identified in the hospital-based Active Malformations Surveillance Program at Brigham and Women's Hospital in Boston, MA from the years 1972 to 1974 and 1979 to 2000. Affected infants were classified based on the anatomy and apparent cause of their deficiencies. The prevalence rate of all types of limb deficiency was 0.79/1,000. Upper limb deficiencies were significantly more common than lower limb deficiencies. There was no significant difference in frequencies between deficiencies on the left and right sides of the body. Longitudinal defects were more common than terminal transverse defects; intercalary defects were uncommon. Longitudinal defects were most likely to occur on the preaxial side of the limb. Almost half of affected infants had affected digits, with normal long bones. The most common apparent cause of limb deficiencies was vascular disruption defects (0.22/1,000), such as amniotic band-related limb deficiency. This new classification system includes deficiency of each long bone, as well as absence of any finger or toe. This system will make it possible to establish the prevalence of each specific phenotype. The large number of distinct apparent causes illustrates the marked etiologic heterogeneity of limb deficiencies. (C) 2011 Wiley-Liss, Inc.
C1 [Holmes, Lewis B.] Brigham & Womens Hosp, Dept Newborn Med, Teratol Unit, Act Malformat Surveillance Program, Boston, MA 02115 USA.
[Gold, Nina B.; Westgate, Marie-Noel; Holmes, Lewis B.] MassGen Hosp Children, Genet Unit, Boston, MA USA.
RP Holmes, LB (reprint author), Brigham & Womens Hosp, Dept Newborn Med, Teratol Unit, Act Malformat Surveillance Program, 75 Francis St, Boston, MA 02115 USA.
EM Nina-Gold@hms.harvard.edu
FU Massachusetts birth Defects Registry
FX This study was supported by funds provided by the Massachusetts birth
Defects Registry, which is part of the National Birth Defects Prevention
Study, a Centers for Disease Control project. We thank the many
pediatricians, geneticists, orthopedists, pathologists, and other
specialists whose careful evaluations and thoughtful diagnoses
contributed to the classification of the affected infants. We also thank
Research Assistant Kathryn Rowan for her assistance with the
classification of the affected infants born between 1994 and 2000.
NR 36
TC 29
Z9 29
U1 1
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1552-4825
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD JUN
PY 2011
VL 155A
IS 6
BP 1225
EP 1235
DI 10.1002/ajmg.a.33999
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 781OV
UT WOS:000291944200004
PM 21557466
ER
PT J
AU Hata, S
Fujishige, S
Araki, Y
Taniguchi, M
Urakami, K
Peskind, E
Akatsu, H
Araseki, M
Yamamoto, K
Martins, RN
Maeda, M
Nishimura, M
Levey, A
Chung, KA
Montine, T
Leverenz, J
Fagan, A
Goate, A
Bateman, R
Holtzman, DM
Yamamoto, T
Nakaya, T
Gandy, S
Suzuki, T
AF Hata, Saori
Fujishige, Sayaka
Araki, Yoichi
Taniguchi, Miyako
Urakami, Katsuya
Peskind, Elaine
Akatsu, Hiroyasu
Araseki, Masahiko
Yamamoto, Kazuo
Martins, Ralph N.
Maeda, Masahiro
Nishimura, Masaki
Levey, Allan
Chung, Kathryn A.
Montine, Thomas
Leverenz, James
Fagan, Anne
Goate, Alison
Bateman, Randall
Holtzman, David M.
Yamamoto, Tohru
Nakaya, Tadashi
Gandy, Sam
Suzuki, Toshiharu
TI Alternative Processing of gamma-Secretase Substrates in Common Forms of
Mild Cognitive Impairment and Alzheimer's Disease: Evidence for
gamma-Secretase Dysfunction
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID BETA-PROTEIN PRECURSOR; IN-VIVO; METABOLISM; CLEAVAGE; MEMBRANE;
ALCADEIN; ENZYME; BRAIN; RATIO
AB Objective: The most common pathogenesis for familial Alzheimer's disease (FAD) involves misprocessing (or alternative processing) of the amyloid precursor protein (APP) by gamma-secretase due to mutations of the presenilin 1 (PS1) gene. This misprocessing/alternative processing leads to an increase in the ratio of the level of a minor gamma-secretase reaction product (A beta 42) to that of the major reaction product (A beta 40). Although no PS1 mutations are present, altered A beta 42/40 ratios are also observed in sporadic Alzheimer's disease (SAD), and these altered ratios apparently reflect deposition of A beta 42 as amyloid.
Methods: Using immunoprecipitation-mass spectrometry with quantitative accuracy, we analyzed in the cerebrospinal fluid (CSF) of various clinical populations the peptide products generated by processing of not only APP but also an unrelated protein, alcadein (Alc). Alc undergoes metabolism by the identical APP alpha-secretases and gamma-secretases, yielding a fragment that we have named p3-Alca because of the parallel genesis of p3-Alc(alpha) peptides and the p3 fragment of APP. As with A beta, both major and minor p3-Alc(alpha)s are generated. We studied the alternative processing of p3-Alc(alpha) in various clinical populations.
Results: We previously reported that changes in the A beta 42/40 ratio showed covariance in a linear relationship with the levels of p3-Alc(alpha) [minor/major] ratio in media conditioned by cells expressing FAD-linked PS1 mutants. Here we studied the speciation of p3-Alc(alpha) in the CSF from 3 groups of human subjects (n 158): elderly nondemented control subjects; mild cognitive impairment (MCI) subjects with a clinical dementia rating (CDR) of 0.5; SAD subjects with CDR of 1.0; and other neurological disease (OND) control subjects. The CSF minor p3-Alc(alpha) variant, p3-Alc(alpha)38, was elevated (p < 0.05) in MCI subjects or SAD subjects, depending upon whether the data were pooled and analyzed as a single cohort or analyzed individually as 3 separate cohorts.
Interpretation: These results suggest that some SAD may involve alternative processing of multiple c-secretase substrates, raising the possibility that the molecular pathogenesis of SAD might involve gamma-secretase dysfunction. ANN NEUROL 2011;69:1026-1031
C1 [Suzuki, Toshiharu] Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Dept Neurosci,Kita Ku, Sapporo, Hokkaido 0600812, Japan.
[Taniguchi, Miyako; Urakami, Katsuya] Tottori Univ, Fac Med, Sch Hlth Sci, Dept Regulat Biol, Yonago, Tottori 683, Japan.
[Peskind, Elaine] Univ Washington, Med Ctr, Dept Psychiat, Seattle, WA 98195 USA.
[Peskind, Elaine] Univ Washington, Med Ctr, Alzheimers Dis Res Ctr, Seattle, WA 98195 USA.
[Peskind, Elaine] VA Puget Sound Hlth Care Ctr, Seattle, WA USA.
[Akatsu, Hiroyasu] Fukushimura Hosp, Choju Med Inst, Toyohashi, Aichi, Japan.
[Yamamoto, Kazuo] Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba, Japan.
[Martins, Ralph N.] Edith Cowan Univ, Ctr Excellence Alzheimers Dis Res & Care, Joondalup, WA, Australia.
[Martins, Ralph N.] Edith Cowan Univ, Sir James McCusker Alzheimers Dis Res Unit, Sch Exercise Biomed & Hlth Sci, Joondalup, WA, Australia.
[Maeda, Masahiro] Immunobiol Labs Co Ltd IBL, Fujioka, Japan.
[Nishimura, Masaki] Shiga Univ Med Sci, Neurol Unit, Mol Neurosci Res Ctr, Otsu, Shiga 52021, Japan.
[Levey, Allan] Emory Univ, Dept Neurol, Emory Alzheimers Dis Res Ctr, Atlanta, GA 30322 USA.
[Chung, Kathryn A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Montine, Thomas] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Fagan, Anne; Bateman, Randall; Holtzman, David M.] Washington Univ, Sch Med, Dept Neurol, Alzheimers Diseaase Reasrearch Ctr, St Louis, MO 63110 USA.
[Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, Alzheimers Dis Res Ctr, New York, NY USA.
[Gandy, Sam] James J Peters Vet Adm Med Ctr, Bronx, NY USA.
RP Suzuki, T (reprint author), Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Dept Neurosci,Kita Ku, Kita12,Nishi6, Sapporo, Hokkaido 0600812, Japan.
EM tsuzuki@pharm.hokudai.ac.jp
RI Hata, Saori /A-3829-2012; Yamamoto, Tohru/A-3801-2012; Suzuki,
Toshiharu/B-5342-2013
OI Yamamoto, Tohru/0000-0002-1652-0233;
FU Ministry of Education, Science, Culture, Sports, and Technology, Japan
[20023001]; Washington University Alzheimer's Disease Research Center
[P50 AG05681, P01AG03991]; University of Washington P50 Alzheimer's
Disease Research Center; US Department of Veterans Affairs; Kurozumi
Medical Foundation; Suzuken Memorial Foundation; National Institute on
Aging [P01 AG10491, P50 AG005138]; Japan Society for the Promotion of
Science (JSPS)
FX This research was supported by a grant from the Ministry of Education,
Science, Culture, Sports, and Technology, Japan (Grants-in-Aid for
Scientific Research on Priority Areas 20023001 to T. S.).; We thank
Patrick Hof, Brandon Wustman, Rosalie Crouch, and Yuhki Saito for
helpful discussions. Some CSF samples from aged nondemented control
subjects and from subjects suffering from various neurological diseases
were provided by the Washington University Biomarkers Core, which is
supported by the Washington University Alzheimer's Disease Research
Center grant P50 AG05681 and P01AG03991. Some CSF samples were provided
by the Washington University Resource Bank, which is supported by P50
AG05681 and P01 AG03991, and the University of Washington Resource Bank,
which is supported by the University of Washington P50 Alzheimer's
Disease Research Center and the US Department of Veterans Affairs. Some
samples were also contributed by the Tottori University School of Health
Sciences.; T. S. and T.N. are supported by Kurozumi Medical Foundation
and Suzuken Memorial Foundation. S. G. is supported by National
Institute on Aging grants P01 AG10491 and P50 AG005138. Authors S. H.,
Y.A., and M. A. are the recipients of research fellowships from the
Japan Society for the Promotion of Science (JSPS) for young scientists.
The other authors report no conflicts of interest.
NR 17
TC 20
Z9 21
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD JUN
PY 2011
VL 69
IS 6
BP 1026
EP 1031
DI 10.1002/ana.22343
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 782JA
UT WOS:000292003100015
PM 21681798
ER
PT J
AU Becker, JA
Hedden, T
Carmasin, J
Maye, J
Rentz, DM
Putcha, D
Fischl, B
Greve, DN
Marshall, GA
Salloway, S
Marks, D
Buckner, RL
Sperling, RA
Johnson, KA
AF Becker, J. Alex
Hedden, Trey
Carmasin, Jeremy
Maye, Jacqueline
Rentz, Dorene M.
Putcha, Deepti
Fischl, Bruce
Greve, Douglas N.
Marshall, Gad A.
Salloway, Stephen
Marks, Donald
Buckner, Randy L.
Sperling, Reisa A.
Johnson, Keith A.
TI Amyloid-beta Associated Cortical Thinning in Clinically Normal Elderly
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; PRECLINICAL
ALZHEIMERS-DISEASE; HUMAN CEREBRAL-CORTEX; NORMAL OLDER-ADULTS;
FUNCTIONAL CONNECTIVITY; STRUCTURAL MRI; TEMPORAL-LOBE; AD DEMENTIA;
VOLUME LOSS
AB Objective: Both amyloid-beta (A beta) deposition and brain atrophy are associated with Alzheimer's disease (AD) and the disease process likely begins many years before symptoms appear. We sought to determine whether clinically normal (CN) older individuals with A beta deposition revealed by positron emission tomography (PET) imaging using Pittsburgh Compound B (PiB) also have evidence of both cortical thickness and hippocampal volume reductions in a pattern similar to that seen in AD.
Methods: A total of 119 older individuals (87 CN subjects and 32 patients with mild AD) underwent PiB PET and high-resolution structural magnetic resonance imaging (MRI). Regression models were used to relate PiB retention to cortical thickness and hippocampal volume.
Results: We found that PiB retention in CN subjects was (1) age-related and (2) associated with cortical thickness reductions, particularly in parietal and posterior cingulate regions extending into the precuneus, in a pattern similar to that observed in mild AD. Hippocampal volume reduction was variably related to Ab deposition.
Interpretation: We conclude that Ab deposition is associated with a pattern of cortical thickness reduction consistent with AD prior to the development of cognitive impairment. ANN NEUROL 2011;69:1032-1042
C1 [Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Dept Radiol,Med Sch, Boston, MA 02114 USA.
[Rentz, Dorene M.; Marshall, Gad A.; Sperling, Reisa A.; Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA.
[Buckner, Randy L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
[Hedden, Trey; Putcha, Deepti; Fischl, Bruce; Greve, Douglas N.; Buckner, Randy L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Rentz, Dorene M.; Marshall, Gad A.; Sperling, Reisa A.; Johnson, Keith A.] Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp, Boston, MA 02114 USA.
[Fischl, Bruce] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Salloway, Stephen] Brown Univ, Dept Neurol, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Salloway, Stephen] Butler Hosp, Memory & Aging Program, Providence, RI 02906 USA.
[Marks, Donald] Tufts Sch Med, Boston, MA USA.
[Buckner, Randy L.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Buckner, Randy L.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Buckner, Randy L.] Howard Hughes Med Inst, Cambridge, MA USA.
RP Johnson, KA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Dept Radiol,Med Sch, Bartlett 507,33 Fruit St, Boston, MA 02114 USA.
EM kajohnson@partners.org
OI Kennedy, Kristen/0000-0001-5373-9026
FU National Institutes of Health (NIH) (National Institute on Aging [NIA]
[R01-AG027435-S1, P50-AG00513421, P01-AG036694, R01-AG021910,
1K23AG033634]; Massachusetts Alzheimer's Disease Research Center (ADRC);
Howard Hughes Medical Institute (HHMI); Alzheimer Association
[IIRG-06-32444, IIRG-08-90934]; Charles H. Farnsworth Trust, Boston, MA;
The Rosalinde and Arthur Gilbert Foundation; NIH; Elan Pharmaceuticals;
Wyeth; Bristol-Myers Squibb; Janssen Immunotherapy; Pfizer Inc.; Bayer;
Eisai Inc.; Myriad Genetics, Inc.; GlaxoSmithKline; Neurochem-Alzhemed;
Cephalon, Inc.; Forest Laboratories Inc.; Alzheimer's Disease
Neuroimaging Initiative; Dominantly Inherited Alzheimer's Network [NIA
1U01AG032438-01]; Aging Brain: DTI, Subcortical Ischemia and Behavior
[NIA 1 R03 AG023916-01A1]; The Norman and Rosalie Fain Family
Foundation; Champlin Foundation; John and Happy White Family Foundation;
NIH/National Institute on Aging; The Alzheimer Association
FX This research was supported by grants from the National Institutes of
Health (NIH) (National Institute on Aging [NIA] R01-AG027435-S1 to R. A.
S. and K.A.J.; P50-AG00513421 to K.A.J. and R. A. S.; P01-AG036694 to R.
A. S., K.A.J, and R. L. B; R01-AG021910 to R. L. B.) 1K23AG033634 to G.
A. M.; Massachusetts Alzheimer's Disease Research Center (ADRC); Howard
Hughes Medical Institute (HHMI) (to R. L. B.); Alzheimer Association
(IIRG-06-32444 to R. A. S. and K.A.J.; IIRG-08-90934 to D. M. R. and
K.A.J.); Charles H. Farnsworth Trust, Boston, MA (to D. M. R.); The
Rosalinde and Arthur Gilbert Foundation/AFAR New Investigation Awards in
Alzheimer's Disease (to G.A.M.) and an anonymous medical foundation.;
J.C., T. H., D. P., J.A.B., J.M., . M. R., G. A. M. and R. L. B. have
none to report. B. F. has received one or more grants and has a grant
pending from the NIH. D. M. is involved with an ongoing phase 3 clinical
trial with Elan Pharmaceuticals and Janssen Immunotherapy, and is on the
speakers' bureaus of Novartis and Pfizer. S. S. serves on the scientific
advisory boards of Elan Pharmaceuticals, Sanofi-Aventis, Pfizer Inc.,
Eisai Inc., and Bristol-Myers Squibb; serves as Associate Editor for the
Journal of Neuropsychiatry and Clinical Neurosciences; receives
publishing royalties for The Frontal Lobes and Neuropsychiatric Illness
(American Psychiatric Press, Inc., 2001), The Neuropsychiatry of Limbic
and Subcortical Disorders (American Psychiatric Press, Inc., 1997), and
Vascular Dementia (Humana Press, 2004); receives honoraria from Eisai
Inc., Pfizer Inc, Novartis, Forest Laboratories Inc., Elan
Pharmaceuticals, and Athena Diagnostics, Inc.; holds corporate
appointments with Merck Serono and Medivation, Inc.; receives research
support from Elan Pharmaceuticals, Wyeth, Bristol-Myers Squibb, Janssen
Immunotherapy, Pfizer Inc., Bayer, and Eisai Inc.; received research
support from Myriad Genetics, Inc., GlaxoSmithKline, Neurochem-Alzhemed,
Cephalon, Inc., and Forest Laboratories Inc.; receives research support
from the Alzheimer's Disease Neuroimaging Initiative, Dominantly
Inherited Alzheimer's Network (NIA 1U01AG032438-01); received research
support from Aging Brain: DTI, Subcortical Ischemia and Behavior (NIA 1
R03 AG023916-01A1); and receives research support from The Norman and
Rosalie Fain Family Foundation, the Champlin Foundation, and the John
and Happy White Family Foundation. D. G. has a grant from the NIH. K. A.
J. has received grants and has grants pending from the NIH/National
Institute on Aging and The Alzheimer Association. R. A. S. has a grant
pending from the NIH/National Institute on Aging.
NR 76
TC 137
Z9 138
U1 0
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD JUN
PY 2011
VL 69
IS 6
BP 1032
EP 1042
DI 10.1002/ana.22333
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 782JA
UT WOS:000292003100016
PM 21437929
ER
PT J
AU Rajewsky, K
AF Rajewsky, K.
TI RAPPAPORT LECTURE: MODELING HUMAN LYMPHOMAGENESIS IN MICE
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Rajewsky, K.] Harvard Univ, Sch Med, Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Rajewsky, K.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 80
EP 80
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300019
ER
PT J
AU Smith, MR
Li, H
Gordon, L
Gascoyne, R
Paietta, E
Forero-Torres, A
Kahl, B
Advani, R
Hong, F
Horning, S
AF Smith, M. R.
Li, H.
Gordon, L.
Gascoyne, R.
Paietta, E.
Forero-Torres, A.
Kahl, B.
Advani, R.
Hong, F.
Horning, S.
TI PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN
UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN
COOPERATIVE ONCOLOGY GROUP E1499
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Smith, M. R.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Li, H.; Hong, F.] Dana Farber Canc Inst, Ctr Stat, Boston, MA 02115 USA.
[Gordon, L.] Northwestern Univ, Chicago, IL 60611 USA.
[Gascoyne, R.] Brit Columbia Canc Agcy, Vancouver, BC, Canada.
[Paietta, E.] Montefiore Med Ctr, New York, NY USA.
[Forero-Torres, A.] Univ Alabama, Birmingham, AL USA.
[Kahl, B.] Univ Wisconsin, Madison, WI 53706 USA.
[Advani, R.] Stanford Univ, Stanford, CA 94305 USA.
[Horning, S.] Genentech Inc, San Francisco, CA USA.
NR 0
TC 2
Z9 2
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 86
EP 87
PG 2
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300034
ER
PT J
AU Chapuy, B
Green, M
Lu, J
Monti, S
Hao, Y
Yeda, K
Rodig, S
Curie, T
Takeyama, K
Golub, T
Kutok, J
Shipp, M
AF Chapuy, B.
Green, M.
Lu, J.
Monti, S.
Hao, Y.
Yeda, K.
Rodig, S.
Curie, T.
Takeyama, K.
Golub, T.
Kutok, J.
Shipp, M.
TI IDENTIFICATION OF A "DELETION BLOCK'' AT 13Q14 THAT PERTURBS MULTIPLE
SIGNALING AND SURVIVAL PATHWAYS IN PRIMARY CLASSICAL HODGKIN LYMPHOMA
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Chapuy, B.; Green, M.; Hao, Y.; Yeda, K.; Takeyama, K.; Shipp, M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lu, J.; Monti, S.; Golub, T.] Broad Inst, Canc Program, Cambridge, MA USA.
[Rodig, S.; Curie, T.; Kutok, J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 101
EP 101
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300076
ER
PT J
AU Gordon, L
Weller, E
Armand, P
Devine, S
Holland, H
Mason, J
Winter, J
Kaminski, M
Nagler, A
AF Gordon, L.
Weller, E.
Armand, P.
Devine, S.
Holland, H.
Mason, J.
Winter, J.
Kaminski, M.
Nagler, A.
TI A PHASE II STUDY OF CT-011, AN ANTI-PD-1 ANTIBODY, AFTER AUSCT IN
RECURRENT/REFRACTORY DLBCL: FIRST ANALYSIS OF PROGRESSION-FREE-SURVIVAL
(PFS), OVERALL SURVIVAL (OS) AND TOXICITY (TOX)
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Gordon, L.; Winter, J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Weller, E.; Armand, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Devine, S.] Ohio State Univ, Columbus, OH 43210 USA.
[Holland, H.] Northside Hosp, Atlanta, GA USA.
[Mason, J.] Scripps Clin, San Diego, CA USA.
[Kaminski, M.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Nagler, A.] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 102
EP 102
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300080
ER
PT J
AU Freedman, A
Kuruvilla, J
Assouline, S
Engert, A
Heo, D
Solal-Celigny, P
Corradini, P
Verhoef, G
Younes, A
Bendiske, J
Ewald, B
Dey, J
Baeck, J
Bilic, S
Rediske, J
Fanale, M
AF Freedman, A.
Kuruvilla, J.
Assouline, S.
Engert, A.
Heo, D.
Solal-Celigny, P.
Corradini, P.
Verhoef, G.
Younes, A.
Bendiske, J.
Ewald, B.
Dey, J.
Baeck, J.
Bilic, S.
Rediske, J.
Fanale, M.
TI ANTI-CD40 MONOCLONAL ANTIBODY LUCATUMUMAB EXHIBITS ANTI-TUMOR ACTIVITY
IN FOLLICULAR LYMPHOMA AND OTHER LYMPHOMA SUBTYPES: PHASE I/II
PRELIMINARY FINDINGS
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
C1 [Freedman, A.] DFCI, Oncol, Boston, MA USA.
[Kuruvilla, J.] Univ Toronto, Toronto, ON, Canada.
[Assouline, S.] McGill Univ, Montreal, PQ, Canada.
[Engert, A.] Univ Cologne, Cologne, Germany.
[Heo, D.] Seoul Natl Univ Hosp, Seoul, South Korea.
[Solal-Celigny, P.] Serv Hematol, Le Mans, France.
[Corradini, P.] Univ Milan, Milan, Italy.
[Verhoef, G.] Univ Hosp Gasthuisberg, Louvain, Belgium.
[Younes, A.; Fanale, M.] MDACC, Houston, TX USA.
[Bendiske, J.; Ewald, B.; Dey, J.; Baeck, J.; Bilic, S.; Rediske, J.] Novartis, Oncol, E Hanover, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 104
EP 104
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300521
ER
PT J
AU De Jong, D
Wahlin, B
Sander, B
Xie, W
Salles, G
Weller, E
AF De Jong, D.
Wahlin, B.
Sander, B.
Xie, W.
Salles, G.
Weller, E.
TI THE RELIABILITY OF IMMUNOHISTOCHEMICAL ANALYSIS OF TUMOR
MICROENVIRONMENT IN FOLLICULAR LYMPHOMA; A VALIDATION STUDY FROM THE
LUNENBURG LYMPHOMA BIOMARKER CONSORTIUM (LLBC)
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [De Jong, D.] Netherlands Canc Inst, Amsterdam, Netherlands.
[Wahlin, B.; Sander, B.] Karolinska Inst, Stockholm, Sweden.
[Xie, W.; Weller, E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Salles, G.] Univ Lyon 1, F-69365 Lyon, France.
NR 0
TC 2
Z9 2
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 108
EP 108
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300089
ER
PT J
AU Roccaro, AM
Sacco, A
Azab, A
Maiso, P
Liu, Y
Zhang, Y
Azab, F
Ngo, HT
Ghobrial, IM
AF Roccaro, A. M.
Sacco, A.
Azab, A.
Maiso, P.
Liu, Y.
Zhang, Y.
Azab, F.
Ngo, H. T.
Ghobrial, I. M.
TI MICRORNA-9*REGULATES HISTONE ACETYLATION IN WALDENSTROM'S
MACROGLOBULINEMIA
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Roccaro, A. M.; Sacco, A.; Azab, A.; Maiso, P.; Liu, Y.; Zhang, Y.; Azab, F.; Ngo, H. T.; Ghobrial, I. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 121
EP 121
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300127
ER
PT J
AU Treon, SP
Hanzis, C
Ioakimidis, L
Tripsas, C
Manning, RJ
Patterson, CJ
Sheehy, P
Turnbull, B
Hunter, ZR
AF Treon, S. P.
Hanzis, C.
Ioakimidis, L.
Tripsas, C.
Manning, R. J.
Patterson, C. J.
Sheehy, P.
Turnbull, B.
Hunter, Z. R.
TI FAMILIAL DISEASE STATUS IS ASSOCIATED WITH AN INFERIOR TREATMENT OUTCOME
IN PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Treon, S. P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hanzis, C.; Ioakimidis, L.; Tripsas, C.; Manning, R. J.; Patterson, C. J.; Sheehy, P.; Turnbull, B.; Hunter, Z. R.] Biobridges, Needham, MA USA.
RI Hunter, Zachary/H-3018-2013
OI Hunter, Zachary/0000-0002-1689-1691
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 121
EP 121
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300128
ER
PT J
AU Shipp, MA
AF Shipp, M. A.
TI INTRODUCTORY LECTURE
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Shipp, M. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 135
EP 135
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300163
ER
PT J
AU Treon, SP
Hanzis, C
Tripsas, C
Ioakimidis, L
Patterson, CJ
Manning, RJ
Sheehy, P
AF Treon, S. P.
Hanzis, C.
Tripsas, C.
Ioakimidis, L.
Patterson, C. J.
Manning, R. J.
Sheehy, P.
TI BENDAMUSTINE ALONE AND IN COMBINATION WITH CD20-DIRECTED MONOCLONAL
ANTIBODY THERAPY IS ACTIVE IN PATIENTS WITH RELAPSED OR REFRACTORY
WALDENSTROM'S MACROGLOBULINEMIA
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Treon, S. P.; Hanzis, C.; Tripsas, C.; Ioakimidis, L.; Patterson, C. J.; Manning, R. J.; Sheehy, P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 189
EP 189
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300333
ER
PT J
AU Kahl, B
Byrd, J
Flinn, I
Wagner-Johnston, N
Spurgeon, S
Benson, D
Furman, R
Brown, J
Coutre, S
Yu, A
AF Kahl, B.
Byrd, J.
Flinn, I.
Wagner-Johnston, N.
Spurgeon, S.
Benson, D.
Furman, R.
Brown, J.
Coutre, S.
Yu, A.
TI SIGNIFICANT CLINICAL ACTIVITY OF CAL-101, AN ISOFORM-SELECTIVE INHIBITOR
OF PHOSPHATIDYLINOSITOL 3 KINASE P110D, IN PATIENTS WITH RELAPSED OR
REFRACTORY INDOLENT AND MANTLE CELL LYMPHOMA
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Kahl, B.] U Wisconsin, Madison, WI USA.
[Byrd, J.; Benson, D.] Ohio State U, Columbus, OH USA.
[Flinn, I.] Sarah Cannon Res Inst & Tennessee Oncol, Bone Marrow Transplant Unit, Nashville, TN USA.
[Wagner-Johnston, N.] Washington U, St Louis, MO USA.
[Spurgeon, S.] Oregon Hlth Sci U, Portland, OR USA.
[Furman, R.] Weill Cornell Med Coll, New York, NY USA.
[Brown, J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Coutre, S.] Stanford U, Stanford, CA USA.
[Yu, A.] Calistoga Pharmaceut, Clin Affairs, Seattle, WA USA.
NR 0
TC 4
Z9 4
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 199
EP 199
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300364
ER
PT J
AU Sacco, A
Roccaro, AM
Azab, A
Maiso, P
Liu, Y
Zhang, Y
Azab, F
Ngo, HT
Ghborial, IM
AF Sacco, A.
Roccaro, A. M.
Azab, A.
Maiso, P.
Liu, Y.
Zhang, Y.
Azab, F.
Ngo, H. T.
Ghborial, I. M.
TI SELECTIVE INHIBITION OF CHYMOTRYPSIN-LIKE ACTIVITY OF THE PROTEASOME
LEADS TO ANTI-TUMOR EFFECT IN WALDENSTROM MACROGLOBULINEMIA, IN VITRO
AND IN VIVO
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 11th International Conference on Malignant Lymphoma
CY JUN 15-18, 2011
CL Lugano, SWITZERLAND
C1 [Sacco, A.; Roccaro, A. M.; Azab, A.; Maiso, P.; Liu, Y.; Zhang, Y.; Azab, F.; Ngo, H. T.; Ghborial, I. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUN
PY 2011
VL 22
SU 4
BP 240
EP 240
PG 1
WC Oncology
SC Oncology
GA 782GK
UT WOS:000291996300498
ER
PT J
AU Jeffres, MN
Shuster, JE
Barclay, SM
AF Jeffres, Meghan N.
Shuster, Jerrica E.
Barclay, Sean M.
TI Treatment of Ciprofloxacin Nonsusceptible Urinary Tract Infections with
Ciprofloxacin
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Letter
ID ANTIBIOTIC-RESISTANCE
C1 [Jeffres, Meghan N.; Barclay, Sean M.] Univ So Nevada, Coll Pharm, Henderson, NV USA.
[Jeffres, Meghan N.; Barclay, Sean M.] Univ Nevada, Sch Med, Dept Internal Med, Las Vegas, NV 89154 USA.
[Shuster, Jerrica E.] Massachusetts Gen Hosp, Dept Pharm, PGY Resident 1, Boston, MA USA.
RP Jeffres, MN (reprint author), Univ So Nevada, Coll Pharm, Henderson, NV USA.
EM mjeffres@usn.edu
NR 5
TC 0
Z9 3
U1 0
U2 3
PU HARVEY WHITNEY BOOKS CO
PI CINCINNATI
PA PO BOX 42696, CINCINNATI, OH 45242 USA
SN 1060-0280
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD JUN
PY 2011
VL 45
IS 6
BP 824
EP 825
DI 10.1345/aph.1P750
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 783XV
UT WOS:000292119100018
PM 21666093
ER
PT J
AU Goldman, RL
Borckardt, JJ
Frohman, HA
O'Neil, PM
Madan, A
Campbell, LK
Budak, A
George, MS
AF Goldman, Rachel L.
Borckardt, Jeffrey J.
Frohman, Heather A.
O'Neil, Patrick M.
Madan, Alok
Campbell, Laura K.
Budak, Amanda
George, Mark S.
TI Prefrontal cortex transcranial direct current stimulation (tDCS)
temporarily reduces food cravings and increases the self-reported
ability to resist food in adults with frequent food craving
SO APPETITE
LA English
DT Article
DE Transcranial direct current stimulation; tDCS; Brain stimulation; Food
cravings; Obesity; Binge eating
ID REAL-TIME FMRI; DRUG-ADDICTION; DOUBLE-BLIND; BRAIN-STIMULATION;
EATING-DISORDERS; OBESITY; ACTIVATION; INVOLVEMENT; MODULATION;
PREVENTION
AB This study examined whether a 20-min session of prefrontal transcranial direct current stimulation (tDCS) (anode over the right prefrontal cortex and cathode over the left prefrontal cortex) would reduce food cravings and increase the self-reported ability to resist foods in 19 healthy individuals who reported frequent food cravings. Participants viewed computerized images of food and used computerized visual analogue scales to rate food cravings and inability to resist foods before, during, and after receiving either real or sham tDCS. This study employed a randomized within-subject crossover design; participants received both real and sham tDCS and were blind to the condition. Food cravings ratings were reduced in both conditions, however, the percent change in cravings ratings from pre- to post-stimulation was significantly greater for real stimulation than for sham. The percent change in inability to resist food from pre- to post-stimulation also showed a greater decrease in the real condition than for sham. Post hoc analyses suggest that active prefrontal tDCS acutely and significantly decreased food cravings ratings for sweet foods and carbohydrates more so than sham tDCS. No significant differences were seen in the amount of food ingested between real and sham tDCS. These findings in healthy subjects indicate that tDCS is able to temporarily reduce food cravings and improve the self-reported ability to resist foods. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Goldman, Rachel L.; Borckardt, Jeffrey J.; O'Neil, Patrick M.; Madan, Alok; Campbell, Laura K.; Budak, Amanda; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Borckardt, Jeffrey J.; Frohman, Heather A.] Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29425 USA.
[George, Mark S.] Med Univ S Carolina, Dept Neurol & Radiol, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Goldman, RL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 1 South,67 President St, Charleston, SC 29425 USA.
EM goldman@musc.edu
OI Goldman, Rachel/0000-0001-6147-3934
FU Covidien through the Obesity Society; National Institute for
Neurological Disorders and Stroke at NIH; Cyberonics Inc.; Neurosciences
Institute at MUSC; National Institute for Nursing Research; American
Society for Gastrointestinal Endoscopy; Arena Pharmaceuticals; Merck
Inc.; Orexigen Therapeutics; Weight Watchers International; Robert Wood
Johnson Foundation; Center for Health Disparities Research at MUSC;
NIH/NINR; Ocera Therapeutics, Inc.; Glaxo-Smith Kline; Jazz
Pharmaceuticals; Brainsway; Cephos; Force Protection; NIH; DOD
FX Dr. Goldman receives research funding from Covidien through the Obesity
Society, Dr. Borckardt receives research funding from the National
Institute for Neurological Disorders and Stroke at NIH, Cyberonics Inc.,
the Neurosciences Institute at MUSC, the National Institute for Nursing
Research, the American Society for Gastrointestinal Endoscopy, and
Covidien through the Obesity Society. Dr. Borckardt is also Consultant
for TIF Management, LLC. Dr. O'Neil receives research funding from Arena
Pharmaceuticals, Merck Inc., Orexigen Therapeutics and Weight Watchers
International, and currently or recently has served as a consultant for
Orexigen Therapeutics, Merck Inc., and Vivus. Dr. Madan receives
research funding from the American Society for Gastrointestinal
Endoscopy, Covidien through the Obesity Society, the Robert Wood Johnson
Foundation, the Center for Health Disparities Research at MUSC,
NIH/NINR, and Ocera Therapeutics, Inc. Dr. George reports research
grants in the past 5 years from Glaxo-Smith Kline, Jazz Pharmaceuticals,
Brainsway, Cephos, and Force Protection as well as the NIH and DOD. He
has been an unpaid advisor to Brainsonix, Brainsway, Neuronetics,
Neostim and Neosync (as they make products related to TMS), and a paid
advisor to Jazz, Cyberonics, Neuropace, and Puretech ventures. The full
amount of his advisory income has never been more than 10% of his
university salary. MUSC has 2 patent applications in Dr. George's name
on combining TMS with MRI. He has no equity investment in any device or
pharmaceutical company.
NR 48
TC 45
Z9 46
U1 4
U2 20
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0195-6663
EI 1095-8304
J9 APPETITE
JI Appetite
PD JUN
PY 2011
VL 56
IS 3
BP 741
EP 746
DI 10.1016/j.appet.2011.02.013
PG 6
WC Behavioral Sciences; Nutrition & Dietetics
SC Behavioral Sciences; Nutrition & Dietetics
GA 781EF
UT WOS:000291912700028
PM 21352881
ER
PT J
AU Rodrigues, GR
Walker, RH
Bader, B
Danek, A
Brice, A
Cazeneuve, C
Russaouen, O
Lopes-Cendess, I
Marques, W
Tumas, V
AF Rodrigues, Guilherme Riccioppo
Walker, Ruth H.
Bader, Benedikt
Danek, Adrian
Brice, Alexis
Cazeneuve, Cecile
Russaouen, Odile
Lopes-Cendess, Iscia
Marques, Wilson, Jr.
Tumas, Vitor
TI Clinical and genetic analysis of 29 Brazilian patients with Huntington's
disease-like phenotype
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE Huntington's disease; Huntington's disease-like; chorea-acanthocytosis;
Huntington's disease-like 2
ID TRINUCLEOTIDE REPEAT EXPANSIONS; SPINOCEREBELLAR ATAXIA;
CHOREA-ACANTHOCYTOSIS; CAG EXPANSION; PHENOCOPIES;
HUNTINGTON-DISEASE-LIKE-2; JUNCTOPHILIN-3; ATROPHY
AB Huntington's disease (HD) is a neurodegenerative disorder characterized by chorea, behavioral disturbances and dementia, caused by a pathological expansion of the CAG trinucleotide in the HTT gene. Several patients have been recognized with the typical HD phenotype without the expected mutation. The objective of this study was to assess the occurrence of diseases such as Huntington's disease-like 2 (HDL2), spinocerebellar ataxia (SCA) 1, SCA2, SCA3, SCA7, dentatorubral-pallidoluysian atrophy (DRPLA) and choreaacanthocytosis (ChAc) among 29 Brazilian patients with a HD-like phenotype. In the group analyzed, we found 3 patients with HDL2 and 2 patients with ChAc. The diagnosis was not reached in 79.3% of the patients. HDL2 was the main cause of the HD-like phenotype in the group analyzed, and is attributable to the African ancestry of this population. However, the etiology of the disease remains undetermined in the majority of the HD negative patients with HD-like phenotype.
C1 [Rodrigues, Guilherme Riccioppo; Marques, Wilson, Jr.; Tumas, Vitor] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Neurosci & Behav Sci, BR-14049900 Ribeirao Preto, SP, Brazil.
[Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA.
[Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA.
[Bader, Benedikt; Danek, Adrian] Univ Munich, Dept Neurol, D-8000 Munich, Germany.
[Brice, Alexis; Cazeneuve, Cecile; Russaouen, Odile] Hosp Pitie Salpetriere, AP HP, Neurogenet Unit, Dept Genet & Cytogenet, Paris, France.
[Lopes-Cendess, Iscia] Univ Estadual Campinas, Sch Med Sci, Dept Med Genet, Campinas, SP, Brazil.
RP Tumas, V (reprint author), Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Neurosci & Behav Sci, Campus Univ, BR-14049900 Ribeirao Preto, SP, Brazil.
EM tumasv@rnp.fmrp.usp.br
RI Danek, Adrian/G-7339-2011; Marques, Wilson/G-4240-2012; Tumas,
Vitor/C-9949-2014
OI Danek, Adrian/0000-0001-8857-5383; Marques, Wilson/0000-0002-4589-2749;
FU Bayerische Forschungsstiftung; German Federal Ministry of Research;
Manchner Universitatsgesellschaft; Deutsch-Franzosische
Hochschulstiftung; Advocacy for Neuroacanthocytosis Patients
FX Dr. Danek serves on the editorial board of Zeitschrift fur
Gerontoneurologie and Translational Neuroscience; has received speaker
honoraria from Merz, Pfizer, Novartis, Janssen-Cilag and Neuro-Update;
receives research support as Principal Investigator from Bayerische
Forschungsstiftung, German Federal Ministry of Research, Manchner
Universitatsgesellschaft, Deutsch-Franzosische Hochschulstiftung, and
Advocacy for Neuroacanthocytosis Patients; and has served as an expert
witness for German courts of justice in medicolegal cases
NR 29
TC 7
Z9 7
U1 0
U2 5
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 2011
VL 69
IS 3
BP 419
EP 423
PG 5
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 783WR
UT WOS:000292115600002
PM 21755114
ER
PT J
AU Siller-Matula, JM
Merhi, Y
Tanguay, JF
Duerschmied, D
McGinness, KE
Pendergrast, PS
Wagner, DD
Schaub, RG
Jilma, B
AF Siller-Matula, J. M.
Merhi, Y.
Tanguay, J. -F
Duerschmied, D.
McGinness, K. E.
Pendergrast, P. S.
Wagner, D. D.
Schaub, R. G.
Jilma, B.
TI ARC15105 A POTENT ANTAGONIST OF VON WILLEBRAND FACTOR (VWF) PLATELET
ACTIVATION AND ADHESION
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Meeting Abstract
C1 Med Univ Vienna, Dept Cardiol, Vienna, Austria.
Montreal Heart Inst, Montreal, PQ, Canada.
Univ Montreal, Montreal, PQ H3C 3J7, Canada.
Harvard Univ, Dept Pathol, Sch Med, Immune Dis Inst Boston, Cambridge, MA 02138 USA.
Univ Med Ctr Freiburg, Dept Cardiol & Angiol, Freiburg, Germany.
Archemix Corp, Cambridge, MA USA.
Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1742-7835
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
PD JUN
PY 2011
VL 109
SU 1
SI SI
BP 25
EP 25
PG 1
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 783RR
UT WOS:000292102200082
ER
PT J
AU Wisco, BE
Nolen-Hoeksema, S
AF Wisco, Blair E.
Nolen-Hoeksema, Susan
TI Effect of visual perspective on memory and interpretation in dysphoria
SO BEHAVIOUR RESEARCH AND THERAPY
LA English
DT Article
DE Depression; Interpretation; Memory; Observer perspective; Distanced
analysis
ID SOCIAL PHOBIA; DISTINGUISHING RUMINATION; DISTANCED-ANALYSIS; DEPRESSED
MOOD; ASKING; BIAS; EXPERIENCES; REFLECTION; SITUATIONS; ANXIETY
AB When engaging in self-reflection, the visual perspective one adopts has important effects on emotional reactivity. Specifically, adopting a distanced stance, or viewing oneself from a third-person perspective, has been found to reduce emotional reactivity to negative autobiographical memories. The effect of adopting this perspective is moderated by depression such that reactivity is not reduced for individuals with particularly low levels of depressive symptoms. In the current study, we examine the effects of visual perspective on two forms of mental imagery in dysphoric and nondysphoric individuals. We attempt to replicate previous findings for recall of sad autobiographical memories and extend this research to interpretation of ambiguous situations. The results suggest that the effects of adopting a distanced stance are not moderated by depressive symptoms and do not extend from memories to interpretations of ambiguous situations. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Wisco, Blair E.; Nolen-Hoeksema, Susan] Yale Univ, Dept Psychol, New Haven, CT 06511 USA.
RP Wisco, BE (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave,116B, Boston, MA 02130 USA.
EM blair.wisco@va.gov
NR 38
TC 12
Z9 13
U1 0
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7967
J9 BEHAV RES THER
JI Behav. Res. Ther.
PD JUN
PY 2011
VL 49
IS 6-7
BP 406
EP 412
DI 10.1016/j.brat.2011.03.012
PG 7
WC Psychology, Clinical
SC Psychology
GA 785IZ
UT WOS:000292224000005
PM 21550018
ER
PT J
AU MacLaren, RD
Gagnon, J
He, R
AF MacLaren, R. David
Gagnon, John
He, Ran
TI Female bias for enlarged male body and dorsal fins in Xiphophorus
variatus
SO BEHAVIOURAL PROCESSES
LA English
DT Article
DE Female preference; Poecilidae; Sensory bias; Sexual selection;
Xiphophorus variants
ID GUPPY POECILIA-RETICULATA; SEXUAL SELECTION; MATE CHOICE; PREEXISTING
BIAS; APPARENT SIZE; GASTEROSTEUS-ACULEATUS; MATING PREFERENCES; PYGMY
SWORDTAIL; MALE TRAITS; LATIPINNA
AB Female preference for male fin elaborations in Poeciliid fishes may be driven by a sensory bias for increased lateral projection area (LPA) that has existed since the lineages diverged from a common ancestor. Previous research supports this hypothesis demonstrating female Poecilia latipinna, Poecilia mexicana, and Poecilia reticulata prefer males of larger body and dorsal fin size, but exhibit no such preferences when controlling for total LPA. In the current study, we further tested this hypothesis by presenting female platys, Xiphophorus variatus, with pairs of dummy males differing in: (1) body size (holding dorsal fin size constant); (2) dorsal fin size (holding body size constant); and (3) dorsal fin: body size ratio (holding total LPA constant). Females spent more time near dummies of greater body and dorsal fin size; however, in the third experiment, neither fin size, body size, nor any particular dorsal fin + body size combination was preferred. These results provide additional support for the LPA and sensory bias hypotheses, demonstrating that female X variatus not only prefer males with "swords", but sailfin-like dorsal fins as well when body size is held constant. Shared preference for increased LPA is consistent with common ancestry of the sensory/neural systems in females of all four species. (C) 2011 Elsevier B.V. All rights reserved.
C1 [MacLaren, R. David] Merrimack Coll, Dept Biol, Mendel Ctr, N Andover, MA 01845 USA.
[Gagnon, John] Immune Dis Inst, Boston, MA 02115 USA.
[He, Ran] Univ Illinois, Champaign, IL 61820 USA.
RP MacLaren, RD (reprint author), Merrimack Coll, Dept Biol, Mendel Ctr, N Andover, MA 01845 USA.
EM maclarenr@merrimack.edu
OI Gagnon, John/0000-0001-6208-5781
FU Merrimack College
FX This study was supported in part by a Merrimack College Faculty
Development Grant. E. ElAchi, and P. Imbriano offered valuable
assistance in data collection and analysis. C. MacLaren and two
anonymous reviewers provided helpful comments on the manuscript. We
thank D. Tombarelli for her assistance in lab maintenance. We also thank
the Xiphophorus Genetic Stock Center, Texas State University, San
Marcos, TX. for supplying the fish used in this study. The research
methods presented herein were described in Research Protocol 1RDM1008
and approved by the Institutional Animal Care and Use Committee of
Merrimack College.
NR 52
TC 8
Z9 8
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-6357
J9 BEHAV PROCESS
JI Behav. Processes
PD JUN
PY 2011
VL 87
IS 2
BP 197
EP 202
DI 10.1016/j.beproc.2011.03.006
PG 6
WC Psychology, Biological; Behavioral Sciences; Zoology
SC Psychology; Behavioral Sciences; Zoology
GA 781AP
UT WOS:000291903300006
PM 21457765
ER
PT J
AU Rodriguez, F
Cohen, A
Betancourt, JR
Green, AR
AF Rodriguez, Fatima
Cohen, Amy
Betancourt, Joseph R.
Green, Alexander R.
TI Evaluation of medical student self-rated preparedness to care for
limited english proficiency patients
SO BMC MEDICAL EDUCATION
LA English
DT Article
ID CROSS-CULTURAL CARE; HEALTH-CARE; RESIDENT PHYSICIANS; LANGUAGE
PROFICIENCY; UNITED-STATES; COMPETENCE; INTERPRETERS; QUALITY;
COMMUNICATION; EDUCATION
AB Background: Patients with limited English proficiency (LEP) represent a growing proportion of the US population and are at risk of receiving suboptimal care due to difficulty communicating with healthcare providers who do not speak their language. Medical school curricula are required to prepare students to care for all patients, including those with LEP, but little is known about how well they achieve this goal. We used data from a survey of medical students' cross-cultural preparedness, skills, and training to specifically explore their self-rated preparedness to care for LEP patients.
Methods: We electronically surveyed students at one northeastern US medical school. We used bivariate analyses to identify factors associated with student self-rated preparedness to care for LEP patients including gender, training year, first language, race/ethnicity, percent LEP and minority patients seen, and skill with interpreters. We used multivariate logistic regression to examine the independent effect of each factor on LEP preparedness. In a secondary analysis, we explored the association between year in medical school and self-perceived skill level in working with an interpreter.
Results: Of 651 students, 416 completed questionnaires (63.9% response rate). Twenty percent of medical students reported being very well or well-prepared to care for LEP patients. Of these, 40% were in their fourth year of training. Skill level working with interpreters, prevalence of LEP patients seen, and training year were correlated (p < 0.001) with LEP preparedness. Using multivariate logistic regression, only student race/ethnicity and self-rated skill with interpreters remained statistically significant. Students in third and fourth years were more likely to feel skilled with interpreters (p < 0.001).
Conclusions: Increasingly, medical students will need to be prepared to care for LEP patients. Our study supports two strategies to improve student preparedness: training students to work effectively with interpreters and increasing student diversity to better reflect the changing US demographics.
C1 [Rodriguez, Fatima; Betancourt, Joseph R.; Green, Alexander R.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Cohen, Amy] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Betancourt, Joseph R.; Green, Alexander R.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Betancourt, Joseph R.; Green, Alexander R.] Massachusetts Gen Hosp, Dispar Solut Ctr, Boston, MA 02114 USA.
RP Green, AR (reprint author), Harvard Univ, Sch Med, 25 Shattuck St, Boston, MA 02215 USA.
EM argreen@partners.org
NR 34
TC 9
Z9 9
U1 1
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6920
J9 BMC MED EDUC
JI BMC Med. Educ.
PD JUN 1
PY 2011
VL 11
AR 26
DI 10.1186/1472-6920-11-26
PG 8
WC Education & Educational Research; Education, Scientific Disciplines
SC Education & Educational Research
GA 785UL
UT WOS:000292256300001
PM 21631943
ER
PT J
AU Weylandt, KH
Krause, LF
Gomolka, B
Chiu, CY
Bilal, S
Nadolny, A
Waechter, SF
Fischer, A
Rothe, M
Kang, JX
AF Weylandt, Karsten H.
Krause, Lena F.
Gomolka, Beate
Chiu, Cheng-Ying
Bilal, Sueleyman
Nadolny, Anja
Waechter, Simon F.
Fischer, Andreas
Rothe, Michael
Kang, Jing X.
TI Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty
acids is associated with increased omega-3 derived lipid mediators and
reduced TNF-alpha
SO CARCINOGENESIS
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; CHEMICAL HEPATOCARCINOGENESIS; TRANSGENIC
MICE; FATTY-ACIDS; HEPATITIS; STEATOHEPATITIS
AB Liver tumors, particularly hepatocellular carcinoma (HCC), are a major cause of morbidity and mortality worldwide. The development of HCC is mostly associated with chronic inflammatory liver disease of various etiologies. Previous studies have shown that omega-3 (n-3) polyunsaturated fatty acids (PUFAs) dampen inflammation in the liver and decrease formation of tumor necrosis factor (TNF)-alpha.
In this study, we used the fat-1 transgenic mouse model, which endogenously forms n-3 PUFA from n-6 PUFA to determine the effect of an increased n-3 PUFA tissue status on tumor formation in the diethylnitrosamine (DEN)-induced liver tumor model.
Our results showed a decrease in tumor formation, in terms of size and number, in fat-1 mice compared with wild-type littermates. Plasma TNF-alpha levels and liver cyclooxygenase-2 expression were markedly lower in fat-1 mice. Furthermore, there was a decreased fibrotic activity in the livers of fat-1 mice. Lipidomics analyses of lipid mediators revealed significantly increased levels of the n-3 PUFA-derived 18-hydroxyeicosapentaenoic acid (18-HEPE) and 17-hydroxydocosahexaenoic acid (17-HDHA) in the livers of fat-1 animals treated with DEN. In vitro experiments showed that 18-HEPE and 17-HDHA could effectively suppress lipopolysacharide-triggered TNF-alpha formation in a murine macrophage cell line.
The results of this study provide evidence that an increased tissue status of n-3 PUFA suppresses liver tumorigenesis, probably through inhibiting liver inflammation. The findings also point to a potential anticancer role for the n-3 PUFA-derived lipid mediators 18-HEPE and 17-HDHA, which can downregulate the important proinflammatory and proproliferative factor TNF-alpha.
C1 [Weylandt, Karsten H.; Krause, Lena F.; Bilal, Sueleyman; Nadolny, Anja; Waechter, Simon F.; Kang, Jing X.] Massachusetts Gen Hosp, Lab Lipid Med & Technol, Boston, MA 02114 USA.
[Weylandt, Karsten H.; Krause, Lena F.; Bilal, Sueleyman; Nadolny, Anja; Waechter, Simon F.; Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Weylandt, Karsten H.; Krause, Lena F.; Gomolka, Beate; Chiu, Cheng-Ying; Bilal, Sueleyman; Nadolny, Anja; Waechter, Simon F.; Fischer, Andreas] Charite, Rudolf Virchow Hosp, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany.
[Rothe, Michael] Lipidomix GmbH, D-13125 Berlin, Germany.
RP Weylandt, KH (reprint author), Massachusetts Gen Hosp, Lab Lipid Med & Technol, 149 13th St,Room 4433, Charlestown, MA 02129 USA.
EM karsten.weylandt@charite.de; jxkang@partners.org
RI Fischer, Andreas/E-9202-2012
OI Fischer, Andreas/0000-0002-5968-4262
FU Boehringer Ingelheim Foundation; American Cancer Society
[RSG-03-140-01-CNE]; National Institutes of Health [NIH R01 113605];
German Research Foundation (Deutsche Forschungsgemeinschaft); MSD Sharp
& Dohme GmbH Oncology Scholarship
FX Boehringer Ingelheim Foundation (to L.F.K.); American Cancer Society
(RSG-03-140-01-CNE); National Institutes of Health (NIH R01 113605)
(both to J.X.K.); German Research Foundation (Deutsche
Forschungsgemeinschaft) and an MSD Sharp & Dohme GmbH Oncology
Scholarship (both to K.H.W.).
NR 23
TC 40
Z9 42
U1 3
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUN
PY 2011
VL 32
IS 6
BP 897
EP 903
DI 10.1093/carcin/bgr049
PG 7
WC Oncology
SC Oncology
GA 782AG
UT WOS:000291979200017
PM 21421544
ER
PT J
AU Di Stefano, L
Dyson, NJ
AF Di Stefano, Luisa
Dyson, Nicholas J.
TI The complex roles of histone demethylases in vivo
SO CELL CYCLE
LA English
DT Editorial Material
ID DROSOPHILA; REMOVAL; NOTCH
C1 [Di Stefano, Luisa; Dyson, Nicholas J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.
RP Dyson, NJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.
EM dyson@helix.mgh.harvard.edu
NR 11
TC 0
Z9 0
U1 0
U2 2
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD JUN 1
PY 2011
VL 10
IS 13
BP 2049
EP 2050
DI 10.4161/cc.10.13.15758
PG 2
WC Cell Biology
SC Cell Biology
GA 786DR
UT WOS:000292284000004
PM 21597322
ER
PT J
AU Barbone, D
Ryan, JA
Kolhatkar, N
Chacko, AD
Jablons, DM
Sugarbaker, DJ
Bueno, R
Letai, AG
Coussens, LM
Fennell, DA
Broaddus, VC
AF Barbone, D.
Ryan, J. A.
Kolhatkar, N.
Chacko, A. D.
Jablons, D. M.
Sugarbaker, D. J.
Bueno, R.
Letai, A. G.
Coussens, L. M.
Fennell, D. A.
Broaddus, V. C.
TI The Bcl-2 repertoire of mesothelioma spheroids underlies acquired
apoptotic multicellular resistance
SO CELL DEATH & DISEASE
LA English
DT Article
DE mitochondria; 3D; chemotherapy; BH3-profiling; bortezomib
ID MALIGNANT PLEURAL MESOTHELIOMA; PROTEASOME INHIBITOR BORTEZOMIB; BH3
MIMETIC ABT-737; CELL LUNG-CANCER; MULTIPLE-MYELOMA; LEUKEMIA-CELLS;
NOXA; MCL-1; INDUCTION; LYMPHOMA
AB Three-dimensional (3D) cultures are a valuable platform to study acquired multicellular apoptotic resistance of cancer. We used spheroids of cell lines and actual tumor to study resistance to the proteasome inhibitor bortezomib in mesothelioma, a highly chemoresistant tumor. Spheroids from mesothelioma cell lines acquired resistance to bortezomib by failing to upregulate Noxa, a pro-apoptotic sensitizer BH3-only protein that acts by displacing Bim, a pro-apoptotic Bax/Bak-activator protein. Surprisingly, despite their resistance, spheroids also upregulated Bim and thereby acquired sensitivity to ABT-737, an inhibitor of antiapoptotic Bcl-2 molecules. Analysis using BH3 profiling confirmed that spheroids acquired a dependence on anti-apoptotic Bcl-2 proteins and were 'primed for death'. We then studied spheroids grown from actual mesothelioma. ABT-737 was active in spheroids grown from those tumors (5/7, similar to 70%) with elevated levels of Bim. Using immunocytochemistry of tissue microarrays of 48 mesotheliomas, we found that most (33, 69%) expressed elevated Bim. In conclusion, mesothelioma cells in 3D alter the expression of Bcl-2 molecules, thereby acquiring both apoptotic resistance and sensitivity to Bcl-2 blockade. Mesothelioma tumors ex vivo also show sensitivity to Bcl-2 blockade that may depend on Bim, which is frequently elevated in mesothelioma. Therefore, mesothelioma, a highly resistant tumor, may have an intrinsic sensitivity to Bcl-2 blockade that can be exploited therapeutically. Cell Death and Disease (2011) 2, e174; doi:10.1038/cddis.2011.58; published online 23 June 2011
C1 [Barbone, D.; Kolhatkar, N.; Broaddus, V. C.] UCSF, SFGH, Lung Biol Ctr, San Francisco, CA 94110 USA.
[Barbone, D.; Chacko, A. D.; Fennell, D. A.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
[Ryan, J. A.; Letai, A. G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Kolhatkar, N.; Jablons, D. M.; Coussens, L. M.] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94110 USA.
[Sugarbaker, D. J.; Bueno, R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA.
RP Barbone, D (reprint author), UCSF, SFGH, Lung Biol Ctr, 1001 Potrero Ave,Box 0841, San Francisco, CA 94110 USA.
EM dario.barbone@ucsf.edu
FU TRDRP [18FT-0120]; Ireland/NCI Consortium [CDV/3679/07]; Department of
Defense [PR080717]
FX This work was supported by a TRDRP fellowship to DB (18FT-0120), an
Ireland/NCI Consortium grant to VCB, DAF and DB (CDV/3679/07) and a
Department of Defense Mesothelioma Program grant to VCB and LMC
(PR080717).
NR 40
TC 20
Z9 20
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN
PY 2011
VL 2
AR e174
DI 10.1038/cddis.2011.58
PG 9
WC Cell Biology
SC Cell Biology
GA 785QF
UT WOS:000292243000010
PM 21697949
ER
PT J
AU Efebera, Y
Blanchard, E
Allam, C
Han, A
Lee, S
Munshi, N
AF Efebera, Yvonne
Blanchard, Elizabeth
Allam, Charles
Han, Andrew
Lee, Saem
Munshi, Nikhil
TI Complete Response to Thalidomide and Dexamethasone in a Patient With
Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathy: A
Case Report and Review of the Literature
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Review
DE MGUS; Multiple myeloma; Necrobiotic xanthogranuloma; Thalidomide
ID MYOCARDIAL LESIONS; PARAPROTEINEMIA; INVOLVEMENT; THERAPY; LYMPHOMA;
MYELOMA
AB Necrobiotic xanthogranuloma (NXG) was first described in 1980 by Kossard and Winkelmann in an article in which they discussed 8 patients with xanthomatous plaques who were noted to have monoclonal gammopathy, predominantly of the Ig(immunoglobulin)G-kappa type.(1) Since then more than 50 patients with this disorder have been described, with approximately 80% of them having an associated monoclonal gammopathy.
We describe the first case, to our knowledge, of NXG with associated monoclonal gammopathy treated with 1 thalidomide plus dexamethasone, achieving complete resolution of the skin lesions and sustaining response more than 3 years after treatment. Clinical Lymphoma, Myeloma & Leukemia, Vol. 11, No. 3, 298-302 (C) 2011 Elsevier Inc. All rights reserved.
C1 [Efebera, Yvonne; Blanchard, Elizabeth; Allam, Charles; Han, Andrew; Lee, Saem; Munshi, Nikhil] Boston VA Healthcare Syst, Boston, MA USA.
[Efebera, Yvonne; Blanchard, Elizabeth] Boston Univ, Med Ctr, Boston, MA 02215 USA.
[Han, Andrew; Lee, Saem; Munshi, Nikhil] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Efebera, Y (reprint author), Ohio State Univ, 320W 10th St,A 346, Columbus, OH 43017 USA.
EM Yvonne.efebera@osumc.edu
RI Efebera, Yvonne/E-3012-2011
FU NCI NIH HHS [K12 CA133250]
NR 32
TC 11
Z9 11
U1 2
U2 5
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 2152-2650
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD JUN
PY 2011
VL 11
IS 3
BP 298
EP 302
DI 10.1016/j.clml.2011.03.020
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA 783ER
UT WOS:000292064800011
PM 21658660
ER
PT J
AU Helfand, M
Tunis, S
Whitlock, EP
Pauker, SG
Basu, A
Chilingerian, J
Harrell, FE
Meltzer, DO
Montori, VM
Shepard, DS
Kent, DM
AF Helfand, Mark
Tunis, Sean
Whitlock, Evelyn P.
Pauker, Stephen G.
Basu, Anirban
Chilingerian, Jon
Harrell, Frank E., Jr.
Meltzer, David O.
Montori, Victor M.
Shepard, Donald S.
Kent, David M.
CA Natl CTSA Strategic Goal Comm Comp
TI A CTSA Agenda to Advance Methods for Comparative Effectiveness Research
SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE
LA English
DT Article
DE patient-centered outcomes research; translational science; comparative
effectiveness; clinical research methods
ID HEALTH TECHNOLOGY-ASSESSMENT; DECISION-MAKING; INDIVIDUAL PATIENTS;
CITIZENS JURIES; CLINICAL-TRIALS; PARTICIPATORY RESEARCH; RESEARCH
PRIORITIES; SYSTEMATIC REVIEWS; COST-EFFECTIVENESS; RANDOMIZED TRIALS
AB Clinical research needs to be more useful to patients, clinicians, and other decision makers. To meet this need, more research should focus on patient-centered outcomes, compare viable alternatives, and be responsive to individual patients' preferences, needs, pathobiology, settings, and values. These features, which make comparative effectiveness research (CER) fundamentally patient-centered, challenge researchers to adopt or develop methods that improve the timeliness, relevance, and practical application of clinical studies.
In this paper, we describe 10 priority areas that address 3 critical needs for research on patient-centered outcomes (PCOR): (1) developing and testing trustworthy methods to identify and prioritize important questions for research; (2) improving the design, conduct, and analysis of clinical research studies; and (3) linking the process and outcomes of actual practice to priorities for research on patient-centered outcomes. We argue that the National Institutes of Health, through its clinical and translational research program, should accelerate the development and refinement of methods for CER by linking a program of methods research to the broader portfolio of large, prospective clinical and health system studies it supports. Insights generated by this work should be of enormous value to PCORI and to the broad range of organizations that will be funding and implementing CER. Clin Trans Sci 2011; Volume 4: 188-198
C1 [Helfand, Mark] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Ctr, Portland, OR 97201 USA.
[Helfand, Mark] Portland VA Med Ctr, Dept Hosp & Specialty Med, Portland, OR USA.
[Tunis, Sean] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA.
[Tunis, Sean] Ctr Med Technol Policy, Baltimore, MD USA.
[Tunis, Sean] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
[Tunis, Sean] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA USA.
[Tunis, Sean] Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USA.
[Whitlock, Evelyn P.] Kaiser Permanente Ctr Hlth Res, Ctr Hlth Res, Portland, OR USA.
[Whitlock, Evelyn P.] Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Portland, OR 97201 USA.
[Pauker, Stephen G.] Tufts Med Ctr, Tufts Clin & Translat Sci Inst, Boston, MA USA.
[Pauker, Stephen G.] Tufts Med Ctr, Dept Med, Inst Clin Res & Hlth Policy Studies, Div Clin Decis Making Informat & Telemed, Boston, MA USA.
[Basu, Anirban] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Basu, Anirban] Univ Washington, Dept Pharm, Seattle, WA 98195 USA.
[Basu, Anirban] Natl Bur Econ Res, Cambridge, MA 02138 USA.
[Chilingerian, Jon] Brandeis Univ, Heller Sch, Sch Social Policy & Management, Waltham, MA 02254 USA.
[Harrell, Frank E., Jr.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
[Meltzer, David O.] Univ Chicago, Ctr Hlth & Social Sci, Chicago, IL 60637 USA.
[Meltzer, David O.] Univ Chicago, Hosp Med, Chicago, IL 60637 USA.
[Montori, Victor M.] Mayo Clin, Healthcare Delivery Res Program, Translating CER Core, Mayo CTSA, Rochester, MN USA.
[Montori, Victor M.] Mayo Clin, Dept Hlth Sci Res, Div Healthcare & Policy Res, Rochester, MN USA.
[Shepard, Donald S.] Brandeis Univ, Heller Sch, Schneider Inst Hlth Policy, Waltham, MA 02254 USA.
[Kent, David M.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Dept Med, Tufts Clin & Translat Sci Inst, Boston, MA USA.
RP Helfand, M (reprint author), Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Ctr, Portland, OR 97201 USA.
EM helfand@ohsu.edu
RI Meltzer, David/C-2926-2009;
OI Meltzer, David/0000-0003-2790-7393; Montori, Victor/0000-0003-0595-2898
FU National Center for Research Resources, NIH, through the CTSA, a
trademark of DHHS, part of the Roadmap Initiative
FX This project has been funded in whole or in part with Federal funds from
the National Center for Research Resources, NIH, through the CTSA, a
trademark of DHHS, part of the Roadmap Initiative, "Re-Engineering the
Clinical Research Enterprise." The manuscript was approved by the CTSA
Consortium Publications Committee.
NR 78
TC 24
Z9 24
U1 1
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1752-8054
J9 CTS-CLIN TRANSL SCI
JI CTS-Clin. Transl. Sci.
PD JUN
PY 2011
VL 4
IS 3
BP 188
EP 198
DI 10.1111/j.1752-8062.2011.00282.x
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 783TR
UT WOS:000292107400014
PM 21707950
ER
PT J
AU Steensma, DP
AF Steensma, David P.
TI The Relevance of Iron Overload and the Appropriateness of Iron Chelation
Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and
Debate
SO CURRENT HEMATOLOGIC MALIGNANCY REPORTS
LA English
DT Article
DE Myelodysplastic syndromes (MDS); Iron overload; Transfusional
hemosiderosis; Deferasirox; Deferoxamine; Iron chelation therapy;
Clinical controversy; Classical dialogue; Labile plasma iron; Ferritin;
Practice guidelines; T2*magnetic resonance imaging
ID PRETRANSPLANTATION SERUM FERRITIN; STEM-CELL TRANSPLANTATION; PROGNOSTIC
IMPACT; SURVIVAL; ANEMIA; MDS; DEFERASIROX; THALASSEMIA; HEMATOPOIESIS;
DEFEROXAMINE
AB Accumulation of excessive amounts of iron in vulnerable organs and tissues, together with elevated plasma and intracellular concentrations of reactive iron molecules, are likely to be harmful to some patients with myelodysplastic syndromes (MDS) who have received numerous red blood cell transfusions. But what is the real magnitude of risks related to iron overload in MDS, and how strong is the evidence that reducing total body iron and labile plasma iron through treatment with chelating drugs is beneficial to patients? Available data can be interpreted in different ways, and as a result, these topics continue to be areas of heated debate among physicians who care for patients with MDS. Using the traditional but rarely employed format of a classical dialogue, I explore here the potential dangers of iron overload and the risks and benefits of iron chelation therapy for patients with MDS.
C1 Harvard Univ, Sch Med, Div Hematol Malignancies, Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Steensma, DP (reprint author), Harvard Univ, Sch Med, Div Hematol Malignancies, Dana Farber Canc Inst, 450 Brookline Ave,Suite D1B30,Mayer 1B21, Boston, MA 02215 USA.
EM david_steensma@dfci.harvard.edu
OI Steensma, David/0000-0001-5130-9284
NR 49
TC 11
Z9 11
U1 0
U2 2
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1558-8211
EI 1558-822X
J9 CURR HEMATOL MALIG R
JI Curr. Hematol. Malig. Rep.
PD JUN
PY 2011
VL 6
IS 2
BP 136
EP 144
DI 10.1007/s11899-011-0084-z
PG 9
WC Oncology; Hematology
SC Oncology; Hematology
GA 023AL
UT WOS:000310005200010
PM 21373838
ER
PT J
AU Barragan, VA
Mejia, ME
Travez, A
Zapata, S
Hartskeerl, RA
Haake, DA
Trueba, GA
AF Barragan, Veronica A.
Eugenia Mejia, Maria
Travez, Andres
Zapata, Sonia
Hartskeerl, Rudy A.
Haake, David A.
Trueba, Gabriel A.
TI Interactions of Leptospira with Environmental Bacteria from Surface
Water
SO CURRENT MICROBIOLOGY
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; 16S RIBOSOMAL-RNA; PATHOGENIC LEPTOSPIRA;
GENUS LEPTOSPIRA; GENOME SEQUENCE; FRESH-WATER; SPIROCHETE; OUTBREAK;
GRADIENT; SURVIVAL
AB Leptospires can persist for months in nutrient-poor aqueous environments prior to transmission to a mammalian host. Interactions with environmental bacteria and biofilm formation are possible mechanisms of persistence of leptospires in the environment. Bacteria isolated from rivers in the Ecuadorian rainforest were tested for their ability to support leptospiral viability. We found that co-culture with Sphingomonas spp., but not Flavobacterium spp. or Delftia spp., enabled survival of L. biflexa and L. meyeri for up to a year in distilled water. We also found that L. interrogans biofilms formed in distilled water contained viable organisms that rapidly dispersed into the planktonic phase in the presence of nutrients in serum or EMJH medium. These data inform our understanding of leptospiral survival strategies that enable long-term persistence in nutrient-poor conditions yet allow rapid mobilization when nutrients become available.
C1 [Barragan, Veronica A.; Eugenia Mejia, Maria; Travez, Andres; Zapata, Sonia; Trueba, Gabriel A.] Univ San Francisco Quito, Inst Microbiol, Quito, Ecuador.
[Haake, David A.] VA Greater Los Angeles Healthcare Syst GLA, Los Angeles, CA USA.
[Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Hartskeerl, Rudy A.] Royal Trop Inst KIT, WHO FAO OIE, Amsterdam, Netherlands.
[Hartskeerl, Rudy A.] Royal Trop Inst KIT, Natl Collaborating Ctr Reference & Res Leptospiro, Dept Biomed Res, Amsterdam, Netherlands.
RP Barragan, VA (reprint author), Univ San Francisco Quito, Inst Microbiol, Diego Robles & Via Interocean,POB 17-1200-841, Quito, Ecuador.
EM vbarragan@usfq.edu.ec
OI Trueba, Gabriel/0000-0003-2617-9021
NR 36
TC 14
Z9 14
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0343-8651
J9 CURR MICROBIOL
JI Curr. Microbiol.
PD JUN
PY 2011
VL 62
IS 6
BP 1802
EP 1806
DI 10.1007/s00284-011-9931-3
PG 5
WC Microbiology
SC Microbiology
GA 790AO
UT WOS:000292561100022
PM 21479795
ER
PT J
AU Fay, K
Economos, C
Lerner, RM
Becker, AE
Sacheck, J
AF Fay, K.
Economos, C.
Lerner, R. M.
Becker, A. E.
Sacheck, J.
TI The association between sports participation and athletic identity with
eating pathology among college-aged males and females
SO EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY
LA English
DT Article
DE Sports participation; gender; perceived weight; body dissatisfaction;
Eating Disorder Inventory
AB The current study examined associations among sports participation (SP), athletic identity (AI), weight status, and eating pathology, and whether these relations differed by gender. Data come from male and female first-year college students who participated in the Tufts Longitudinal Health Study (TLHS) between 1999-2007 (N=712). Relations among SP, AI, actual and perceived weight statuses, Eating Disorders Inventory (EDI) subscale scores, and indices of body shape concern and restrictive eating were examined with hierarchical ordinary least squares (OLS) regression. Associations between SP and eating pathology among females were moderated by perceived weight status. By contrast, relations between males' EDI subscales scores and SP were moderated by ethnicity, as well as by actual weight status. Our findings support that sports participation alone neither promotes nor protects against eating pathology among males and females. (Eating Weight Disord. 16: e102-e112, 2011). (C)2011, Editrice Kurtis
C1 [Fay, K.; Lerner, R. M.] Tufts Univ, Inst Appl Res Youth Dev, Medford, MA 02155 USA.
[Economos, C.; Sacheck, J.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
[Becker, A. E.] Massachusetts Gen Hosp, Dept Psychiat, Eating Disorders Clin & Res Program, Boston, MA 02114 USA.
[Becker, A. E.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
RP Fay, K (reprint author), Tufts Univ, Inst Appl Res Youth Dev, 3rd Floor Lincoln Filene Bldg, Medford, MA 02155 USA.
EM kristen.e.fay@gmail.com
NR 46
TC 3
Z9 3
U1 3
U2 14
PU EDITRICE KURTIS S R L
PI MILAN
PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY
SN 1124-4909
J9 EAT WEIGHT DISORD-ST
JI Eat. Weight Disord.-Stud. Anorex.
PD JUN
PY 2011
VL 16
IS 2
BP E102
EP E112
PG 11
WC Psychiatry
SC Psychiatry
GA V28AG
UT WOS:000208653100005
PM 21989094
ER
PT J
AU Ebeling, H
Wannas, A
Mattila, ML
Hurtig, T
Kuusikko-Gauffin, S
Jussila, K
Joskitt, L
Joukamaa, M
Moilanen, I
Pauls, DL
AF Ebeling, Hanna
Wannas, Annina
Mattila, Marja-Leena
Hurtig, Tuula
Kuusikko-Gauffin, Sanna
Jussila, Katja
Joskitt, Leena
Joukamaa, Matti
Moilanen, Irma
Pauls, David L.
TI Alexithymia among ASD children and their family members
SO EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Ebeling, Hanna; Wannas, Annina; Mattila, Marja-Leena; Hurtig, Tuula; Kuusikko-Gauffin, Sanna; Jussila, Katja; Joskitt, Leena; Moilanen, Irma] Univ Oulu, SF-90100 Oulu, Finland.
[Ebeling, Hanna; Wannas, Annina; Mattila, Marja-Leena; Kuusikko-Gauffin, Sanna; Jussila, Katja; Joskitt, Leena; Moilanen, Irma] Univ Hosp Oulu, Inst Clin Med, Dept Child Psychiat, Oulu, Finland.
[Hurtig, Tuula] Univ Hosp Oulu, Inst Clin Med, Oulu, Finland.
[Hurtig, Tuula] Univ Hosp Oulu, Inst Hlth Sci, Dept Child Psychiat, Oulu, Finland.
[Joukamaa, Matti] Univ Tampere, FIN-33101 Tampere, Finland.
[Joukamaa, Matti] Tampere Univ Hosp, Social Psychiat Unit, Dept Psychiat, Tampere, Finland.
[Pauls, David L.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
[Pauls, David L.] Psychiat & Neurodev Genet Unit, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1018-8827
EI 1435-165X
J9 EUR CHILD ADOLES PSY
JI Eur. Child Adolesc. Psych.
PD JUN
PY 2011
VL 20
IS 1
SU S
MA W2-01-4
BP S104
EP S105
PG 2
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA V47CB
UT WOS:000209928800319
ER
PT J
AU Kuusikko-Gauffin, S
Jansson-Verkasalo, E
Carter, AS
Pollock-Wurman, R
Jussila, K
Mattila, ML
Rahko, J
Ebeling, H
Moilanen, I
Pauls, D
AF Kuusikko-Gauffin, Sanna
Jansson-Verkasalo, Eira
Carter, Alice S.
Pollock-Wurman, Rachel
Jussila, Katja
Mattila, Marja-Leena
Rahko, Jukka
Ebeling, Hanna
Moilanen, Irma
Pauls, David
TI Neuropsychological performance in families with Autism Spectrum
Disorders
SO EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Kuusikko-Gauffin, Sanna; Jussila, Katja; Mattila, Marja-Leena; Rahko, Jukka; Ebeling, Hanna; Moilanen, Irma] Univ Oulu, SF-90100 Oulu, Finland.
[Kuusikko-Gauffin, Sanna; Jussila, Katja; Mattila, Marja-Leena; Rahko, Jukka; Ebeling, Hanna; Moilanen, Irma] Univ Hosp Oulu, Dept Child Psychiat, Oulu, Finland.
[Jansson-Verkasalo, Eira] Univ Turku, Dept Behav Sci & Philosophy, SF-20500 Turku, Finland.
[Carter, Alice S.] Univ Massachusetts, Boston, MA 02125 USA.
[Pollock-Wurman, Rachel] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
[Pauls, David] Harvard Med Sch, Massachusetts Gen Hosp, Psychiat & Neurodev Genet, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1018-8827
EI 1435-165X
J9 EUR CHILD ADOLES PSY
JI Eur. Child Adolesc. Psych.
PD JUN
PY 2011
VL 20
IS 1
SU S
MA W2-01-2
BP S104
EP S104
PG 1
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA V47CB
UT WOS:000209928800317
ER
PT J
AU Pauls, D
AF Pauls, David
TI Symptoms and everyday life in children and adolescents with Autism
Spectrum Disorder
SO EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Pauls, David] Harvard Med Sch, Massachusetts Gen Hosp, Psychiat & Neurodev Genet, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1018-8827
EI 1435-165X
J9 EUR CHILD ADOLES PSY
JI Eur. Child Adolesc. Psych.
PD JUN
PY 2011
VL 20
IS 1
SU S
MA S2-04-S
BP S13
EP S13
PG 1
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA V47CB
UT WOS:000209928800021
ER
PT J
AU Pollock-Wurman, R
Carter, A
Kuusikko-Gauffin, S
Jusilla, K
Moilanen, I
Pauls, D
AF Pollock-Wurman, Rachel
Carter, Alice
Kuusikko-Gauffin, Sanna
Jusilla, Katja
Moilanen, Irma
Pauls, David
TI Auditory perception of heartbeat: familial patterns of anxiety
sensitivity, child temperament, and clinical implications for a new
methodology
SO EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
LA English
DT Meeting Abstract
C1 [Pollock-Wurman, Rachel] Harvard Univ, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA.
[Carter, Alice] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA.
[Kuusikko-Gauffin, Sanna; Jusilla, Katja; Moilanen, Irma] Univ Oulu, SF-90100 Oulu, Finland.
[Moilanen, Irma] Univ Hosp Oulu, Oulu, Finland.
[Pauls, David] Harvard Univ, Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1018-8827
EI 1435-165X
J9 EUR CHILD ADOLES PSY
JI Eur. Child Adolesc. Psych.
PD JUN
PY 2011
VL 20
IS 1
SU S
MA M2-05-4
BP S45
EP S45
PG 1
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA V47CB
UT WOS:000209928800127
ER
PT J
AU Vrooman, LM
Neuberg, DS
Stevenson, KE
Asselin, BL
Athale, UH
Clavell, L
Cole, PD
Kelly, KM
Larsen, EC
Laverdiere, C
Michon, B
Schorin, M
Schwartz, CL
Cohen, HJ
Lipshultz, SE
Silverman, LB
Sallan, SE
AF Vrooman, Lynda M.
Neuberg, Donna S.
Stevenson, Kristen E.
Asselin, Barbara L.
Athale, Uma H.
Clavell, Luis
Cole, Peter D.
Kelly, Kara M.
Larsen, Eric C.
Laverdiere, Caroline
Michon, Bruno
Schorin, Marshall
Schwartz, Cindy L.
Cohen, Harvey J.
Lipshultz, Steven E.
Silverman, Lewis B.
Sallan, Stephen E.
TI The low incidence of secondary acute myelogenous leukaemia in children
and adolescents treated with dexrazoxane for acute lymphoblastic
leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Dexrazoxane; Acute lymphoblastic leukemia; Secondary acute myelogenous
leukemia; Childhood leukemia; Second malignant neoplasm
ID CHILDHOOD HODGKINS-DISEASE; ADVANCED BREAST-CANCER; ACUTE
MYELOID-LEUKEMIA; MALIGNANT NEOPLASMS; COMPETING RISK; TRIAL;
EPIPODOPHYLLOTOXINS; CARDIOTOXICITY; ASPARAGINASE; CHEMOTHERAPY
AB Background: Dexrazoxane reduces the risk of anthracycline-related cardiotoxicity. In a study of children with Hodgkin lymphoma, the addition of dexrazoxane may have been associated with a higher risk for developing second malignant neoplasms (SMNs) including acute myelogenous leukaemia (AML) and myelodysplastic syndrome (MDS). We determined the incidence of SMNs in children and adolescents with acute lymphoblastic leukaemia (ALL) who were treated with dexrazoxane.
Methods: Between 1996 and 2010, the Dana-Faber Cancer Institute ALL Consortium conducted three consecutive multicentre trials for children with newly diagnosed ALL. In the first (1996-2000), high risk patients were randomly assigned to receive doxorubicin (30 mg/m(2)/dose, cumulative dose 300 mg/m(2)) preceded by dexrazoxane (300 mg/m(2)/dose, 10 doses), or the same dose of doxorubicin without dexrazoxane, during induction and intensification phases. In subsequent trials (2000-2005 and 2005-2010), all high risk and very high risk patients received doxorubicin preceded by dexrazoxane. Cases of SMNs were collected prospectively and were pooled for analysis. The frequency and 5-year cumulative incidence (CI) of SMNs were determined for patients who had received dexrazoxane.
Findings: Among 553 patients treated with dexrazoxane (1996-2000, N = 101; 2000-2005, N = 196; and 2005-2010, N = 256), the number of SMNs observed by protocol was 0 (median follow-up 9.6 years), 0 (median follow-up 5.2 years), and 1 (median follow-up 2.1 years). The only SMN was a case of AML, which developed in a patient with MLL-rearranged ALL 2.14 years after initial diagnosis. The overall 5-year CI of SMNs for all 553 patients was 0.24 +/- 0.24%. Interpretation: In a large population of children with high risk ALL who received dexrazoxane as a cardioprotectant drug, the occurrence of secondary AML was a rare event. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Vrooman, Lynda M.; Neuberg, Donna S.; Stevenson, Kristen E.; Silverman, Lewis B.; Sallan, Stephen E.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Vrooman, Lynda M.; Silverman, Lewis B.; Sallan, Stephen E.] Childrens Hosp, Boston, MA 02115 USA.
[Asselin, Barbara L.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
[Athale, Uma H.] McMaster Univ, Hamilton, ON, Canada.
[Clavell, Luis] San Jorge Childrens Hosp, San Juan, PR USA.
[Cole, Peter D.] Childrens Hosp Montefiore, Albert Einstein Coll Med, Bronx, NY USA.
[Kelly, Kara M.] Columbia Univ, Med Ctr, Morgan Stanley Childrens Hosp New York Presbyteri, New York, NY 10027 USA.
[Larsen, Eric C.] Maine Childrens Canc Program, Portland, ME USA.
[Laverdiere, Caroline] Univ Montreal, Hosp St Justine, Montreal, PQ, Canada.
[Michon, Bruno] Ctr Hosp Univ Quebec, Quebec City, PQ, Canada.
[Schorin, Marshall] Inova Fairfax Hosp Children, Falls Church, VA USA.
[Schwartz, Cindy L.] Brown Univ, Warren Alpert Med Sch, Hasbro Childrens Hosp, Providence, RI 02912 USA.
[Cohen, Harvey J.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Lipshultz, Steven E.] Univ Miami, Leonard M Miller Sch Med, Miami, FL USA.
RP Vrooman, LM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM lynda_vrooman@dfci.harvard.edu
FU National Institutes of Health [CA68484]; Michael Garil Fund; National
Cancer Institute of the National Institutes of Health (Bethesda, MD) [5
P01CA068484]
FX The National Institutes of Health CA68484 and the Michael Garil Fund.;
This work was supported in part by Grant 5 P01CA068484 from the National
Cancer Institute of the National Institutes of Health (Bethesda, MD) and
the Michael Garil Fund.
NR 43
TC 42
Z9 43
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD JUN
PY 2011
VL 47
IS 9
BP 1373
EP 1379
DI 10.1016/j.ejca.2011.03.022
PG 7
WC Oncology
SC Oncology
GA 781CA
UT WOS:000291907000012
PM 21514146
ER
PT J
AU Kolossov, VL
Spring, BQ
Clegg, RM
Henry, JJ
Sokolowski, A
Kenis, PJA
Gaskins, HR
AF Kolossov, Vladimir L.
Spring, Bryan Q.
Clegg, Robert M.
Henry, Jennifer J.
Sokolowski, Anna
Kenis, Paul J. A.
Gaskins, H. Rex
TI Development of a high-dynamic range, GFP-based FRET probe sensitive to
oxidative microenvironments
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE redox-sensitive linker; green fluorescent protein variants; genetically
encoded biosensor; glutathione; redox potential; Forster resonance
energy transfer
ID GREEN FLUORESCENT PROTEIN; INTRACELLULAR REDOX CONDITIONS; GLUTATHIONE;
INDICATORS; OPTIMIZATION; CELL; LINKERS; SENSORS; BIOLOGY; DESIGN
AB We report the optimization of a novel redox-sensitive probe with enhanced dynamic range and an exceptionally well-positioned oxidative midpoint redox potential. The present work characterizes factors that contribute to the improved Forster resonance energy transfer (FRET) performance of this green fluorescent protein (GFP)-based redox sensor. The alpha-helical linker, which separates the FRET donor and acceptor, has been extended in the new probe and leads to a decreased FRET efficiency in the linker's reduced, 'FRET-off' state. Unexpectedly, the FRET efficiency is increased in the new linker's oxidized, 'FRET-on' state compared with the parent probe, in spite of the longer linker sequence. The combination of a lowered baseline 'FRET-off' and an increased 'FRET-on' signal significantly improves the dynamic range of the probe for a more robust discrimination of its reduced and oxidized linker states. Mutagenesis of the cysteine residues within the alpha-helix linker reveals the importance of the fourth, C-terminal cysteine and the relative insignificance of the second cysteine in forming the disulfide bridge to clamp the linker into the high-FRET, oxidized state. To further optimize the performance of the redox probe, various cyan fluorescent protein (CFP)/yellow fluorescent protein (YFP) FRET pairs, placed at opposite ends of the improved redox linker (RL7), were quantitatively compared and exchanged. We found that the CyPet/YPet and ECFP/YPet FRET pairs when attached to RL7 do not function well as sensitive redox probes due to a strong tendency to form heterodimers, which disrupt the alpha-helix. However, monomeric versions of CyPet and YPet (mCyPet and mYPet) eliminate dimerization and restore redox sensitivity of the probe. The best performing probe, ECFP-RL7-EYFP, exhibits an approximately six-fold increase in FRET efficiency in vitro when passing from the oxidized to the reduced state. We determined the midpoint redox potential of the probe to be -143 +/- 6 mV, which is ideal for measuring glutathione (GSH/GSSG) redox potentials in oxidative compartments of mammalian cells (e.g. the endoplasmic reticulum).
C1 [Kolossov, Vladimir L.; Clegg, Robert M.; Henry, Jennifer J.; Sokolowski, Anna; Kenis, Paul J. A.; Gaskins, H. Rex] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA.
[Spring, Bryan Q.; Clegg, Robert M.] Univ Illinois, Dept Phys, Urbana, IL 61801 USA.
[Kenis, Paul J. A.] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA.
[Gaskins, H. Rex] Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA.
[Gaskins, H. Rex] Univ Illinois, Dept Pathobiol, Urbana, IL 61801 USA.
[Gaskins, H. Rex] Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA.
[Spring, Bryan Q.; Clegg, Robert M.] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.
[Spring, Bryan Q.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Spring, Bryan Q.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Sokolowski, Anna] Univ Illinois, Coll Med, Chicago, IL 60612 USA.
RP Kolossov, VL (reprint author), Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA.
EM viadimer@illinois.edu; hgaskins@illinois.edu
RI Kenis, Paul/S-7229-2016
OI Kenis, Paul/0000-0001-7348-0381
FU National Institutes of Health (NIH) [R21-EB004513, R33-CA137719]
FX This work was supported by National Institutes of Health (NIH) grants:
R21-EB004513 and R33-CA137719 to PJAK and HRG.
NR 42
TC 12
Z9 12
U1 0
U2 21
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 1535-3702
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD JUN
PY 2011
VL 236
IS 6
BP 681
EP 691
DI 10.1258/ebm.2011.011009
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 784AZ
UT WOS:000292127300006
PM 21606117
ER
PT J
AU Lin, E
Grinspoon, S
Wang, T
Miller, KK
AF Lin, Eleanor
Grinspoon, Steven
Wang, Thomas
Miller, Karen K.
TI Effects of oral contraceptives on natriuretic peptide levels in women
with hypothalamic amenorrhea: a pilot study
SO FERTILITY AND STERILITY
LA English
DT Editorial Material
DE Natriuretic peptides; oral contraceptives; androgens
ID POSTMENOPAUSAL WOMEN; YOUNG-WOMEN; AGE; GENDER; ATRIAL; TESTOSTERONE;
ESTRADIOL; THERAPY; IMPACT; RATS
AB Natriuretic peptides, which are important regulators of salt handling and blood pressure, are 60%-75% higher in healthy young women than in men, consistent with a gender dimorphism. In this randomized, placebo-controlled study in women with functional hypothalamic amenorrhea, we show that administration of oral contraceptives (OC) increases natriuretic peptide levels and that end-of-study free T levels are inversely associated with amino-terminal pro-B-type natriuretic peptide levels, consistent with the hypothesis that natriuretic peptide levels may be mediated by differences in gonadal steroid concentrations-estrogens (E) or androgens. (Fertil Steril (R) 2011; 95: 2605-7. (C) 2011 by American Society for Reproductive Medicine.)
C1 [Lin, Eleanor; Grinspoon, Steven; Miller, Karen K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
[Lin, Eleanor; Grinspoon, Steven; Wang, Thomas; Miller, Karen K.] Harvard Univ, Sch Med, Boston, MA USA.
[Wang, Thomas] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Miller, KK (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B, Boston, MA 02114 USA.
EM KKMiller@Partners.org
FU Ortho-McNeil Pharmaceuticals; National Institutes of Health
[M01-RR-01066, T32-DK-007028-36]
FX Supported in part by an investigator-initiated grant from Ortho-McNeil
Pharmaceuticals and National Institutes of Health grant M01-RR-01066 and
T32-DK-007028-36.
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD JUN
PY 2011
VL 95
IS 8
BP 2605
EP 2607
DI 10.1016/j.fertnstert.2011.04.064
PG 3
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 782TI
UT WOS:000292034100074
PM 21620395
ER
PT J
AU Jang, JY
Chung, RT
AF Jang, Jae Young
Chung, Raymond T.
TI Chronic Hepatitis C
SO GUT AND LIVER
LA English
DT Review
DE Chronic hepatitis C; Virology; Therapeutics
ID SUSTAINED VIROLOGICAL RESPONSE; HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-2A
PLUS RIBAVIRIN; DEPENDENT RNA-POLYMERASE; CHRONIC-HEMODIALYSIS PATIENTS;
RENAL-TRANSPLANT RECIPIENTS; ADAPTIVE IMMUNE-RESPONSES; NONSTRUCTURAL
PROTEIN 5A; HIV-INFECTED PATIENTS; HEPATOCELLULAR-CARCINOMA
AB The goal of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection is to attain a sustained virologic response (SVR), which is defined as undetectable serum HCV-RNA levels at 6 months after the cessation of treatment. Major improvements in antiviral therapy for chronic hepatitis C have occurred in the past decade. The addition of ribavirin to interferon-alfa therapy and the introduction of pegylated interferon (PEG-IFN) have substantially improved SVR rates in patients with chronic hepatitis C. The optimization of HCV therapy with PEG-IFN and ribavirin continues to evolve. Studies are ongoing that use viral kinetics to tailor therapy to an individual's antiviral response and determine the ideal length of treatment to maximize the chance of SVR. Improved SVR can be achieved with new specific inhibitors that target the HCV NS3/4A protease and the NS5B polymerase. Several long-term follow-up studies have shown that SVR, when achieved, is associated with a very low risk of virologic relapse. Furthermore, antiviral therapy can reduce the morbidity and mortality rates associated with chronic hepatitis C by reducing fibrosis progression, the incidence of cirrhosis, and hepatocellular carcinoma. (Gut Liver 2011;5:117-132)
C1 [Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Gastrointestinal Unit, Boston, MA 02114 USA.
[Jang, Jae Young] Soonchunhyang Univ, Coll Med, Inst Digest Res, Ctr Digest Dis,Dept Internal Med, Seoul, South Korea.
RP Chung, RT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Gastrointestinal Unit, Warren 1007, Boston, MA 02114 USA.
EM rtchung@partners.org
NR 151
TC 14
Z9 18
U1 0
U2 1
PU EDITORIAL OFFICE GUT & LIVER
PI SEOUL
PA 305 LOTTE GOLD ROSE II, 890-59, DAECHI 4-DONG, GANGNAM-GU, SEOUL,
135-839, SOUTH KOREA
SN 1976-2283
J9 GUT LIVER
JI Gut Liver
PD JUN
PY 2011
VL 5
IS 2
BP 117
EP 132
DI 10.5009/gnl.2011.5.2.117
PG 16
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 783II
UT WOS:000292074300001
PM 21814590
ER
PT J
AU Swenson, ER
AF Swenson, Erik R.
TI Con: Rebuttal
SO HIGH ALTITUDE MEDICINE & BIOLOGY
LA English
DT Editorial Material
ID ALTITUDE PULMONARY-EDEMA; RECREATIONAL CLIMBERS; LUNG; MODULATION;
BARRIER; HYPOXIA; FLUID
C1 Univ Washington, Med Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Swenson, ER (reprint author), Univ Washington, Med Serv, VA Puget Sound Hlth Care Syst, S-111 PULM,1660 S Columbian Way, Seattle, WA 98108 USA.
EM eswenson@u.washington.edu
NR 13
TC 2
Z9 2
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1527-0297
J9 HIGH ALT MED BIOL
JI High Alt. Med. Biol.
PD SUM
PY 2011
VL 12
IS 2
BP 131
EP 132
DI 10.1089/ham.2011.1010
PG 2
WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
GA 786EJ
UT WOS:000292285800006
PM 21718160
ER
PT J
AU Hirota, SA
Ng, J
Lueng, A
Khajah, M
Parhar, K
Li, Y
Lam, V
Potentier, MS
Ng, K
Bawa, M
McCafferty, DM
Rioux, KP
Ghosh, S
Xavier, RJ
Colgan, SP
Tschopp, J
Muruve, D
MacDonald, JA
Beck, PL
AF Hirota, Simon A.
Ng, Jeffrey
Lueng, Alan
Khajah, Maitham
Parhar, Ken
Li, Yan
Lam, Victor
Potentier, Mireille S.
Ng, Kelvin
Bawa, Misha
McCafferty, Donna-Marie
Rioux, Kevin P.
Ghosh, Subrata
Xavier, Ramnik J.
Colgan, Sean P.
Tschopp, Jurg
Muruve, Daniel
MacDonald, Justin A.
Beck, Paul L.
TI NLRP3 Inflammasome Plays a Key Role in the Regulation of Intestinal
Homeostasis
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE NLRP3; inflammasome; defensin; microbiota; neutrophil
ID ILEAL CROHNS-DISEASE; NITRIC-OXIDE SYNTHASE; ALPHA-DEFENSIN EXPRESSION;
BOWEL-DISEASE; NALP3 INFLAMMASOME; HUMAN BETA-DEFENSIN-2;
ULCERATIVE-COLITIS; PERIODIC SYNDROMES; RIBOSOMAL-RNA; PANETH CELLS
AB Background: Attenuated innate immune responses to the intestinal microbiota have been linked to the pathogenesis of Crohn's disease (CD). Recent genetic studies have revealed that hypofunctional mutations of NLRP3, a member of the NOD-like receptor (NLR) superfamily, are associated with an increased risk of developing CD. NLRP3 is a key component of the inflammasome, an intracellular danger sensor of the innate immune system. When activated, the inflammasome triggers caspase-1-dependent processing of inflammatory mediators, such as IL-1 beta and IL-18.
Methods: In the current study we sought to assess the role of the NLRP3 inflammasome in the maintenance of intestinal homeostasis through its regulation of innate protective processes. To investigate this role, Nlrp3(-/-) and wildtype mice were assessed in the dextran sulfate sodium and 2,4,6-trinitrobenzenesulfonic acid models of experimental colitis.
Results: Nlrp3(-/-) mice were found to be more susceptible to experimental colitis, an observation that was associated with reduced IL-1 beta, reduced antiinflammatory cytokine IL-10, and reduced protective growth factor TGF-beta. Macrophages isolated from Nlrp3(-/-) mice failed to respond to bacterial muramyl dipeptide. Furthermore, Nlrp3-deficient neutrophils exhibited reduced chemotaxis and enhanced spontaneous apoptosis, but no change in oxidative burst. Lastly, Nlrp3(-/-) mice displayed altered colonic beta-defensin expression, reduced colonic antimicrobial secretions, and a unique intestinal microbiota.
Conclusions: Our data confirm an essential role for the NLRP3 inflammasome in the regulation of intestinal homeostasis and provide biological insight into disease mechanisms associated with increased risk of CD in individuals with NLRP3 mutations.
C1 [Hirota, Simon A.; Ng, Jeffrey; Lueng, Alan; Khajah, Maitham; Parhar, Ken; Li, Yan; Lam, Victor; Potentier, Mireille S.; Ng, Kelvin; Bawa, Misha; McCafferty, Donna-Marie; Rioux, Kevin P.; Ghosh, Subrata; MacDonald, Justin A.; Beck, Paul L.] Univ Calgary, Gastrointestinal Res Grp, Calgary, AB T2N 4N1, Canada.
[Hirota, Simon A.; Lueng, Alan; Lam, Victor; Potentier, Mireille S.; Rioux, Kevin P.; Ghosh, Subrata; Beck, Paul L.] Univ Calgary, Inflammat Res Network, Calgary, AB T2N 4N1, Canada.
[Ng, Jeffrey; Muruve, Daniel] Univ Calgary, Immunol Res Grp, Calgary, AB T2N 4N1, Canada.
[Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol,MIT,Broad Inst, Boston, MA USA.
[Colgan, Sean P.] Univ Colorado, Hlth Sci Ctr, Div Gastroenterol, Mucosal Inflammat Program, Denver, CO USA.
[Tschopp, Jurg] Univ Lausanne, Dorigny, Switzerland.
RP Hirota, SA (reprint author), Univ Calgary, Gastrointestinal Res Grp, Calgary, AB T2N 4N1, Canada.
EM simon.hirota@ucalgary.ca
OI MacDonald, Justin/0000-0002-9238-8473
FU CAG/CIHR; AHFMR; CRC; NIH [DK50189, DE13499, HL60569]; CCFA
FX Supported by a CAG/CIHR and AHFMR fellowships (to S. H.), CRC and AHFMR
Senior Scholar award (to J.A.M.), NIH grants DK50189, DE13499 and
HL60569 (to S. P. C.), a grant from the CCFA (to S. P. C.), and AHFMR
Clinical Investigator (to P.L.B.).
NR 70
TC 122
Z9 126
U1 3
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JUN
PY 2011
VL 17
IS 6
BP 1359
EP 1372
DI 10.1002/ibd.21478
PG 14
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 761ZQ
UT WOS:000290442400035
PM 20872834
ER
PT J
AU Berlanga, M
Paster, BJ
Grandcolas, P
Guerrero, R
AF Berlanga, Mercedes
Paster, Bruce J.
Grandcolas, Philippe
Guerrero, Ricardo
TI Comparison of the gut microbiota from soldier and worker castes of the
termite Reticulitermes grassei
SO INTERNATIONAL MICROBIOLOGY
LA English
DT Article
DE Reticulitermes grassei; termite castes; termite gut microbiota;
Spirochaetes; Actinobacteria; 'Endomicrobia'; Wolbachia;
PHA-accumulating bacteria
ID IN-SITU IDENTIFICATION; PHYLOGENETIC DIVERSITY; SYMBIONTS; BACTERIA;
HINDGUT; PHYLUM; HOST; ENDOMICROBIA; COEVOLUTION; COMMUNITIES
AB The bacterial microbiota from the whole gut of soldier and worker castes of the termite Reticulitermes grassei was isolated and studied. In addition, the 16S rDNA bacterial genes from gut DNA were PCR-amplified using Bacteria-selective primers, and the 16S rDNA amplicons subsequently cloned into Escherichia coli. Sequences of the cloned inserts were then used to determine closest relatives by comparison with published sequences and with sequences from our previous work. The clones were found to be affiliated with the phyla Spirochaetes, Proteobacteria, Firmicutes, Bacteroidetes, Actinobacteria, Synergistetes, Verrucomicrobia, and candidate phyla Termite Group 1 (TG1) and Termite Group 2 (TG2). No significant differences were observed with respect to the relative bacterial abundances between soldier and worker phylotypes. The phylotypes obtained in this study were compared with reported sequences from other termites, especially those of phylotypes related to Spirochaetes, Wolbachia (an Alphaproteobacteria), Actinobacteria, and TG1. Many of the clone phylotypes detected in soldiers grouped with those of workers. Moreover, clones CRgS91 (soldiers) and CRgW68 (workers), both affiliated with 'Endomicrobia', were the same phylotype. Soldiers and workers also seemed to have similar relative protist abundances. Heterotrophic, poly-beta-hydroxyalkanoate-accumulating bacteria were isolated from the gut of soldiers and shown to be affiliated with Actinobacteria and Gammaproteobacteria. We noted that Wolbachia was detected in soldiers but not in workers. Overall, the maintenance by soldiers and workers of comparable axial and radial redox gradients in the gut is consistent with the similarities in the prokaryotes and protists comprising their microbiota. [Int Microbiol 2011; 14(2):83-93]
C1 [Berlanga, Mercedes] Univ Barcelona, Dept Microbiol & Parasitol, Fac Pharm, E-08028 Barcelona, Spain.
[Paster, Bruce J.] Forsyth Inst, Dept Mol Genet, Cambridge, MA USA.
[Paster, Bruce J.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Grandcolas, Philippe] Museum Natl Hist Nat, Dept Systemat & Evolut, F-75231 Paris, France.
[Guerrero, Ricardo] Univ Barcelona, Dept Microbiol, Fac Biol, E-08028 Barcelona, Spain.
RP Berlanga, M (reprint author), Univ Barcelona, Dept Microbiol & Parasitol, Fac Pharm, Av Joan XXIII S-N, E-08028 Barcelona, Spain.
EM mberlanga@ub.edu
OI Berlanga, Mercedes/0000-0002-7305-7046
FU Spanish Ministry of Science and Technology [CGL2009-08922]; NIH from the
National Institute of Dental & Craniofacial Research [DE-11443,
DE-10374]
FX We thank Dr. Miguel Gaju, from the University of Cordoba, Spain, for
providing us with the termite material and for critically reading the
manuscript. This work was supported by grant CGL2009-08922 (Spanish
Ministry of Science and Technology) to RG, and by NIH grants DE-11443
and DE-10374 from the National Institute of Dental & Craniofacial
Research to BJP. We thank Ruben Duro for the photographs.
NR 42
TC 10
Z9 10
U1 1
U2 18
PU VIGUERA EDITORES, S L
PI BARCELONA
PA PLAZA TETUAN, 7, BARCELONA, E-08010, SPAIN
SN 1139-6709
J9 INT MICROBIOL
JI Int. Microbiol.
PD JUN
PY 2011
VL 14
IS 2
BP 83
EP 93
DI 10.2436/20.1501.01.138
PG 11
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 941MI
UT WOS:000303966900003
PM 22069152
ER
PT J
AU Weyman, AE
AF Weyman, Arthur E.
TI Assessment of Mitral Stenosis: Role of Real-Time 3D TEE
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Editorial Material
DE mitral stenosis; transesophageal echocardiography
ID PRESSURE HALF-TIME; VALVE-AREA; 2-DIMENSIONAL ECHOCARDIOGRAPHY;
3-DIMENSIONAL ECHOCARDIOGRAPHY; ORIFICE AREA; ULTRASOUND; GEOMETRY
C1 Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
RP Weyman, AE (reprint author), Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St,VBK 508, Boston, MA 02114 USA.
EM aweyman@partners.org
NR 17
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
EI 1876-7591
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD JUN
PY 2011
VL 4
IS 6
BP 589
EP 591
DI 10.1016/j.jcmg.2011.04.005
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 782WH
UT WOS:000292042900004
PM 21679892
ER
PT J
AU Quraishi, SA
Schuler, GH
Janicki, PK
AF Quraishi, Sadeq A.
Schuler, Gregg H.
Janicki, Piotr K.
TI 5 HT3-receptor antagonists and cardiac repolarization time in patients
expressing a novel genetic target associated with baseline QTc interval
abnormalities
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article
DE QT; QTc; 5 HT3-receptor antagonist; NOSA1P; SNP rs10494366;
Postoperative nausea; PONV
ID POSTOPERATIVE NAUSEA; GENERAL-POPULATION; PROLONGATION; ONDANSETRON;
DROPERIDOL; MORTALITY; RISK; METOCLOPRAMIDE; FAMILIES; DEATH
AB Study Objective: To investigate whether a common single nucleotide polymorphism (SNP), rs10494366, is associated with significant prolongation of the QTc interval following administration of 5-HT3-receptor antagonists in the perioperative setting.
Design: Post-hoc analysis of deoxyribonucleic acid (DNA) samples and electrocardiographic (ECG) data from an established perioperative genomics database.
Setting: University teaching hospital.
Measurements: DNA samples of 132 ASA physical status 1, 2, and 3 patients were obtained from an established genomic database of surgical patients who had received either granisetron or dolasetron as part of their general anesthesia plan. ECG recordings were collected on all subjects before administration of antiemetic medication, then 10 minutes after drug injection. DNA analysis was performed using TaqMan real-time PCR genotyping assay. Results from the TaqMan real-time PCR assay were used to calculate relative frequencies of the T (major) and G (Minor) alleles, in addition to calculating the genotype frequencies. QTc intervals were calculated according to Bazett's formula.
Results: Relative frequencies for T and G alleles were 0.63 and 0.37, respectively. The relative. frequencies of the pertinent genotypes were TT 39.4%, TG 46.9%, and GG 13.7%. No significant difference was noted in QTc interval pre-antiemetic or post-antiemetic drug administration for the homozygous carriers of the minor allele GG (P = 0.059), but a significant difference was seen in the pre-drug and post-drug QTc intervals in the heterozygous and homozygous carriers of the major allele TG and TT (P = 0.003 and P = 0.017, respectively). Compared with homozygous carriers of the minor allele, absolute risk increase for QTc interval prolongation after antiemetic administration was 0.08 and 0.15 in heterozygous and homozygous carriers of the major allele, respectively.
Conclusion: Homozygous and. heterozygous carrier status for the major SNP, rs10494366 allele (7), in intron I of the human NOSA1P gene may be associated with an increased risk of QTc interval prolongation following administration of 5-HT3-receptor antagonists in the perioperative setting, when compared with homozygotes for the minor (G) allele. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Quraishi, Sadeq A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Quraishi, Sadeq A.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.
[Schuler, Gregg H.; Janicki, Piotr K.] Penn State Univ, Coll Med, Dept Anesthesiol, Hershey, PA 15033 USA.
[Schuler, Gregg H.; Janicki, Piotr K.] Penn State Univ, Coll Med, Perioperat Genom Lab, Hershey, PA 15033 USA.
RP Quraishi, SA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, GRJ 402, Boston, MA 02114 USA.
EM squraishi@partners.org
FU Department of Anesthesiology, Penn State College of Medicine, Hershey,
PA
FX Financial support: Department funds from the Department of
Anesthesiology, Penn State College of Medicine, Hershey, PA, only.
NR 31
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD JUN
PY 2011
VL 23
IS 4
BP 297
EP 302
DI 10.1016/j.jclinane.2010.11.003
PG 6
WC Anesthesiology
SC Anesthesiology
GA 782NH
UT WOS:000292015900009
PM 21663814
ER
PT J
AU Trivedi, MH
Wisniewski, SR
Morris, DW
Fava, M
Gollan, JK
Warden, D
Nierenberg, AA
Gaynes, BN
Husain, MM
Luther, JF
Zisook, S
Rush, AJ
AF Trivedi, Madhukar H.
Wisniewski, Stephen R.
Morris, David W.
Fava, Maurizio
Gollan, Jackie K.
Warden, Diane
Nierenberg, Andrew A.
Gaynes, Bradley N.
Husain, Mustafa M.
Luther, James F.
Zisook, Sidney
Rush, A. John
TI Concise Health Risk Tracking Scale: A Brief Self-Report and Clinician
Rating of Suicidal Risk
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID MEASUREMENT-BASED CARE; DIAGNOSTIC SCREENING QUESTIONNAIRE;
STAR-ASTERISK-D; REPORT QIDS-SR; DEPRESSIVE SYMPTOMATOLOGY; PSYCHOMETRIC
EVALUATION; QUICK INVENTORY; IDEATION; EVENTS; CLASSIFICATION
AB Objective: Monitoring suicidality and risk following initiation of antidepressant treatment is an essential component of clinical care, but few brief, reliable ratings of suicidal ideation and behavior in adults are available. This report evaluates the psychometric properties of a brief self- and clinician-rated measure of factors related to the risk of suicide attempt or completion.
Method: Adult outpatients with nonpsychotic major depressive disorder (MDD) (n =240) were enrolled from July 2007 through February 2008 and treated in an 8-week, open-label trial with the clinician's choice of a selective serotonin reuptake inhibitor at 6 primary care and 9 psychiatric clinical care settings in the National Institute of Mental Health-funded Depression Trials Network. Diagnosis of MDD was determined by the Psychiatric Diagnostic Screening Questionnaire and an MDD checklist based on DSM-IV-TR criteria. Suicidal ideation and behavior are 1 of 9 symptoms of MDD (depressed mood, loss of interest, appetite or weight change, sleep disturbance, reduced concentration or indecisiveness, fatigue or decreased energy, psychomotor agitation or retardation, feelings of worthlessness, or excessive guilt). The newly developed Concise Health Risk Tracking (CHRT) scale was administered both as the CHRT Self-Report (CHRT-SR) and Clinician Rating (CHRT-C) scales. Psychometric evaluations were conducted on both scales.
Results: The internal consistency (Cronbach alpha) was .77 for the 7-item CHRT-C and .78 for the 7-item CHRT-SR with a consistent factor structure, and 3 independent factors (current suicidal thoughts and plans, perceived lack of social support, and hopelessness) for both versions.
Conclusions: The 7-item CHRT-C and the 7-item CHRT-SR have excellent psychometric properties and can be used to monitor suicidal risk in clinical practice and research settings. Whether either scale will predict suicide attempts or completions in actual practice would require a very large prospective study sample.
C1 [Trivedi, Madhukar H.; Morris, David W.; Warden, Diane; Husain, Mustafa M.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Wisniewski, Stephen R.; Luther, James F.] Univ Pittsburgh, Epidemiol Data Ctr, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
[Fava, Maurizio; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Depress & Clin Res Program, Boston, MA 02114 USA.
[Gollan, Jackie K.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Gaynes, Bradley N.] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA.
[Zisook, Sidney] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Zisook, Sidney] Vet Affairs Med Ctr, San Diego, CA 92161 USA.
[Rush, A. John] Duke Natl Univ Singapore, Off Clin Sci, Singapore, Singapore.
RP Trivedi, MH (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Madhukar.Trivedi@UTSouthwestern.edu
OI Wisniewski, Stephen/0000-0002-3877-9860; Gaynes,
Bradley/0000-0002-8283-5030; Rush, Augustus/0000-0003-2004-2382
FU Bristol-Myers Squibb; Cephalon; Corcept Therapeutics; Cyberonics; Eli
Lilly; Forest; GlaxoSmithKline; Janssen; Merck; National Institute of
Mental Health (NIMH) [N01MH90003]; National Alliance for Research in
Schizophrenia and Depression (NARSAD); Novartis; Pfizer; Pharmacia
Upjohn; Predix; Solvay; Wyeth-Ayerst; Abbott; Alkermes; Aspect Medical
Systems; AstraZeneca; BioResearch; BrainCells; CeNeRx BioPharma;
Clinical Trials Solutions; Clintara; Covidien; EnVivo Pharmaceuticals;
Euthymics Bioscience; Ganeden Biotech; Icon Clinical Research; i3
Innovus/Ingenix; Johnson & Johnson Pharmaceutical Research Development;
Lichtwer Pharma GmbH; Lorex; National Center for Complementary and
Alternative Medicine; National Institute of Drug Abuse (NIDA); Novartis
AG; Organon; PamLab; Pharmavite; Photothera; Roche; RCT Logic;
Sanofi-Aventis; Shire; Synthelabo; Northwestern Memorial Hospital
Women's Board; Evergreen Invitational Award; Educational Foundation of
America; American Foundation of Suicide Prevention; Brain Research
Foundation; American Psychological Association; Agency for Healthcare
Research and Quality; Wyss Institute for Biologically Inspired
Engineering; Robert Wood Johnson Foundation; M-3 Corporation; Ovation;
Stanley Medical Research Institute; Magstim; Advanced Neuromodulation
Systems; Veterans Affairs Cooperative Studies Program; American
Foundation for Suicide Prevention; Best Practice Project Management;
Brain Resource; Bristol-Myers Squibb/Otsuka; Gerson Lehrman Group; Jazz;
Magellan Health Services; Neuronetics; Ono; Otsuka; University of
Michigan; Transcept; Urban Institute
FX Dr Trivedi has been a consultant for Abbott, Akzo (Organon),
AstraZeneca, Bayer, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli
Lilly, Fabre-Kramer, Forest, GlaxoSmithKline; Janssen, Johnson & Johnson
PRD, Eli Lilly, Meade Johnson, Neuronetics, Parke-Davis, Pfizer,
Pharmacia & Upjohn, Sepracor, Solvay, VantagePoint, and Wyeth-Ayerst;
has served on speakers bureaus for Abdi Brahim, Akzo (Organon),
Bristol-Myers Squibb, Cephalon, Cyberonics, Forest, GlaxoSmithKline,
Janssen, Eli Lilly, Pharmacia & Upjohn, Solvay, and Wyeth-Ayerst; and
has received grant support from Bristol-Myers Squibb, Cephalon, Corcept
Therapeutics, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen,
Merck, National Institute of Mental Health (NIMH), National Alliance for
Research in Schizophrenia and Depression (NARSAD), Novartis, Pfizer,
Pharmacia & Upjohn, Predix, Solvay, and Wyeth-Ayerst. Dr Wisniewski has
been a consultant for Cyberonics, ImaRx Therapeutics, Bristol-Myers
Squibb, Organon, Case-Western University, Singapore Clinical Research
Institute, Dey, and Venebio.; Dr Fava has received research support from
Abbott, Alkermes, Aspect Medical Systems, AstraZeneca, BioResearch,
BrainCells, Bristol-Myers Squibb, Cephalon, CeNeRx BioPharma, Clinical
Trials Solutions, Clintara, Covidien, Eli Lilly, EnVivo Pharmaceuticals,
Euthymics Bioscience, Forest, Ganeden Biotech, GlaxoSmithKline, Icon
Clinical Research, i3 Innovus/Ingenix, Johnson & Johnson Pharmaceutical
Research & Development, Lichtwer Pharma GmbH, Lorex, NARSAD, National
Center for Complementary and Alternative Medicine, National Institute of
Drug Abuse (NIDA), NIMH, Novartis AG, Organon, PamLab, Pfizer,
Pharmavite, Photothera, Roche, RCT Logic, Sanofi-Aventis, Shire, Solvay,
Synthelabo, and Wyeth-Ayerst; has provided advisory/consulting services
to Abbott, Affectis Pharmaceuticals AG, Alkermes, Amarin Pharma, Aspect
Medical Systems, AstraZeneca, Auspex, Bayer AG, Best Practice Project
Management, BioMarin Pharmaceuticals, Biovail, BrainCells, Bristol-Myers
Squibb, CeNeRx BioPharma, Cephalon, Clinical Trials Solutions, CNS
Response, Compellis, Cypress, DiagnoSearch Life Sciences (P), Dinippon
Sumitomo Pharma, Dov, Edgemont, Eisai, Eli Lilly, ePharmaSolutions,
EPIX, Euthymics Bioscience, Fabre-Kramer, Forest, GenOmind,
GlaxoSmithKline, Grunenthal GmbH, i3 Innovus/Ingenis, Janssen, Jazz,
Johnson & Johnson Pharmaceutical Research & Development, Knoll,
Labopharm, Lorex, Lundbeck, MedAvante, Merck, MSI Methylation Sciences,
Naurex, Neuronetics, NextWave Pharmaceuticals, Novartis AG, Nutrition
21, Orexigen Therapeutics, Organon, Otsuka, PamLab, Pfizer, PharmaStar,
Pharmavite, PharmoRx Therapeutics, Precision Human Biolaboratory, Prexa
Pharmaceuticals, Puretech Ventures, PsychoGenics, Psylin Neurosciences,
Rexahn Pharmaceuticals, Ridge Diagnostics, Roche, RCT Logic,
Sanofi-Aventis, Sepracor, Servier Laboratories, Schering-Plough, Solvay,
Somaxon, Somerset, Sunovion, Supernus, Synthelabo, Takeda, Tal Medical,
Tetragenex, TransForm Pharmaceuticals, Transcept, and Vanda; has
speaking/publishing relationships with Adamed, Advanced Meeting
Partners, American Psychiatric Association, American Society of Clinical
Psychopharmacology, AstraZeneca, Belvoir Media Group, Boehringer
Ingelheim GmbH, Bristol-Myers Squibb, Cephalon, CME Institute/Physicians
Postgraduate Press, Eli Lilly, Forest, GlaxoSmithKline, Imedex,
Massachusetts General Hospital (MGH) Psychiatry Academy/Primedia, MGH
Psychiatry Academy/Reed Elsevier, Novartis AG, Organon, Pfizer,
PharmaStar, United BioSource, and Wyeth-Ayerst; has equity holdings
(exclding mutual funds/blinded trusts) with Compellis; has received
royalty/patent or other income for Sequential Parallel Comparison Design
(SPCD) and patent application for a combination of azapirones and
bupropion in major depressive disorder; has received copyright royalties
for the MGH Cognitive & Physical Functioning Questionnaire, Sexual
Functioning Inventory, Antidepressant Treatment Response Questionnaire,
Sexual Functioning Inventory, Antidepressant Treatment Response
Questionnaire, Discontinuation-Emergent Signs & Symptoms Scale, and
State vs Trait, Accessibility, Facial Validity, Exological Validity,
Rule of 3 P's (SAFER); and has received a patent for research and
licensing of SPCD with RCT Logic; Lippincott, Williams & Wilkins; World
Scientific Publishing.; Dr Gollan has received grant/research support
from NIMH, Northwestern Memorial Hospital Women's Board, Evergreen
Invitational Award, NARSAD, Educational Foundation of America, American
Foundation of Suicide Prevention, and Brain Research Foundation and
other financial or material supportfrom the American Psychological
Association. Dr Warden has owned stock in Pfizer, and Bristol-Myers
Squibb within the last five years and has received funding from NARSAD.
Dr Nierenberg has been a consultant for Appliance Computing, Medergy,
Brain Cells, Johnson & Johnson, Labopharm, Merck, PGx Health, Targacept,
and Takeda/Lundbeck; has received grant/research support from Agency for
Healthcare Research and Quality, NIMH, PamLab, Pfizer, Shire, and Wyss
Institute for Biologically Inspired Engineering; has also received
honoraria from American Society for Clinical Psychopharmacology,
American Professional Society of ADHD and Related Disorders, Belvior
Publishing, Canadian Psychiatric Assoc, CNS Spectrums, Dartmouth Medical
School, Johns Hopkins Medical School, MBL Publishing, Montreal McGill
Douglas Hospital, Northeast Counseling Center Directors, PamLab,
Physicians Postgraduate Press, SciMed, Slack Med, University of Florida,
WebMD, and Wolters Klower Publishing; has been a presenter for MGH
Psychiatry Academy (MGHPA talks are supported through Independent
Medical Education [IME] grants from the following pharmaceutical
companies in 2008: AstraZeneca, Eli Lilly, and Janssen); is on the
advisory boards of Appliance Computing, Brain Cells, InfoMedic, Johnson
& Johnson, Takeda/Lundbeck, and Targacept; owns stock options in
Appliance Computing and Brain Cells; and, through Massachusetts General
Hospital, is named for copyrights to The Clinical Positive Affect Scale
and the MGH Structured Clinical Interview for the Montgomery-Asberg
Depression Scale, exclusively licensed to the Clinical Trials Network
and Institute. Dr Gaynes has received grants and research support from
NIMH, Agency for Healthcare Research and Quality, Robert Wood Johnson
Foundation, M-3 Corporation, Bristol-Myers Squibb, Novartis, Pfizer, and
Ovation; has performed as an advisor or consultant for Bristol-Myers
Squibb, Pfizer, Shire, and Wyeth-Ayerst; and has also received a
speaker's honorarium from GlaxoSmithKline. Dr Husain has received
research support from NIMH, Stanley Medical Research Institute,
Cyberonics, Neuronetics, Magstim, and Advanced Neuromodulation Systems;
and has served on advisory boards or speakers bureaus for Cyberonics,
Avinar, Cerebrio, AstraZeneca, Bristol-Myers Squibb, Optima/Forest,
GlaxoSmithKline, Forest, and Janssen. Dr Zisook receives grant support
from the NIMH, the Veterans Affairs Cooperative Studies Program, the
American Foundation for Suicide Prevention, and PamLab. Dr Rush has
received consultant fees from Advanced Neuromodulation Systems,
AstraZeneca, Best Practice Project Management, Brain Resource,
Bristol-Myers Squibb/Otsuka, Cyberonics, Forest, Gerson Lehrman Group,
GlaxoSmithKline, Jazz, Magellan Health Services, Merck, Neuronetics,
Novartis, Ono, Organon, Otsuka, PamLab, Pfizer, University of Michigan,
Transcept, Urban Institute, and Wyeth-Ayerst; has received speaking fees
from Cyberonics, Forest, GlaxoSmithKline, and Otsuka; has received
royalties from Guilford Publications, Healthcare Technology Systems, and
University of Texas Southwestern Medical Center; has received research
support from NIMH and the Stanley Medical Research Institute; and has
owned shares of stock in Pfizer. Dr Morris and Mr Luther have no
disclosures to report.; This project was funded by the NIMH under
contract N01MH90003 to University of Texas Southwestern Medical Center
at Dallas (primary investigator, Dr Trivedi).
NR 29
TC 32
Z9 32
U1 1
U2 7
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUN
PY 2011
VL 72
IS 6
BP 757
EP 764
DI 10.4088/JCP.11m06837
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 786XJ
UT WOS:000292340900004
PM 21733476
ER
PT J
AU Trivedi, MH
Wisniewski, SR
Morris, DW
Fava, M
Kurian, BT
Gollan, JK
Nierenberg, AA
Warden, D
Gaynes, BN
Luther, JF
Rush, AJ
AF Trivedi, Madhukar H.
Wisniewski, Stephen R.
Morris, David W.
Fava, Maurizio
Kurian, Benji T.
Gollan, Jackie K.
Nierenberg, Andrew A.
Warden, Diane
Gaynes, Bradley N.
Luther, James F.
Rush, A. John
TI Concise Associated Symptoms Tracking Scale: A Brief Self-Report and
Clinician Rating of Symptoms Associated With Suicidality
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID DIAGNOSTIC SCREENING QUESTIONNAIRE; MEASUREMENT-BASED CARE;
STAR-ASTERISK-D; DEPRESSIVE SYMPTOMATOLOGY IDS; REPORT QIDS-SR; MAJOR
DEPRESSION; PSYCHOMETRIC PROPERTIES; ANXIOUS DEPRESSION; QUICK
INVENTORY; RELIABILITY
AB Objective: US Food and Drug Administration (FDA) warnings recommend monitoring negative symptoms associated with the initiation of antidepressant medications as these symptoms may interfere with full recovery and pose safety concerns. There is currently no brief, reliable rating instrument for assessing treatment-emergent, negative symptoms. We evaluated the psychometric properties of 2 versions of the newly developed 17-item Concise Associated Symptom Tracking (CAST) scale, the CAST Clinician Rating (CAST-C) and CAST Self-Rated (CAST-SR), which are brief instruments designed to measure the 5 relevant associated symptom domains (irritability, anxiety, mania, insomnia, and panic).
Method: The study enrolled 265 outpatients with major depressive disorder (MDD), from July 2007 through February 2008, into an 8-week, open-label trial with a selective serotonin reuptake inhibitor. Diagnosis of MDD was determined by the Psychiatric Diagnostic Screening questionnaire and an MDD checklist based on DSM-IV-TR criteria. Suicidality (suicidal ideation with associated behaviors) is 1 of 9 symptoms of MDD (depressed mood, loss of interest, appetite or weight change, sleep disturbance, reduced concentration or indecisiveness, fatigue or decreased energy, psychomotor agitation or retardation, feelings of worthlessness or excessive guilt). Psychometric evaluations were conducted on both versions of the CAST.
Results: Cronbach alpha was .80 (CAST-C) and .81 (CAST-SR). Factor analysis identified 5 factors for each scale: (1) irritability, (2) anxiety, (3) mania, (4) insomnia, and (5) panic. When the item that cross-loaded on 2 factors was eliminated, the 16-item solution had a better goodness of fit (CAST-C: 0.90 vs 0.87; CAST-SR: 0.88 vs 0.84). Cronbach a for the 16-item versions was .77 (CAST-C) and .78 (CAST-SR). The 5 associated CAST symptom domains correlated well with other standard measures of these domains.
Conclusions: The 16-item CAST-C and CAST-SR demonstrated excellent psychometric properties. These are potentially useful measures for monitoring treatment-emergent negative symptoms associated with antidepressants, as recommended by the FDA.
C1 [Trivedi, Madhukar H.; Morris, David W.; Kurian, Benji T.; Warden, Diane] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Wisniewski, Stephen R.; Luther, James F.] Univ Pittsburgh, Epidemiol Data Ctr, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
[Fava, Maurizio; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Clin Psychopharmacol Unit, Boston, MA 02114 USA.
[Gollan, Jackie K.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Gaynes, Bradley N.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA.
[Rush, A. John] Duke Natl Univ Singapore, Off Clin Sci, Singapore, Singapore.
RP Trivedi, MH (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Madhukar.Trivedi@UTSouthwestern.edu
OI Wisniewski, Stephen/0000-0002-3877-9860; Gaynes,
Bradley/0000-0002-8283-5030; Rush, Augustus/0000-0003-2004-2382
FU Bristol-Myers Squibb; Cephalon; Corcept Therapeutics; Cyberonics; Eli
Lilly; Forest; GlaxoSmithKline; Janssen; Merck; National Institute of
Mental Health (NIMH) [N01MH90003]; National Alliance for Research in
Schizophrenia and Depression (NARSAD); Novartis; Pfizer; Pharmacia
Upjohn; Predix; Solvay; Wyeth-Ayerst; Abbott; Alkermes; Aspect Medical
Systems; AstraZeneca; BioResearch; Brain Cells; CeNeRx BioPharma;
Clinical Trials Solutions; Clintara; Covidien; En Vivo Pharmaceuticals;
Euthymics Bioscience; Ganeden Biotech; Icon Clinical Research; i3
Innovus/Ingenix; Johnson & Johnson Pharmaceutical Research Development;
Lichtwer Pharma GmbH; Lorex; National Center for Complementary and
Alternative Medicine; National Institute of Drug Abuse (NIDA); NIMH;
Novartis AG; Organon; PamLab; Pharmavite; Photothera; Roche; RCT Logic;
Sanofi-Aventis; Shire; Synthelabo; Targacept; Northwestern Memorial
Hospital Women's Board; Evergreen Invitational Award; Educational
Foundation of America; American Foundation of Suicide Prevention; Brain
Research Foundation; American Psychological Association; Agency for
Healthcare Research and Quality; Wyss Institute for Biologically
Inspired Engineering; Robert Wood Johnson Foundation; M-3 Corporation;
Ovation; Advanced Neuromodulation Systems; Best Practice Project
Management; Brain Resource; Bristol-Myers Squibb/Otsuka; Gerson Lehrman
Group; Jazz; Magellan Health Services; Neuronetics; Ono; Otsuka;
University of Michigan; Transcept; Urban Institute; Stanley Medical
Research Institute
FX Dr Trivedi has been a consultant for Abbott, Akzo (Organon),
AstraZeneca, Bayer, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli
Lilly, Fabre-Kramer, Forest, GlaxoSmithKline; Janssen, Johnson & Johnson
PRD, Eli Lilly, Meade Johnson, Neuronetics, Parke-Davis, Pfizer,
Pharmacia & Upjohn, Sepracor, Solvay, VantagePoint, and Wyeth-Ayerst;
has served on speakers bureaus for Abdi Brahim, Akzo (Organon),
Bristol-Myers Squibb, Cephalon, Cyberonics, Forest, GlaxoSmithKline,
Janssen, Eli Lilly, Pharmacia & Upjohn, Solvay, and Wyeth-Ayerst; and
has received grant support from Bristol-Myers Squibb, Cephalon, Corcept
Therapeutics, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen,
Merck, National Institute of Mental Health (NIMH), National Alliance for
Research in Schizophrenia and Depression (NARSAD), Novartis, Pfizer,
Pharmacia & Upjohn, Predix, Solvay, and Wyeth-Ayerst. Dr Wisniewski has
been a consultant for Cyberonics, ImaRx Therapeutics, Bristol-Myers
Squibb, Organon, Case-Western University, Singapore Clinical Research
Institute, Dey, and Venebio.; Dr Fava has received research support from
Abbott, Alkermes, Aspect Medical Systems, AstraZeneca, BioResearch,
Brain Cells, Bristol-Myers Squibb, Cephalon, CeNeRx BioPharma, Clinical
Trials Solutions, Clintara, Covidien, Eli Lilly, En Vivo
Pharmaceuticals, Euthymics Bioscience, Forest, Ganeden Biotech,
GlaxoSmithKline, Icon Clinical Research, i3 Innovus/Ingenix, Johnson &
Johnson Pharmaceutical Research & Development, Lichtwer Pharma GmbH,
Lorex, NARSAD, National Center for Complementary and Alternative
Medicine, National Institute of Drug Abuse (NIDA), NIMH, Novartis AG,
Organon, PamLab, Pfizer, Pharmavite, Photothera, Roche, RCT Logic,
Sanofi-Aventis, Shire, Solvay, Synthelabo, and Wyeth-Ayerst; has
provided advisory/consulting services to Abbott, Affectis
Pharmaceuticals AG, Alkermes, Amarin Pharma, Aspect Medical Systems,
AstraZeneca, Auspex, Bayer AG, Best Practice Project Management,
BioMarin Pharmaceuticals, Biovail, Brain Cells, Bristol-Myers Squibb,
CeNeRx BioPharma, Cephalon, Clinical Trials Solutions, CNS Response,
Compellis, Cypress, DiagnoSearch Life Sciences (P), Dinippon Sumitomo
Pharma, Dov, Edgemont, Eisai, Eli Lilly, ePharmaSolutions, EPIX,
Euthymics Bioscience, Fabre-Kramer, Forest, GenOmind, GlaxoSmithKline,
Grunenthal GmbH, i3 Innovus/Ingenis, Janssen, Jazz, Johnson & Johnson
Pharmaceutical Research 8c Development, Knoll, Labopharm, Lorex,
Lundbeck, MedAvante, Merck, MSI Methylation Sciences, Naurex,
Neuronetics, Next Wave Pharmaceuticals, Novartis AG, Nutrition 21,
Orexigen Therapeutics, Organon, Otsuka, PamLab, Pfizer, PharmaStar,
Pharmavite, PharmoRx Therapeutics, Precision Human Biolaboratory, Prexa
Pharmaceuticals, Puretech Ventures, PsychoGenics, Psylin Neurosciences,
Rexahn Pharmaceuticals, Ridge Diagnostics, Roche, RCT Logic,
Sanofi-Aventis, Sepracor, Servier Laboratories, Schering-Plough, Solvay,
Somaxon, Somerset, Sunovion, Supernus, Synthelabo, Takeda, Tal Medical,
Tetragenex, Trans Form Pharmaceuticals, Transcept, and Vanda; has
speaking/publishing relationships with Adamed, Advanced Meeting
Partners, American Psychiatric Association, American Society of Clinical
Psychopharmacology, AstraZeneca, Belvoir Media Group, Boehringer
Ingelheim GmbH, Bristol-Myers Squibb, Cephalon, CME Institute/Physicians
Postgraduate Press, Eli Lilly, Forest, GlaxoSmithKline, Imedex,
Massachusetts General Hospital (MGH) Psychiatry Academy/Primedia, MGH
Psychiatry Academy/Reed Elsevier, Novartis AG, Organon, Pfizer,
PharmaStar, United BioSource, and Wyeth-Ayerst; has equity
holdings(excluding mutual funds/blinded trusts) with Compellis; has
received royalty/patent or other income for Sequential Parallel
Comparison Design (SPCD) and patent application for a combination of
azapirones and bupropion in major depressive disorder; has received
copyright royalties for the MGH Cognitive & Physical Functioning
Questionnaire, Sexual Functioning Inventory, Antidepressant Treatment
Response Questionnaire, Discontinuation-Emergent Signs & Symptoms Scale,
and State vs Trait, Accessibility, Facial Validity, Exological Validity,
Rule of 3 P's (SAFER); and has received a patent for research and
licensing of SPCD with RCT Logic; Lippincott, Williams & Wilkins; World
Scientific Publishing. Dr Kurian has received research support from
Targacept and Pfizer.; Dr Gollan has received grant/research support
from NIMH, Northwestern Memorial Hospital Women's Board, Evergreen
Invitational Award, NARSAD, Educational Foundation of America, American
Foundation of Suicide Prevention, and Brain Research Foundation and
other financial or material support from he American Psychological
Association. Dr Nierenberg has been a consultant for Appliance
Computing, Medergy, Brain Cells, Johnson and Johnson, Labopharm, Merck,
PGx Health, Targacept, and Takeda/Lundbeck; has received grant/research
support from Agency for Healthcare Research and Quality, NIMH, PamLab,
Pfizer, Shire, and Wyss Institute for Biologically Inspired Engineering;
has also received honoraria from American Society for Clinical
Psychopharmacology, American Professional Society of ADHD and Related
Disorders, Belvior Publishing, Canadian Psychiatric Assoc, CNS
Spectrums, Dartmouth Medical School, Johns Hopkins Medical School, MBL
Publishing, Montreal McGill Douglas Hospital, Northeast Counseling
Center Directors, PamLab, Physicians Postgraduate Press, SciMed, Slack
Med, University of Florida, WebMD, and Wolters Klower Publishing; has
been a presenter for MGH Psychiatry Academy (MGHPA talks are supported
through Independent Medical Education [IME] grants from the following
pharmaceutical companies in 2008: AstraZeneca, Eli Lilly, and Janssen);
is on the advisory boards of Appliance Computing, Brain Cells,
InfoMedic, Johnson & Johnson, Takeda/Lundbeck, and Targacept; owns stock
options in Appliance Computing and Brain Cells; and, through
Massachusetts General Hospital, is named for copyrights to The Clinical
Positive Affect Scale and the MGH Structured Clinical Interview for the
Montgomery-Asberg Depression Scale, exclusively licensed to the Clinical
Trials Network and Institute. Dr Warden has owned stock in Pfizer, and
Bristol-Myers Squibb within the last five years and has received funding
from NARSAD. Dr Gaynes has received grants and research support from
NIMH, Agency for Healthcare Research and Quality, Robert Wood Johnson
Foundation, M-3 Corporation, Bristol-Myers Squibb, Novartis, Pfizer, and
Ovation; has performed as an advisor or consultant for Bristol-Myers
Squibb, Pfizer, Shire, and Wyeth-Ayerst; and has also received a
speaker's honorarium from GlaxoSmithKline. Dr Rush has received
consultant fees from Advanced Neuromodulation Systems, AstraZeneca, Best
Practice Project Management, Brain Resource, Bristol-Myers
Squibb/Otsuka, Cyberonics, Forest, Gerson Lehrman Group,
GlaxoSmithKline, Jazz, Magellan Health Services, Merck, Neuronetics,
Novartis, Ono, Organon, Otsuka, PamLab, Pfizer, University of Michigan,
Transcept, Urban Institute, and Wyeth-Ayerst; has received speaking fees
from Cyberonics, Forest, GlaxoSmithKline, and Otsuka; has received
royalties from Guilford Publications, Healthcare Technology Systems, and
University of Texas Southwestern Medical Center; has received research
support from NIMH and the Stanley Medical Research Institute; and has
owned shares of stock in Pfizer. Dr Morris and Mr Luther have no
disclosures to report. This project was funded by the NIMH under
contract N01MH90003 to University of Texas Southwestern Medical Center
at Dallas (primary investigator, M.H.T.).
NR 41
TC 12
Z9 12
U1 3
U2 7
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUN
PY 2011
VL 72
IS 6
BP 765
EP 774
DI 10.4088/JCP.11m06840
PG 10
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 786XJ
UT WOS:000292340900005
PM 21733477
ER
PT J
AU Fan, XD
Liu, EY
Hoffman, VP
Potts, AJ
Sharma, B
Henderson, DC
AF Fan, Xiaoduo
Liu, Emily Y.
Hoffman, Vicki Poole
Potts, Alison J.
Sharma, Bikash
Henderson, David C.
TI Triglyceride/High-Density Lipoprotein Cholesterol Ratio: A Surrogate to
Predict Insulin Resistance and Low-Density Lipoprotein Cholesterol
Particle Size in Nondiabetic Patients With Schizophrenia
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID ISCHEMIC-HEART-DISEASE; TREATMENT PANEL-III; DIABETES-MELLITUS;
CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; ATYPICAL
ANTIPSYCHOTICS; SECRETORY DYSFUNCTION; HDL-CHOLESTEROL; PHENOTYPE-B
AB Objective: Insulin resistance, changes in lipid parameters, and cardiometabolic adverse events have been reported in some patients during clinical trials of antipsychotic agents. The present study examined whether the triglyceride/high-density lipoprotein (HDL) ratio can be used as a better surrogate than other conventional lipid measures (low-density lipoprotein [LDL], HDL, triglyceride) in predicting insulin resistance and LDL particle size in nondiabetic patients with schizophrenia.
Method: Outpatients 18 to 75 years old diagnosed with schizophrenia or schizoaffective disorder (DSM-IV criteria) and receiving olanzapine, risperidone, or typical antipsychotics participated in a multicenter, cross-sectional study. Fasting blood samples were obtained to determine the levels of glucose, insulin, lipids, and lipid particle size. The study was conducted from July 2001 to March 2002.
Results: In the sample of 206 patients, significant correlations were found between various lipid measures (LDL, HDL, triglyceride, and triglyceride/HDL ratio) and the homeostasis model of assessment of insulin resistance (P<.05). However, stepwise multiple regression analysis suggested that the triglyceride/HDL ratio is a stronger predictor of insulin resistance and of LDL particle size than other conventional lipoprotein measures after other potential confounding variables, including age, gender, race, family history of diabetes, body mass index, and antipsychotic agent, were taken into consideration (P<.001). Further, logistic regression analysis indicated that the triglyceride/HDL ratio and male gender predict the existence of a small LDL particle size pattern (pattern B LDL phenotype), with a sensitivity of 75.9% and a specificity of 85.4%.
Conclusions: The triglyceride/HDL ratio, a simple, readily available and inexpensive measure, can be a useful surrogate to identify those with insulin resistance as well as those with more atherogenic small LDL particles in nondiabetic patients with schizophrenia. J Clin Psychiatry 2011;72(6):806-812 (C) Copyright 2010 Physicians Postgraduate Press, Inc.
C1 [Fan, Xiaoduo; Sharma, Bikash; Henderson, David C.] Massachusetts Gen Hosp, Dept Psychiat, Schizophrenia Program, Boston, MA 02114 USA.
[Fan, Xiaoduo; Henderson, David C.] Harvard Univ, Sch Med, Boston, MA USA.
[Liu, Emily Y.] Partners Community Healthcare Inc, Haverhill, MA USA.
[Hoffman, Vicki Poole; Potts, Alison J.] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA.
RP Fan, XD (reprint author), Freedom Trail Clin, 25 Staniford St, Boston, MA 02114 USA.
EM xfan@partners.org
FU Eli Lilly
FX The original study was sponsored by Eli Lilly.
NR 48
TC 19
Z9 20
U1 2
U2 5
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 240008, MEMPHIS, TN 38124 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUN
PY 2011
VL 72
IS 6
BP 806
EP 812
DI 10.4088/JCP.09m05107yel
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 786XJ
UT WOS:000292340900010
PM 21208572
ER
PT J
AU Howard, ZD
Rempell, JS
Nadel, ES
Brown, DFM
AF Howard, Zoe D.
Rempell, Joshua S.
Nadel, Eric S.
Brown, David F. M.
TI FEVER AND RIGIDITY
SO JOURNAL OF EMERGENCY MEDICINE
LA English
DT Editorial Material
ID NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONS-DISEASE; CLINICAL-FEATURES;
WITHDRAWAL; THERAPY
C1 [Rempell, Joshua S.; Nadel, Eric S.; Brown, David F. M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Howard, Zoe D.; Rempell, Joshua S.; Nadel, Eric S.; Brown, David F. M.] Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA.
[Nadel, Eric S.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA.
RP Brown, DFM (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Founders 114,55 Fruit St, Boston, MA 02114 USA.
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0736-4679
EI 1090-1280
J9 J EMERG MED
JI J. Emerg. Med.
PD JUN
PY 2011
VL 40
IS 6
BP 668
EP 670
DI 10.1016/j.jemermed.2010.10.015
PG 3
WC Emergency Medicine
SC Emergency Medicine
GA 781TX
UT WOS:000291960500012
PM 21074960
ER
PT J
AU Guo, JJ
Yang, XH
Weston, DJ
Chen, JG
AF Guo, Jianjun
Yang, Xiaohan
Weston, David J.
Chen, Jin-Gui
TI Abscisic Acid Receptors: Past, Present and Future
SO JOURNAL OF INTEGRATIVE PLANT BIOLOGY
LA English
DT Article
DE ABA; ChlH/ABAR/CCH/GUN5; FCA; GCR2; GTG1/GTG2; PYL/PYL/RCAR
ID CHELATASE H-SUBUNIT; EARLY SEEDLING DEVELOPMENT; ACTIVATED
PROTEIN-KINASES; THALIANA SUSPENSION CELLS; DROUGHT STRESS TOLERANCE;
COMMELINA GUARD-CELLS; SIGNAL-TRANSDUCTION; ARABIDOPSIS-THALIANA;
MG-CHELATASE; TRANSCRIPTION FACTORS
AB Abscisic acid (ABA) is the key plant stress hormone. Consistent with the earlier studies in support of the presence of both membrane-and cytoplasm-localized ABA receptors, recent studies have identified multiple ABA receptors located in various subcellular locations. These include a chloroplast envelope-localized receptor (the H subunit of Chloroplast Mg2+-chelatase/ABA Receptor), two plasma membrane-localized receptors (G-protein Coupled Receptor 2 and GPCR-type G proteins), and one cytosol/nucleus-localized Pyrabactin Resistant (PYR)/PYR-Like (PYL)/Regulatory Component of ABA Receptor 1 (RCAR). Although the downstream molecular events for most of the identified ABA receptors are currently unknown, one of them, PYR/PYL/RCAR was found to directly bind and regulate the activity of a long-known central regulator of ABA signaling, the A-group protein phosphatase 2C (PP2C). Together with the Sucrose Non-fermentation Kinase Subfamily 2 (SnRK2s) protein kinases, a central signaling complex (ABA-PYR-PP2Cs-SnRK2s) that is responsible for ABA signal perception and transduction is supported by abundant genetic, physiological, biochemical and structural evidence. The identification of multiple ABA receptors has advanced our understanding of ABA signal perception and transduction while adding an extra layer of complexity.
C1 [Yang, Xiaohan; Weston, David J.; Chen, Jin-Gui] Oak Ridge Natl Lab, Biosci Div, Oak Ridge, TN 37831 USA.
[Guo, Jianjun] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
[Guo, Jianjun] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
RP Chen, JG (reprint author), Oak Ridge Natl Lab, Biosci Div, Oak Ridge, TN 37831 USA.
EM chenj@ornl.gov
RI Chen, Jin-Gui/A-4773-2011; Weston, David/A-9116-2011; guo,
jianjun/G-6852-2013; Yang, Xiaohan/A-6975-2011
OI Chen, Jin-Gui/0000-0002-1752-4201; Weston, David/0000-0002-4794-9913;
Yang, Xiaohan/0000-0001-5207-4210
FU U.S. Department of Energy [DE-AC05-00OR22725]; Laboratory Directed
Research and Development Program of Oak Ridge National Laboratory; U.S.
Department of Energy, Office of Science, Biological and Environmental
Research
FX Support for this research was provided by the U.S. Department of Energy,
Office of Science, Biological and Environmental Research Programs, and
the Laboratory Directed Research and Development Program of Oak Ridge
National Laboratory. Oak Ridge National Laboratory is managed by
UT-Battelle, LLC, for the U.S. Department of Energy under contract
DE-AC05-00OR22725.
NR 99
TC 22
Z9 27
U1 4
U2 48
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1672-9072
EI 1744-7909
J9 J INTEGR PLANT BIOL
JI J. Integr. Plant Biol.
PD JUN
PY 2011
VL 53
IS 6
BP 469
EP 479
DI 10.1111/j.1744-7909.2011.01044.x
PG 11
WC Biochemistry & Molecular Biology; Plant Sciences
SC Biochemistry & Molecular Biology; Plant Sciences
GA 783MW
UT WOS:000292088600006
PM 21554537
ER
PT J
AU Mull, HJ
Nebeker, JR
Shimada, SL
Kaafarani, HMA
Rivard, PE
Rosen, AK
AF Mull, Hillary J.
Nebeker, Jonathan R.
Shimada, Stephanie L.
Kaafarani, Haytham M. A.
Rivard, Peter E.
Rosen, Amy K.
TI Consensus Building for Development of Outpatient Adverse Drug Event
Triggers
SO JOURNAL OF PATIENT SAFETY
LA English
DT Article
DE adverse drug events; trigger; patient safety; Delphi process
AB Objectives: Adverse drug event (ADE) detection is an important priority of patient safety research. Trigger tools have been developed to help identify ADEs. As part of a larger study, we developed complex and specific trigger algorithms intended for concurrent use with clinical care to detect outpatient ADEs. This article assesses the use of a modified Delphi process to obtain expert consensus on the value of these triggers.
Methods: We selected a panel of distinguished clinical and research experts to participate in the modified Delphi process. We created a set of outpatient ADE triggers based on literature review, clinical input, and methodological expertise. The importance of the targeted ADEs, associated drug classes, and trigger logic was used to rate each trigger. Specific criteria were developed to establish consensus.
Results: The modified Delphi process established consensus on 6 outpatient ADE triggers to test with patient-level data based on high ratings of utility for patient-level interventions. These triggers focused on detecting ADEs caused by the following drugs or drug classes: bone marrow toxins, potassium raisers, potassium reducers, creatinine, warfarin, and sedative hypnotics. Participants reported including all aspects of the trigger in their ratings, despite our efforts to separate evaluation of clinical need and trigger logic. Participants' expertise affected the evaluation of trigger rules, leading to contradictory feedback on how to improve trigger design.
Conclusions: The efficiency of the modified Delphi method could be improved by allowing participants to produce an overall summary score that incorporates both the clinical value and the general logic of the trigger. Revising and improving trigger design should be conducted in a separate process limited only to trigger experts.
C1 [Mull, Hillary J.; Rivard, Peter E.; Rosen, Amy K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA 02130 USA.
[Mull, Hillary J.; Shimada, Stephanie L.; Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Nebeker, Jonathan R.] Salt Lake City VA Med Ctr, Salt Lake City, UT USA.
[Nebeker, Jonathan R.] Univ Utah, Salt Lake City, UT USA.
[Shimada, Stephanie L.] Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Kaafarani, Haytham M. A.] Tufts Med Ctr, Dept Surg, Boston, MA USA.
[Rivard, Peter E.] Suffolk Univ, Boston, MA 02114 USA.
RP Mull, HJ (reprint author), VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, 150 S Huntington Ave,152M, Boston, MA 02130 USA.
EM hjmull@bu.edu
FU Agency for Healthcare Research and Quality [HHSA29020060012]
FX This research was funded through contract no. HHSA29020060012 Task Order
no. 3 awarded to Amy Rosen, PhD, by the Agency for Healthcare Research
and Quality.
NR 26
TC 5
Z9 5
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1549-8417
J9 J PATIENT SAF
JI J. Patient Saf.
PD JUN
PY 2011
VL 7
IS 2
BP 66
EP 71
DI 10.1097/PTS.0b013e31820c98ba
PG 6
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA V27KO
UT WOS:000208612300002
PM 21587117
ER
PT J
AU Carbo, AR
Tess, AV
Roy, C
Weingart, SN
AF Carbo, Alexander R.
Tess, Anjala V.
Roy, Christopher
Weingart, Saul N.
TI Developing a High-Performance Team Training Framework for Internal
Medicine Residents: The ABC'S of Teamwork
SO JOURNAL OF PATIENT SAFETY
LA English
DT Article
DE teamwork; residents; communication
AB Objectives: Effective teamwork and communication can prevent error and mitigate harm. High-performance team training was developed in the aviation industry for flight crews and is being incorporated in health care settings, such as emergency departments, operating rooms, and labor and delivery suites. We translated and adapted high-performance teamwork and communication principles from other industries and other disciplines to an inpatient internal medicine environment.
Methods: We selected key principles from aviation and anesthesia crew training programs in 2004 and organized them into the ABC'S of teamwork. These included appropriate Assertiveness, effective Briefings, Callback and verification, Situational awareness, and Shared mental models. Based on this content, we developed a training session for internal medicine residents and faculty, and evaluated learners' patient safety attitudes and knowledge before and after training with a written survey.
Results: More than 50 residents participated in the module. The percentage of correct answers on a question related to key teamwork principles increased from 35% before training to 67% after training (P = 0.03). Before training, 65% of the residents reported that they "would feel comfortable telling a senior clinician his/her plan was unsafe''; this increased to 94% after training (P - 0.005). After the training session, residents were able to provide examples from their clinical practice that emphasized all of the ABC'S of teamwork.
Conclusions: Teamwork principles can be adapted from other disciplines and applied to internal medicine. After a single session, residents displayed greater knowledge of teamwork principles and reported changed attitudes toward key teamwork behaviors.
C1 [Carbo, Alexander R.] Beth Israel Deaconess Med Ctr, Hosp Med Program, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Carbo, Alexander R.; Tess, Anjala V.; Roy, Christopher; Weingart, Saul N.] Harvard Univ, Sch Med, Boston, MA USA.
[Roy, Christopher] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Weingart, Saul N.] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA.
RP Carbo, AR (reprint author), Beth Israel Deaconess Med Ctr, Hosp Med Program, Div Gen Med & Primary Care, Palmer Baker 2nd Floor,330 Brookline Ave, Boston, MA 02215 USA.
EM acarbo@bidmc.harvard.edu
NR 23
TC 11
Z9 12
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1549-8417
J9 J PATIENT SAF
JI J. Patient Saf.
PD JUN
PY 2011
VL 7
IS 2
BP 72
EP 76
DI 10.1097/PTS.0b013e31820dbe02
PG 5
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA V27KO
UT WOS:000208612300003
PM 21587118
ER
PT J
AU Smith, DE
Johnson, JL
Harrington, T
Kitchen, L
Albertson, L
Lane, E
AF Smith, Denise E.
Johnson, Jennifer L.
Harrington, Tim
Kitchen, Linda
Albertson, LaVonne
Lane, Ellen
TI POST PACU CLIENT SURVEY
SO JOURNAL OF PERIANESTHESIA NURSING
LA English
DT Meeting Abstract
C1 [Smith, Denise E.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1089-9472
J9 J PERIANESTH NURS
JI J. PeriAnesthesia Nurs.
PD JUN
PY 2011
VL 26
IS 3
BP 196
EP 196
PG 1
WC Nursing
SC Nursing
GA 781DS
UT WOS:000291911400054
ER
PT J
AU Guze, K
Short, M
Zeng, H
Lerman, M
Sonis, S
AF Guze, K.
Short, M.
Zeng, H.
Lerman, M.
Sonis, S.
TI Comparison of molecular images as defined by Raman spectra between
normal mucosa and squamous cell carcinoma in the oral cavity
SO JOURNAL OF RAMAN SPECTROSCOPY
LA English
DT Article
DE Raman; oral cancer; in vivo; biomarker; confocal
ID HUMAN SKIN; SPECTROSCOPY; TISSUE; CANCER; DNA; MICROSPECTROSCOPY;
AUTOFLUORESCENCE; CHOLESTEROL; ACTIVATION; MICROSCOPY
AB Raman spectroscopy has been effectively applied to clinically differentiate normal and cancerous mucosal tissues. Micro-Raman spectroscopy provides a tool to better understand the molecular basis for the Raman clinical signal. The objective of the current study was to utilize micro-Raman spectroscopy to define the molecular/spectral differences between normal and abnormal squamous cell carcinoma (SCC) in oral mucosa (in vitro). Understanding this may help in identifying unique spectra or may be useful for in vivo application of this technology. Micro-Raman (confocal) spectroscopy was used to obtain molecular images of normal and SCC cells of human oral mucosa. Four fresh flashed-frozen tumor and four matched normal tongue specimens were studied. The spectra covered a wavenumber range from 300 to 4000 cm(-1) with a spectral resolution of 8 cm(-1) and a spatial resolution of 1.0 mu m. The cells were located within thin sections of tongue mucosa biopsies. The excitation wavelength of 515 nm was used. We were able to obtain Raman images with rich information about the spectroscopic and structural features within the cytoplasm, cell membrane, and cell nuclei. Significant spectral differences were observed between the Raman images of normal and malignant squamous cells. The heterogeneity of tumor cells within the abnormal tissue was also demonstrated. Spectral differences demonstrated between both tissue types have provided important information regarding the origins of specific signals within the cells of each tissue type. In our search for specific spectral biomarkers, we believe that a cell surface protein, greatly upregulated in SCC cells, was discovered at 1583 cm(-1). Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Guze, K.; Lerman, M.; Sonis, S.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02114 USA.
[Short, M.; Zeng, H.] British Columbia Canc Res Ctr, Integrat Oncol Dept, Vancouver, BC V5Z 1L3, Canada.
[Lerman, M.; Sonis, S.] Harvard Farber Canc Ctr, Div Oral Med, Boston, MA USA.
RP Guze, K (reprint author), Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02114 USA.
EM Kevin_Guze@hsdm.harvard.edu
NR 47
TC 20
Z9 20
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0377-0486
J9 J RAMAN SPECTROSC
JI J. Raman Spectrosc.
PD JUN
PY 2011
VL 42
IS 6
BP 1232
EP 1239
DI 10.1002/jrs.2838
PG 8
WC Spectroscopy
SC Spectroscopy
GA 782EH
UT WOS:000291990300005
ER
PT J
AU Patti, JA
AF Patti, John A.
TI Without a Strong Team, We Cannot Advance
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Patti, JA (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND 202, Boston, MA 02114 USA.
EM jpatti@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUN
PY 2011
VL 8
IS 6
BP 375
EP 376
DI 10.1016/j.jacr.2011.03.012
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 971JY
UT WOS:000306201400001
PM 21636046
ER
PT J
AU Ho, VB
van Geertruyden, PH
Yucel, EK
Rybicki, FJ
Baum, RA
Desjardins, B
Flamm, SD
Foley, WD
Jaff, MR
Koss, SA
Mammen, L
Mansour, MA
Mohler, ER
Narra, VR
Schenker, MP
AF Ho, Vincent B.
van Geertruyden, Peter H.
Yucel, E. Kent
Rybicki, Frank J.
Baum, Richard A.
Desjardins, Benoit
Flamm, Scott D.
Foley, W. Dennis
Jaff, Michael R.
Koss, Scott A.
Mammen, Leena
Mansour, M. Ashraf
Mohler, Emile R., III
Narra, Vamsidhar R.
Schenker, Matthew P.
TI ACR Appropriateness Criteria (R) on Suspected Lower Extremity Deep Vein
Thrombosis
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Appropriateness Criteria (R); vein thrombosis; ultrasonography; computed
tomography; magnetic resonance imaging; phlebography
ID VENOUS THROMBOSIS; CONTRAST VENOGRAPHY; SONOGRAPHY; ULTRASONOGRAPHY;
METAANALYSIS; STRATEGIES; ULTRASOUND; DIAGNOSIS; ACCURACY; CT
AB Lower extremity deep vein thrombosis (DVT) is a common clinical concern, with an incidence that increases with advanced age. DVT typically begins below the knee but may extend proximally and result in pulmonary embolism. Pulmonary embolism can occur in 50% to 60% of patients with untreated DVT and can be fatal. Although clinical examination and plasma D-dimer blood evaluation can often predict the presence of DVT, imaging remains critical for the diagnostic confirmation and treatment planning of DVT. Patients with above-the-knee or proximal DVT have a high risk for pulmonary embolism and are recommended to receive anticoagulation therapy. On the other hand, patients with below-the-knee or distal DVT rarely experience pulmonary embolism, and anticoagulation therapy in these patients remains controversial. However, one sixth of patients with distal DVT may experience extension of their thrombus above the knee and therefore are recommended. to undergo serial imaging assessment at 1 week to exclude proximal DVT extension if anticoagulation therapy is not initiated. Ultrasound is the preferred imaging method for evaluation of patients with newly suspected lower extremity DVT. Magnetic resonance and CT venography can be especially helpful for the evaluation of suspected DVT in the pelvis and thigh. Contrast x-ray venography, the historic gold standard for DVT assessment, is now less commonly performed and primarily reserved for patients with more complex presentations such as those with suspected recurrent acute DVT.
C1 [Ho, Vincent B.; van Geertruyden, Peter H.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
[Yucel, E. Kent] Tufts Med Ctr, Boston, MA USA.
[Rybicki, Frank J.; Baum, Richard A.; Schenker, Matthew P.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Desjardins, Benoit; Mohler, Emile R., III] Univ Penn, Philadelphia, PA 19104 USA.
[Flamm, Scott D.] Cleveland Clin, Cleveland, OH 44106 USA.
[Foley, W. Dennis] Froedtert Hosp E, Milwaukee, WI USA.
[Jaff, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jaff, Michael R.; Mohler, Emile R., III] Amer Coll Cardiol, Bethesda, MD USA.
[Koss, Scott A.] Radiol Waukesha, Waukesha, WI USA.
[Mammen, Leena] Adv Radiol Serv, Grand Rapids, MI USA.
[Mansour, M. Ashraf] Vasc Associates, Grand Rapids, MI USA.
[Mansour, M. Ashraf] Soc Vasc Surg, Chicago, IL USA.
[Narra, Vamsidhar R.] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA.
RP Ho, VB (reprint author), Amer Coll Radiol, 1891 Preston White Dr, Reston, VA 20191 USA.
EM vho@usuhs.mil
NR 21
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUN
PY 2011
VL 8
IS 6
BP 383
EP 387
DI 10.1016/j.jacr.2011.02.016
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 971JY
UT WOS:000306201400006
PM 21636051
ER
PT J
AU Singh, S
Kalra, MK
Thrall, JH
Mahesh, M
AF Singh, Sarabjeet
Kalra, Mannudeep K.
Thrall, James H.
Mahesh, Mahadevappa
TI Automatic Exposure Control in CT: Applications and Limitations
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
ID TUBE CURRENT MODULATION; Z-AXIS MODULATION; DOSE REDUCTION; ROW CT;
ONLINE MODULATION; IMAGE QUALITY; OPTIMIZATION; NECK
C1 [Singh, Sarabjeet; Kalra, Mannudeep K.; Thrall, James H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
[Mahesh, Mahadevappa] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA.
RP Singh, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
EM mmahesh@jhmi.edu
NR 14
TC 12
Z9 12
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUN
PY 2011
VL 8
IS 6
BP 446
EP 449
DI 10.1016/j.jacr.2011.03.001
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 971JY
UT WOS:000306201400017
PM 21636062
ER
PT J
AU Rosen, AK
Itani, KMF
AF Rosen, Amy K.
Itani, Kamal M. F.
TI Validating the Patient Safety Indicators in the Veterans Health
Administration: Are They Ready for Prime Time?
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Editorial Material
C1 [Rosen, Amy K.] VA Boston Healthcare Syst, COLMR, Boston, MA 02130 USA.
[Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Rosen, Amy K.; Itani, Kamal M. F.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Itani, Kamal M. F.] VA Boston Healthcare Syst, Dept Surg, Boston, MA 02130 USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rosen, AK (reprint author), VA Boston Healthcare Syst, COLMR, 150 S Huntington Ave,152M, Boston, MA 02130 USA.
EM akrosen@bu.edu
NR 15
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 921
EP 923
DI 10.1016/j.jamcollsurg.2010.12.053
PG 3
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600002
PM 21620288
ER
PT J
AU Kaafarani, HMA
Borzecki, AM
Itani, KMF
Loveland, S
Mull, HJ
Hickson, K
MacDonald, S
Shin, M
Rosen, AK
AF Kaafarani, Haytham M. A.
Borzecki, Ann M.
Itani, Kamal M. F.
Loveland, Susan
Mull, Hillary J.
Hickson, Kathleen
MacDonald, Sally
Shin, Marlena
Rosen, Amy K.
TI Validity of Selected Patient Safety Indicators: Opportunities and
Concerns
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID QUALITY IMPROVEMENT PROGRAM; POSITIVE PREDICTIVE-VALUE; MORTALITY
CONFERENCE; COMPLICATIONS; MORBIDITY
AB BACKGROUND: The Agency for Healthcare Research and Quality (AHRQ) recently designed the Patient Safety Indicators (PSIs) to detect potential safety-related adverse events. The National Quality Forum has endorsed several of these ICD-9-CM-based indicators as quality-of-care measures. We examined the positive predictive value (PPV) of 3 surgical PSIs: postoperative pulmonary embolus and deep vein thrombosis (pPE/DVT), iatrogenic pneumothorax (iPTX), and accidental puncture and laceration (APL).
STUDY DESIGN: We applied the AHRQ PSI software (v.3.1a) to fiscal year 2003 to 2007 Veterans Health Administration (VA) administrative data to identify (flag) patients suspected of having a pPE/DVT, iPTX, or APL. Two trained nurse abstractors reviewed a sample of 336 flagged medical records (112 records per PSI) using a standardized instrument. Inter-rater reliability was assessed.
RESULTS: Of 2,343,088 admissions, 6,080 were flagged for pPE/DVT (0.26%), 1,402 for iPTX (0.06%), and 7,203 for APL (0.31%). For pPE/DVT, the PPV was 43% (95% CI, 34% to 53%); 21% of cases had inaccurate coding (eg, arterial not venous thrombosis); and 36% featured thromboembolism present on admission or preoperatively. For iPTX, the PPV was 73% (95% CI, 64% to 81%); 18% had inaccurate coding (eg, spontaneous pneumothorax), and 9% were pneumothoraces present on admission. For APL, the PPV was 85% (95% CI, 77% to 91%); 10% of cases had coding inaccuracies and 5% indicated injuries present on admission. However, 27% of true APLs were minor injuries requiring no surgical repair (eg, small serosal bowel tear). Inter-rater reliability was >90% for all 3 PSIs.
CONCLUSIONS: Until coding revisions are implemented, these PSIs, especially pPE/DVT, should be used primarily for screening and case-finding. Their utility for public reporting and pay-for-performance needs to be reassessed. (J Am Coll Surg 2011;212:924-934. (C) 2011 by the American College of Surgeons)
C1 [Loveland, Susan; Mull, Hillary J.; Shin, Marlena; Rosen, Amy K.] VA Boston Healthcare Syst, COLMR, Boston, MA 02130 USA.
[Kaafarani, Haytham M. A.] Tufts Univ, Sch Med, Dept Surg, Tufts Med Ctr, Boston, MA 02111 USA.
[Kaafarani, Haytham M. A.] Ctr Hlth Qual Outcomes & Econ Res, Boston, MA USA.
[Borzecki, Ann M.; Mull, Hillary J.; Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Borzecki, Ann M.; Itani, Kamal M. F.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
[Borzecki, Ann M.; Hickson, Kathleen; MacDonald, Sally] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Itani, Kamal M. F.; Hickson, Kathleen] VA Boston Healthcare Syst, Dept Surg, W Roxbury, MA USA.
RP Rosen, AK (reprint author), VA Boston Healthcare Syst, COLMR, 150 S Huntington Ave, Boston, MA 02130 USA.
EM akrosen@bu.edu
NR 24
TC 59
Z9 60
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 924
EP 934
DI 10.1016/j.jamcollsurg.2010.07.007
PG 11
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600003
PM 20869268
ER
PT J
AU Borzecki, AM
Kaafarani, HMA
Utter, GH
Romano, PS
Shin, MH
Chen, Q
Itani, KMF
Rosen, AK
AF Borzecki, Ann M.
Kaafarani, Haytham M. A.
Utter, Garth H.
Romano, Patrick S.
Shin, Marlena H.
Chen, Qi
Itani, Kamal M. F.
Rosen, Amy K.
TI How Valid is the AHRQ Patient Safety Indicator "Postoperative
Respiratory Failure"?
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID COLLEGE-OF-PHYSICIANS; NONCARDIOTHORACIC SURGERY; PULMONARY
COMPLICATIONS; STRATEGIES; PROGRAM; CARE
AB BACKGROUND: The Agency for Healthcare Research and Quality Patient Safety Indicator postoperative respiratory failure (PRF) uses administrative data to screen for potentially preventable respiratory failure after elective surgery based on a respiratory failure diagnosis or an intubation or ventilation procedure code. Data on PRF accuracy in identifying true events is scant; a recent study using University HealthSystem Consortium data found a positive predictive value (PPV) of 83%. We examined the indicator's PPV in the Veterans Health Administration.
STUDY DESIGN: We applied the Patient Safety Indicator software (v.3.1a) to fiscal year 2003-2007 VA discharge data. Trained abstractors reviewed medical records of 112 software-flagged PRF cases. We calculated the PPV and examined false positives to determine reasons for incorrect identification and true positives to determine clinical consequences and potential risk factors of PRF.
RESULTS: Seventy-five cases were true positive (PPV 67%; 95% CI, 57-76%); 13% were identified by a diagnosis code, 53% by a procedure code, 33% by both. Of false positives, 19% represented coding errors, 76% represented nonelective admissions. Of true positives, 28% of patients died, 56% had an American Society of Anesthesiologists level higher than II. Of associated index procedures, 53% were abdominal/pelvic, and 56% lasted >3 hours.
CONCLUSIONS: Based on our and University HealthSystem Consortium's findings, PRF should continue to be used as a screen for potential patient-safety events. Its PPV could be substantially improved in the Veterans Health Administration through introduction of an admission status code. Many PRF-identified cases appeared to be at high risk, based on patient and procedure-related factors. The degree to which such cases are truly preventable events requires additional assessment. (J Am Coll Surg 2011;212:935-945. (C) 2011 by the American College of Surgeons)
C1 [Borzecki, Ann M.] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Borzecki, Ann M.; Chen, Qi; Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Borzecki, Ann M.; Itani, Kamal M. F.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Kaafarani, Haytham M. A.] Tufts Med Ctr, Dept Surg, Boston, MA USA.
[Itani, Kamal M. F.] VA Boston Healthcare Syst, Dept Surg, Boston, MA USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
[Shin, Marlena H.; Chen, Qi; Rosen, Amy K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
[Utter, Garth H.; Romano, Patrick S.] Univ Calif Davis, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA.
[Utter, Garth H.] Univ Calif Davis, Dept Surg, Sacramento, CA 95817 USA.
[Romano, Patrick S.] Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA.
RP Borzecki, AM (reprint author), Bedford VA Hosp 152, CHQOER, 200 Springs Rd, Bedford, MA 01730 USA.
EM amb@bu.edu
RI Romano, Patrick/N-4225-2014;
OI Romano, Patrick/0000-0001-6749-3979; Utter, Garth/0000-0001-7747-3429
FU Department of Veterans Affairs Health Services Research and Development
service [SDR 07-002]
FX Supported by the Department of Veterans Affairs Health Services Research
and Development service grant number SDR 07-002.
NR 28
TC 20
Z9 20
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 935
EP 945
DI 10.1016/j.jamcollsurg.2010.09.034
PG 11
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600004
PM 21474343
ER
PT J
AU Borzecki, AM
Kaafarani, H
Cevasco, M
Hickson, K
MacDonald, S
Shin, M
Itani, KMF
Rosen, AK
AF Borzecki, Ann M.
Kaafarani, Haytham
Cevasco, Marisa
Hickson, Kathleen
MacDonald, Sally
Shin, Marlena
Itani, Kamal M. F.
Rosen, Amy K.
TI How Valid is the AHRQ Patient Safety Indicator "Postoperative Hemorrhage
or Hematoma"?
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID COMPLICATIONS SCREENING-PROGRAM; CARE; PERFORM
AB BACKGROUND: Postoperative hemorrhage or hematoma (PHH), an Agency for Healthcare Research and Quality Patient Safety Indicator, uses administrative data to detect cases of potentially preventable postsurgical bleeding requiring a reparative procedure. How accurately it identifies true events is unknown. We therefore determined PHH's positive predictive value.
STUDY DESIGN: Using Patient Safety Indicator software (v.3.1a) and fiscal year 2003-2007 discharge data from 28 Veterans Health Administration hospitals, we identified 112 possible cases of PHH. Based on medical record abstraction, we characterized cases as true (TPs) or false positives (FPs), calculated positive predictive value, and analyzed FPs to ascertain reasons for incorrect identification and TPs to determine PHH-associated clinical consequences and risk factors.
RESULTS: Eighty-four cases were TPs (positive predictive value, 75%; 95% CI, 66-83%); 63% had a hematoma diagnosis, 30% had a hemorrhage diagnosis, 7% had both. Reasons for FPs included events present on admission (29%); hemorrhage/hematoma identified and controlled during the original procedure rather than postoperatively (21%); or postoperative hemorrhage/hematoma that did not require a procedure (18%). Most TPs (82%) returned to the operating room for hemorrhage/hematoma management; 64% required blood products and 7% died in-hospital. The most common index procedures resulting in postoperative hemorrhage/ hematoma were vascular (38%); 56% were performed by a physician-in-training (under supervision). We found no substantial association between physician training status or perioperative anticoagulant use and bleeding risk.
CONCLUSIONS: PHH's accuracy could be improved by coding enhancements, such as adopting present on admission codes or associating a timing factor with codes dealing with bleeding control. The ability of PHH to identify events representing quality of care problems requires additional evaluation. (J Am Coll Surg 2011; 212: 946-953. (C) 2011 by the American College of Surgeons)
C1 [Borzecki, Ann M.; Hickson, Kathleen; MacDonald, Sally] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Borzecki, Ann M.; Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Borzecki, Ann M.; Itani, Kamal M. F.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Kaafarani, Haytham] Tufts Univ, Sch Med, Dept Surg, Tufts Med Ctr, Boston, MA 02111 USA.
[Cevasco, Marisa; Itani, Kamal M. F.] VA Boston Healthcare Syst, Dept Surg, Boston, MA USA.
[Cevasco, Marisa] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Shin, Marlena; Rosen, Amy K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
RP Borzecki, AM (reprint author), Bedford VA Hosp 152, CHQOER, 200 Springs Rd, Bedford, MA 01730 USA.
EM amb@bu.edu
FU Department of Veterans Affairs Health Services Research and Development
service [SDR 07-002]
FX The study was funded by a Department of Veterans Affairs Health Services
Research and Development service grant number SDR 07-002.
NR 25
TC 15
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 946
EP U214
DI 10.1016/j.jamcollsurg.2010.09.033
PG 10
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600005
PM 21474344
ER
PT J
AU Cevasco, M
Borzecki, AM
Chen, Q
Zrelak, PA
Shin, M
Romano, PS
Itani, KMF
Rosen, AK
AF Cevasco, Marisa
Borzecki, Ann M.
Chen, Qi
Zrelak, Patricia A.
Shin, Marlena
Romano, Patrick S.
Itani, Kamal M. F.
Rosen, Amy K.
TI Positive Predictive Value of the AHRQ Patient Safety Indicator
"Postoperative Sepsis": Implications for Practice and Policy
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID VENOUS THROMBOEMBOLISM
AB BACKGROUND: Patient Safety Indicator (PSI) 13, or "Postoperative Sepsis," of the Agency for Healthcare Quality and Research (AHRQ), was recently adopted as part of a composite measure of patient safety by the Centers for Medicare and Medicaid Services (CMS). We sought to examine its positive predictive value (PPV) by determining how well it identifies true cases of postoperative sepsis.
STUDY DESIGN: Two retrospective cross-sectional studies of hospitalization records that met PSI 13 criteria were conducted, one within the Veterans Administration (VA) Hospitals from fiscal years (FY) 2003 to 2007, and one within community hospitals between October 1, 2005 and March 31, 2007. Trained abstractors reviewed medical records from each database using standardized abstraction instruments. We determined the PPV of the indicator and performed descriptive analyses of cases.
RESULTS: Of 112 cases flagged and reviewed within the VA system, 59 were true events of postoperative sepsis, yielding a PPV of 53% (95% CI 42% to 64%). Within the community hospital sector, of 164 flagged and reviewed cases, 67 were true cases of postoperative sepsis, yielding a PPV of 41% (95% CI 28% to 54%). False positives were due to infections that were present on admission, urgent or emergent cases, no clinical diagnosis of sepsis, or other coding limitations such as nonspecific shock in postoperative patients.
CONCLUSIONS: PSI 13 has relatively poor predictive ability to identify true cases of postoperative sepsis in both the VA and nonfederal sectors. The lack of information on diagnosis timing, confusion about the definition of elective admission, and coding limitations were the major reasons for false positives. As it currently stands, the use of PSI 13 as a stand-alone measure for hospital reporting appears premature. (J Am Coll Surg 2011;212:954-961. (C) 2011 by the American College of Surgeons)
C1 [Cevasco, Marisa] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Cevasco, Marisa; Itani, Kamal M. F.] VA Boston Healthcare Syst, Dept Surg, Boston, MA USA.
[Borzecki, Ann M.; Chen, Qi; Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Borzecki, Ann M.; Itani, Kamal M. F.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Chen, Qi; Shin, Marlena; Rosen, Amy K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
[Borzecki, Ann M.] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Zrelak, Patricia A.; Romano, Patrick S.] Univ Calif Davis, Ctr Healthcare Policy & Res, Davis, CA 95616 USA.
[Romano, Patrick S.] Univ Calif Davis, Div Gen Med, Davis, CA 95616 USA.
RP Cevasco, M (reprint author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.
RI Romano, Patrick/N-4225-2014;
OI Romano, Patrick/0000-0001-6749-3979; Zrelak,
Patricia/0000-0002-5977-6503
FU US Agency for Healthcare Research and Quality [290-04-0020]
FX This work was supported in part by the US Agency for Healthcare Research
and Quality contract 290-04-0020.
NR 18
TC 22
Z9 22
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 954
EP 961
DI 10.1016/j.jamcollsurg.2010.11.013
PG 8
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600006
PM 21474345
ER
PT J
AU Cevasco, M
Borzecki, AM
McClusky, DA
Chen, Q
Shin, MH
Itani, KMF
Rosen, AK
AF Cevasco, Marisa
Borzecki, Ann M.
McClusky, David A., III
Chen, Qi
Shin, Marlena H.
Itani, Kamal M. F.
Rosen, Amy K.
TI Positive Predictive Value of the AHRQ Patient Safety Indicator
"Postoperative Wound Dehiscence"
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID VENOUS THROMBOEMBOLISM
AB BACKGROUND: The Agency for Healthcare Research and Quality patient safety indicator (PSI) 14, or "postoperative wound dehiscence," is 1 of 4 PSIs recently adopted by the Centers for Medicare & Medicaid Services to compare quality and safety across hospitals. We determined how well it identifies true cases of postoperative wound dehiscence by examining its positive predictive value (PPV).
STUDY DESIGN: A retrospective cross-sectional study of hospitalization records that met PSI 14 criteria was conducted within the Veterans Health Administration hospitals from fiscal years 2003 to 2007. Trained abstractors used standardized abstraction instruments to review electronic medical records. We determined the PPV of the indicator and performed descriptive analyses of cases.
RESULTS: Of the 112 reviewed cases, 97 were true events of postoperative wound dehiscence, yielding a PPV of 87% (95% CI 79% to 92%). Sixty-one percent (n = 59) of true positive cases had at least 1 risk factor, such as low albumin level, COPD, or superficial wound infection. False positives were due to coding errors, such as cases in which the patient's abdomen was intentionally left open during the index procedure.
CONCLUSIONS: PSI 14 has relatively good predictive ability to identify true cases of postoperative wound dehiscence. It has the highest PPV among all PSIs evaluated within the Veterans Health Administration system. Inaccurate coding was the reason for false positives. Providing additional training to medical coders could potentially improve the PPV of this indicator. At present, this PSI is a promising measure for both quality improvement and performance measurement; however, its use in pay-for-performance efforts seems premature. (J Am Coll Surg 2011; 212: 962-967. (C) 2011 by the American College of Surgeons)
C1 [Cevasco, Marisa] VA Boston Healthcare Syst, Dept Surg, W Roxbury Div, W Roxbury, MA 02132 USA.
[Cevasco, Marisa] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Borzecki, Ann M.] Bedford VA Med Ctr, Ctr Healthcare Qual Outcomes & Econ Res, Bedford, MA USA.
[Borzecki, Ann M.; Chen, Qi; Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Borzecki, Ann M.; Itani, Kamal M. F.] Sch Med, Boston, MA USA.
[McClusky, David A., III] Emory Univ Hosp, Dept Surg, Atlanta, GA 30322 USA.
[McClusky, David A., III] VA Atlanta Healthcare Syst, Atlanta, GA USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
RP Cevasco, M (reprint author), VA Boston Healthcare Syst, Dept Surg, W Roxbury Div, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM mcevasco@partners.org
NR 21
TC 17
Z9 17
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 962
EP 967
DI 10.1016/j.jamcollsurg.2011.01.053
PG 6
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600007
PM 21489829
ER
PT J
AU Borzecki, AM
Cevasco, M
Chen, Q
Shin, M
Itani, KMF
Rosen, AK
AF Borzecki, Ann M.
Cevasco, Marisa
Chen, Qi
Shin, Marlena
Itani, Kamal M. F.
Rosen, Amy K.
TI How Valid is the AHRQ Patient Safety Indicator "Postoperative
Physiologic and Metabolic Derangement"?
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID ACUTE-RENAL-FAILURE; CONTRAST-INDUCED NEPHROPATHY; RISK-FACTORS;
COMPLICATIONS; SURGERY; DYSFUNCTION; OUTCOMES; PROGRAM
AB BACKGROUND: The Agency for Healthcare Research and Quality Patient Safety Indicator postoperative physiologic and metabolic derangement (PMD) uses ICD-9-CM codes to screen for potentially preventable acute kidney injury (AKI) requiring dialysis plus diabetes-related complications after elective surgery. Data on PMD's accuracy in identifying true events are limited. We examined the indicator's positive predictive value (PPV) in the Veterans Health Administration (VA).
STUDY DESIGN: Trained abstractors reviewed medical records of 119 PSI software-flagged PMD cases. We calculated PPVs overall and separately for renal-and diabetes-related complications. We also examined false positives to determine reasons for incorrect identification, and true positives to determine PMD-related outcomes and risk factors.
RESULTS: Overall 75 cases were true positives (PPV 63%, 95% CI 54% to 72%); 73 of 104 AKI cases were true positives (PPV 70%, 60% to 79%); only 2 of 15 diabetes cases were true positives (PPV 13%, 2% to 40%). Of all false positives, 70% represented nonelective admissions and 23% had the complication present on admission. Of AKI true positives, 37% died and 26% were discharged on dialysis; 55% had chronic kidney disease (>= stage 3) present on admission. Cardiac surgery represented the largest category of AKI-associated index procedures (30%). AKI was most commonly attributed to perioperative renal hypoperfusion (84% of true positives), followed by nephrotoxins (33%) including contrast (11%).
CONCLUSIONS: Due to its low PPV, we recommend removing diabetes complications from the indicator and focusing on AKI. PMD's PPV could be significantly improved by using present-on-admission codes, and specific to the VA, by introduction of admission status codes. Many PMD-identified cases appeared to be at high risk based on patient-and procedure-related factors. The degree to which such cases are truly preventable events requires further assessment. (J Am Coll Surg 2011; 212: 968-976. (C) 2011 by the American College of Surgeons)
C1 [Borzecki, Ann M.] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Borzecki, Ann M.; Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Borzecki, Ann M.; Itani, Kamal M. F.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Cevasco, Marisa; Itani, Kamal M. F.] VA Boston Healthcare Syst, Dept Surg, Boston, MA USA.
[Cevasco, Marisa] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Chen, Qi; Shin, Marlena; Rosen, Amy K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
RP Borzecki, AM (reprint author), Bedford VA Hosp 152, CHQOER, 200 Springs Rd, Bedford, MA 01730 USA.
EM amb@bu.edu
FU Department of Veterans Affairs Health Services Research and Development
Service [SDR 07-002]
FX Supported by Department of Veterans Affairs Health Services Research and
Development Service grant number SDR 07-002.
NR 38
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 968
EP U239
DI 10.1016/j.jamcollsurg.2011.01.001
PG 11
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600008
PM 21489834
ER
PT J
AU Chen, Q
Rosen, AK
Cevasco, M
Shin, M
Itani, KMF
Borzecki, AM
AF Chen, Qi
Rosen, Amy K.
Cevasco, Marisa
Shin, Marlena
Itani, Kamal M. F.
Borzecki, Ann M.
TI Detecting Patient Safety Indicators: How Valid Is "Foreign Body Left
During Procedure" in the Veterans Health Administration?
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID ADVERSE EVENTS; MEDICAL DEVICE; SPONGES; HOSPITALS; SURGERY; COUNT
AB BACKGROUND: The Agency for Healthcare Research and Quality (AHRQ) developed patient safety indicator (PSI) 5, "Foreign body left during procedure," to flag accidental foreign bodies in surgical and medical procedures. This study examined how well this indicator identifies true foreign body events in the Veterans Health Administration (VA).
STUDY DESIGN: This was a retrospective study within 28 selected VA hospitals from fiscal year 2003 to 2007. Trained abstractors reviewed medical charts flagged by PSI 5 and determined true foreign body cases. We calculated the positive predictive value (PPV) of this indicator and performed descriptive analyses of true positive and false positive cases.
RESULTS: Of the 652,093 eligible cases, 93 were flagged by PSI 5 (0.14 per 1,000). Forty-two were true positives, yielding a PPV of 45% (95% CI 35% to 56%). False positives were due to a foreign body that was present on admission (57%) or coding errors (43%). True foreign bodies were associated with surgical (n = 23) and medical (n = 19) procedures. The most common type of surgical foreign body was a sponge (52%). Overall, approximately 40% of foreign bodies were related to a device failure or malfunction (30% surgical vs 53% medical foreign bodies). Postoperative complications included pain (24%), infection (12%), adhesions (5%), and bowel obstruction (5%).
CONCLUSIONS: The reported rate of foreign body events as detected by PSI 5 is low in the VA, but occurs in both surgical and medical procedures. Despite widespread implementation of surgical counts, quality improvement efforts should focus on novel ways to eliminate this " never event" from operations. Future studies are needed to better understand the preventability of medical procedure-associated foreign bodies and particularly, device failure-related foreign bodies. (J Am Coll Surg 2011;212:977-983. (C) 2011 by the American College of Surgeons)
C1 [Chen, Qi; Rosen, Amy K.; Shin, Marlena] VA Boston Healthcare Syst, COLMR, Boston, MA 02130 USA.
[Cevasco, Marisa; Itani, Kamal M. F.] VA Boston Healthcare Syst, Dept Surg, Boston, MA 02130 USA.
[Chen, Qi; Rosen, Amy K.; Borzecki, Ann M.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA.
[Cevasco, Marisa] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Rosen, Amy K.; Itani, Kamal M. F.; Borzecki, Ann M.] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Borzecki, Ann M.] Bedford VAMC, CHQOER, Bedford, MA USA.
RP Rosen, AK (reprint author), VA Boston Healthcare Syst, COLMR, 150 S Huntington Ave, Boston, MA 02130 USA.
EM akrosen@bu.edu
FU Department of Veterans Affairs Health Services Research and Development
service [SDR 07-002]
FX Supported by Department of Veterans Affairs Health Services Research and
Development service grant number SDR 07-002.
NR 20
TC 17
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 977
EP 983
DI 10.1016/j.jamcollsurg.2011.02.003
PG 7
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600009
PM 21489830
ER
PT J
AU Cevasco, M
Borzecki, AM
O'Brien, WJ
Chen, Q
Shin, MH
Itani, KMF
Rosen, AK
AF Cevasco, Marisa
Borzecki, Ann M.
O'Brien, William J.
Chen, Qi
Shin, Marlena H.
Itani, Kamal M. F.
Rosen, Amy K.
TI Validity of the AHRQ Patient Safety Indicator "Central Venous
Catheter-Related Bloodstream Infections"
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
AB BACKGROUND: "Central venous catheter-related bloodstream infections" (CR-BSIs) is one of the patient safety indicators (PSI 7) developed by the Agency for Healthcare Research and Quality (AHRQ) to screen for potential safety events. We sought to investigate the validity of this PSI using the medical record as the gold standard.
STUDY DESIGN: We conducted a retrospective cross-sectional study of all hospitalization records that met the criteria for PSI 7 within Veterans Health Administration (VA) hospitals from fiscal years 2003 to 2007. Trained abstractors used a standardized abstraction tool to review electronic medical records for the presence of a CR-BSI and the clinical circumstances surrounding the event. We determined the validity of this PSI by calculating its positive predictive value (PPV), and analyzed both true and false positive cases.
RESULTS: Of 112 reviewed cases, 42 were true events of CR-BSIs, yielding a PPV of 38% (95% CI 29% to 47%). Seventy cases were false positives; these were attributed to correct ICD-9-CM codes but had diagnoses that fell outside the scope of the indicator (n = 28, 40%), coding inaccuracies (n = 21, 30%); and present on admission (POA) diagnoses (n = 21; 30%). Among the 42 patients with CR-BSIs, catheters were left in place for an average of 11 days, and 20% (n = 8) were placed in the femoral position.
CONCLUSIONS: PSI 7 has relatively poor predictive ability for identifying true events. Coding-related issues were the main reason for the low PPV. Implementing POA codes and using more specific ICD-9-CM codes would improve its validity. As it currently stands, PSI 7 should not be used as a pay-for-performance measure, but should be limited to use in internal quality improvement efforts. (J Am Coll Surg 2011;212:984-990. (C) 2011 by the American College of Surgeons)
C1 [O'Brien, William J.; Chen, Qi; Shin, Marlena H.; Rosen, Amy K.] VA Boston Healthcare Syst, COLMR, Boston, MA 02130 USA.
[Cevasco, Marisa; Itani, Kamal M. F.] VA Boston Healthcare Syst, Dept Surg, Boston, MA 02130 USA.
[Cevasco, Marisa] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Borzecki, Ann M.; Chen, Qi; Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA.
[Borzecki, Ann M.; Itani, Kamal M. F.] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
[Borzecki, Ann M.] Bedford VAMC, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
RP Rosen, AK (reprint author), VA Boston Healthcare Syst, COLMR, 150 S Huntington Ave,152 M, Boston, MA 02130 USA.
EM akrosen@bu.edu
NR 20
TC 21
Z9 21
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 984
EP 990
DI 10.1016/j.jamcollsurg.2011.02.005
PG 7
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600010
PM 21489833
ER
PT J
AU Livhits, M
Gibbons, MM
de Virgilio, C
O'Connell, JB
Leonardi, MJ
Ko, CY
Zingmond, DS
AF Livhits, Masha
Gibbons, Melinda Maggard
de Virgilio, Christian
O'Connell, Jessica B.
Leonardi, Michael J.
Ko, Clifford Y.
Zingmond, David S.
TI Coronary Revascularization after Myocardial Infarction Can Reduce Risks
of Noncardiac Surgery
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID PERIOPERATIVE CARDIOVASCULAR EVALUATION; MAJOR VASCULAR-SURGERY; CARDIAC
RISK; ARTERY DISEASE; INDEX; INTERVENTION; ANGIOPLASTY; OPERATIONS;
OUTCOMES
AB BACKGROUND: Recent studies suggest that preoperative coronary revascularization overall does not improve outcomes after noncardiac surgery. It is not known whether this holds true for high-risk patients with a history of recent MI. Our objective was to determine whether preoperative revascularization improves outcomes after noncardiac surgery in patients with a recent MI.
STUDY DESIGN: Using the California Patient Discharge Database, we retrospectively analyzed patients with a recent MI who underwent hip surgery, cholecystectomy, bowel resection, elective abdominal aortic aneurysm repair, and lower extremity amputation from 1999 to 2004 (n = 16,478). Postoperative 30-day reinfarction and 30-day and 1-year mortality were compared for patients who underwent preoperative revascularization (percutaneous transluminal coronary angioplasty, coronary stenting, or coronary artery bypass graft) and those who were not revascularized using univariate analyses and multivariate logistic regression. Relative risks with 95% confidence intervals were estimated using bootstrapping with 1,000 repetitions.
RESULTS: Patients with a recent MI who were revascularized before surgery had an approximately 50% decreased rate of reinfarction (5.1% versus 10.0%; p < 0.001) and 30-day (5.2% versus 11.3%; p < 0.001) and 1-year mortality (18.3% versus 35.8%; p < 0.001) compared with those who were not. Stenting within 1 month of surgery was associated with a trend toward increased reinfarction (relative risk: 1.36; 95% CI, 0.96-1.97), and coronary artery bypass graft was associated with a decreased risk (relative risk: 0.70; 95% CI, 0.55-0.95).
CONCLUSIONS: This large sample representing real world practice suggests that patients with a recent MI can benefit from preoperative revascularization. Coronary artery bypass graft can improve outcomes more than stenting, especially when surgery is necessary within 1 month of revascularization, but additional prospective studies are indicated. (J Am Coll Surg 2011; 212: 1018-1026. (C) 2011 by the American College of Surgeons)
C1 [Livhits, Masha; Gibbons, Melinda Maggard; O'Connell, Jessica B.; Leonardi, Michael J.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Livhits, Masha; Gibbons, Melinda Maggard; O'Connell, Jessica B.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[Zingmond, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Gibbons, Melinda Maggard] OliveView UCLA, Dept Surg, Sylmar, CA USA.
[de Virgilio, Christian] Harbor UCLA Med Ctr, Dept Surg, Torrance, CA 90509 USA.
[de Virgilio, Christian] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA.
RP Livhits, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,72-215 CHS, Los Angeles, CA 90095 USA.
EM mlivhits@mednet.ucla.edu
FU VA Department of Surgery; Robert Wood Johnson Physician Faculty; NIA
[1K08AG023024]
FX The VA Department of Surgery provided support for Drs Livhits and
Gibbons. Dr Gibbons' time was supported in part by a grant from the
Robert Wood Johnson Physician Faculty Scholars program. Dr Zingmond was
supported by an NIA Mentored Clinical Scientist Award (1K08AG023024).
NR 24
TC 12
Z9 12
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 1018
EP 1026
DI 10.1016/j.jamcollsurg.2011.02.018
PG 9
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600014
PM 21441043
ER
PT J
AU Ingraham, AM
Cohen, ME
Raval, MV
Ko, CY
Nathens, AB
AF Ingraham, Angela M.
Cohen, Mark E.
Raval, Mehul V.
Ko, Clifford Y.
Nathens, Avery B.
TI Variation in Quality of Care after Emergency General Surgery Procedures
in the Elderly
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID SURGICAL OUTCOMES; GASTRIC-CANCER; UNITED-STATES; RISK; POPULATION;
MORTALITY; IMPACT; AGE; ESOPHAGUS; CARCINOMA
AB BACKGROUND: The elderly (age >= 65 years) comprise an increasing proportion of patients undergoing emergency general surgery (EGS) procedures and have distinct needs compared with the young. We postulated that the needs of the elderly require different processes of care than those required for the young to assure optimal outcomes. To explore this hypothesis, we evaluated 30-day outcomes following EGS procedures in the young and the elderly and determined whether hospital performance was consistent across these 2 age strata.
STUDY DESIGN: With data from the American College of Surgeons National Surgical Quality Improvement Program (2005 to 2008), regression models were constructed for serious morbidity and mortality for all patients undergoing EGS procedures and separately for young and elderly patients. These models allowed for estimation of the risk of adverse outcomes associated with advanced age and the generation of hospital-level observed to expected (O/E) ratios. We evaluated the correlation between hospital O/Eratios for the young and the elderly and the concordance of outlier status (hospitals with CIs of O/E ratios excluding 1) with weighted kappa across these 2 age groups.
RESULTS: Among 68,003 procedures at 186 hospitals, elderly patients had a higher crude and adjusted risk for serious morbidity (27.9% versus 9.7%, p < 0.0001; odds ratio 1.17,95% CI 1.10 to 1.24) and mortality (15.2% versus 2.5%, p < 0.0001; odds ratio 2.29, 95% CI 2.09 to 2.51). When outcomes for elderly versus younger patients were compared, there was fair to moderate agreement on hospital performance for serious morbidity (r = 0.43; kappa = 0.30) but not for mortality (r = 0.10; kappa = 0.17).
CONCLUSIONS: Elderly patients are at substantially greater risk for adverse events following EGS procedures. Hospitals had only slight agreement in mortality outcomes in the elderly compared with those in young patients. Processes of care that may account for this disparity should be further investigated. (J Am Coll Surg 2011;212:1039-1048. (C) 2011 by the American College of Surgeons)
C1 [Ingraham, Angela M.] Univ Cincinnati, Dept Surg, Coll Med, Cincinnati, OH 45267 USA.
[Ingraham, Angela M.; Cohen, Mark E.; Raval, Mehul V.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Raval, Mehul V.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Nathens, Avery B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Div Surg & Trauma, Toronto, ON M5B 1W8, Canada.
RP Ingraham, AM (reprint author), Univ Cincinnati, Dept Surg, Coll Med, ML 0558,231 Albert Sabin Way,Room 1586, Cincinnati, OH 45267 USA.
EM aingraham@facs.org
OI Raval, Mehul/0000-0002-1527-2661
FU American College of Surgeons; John Gray Research Fellowship; Daniel F
and Ada L Rice Foundation; Canada Research Chair in Systems of Trauma
Care
FX Drs Ingraham and Raval are supported by the Clinical Scholar in
Residence Program at the American College of Surgeons. Dr Raval is also
supported by the John Gray Research Fellowship and the Daniel F and Ada
L Rice Foundation. Dr Nathens is supported by a Canada Research Chair in
Systems of Trauma Care.
NR 35
TC 21
Z9 21
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 1039
EP 1048
DI 10.1016/j.jamcollsurg.2011.03.001
PG 10
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600017
PM 21620289
ER
PT J
AU Lawson, EH
Wang, X
Cohen, ME
Hall, BL
Tanzman, H
Ko, CY
AF Lawson, Elise H.
Wang, Xue
Cohen, Mark E.
Hall, Bruce Lee
Tanzman, Howard
Ko, Clifford Y.
TI Morbidity and Mortality after Colorectal Procedures: Comparison of Data
from the American College of Surgeons Case Log System and the ACS NSQIP
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID SURGICAL QUALITY IMPROVEMENT; DATABASES
AB BACKGROUND: Improving the quality of surgical care depends upon collection of robust data. The American College of Surgeons Case Log System enables surgeons to self-report patient risk factors and outcomes. In contrast, the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) uses trained data abstractors to record similar data and uses a strict data collection methodology. The objective of this study was to assess bias in data entry for colorectal cases by comparing data in these 2 registries.
STUDY DESIGN: One year of NSQIP (July 1, 2008 to June 30, 2009) and 7 years of Case Log (2003 to 2010) data were examined. Colorectal cases were identified by current procedural terminology code. The frequencies of comparably defined variables were compared, and mortality models were developed using logistic regression. Observed and expected mortality rates were compared.
RESULTS: Rates of most risk factor and outcome variables were significantly higher in NSQIP than those in Case Log. NSQIP had a higher unadjusted mortality rate (4.46% versus 3.69%, p < 0.001); however, the adjusted odds of mortality was significantly higher in Case Log (odds ratio 1.32, p < 0.05). The Case Log model overpredicted mortality in NSQIP by 22%, whereas the NSQIP model underpredicted mortality in Case Log by 12%.
CONCLUSIONS: Significant differences exist between risk factor and outcome data in NSQIP and Case Log for colorectal procedures. These differences demonstrate the need for standardized data collection methods, as is required by NSQIP, including use of standard definitions, adherence to a follow-up period for outcomes, and use of audits. These measures would improve the validity of using a self-reported database to evaluate and benchmark performance. (J Am Coll Surg 2011; 212:1077-1085. (C) 2011 by the American College of Surgeons)
C1 [Lawson, Elise H.] Univ Calif Los Angeles, Med Ctr, Dept Surg, Los Angeles, CA 90095 USA.
[Lawson, Elise H.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Wang, Xue; Cohen, Mark E.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA.
[Hall, Bruce Lee] Washington Univ, Sch Med, St Louis, MO USA.
[Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA.
RP Lawson, EH (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Surg, CHS 72-215,10833 LeConte Ave, Los Angeles, CA 90095 USA.
EM elawson@mednet.ucla.edu
FU Robert Wood Johnson Foundation through the American College of Surgeons
FX Dr Lawson was supported by the Robert Wood Johnson Foundation Clinical
Scholars Program through the American College of Surgeons.
NR 10
TC 14
Z9 14
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUN
PY 2011
VL 212
IS 6
BP 1077
EP 1085
DI 10.1016/j.jamcollsurg.2011.03.002
PG 9
WC Surgery
SC Surgery
GA 782BD
UT WOS:000291981600021
PM 21470879
ER
PT J
AU Chester, JG
Rudolph, JL
AF Chester, Jennifer Gonik
Rudolph, James L.
TI Vital Signs in Older Patients: Age-Related Changes
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Review
DE Aged; vital sign; pulse; blood pressure
ID HEART-RATE-VARIABILITY; NURSING-HOME RESIDENTS; ORTHOSTATIC HYPOTENSION;
PRESSURE RESPONSES; BODY-TEMPERATURE; CIRCADIAN-RHYTHM; RESPIRATORY
RATE; HEALTHY HUMANS; RISK-FACTORS; SYSTEM
AB Vital signs are objective measures of physiological function that are used to monitor acute and chronic disease and thus serve as a basic communication tool about patient status. The purpose of this analysis was to review age-related changes of traditional vital signs (blood pressure, pulse, respiratory rate, and temperature) with a focus on age-related molecular changes, organ system changes, systemic changes, and altered compensation to stressors. The review found that numerous physiological and pathological changes may occur with age and alter vital signs. These changes tend to reduce the ability of organ systems to adapt to physiological stressors, particularly in frail older patients. Because of the diversity of age-related physiological changes and comorbidities in an individual, single-point measurements of vital signs have less sensitivity in detecting disease processes. However, serial vital sign assessments may have increased sensitivity, especially when viewed in the context of individualized reference ranges. Vital sign change with age may be subtle because of reduced physiological ranges. However, change from an individual reference range may indicate important warning signs and thus may require additional evaluation to understand potential underlying pathological processes. As a result, individualized reference ranges may provide improved sensitivity in frail, older patients. (J Am Med Dir Assoc 2011; 12: 337-343)
C1 [Chester, Jennifer Gonik] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Rudolph, James L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rudolph, JL (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA.
EM jrudolph@partners.org
FU American Federation for Aging Research [5-T35-AG026781-05]; Einstein
Research Scholarship; VA Rehabilitation Research and Development Career
Development Award
FX This project was supported by funding from the American Federation for
Aging Research (5-T35-AG026781-05), the Einstein Research Scholarship,
and the VA Rehabilitation Research and Development Career Development
Award. The financial sponsors played no role in the design, execution,
analysis or interpretation of data, or in the writing of the study.
NR 67
TC 20
Z9 23
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD JUN
PY 2011
VL 12
IS 5
BP 337
EP 343
DI 10.1016/j.jamda.2010.04.009
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 783DI
UT WOS:000292061300005
PM 21450180
ER
PT J
AU Hanlon, JT
Wang, XG
Handler, SM
Weisbord, S
Pugh, MJ
Semla, T
Stone, RA
Aspinall, SL
AF Hanlon, Joseph T.
Wang, Xiaogiang
Handler, Steven M.
Weisbord, Steven
Pugh, Mary Jo
Semla, Todd
Stone, Roslyn A.
Aspinall, Sherrie L.
TI Potentially Inappropriate Prescribing of Primarily Renally Cleared
Medications for Older Veterans Affairs Nursing Home Patients
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American-Geriatrics-Society
CY MAY 12-15, 2010
CL Orlando, FL
SP Amer Geriatr Soc
ID CHRONIC KIDNEY-DISEASE; MINIMUM DATA SET; TERM-CARE FACILITIES;
CREATININE CLEARANCE; COGNITIVE PERFORMANCE; ELDERLY-PATIENTS; DRUG;
GUIDELINES; VALIDATION; FRAIL
AB Background: Inappropriate prescribing of primarily renally cleared medications in older patients with kidney disease can lead to adverse outcomes.
Objectives: To estimate the prevalence of potentially inappropriate prescribing of 21 primarily renally cleared medications based on 2 separate estimates of renal function and to identify factors associated with this form of suboptimal prescribing in older VA nursing home (NH) patients.
Design: Longitudinal study
Participants: Participants were 1304 patients, aged 65 years or older, admitted between January 1, 2004, and June 30, 2005, for 90 days or more to 1 of 133 VA NHs.
Main Measures: Potentially inappropriate prescribing of primarily renally cleared medications determined by estimating creatinine clearance using the Cockcroft Gault (CG) and Modification of Diet in Renal Disease (MDRD) equations and applying explicit guidelines for contraindicated medications and dosing.
Key Results: The median estimated creatinine clearance via CG was 67 mL/min, whereas it was 80 mL/min/1.73m(2) with the MDRD. Overall, 11.89% patients via CG and only 5.98% via MDRD had evidence of potentially inappropriate prescribing of at least 1 renally cleared medication. The most commonly involved medications were ranitidine, glyburide, gabapentin, and nitrofurantoin. Factors associated with potentially inappropriate prescribing as per the CG were age older than 85 (adjusted odds ratio [AOR] 4.24, 95% confidence interval [CI] 2.42-7.43), obesity (AOR 0.26, 95% CI 0.14-0.50) and having multiple comorbidities (AOR 1.09 for each unit increase in the Charlson comorbidity index, 95% CI 1.01-1.19).
Conclusions: Potentially inappropriate prescribing of renally cleared medications is common in older VA NH patients. Intervention studies to improve the prescribing of primarily renally cleared medications in nursing homes are needed. (J Am Med Dir Assoc 2011; 12: 377-383)
C1 [Hanlon, Joseph T.; Handler, Steven M.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.; Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.
[Hanlon, Joseph T.; Handler, Steven M.] VAPHS, GRECC, Pittsburgh, PA USA.
[Hanlon, Joseph T.; Wang, Xiaogiang; Handler, Steven M.; Weisbord, Steven; Stone, Roslyn A.; Aspinall, Sherrie L.] CHERP, Pittsburgh, PA USA.
[Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA.
[Weisbord, Steven] Univ Pittsburgh, Sch Med, Renal Sect, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA.
[Weisbord, Steven] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
[Pugh, Mary Jo] Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA.
[Semla, Todd; Aspinall, Sherrie L.] US Dept Vet Affairs, VA Pharm Benefits Management Serv, Hines, IL USA.
[Semla, Todd] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Semla, Todd] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL USA.
[Stone, Roslyn A.] Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Med Geriatr, Kaufman Med Bldg,Suite 514,3471 5th Ave, Pittsburgh, PA 15213 USA.
EM jth14@pitt.edu
OI Handler, Steven/0000-0002-3940-3224; Pugh, Mary Jo/0000-0003-4196-7763
FU AHRQ HHS [R01 HS017695]; NCRR NIH HHS [K12 RR023267]; NIA NIH HHS [K07
AG033174-01A1, K07 AG033174, K07 AG033174-02, K07 AG033174-03,
K07AG033174, P30 AG024827, P30AG024827, R01 AG027017, R01 AG034056, R01
AG034056-01, R01 AG034056-02, R01AG027017, R01AG034056, R56 AG027017,
R56 AG027017-04, T32 AG021885]; NIMH NIH HHS [R34 MH082682]; NINR NIH
HHS [R01 NR010135]
NR 39
TC 23
Z9 23
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD JUN
PY 2011
VL 12
IS 5
BP 377
EP 383
DI 10.1016/j.jamda.2010.04.008
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 783DI
UT WOS:000292061300010
PM 21450179
ER
PT J
AU Potosky, AL
Malin, JL
Kim, B
Chrischilles, EA
Makgoeng, SB
Howlader, N
Weeks, JC
AF Potosky, Arnold L.
Malin, Jennifer L.
Kim, Benjamin
Chrischilles, Elizabeth A.
Makgoeng, Solomon B.
Howlader, Nadia
Weeks, Jane C.
TI Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for
Cost Savings and Improved Outcomes
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID RECEIVING CHEMOTHERAPY; AMERICAN-SOCIETY; CANCER; GUIDELINES;
SURVEILLANCE; COMORBIDITY; PATTERNS
AB Myeloid colony-stimulating factors (CSFs) decrease the risk of febrile neutropenia (FN) from high-risk chemotherapy regimens administered to patients at 20% or greater risk of FN, but little is known about their use in clinical practice. We evaluated CSF use in a multiregional population-based cohort of lung and colorectal cancer patients (N = 1849). Only 17% (95% confidence interval [CI] = 8% to 26%) patients treated with high-risk chemotherapy regimens received CSFs, compared with 18% (95% CI = 16% to 20%) and 10% (95% CI = 8% to 12%) of patients treated with intermediate- (10%-20% risk of FN) and low-risk (<10% risk of FN) chemotherapy regimens, respectively. Using a generalized estimating equation model, we found that enrollment in a health maintenance organization (HMO) was strongly associated with a lower adjusted odds of discretionary CSF use, compared with non-HMO patients (odds ratio = 0.44, 95% CI = 0.32 to 0.60, P < .001). All statistical tests were two-sided. Overall, 96% (95% CI = 93% to 98%) of CSFs were administered in scenarios where CSF therapy is not recommended by evidence-based guidelines. This finding suggests that policies to decrease CSF use in patients at lower or intermediate risk of FN may yield substantial cost savings without compromising patient outcomes.
C1 [Potosky, Arnold L.; Makgoeng, Solomon B.; Howlader, Nadia] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
[Malin, Jennifer L.; Kim, Benjamin] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Malin, Jennifer L.; Kim, Benjamin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Malin, Jennifer L.; Kim, Benjamin] RAND Corp, Santa Monica, CA USA.
[Malin, Jennifer L.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Chrischilles, Elizabeth A.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA.
[Weeks, Jane C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Potosky, AL (reprint author), Georgetown Univ, Lombardi Comprehens Canc Ctr, 3300 Whitehaven St NW,Ste 4100, Washington, DC 20007 USA.
EM alp49@georgetown.edu
FU National Cancer Institute [U01 CA093344]; Primary Data Collection and
Research Centers (Dana-Farber Cancer Institute and the Cancer Research
Network) [U01 CA093332]; Harvard Medical School; Northern California
Cancer Center [U01 CA093324]; RAND; University of California Los Angeles
[U01 CA093348]; University of Alabama at Birmingham [U01 CA093329];
University of Iowa [U01 CA093339]; University of North Carolina [U01 CA
093326]; Department of Veterans Affairs [CRS 02-164]
FX The work of the Cancer Care Outcomes Research and Surveillance
Consortium (CanCORS) was supported by grants from the National Cancer
Institute to the Statistical Coordinating Center (U01 CA093344); Primary
Data Collection and Research Centers (Dana-Farber Cancer Institute and
the Cancer Research Network) (U01 CA093332); Harvard Medical School and
Northern California Cancer Center (U01 CA093324); RAND and University of
California Los Angeles (U01 CA093348); University of Alabama at
Birmingham (U01 CA093329); University of Iowa (U01 CA093339); University
of North Carolina (U01 CA 093326); and by a grant from the Department of
Veterans Affairs to the Durham Veterans Affairs Medical Center (CRS
02-164).
NR 18
TC 40
Z9 42
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD JUN
PY 2011
VL 103
IS 12
BP 979
EP 982
DI 10.1093/jnci/djr152
PG 4
WC Oncology
SC Oncology
GA 784ZP
UT WOS:000292197500011
PM 21670423
ER
PT J
AU Pantaleo, MA
Astolfi, A
Indio, V
Moore, R
Thiessen, N
Heinrich, MC
Gnocchi, C
Santini, D
Catena, F
Formica, S
Martelli, PL
Casadio, R
Pession, A
Biasco, G
AF Pantaleo, Maria A.
Astolfi, Annalisa
Indio, Valentina
Moore, Richard
Thiessen, Nina
Heinrich, Michael C.
Gnocchi, Chiara
Santini, Donatella
Catena, Fausto
Formica, Serena
Martelli, Pier Luigi
Casadio, Rita
Pession, Andrea
Biasco, Guido
TI SDHA Loss-of-Function Mutations in KIT-PDGFRA Wild-Type Gastrointestinal
Stromal Tumors Identified by Massively Parallel Sequencing
SO JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID CARNEY-STRATAKIS-SYNDROME; SUCCINATE-DEHYDROGENASE; THERAPEUTIC TARGET;
MOLECULAR-GENETICS; IMATINIB; EXPRESSION; PARAGANGLIOMA; DISEASE
AB Approximately 10%-15% of gastrointestinal stromal tumors (GISTs) in adults do not harbor any mutation in the KIT or PDGFRA genes (ie, KIT/PDGFRA wild-type GISTs). Recently, mutations in SDHB and SDHC (which encode succinate dehydrogenase subunits B and C, respectively) but not in SDHA and SDHD (which encode subunits A and D, respectively) were identified in KIT/PDGFRA wild-type GISTs. To search for novel pathogenic mutations, we sequenced the tumor transcriptome of two young adult patients who developed sporadic KIT/PDGFRA wild-type GISTs by using a massively parallel sequencing approach. The only variants identified as disease related by computational analysis were in SDHA. One patient carried the homozygous nonsense mutation p.Ser384X, the other patient was a compound heterozygote harboring a p.Arg31X nonsense mutation and a p.Arg589Trp missense mutation. The heterozygous nonsense mutations in both patients were present in germline DNA isolated from peripheral blood. Protein structure analysis indicates that all three mutations lead to functional inactivation of the protein. This is the first report, to our knowledge, that identifies SDHA inactivation as a common oncogenic event in GISTs that lack a mutation in KIT and PDGFRA.
C1 [Pantaleo, Maria A.; Biasco, Guido] Univ Bologna, Dept Hematol & Oncol Sci L&A Seragnoli, St Orsola Malpighi Hosp, I-40138 Bologna, Italy.
[Santini, Donatella] Univ Bologna, Pathol Unit, St Orsola Malpighi Hosp, I-40138 Bologna, Italy.
[Catena, Fausto] Univ Bologna, Dept Surg & Transplantat, St Orsola Malpighi Hosp, I-40138 Bologna, Italy.
[Pantaleo, Maria A.; Astolfi, Annalisa; Indio, Valentina; Formica, Serena; Pession, Andrea; Biasco, Guido] Univ Bologna, Giorgio Prodi Canc Res Ctr, I-40138 Bologna, Italy.
[Indio, Valentina; Martelli, Pier Luigi; Casadio, Rita] Univ Bologna, Biocomp Grp, Dept Biol, I-40138 Bologna, Italy.
[Moore, Richard; Thiessen, Nina] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada.
[Heinrich, Michael C.] Portland VA Med Ctr, Dept Med, Portland, OR USA.
[Heinrich, Michael C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Gnocchi, Chiara] Novartis Oncol, Origgio, Italy.
[Formica, Serena; Pession, Andrea] Univ Bologna, Pediat Unit, Dept Gynecol Obstet & Pediat Sci, I-40138 Bologna, Italy.
RP Pantaleo, MA (reprint author), Univ Bologna, Dept Hematol & Oncol Sci LA Seragnoli, St Orsola Malpighi Hosp, Via Massarenti 9, I-40138 Bologna, Italy.
EM maria.pantaleo@unibo.it
RI Indio, Valentina/G-1869-2011; Martelli, Pier Luigi/I-8824-2012; Casadio,
Rita/K-4814-2015;
OI Martelli, Pier Luigi/0000-0002-0274-5669; Casadio,
Rita/0000-0002-7462-7039; PANTALEO, MARIA
ABBONDANZA/0000-0002-0177-6957; astolfi, annalisa/0000-0002-2732-0747;
Indio, Valentina/0000-0002-8854-3821
FU Novartis Oncology, Origgio, Italy; VA Merit Review grant; GIST Cancer
Research Fund; Life Raft Group; Novartis Oncology
FX Novartis Oncology, Origgio, Italy; VA Merit Review grant (to M.C.H.);
GIST Cancer Research Fund (to M.C.H.); Life Raft Group (to M.C.H.);
Novartis Oncology (to M.C.H.).
NR 24
TC 70
Z9 72
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 J NATL CANCER I
JI J. Natl. Cancer Inst.
PD JUN
PY 2011
VL 103
IS 12
BP 983
EP 987
DI 10.1093/jnci/djr130
PG 5
WC Oncology
SC Oncology
GA 784ZP
UT WOS:000292197500012
PM 21505157
ER
PT J
AU Aisner, J
Manola, J
Dakhil, S
Stella, PJ
Schiller, J
AF Aisner, Joseph
Manola, Judith
Dakhil, Shaker
Stella, Phillip J.
Schiller, Joan
TI VANDETANIB PLUS CHEMOTHERAPY FOR INDUCTION THERAPY FOLLOWED BY
VANDETANIB OR PLACEBO AS MAINTENANCE FOR ADVANCED NON-SMALL-CELL LUNG
CANCER (NSCLC): EFFICACY AND TOXICITIES UPDATE. A PHASE II PRECOG, LLC
STUDY (PRE0501)
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Tyrosine kinase inhibitor toxicities; Advanced Non-Small Cell Lung
Cancer; maintenance therapy
C1 [Aisner, Joseph] Canc Inst New Jersey, New Brunswick, NJ USA.
[Manola, Judith] Dana Farber Canc Inst, Boston, MA USA.
[Schiller, Joan] Univ Texas SW Med Ctr, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU S
BP S1258
EP S1258
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 779HX
UT WOS:000291769801100
ER
PT J
AU Blackhall, FH
Petersen, JA
Wilner, K
Hirsh, V
Shaw, AT
Kim, DW
Solomon, B
Janne, PA
Reisman, AL
Polli, A
Mundayat, R
Bottomley, A
AF Blackhall, Fiona H.
Petersen, Jennifer A.
Wilner, Keith
Hirsh, Vera
Shaw, Alice T.
Kim, Dong-Wan
Solomon, Ben
Janne, Pasi A.
Reisman, Arlene L.
Polli, Anna
Mundayat, Rajiv
Bottomley, Andrew
TI PROFILE 1005: PRELIMINARY PATIENT-REPORTED OUTCOMES (PROS) FROM AN
ONGOING PHASE 2 STUDY OF CRIZOTINIB (PF-02341066) IN ANAPLASTIC LYMPHOMA
KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Crizotinib; PF-02341066; Non-small cell lung cancer; Symptons
C1 [Blackhall, Fiona H.] Christie Hosp NHS Trust, Manchester, Lancs, England.
[Petersen, Jennifer A.] Pfizer Oncol, Hlth Econ & Global Outcomes Res, New York, NY USA.
[Wilner, Keith] Pfizer Oncolgoy, Oncol Business Unit, New York, NY USA.
[Hirsh, Vera] McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 2T5, Canada.
[Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Kim, Dong-Wan] Seoul Natl Univ Hosp, Seoul, South Korea.
[Solomon, Ben] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Janne, Pasi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Cambridge, MA 02138 USA.
[Reisman, Arlene L.] Pfizer Oncol, Specialty BU, Stat, New York, NY USA.
[Mundayat, Rajiv] Pfizer Oncol, Specialty Care Business Unit, Stat, New York, NY USA.
RI Blackhall, Fiona/N-2186-2015
OI Blackhall, Fiona/0000-0001-8716-3395
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S413
EP S414
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802130
ER
PT J
AU Boyle, T
Haney, J
Lenhart, P
Montoya, R
Chesnut, P
Merrick, D
Camidge, RD
Franklin, W
AF Boyle, Theresa
Haney, Jerry
Lenhart, Patricia
Montoya, Rosita
Chesnut, Patrick
Merrick, Daniel
Camidge, Ross D.
Franklin, Wilbur
TI CORRELATION OF THYMIDYLATE SYNTHASE GENOTYPE AND PROTEIN EXPRESSION AND
ASSOCIATION WITH LUNG CANCER SURVIVAL
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE thymidylate synthase; genotype; protein; NSCLC; polymorphism; VNTR
C1 [Boyle, Theresa; Haney, Jerry; Lenhart, Patricia; Montoya, Rosita; Chesnut, Patrick; Camidge, Ross D.; Franklin, Wilbur] Univ Colorado Denver, Denver, CO USA.
[Merrick, Daniel] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU S
BP S1084
EP S1085
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 779HX
UT WOS:000291769800262
ER
PT J
AU Campbell, AK
Blackhal, FH
Gadgeel, SM
Janne, PA
Park, K
Mundayat, R
Letrent, SP
Boyer, M
O'Connell, J
Ramalingam, S
AF Campbell, Alicyn K.
Blackhal, Fiona H.
Gadgeel, Shirish M.
Janne, Pasi A.
Park, Keunchil
Mundayat, Rajiv
Letrent, Stephen P.
Boyer, Michael
O'Connell, Joseph
Ramalingam, Suresh
TI GASTROINTESTINAL TOXICITY OF THE PAN-HER TYROSINE KINASE INHIBITOR (TKI)
PF299804: ASSESSMENT BY PATIENT-REPORTED OUTCOMES IN 2ND/3RD-LINE AND
REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC)
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE EGFR TKI; Patient Reported Outcomes; Gastrointestinal Toxicity;
PF-00299804
C1 [Campbell, Alicyn K.; Letrent, Stephen P.] Pfizer Oncol, Clin Dev & Med Affairs, New York, NY USA.
[Blackhal, Fiona H.] Christie NHS Fdn Trust, Manchester, Lancs, England.
[Gadgeel, Shirish M.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48202 USA.
[Janne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA.
[Park, Keunchil] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hem Onc, Seoul, South Korea.
[Mundayat, Rajiv] Pfizer Oncol, Specialty Care Business Unit, Stat, New York, NY USA.
[Boyer, Michael] Sydney Canc Ctr, Sydney, NSW, Australia.
[O'Connell, Joseph] Pfizer Oncol, Oncol, New York, NY USA.
[Ramalingam, Suresh] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU S
BP S1184
EP S1185
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 779HX
UT WOS:000291769800397
ER
PT J
AU Campbell, AK
Boyer, M
Giaccone, G
Janne, PA
Kim, DW
Park, K
Ramalingam, S
Reckamp, KL
Mundayat, R
Letrent, SP
O'Connell, J
Lacouture, ME
AF Campbell, Alicyn K.
Boyer, Michael
Giaccone, Giuseppe
Janne, Pasi A.
Kim, Dong-Wan
Park, Keunchil
Ramalingam, Suresh
Reckamp, Karen L.
Mundayat, Rajiv
Letrent, Stephen P.
O'Connell, Joseph
Lacouture, Mario E.
TI DERMATOLOGIC ADVERSE EVENTS OF THE PAN-HER TYROSINE KINASE INHIBITOR
(TKI) PF299804: ASSESSMENT BY PATIENT-REPORTED OUTCOMES IN 2ND/3RD-LINE
AND REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC)
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE PF-00299804; Dermatologic Toxicity; Patient Reported Outcomes; EGFR TKI
C1 [Campbell, Alicyn K.; Letrent, Stephen P.] Pfizer Oncol, Clin Dev & Med Affairs, New York, NY USA.
[Boyer, Michael] Sydney Canc Ctr, Sydney, NSW, Australia.
[Giaccone, Giuseppe] NCI, Med Oncol Branch, Bethesda, MD 20892 USA.
[Janne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA.
[Kim, Dong-Wan] Seoul Natl Univ Hosp, Seoul, South Korea.
[Park, Keunchil] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hem Onc, Seoul, South Korea.
[Ramalingam, Suresh] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Reckamp, Karen L.] City Hope Natl Med Ctr, Med Oncol, Duarte, CA USA.
[Mundayat, Rajiv] Pfizer Oncol, Specialty Care Business Unit, Stat, New York, NY USA.
[O'Connell, Joseph] Pfizer Oncol, Oncol, New York, NY USA.
[Lacouture, Mario E.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU S
BP S1185
EP S1186
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 779HX
UT WOS:000291769800398
ER
PT J
AU Choi, NC
Chun, T
Niemierko, A
Ancukiewicz, M
Fischman, A
AF Choi, Noah C.
Chun, Tristen
Niemierko, Andrzej
Ancukiewicz, Marek
Fischman, Alan
TI METABOLIC RESPONSES MEASURED WITH SIMPLIFIED KINETIC METHOD AND STANDARD
UPTAKE VALUE OF 18F-FDG PET SHORTLY AFTER RADIOTHERAPY OR RADIOTHERAPY
OF CHEMORADIOTHERAPY: ROBUST BIOMARKERS FOR PREDICTING THERAPY OUTCOME
IN LUNG CANCER
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
C1 [Choi, Noah C.; Chun, Tristen; Niemierko, Andrzej; Ancukiewicz, Marek] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA.
[Fischman, Alan] Harvard Univ, Shriners Burns Inst, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S528
EP S528
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802274
ER
PT J
AU Cortot, AB
Repellin, CE
Shimamura, T
Capelletti, M
Zejnullahu, K
Christensen, J
Wong, KK
Gray, N
Janne, PA
AF Cortot, Alexis B.
Repellin, Claire E.
Shimamura, Takeshi
Capelletti, Marzia
Zejnullahu, Kreshnik
Christensen, James
Wong, Kwok-Kin
Gray, Natanael
Janne, Pasi A.
TI RESISTANCE TO EGFR T790M KINASE INHIBITORS THROUGH A MULTISTEP PROCESS
INVOLVING THE IGF1R PATHWAY
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE irreversible inhibitors; EGFR; T790M; Resistance
C1 [Cortot, Alexis B.; Repellin, Claire E.; Shimamura, Takeshi; Capelletti, Marzia; Zejnullahu, Kreshnik; Wong, Kwok-Kin; Gray, Natanael; Janne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA.
[Christensen, James] Pfizer Global Res & Dev, Dept Res Pharmacol, Groton, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S393
EP S394
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802105
ER
PT J
AU Cuffe, S
Graziano, S
Bourredjem, A
Pignon, JP
Ezzalfani, M
Seymour, L
Strevel, E
Burkes, R
Capelletti, M
Janne, PA
Tsao, MS
Shepherd, FA
AF Cuffe, Sinead
Graziano, Stephen
Bourredjem, Abderrahmane
Pignon, Jean-Pierre
Ezzalfani, Monia
Seymour, Lesley
Strevel, Elizabeth
Burkes, Ronald
Capelletti, Marzia
Janne, Pasi A.
Tsao, Ming S.
Shepherd, Frances A.
CA Lace-Bio Grp
TI A POOLED EXPLORATORY ANALYSIS OF THE IMPACT OF TUMOR SIZE AND KRAS
MUTATIONS ON SURVIVAL BENEFIT FROM ADJUVANT PLATINUM-BASED CHEMOTHERAPY
(ACT) IN NODE NEGATIVE (N0) NON-SMALL CELL LUNG CANCER (NSCLC)
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE KRAS mutation; Tumor size; Non-small cell lung cancer; Adjuvant
chemotherapy
C1 [Cuffe, Sinead; Shepherd, Frances A.] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON, Canada.
[Graziano, Stephen] SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA.
[Bourredjem, Abderrahmane; Ezzalfani, Monia; Lace-Bio Grp] Inst Gustave Roussy, Dept Biostat & Epidemiol, Villejuif, France.
[Burkes, Ronald] Mt Sinai Hosp, Toronto, ON, Canada.
[Capelletti, Marzia; Janne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA.
[Tsao, Ming S.] Princess Margaret Hosp, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S462
EP S463
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802189
ER
PT J
AU Gaissert, HA
AF Gaissert, Henning A.
TI ROLE OF ADJUVANT RADIOTHERAPY IN THE SURGICAL TREATMENT OF TRACHEAL
CARCINOMA
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE squamous cell carcinoma; Trachea; Trachel tumor; Adenoid cystic
carcinoma
C1 [Gaissert, Henning A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S70
EP S71
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855801023
ER
PT J
AU Gandhi, L
Butaney, M
Shaw, AT
Bahleda, R
Fiel, K
Wolanski, A
Turnbull, K
Berkenblit, A
Johnson, BE
Janne, PA
Soria, JC
Shapiro, G
AF Gandhi, Leena
Butaney, Mohit
Shaw, Alice T.
Bahleda, Rastislav
Fiel, Kathleen
Wolanski, Andrew
Turnbull, Kathleen
Berkenblit, Anna
Johnson, Bruce E.
Janne, Pasi A.
Soria, Jean-Charles
Shapiro, Geoffrey
TI HER2 MUTATIONS IN NON-SMALL CELL LUNG CANCER: PRELIMINARY EFFICACY OF
TARGETED THERAPY WITH NERATINIB plus TORISEL ON A PHASE I TRIAL.
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE HER2; neratinib; torisel; lung
C1 [Gandhi, Leena; Butaney, Mohit; Fiel, Kathleen; Wolanski, Andrew; Johnson, Bruce E.; Janne, Pasi A.; Shapiro, Geoffrey] Dana Farber Canc Inst, Boston, MA USA.
[Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Bahleda, Rastislav; Soria, Jean-Charles] Inst Gustave Roussy, Villejuif, France.
[Turnbull, Kathleen; Berkenblit, Anna] Pfizer Inc, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S665
EP S666
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855803073
ER
PT J
AU Gao, YJ
Xiao, Q
Ma, HM
Li, L
Liu, J
Feng, Y
Fang, ZY
Wu, J
Han, XK
Zhang, JH
Sun, YH
Wu, GW
Padera, R
Chen, HQ
Wong, KK
Ge, GX
Ji, HB
AF Gao, Yijun
Xiao, Qian
Ma, Huimin
Li, Li
Liu, Jun
Feng, Yan
Fang, Zhaoyuan
Wu, Jing
Han, Xiangkun
Zhang, Junhua
Sun, Yihua
Wu, Gongwei
Padera, Robert
Chen, Haiquan
Wong, Kwok-Kin
Ge, Gaoxiang
Ji, Hongbin
TI IDENTIFICATION OF LYSYL OXIDASE AS A DIAGNOSIS AND PROGNOSIS BIOMARKER
AND A THERAPEUTIC TARGET IN LUNG CANCER
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE lysyl oxidase; extracellular matrix; LKB1; lung cancer metastasis
C1 [Zhang, Junhua; Sun, Yihua; Chen, Haiquan] Fudan Univ, Dept Thorac Surg, Shanghai Canc Ctr, Shanghai, Peoples R China.
[Padera, Robert] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Wong, Kwok-Kin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ji, Hongbin] Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, Lab Mol Cell Biol, Beijing 100864, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S684
EP S685
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855803096
ER
PT J
AU Gill, RR
Yeap, B
Matsuoka, S
Wolf, AS
Bueno, R
Hatabu, H
Sugarbaker, DJ
Richards, WG
AF Gill, Ritu R.
Yeap, Beow
Matsuoka, Shin
Wolf, Andrea S.
Bueno, Raphael
Hatabu, Hiroto
Sugarbaker, David J.
Richards, William G.
TI STAGE-INDEPENDENT PREOPERATIVE PROGNOSTIC GROUPING OF SURGICALLY-TREATED
PATIENTS WITH EPITHELIAL MALIGNANT PLEURAL MESOTHELIOMA
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Prognosis; mesothelioma; Surgery
C1 [Gill, Ritu R.; Matsuoka, Shin; Wolf, Andrea S.; Bueno, Raphael; Hatabu, Hiroto; Sugarbaker, David J.; Richards, William G.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Yeap, Beow] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S486
EP S487
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802220
ER
PT J
AU Hammerman, P
Sivachenko, A
Pho, N
Cherniak, A
Ramos, A
Getz, G
Meyerson, M
AF Hammerman, Peter
Sivachenko, Andrey
Pho, Nam
Cherniak, Andrew
Ramos, Alex
Getz, Gad
Meyerson, Matthew
TI GENOMIC CHARACTERIZATION AND TARGETED THERAPEUTICS IN SQUAMOUS CELL LUNG
CANCER
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE targeted therapies; squamous cell lung cancer; cancer genomics
C1 [Hammerman, Peter; Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA USA.
[Sivachenko, Andrey; Pho, Nam; Cherniak, Andrew; Ramos, Alex; Getz, Gad] Broad Inst, Canc Program, Cambridge, MA USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S39
EP S39
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855801001
ER
PT J
AU Heon, S
Yeap, B
Lindeman, NI
Rabin, MS
Jackman, DM
Johnson, BE
AF Heon, Stephanie
Yeap, Beow
Lindeman, Neal I.
Rabin, Michael S.
Jackman, David M.
Johnson, Bruce E.
TI RATES OF CENTRAL NERVOUS SYSTEM (CNS) METASTASES IN PATIENTS WITH
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND SOMATIC EGFR MUTATIONS
INITIALLY TREATED WITH GEFITINIB OR ERLOTINIB VERSUS CHEMOTHERAPY
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Secondary brain neoplasms; Secondary meningeal neoplasms; Non-small cell
lung cancer; Epidermal growth factor receptor tyrosine kinase inhibitors
C1 [Heon, Stephanie; Rabin, Michael S.; Jackman, David M.; Johnson, Bruce E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yeap, Beow] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Lindeman, Neal I.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S658
EP S659
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855803064
ER
PT J
AU Hudish, TM
Opincariu, LI
Mozer, AB
Johnson, MS
Cleaver, TG
Malkoski, SP
Merrick, DT
Keith, RL
AF Hudish, Tyler M.
Opincariu, Laura I.
Mozer, Anthony B.
Johnson, Micah S.
Cleaver, Timothy G.
Malkoski, Stephen P.
Merrick, Daniel T.
Keith, Robert L.
TI N-NITROSO-TRIS-CHLOROETHYLUREA INDUCES PRE-MALIGNANT SQUAMOUS DYSPLASIA
IN MICE
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE NTCU; squamous cell carcinoma; Lung cancer; prostaglandin
C1 [Keith, Robert L.] Denver VA Med Ctr, Div Pulm Sci & Crit Care Med, Denver, CO USA.
[Cleaver, Timothy G.; Malkoski, Stephen P.] Univ Colorado Denver, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU S
BP S1095
EP S1096
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 779HX
UT WOS:000291769800276
ER
PT J
AU Janne, PA
Wang, XF
Socinski, MA
Crawford, J
Gu, L
Capelletti, M
Edelman, MJ
Villalona-Calero, MA
Kratzke, RA
Vokes, E
Miller, VA
AF Janne, Pasi A.
Wang, Xiaofei
Socinski, Mark A.
Crawford, Jeffrey
Gu, Lin
Capelletti, Marzia
Edelman, Martin J.
Villalona-Calero, Miguel A.
Kratzke, Robert A.
Vokes, Everett
Miller, Vincent A.
TI OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS
TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH
CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406.
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE EGFR mutation; erlotinib; Randomized Phase II clinical trial
C1 [Janne, Pasi A.; Capelletti, Marzia] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA.
[Wang, Xiaofei; Gu, Lin] Duke Univ, Durham, NC 27706 USA.
[Socinski, Mark A.] Univ N Carolina, Chapel Hill, NC 27515 USA.
[Crawford, Jeffrey] Duke Univ, Med Ctr, Durham, NC 27706 USA.
[Edelman, Martin J.] Univ Maryland, Ctr Canc, College Pk, MD 20742 USA.
[Villalona-Calero, Miguel A.] Ohio State Univ, Columbus, OH 43210 USA.
[Kratzke, Robert A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Vokes, Everett] Univ Chicago, Chicago, IL 60637 USA.
[Miller, Vincent A.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S447
EP S448
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802172
ER
PT J
AU Janne, PA
AF Janne, Pasi A.
TI NOVEL TARGETS AND THERAPIES IN NON-SMALL CELL LUNG CANCER
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Somatic Mutation; Non-small cell lung cancer; kinase inhibitor; HER2
C1 [Janne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S93
EP S93
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855801047
ER
PT J
AU Johnson, BE
Kris, MG
Kwiatkowski, D
Iafrate, AJ
Wistuba, II
Shyr, Y
Engelman, J
Khuri, FR
Dubinett, S
Pao, W
Rudin, C
Schiller, J
Haura, EB
Blumenschein, G
Simon, G
Giaccone, G
Koehler, E
Kugler, K
Minna, JD
Bunn, P
AF Johnson, Bruce E.
Kris, Mark G.
Kwiatkowski, David
Iafrate, A. J.
Wistuba, Ignacio I.
Shyr, Yu
Engelman, Jeff
Khuri, Fadlo R.
Dubinett, Steven
Pao, William
Rudin, Charles
Schiller, Joan
Haura, Eric B.
Blumenschein, George
Simon, George
Giaccone, Giuseppe
Koehler, Elizabeth
Kugler, Kelly
Minna, John D.
Bunn, Paul
TI CLINICAL CHARACTERISTICS OF PLANNED 1000 PATIENTS WITH ADENOCARCINOMA OF
LUNG (ACL) UNDERGOING GENOMIC CHARACTERIZATION IN THE US LUNG CANCER
MUTATION CONSORTIUM (LCMC)
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE lung neoplasm; genomic changes; Epidermal growth factor receptor;
EML4-ALK
C1 [Johnson, Bruce E.; Kwiatkowski, David] Dana Farber Canc Inst, Boston, MA USA.
[Kris, Mark G.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA.
[Iafrate, A. J.; Engelman, Jeff] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Wistuba, Ignacio I.; Blumenschein, George] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Shyr, Yu; Koehler, Elizabeth] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA.
[Khuri, Fadlo R.] Emory Univ, Atlanta, GA 30322 USA.
[Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care, Los Angeles, CA 90095 USA.
[Pao, William] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Rudin, Charles] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21218 USA.
[Schiller, Joan] Univ Texas Southwestern Med Ctr, Div Hematol Oncol, Dallas, TX USA.
[Haura, Eric B.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Simon, George] Med Univ S Carolina, Charleston, SC USA.
[Giaccone, Giuseppe] NCI, Bethesda, MD 20892 USA.
[Kugler, Kelly] Univ Colorado, Ctr Canc, Div Med Oncol, Boulder, CO 80309 USA.
[Minna, John D.] Univ Texas Southwestern Med Ctr, Dallas, TX USA.
[Bunn, Paul] Univ Colorado, Denver Sch Med, Div Med Oncol, Boulder, CO 80309 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S344
EP S345
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802041
ER
PT J
AU Kim, JH
Zo, JI
Nakayama, H
De Pas, T
Dahabreh, J
Zielinski, M
Altorki, N
Vanakesa, T
Park, K
Leszek, H
Suzuki, K
Strausz, J
Gonzalez, EE
Mitsudomi, T
Thongprasert, S
Sequist, L
Shen, KR
Spiessens, B
Debruyne, C
Vansteenkiste, J
AF Kim, Joo-Hang
Zo, Jae Ill
Nakayama, Haruhiko
De Pas, Tommaso
Dahabreh, Jubrail
Zielinski, Marcin
Altorki, Nasser
Vanakesa, Tonu
Park, Keunchil
Leszek, Herjan
Suzuki, Kenji
Strausz, Janos
Esteban Gonzalez, Emilio
Mitsudomi, Tetsuya
Thongprasert, Sumitra
Sequist, Lecia
Shen, K. Robert
Spiessens, Bart
Debruyne, Channa
Vansteenkiste, Johan
TI PATIENT AND TUMOR CHARACTERISTICS IMPACTING ON MAGE-A3 EXPRESSION:
SCREENING DATA FROM THE MAGRIT PHASE III TRIAL
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE MAGE-A3; Antigen-Specific Cancer Immunotherapeutic; Non-small cell lung
cancer
C1 [Kim, Joo-Hang] Yonsei Canc Ctr, Seoul, South Korea.
[Nakayama, Haruhiko] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan.
[Altorki, Nasser] Cornell Univ, Weil Med Coll, Ithaca, NY 14853 USA.
[Vanakesa, Tonu] North Estonia Med Ctr, Tartu, Estonia.
[Park, Keunchil] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[Suzuki, Kenji] Juntendo Univ Hosp, Tokyo, Japan.
[Strausz, Janos] Koranyi Natl Inst Pulmonol, Budapest, Hungary.
[Esteban Gonzalez, Emilio] Hosp Cent Asturias, Oviedo, Spain.
[Mitsudomi, Tetsuya] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan.
[Thongprasert, Sumitra] Chiang Mai Univ, Maharaj Nakorn Chiangmai Hosp, Chiangmai, Thailand.
[Sequist, Lecia] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Shen, K. Robert] Mayo Clin, Rochester, MN USA.
[Vansteenkiste, Johan] Univ Hosp Gasthuisberg, Louvain, Belgium.
NR 0
TC 1
Z9 1
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S662
EP S663
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855803068
ER
PT J
AU Mauguen, A
Michiels, S
Burdett, S
Tierney, JF
Sause, W
Mandrekar, SJ
Dahlberg, SE
Shepherd, FA
Parmar, M
Perry, MC
O'Brien, M
Le Pechoux, C
Pignon, JP
AF Mauguen, Audrey
Michiels, Stefan
Burdett, Sarah
Tierney, Jayne F.
Sause, William
Mandrekar, Sumithra J.
Dahlberg, Suzanne E.
Shepherd, Frances A.
Parmar, Mahesh
Perry, Michael C.
O'Brien, Mary
Le Pechoux, Cecile
Pignon, Jean-Pierre
CA Surrogate Lung Project
TI EVALUATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR
OVERALL SURVIVAL WHEN EVALUATING THE EFFECT OF CHEMOTHERAPY AND
RADIOTHERAPY IN LOCALLY ADVANCED LUNG CANCER USING DATA FROM FOUR
INDIVIDUAL PATIENT DATA META-ANALYSES
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE surrogate endpoint; Non-small cell lung cancer; meta-analysis; survival
C1 [Mauguen, Audrey; Surrogate Lung Project] Inst Gustave Roussy, Serv Biostat, Villejuif, France.
[Burdett, Sarah; Tierney, Jayne F.] MRC, Metaanal Grp, Clin Trials Unit, London W1N 4AL, England.
[Mandrekar, Sumithra J.] Mayo Clin, Rochester, MN USA.
[Dahlberg, Suzanne E.] Dana Farber Canc Inst, Boston, MA USA.
[Dahlberg, Suzanne E.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
[Shepherd, Frances A.] Princess Margaret Hosp, Toronto, ON, Canada.
[Parmar, Mahesh] MRC, Clin Trial Unit London, London W1N 4AL, England.
[O'Brien, Mary] Royal Marsden Hosp, Lung Unit, London, England.
[Le Pechoux, Cecile] Inst Gustave Roussy, Villejuif, France.
RI Michiels, Stefan/L-1516-2013
OI Michiels, Stefan/0000-0002-6963-2968
NR 0
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S464
EP S465
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802192
ER
PT J
AU Merrick, DT
Coldren, CD
Franklin, W
Sugita, M
Miller, YE
Keith, RL
Kennedy, TC
Chesnut, P
Mascaux, C
Hirsch, FR
Geraci, MW
Nemenoff, R
AF Merrick, Daniel T.
Coldren, Chris D.
Franklin, Wilbur
Sugita, Michio
Miller, York E.
Keith, Robert L.
Kennedy, Timothy C.
Chesnut, Patrick
Mascaux, Celine
Hirsch, Fred R.
Geraci, Mark W.
Nemenoff, Raphael
TI IDENTIFICATION OF ALTERATIONS IN GENE EXPRESSION THAT DISTINGUISH
PERSISTENT FROM REGRESSIVE BRONCHIAL DYSPLASIA
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Bronchial dysplasia; Persistence; gene expression
C1 [Merrick, Daniel T.] Denver VAMC, Denver, CO USA.
[Franklin, Wilbur; Miller, York E.; Keith, Robert L.; Kennedy, Timothy C.; Chesnut, Patrick; Mascaux, Celine; Hirsch, Fred R.; Geraci, Mark W.] Univ Colorado, Ctr Canc, Sch Med, Boulder, CO 80309 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU S
BP S1097
EP S1098
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 779HX
UT WOS:000291769800278
ER
PT J
AU Merrick, DT
Bessessen, M
Johnson, SC
Clagett, TA
Jackson, MK
Keith, RL
Byers, TE
Feser, WJ
Franklin, W
Bunn, P
Miller, YE
AF Merrick, Daniel T.
Bessessen, Mary
Johnson, Steven C.
Clagett, Thomas A.
Jackson, Mary K.
Keith, Robert L.
Byers, Tim E.
Feser, William J.
Franklin, Wilbur
Bunn, Paul
Miller, York E.
TI BRONCHIAL DYSPLASIA IS MORE FREQUENT AND MORE ATYPICAL IN BIOPSY AND
SPUTUM MATERIAL FROM HIV INFECTED SUBJECTS: A PRELIMINARY REPORT FROM AN
ONGOING STUDY
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE HIV infection; Sputum; bronchial biopsy; Bronchial dysplasia
C1 [Merrick, Daniel T.; Bessessen, Mary] Denver VAMC, Denver, CO USA.
[Bunn, Paul] Univ Colorado, Ctr Canc, Sch Med, Boulder, CO 80309 USA.
[Keith, Robert L.; Miller, York E.] Vet Adm Med Ctr, Div Pulm Sci & Crit Care Med, Los Angeles, CA USA.
[Feser, William J.] Colorado Sch Publ Hlth, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU S
BP S1096
EP S1097
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 779HX
UT WOS:000291769800277
ER
PT J
AU Miller, YE
Blatchford, PJ
Franklin, W
Kennedy, TC
Merrick, D
Minna, JD
Kelly, K
Mao, J
Massion, PP
Wilson, DO
Hirsch, FR
Bunn, P
Geraci, MW
Kittelson, JK
Keith, RL
AF Miller, York E.
Blatchford, Patrick J.
Franklin, Wilbur
Kennedy, Timothy C.
Merrick, Daniel
Minna, John D.
Kelly, Karen
Mao, Jenny
Massion, Pierre P.
Wilson, David O.
Hirsch, Fred R.
Bunn, Paul
Geraci, Mark W.
Kittelson, John K.
Keith, Robert L.
TI ILOPROST IMPROVES ENDOBRONCHIAL DYSPLASIA IN FORMER SMOKERS:
IMPLICATIONS FOR PHASE II CHEMOPREVENTION TRIAL DESIGN
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE prostacyclin; chemoprevention; Lung cancer; premalignancy
C1 [Miller, York E.; Keith, Robert L.] Vet Adm Med Ctr, Div Pulm Sci & Crit Care Med, Nashville, TN USA.
[Franklin, Wilbur; Kennedy, Timothy C.; Hirsch, Fred R.; Kittelson, John K.] Univ Colorado Denver, Denver, CO 80202 USA.
[Merrick, Daniel] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Minna, John D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA.
[Kelly, Karen] Uc Davis, Davis, CA USA.
[Mao, Jenny] Univ New Mexico, Albuquerque, NM 87131 USA.
[Massion, Pierre P.] Vanderbilt Univ, Nashville, TN USA.
[Wilson, David O.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU S
BP S1401
EP S1402
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 779HX
UT WOS:000291769801303
ER
PT J
AU Ramalingam, S
Spigel, D
Steins, M
Engelman, J
Novello, S
Eberhardt, W
Schneider, C
Crino, L
Janne, PA
Liu, L
Chen, D
Brownstein, C
Reck, M
AF Ramalingam, Suresh
Spigel, David
Steins, Martin
Engelman, Jeffrey
Novello, Silvia
Eberhardt, Wilfried
Schneider, Claus
Crino, Lucio
Janne, Pasi A.
Liu, Lian
Chen, David
Brownstein, Carrie
Reck, Martin
TI R1507, A MONOCLONAL ANTIBODY TO INSULIN-LIKE GROWTH FACTOR RECEPTOR-1
(IGF-1R), IN COMBINATION WITH ERLOTINIB FOR ADVANCED STAGE NON-SMALL
CELL LUNG CANCER (NSCLC): A PLACEBO-CONTROLLED, RANDOMIZED PHASE II
STUDY
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE NSCLC; IGF-1R; R1507; erlotinib
C1 [Ramalingam, Suresh] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Spigel, David] Sarah Cannon Res Inst, Nashville, TN USA.
[Steins, Martin] Thorax Klin, Heidelberg, Germany.
[Engelman, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Novello, Silvia] Univ Turin, Aou San Luigi, Italy.
[Eberhardt, Wilfried] Univ Duisburg Essen, Essen, Germany.
[Schneider, Claus] Zent Klin, Bad Berka, Germany.
[Crino, Lucio] Univ Perugia, I-06100 Perugia, Italy.
[Janne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA.
[Liu, Lian] Roche Pharmaceut, Shanghai, Peoples R China.
[Chen, David; Brownstein, Carrie] Roche Pharmaceut, New York, NY USA.
[Reck, Martin] Krankenhaus Grosshansdorf, Zentrum Pneumol & Thoraxchirurg, Grosshansdorf, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S605
EP S605
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802376
ER
PT J
AU Riely, GJ
Kim, DW
Crino, L
Janne, PA
Blackhall, FH
Camidge, DR
Hirsh, V
Mok, TSK
Solomon, B
Soria, JC
Park, K
Gadgeel, SM
Martins, RG
Han, JY
De Pas, T
Bottomley, A
Polli, A
Petersen, JA
Tassell, VR
Shaw, AT
AF Riely, Gregory J.
Kim, Dong-Wan
Crino, Lucio
Janne, Pasi A.
Blackhall, Fiona H.
Camidge, David R.
Hirsh, Vera
Mok, Tony S. K.
Solomon, Ben
Soria, Jean-Charles
Park, Keunchil
Gadgeel, Shirish M.
Martins, Renato G.
Han, Ji-Youn
De Pas, Tommaso
Bottomley, Andrew
Polli, Anna
Petersen, Jennifer A.
Tassell, Vanessa R.
Shaw, Alice T.
TI PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED
NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Crizotinib; PF-02341066; Non-small cell lung cancer
C1 [Riely, Gregory J.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Kim, Dong-Wan] Seoul Natl Univ Hosp, Seoul, South Korea.
[Crino, Lucio] Azienda Osped Perugia, Div Med, Perugia, Italy.
[Janne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA.
[Blackhall, Fiona H.] Christie NHS Fdn Trust, Manchester, Lancs, England.
[Camidge, David R.] Univ Colorado Denver, Aurora, CO 80045 USA.
[Hirsh, Vera] McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 2T5, Canada.
[Mok, Tony S. K.] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.
[Solomon, Ben] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia.
[Park, Keunchil] Sungkyunkwan Univ, Sch Med, Dept Med, Div Hem Onc, Seoul, South Korea.
[Gadgeel, Shirish M.] Ayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
[Martins, Renato G.] Univ Washington, Seattle, WA 98195 USA.
[De Pas, Tommaso] European Inst Oncol, Thorac Oncol Unit, Milan, Italy.
[Petersen, Jennifer A.] Pfizer Oncol, Hlth Econ & Global Outcomes Res, New York, NY USA.
[Tassell, Vanessa R.] Pfizer Oncol, Clin Res & Dev, New York, NY USA.
[Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RI Blackhall, Fiona/N-2186-2015
OI Blackhall, Fiona/0000-0001-8716-3395
NR 0
TC 4
Z9 4
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S411
EP S412
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802128
ER
PT J
AU Roelofs, E
Engelsman, M
Rasch, C
Persoon, L
Qamhiyeh, S
De Ruysscher, D
Verhaegen, F
Pijls-Johannesma, M
Lambin, P
AF Roelofs, Erik
Engelsman, Martijn
Rasch, Coen
Persoon, Lucas
Qamhiyeh, Sima
De Ruysscher, Dirk
Verhaegen, Frank
Pijls-Johannesma, Madelon
Lambin, Philippe
TI COMPARING RADIOTHERAPY WITH PHOTONS AND PROTONS FOR NON-SMALL CELL LUNG
CANCER: RESULTS OF A MULTICENTRIC IN SILICO CLINICAL TRIAL
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE In silico planning study; Particle therapy; NSCLC; Radiotherapy
C1 [Roelofs, Erik; Persoon, Lucas; Qamhiyeh, Sima; De Ruysscher, Dirk; Verhaegen, Frank; Pijls-Johannesma, Madelon; Lambin, Philippe] Maastricht Univ Med Ctr, Dept Radiat Oncol MAASTRO, Grow Sch Oncol & Dev Biol, Maastricht, Netherlands.
[Engelsman, Martijn] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Engelsman, Martijn] Harvard Univ, Sch Med, MGH, Cambridge, MA 02138 USA.
[Rasch, Coen] Netherlands Canc Inst NKI, Amsterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S807
EP S807
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855803268
ER
PT J
AU Rudin, C
Garon, EB
De Oliveira, MR
Bonomi, P
Camidge, RD
Chu, Q
Giaccone, G
Khaira, D
Ramalingam, S
Ranson, M
Hann, C
Mckeegan, E
Chyla, B
Dowell, BL
Chakravartty, A
Nolan, C
Busman, T
Mabry, M
Krivoshik, A
Humerickhouse, R
Shapiro, G
Gandhi, L
AF Rudin, Charles
Garon, Edward B.
De Oliveira, Moacyr Ribeiro
Bonomi, Philip
Camidge, Ross D.
Chu, Quincy
Giaccone, Giuseppe
Khaira, Divis
Ramalingam, Suresh
Ranson, Malcolm
Hann, Christine
Mckeegan, Evelyn
Chyla, Brenda
Dowell, Barry L.
Chakravartty, Arunava
Nolan, Catherine
Busman, Todd
Mabry, Mack
Krivoshik, Andrew
Humerickhouse, Rod
Shapiro, Geoffrey
Gandhi, Leena
TI PATIENT OUTCOME AND EXPLORATORY ANALYSIS FROM A PHASE 2A STUDY OF
NAVITOCLAX (ABT-263) IN PATIENTS WITH ADVANCED/RELAPSED SMALL CELL LUNG
CANCER (SCLC)
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Navitoclax; Phase 2 Trial; SCLC; apoptosis
C1 [Rudin, Charles] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21218 USA.
[Garon, Edward B.] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[De Oliveira, Moacyr Ribeiro] Northwest Med Specialties Pllc, Oncol, Tacoma, WA USA.
[Bonomi, Philip] Rush Univ, Med Ctr, Chicago, IL USA.
[Camidge, Ross D.] Univ Calif Davis, Ctr Canc, Davis, CA 95616 USA.
[Chu, Quincy] Alberta Hlth Serv, Calgary, AB, Canada.
[Giaccone, Giuseppe] NCI, Bethesda, MD 20892 USA.
[Khaira, Divis] Sunterra Oncol Associates, Peoria, IL USA.
[Ramalingam, Suresh] Emory Univ, Atlanta, GA 30322 USA.
[Ranson, Malcolm] Christie NHS Fdn Trust, Cambridge, England.
[Hann, Christine] Johns Hopkins Univ, Baltimore, MD 21218 USA.
[Mckeegan, Evelyn; Chyla, Brenda; Dowell, Barry L.; Chakravartty, Arunava; Nolan, Catherine; Busman, Todd; Mabry, Mack; Krivoshik, Andrew; Humerickhouse, Rod] Abbott, Abbott Pk, IL USA.
[Shapiro, Geoffrey; Gandhi, Leena] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S644
EP S645
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855803045
ER
PT J
AU Sasaki, T
Koivunen, J
Ogino, A
Okuda, K
Yanagita, M
Cappelletti, M
Wilner, K
Christensen, J
Eck, M
Gray, N
Janne, PA
AF Sasaki, Takaaki
Koivunen, Jussi
Ogino, Atsuko
Okuda, Katsuhiro
Yanagita, Masahiko
Cappelletti, Marzia
Wilner, Keith
Christensen, James
Eck, Michael
Gray, Natanael
Janne, Pasi A.
TI ANAPLASTIC LYMPHOMA KINASE (ALK) DEPENDENT AND CO-DEPENDENT MECHANISMS
OF RESISTANCE TO ALK KINASE INHIBITORS IN EML4-ALK NON-SMALL CELL LUNG
CANCER
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Non-small cell lung cancer; gene translocation; kinase inhibitor;
anaplastic large cell kinase
C1 [Sasaki, Takaaki] Asahikawa Med Univ Hosp, Resp Ctr, Asahikawa, Hokkaido, Japan.
[Koivunen, Jussi] Oulu Univ Hosp, Dept Oncol & Hematol, Oulu, Finland.
[Ogino, Atsuko; Okuda, Katsuhiro; Yanagita, Masahiko; Cappelletti, Marzia; Eck, Michael; Gray, Natanael] Dana Farber Canc Inst, Boston, MA USA.
[Wilner, Keith; Christensen, James] Pfizer Global Res & Dev, Dept Res Pharmacol, New York, NY USA.
[Janne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S421
EP S422
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802140
ER
PT J
AU Shaw, AT
Yeap, B
Solomon, B
Riely, GJ
Iafrate, AJ
Shapiro, G
Costa, DB
Butaney, M
Ou, SHI
Maki, R
Bang, YJ
Varella-Garcia, M
Salgia, R
Wilner, K
Kulig, K
Selaru, P
Tang, YY
Kwak, E
Clark, J
Camidge, DR
AF Shaw, Alice T.
Yeap, Beow
Solomon, Ben
Riely, Gregory J.
Iafrate, A. J.
Shapiro, Geoffrey
Costa, Daniel B.
Butaney, Mohit
Ou, Sai-Hong I.
Maki, Robert
Bang, Yung-Jue
Varella-Garcia, Marileila
Salgia, Ravi
Wilner, Keith
Kulig, Kimary
Selaru, Paulina
Tang, Yiyun
Kwak, Eunice
Clark, Jeffrey
Camidge, David R.
TI CRIZOTINIB IMPROVES OVERALL SURVIVAL OF ALK-POSITIVE PATIENTS WITH
ADVANCED NSCLC COMPARED WITH HISTORICAL CONTROLS
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE ALK; Crizotinib; Tyrosine kinase inhibitor
C1 [Shaw, Alice T.; Yeap, Beow; Iafrate, A. J.; Kwak, Eunice; Clark, Jeffrey] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Solomon, Ben] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Riely, Gregory J.; Maki, Robert] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Shapiro, Geoffrey; Butaney, Mohit] Dana Farber Canc Inst, Boston, MA USA.
[Costa, Daniel B.] Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Bang, Yung-Jue] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.
[Varella-Garcia, Marileila; Camidge, David R.] Univ Colorado, Boulder, CO 80309 USA.
[Salgia, Ravi] Univ Chicago, Chicago, IL 60637 USA.
[Tang, Yiyun] Pfizer Inc, Oncol, New York, NY USA.
NR 0
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S412
EP S413
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802129
ER
PT J
AU Socinski, MA
Koczywas, M
Goldman, J
Paschold, E
Horn, L
Lufkin, J
Blackman, RK
Teofilovici, F
Shapiro, G
AF Socinski, Mark A.
Koczywas, Marianna
Goldman, Jonathan
Paschold, Eugene
Horn, Leora
Lufkin, Joelle
Blackman, Ronald K.
Teofilovici, Florentina
Shapiro, Geoffrey
TI AN OPEN-LABEL PHASE II STUDY OF THE HSP90 INHIBITOR GANETESPIB
(STA-9090) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Non-small Cell Lung Carcinoma; STA-9090; Hsp90 inhibitor; Ganetespib
C1 [Socinski, Mark A.] Lineberger Comprehens Canc Ctr, Multidisciplinary Thorac Oncol Program, Chapel Hill, NC USA.
[Koczywas, Marianna] City Hope Natl Med Ctr, Duarte, CA USA.
[Goldman, Jonathan] Premiere Oncol, Naples, FL USA.
[Paschold, Eugene] Piedmont Hematol Oncol Associates, Elkin, NC USA.
[Horn, Leora] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Lufkin, Joelle; Blackman, Ronald K.; Teofilovici, Florentina] Synta Pharmaceut, Lexington, MA USA.
[Shapiro, Geoffrey] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S467
EP S468
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802195
ER
PT J
AU Soria, JC
Brambilla, E
Le Teuff, G
Tsao, MS
Janne, PA
Hainaut, P
Taron, M
Kratzke, RA
Shepherd, FA
Pignon, JP
AF Soria, Jean-Charles
Brambilla, Elisabeth
Le Teuff, Gwenael
Tsao, Ming S.
Janne, Pasi A.
Hainaut, Pierre
Taron, Miquel
Kratzke, Robert A.
Shepherd, Frances A.
Pignon, Jean-Pierre
CA Lace-Bio Grp
TI A POOLED ANALYSIS TO EVALUATE THE PROGNOSIS AND PREDICTIVE VALUE OF EGFR
MUTATION ON SURVIVAL IN PATIENTS WITH KRAS WILD-TYPE LUNG ADENOCARCINOMA
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE EGFR mutation; meta-analysis; predictive value; lung adenocarcinoma
C1 [Soria, Jean-Charles] Inst Gustave Roussy, Dept Med, Villejuif, France.
[Brambilla, Elisabeth] INSERM, Inst Albert Bonniot, U823, F-75654 Paris 13, France.
[Le Teuff, Gwenael; Pignon, Jean-Pierre] Inst Gustave Roussy, Villejuif, France.
[Tsao, Ming S.; Shepherd, Frances A.] Princess Margaret Hosp, Toronto, ON, Canada.
[Janne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA.
[Hainaut, Pierre] Int Agcy Res Canc, Lyon, France.
[Taron, Miquel] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
[Kratzke, Robert A.] Univ Minnesota, Minneapolis, MN 55455 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S617
EP S617
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855803007
ER
PT J
AU Wakelee, HA
Dahlberg, SE
Keller, SM
Gandara, DR
Graziano, S
Leighl, NB
Adjei, AA
Schiller, J
AF Wakelee, Heather A.
Dahlberg, Suzanne E.
Keller, Steven M.
Gandara, David R.
Graziano, Stephen
Leighl, Natasha B.
Adjei, Alex A.
Schiller, Joan
TI INTERIM REPORT OF ON-STUDY DEMOGRAPHICS AND TOXICITY FROM EASTERN
COOPERATIVE ONCOLOGY GROUP (ECOG) E1505, A PHASE III RANDOMIZED TRIAL OF
ADJUVANT CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB FOR COMPLETELY
RESECTED EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Meeting Abstract
DE Adjuvant chemotherapy; bevacizumab
C1 [Wakelee, Heather A.] Stanford Univ, Stanford, CA 94305 USA.
[Dahlberg, Suzanne E.] Dana Farber Canc Inst, Boston, MA USA.
[Dahlberg, Suzanne E.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
[Keller, Steven M.] Montefiore Med Ctr, Bronx, NY USA.
[Gandara, David R.] Univ Calif Davis, Ctr Canc, Davis, CA USA.
[Graziano, Stephen] SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA.
[Leighl, Natasha B.] Princess Margaret Hosp, Toronto, ON, Canada.
[Leighl, Natasha B.] Univ Toronto, Toronto, ON M5S 1A1, Canada.
[Adjei, Alex A.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Schiller, Joan] Univ Texas Southwestern Med Ctr, Div Hematol Oncol, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
EI 1556-1380
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD JUN
PY 2011
VL 6
IS 6
SU 2
BP S464
EP S464
PG 1
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA V31AF
UT WOS:000208855802191
ER
PT J
AU Rutzen-Lopez, H
Khanna, V
Reynolds, MR
AF Rutzen-Lopez, H.
Khanna, V.
Reynolds, M. R.
TI Atrial fibrillation: epidemiology, prognosis and therapy
SO MINERVA MEDICA
LA English
DT Article
DE Atrial fibrillation; Tachycardia; Tachycardia, therapy
ID QUALITY-OF-LIFE; APPENDAGE TRANSCATHETER OCCLUSION; RISK STRATIFICATION
SCHEMES; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION;
RHYTHM MANAGEMENT AFFIRM; VENTRICULAR RATE CONTROL; EURO HEART SURVEY;
STROKE PREVENTION; CLINICAL-TRIAL
AB Atrial fibrillation is the most common cardiac tachyarrhythmia encountered in clinical practice affecting 1% of the population. It is characterized by uncoordinated atrial activation that can lead to embolic complications and reduction in cardiac output resulting in significant morbidity, mortality and a reduction in quality of life. The three major goals in the management of atrial fibrillation are rate control, prevention of thromboembolism and correction of rhythm disturbance. This article will review up-to-date thinking about strategies for achieving each of these fundamental goals of AF care, with an emphasis on new drugs such as dabigatran and dronedarone and emerging non-pharmacologic therapies such as catheter ablation and left atrial appendage exclusion. After many years with relatively few new treatments, the past few years have seen a number of exciting developments which will hopefully improve clincian's ability to improve the outcomes of patients with this chronic and troublesome condition.
C1 [Rutzen-Lopez, H.; Khanna, V.; Reynolds, M. R.] Beth Israel Deaconess Med Ctr, VA Boston Healthcare Syst, Boston, MA 02215 USA.
RP Reynolds, MR (reprint author), Beth Israel Deaconess Med Ctr, VA Boston Healthcare Syst, 185 Pilgrim Rd,Baker 4, Boston, MA 02215 USA.
EM mreynold@bidmc.harvard.edu
NR 94
TC 4
Z9 4
U1 0
U2 4
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026-4806
EI 1827-1669
J9 MINERVA MED
JI Minerva Med.
PD JUN
PY 2011
VL 102
IS 3
BP 187
EP 208
PG 22
WC Medicine, General & Internal
SC General & Internal Medicine
GA 781US
UT WOS:000291962600003
PM 21593721
ER
PT J
AU Liang, QL
Ouyang, XS
Schneider, L
Zhang, JH
AF Liang, Qiuli
Ouyang, Xiaosen
Schneider, Lonnie
Zhang, Jianhua
TI Reduction of mutant huntingtin accumulation and toxicity by lysosomal
cathepsins D and B in neurons
SO MOLECULAR NEURODEGENERATION
LA English
DT Article
DE huntingtin; lysosome; cathepsin; autophagy
ID AGGREGATE-PRONE PROTEINS; AUTOPHAGY INDUCTION; PARKINSONS-DISEASE;
ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; FRAGMENTS; DEGRADATION; PROTEASOME;
CLEARANCE; APOPTOSIS
AB Background: Huntington's disease is caused by aggregation of mutant huntingtin (mHtt) protein containing more than a 36 polyQ repeat. Upregulation of macroautophagy was suggested as a neuroprotective strategy to degrade mutant huntingtin. However, macroautophagy initiation has been shown to be highly efficient in neurons whereas lysosomal activities are rate limiting. The role of the lysosomal and other proteases in Huntington is not clear. Some studies suggest that certain protease activities may contribute to toxicity whereas others are consistent with protection. These discrepancies may be due to a number of mechanisms including distinct effects of the specific intermediate digestion products of mutant huntingtin generated by different proteases. These observations suggested a critical need to investigate the consequence of upregulation of individual lysosomal enzyme in mutant huntingtin accumulation and toxicity.
Results: In this study, we used molecular approaches to enhance lysosomal protease activities and examined their effects on mutant huntingtin level and toxicity. We found that enhanced expression of lysosomal cathepsins D and B resulted in their increased enzymatic activities and reduced both full-length and fragmented huntingtin in transfected HEK cells. Furthermore, enhanced expression of cathepsin D or B protected against mutant huntingtin toxicity in primary neurons, and their neuroprotection is dependent on macroautophagy.
Conclusions: These observations demonstrate a neuroprotective effect of enhancing lysosomal cathepsins in reducing mutant huntingtin level and toxicity in transfected cells. They highlight the potential importance of neuroprotection mediated by cathepsin D or B through macroautophagy.
C1 [Liang, Qiuli; Ouyang, Xiaosen; Schneider, Lonnie; Zhang, Jianhua] Univ Alabama, Dept Pathol, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
[Ouyang, Xiaosen; Zhang, Jianhua] Univ Alabama, Dept Vet Affairs, Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Zhang, JH (reprint author), Univ Alabama, Dept Pathol, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
EM zhanja@uab.edu
RI zhang, jianhua/D-3404-2009; di Ronza, Alberto/H-7674-2016
OI di Ronza, Alberto/0000-0002-9813-5143
FU CHDI foundation [NIHR01-NS064090]; UAB [NS47466, NS57098]
FX This work was supported by a grant from the CHDI foundation,
NIHR01-NS064090 and a VA merit award to Dr. Jianhua Zhang, and by UAB
Neuroscience Core Facilities (NS47466 and NS57098). We are grateful to
Drs. Michelle Gray, Mathieu Lesort, Paula Dietrich, Ioannis Dragatsis,
Deanna Marchionini and Victor Darley-Usmar for technical help and
discussions.
NR 38
TC 18
Z9 18
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-1326
J9 MOL NEURODEGENER
JI Mol. Neurodegener.
PD JUN 1
PY 2011
VL 6
AR 37
DI 10.1186/1750-1326-6-37
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 786PW
UT WOS:000292321400001
PM 21631942
ER
PT J
AU King, AE
Mintz, J
Royall, DR
AF King, Alisha E.
Mintz, Jim
Royall, Donald R.
TI Meta-Analysis of I-123-MIBG Cardiac Scintigraphy for the Diagnosis of
Lewy Body-Related Disorders
SO MOVEMENT DISORDERS
LA English
DT Article
DE dementia with Lewy bodies; Parkinson's disease; multiple system atrophy;
Alzheimer's disease; parasomnias
ID MULTIPLE SYSTEM ATROPHY; PURE AUTONOMIC FAILURE; PARKINSONS-DISEASE;
SYMPATHETIC DENERVATION; ALPHA-SYNUCLEIN; BODIES; DEMENTIA;
DEGENERATION; NERVE
AB Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac I-123-metaiodo-benzylguanidine uptake in Lewy body-related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered I-123-metaiodobenzylguanidine cardiac scintigraphy a "supportive'' diagnostic feature, based on limited evidence. We report a meta-analysis of the literature and an assessment of the utility of I-123-metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty-six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed-effects regression model was used to analyze the delayed mean heart-to-mediastinum ratio of I-123-metaiodobenzylguanidine uptake. I-123-metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart-to-mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. I-123-metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. (C) 2011 Movement Disorder Society
C1 [King, Alisha E.; Mintz, Jim; Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78284 USA.
[Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78284 USA.
[Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78284 USA.
[Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78284 USA.
[Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div GRECC, San Antonio, TX USA.
RP Royall, DR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.
EM Royall@uthscsa.edu
FU estate of Julia and Van Buren Parr
FX This study has been supported by the estate of Julia and Van Buren Parr.
NR 33
TC 32
Z9 33
U1 2
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUN
PY 2011
VL 26
IS 7
BP 1218
EP 1224
DI 10.1002/mds.23659
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 780NF
UT WOS:000291863600010
PM 21480373
ER
PT J
AU Jain, S
Siegle, GJ
Gu, C
Moore, CG
Ivanco, LS
Studenski, S
Greenamyre, JT
Steinhauer, SR
AF Jain, Samay
Siegle, Greg J.
Gu, Chen
Moore, Charity G.
Ivanco, Larry S.
Studenski, Stephanie
Greenamyre, J. Timothy
Steinhauer, Stuart R.
TI Pupillary Unrest Correlates With Arousal Symptoms and Motor Signs in
Parkinson Disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE nonmotor features; Parkinson's disease; pupil; sleep disorders;
autonomic dysfunction
ID NONMOTOR SYMPTOMS; DIAGNOSIS; SCALE
AB Background: Arousal symptoms (e. g., sleepiness) are common in Parkinson's disease, and pupillary unrest (spontaneous changes in pupil diameter) is positively associated with sleepiness. We explored pupillary unrest in Parkinson's disease.
Methods: Arousal symptoms (Epworth sleepiness scale and sleep/fatigue domain of the nonmotor symptoms scale for Parkinson's disease) and pupillary unrest were assessed in 31 participants (14 patients with Parkinson's disease, 17 controls). Effect sizes and t tests compared patients with Parkinson's disease with control participants. Correlation coefficients were calculated among arousal symptoms, pupillary unrest, and Unified Parkinson Disease Rating Scale Part III. Linear regression was performed with arousal symptoms or pupillary unrest as outcome.
Results: Participants with Parkinson's disease reported more arousal symptoms than controls. Pupillary unrest, arousal symptoms, and Unified Parkinson Disease Rating Scale Part III were positively correlated. The association between nonmotor symptoms scale-sleep score and pupillary unrest was higher in participants with Parkinson's disease than controls and higher in those with more Parkinsonian motor signs. Unified Parkinson Disease Rating Scale Part III was positively associated with pupillary unrest.
Conclusions: Pupillary unrest correlates with motor and nonmotor features associated with Lewy-related pathology, suggesting it may be a nonmotor marker of progression in Parkinson's disease. (C) 2011 Movement Disorder Society
C1 [Jain, Samay] Univ Pittsburgh, Med Ctr, Dept Neurol, Sch Med,Movement Disorders Div, Pittsburgh, PA 15213 USA.
[Jain, Samay; Greenamyre, J. Timothy] Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA USA.
[Greenamyre, J. Timothy; Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Jain, S (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol, Sch Med,Movement Disorders Div, 3471 5th Ave,Suite 811,Kaufmann Med Bldg, Pittsburgh, PA 15213 USA.
EM jains@upmc.edu
OI Moore, Charity/0000-0002-0060-0124; Greenamyre, J.
Timothy/0000-0003-3468-7878
FU NIH [KL2 RR024154, KMH082998, MH55762, UL1 RR024153, P30 AG-024827];
Department of Veterans Affairs; American Parkinson Disease Association
Center for Advanced Research at the University of Pittsburgh
FX This study was funded by NIH grants KL2 RR024154, KMH082998, MH55762,
UL1 RR024153, and P30 AG-024827, the Department of Veterans Affairs, and
the American Parkinson Disease Association Center for Advanced Research
at the University of Pittsburgh.
NR 10
TC 6
Z9 6
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUN
PY 2011
VL 26
IS 7
BP 1344
EP 1347
DI 10.1002/mds.23628
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 780NF
UT WOS:000291863600028
PM 21506163
ER
PT J
AU Dubin, R
Shlipak, M
Li, YM
Ix, J
de Boer, IH
Jenny, N
Peralta, CA
AF Dubin, Ruth
Shlipak, Michael
Li, Yongmei
Ix, Joachim
de Boer, Ian H.
Jenny, Nancy
Peralta, Carmen A.
TI Racial differences in the association of pentraxin-3 with kidney
dysfunction: the Multi-Ethnic Study of Atherosclerosis
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE C-reactive protein; estimated glomerular filtration rate by cystatin;
pentraxin-3; race/ethnicity; serum amyloid protein
ID ACUTE MYOCARDIAL-INFARCTION; STAGE RENAL-DISEASE; SERUM CYSTATIN-C;
CARDIOVASCULAR-DISEASE; ELDERLY PERSONS; UNITED-STATES; PTX3;
HYPERTENSION; MORTALITY; ADULTS
AB Background. Pentraxin-3 (PTX3), an inflammatory marker thought to be related to vascular inflammation, is elevated in advanced chronic kidney disease (CKD). Whether PTX3 is associated with mild to moderate kidney dysfunction is unknown.
Methods. We tested associations of proteins in the pentraxin family [PTX3, C-reactive protein (CRP) and serum amyloid protein (SAP)] with estimated glomerular filtration rate by cystatin C (eGFRcys) and microalbuminuria among 2824 participants in the Multi-Ethnic Study of Atherosclerosis. Associations were tested using multivariable linear regression with adjustment for demographics (age, gender, annual income), comorbidities (diabetes, hypertension, smoking, body mass index, low-density lipoprotein, high-density lipoprotein, triglycerides, ACE inhibitor and statin use) and systemic inflammation [interleukin-6 (IL-6)].
Results. Among the 2824 participants, mean age was 62 years and mean eGFRcys was 94 mL/min/1.73 m(2); 25% were white, 25% Chinese, 25% African-American and 25% Hispanic. Among all participants after full adjustment, higher PTX3 was associated with lower eGFRcys independently of IL-6 (beta-3.0 mL/min/1.73 m(2) per unit increase in lnPTX3, P < 0.001). In contrast, CRP and SAP were associated with eGFRcys in demographic adjusted models, but these associations were attenuated after adjustment for comorbidities and IL-6 (lnCRP beta-0.06, P = 0.9; lnSAP beta-0.35, P = 0.7). There was a significant interaction with race/ethnicity (P < 0.001) in the association of PTX3 and eGFRcys. After adjustment for demographics, comorbidities and IL-6, this association was significant in blacks (beta-5.7 mL/min/1.73 m(2) per unit increase in lnPTX3, P = 0.002) but not in Hispanics (beta-2.4, P = 0.1), Chinese (beta-0.91, P = 0.5) or whites (beta-0.26, P = 0.9). PTX3 and CRP, but not SAP, had correlations with microalbuminuria in unadjusted models (Spearman coefficients PTX3 0.05, P = 0.005; CRP 0.07, P < 0.001; SAP 0.013, P = 0.5), but these were attenuated after full adjustment.
Conclusions. Endovascular inflammation may be an important mechanism associated with early kidney dysfunction, particularly among blacks. This mechanism appears to be independent of IL-6-regulated pathways.
C1 [Dubin, Ruth; Shlipak, Michael; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA.
[Shlipak, Michael; Peralta, Carmen A.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA.
[Ix, Joachim] Univ Calif San Diego, San Diego Vet Affairs Healthcare Syst, La Jolla, CA 92093 USA.
[de Boer, Ian H.] Univ Washington, Dept Nephrol, Seattle, WA 98195 USA.
[Jenny, Nancy] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA.
RP Dubin, R (reprint author), Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA.
EM ruth.dubin@ucsf.edu
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169];
NIH, NIDDK [1K23DK082793-01]
FX This research was supported by contracts N01-HC-95159 through
N01-HC-95169 from the National Heart, Lung, and Blood Institute. The
authors thank the other investigators, the staff and the participants of
the MESA study for their valuable contributions. A full list of
participating MESA investigators and institutions can be found at
http://www.mesa-nhlbi.org. C.P. is supported with NIH funding by NIDDK
Grant #1K23DK082793-01.
NR 30
TC 16
Z9 16
U1 3
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD JUN
PY 2011
VL 26
IS 6
BP 1903
EP 1908
DI 10.1093/ndt/gfq648
PG 6
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 786SV
UT WOS:000292329100022
PM 21079193
ER
PT J
AU Day, EC
Li, YM
Diez-Roux, A
Kandula, N
Moran, A
Rosas, S
Shlipak, MG
Peralta, CA
AF Day, Erica Chan
Li, Yongmei
Diez-Roux, Ana
Kandula, Namratha
Moran, Andrew
Rosas, Sylvia
Shlipak, Michael G.
Peralta, Carmen A.
TI Associations of acculturation and kidney dysfunction among Hispanics and
Chinese from the Multi-Ethnic Study of Atherosclerosis (MESA)
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE acculturation; cystatin C; kidney function
ID STAGE RENAL-DISEASE; UNITED-STATES; CYSTATIN-C; RACIAL-DIFFERENCES;
CARDIOVASCULAR EVENTS; SOCIOECONOMIC-STATUS; HEALTH BEHAVIORS;
AFRICAN-AMERICAN; ASIAN-AMERICANS; ELDERLY PERSONS
AB Background. Acculturation affects health, but it has never been studied with kidney disease.
Methods. We studied the association of language spoken at home, generation and birth place with kidney function among Hispanics and Chinese in the Multi-Ethnic Study of Atherosclerosis (n = 2999). Kidney function was determined by cystatin C (eGFRcys) and albumin/creatinine ratio (ACR). We evaluated mediators in models: Model 1 = age, sex, income, education; Model 2 = Model 1 + behaviors; and Model 3 = Model 1 + comorbidities.
Results. Among Hispanics, speaking mixed Spanish/English was significantly associated with lower eGFRcys (-2.83 mL/min/1.73 m(2), -5.69-0.04) and higher ACR (RD 40%, 17-68%) compared with speaking Spanish only; this was mildly attenuated by behaviors (-2.29, -5.33-0.75; RD 42%, 18-72%) but not comorbidities (-3.04, -5.83 to -0.23); RD 35%, 14-59%). US-born Hispanics had lower eGFRcys compared with foreign-born Hispanics [1.83 mL/min/1.73 m(2) lower (0.97-1.31) for Generation 1; 1.37 mL/min/1.73 m(2) lower (0.75-1.57) for Generation >= 2]. In contrast, Chinese who spoke any English had higher eGFRcys (2.53, 95% CI: -1.70-6.78), but similar ACR (RD -5%, 95% CI: -26-23%) compared with those speaking Chinese only, but associations were not statistically significant.
Conclusion. Higher acculturation was associated with worse kidney function in Hispanics, mediated perhaps by behavioral factors but not comorbidities. Associations may be in the opposite direction among Chinese. Future studies are needed to elucidate these mechanisms.
C1 [Day, Erica Chan; Li, Yongmei; Shlipak, Michael G.; Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Diez-Roux, Ana] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
[Kandula, Namratha] Northwestern Univ, Sch Publ Hlth, Chicago, IL 60611 USA.
[Moran, Andrew] Columbia Univ, New York, NY USA.
[Rosas, Sylvia] Univ Penn, Philadelphia, PA 19104 USA.
[Shlipak, Michael G.; Peralta, Carmen A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Day, EC (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.
EM erica.chan@va.gov
RI Rosas, Sylvia/D-1106-2009
FU National Heart, Lung, and Blood Institute [N01-HC-95159]
FX This research was supported by contracts N01-HC-95159 from the National
Heart, Lung, and Blood Institute. The authors thank the other
investigators, the staff and the participants of the MESA study for
their valuable contributions. A full list of participating MESA
investigators and institutions can be found at
http://www.mesa-nhlbi.org.
NR 49
TC 7
Z9 7
U1 3
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD JUN
PY 2011
VL 26
IS 6
BP 1909
EP 1916
DI 10.1093/ndt/gfq676
PG 8
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 786SV
UT WOS:000292329100023
PM 21051500
ER
PT J
AU Lassman, AB
Iwamoto, FM
Cloughesy, TF
Aldape, KD
Rivera, AL
Eichler, AF
Louis, DN
Paleologos, NA
Fisher, BJ
Ashby, LS
Cairncross, JG
Roldan, GB
Wen, PY
Ligon, KL
Schiff, D
Robins, HI
Rocque, BG
Chamberlain, MC
Mason, WP
Weaver, SA
Green, RM
Kamar, FG
Abrey, LE
DeAngelis, LM
Jhanwar, SC
Rosenblum, MK
Panageas, KS
AF Lassman, Andrew B.
Iwamoto, Fabio M.
Cloughesy, Timothy F.
Aldape, Kenneth D.
Rivera, Andreana L.
Eichler, April F.
Louis, David N.
Paleologos, Nina A.
Fisher, Barbara J.
Ashby, Lynn S.
Cairncross, J. Gregory
Roldan, Gloria B.
Wen, Patrick Y.
Ligon, Keith L.
Schiff, David
Robins, H. Ian
Rocque, Brandon G.
Chamberlain, Marc C.
Mason, Warren P.
Weaver, Susan A.
Green, Richard M.
Kamar, Francois G.
Abrey, Lauren E.
DeAngelis, Lisa M.
Jhanwar, Suresh C.
Rosenblum, Marc K.
Panageas, Katherine S.
TI International retrospective study of over 1000 adults with anaplastic
oligodendroglial tumors
SO NEURO-ONCOLOGY
LA English
DT Article
DE oligodendroglioma; oligo-astrocytoma; PCV; temozolomide; 1p19q
ID PHASE-III TRIAL; TERM-FOLLOW-UP; ADJUVANT TEMOZOLOMIDE; EUROPEAN
ORGANIZATION; MALIGNANT GLIOMA; GRADE GLIOMAS; CHEMOTHERAPY;
RADIOTHERAPY; PROCARBAZINE; VINCRISTINE
AB Treatment for newly diagnosed anaplastic oligodendroglial tumors is controversial. Radiotherapy (RT) alone and in combination with chemotherapy (CT) are the most well studied strategies. However, CT alone is often advocated, especially in cases with 1p19q codeletion. We retrospectively identified 1013 adults diagnosed from 1981-2007 treated initially with RT alone (n = 200), CT + RT (n = 528), CT alone (n = 201), or other strategies (n = 84). Median overall survival (OS) was 6.3 years and time to progression (TTP) was 3.1 years. 1p19q codeletion correlated with longer OS and TTP than no 1p or 19q deletion. In codeleted cases, median TTP was longer following CT + RT (7.2 y) than following CT (3.9 y, P = .003) or RT (2.5 y, P < .001) alone but without improved OS; median TTP was longer following treatment with PCV alone than temozolomide alone (7.6 vs. 3.3 y, P = .019). In cases with no deletion, median TTP was longer following CT + RT (3.1 y) than CT (0.9 y, P = .0124) or RT (1.1 y, P < .0001) alone; OS also favored CT + RT (median 5.0 y) over CT (2.2 y, P = .02) or RT (1.9 y, P < .0001) alone. In codeleted cases, CT alone did not appear to shorten OS in comparison with CT + RT, and PCV appeared to offer longer disease control than temozolomide but without a clear survival advantage. Combined CT + RT led to longer disease control and survival than did CT or RT alone in cases with no 1p19q deletion. Ongoing trials will address these issues prospectively.
C1 [Lassman, Andrew B.; Iwamoto, Fabio M.; Abrey, Lauren E.; DeAngelis, Lisa M.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA.
[Jhanwar, Suresh C.; Rosenblum, Marc K.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
[Panageas, Katherine S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol Biostat, New York, NY 10021 USA.
Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, New York, NY 10021 USA.
[Cloughesy, Timothy F.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Aldape, Kenneth D.; Rivera, Andreana L.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
[Eichler, April F.; Louis, David N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Paleologos, Nina A.] Univ Chicago, N Shore Univ HealthSyst, Evanston Hosp, Pritzker Sch Med,Kellogg Canc Ctr, Evanston, IL USA.
[Fisher, Barbara J.] London Reg Canc Program, London, ON, Canada.
[Ashby, Lynn S.] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
[Cairncross, J. Gregory; Roldan, Gloria B.] Univ Calgary, Calgary, AB, Canada.
[Ligon, Keith L.] Brigham & Womens Hosp, Childrens Hosp Boston, Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Schiff, David] Univ Virginia Hlth Syst, Charlottesville, VA USA.
[Robins, H. Ian; Rocque, Brandon G.] Univ Wisconsin, Madison, WI USA.
[Chamberlain, Marc C.] Univ Washington, Seattle, WA 98195 USA.
[Chamberlain, Marc C.] Seattle Canc Care Alliance, Seattle, WA USA.
[Mason, Warren P.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
[Weaver, Susan A.] Albany Med Ctr, Albany, NY USA.
[Green, Richard M.] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA.
[Kamar, Francois G.] Clemenceau Med Ctr, Beirut, Lebanon.
[Kamar, Francois G.] Univ St Esprit Kaslik, Byblos, Lebanon.
RP Lassman, AB (reprint author), Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA.
EM lassmana@mskcc.org
OI kamar , francois/0000-0001-8470-5515
FU National Brain Tumor Society; Susan Smith Klein Brain Tumor Fund; Daniel
E. Rich Fund, Merck Co.; Sigma Tau Pharmaceuticals
FX Funding was provided by the National Brain Tumor Society, Susan Smith
Klein Brain Tumor Fund, Daniel E. Rich Fund, Merck & Co. (formerly
Schering Corp.), and Sigma Tau Pharmaceuticals. Funding sources had no
access to patient data and no role in conceiving or designing the study;
or in data collection, analysis, or interpretation of results.
NR 30
TC 62
Z9 64
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2011
VL 13
IS 6
BP 649
EP 659
DI 10.1093/neuonc/nor040
PG 11
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 781FS
UT WOS:000291916600009
PM 21636710
ER
PT J
AU Wefel, JS
Cloughesy, T
Zazzali, JL
Zheng, MX
Prados, M
Wen, PY
Mikkelsen, T
Schiff, D
Abrey, LE
Yung, WKA
Paleologos, N
Nicholas, MK
Jensen, R
Vredenburgh, J
Das, A
Friedman, HS
AF Wefel, Jeffrey S.
Cloughesy, Timothy
Zazzali, James L.
Zheng, Maoxia
Prados, Michael
Wen, Patrick Y.
Mikkelsen, Tom
Schiff, David
Abrey, Lauren E.
Yung, W. K. Alfred
Paleologos, Nina
Nicholas, Martin K.
Jensen, Randy
Vredenburgh, James
Das, Asha
Friedman, Henry S.
TI Neurocognitive function in patients with recurrent glioblastoma treated
with bevacizumab
SO NEURO-ONCOLOGY
LA English
DT Article
DE bevacizumab; cognitive function; glioblastoma; quality of life
ID HIGH-GRADE GLIOMA; QUALITY-OF-LIFE; COGNITIVE FUNCTION; MALIGNANT
GLIOMA; CLINICAL-TRIALS; NORMATIVE DATA; PHASE-II; PROGRESSION;
CRITERIA; TUMORS
AB Neurocognitive decline is a frequent adverse effect of glioblastoma. Antitumor therapies that are efficacious, as measured by traditional endpoints such as objective response (OR) and progression-free survival (PFS), and have beneficial effects on neurocognitive function (NCF) are of clinical benefit to these patients. We evaluated neurocognitive changes across time in 167 patients with recurrent glioblastoma treated with bevacizumab-based therapy in BRAIN, a phase II, randomized, multicenter trial. All patients underwent MRI and neurocognitive testing at baseline and every 6 weeks thereafter. Memory, visuomotor scanning speed, and executive function were evaluated using the Hopkins Verbal Learning Test Revised, the Trail Making Test, and the Controlled Oral Word Association test, respectively. NCF relative to baseline for patients with an OR, PFS >6 months, or disease progression was evaluated at time of OR, 24 weeks, and time of progression, respectively. For patients with an OR or PFS >6 months, median standardized test scores were examined from baseline to week 24. Most patients with an OR or PFS >6 months had poorer NCF performance compared to the general population at baseline and had improved or stable NCF at the time of response or at the 24-week assessment, respectively; most patients with progressive disease had neurocognitive decline at the time of progression. For patients with an OR or PFS >6 months, median standardized test scores were largely stable across the first 24 weeks on study. Neurocognitive testing was an objective, valid, and feasible method of monitoring NCF in patients with recurrent glioblastoma.
C1 [Wefel, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, Sect Neuropsychol, Dept Neurooncol, Unit 431, Houston, TX 77230 USA.
[Cloughesy, Timothy] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA.
[Zazzali, James L.; Zheng, Maoxia; Das, Asha] Genentech Inc, San Francisco, CA 94080 USA.
[Prados, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA.
[Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA.
[Mikkelsen, Tom] Henry Ford Hosp, Hermelin Brain Tumor Ctr, Detroit, MI 48202 USA.
[Schiff, David] Univ Virginia, Dept Neurol, Charlottesville, VA USA.
[Abrey, Lauren E.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA.
[Paleologos, Nina] NorthShore Univ HealthSyst, Dept Neurol, Evanston, IL USA.
[Nicholas, Martin K.] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA.
[Jensen, Randy] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Vredenburgh, James; Friedman, Henry S.] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC USA.
RP Wefel, JS (reprint author), Univ Texas MD Anderson Canc Ctr, Sect Neuropsychol, Dept Neurooncol, Unit 431, POB 301402, Houston, TX 77230 USA.
EM jwefel@mdanderson.org
FU Genentech, Inc.; Genentech; Roche
FX This work was supported by Genentech, Inc.; Jeffrey S. Wefel has served
as a consultant for Genentech, Roche, and Exelixis and as an advisor for
Genentech. Timothy Cloughesy has served as a consultant for Roche,
Genentech, Exelixis, Merck, and Astra Zeneca. James L. Zazzali is an
employee of Genentech and owns stock in Roche. Maoxia Zheng is an
employee of Genentech and owns stock in Roche. Michael Prados has
provided uncompensated expert FDA testimony on behalf of Genentech.
Patrick Y. Wen has received research support from and has served on an
advisory board for Genentech. Tom Mikkelsen has received honoraria and
speaking fees from Genentech. David Schiff has served on Genentech
advisory boards each of the last 3 years. Lauren E. Abrey has received
honoraria and consulting fees from Genentech and Roche. W.K. Alfred Yung
has had consulting relationships with Novartis and Merck/Schering Plough
and advisory affiliations with Novartis, Eden, and Merck. Nina
Paleologos has served as a speaker for Merck and Genentech and a
consultant for Merck, Genentech, and Eisai. Martin K. Nicholas has
served on an advisory board for Genentech. James Vredenburgh has
received consulting fees, honoraria, and speaker fees from Genentech and
Roche. Asha Das is an employee of Genentech and owns stock in Roche.
Henry S. Friedman has served as a paid consultant and speaker for
Genentech.
NR 32
TC 40
Z9 40
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2011
VL 13
IS 6
BP 660
EP 668
DI 10.1093/neuonc/nor024
PG 9
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 781FS
UT WOS:000291916600010
PM 21558074
ER
PT J
AU Huijbers, W
Pennartz, CMA
Rubin, DC
Daselaar, SM
AF Huijbers, Willem
Pennartz, Cyriel M. A.
Rubin, David C.
Daselaar, Sander M.
TI Imagery and retrieval of auditory and visual information: Neural
correlates of successful and unsuccessful performance
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Episodic memory; Imagery; fMRI; Visual; Auditory
ID EPISODIC MEMORY RETRIEVAL; MEDIAL TEMPORAL-LOBE; EVENT-RELATED FMRI;
RECOGNITION MEMORY; AUTOBIOGRAPHICAL MEMORY; MENTAL-IMAGERY; PREFRONTAL
CORTEX; PARIETAL CORTEX; FUNCTIONAL MRI; COGNITIVE NEUROSCIENCE
AB Remembering past events - or episodic retrieval - consists of several components. There is evidence that mental imagery plays an important role in retrieval and that the brain regions supporting imagery overlap with those supporting retrieval. An open issue is to what extent these regions support successful vs. unsuccessful imagery and retrieval processes. Previous studies that examined regional overlap between imagery and retrieval used uncontrolled memory conditions, such as autobiographical memory tasks, that cannot distinguish between successful and unsuccessful retrieval. A second issue is that fMRI studies that compared imagery and retrieval have used modality-aspecific cues that are likely to activate auditory and visual processing regions simultaneously. Thus, it is not clear to what extent identified brain regions support modality-specific or modality-independent imagery and retrieval processes. In the current fMRI study, we addressed this issue by comparing imagery to retrieval under controlled memory conditions in both auditory and visual modalities. We also obtained subjective measures of imagery quality allowing us to dissociate regions contributing to successful vs. unsuccessful imagery. Results indicated that auditory and visual regions contribute both to imagery and retrieval in a modality-specific fashion. In addition, we identified four sets of brain regions with distinct patterns of activity that contributed to imagery and retrieval in a modality-independent fashion. The first set of regions, including hippocampus, posterior cingulate cortex, medial prefrontal cortex and angular gyrus, showed a pattern common to imagery/retrieval and consistent with successful performance regardless of task. The second set of regions, including dorsal precuneus, anterior cingulate and dorsolateral prefrontal cortex, also showed a pattern common to imagery and retrieval, but consistent with unsuccessful performance during both tasks. Third, left ventrolateral prefrontal cortex showed an interaction between task and performance and was associated with successful imagery but unsuccessful retrieval. Finally, the fourth set of regions, including ventral precuneus, midcingulate cortex and supramarginal gyrus, showed the opposite interaction, supporting unsuccessful imagery, but successful retrieval performance. Results are discussed in relation to reconstructive, attentional, semantic memory, and working memory processes. This is the first study to separate the neural correlates of successful and unsuccessful performance for both imagery and retrieval and for both auditory and visual modalities. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Huijbers, Willem; Pennartz, Cyriel M. A.; Daselaar, Sander M.] Univ Amsterdam, Fac Sci, Swammerdam Inst Life Sci, Amsterdam, Netherlands.
[Huijbers, Willem] Brigham & Womens Hosp, Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA.
[Rubin, David C.; Daselaar, Sander M.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA.
[Rubin, David C.] Aarhus Univ, Ctr Autobiog Memory Res, Aarhus, Denmark.
RP Huijbers, W (reprint author), Univ Amsterdam, Fac Sci, Swammerdam Inst Life Sci, Amsterdam, Netherlands.
EM huijbers@nmr.mgh.harvard.edu
RI daselaar, sander/J-3054-2012; Huijbers, Willem/D-5273-2013
OI daselaar, sander/0000-0003-2995-6877;
FU Amsterdam Brain Imaging Platform (ABIP); Netherlands Organization for
Scientific Research (NWO) [918.46.609]; NWO [916.66.022]
FX The authors sincerely thank the reviewer for providing constructive
comments. Funding: WH. was supported by the Amsterdam Brain Imaging
Platform (ABIP), CMP. by the Netherlands Organization for Scientific
Research (NWO) grant 918.46.609 and SMD. by NWO grant 916.66.022 and
ABIP.
NR 82
TC 46
Z9 47
U1 6
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD JUN
PY 2011
VL 49
IS 7
BP 1730
EP 1740
DI 10.1016/j.neuropsychologia.2011.02.051
PG 11
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 782LA
UT WOS:000292009400010
PM 21396384
ER
PT J
AU Otonari-Yamamoto, M
Nakajima, K
Tsuji, Y
Curtin, HD
Hanyuda, H
Okano, T
Sano, T
AF Otonari-Yamamoto, Mika
Nakajima, Koh
Tsuji, Yuriko
Curtin, Hugh D.
Hanyuda, Hitoshi
Okano, Tomohiro
Sano, Tsukasa
TI Mylohyoid muscle defects: comparison of CT findings and dissected
specimens
SO ORAL RADIOLOGY
LA English
DT Article
DE Mylohyoid muscle; Defect; Sublingual gland; CT
ID SUBLINGUAL GLAND; HERNIATION; BOUTONNIERE
AB To investigate whether CT images reflect the anatomical condition of mylohyoid muscle defects by confirmation with subsequent dissection of cadavers, and to evaluate whether CT images are useful for detecting such defects.
CT scans of the head and upper neck were performed in six cadavers. Multiplanar reconstruction was carried out to obtain 2-mm-thick axial and coronal images of the mylohyoid muscle. The number of defects was determined. All the cadavers were subsequently dissected for comparison with the CT findings. The contents of the defects were also identified.
CT demonstrated the presence of one or more mylohyoid defects in four of the six cadavers. Defects were seen bilaterally in three of the four cadavers. Five of eight defects were observed on both axial and coronal images, whereas two were not observed on coronal images and one was not observed on axial images. The defects contained part of the sublingual gland bilaterally in one cadaver and unilaterally in another. In one cadaver, the submental artery passed through the defect bilaterally. In the other cadaver, there were bilateral defects without any substantial contents.
Our results indicate that mylohyoid defects are commonly seen anatomically, and that some of them show herniation of the sublingual gland. CT images can demonstrate mylohyoid defects on multiplanar reconstructed images.
C1 [Otonari-Yamamoto, Mika; Hanyuda, Hitoshi; Sano, Tsukasa] Tokyo Dent Coll, Dept Oral & Maxillofacial Radiol, Mihama Ku, Chiba 2618502, Japan.
[Nakajima, Koh] Showa Univ, Sch Dent, Dept Oral Anat & Dev Biol, Tokyo 142, Japan.
[Tsuji, Yuriko; Okano, Tomohiro] Showa Univ, Sch Dent, Dept Radiol, Tokyo 142, Japan.
[Curtin, Hugh D.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
RP Otonari-Yamamoto, M (reprint author), Tokyo Dent Coll, Dept Oral & Maxillofacial Radiol, Mihama Ku, 1-2-2 Masago, Chiba 2618502, Japan.
EM myamamoto@tdc.ac.jp
FU [15791077]
FX This work was supported by a Grant-in-Aid for Young Scientists (B)
(15791077).
NR 9
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0911-6028
J9 ORAL RADIOL
JI Oral Radiol.
PD JUN
PY 2011
VL 27
IS 1
BP 50
EP 56
DI 10.1007/s11282-011-0066-9
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 782XN
UT WOS:000292046200008
ER
PT J
AU Osguthorpe, JD
AF Osguthorpe, J. David
TI The Evolution of Understanding Inhalant Allergy
SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Inhalant allergy; Atopy; Immunotherapy; Skin testing; Pharmacotherapy;
Allergen; Immunoglobulin E
ID HOUSE-DUST ALLERGEN; HAY-FEVER; PROPHYLACTIC INOCULATION; OTOLARYNGIC
ALLERGY; POLLEN THERAPY; T-CELLS; IMMUNOTHERAPY; ASTHMA; RHINITIS;
MECHANISMS
AB This article summarizes the developments that led to the current approach to immunotherapy. These developments were characterized in the early years by empirically derived successive approximations to arrive at effective injection regimens, in the middle years by a sorting through of the wide variations in practice with placebo-controlled clinical trials, and more recently by a closer association of clinical and laboratory measures to better define evidence-based practices. The pace of investigation along with the scientific quality continues to increase.
C1 [Osguthorpe, J. David] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
RP Osguthorpe, JD (reprint author), Ralph Johnson Vet Adm Hosp, Surg Serv, 109 Bee St, Charleston, SC 29401 USA.
EM John.Osguthorpe@va.gov
NR 94
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0030-6665
EI 1557-8259
J9 OTOLARYNG CLIN N AM
JI Otolaryngol. Clin. N. Am.
PD JUN
PY 2011
VL 44
IS 3
BP 519
EP +
DI 10.1016/j.otc.2011.03.008
PG 18
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 782KK
UT WOS:000292007200002
PM 21621043
ER
PT J
AU Gordon, BR
AF Gordon, Bruce R.
TI The Allergic March: Can We Prevent Allergies and Asthma?
SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Allergic march; Atopic march; Hygiene hypothesis; Eczema; Asthma;
Probiotics; Chemical pollution; Inhalant allergen immunotherapy
ID PLACEBO-CONTROLLED TRIAL; FOLLOW-UP; ATOPIC-DERMATITIS; SUBLINGUAL
IMMUNOTHERAPY; EARLY-CHILDHOOD; MILK ALLERGY; BIRTH COHORT;
DOUBLE-BLIND; RISK-FACTORS; BREAST-MILK
AB The allergic march is a progression of atopic disease from eczema to asthma, and then to allergic rhinoconjunctivitis. It appears to be caused by a regional allergic response with breakdown of the local epithelial barrier that initiates systemic allergic inflammation. Genetic and environmental factors predispose to developing the allergic march. There are data to support 4 possible interventions to prevent the allergic march from progressing to asthma: (1) supplements of dietary probiotics, (2) exclusive breast feeding during the first few months of life, or, alternatively (3) use of extensively hydrolyzed infant formulas, (4) treatment with inhalant allergen immunotherapy by either subcutaneous or sublingual methods.
C1 [Gordon, Bruce R.] Cape Cod Hosp, Dept Surg, Hyannis, MA 02601 USA.
[Gordon, Bruce R.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Gordon, Bruce R.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Gordon, Bruce R.] Cape Cod ENT, Hyannis, MA 02601 USA.
RP Gordon, BR (reprint author), Cape Cod Hosp, Dept Surg, 27 Pk St, Hyannis, MA 02601 USA.
EM docbruce@comcast.net
NR 64
TC 14
Z9 15
U1 1
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0030-6665
EI 1557-8259
J9 OTOLARYNG CLIN N AM
JI Otolaryngol. Clin. N. Am.
PD JUN
PY 2011
VL 44
IS 3
BP 765
EP +
DI 10.1016/j.otc.2011.03.006
PG 14
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 782KK
UT WOS:000292007200019
PM 21621060
ER
PT J
AU Oldham, RL
Dobscha, SK
Goy, ER
Ganzini, L
AF Oldham, Robert L.
Dobscha, Steven K.
Goy, Elizabeth R.
Ganzini, Linda
TI Attachment styles of Oregonians who request physician-assisted death
SO PALLIATIVE & SUPPORTIVE CARE
LA English
DT Article
DE Physician-assisted death; Terminally ill; Attachment styles; Oregon
Death with Dignity Act
ID ASSOCIATION; SUICIDE; PATIENT; MODEL
AB Objective: Qualitative analyses suggest that requests for physician-assisted death (PAD) may often be the culmination of a person's lifelong pattern of concern with issues such as control, autonomy, self-sufficiency, distrust of others, and avoidance of intimacy. Such characteristics may be measured by attachment style. We compared family members' reports of attachment style in Oregonians who did and did not request PAD.
Method: Eighty-four family members of terminally ill patients who requested PAD before death and 63 members of a comparison group that included family members of terminally ill Oregonians who died without requesting PAD rated their loved ones' attachment style in a one-time survey.
Results: Individuals who requested PAD were most often described as having dismissive personality styles (56%) compared to 41% of comparison individuals, and on continuous measures of relational style, the highest mean score among PAD requesters was for dismissive style. There were marginally significant differences in the proportions of each attachment style when comparing the two groups (p = 0.08).
Significance of results: Patients' attachment styles may be an important factor in requests for PAD. Recognition of a patient's attachment style may improve the ability of the physician to maintain a constructive relationship with the patient throughout the dying process.
C1 [Oldham, Robert L.; Dobscha, Steven K.; Goy, Elizabeth R.; Ganzini, Linda] Dept Vet Affairs, Portland, OR USA.
[Oldham, Robert L.; Dobscha, Steven K.; Goy, Elizabeth R.; Ganzini, Linda] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Ganzini, L (reprint author), Portland VA Med Ctr, Div Mental Hlth, R&D 66,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM linda.ganzini@va.gov
NR 19
TC 4
Z9 4
U1 5
U2 9
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1478-9515
J9 PALLIAT SUPPORT CARE
JI Palliat. Support Care
PD JUN
PY 2011
VL 9
IS 2
BP 123
EP 128
DI 10.1017/S1478951510000660
PG 6
WC Health Policy & Services
SC Health Care Sciences & Services
GA 022WR
UT WOS:000309995400002
PM 24468479
ER
PT J
AU Raffetto, JD
AF Raffetto, J. D.
TI Superficial thrombophlebitis in varicose vein disease: the particular
role of methylenetetrahydrofolate reductase
SO PHLEBOLOGY
LA English
DT Editorial Material
ID VENOUS THROMBOSIS; DEEP VEINS; THROMBOPHILIA
C1 Harvard Univ, Sch Med, Brigham & Womens Hosp, VA Boston Healthcare Syst, Cambridge, MA 02138 USA.
RP Raffetto, JD (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, VA Boston Healthcare Syst, Cambridge, MA 02138 USA.
EM joseph.raffetto@med.ra.gov
NR 9
TC 2
Z9 2
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0268-3555
J9 PHLEBOLOGY
JI Phlebology
PD JUN
PY 2011
VL 26
IS 4
BP 133
EP 134
DI 10.1258/phleb.2011.011e02
PG 2
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 785NM
UT WOS:000292235700001
PM 21690171
ER
PT J
AU Sheikh, A
Khanam, F
Abu Sayeed, M
Rahman, T
Pacek, M
Hu, YH
Rollins, A
Bhuiyan, MS
Rollins, S
Kalsy, A
Arifuzzaman, M
Leung, DT
Sarracino, DA
Krastins, B
Charles, RC
LaRocque, RC
Cravioto, A
Calderwood, SB
Brooks, WA
Harris, JB
LaBaer, J
Qadri, F
Ryan, ET
AF Sheikh, Alaullah
Khanam, Farhana
Abu Sayeed, Md.
Rahman, Taibur
Pacek, Marcin
Hu, Yanhui
Rollins, Andrea
Bhuiyan, Md. Saruar
Rollins, Sean
Kalsy, Anuj
Arifuzzaman, Mohammad
Leung, Daniel T.
Sarracino, David A.
Krastins, Bryan
Charles, Richelle C.
LaRocque, Regina C.
Cravioto, Alejandro
Calderwood, Stephen B.
Brooks, W. Abdullah
Harris, Jason B.
LaBaer, Joshua
Qadri, Firdausi
Ryan, Edward T.
TI Interferon-gamma and Proliferation Responses to Salmonella enterica
Serotype Typhi Proteins in Patients with S. Typhi Bacteremia in Dhaka,
Bangladesh
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID T-CELL RESPONSES; MEDIATED IMMUNE-RESPONSES; COMPLETE GENOME SEQUENCE;
CLASS IB MOLECULES; SEROVAR TYPHI; PROTEOMIC ANALYSIS; ORAL
IMMUNIZATION; VIBRIO-CHOLERAE; VACCINE; INFECTION
AB Background: Salmonella enterica serotype Typhi is a human-restricted intracellular pathogen and the cause of typhoid fever. Cellular immune responses are required to control and clear Salmonella infection. Despite this, there are limited data on cellular immune responses in humans infected with wild type S. Typhi.
Methodology/Principal Findings: For this work, we used an automated approach to purify a subset of S. Typhi proteins identified in previous antibody-based immuno-affinity screens and antigens known to be expressed in vivo, including StaF-putative fimbrial protein-STY0202, StbB-fimbrial chaperone-STY0372, CsgF-involved in curli production-STY1177, CsgD-putative regulatory protein-STY1179, OppA-periplasmic oligopeptide binding protein precursor-STY1304, PagC-outer membrane invasion protein-STY1878, and conserved hypothetical protein-STY2195; we also generated and analyzed a crude membrane preparation of S. Typhi (MP). In comparison to samples collected from uninfected Bangladeshi and North American participants, we detected significant interferon-c responses in PBMCs stimulated with MP, StaF, StbB, CsgF, CsgD, OppA, STY2195, and PagC in patients bacteremic with S. Typhi in Bangladesh. The majority of interferon-c expressing T cells were CD4 cells, although CD8 responses also occurred. We also assessed cellular proliferation responses in bacteremic patients, and confirmed increased responses in infected individuals to MP, StaF, STY2195, and PagC in convalescent compared to acute phase samples and compared to controls. StaF is a fimbrial protein homologous to E. coli YadK, and contains a Pfam motif thought to be involved in cellular adhesion. PagC is expressed in vivo under the control of the virulence-associated PhoP-regulon required for intra-macrophage survival of Salmonella. STY2195 is a conserved hypothetical protein of unknown function.
Conclusion/Significance: This is the first analysis of cellular immune responses to purified S. Typhi antigens in patients with typhoid fever. These results indicate that patients generate significant CD4 and CD8 interferon-c responses to specific S. Typhi antigens during typhoid fever, and that these responses are elevated at the time of clinical presentation. These observations suggest that an interferon-c based detection system could be used to diagnose individuals with typhoid fever during the acute stage of illness.
C1 [Sheikh, Alaullah; Khanam, Farhana; Abu Sayeed, Md.; Rahman, Taibur; Bhuiyan, Md. Saruar; Arifuzzaman, Mohammad; Leung, Daniel T.; Cravioto, Alejandro; Brooks, W. Abdullah; Qadri, Firdausi] ICDDR B, Dhaka, Bangladesh.
[Sheikh, Alaullah; Rollins, Andrea; Bhuiyan, Md. Saruar; Rollins, Sean; Kalsy, Anuj; Arifuzzaman, Mohammad; Leung, Daniel T.; Charles, Richelle C.; LaRocque, Regina C.; Calderwood, Stephen B.; Harris, Jason B.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Pacek, Marcin; Hu, Yanhui; LaBaer, Joshua] Harvard Inst Prote, Cambridge, MA USA.
[Rollins, Sean; Leung, Daniel T.; Charles, Richelle C.; LaRocque, Regina C.; Calderwood, Stephen B.; Ryan, Edward T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Sarracino, David A.; Krastins, Bryan] Thermo Fisher Sci, Cambridge, MA USA.
[Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.
[LaBaer, Joshua] Arizona State Univ, Tempe, AZ USA.
[Ryan, Edward T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Sheikh, A (reprint author), ICDDR B, Dhaka, Bangladesh.
EM alaullah@icddrb.org
OI Rollins, Sean/0000-0002-3724-1989
FU International Centre for Diarrhoeal Disease Research, Bangladesh;
National Institutes of Health; National Institute of Allergy &
Infectious Diseases [AI072599, AI077883, AI058935]; Swedish Sida; Johns
Hopkins Bloomberg School of Public Health; ICDDR, B-US Centers for
Disease Control and Prevention; ICDDR; Fogarty International Center
[TW05572, TW007409, TW07144]; FIC [TW05572]; Harvard Initiative for
Global Health; Howard Hughes Medical Institute
FX This work was supported by the International Centre for Diarrhoeal
Disease Research, Bangladesh (www.icddrb.org) and grants from the
National Institutes of Health, including the National Institute of
Allergy & Infectious Diseases (AI072599 [ETR], AI077883 [ETR], AI058935
[RCC, SBC]); Swedish Sida (FQ); the PneumoADIP Project of the Johns
Hopkins Bloomberg School of Public Health (WAB); a ICDDR, B-US Centers
for Disease Control and Prevention Cooperative Agreement (WAB); ICDDR, B
core funds (FQ, WAB); a Training Grant in Vaccine Development from the
Fogarty International Center (TW05572 [AS, MSB, FQ]); an American
Recovery and Reinvestment Act (ARRA) FIC Post-doctoral Fellowship in
Global Infectious Diseases (TW05572 [RCC, DTL]); Career Development
Awards (K01) from the Fogarty International Center (TW007409 [JBH],
TW07144 [RCL]) and the Harvard Initiative for Global Health
Post-doctoral Fellowship in Global Infectious Diseases (DTL); and a
Physician Scientist Early Career Award from the Howard Hughes Medical
Institute (RCL). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 60
TC 12
Z9 12
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2011
VL 5
IS 6
AR e1193
DI 10.1371/journal.pntd.0001193
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 784EZ
UT WOS:000292139600031
PM 21666798
ER
PT J
AU Haim, H
Strack, B
Kassa, A
Madani, N
Wang, LP
Courter, JR
Princiotto, A
McGee, K
Pacheco, B
Seaman, MS
Smith, AB
Sodroski, J
AF Haim, Hillel
Strack, Bettina
Kassa, Aemro
Madani, Navid
Wang, Liping
Courter, Joel R.
Princiotto, Amy
McGee, Kathleen
Pacheco, Beatriz
Seaman, Michael S.
Smith, Amos B., III
Sodroski, Joseph
TI Contribution of Intrinsic Reactivity of the HIV-1 Envelope Glycoproteins
to CD4-Independent Infection and Global Inhibitor Sensitivity
SO PLOS PATHOGENS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY;
CORECEPTOR-BINDING-SITE; GP120 INNER DOMAIN; NEUTRALIZING ANTIBODIES;
CD4 INDEPENDENCE; CELL-LINE; ATOMIC-STRUCTURE; SOLUBLE CD4; IN-VIVO
AB Human immunodeficiency virus (HIV-1) enters cells following sequential activation of the high-potential-energy viral envelope glycoprotein trimer by target cell CD4 and coreceptor. HIV-1 variants differ in their requirements for CD4; viruses that can infect coreceptor-expressing cells that lack CD4 have been generated in the laboratory. These CD4-independent HIV-1 variants are sensitive to neutralization by multiple antibodies that recognize different envelope glycoprotein epitopes. The mechanisms underlying CD4 independence, global sensitivity to neutralization and the association between them are still unclear. By studying HIV-1 variants that differ in requirements for CD4, we investigated the contribution of CD4 binding to virus entry. CD4 engagement exposes the coreceptor-binding site and increases the "intrinsic reactivity" of the envelope glycoproteins; intrinsic reactivity describes the propensity of the envelope glycoproteins to negotiate transitions to low-erenergy states upon stimulation. Coreceptor-binding site exposure and increased intrinsic reactivity promote formation/exposure of the HR1 coiled coil on the gp41 transmembrane glycoprotein and allow virus entry upon coreceptor binding. Intrinsic reactivity also dictates the global sensitivity of HIV-1 to perturbations such as exposure to cold and the binding of antibodies and small molecules. Accordingly, CD4 independence of HIV-1 was accompanied by increased susceptibility to inactivation by these factors. We investigated the role of intrinsic reactivity in determining the sensitivity of primary HIV-1 isolates to inhibition. Relative to the more common neutralization-resistant ("Tier 2-like") viruses, globally sensitive ("Tier 1") viruses exhibited increased intrinsic reactivity, i.e., were inactivated more efficiently by cold exposure or by a given level of antibody binding to the envelope glycoprotein trimer. Virus sensitivity to neutralization was dictated both by the efficiency of inhibitor/antibody binding to the envelope glycoprotein trimer and by envelope glycoprotein reactivity to the inhibitor/antibody binding event. Quantitative differences in intrinsic reactivity contribute to HIV-1 strain variability in global susceptibility to neutralization and explain the long-observed relationship between increased inhibitor sensitivity and decreased entry requirements for target cell CD4.
C1 [Haim, Hillel; Strack, Bettina; Kassa, Aemro; Madani, Navid; Wang, Liping; Princiotto, Amy; McGee, Kathleen; Pacheco, Beatriz; Sodroski, Joseph] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS,Div AIDS, Boston, MA 02115 USA.
[Courter, Joel R.; Smith, Amos B., III] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
[Seaman, Michael S.] Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA.
[Sodroski, Joseph] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Haim, H (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS,Div AIDS, 44 Binney St, Boston, MA 02115 USA.
EM joseph_sodroski@dfci.harvard.edu
FU NRSA [NIH T32 AI007387]; National Institutes of Health [AI024755,
AI067854]; CFAR [AI060354]; International AIDS Vaccine Initiative;
William F. McCarty-Cooper
FX H.H. was supported by an NRSA Postdoctoral Training Grant in AIDS
Research (NIH T32 AI007387). The National Institutes of Health
(AI024755, AI067854 and CFAR Award AI060354), the International AIDS
Vaccine Initiative and the late William F. McCarty-Cooper supported this
research. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 94
TC 51
Z9 51
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUN
PY 2011
VL 7
IS 6
AR e1002101
DI 10.1371/journal.ppat.1002101
PG 23
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 787MC
UT WOS:000292379600037
PM 21731494
ER
PT J
AU Pukkila-Worley, R
Ausubel, FM
Mylonakis, E
AF Pukkila-Worley, Read
Ausubel, Frederick M.
Mylonakis, Eleftherios
TI Candida albicans Infection of Caenorhabditis elegans Induces Antifungal
Immune Defenses
SO PLOS PATHOGENS
LA English
DT Article
ID GATA TRANSCRIPTION FACTOR; HEAT-SHOCK RESPONSE; INNATE IMMUNITY; C.
ELEGANS; SIGNALING PATHWAY; FUNGAL-INFECTIONS; LIFE-SPAN; SYSTEM; GENES;
RECOGNITION
AB Candida albicans yeast cells are found in the intestine of most humans, yet this opportunist can invade host tissues and cause life-threatening infections in susceptible individuals. To better understand the host factors that underlie susceptibility to candidiasis, we developed a new model to study antifungal innate immunity. We demonstrate that the yeast form of C. albicans establishes an intestinal infection in Caenorhabditis elegans, whereas heat-killed yeast are avirulent. Genome-wide, transcription-profiling analysis of C. elegans infected with C. albicans yeast showed that exposure to C. albicans stimulated a rapid host response involving 313 genes (124 upregulated and 189 downregulated, similar to 1.6% of the genome) many of which encode antimicrobial, secreted or detoxification proteins. Interestingly, the host genes affected by C. albicans exposure overlapped only to a small extent with the distinct transcriptional responses to the pathogenic bacteria Pseudomonas aeruginosa or Staphylococcus aureus, indicating that there is a high degree of immune specificity toward different bacterial species and C. albicans. Furthermore, genes induced by P. aeruginosa and S. aureus were strongly over-represented among the genes downregulated during C. albicans infection, suggesting that in response to fungal pathogens, nematodes selectively repress the transcription of antibacterial immune effectors. A similar phenomenon is well known in the plant immune response, but has not been described previously in metazoans. Finally, 56% of the genes induced by live C. albicans were also upregulated by heat-killed yeast. These data suggest that a large part of the transcriptional response to C. albicans is mediated through "pattern recognition," an ancient immune surveillance mechanism able to detect conserved microbial molecules (so-called pathogen-associated molecular patterns or PAMPs). This study provides new information on the evolution and regulation of the innate immune response to divergent pathogens and demonstrates that nematodes selectively mount specific antifungal defenses at the expense of antibacterial responses.
C1 [Pukkila-Worley, Read; Mylonakis, Eleftherios] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Pukkila-Worley, Read; Ausubel, Frederick M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Pukkila-Worley, Read; Ausubel, Frederick M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
RP Pukkila-Worley, R (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
EM ausubel@molbio.mgh.harvard.edu; emylonakis@partners.org
FU Cancer Research Institute; National Institutes of Health [AI081747,
AI075286, AI079569, AI044220, AI064332]; Astellas Pharamceuticals, Inc.
FX This study was supported by the Irvington Institute Fellowship Program
of the Cancer Research Institute (to RPW) and by the following grants
from the National Institutes of Health: K08 award AI081747 (to RPW), R01
award AI075286 (to EM), R21 award AI079569 (to EM), P01 award AI044220
(to FMA) and R01 award AI064332 (to FMA). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.; RPW has served as a consultant for
Optimer Pharmaceuticals, Inc. EM has received research support from and
served on an advisory board for Astellas Pharamceuticals, Inc. The
authors report no other potential conflicts of interest.
NR 91
TC 46
Z9 46
U1 6
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUN
PY 2011
VL 7
IS 6
AR e1002074
DI 10.1371/journal.ppat.1002074
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 787MC
UT WOS:000292379600012
PM 21731485
ER
PT J
AU Sitia, G
Iannacone, M
Aiolfi, R
Isogawa, M
van Rooijen, N
Scozzesi, C
Bianchi, ME
von Andrian, UH
Chisari, FV
Guidotti, LG
AF Sitia, Giovanni
Iannacone, Matteo
Aiolfi, Roberto
Isogawa, Masanori
van Rooijen, Nico
Scozzesi, Cristina
Bianchi, Marco E.
von Andrian, Ulrich H.
Chisari, Francis V.
Guidotti, Luca G.
TI Kupffer Cells Hasten Resolution of Liver Immunopathology in Mouse Models
of Viral Hepatitis
SO PLOS PATHOGENS
LA English
DT Article
ID CYTOTOXIC T-LYMPHOCYTES; CHROMATIN PROTEIN HMGB1; B-VIRUS-REPLICATION;
TRANSGENIC MICE; IN-VIVO; CHORIOMENINGITIS VIRUS; MURINE MODEL;
MACROPHAGES; INJURY; DEPLETION
AB Kupffer cells (KCs) are widely considered important contributors to liver injury during viral hepatitis due to their proinflammatory activity. Herein we utilized hepatitis B virus (HBV)-replication competent transgenic mice and wild-type mice infected with a hepatotropic adenovirus to demonstrate that KCs do not directly induce hepatocellular injury nor do they affect the pathogenic potential of virus-specific CD8 T cells. Instead, KCs limit the severity of liver immunopathology. Mechanistically, our results are most compatible with the hypothesis that KCs contain liver immunopathology by removing apoptotic hepatocytes in a manner largely dependent on scavenger receptors. Apoptotic hepatocytes not readily removed by KCs become secondarily necrotic and release high-mobility group box 1 (HMGB-1) protein, promoting organ infiltration by inflammatory cells, particularly neutrophils. Overall, these results indicate that KCs resolve rather than worsen liver immunopathology.
C1 [Sitia, Giovanni; Iannacone, Matteo; Aiolfi, Roberto; Guidotti, Luca G.] Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, I-20132 Milan, Italy.
[Iannacone, Matteo; von Andrian, Ulrich H.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
[Iannacone, Matteo; von Andrian, Ulrich H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Isogawa, Masanori; Chisari, Francis V.; Guidotti, Luca G.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
[van Rooijen, Nico] Free Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, Amsterdam, Netherlands.
[Scozzesi, Cristina] DiaPro Diagnost Bioprobes, Milan, Italy.
[Bianchi, Marco E.] Univ Vita Salute San Raffaele, Milan, Italy.
[Bianchi, Marco E.] Ist Sci San Raffaele, Div Genet & Cell Biol, I-20132 Milan, Italy.
RP Sitia, G (reprint author), Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, I-20132 Milan, Italy.
EM sitia.giovanni@hsr.it; iannacone.matteo@hsr.it; guidotti@scripps.edu
RI Chisari, Francis/A-3086-2008; von Andrian, Ulrich/A-5775-2008; Sitia,
Giovanni/K-1036-2016;
OI Sitia, Giovanni/0000-0003-1024-9128; Guidotti, Luca
G./0000-0002-0205-2678; Chisari, Francis/0000-0002-4832-1044; Iannacone,
Matteo/0000-0002-9370-2671; Bianchi, Marco Emilio/0000-0002-5329-6445
FU NIH [R01-AI40696, R01-AI20001, R01-CA40489, R01-AI079060]; Italian
Association for Cancer Research (AIRC) [4643, 6278]; European Research
Council (ERC) [250219]; Istituto Superiore di Sanita' (Italy) [50G.36];
Ministero della Salute (Italy) [GR08.17]; European Community
[MC-IRG-2010-268129]; Giovanni-Armenise Harvard Foundation
FX This work was supported by grants: R01-AI40696 (LGG), R01-AI20001 and
R01-CA40489 (FVC), and R01-AI079060 (M. Isogawa) from the NIH; 4643 and
6278 (LGG) from the Italian Association for Cancer Research (AIRC);
250219 (LGG) from the European Research Council (ERC); 50G.36 (GS) from
the Istituto Superiore di Sanita' (Italy); GR08.17 (GS) from Ministero
della Salute (Italy); MC-IRG-2010-268129 (M. Iannacone) from the 7th
European Community Framework Programme and a grant from the
Giovanni-Armenise Harvard Foundation (M. Iannacone). The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 60
TC 41
Z9 43
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUN
PY 2011
VL 7
IS 6
AR e1002061
DI 10.1371/journal.ppat.1002061
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 787MC
UT WOS:000292379600003
PM 21655107
ER
PT J
AU Collinger, JL
Dicianno, BE
Weber, DJ
Cui, XT
Wang, W
Brienza, DM
Boninger, ML
AF Collinger, Jennifer L.
Dicianno, Brad E.
Weber, Douglas J.
Cui, Xinyan Tracy
Wang, Wei
Brienza, David M.
Boninger, Michael L.
TI Integrating Rehabilitation Engineering Technology With Biologics
SO PM&R
LA English
DT Article
ID FUNCTIONAL ELECTRICAL-STIMULATION; SPINAL-CORD-INJURY; NEURAL
STEM-CELLS; ACUTE INFLAMMATORY RESPONSE; COMMON PERONEAL NERVE; MOTOR
CORTICAL REPRESENTATION; SILICON MICROELECTRODE ARRAYS; REDUCED
MATHEMATICAL-MODEL; FAST-TWITCH MUSCLE; CEREBRAL-CORTEX
AB Rehabilitation engineers apply engineering principles to improve function or to solve challenges faced by persons with disabilities. It is critical to integrate the knowledge of biologics into the process of rehabilitation engineering to advance the field and maximize potential benefits to patients. Some applications in particular demonstrate the value of a symbiotic relationship between biologics and rehabilitation engineering. In this review we illustrate how researchers working with neural interfaces and integrated prosthetics, assistive technology, and biologics data collection are currently integrating these 2 fields. We also discuss the potential for further integration of biologics and rehabilitation engineering to deliver the best technologies and treatments to patients. Engineers and clinicians must work together to develop technologies that meet clinical needs and are accessible to the intended patient population. PM 122011;3:S148-S157
C1 [Collinger, Jennifer L.; Dicianno, Brad E.; Weber, Douglas J.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Pittsburgh, PA 15206 USA.
[Collinger, Jennifer L.; Dicianno, Brad E.; Weber, Douglas J.; Wang, Wei; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA.
[Dicianno, Brad E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Dicianno, Brad E.; Brienza, David M.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA.
[Weber, Douglas J.; Cui, Xinyan Tracy; Wang, Wei; Brienza, David M.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
RP Collinger, JL (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, 6425 Penn Ave,4th Floor, Pittsburgh, PA 15206 USA.
EM collingr@pitt.edu
FU Office of Research and Development, Rehabilitation Research &
Development Service, Department of Veterans Affairs [B6789C]; National
Institute on Disability and Rehabilitation Research Rehabilitation
Engineering Research Center on Spinal Cord Injury [H133E070024];
National Institute on Disability and Rehabilitation Research Model
Center on Spinal Cord Injury [H133N060019]
FX This study was supported by the Office of Research and Development,
Rehabilitation Research & Development Service, Department of Veterans
Affairs, grant No. B6789C; the National Institute on Disability and
Rehabilitation Research Rehabilitation Engineering Research Center on
Spinal Cord Injury, grant No. H133E070024; and the National Institute on
Disability and Rehabilitation Research Model Center on Spinal Cord
Injury, grant No. H133N060019. The contents of this article do not
represent the views of the Department of Veterans Affairs or the United
States government.
NR 118
TC 1
Z9 1
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD JUN
PY 2011
VL 3
IS 6
SU S
BP S148
EP S157
DI 10.1016/j.pmrj.2011.03.011
PG 10
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 961BB
UT WOS:000305437800024
PM 21703573
ER
PT J
AU Ko, DN
Perez-Cruz, P
Blinderman, CD
AF Ko, Danielle N.
Perez-Cruz, Pedro
Blinderman, Craig D.
TI Ethical Issues in Palliative Care
SO PRIMARY CARE
LA English
DT Article
DE Palliative care; Ethics; End of life; Autonomy; Palliative sedation
ID ILL HOSPITALIZED-PATIENTS; OF-LIFE CARE; ADVANCE DIRECTIVES;
DECISION-MAKING; PAIN MANAGEMENT; TERMINAL SEDATION; CANCER-PATIENTS;
INTENSIVE-CARE; END; DEATH
AB Ethical problems in medicine are common, especially when caring for patients at the end of life. However, many of these issues are not adequately identified in the outpatient setting. Primary care providers are in a unique and privileged position to identify ethical issues, prevent future conflicts, and help patients make medical decisions that are consistent with their individual values and preferences. This article describes some of the more common ethical issues faced by primary care physicians caring for patients with life-limiting illness.
C1 [Blinderman, Craig D.] Columbia Univ, Dept Anesthesiol, New York, NY 10032 USA.
[Ko, Danielle N.; Perez-Cruz, Pedro] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
[Ko, Danielle N.; Perez-Cruz, Pedro] Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA.
[Ko, Danielle N.] Harvard Univ, Sch Med, Div Med Eth, Boston, MA 02115 USA.
[Perez-Cruz, Pedro] Catholic Univ, Sch Med, Dept Internal Med, Santiago, Chile.
RP Blinderman, CD (reprint author), Columbia Univ, Dept Anesthesiol, 622 W 168th St,PH5-530B, New York, NY 10032 USA.
EM cdb21@columbia.edu
NR 65
TC 2
Z9 2
U1 4
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0095-4543
EI 1558-299X
J9 PRIMARY CARE
JI Primary Care
PD JUN
PY 2011
VL 38
IS 2
BP 183
EP +
DI 10.1016/j.pop.2011.03.003
PG 12
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 782KI
UT WOS:000292006900005
PM 21628034
ER
PT J
AU Lee, KB
Murray, SS
Taghavi, CE
Song, KJ
Brochmann, EJ
Johnson, JS
Keorochana, G
Liao, JC
Wang, JC
AF Lee, Kwang-Bok
Murray, Samuel S.
Taghavi, Cyrus E.
Song, Kyung-Jin
Brochmann, Elsa J.
Johnson, Jared S.
Keorochana, Gun
Liao, Jen-Chung
Wang, Jeffrey C.
TI Bone morphogenetic protein-binding peptide reduces the inflammatory
response to recombinant human bone morphogenetic protein-2 and
recombinant human bone morphogenetic protein-7 in a rodent model of
soft-tissue inflammation
SO SPINE JOURNAL
LA English
DT Article
DE Soft-tissue edema; rhBMP-7; rhBMP-2; BMP-binding peptide; MIPAV
ID ANTERIOR CERVICAL-SPINE; SAFETY PROFILE; FUSION; RHBMP-2; SURGERY;
CARRIER; MATRIX; BMP-2; RATS
AB BACKGROUND CONTEXT: Bone morphogenetic protein (BMP)-2 and BMP-7 are used to enhance bone formation in spine surgery, but the use of these materials is associated with side effects including inflammation, especially in the soft tissues of the neck. Bone morphogenetic protein-binding peptide (BBP) binds BMP-2 and BMP-7 and imparts a "slow-release" property to collagen carrier.
PURPOSE: To test the hypothesis that the addition of BBP will reduce the soft-tissue inflammation induced by the implantation of BMP-2 and BMP-7 on a collagen sponge.
STUDY DESIGN/SETTING: Prospective in vivo rodent model of inflammation.
METHODS: We implanted six different materials absorbed onto collagen sponges: absorbable collagen sponge (ACS) alone; BBP alone; recombinant human bone morphogenetic protein (rhBMP)-2 alone; rhBMP-2 plus BBP; rhBMP-7 alone; and rhBMP-7 plus BBP. Sponges were implanted bilaterally (subcutaneously [SC] and intramuscularly [IM]) into the backs of rats. Using magnetic resonance imaging, inflammation was assessed in terms of soft-tissue edema volume at 3 hours and at 2, 4, and 7 days. The animal subjects were killed on Day 7, and the dimensions of the inflammatory mass were measured manually in the case of SC tissue and those of the inflammatory zone were determined subsequently by microscopic examination in the case of muscle.
RESULTS: Both the SC and the IM soft-tissue edema volumes in the rhBMP-2 plus BBP and the rhBMP-7 plus BBP groups were significantly lower than those observed in the rhBMP-2 alone and rhBMP-7 alone groups. The edema volume associated with BBP alone was greater than that associated with ACS alone but less than that associated with the other treatment groups. The measurements of inflammatory masses and zone yielded similar results.
CONCLUSIONS: Bone morphogenetic protein-binding peptide may reduce the inflammatory response associated with the use of rhBMP-2 and rhBMP-7 in a rodent model of inflammation and in a form that has previously been shown to enhance the activity of BMPs. These preliminary studies suggest that BBP may have the potential to be used in the future to improve healing and reduce soft-tissue swelling in surgical applications of BMPs. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Lee, Kwang-Bok; Taghavi, Cyrus E.; Johnson, Jared S.; Keorochana, Gun; Liao, Jen-Chung; Wang, Jeffrey C.] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA 90404 USA.
[Lee, Kwang-Bok; Song, Kyung-Jin] Chonbuk Natl Univ, Sch Med, Chonbuk Natl Univ Hosp, Dept Orthopaed Surg,Res Inst Clin Med, Jeonju 561712, South Korea.
[Murray, Samuel S.; Brochmann, Elsa J.] VA Greater Los Angeles Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Sepulveda, CA 90073 USA.
[Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA.
[Murray, Samuel S.; Wang, Jeffrey C.] Univ Calif Los Angeles, Biomed Engn Interdept Program, Los Angeles, CA 90095 USA.
[Keorochana, Gun] Mahidol Univ, Ramathibodi Hosp, Dept Orthopaed, Bangkok 10400, Thailand.
[Liao, Jen-Chung] Chang Gung Univ, Chang Gung Mem Hosp, Dept Orthopaed, Tao Yuan 333, Taiwan.
RP Wang, JC (reprint author), Univ Calif Los Angeles, Dept Orthopaed Surg, Comprehens Spine Ctr, 1250 16th St,7th Floor Tower,745, Santa Monica, CA 90404 USA.
EM jwang@mednet.ucla.edu
FU UCLA; Lanx; IsoTis [01/2010]; Medtronics; Department of Veterans Affairs
FX K-BL: Nothing to disclose. SSM: Royalties: UCLA (A); Consulting: Lanx
(E, paid directly to institution/employer); Research Support (Staff
and/or Materials): Lanx (E, paid directly to institution/employer);
Grants: Lanx (E, paid directly to institution/employer); Other: IsoTis
(Nonfinancial); Relationships Outside the One-Year Requirement: IsoTis
(01/2010, sponsored research, F). CET: Nothing to disclose. K-JS:
Nothing to disclose. EJB: Disclosure unavailable. JSJ: Nothing to
disclose. GK: Nothing to disclose. J-CL: Nothing to disclose. JCW:
Royalties: Medtronics (D), Stryker (C), Seaspine (E), Osprey (C),
Aesculap (C), Biomet (F), Amedica (C), Zimmer (D), Alphatech (F); Stock
Ownership: Fziomed (2,500 Shares, < 1% of entity); Private Investments:
Promethean Spine (B, < 1% of entity), Paradigm spine (B, < 1% of
entity), Benevenue (C, < 1% of entity), NexGen (B, < 1% of entity), K2
medical (B, < 1% of entity), Pioneer (B, < 1% of entity), Amedica (D, <
1% of entity), Vertiflex (B, < 1% of entity), Electrocore (C, < 1% of
entity), Surgitech (C, < 1% of entity), Invuity (10,000 Shares, < 1% of
entity), Axiomed (25,000 Shares, < 1% of entity); Board of Directors:
North American Spine Society (Nonfinancial), Cervical Spine Research
Society (Nonfinancial); Scientific Advisory Board: VG Innovations (5,000
options, < 1% of entity), Corespine (2,000 options, < 1% of entity),
Expanding Orthopaedics (33,000, < 1% of entity), Syndicom (66,125
shares, < 1% of entity), Osprey (10 options, < 1% of entity), Amedica
(35,416 options, < 1% of entity), Bone Biologics (51,255 shares, < 1% of
entity), Curative Biosciences (1,875 options, < 1% of entity), Facet
Solutions (35,000 options, < 1% of entity), PearlDiver (25,000 options,
< 1% of entity), Pioneer (3,636 options, < 1% of entity), Seaspine (11
options, < 1% of entity), Axis (Nonfinancial).; This work was supported,
in part, by the Department of Veterans Affairs.
NR 30
TC 23
Z9 23
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1529-9430
EI 1878-1632
J9 SPINE J
JI Spine Journal
PD JUN
PY 2011
VL 11
IS 6
BP 568
EP 576
DI 10.1016/j.spinee.2011.02.001
PG 9
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 786PJ
UT WOS:000292320100020
PM 21729805
ER
PT J
AU Ruggiero, KJ
Gros, DF
McCauley, J
de Arellano, MA
Danielson, CK
AF Ruggiero, Kenneth J.
Gros, Daniel F.
McCauley, Jenna
de Arellano, Michael A.
Danielson, Carla Kmett
TI Rural Adults' Use of Health-Related Information Online: Data from a 2006
National Online Health Survey
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE rural; Internet; health information
ID URBAN DIFFERENCES; DIGITAL DIVIDE; MENTAL-HEALTH; INTERNET; CARE;
ACCESS; COMMUNICATION; CHALLENGES; PROGRAM; TRIAL
AB Objective: The objective of this study was to examine access and use of health-related information online in rural versus nonrural Internet users, using national data from the 2006 Pew Internet and American Life Project. Materials and Methods: A national telephone survey of 2,928 adults in August 2006 yielded a sample of 1,992 adults who use the Internet regularly. A structured interview was administered to assess frequency of Internet use and access and use of health-related information online. Results: Most Internet-using rural adults search for health-related information online; two-thirds seek information about specific medical problems and over half seek information about treatment. Three-fifths of rural adults surveyed stated that online health-related information affected the decisions they made in health maintenance and managing treatment of an illness. More than one-third reported being significantly helped by information they found, whereas one-fourth reported being confused. Comparisons between rural and nonrural Internet users suggested that rural users were more likely to seek information about smoking cessation (chi(2) [1, N = 1,990] = 7.91, p < 0.01) and mental health issues (chi(2) [1, N = 1,988] = 3.71, p = 0.05), less likely to seek information about a particular doctor or hospital (chi(2) [1, N = 1,983] = 15.49, p < 0.001), and more likely to report being helped (chi(2) [1, N = 1,534] = 5.24, p < 0.05)-but also confused (chi(2) [1, N = 1,592] = 9.83, p < 0.01)-by information they found. Conclusions: Rural Americans are increasingly using the Internet to acquire information about chronic disease, mental health, doctors, and treatment options. Priorities should include further development and rigorous evaluation of online resources to ensure high-quality, more direct tailoring of resources to rural families and development of tools to assist consumers in assessing the credibility of online information.
C1 [Ruggiero, Kenneth J.; Gros, Daniel F.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
[Ruggiero, Kenneth J.; Gros, Daniel F.; McCauley, Jenna; de Arellano, Michael A.; Danielson, Carla Kmett] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
RP Ruggiero, KJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA.
EM ruggierk@musc.edu
FU VA HSRD Grant [MHI 08-105-2]; NIMH [R34 MH77149, R01 MH81056, P60
MH082598, T32 MH018869, R21 MH086313]; NIDA [K23 DA018686]
FX K.J. Ruggiero is a core investigator of VA HSR&D REAP (REA 08261; PI:
Egede) and is supported by VA HSR&D Grant MHI 08-105-2 and NIMH Grants
R34 MH77149 (PI: Ruggiero), R01 MH81056 (PI: Ruggiero), and P60 MH082598
(PI: Norris). Dr. J. McCauley is supported by NIMH Grant T32 MH018869.
Dr. C.K. Danielson is supported by NIDA K23 DA018686 and NIMH R21
MH086313 (PI: C.K. Danielson). The authors thank Wendy Muzzy of the
Medical University of South Carolina and Susannah Fox of the Pew
Internet and American Life Project for their valuable assistance.
NR 38
TC 9
Z9 9
U1 1
U2 12
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD JUN
PY 2011
VL 17
IS 5
BP 329
EP 334
DI 10.1089/tmj.2010.0195
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 784ZX
UT WOS:000292198300004
PM 21524201
ER
PT J
AU Knapp, H
Chan, K
Anaya, HD
Goetz, MB
AF Knapp, Herschel
Chan, Kee
Anaya, Henry D.
Goetz, Matthew B.
TI Interactive Internet-Based Clinical Education: An Efficient and
Cost-Savings Approach to Point-of-Care Test Training
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE HIV; online; Internet; in-service; education; cost savings; distance
learning
ID EMERGENCY-DEPARTMENT; HIV; RECOMMENDATIONS; BARRIERS; DISEASE; WOMEN;
RISK
AB Background: We successfully created and implemented an effective HIV rapid testing training and certification curriculum using traditional in-person trainings at multiple sites within the U. S. Department of Veterans Affairs (VA) Healthcare System. Objective: Considering the multitude of geographically remote facilities in the nationwide VA system, coupled with the expansion of HIV diagnostics, we developed an alternate training method that is affordable, efficient, and effective. Methods: Using materials initially developed for in-person HIV rapid test in-services, we used a distance learning model to offer this training via live audiovisual online technology to educate clinicians at a remote outpatient primary care VA facility. Results: Participants' evaluation metrics showed that this form of remote education is equivalent to in-person training; additionally, HIV testing rates increased considerably in the months following this intervention. Although there is a one-time setup cost associated with this remote training protocol, there is potential cost savings associated with the point-of-care nurse manager's time productivity by using the Internet in-service learning module for teaching HIV rapid testing. If additional in-service training modules are developed into Internet-based format, there is the potential for additional cost savings. Our cost analysis demonstrates that the remote in-service method provides a more affordable and efficient alternative compared with in-person training. Conclusions: The online in-service provided training that was equivalent to in-person sessions based on first-hand supervisor observation, participant satisfaction surveys, and follow-up results. This method saves time and money, requires fewer personnel, and affords access to expert trainers regardless of geographic location. Further, it is generalizable to trainings beyond HIV rapid testing. Based on these consistent implementation successes, we plan to expand use of online training to include remote VA satellite facilities spanning several states for a variety of diagnostic devices. Ultimately, Internet-based training has the potential to provide "big city'' quality of care to patients at remote (rural) clinics.
C1 [Knapp, Herschel; Chan, Kee; Anaya, Henry D.; Goetz, Matthew B.] VA Greater Los Angeles Hlth Serv Res, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90073 USA.
[Knapp, Herschel; Chan, Kee; Anaya, Henry D.; Goetz, Matthew B.] VA Greater Los Angeles Healthcare Syst, Dev Ctr Excellence, Los Angeles, CA 90073 USA.
[Chan, Kee] Edith Nurse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Chan, Kee] Boston Univ, Dept Hlth Sci, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA.
[Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA.
[Goetz, Matthew B.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Dept Med, Los Angeles, CA USA.
RP Knapp, H (reprint author), VA Greater Los Angeles Hlth Serv Res, Ctr Study Healthcare Provider Behav, 11301 Wilshire Blvd,M-C 111-G, Los Angeles, CA 90073 USA.
EM herschel.knapp@va.gov
OI Goetz, Matthew/0000-0003-4542-992X
NR 17
TC 5
Z9 6
U1 1
U2 9
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD JUN
PY 2011
VL 17
IS 5
BP 335
EP 340
DI 10.1089/tmj.2010.0187
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 784ZX
UT WOS:000292198300005
PM 21492031
ER
PT J
AU Morishita, M
Ono, N
Miyai, K
Nakagawa, T
Hanyu, R
Nagao, M
Kamolratanakul, P
Notomi, T
Rittling, SR
Denhardt, DT
Kronenberg, HM
Ezura, Y
Hayata, T
Nakamoto, T
Noda, M
AF Morishita, Maki
Ono, Noriaki
Miyai, Kentano
Nakagawa, Tomomi
Hanyu, Ryo
Nagao, Masashi
Kamolratanakul, Paksinee
Notomi, Takuya
Rittling, Susan R.
Denhardt, David T.
Kronenberg, Henry M.
Ezura, Yoichi
Hayata, Tadayoshi
Nakamoto, Tetsuya
Noda, Masaki
TI Osteopontin deficiency enhances parathyroid hormone/parathyroid hormone
related peptide receptor (PPR) signaling-induced alteration in tooth
formation and odontoblastic morphology
SO TISSUE & CELL
LA English
DT Article
DE Osteopontin; Parathyroid hormone; Receptor; Signaling; Tooth formation;
Odontoblast
AB Parathyroid hormone/parathyroid hormone-related protein receptor (PPR) signaling is known to be involved in tooth development. In bone, extracellular matrix protein osteopontin (OPN) is a negative regulator of PPR signaling in bone formation. However, the role of OPN in modulation of PPR action in tooth development is not understood. Therefore, we examined the tooth in double mutant mice. Constitutively active PPR was expressed specifically in the odontoblasts and osteoblasts (caPPR-tg) in the presence or absence of OPN. Radiographic analysis indicated that the length of the third molar (M3) and the incisor was decreased in the caPPR-tg mice compared to wild type, and such reduction in molar and incisor length was further enhanced in the absence of OPN (caPPR-tg OPN-KO). With respect to histology of incisors, caPPR-tg induced high cellularity and irregularity in odontoblastic shape and this was enhanced by the absence of OPN. These morphological observations suggest that OPN modulates PPR signaling that are involved in tooth formation. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Morishita, Maki; Ono, Noriaki; Miyai, Kentano; Nakagawa, Tomomi; Hanyu, Ryo; Nagao, Masashi; Kamolratanakul, Paksinee; Notomi, Takuya; Ezura, Yoichi; Hayata, Tadayoshi; Nakamoto, Tetsuya; Noda, Masaki] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Bunkyo Ku, Tokyo 1138510, Japan.
[Rittling, Susan R.] Forsyth Inst, Boston, MA 02115 USA.
[Denhardt, David T.] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08701 USA.
[Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Kronenberg, Henry M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Nakamoto, Tetsuya; Noda, Masaki] Tokyo Med & Dent Univ, Global Ctr Excellence Program Mol Sci Tooth & Bon, Tokyo 1138510, Japan.
RP Noda, M (reprint author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, 1-5-45 Yushima, Tokyo 1138510, Japan.
EM noda.mph@mri.tmd.ac.jp
RI Ezura, Yoichi/L-9485-2016
FU Japanese Ministry of Education (Global Center of Excellent (GCOE)
program, 21st Century Center of Excellence (COE)) [17012008, 18109011,
18659438, 18123456, 20013014]; Japan Space forum; NASDA; ABJS (Advanced
Bone and Joint Science) Strategic Research Networks Projects; Japan
Society for Promotion of Science Core to Core Program; Research for the
Future Program, Genome Science
FX This work was supported by the grants-in-aid from the Japanese Ministry
of Education (Global Center of Excellent (GCOE) program, 21st Century
Center of Excellence (COE), 17012008, 18109011, 18659438, 18123456,
20013014), grants from Japan Space forum, NASDA, and ABJS (Advanced Bone
and Joint Science) Strategic Research Networks Projects, in Japan
Society for Promotion of Science Core to Core Program, Research for the
Future Program, Genome Science.
NR 20
TC 3
Z9 3
U1 0
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0040-8166
J9 TISSUE CELL
JI Tissue Cell
PD JUN
PY 2011
VL 43
IS 3
BP 196
EP 200
DI 10.1016/j.tice.2011.02.003
PG 5
WC Anatomy & Morphology; Cell Biology
SC Anatomy & Morphology; Cell Biology
GA V29HB
UT WOS:000208738400008
PM 21511320
ER
PT J
AU Zhou, LB
Pomerantseva, I
Bassett, EK
Bowley, CM
Zhao, X
Bichara, DA
Kulig, KM
Vacanti, JP
Randolph, MA
Sundback, CA
AF Zhou, Libin
Pomerantseva, Irina
Bassett, Erik K.
Bowley, Chris M.
Zhao, Xing
Bichara, David A.
Kulig, Katherine M.
Vacanti, Joseph P.
Randolph, Mark A.
Sundback, Cathryn A.
TI Engineering Ear Constructs with a Composite Scaffold to Maintain
Dimensions
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID IN-VITRO; SHAPED CARTILAGE; TISSUE; COLLAGEN; CHONDROCYTES; IMPLANTS;
MODEL; TRANSPLANTATION; RECONSTRUCTION; REGENERATION
AB Engineered cartilage composed of a patient's own cells can become a feasible option for auricular reconstruction. However, distortion and shrinkage of ear-shaped constructs during scaffold degradation and neocartilage maturation in vivo have hindered the field. Scaffolds made of synthetic polymers often generate degradation products that cause an inflammatory reaction and negatively affect neocartilage formation in vivo. Porous collagen, a natural material, is a promising candidate; however, it cannot withstand the contractile forces exerted by skin and surrounding tissue during normal wound healing. We hypothesised that a permanent support in the form of a coiled wire embedded into a porous collagen scaffold will maintain the construct's size and ear-specific shape. Half-sized human adult ear-shaped fibrous collagen scaffolds with and without embedded coiled titanium wire were seeded with sheep auricular chondrocytes, cultured in vitro for up to 2 weeks, and implanted subcutaneously on the backs of nude mice. After 6 weeks, the dimensional changes in all implants with wire support were minimal (2.0% in length and 4.1% in width), whereas significant reduction in size occurred in the constructs without embedded wire (14.4% in length and 16.5% in width). No gross distortion occurred over the in vivo study period. There were no adverse effects on neocartilage formation from the embedded wire. Histologically, mature neocartilage extracellular matrix was observed throughout all implants. The amount of DNA, glycosaminoglycan, and hydroxyproline in the engineered cartilage were similar to that of native sheep ear cartilage. The embedded wire support was essential for avoiding shrinkage of the ear-shaped porous collagen constructs.
C1 [Zhou, Libin; Pomerantseva, Irina; Bassett, Erik K.; Kulig, Katherine M.; Vacanti, Joseph P.; Sundback, Cathryn A.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Zhou, Libin; Pomerantseva, Irina; Bassett, Erik K.; Kulig, Katherine M.; Vacanti, Joseph P.; Sundback, Cathryn A.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA.
[Zhou, Libin] Fourth Mil Med Univ, Dept Oral & Maxillofacial Surg, Sch Stomatol, Xian, Shaanxi, Peoples R China.
[Pomerantseva, Irina; Zhao, Xing; Bichara, David A.; Vacanti, Joseph P.; Randolph, Mark A.; Sundback, Cathryn A.] Harvard Univ, Sch Med, Boston, MA USA.
[Bowley, Chris M.] Kensey Nash Corp, Exton, PA USA.
[Zhao, Xing; Bichara, David A.; Randolph, Mark A.] Massachusetts Gen Hosp, Plast Surg Res Labs, Boston, MA 02114 USA.
RP Vacanti, JP (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,Warren 1151, Boston, MA 02114 USA.
EM jvacanti@partners.org
FU Armed Forces Institute of Regenerative Medicine [W81XWH-08-2-0034]; U.S.
Army Medical Research; China Scholarship Council
FX This research was sponsored by the Armed Forces Institute of
Regenerative Medicine award number W81XWH-08-2-0034. The U.S. Army
Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick
MD 21702-5014, is the awarding and administering acquisition office. The
content of the article does not necessarily reflect the position or the
policy of the Government, and no official endorsement should be
inferred. Dr. Libin Zhou was sponsored by China Scholarship Council for
his study in Massachusetts General Hospital.
NR 35
TC 35
Z9 36
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD JUN
PY 2011
VL 17
IS 11-12
BP 1573
EP 1581
DI 10.1089/ten.tea.2010.0627
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA 773WQ
UT WOS:000291342600011
PM 21284558
ER
PT J
AU Berendsen, TA
Izamis, ML
Xu, H
Liu, Q
Hertl, M
Berthiaume, F
Yarmush, ML
Uygun, K
AF Berendsen, T. A.
Izamis, M. L.
Xu, H.
Liu, Q.
Hertl, M.
Berthiaume, F.
Yarmush, M. L.
Uygun, K.
TI Hepatocyte Viability and Adenosine Triphosphate Content Decrease
Linearly Over Time During Conventional Cold Storage of Rat Liver Grafts
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID OF-WISCONSIN SOLUTION; TRANSPLANTATION MODEL; DONOR CRITERIA; PERFUSION;
PRESERVATION; INJURY; ARTERIALIZATION; REPERFUSION; FAILURE; FLUSH
AB Introduction. The gold standard in organ preservation is static cold storage (SCS) using University of Wisconsin solution (UW). Although it is well-known that there is a finite limit to SCS preservation, and that there is a correlation between the adenosine triphosphate (ATP) levels and organ function post-preservation, a quantitative relationship has not been established, which is important in understanding the fundamental limitations to preservation, minimizing cold ischemic injury, and hence maximizing use of the donor organ pool.
Aim. This study determines the time limits of cellular viability and metabolic function during SCS, and characterizes the relationship between cellular viability and energetic state using clinically relevant techniques in organ preservation.
Methods. Rat livers were procured and stored using conventional storage in UW solution at 4 degrees C. Viability was assessed by determining the amount of viable hepatocytes and intracellular ATP content after 0, 24, 48, 72, and 120 hours of storage.
Results. Numbers of viable hepatocytes that were isolated from these livers decreased steadily during SCS. After 5 days, viable hepatocytes decreased from 25.95 X 10(6) to 0.87 x 10(6) cells/gram tissue. Intracellular ATP content decreased from 9.63 to 0.93 moles/g tissue. Statistical analysis of variance established a linear relation for both parameters as a function of time (P < .05).
Conclusion. The linear correlation between hepatocyte viability, ATP content, and storage time suggests a shared physiological foundation. These findings confirm ATP as direct predictor for organ quality in the context of liver preservation, which will aid quantitative assessment of donor organs for various applications.
C1 [Berendsen, T. A.; Izamis, M. L.; Xu, H.; Liu, Q.; Berthiaume, F.; Yarmush, M. L.; Uygun, K.] Harvard Univ, Sch Med, Ctr Engn Med, Shriners Hosp Children, Boston, MA 02114 USA.
[Berendsen, T. A.; Izamis, M. L.; Xu, H.; Liu, Q.; Berthiaume, F.; Yarmush, M. L.; Uygun, K.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Berthiaume, F.; Yarmush, M. L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA.
[Hertl, M.] Massachusetts Gen Hosp, Transplantat Unit, Boston, MA 02114 USA.
RP Uygun, K (reprint author), Harvard Univ, Sch Med, Ctr Engn Med, Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA.
EM uygun.korkut@mgh.harvard.edu
RI Liu, Qiang/M-5922-2013
FU Professor Michael-van Vloten Foundation; National Institutes of Health
[R01 DK59766, R01 EB 008678, R00 DK080942]; Shriners Hospitals for
Children
FX Tim Berendsen was funded by the Professor Michael-van Vloten Foundation,
National Institutes of Health (R01 DK59766, R01 EB 008678, R00
DK080942), Shriners Hospitals for Children.
NR 25
TC 18
Z9 18
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2011
VL 43
IS 5
BP 1484
EP 1488
DI 10.1016/j.transproceed.2010.12.066
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 786CI
UT WOS:000292279800019
PM 21693222
ER
PT J
AU Vaidya, S
Dighe, M
Bhargava, P
Dick, AA
AF Vaidya, S.
Dighe, M.
Bhargava, P.
Dick, A. A.
TI Chronic Hepatic Artery Occlusion with Collateral Formation: Imaging
Findings and Outcomes
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID LIVER-TRANSPLANTATION; PSEUDOSTRING SIGN; VASA VASORUM; THROMBOSIS;
DOPPLER
AB Objective. The imaging findings, clinical presentation, and outcome in post liver transplantation patients with hepatic arterial collaterals are reviewed.
Materials and Methods. Adult post orthotopic liver transplantation patients who underwent an angiography at our institution for suspected hepatic arterial abnormality during an approximately 10-year period were included in our study. A retrospective review of all cases that had hepatic arterial collaterals detected on angiography was then performed. Angiographic findings were correlated with the findings on ultrasound and other imaging studies. Liver function at the time of angiography was recorded. Clinical outcomes were reviewed.
Results. Of the 129 angiographies performed in the approximately 10-year period, 24 (19.4%) were found to have collaterals on angiography. Maximum size of the collaterals seen on angiography was 3 mm. Twenty patients (83%) with collaterals are currently alive. Twelve patients (50%) had a normal outcome and did not develop any complications on follow-up; however, the rest developed complications. Eleven patients (41.7%) had complication related to the liver ischemia and 2 patients (8.3%) developed malignancy (posttransplant lymphoproliferative disease).
Conclusion. Collaterals seen in patients with chronic hepatic artery occlusion are usually small in caliber and their significance is unclear. Recognition and understanding of this phenomenon is important as this subset of patients may not need urgent surgical re-exploration/vascular intervention.
C1 [Vaidya, S.; Dighe, M.; Bhargava, P.] Univ Washington, Dept Radiol, Med Ctr, Seattle, WA 98195 USA.
[Bhargava, P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Dick, A. A.] Univ Washington, Dept Surg, Div Transplant Surg, Med Ctr, Seattle, WA 98195 USA.
RP Dighe, M (reprint author), Univ Washington, Dept Radiol, Med Ctr, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA.
EM dighe@uw.edu
OI Bhargava, Puneet/0000-0002-3849-9666
NR 10
TC 8
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2011
VL 43
IS 5
BP 1770
EP 1776
DI 10.1016/j.transproceed.2011.03.034
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 786CI
UT WOS:000292279800073
PM 21693276
ER
PT J
AU Cooperberg, MR
AF Cooperberg, Matthew R.
TI Bone Scan Overuse in Staging of Prostate Cancer: An Analysis of a
Veterans Affairs Cohort EDITORIAL COMMENT
SO UROLOGY
LA English
DT Editorial Material
ID CONTEMPORARY TRENDS; UPDATE
C1 [Cooperberg, Matthew R.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Cooperberg, Matthew R.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Cooperberg, MR (reprint author), UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
EI 1527-9995
J9 UROLOGY
JI Urology
PD JUN
PY 2011
VL 77
IS 6
BP 1336
EP 1337
DI 10.1016/j.urology.2011.02.010
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 769VX
UT WOS:000291047500021
PM 21624594
ER
PT J
AU Lustgarten, MS
Jang, YC
Liu, YH
Qi, WB
Qin, YJ
Dahia, PL
Shi, Y
Bhattacharya, A
Muller, FL
Shimizu, T
Shirasawa, T
Richardson, A
Van Remmen, H
AF Lustgarten, Michael S.
Jang, Youngmok C.
Liu, Yuhong
Qi, Wenbo
Qin, Yuejuan
Dahia, Patricia L.
Shi, Yun
Bhattacharya, Arunabh
Muller, Florian L.
Shimizu, Takahiko
Shirasawa, Takuji
Richardson, Arlan
Van Remmen, Holly
TI MnSOD deficiency results in elevated oxidative stress and decreased
mitochondrial function but does not lead to muscle atrophy during aging
SO AGING CELL
LA English
DT Article
DE age-related muscle atrophy; oxidative stress; mitochondrial function
ID BODY-COMPOSITION ANALYSIS; HUMAN SKELETAL-MUSCLE;
SUCCINATE-DEHYDROGENASE; SUPEROXIDE-DISMUTASE; ACONITASE ACTIVITY;
ESCHERICHIA-COLI; MAMMALIAN-CELLS; MOUSE HINDLIMB; COMPLEX I; MICE
AB P>In a previous study, we reported that a deficiency in MnSOD activity (approximately 80% reduction) targeted to type IIB skeletal muscle fibers was sufficient to elevate oxidative stress and to reduce muscle function in young adult mice (TnIFastCreSod2fl/fl mice). In this study, we used TnIFastCreSod2fl/fl mice to examine the effect of elevated oxidative stress on mitochondrial function and to test the hypothesis that elevated oxidative stress and decreased mitochondrial function over the lifespan of the TnIFastCreSod2fl/fl mice would be sufficient to accelerate muscle atrophy associated with aging. We found that mitochondrial function is reduced in both young and old TnIFastCreSod2fl/fl mice, when compared with control mice. Complex II activity is reduced by 47% in young and by approximately 90% in old TnIFastCreSod2fl/fl mice, and was found to be associated with reduced levels of the catalytic subunits for complex II, SDHA and SDHB. Complex II-linked mitochondrial respiration is reduced by approximately 70% in young TnIFastCreSod2fl/fl mice. Complex II-linked mitochondrial Adenosine-Tri-Phosphate (ATP) production is reduced by 39% in young and was found to be almost completely absent in old TnIFastCreSod2fl/fl mice. Furthermore, in old TnIFastCreSod2fl/fl mice, aconitase activity is almost completely abolished; mitochondrial superoxide release remains > 2-fold elevated; and oxidative damage (measured as F(2)- isoprostanes) is increased by 30% relative to age-matched controls. These data show that despite elevated skeletal muscle-specific mitochondrial oxidative stress, oxidative damage, and complex II-linked mitochondrial dysfunction, age-related muscle atrophy was not accelerated in old TnIFastCreSod2fl/fl mice, suggesting mitochondrial oxidative stress may not be causal for age-related muscle atrophy.
C1 [Lustgarten, Michael S.; Jang, Youngmok C.; Qi, Wenbo; Bhattacharya, Arunabh; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Lustgarten, Michael S.; Shi, Yun] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Jang, Youngmok C.; Liu, Yuhong; Bhattacharya, Arunabh; Muller, Florian L.; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Qin, Yuejuan; Dahia, Patricia L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Hematol & Med Oncol, San Antonio, TX 78229 USA.
[Shimizu, Takahiko; Shirasawa, Takuji] Tokyo Metropolitan Inst Gerontol, Res Team Mol Biomarkers, Tokyo, Japan.
[Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM vanremmen@uthscsa.edu
FU NIH [P01AG020591]; VA Merit grant; NIA [5T3-AG021890-02]
FX We thank Corinne Price for editing the manuscript. This work was funded
by NIH grant P01AG020591, a VA Merit grant (HVR), and NIA Training Grant
5T3-AG021890-02.
NR 54
TC 30
Z9 31
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1474-9718
J9 AGING CELL
JI Aging Cell
PD JUN
PY 2011
VL 10
IS 3
BP 493
EP 505
DI 10.1111/j.1474-9726.2011.00695.x
PG 13
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 763CR
UT WOS:000290531900013
PM 21385310
ER
PT J
AU Qu, WC
Stineman, MG
Streim, JE
Xie, DW
AF Qu, Wenchun
Stineman, Margaret G.
Streim, Joel E.
Xie, Dawei
TI Understanding the Linkages Between Perceived Causative Impairment and
Activity Limitations Among Older People Living in the Community A
Population-Based Assessment
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Activities of Daily Living; Brain Disease; Aging; Classification; ICF
ID HOME CARE; DISABILITY; REHABILITATION; OUTCOMES; SYSTEM; COSTS
AB Qu W, Stineman MG, Streim JE, Xie D: Understanding the linkages between perceived causative impairment and activity limitations among older people living in the community: a population-based assessment. Am J Phys Med Rehabil 2011;90:466-476.
Objective: The aim of this study was to better understand the linkages between impairment and activity limitation among groups of elderly community-living persons.
Design: This study used a United States population-based complex survey with weights used to make accurate population prevalence estimates from the 1994 National Health Interview Survey on Disability. Included were 2429 persons 70 yrs or older with one or more activity of daily living or instrumental activity of daily living-only activity limitations. Limitations were addressed according to the impairment(s) perceived to be causing them.
Results: Musculoskeletal impairments accounted for more than one-third of all perceived causes. The odds of having any activity of daily living limitations for persons whose limitations were attributed to musculoskeletal impairments and to brain or behavioral impairments were 2.12 times (95% confidence interval, 1.63-2.76) and 3.00 times (95% confidence interval, 2.23-4.03) the odds for the reference group of cardiopulmonary and hematology impairment.
Conclusions: Although musculoskeletal impairments were the most common cause of activity limitation, impairments associated with brain or behavioral disturbance were perceived as most disabling.
C1 [Qu, Wenchun; Stineman, Margaret G.] Univ Penn, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.
[Stineman, Margaret G.; Xie, Dawei] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Streim, Joel E.] Univ Penn, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA.
[Qu, Wenchun] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA.
[Streim, Joel E.] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Philadelphia, PA USA.
RP Stineman, MG (reprint author), 101 Ralston Penn Ctr,3615 Chestnut St, Philadelphia, PA 19104 USA.
FU National Institute of Aging of the National Institutes of Health
[AG032420-01A1]; Ruth L. Kirschstein National Research Service Award
[(T32) 5-T32-HD-007425]
FX Supported by the National Institute of Aging of the National Institutes
of Health (AG032420-01A1) and by the Ruth L. Kirschstein National
Research Service Award Institutional Research Training grant (T32)
5-T32-HD-007425 (supported W.Q. while at the University of
Pennsylvania).
NR 34
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD JUN
PY 2011
VL 90
IS 6
BP 466
EP 476
DI 10.1097/PHM.0b013e318214ec02
PG 11
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 761WV
UT WOS:000290433200004
PM 21430511
ER
PT J
AU Lue, A
Chernev, I
Yan, K
AF Lue, Aurora
Chernev, Ivan
Yan, Kun
TI Extra-Articular Osteochondromatosis
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Editorial Material
C1 [Lue, Aurora] Tufts Med Ctr, Dept Rehabil Med, Boston, MA 02111 USA.
[Chernev, Ivan] Boston Univ, Med Ctr, Dept Rehabil Med, Boston, MA USA.
[Yan, Kun] Vet Hlth Adm, Boston Healthcare Syst, Dept Phys Med & Rehabil, Boston, MA USA.
RP Lue, A (reprint author), Tufts Med Ctr, Dept Rehabil Med, 800 Washington St, Boston, MA 02111 USA.
NR 3
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD JUN
PY 2011
VL 90
IS 6
BP 519
EP 519
DI 10.1097/PHM.0b013e3181c5663d
PG 1
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 761WV
UT WOS:000290433200009
PM 20531163
ER
PT J
AU Laury, AR
Perets, R
Piao, HY
Krane, JF
Barletta, JA
French, C
Chirieac, LR
Lis, R
Loda, M
Hornick, JL
Drapkin, R
Hirsch, MS
AF Laury, Anna R.
Perets, Ruth
Piao, Huiying
Krane, Jeffrey F.
Barletta, Justine A.
French, Christopher
Chirieac, Lucian R.
Lis, Rosina
Loda, Massimo
Hornick, Jason L.
Drapkin, Ronny
Hirsch, Michelle S.
TI A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE PAX8; immunohistochemistry; carcinoma; Mullerian; renal; thyroid;
ovarian; thymus
ID RENAL-CELL CARCINOMA; PAIRED BOX GENE; THYROID DYSGENESIS; SEROUS
CARCINOMAS; OVARIAN-CARCINOMA; FALLOPIAN-TUBE; CANCER; MARKER;
DIFFERENTIATION; ADENOCARCINOMA
AB PAX8 is a paired-box gene important in embryogenesis of the thyroid, Mullerian, and renal/upper urinary tracts, and expression of PAX8 has been previously described in carcinomas from each of these sites. However, a large study including a wide variety of epithelial neoplasms from multiple organ sites other than the thyroid, kidney, or Mullerian system has not been performed. The goal of this study was to evaluate the utility of PAX8 immunostaining based on the evaluation of a wide range of epithelial tumors. PAX8 immunohistochemistry was performed on 1357 tumors (486 tumors in whole-tissue sections and 871 tumors in tissue microarrays, predominantly epithelial) from multiple organs. Only nuclear staining was scored as positive, and tumors were evaluated for the extent and intensity of staining. Western blot analysis with PAX8 was also performed on multiple tumor cell lines. Nuclear PAX8 staining was present in 91% (60 of 66) of thyroid tumors, 90% (158 of 176) of renal cell carcinomas (RCCs), 81% (13 of 16) of renal oncocytomas, 99% (164 of 165) of high-grade ovarian serous carcinomas, 71% (32 of 49) of nonserous ovarian epithelial neoplasms, 91% (10 of 11) of cervical epithelial lesions, and 98% (152 of 155) of endometrial adenocarcinomas. Of the remaining 719 evaluated tumors, only 30 cases (4%), including 12 thymic neoplasms, 3 bladder urothelial carcinomas, 4 lung squamous cell carcinomas, 2 esophageal adenocarcinomas, 1 pancreatic adenocarcinoma, 2 cholangiocarcinomas, 1 ovarian Sertoli-Leydig cell tumor, 1 ovarian sex cord stromal tumor, 3 testicular mixed germ cell tumors, and 1 acinic cell carcinoma, showed at least weak or focal PAX8 positivity. The unexpected finding was diffuse, moderate staining of PAX8 in a subset of thymomas and thymic carcinomas. The 689 remaining tumors, including but not limited to those from the prostate, colon, stomach, liver, adrenal gland, and head and neck, and small cell carcinomas from the lung, cervix, and ovary, were PAX8 negative. PAX8 specificity was confirmed by Western blot analysis, as expression was detected only in ovarian and RCC cell lines. These results show that PAX8 is a highly sensitive marker for thyroid, renal, Mullerian, and thymic tumors. Importantly, all lung adenocarcinomas, breast and adrenal neoplasms, and the majority of gastrointestinal tumors were negative for PAX8. Therefore, PAX8 is an excellent marker for confirming primary tumor site. In a subset of cases, additional markers, including but not limited to thyroid transcription factor-1, RCC, and Wilms tumor-1, may be needed to distinguish between the 3 most common PAX8-positive tumors.
C1 [Laury, Anna R.; Krane, Jeffrey F.; Barletta, Justine A.; French, Christopher; Chirieac, Lucian R.; Loda, Massimo; Hornick, Jason L.; Drapkin, Ronny; Hirsch, Michelle S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Hirsch, Michelle S.] Brigham & Womens Hosp, Womens & Perinatal Pathol Div, Dept Pathol, Boston, MA 02115 USA.
[Perets, Ruth; Piao, Huiying; Lis, Rosina; Loda, Massimo; Drapkin, Ronny] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, Boston, MA 02115 USA.
[Laury, Anna R.; Krane, Jeffrey F.; Barletta, Justine A.; French, Christopher; Chirieac, Lucian R.; Loda, Massimo; Hornick, Jason L.; Drapkin, Ronny; Hirsch, Michelle S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Hirsch, MS (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Amory 3, Boston, MA 02115 USA.
EM mhirsch1@partners.org
RI Drapkin, Ronny/E-9944-2016
OI Drapkin, Ronny/0000-0002-6912-6977
FU Harvard Medical School Center of Excellence in Women's Health; Dana
Farber Cancer Institute; Ovarian Cancer Research Fund
FX Supported in part by a Harvard Medical School Center of Excellence in
Women's Health Grant (MSH), a Dana Farber Cancer Institute Friends Award
(MSH), and by the Ann Schreiber Program of Excellence Grant from the
Ovarian Cancer Research Fund (RP).
NR 46
TC 137
Z9 140
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD JUN
PY 2011
VL 35
IS 6
BP 816
EP 826
DI 10.1097/PAS.0b013e318216c112
PG 11
WC Pathology; Surgery
SC Pathology; Surgery
GA 763NW
UT WOS:000290567400005
PM 21552115
ER
PT J
AU King, ER
Tung, CS
Tsang, YTM
Zu, ZF
Lok, GTM
Deavers, MT
Malpica, A
Wolf, JK
Lu, KH
Birrer, MJ
Mok, SC
Gershenson, DM
Wong, KK
AF King, Erin R.
Tung, Celestine S.
Tsang, Yvonne T. M.
Zu, Zhifei
Lok, Gabriel T. M.
Deavers, Michael T.
Malpica, Anais
Wolf, Judith K.
Lu, Karen H.
Birrer, Michael J.
Mok, Samuel C.
Gershenson, David M.
Wong, Kwong-Kwok
TI The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With
Differentiation and Survival in Ovarian Cancer
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE AGR3; BCMP11; ovarian cancer; biomarker; cilia
ID PRIMARY CILIARY DYSKINESIA; GRADE SEROUS CARCINOMA; BORDERLINE TUMORS;
2-TIER SYSTEM; EXPRESSION; SPERM; PATHOGENESIS; COMPONENT
AB Low-grade (LG) serous ovarian carcinoma is believed to arise from serous borderline ovarian tumors; yet the progression from serous borderline tumors to LG serous ovarian carcinoma remains poorly understood. The purpose of this study was to identify differentially expressed genes between the 2 groups. Expression profiles were generated from 6 human ovarian surface epithelia, 8 serous borderline ovarian tumors (SBOTs), 13 LG serous ovarian carcinomas, and 24 high-grade (HG) serous ovarian carcinomas. The anterior gradient homolog 3 (AGR3) gene was found to be highly upregulated in serous borderline ovarian tumors. This finding was validated by real-time quantitative reverse-transcription polymerase chain reaction, Western blotting, and immunohistochemistry. Anti-AGR3 immunohistochemistry was performed on an additional 56 LG and 103 HG tissues, and the results were correlated with clinical data. Expression profiling determined that 1254 genes were differentially expressed (P < 0.005) among SBOT, LG, and HG tumors. SBOTs exhibited robust positive staining for AGR3, with a lower percentage of tumor cells stained in LG and HG. Immunofluorescence staining indicated that AGR3 expression was limited to ciliated cells. Tumor samples with a high percentage (> 10%) of AGR3 positively stained tumor cells were associated with improved longer median survival in both the LG (P = 0.013) and HG (P = 0.008) serous ovarian carcinoma groups. The progression of SBOT to LG serous ovarian carcinoma may involve the dedifferentiation of ciliated cells. AGR3 could serve as a prognostic marker for survival in patients with LG and HG serous ovarian carcinomas.
C1 [Wong, Kwong-Kwok] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1362, Houston, TX 77030 USA.
[Deavers, Michael T.; Malpica, Anais] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
[Birrer, Michael J.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
RP Wong, KK (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1362, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM kkwong@mdanderson.org
OI Wong, Kwong-Kwok/0000-0002-0375-6669
FU National Institutes of Health; University of Texas MD Anderson Cancer
Center [P50 CA08369, R01CA133057, RC4CA156551]; MD Anderson's Cancer
Center [CA016672]; Hera Foundation; Entertainment Industry Foundation;
Marsha Rivkin Center; Blanton-Davis Ovarian Cancer Research Program;
NCI-DHHS-NIH [T32 CA101642]; CUHK
FX The authors declare that neither pharmaceutical nor industry support was
provided for this work. Funding for this project was received from the
National Institutes of Health, including The University of Texas MD
Anderson Cancer Center Specialized Program of Research Excellence in
Ovarian Cancer (P50 CA08369), grant R01CA133057, grant RC4CA156551, and
MD Anderson's Cancer Center Support Grant (CA016672); the Hera
Foundation; the Entertainment Industry Foundation; Marsha Rivkin Center;
and the Blanton-Davis Ovarian Cancer Research Program. Authors ERK and
CST are supported by NCI-DHHS-NIH T32 Training Grant (T32 CA101642).
GTML is partly supported by the Molecular Biology Program, CUHK.
NR 30
TC 26
Z9 27
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD JUN
PY 2011
VL 35
IS 6
BP 904
EP 912
DI 10.1097/PAS.0b013e318212ae22
PG 9
WC Pathology; Surgery
SC Pathology; Surgery
GA 763NW
UT WOS:000290567400017
PM 21451362
ER
PT J
AU Mullins, RJ
Camargo, CA
AF Mullins, R. J.
Camargo, C. A., Jr.
TI Shining a light on vitamin D and its impact on the developing immune
system
SO CLINICAL AND EXPERIMENTAL ALLERGY
LA English
DT Editorial Material
ID 25-HYDROXYVITAMIN D; D INSUFFICIENCY; PREGNANCY; CHILDHOOD; BIRTH;
SUPPLEMENTATION; COHORT; ASTHMA; RISK; AGE
AB Cite this as: R. J. Mullins and C. A. Camargo Jr, Clinical & Experimental Allergy, 2011 (41) 766-768.
C1 [Mullins, R. J.] John James Med Ctr, Deakin, ACT 2600, Australia.
[Mullins, R. J.] Australian Natl Univ, Sch Med, Canberra, ACT, Australia.
[Mullins, R. J.] Univ Canberra, Fac Hlth, Canberra, ACT 2601, Australia.
[Camargo, C. A., Jr.] Harvard Univ, Sch Med, Div Rheumatol Allergy & Immunol, Dept Emergency Med, Boston, MA USA.
[Camargo, C. A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
RP Mullins, RJ (reprint author), John James Med Ctr, Suite 1,175 Strickland Crescent, Deakin, ACT 2600, Australia.
EM rmullins@allergycapital.com.au
OI Mullins, Raymond/0000-0002-0267-1591
NR 22
TC 12
Z9 12
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-7894
EI 1365-2222
J9 CLIN EXP ALLERGY
JI Clin. Exp. Allergy
PD JUN
PY 2011
VL 41
IS 6
BP 766
EP 768
DI 10.1111/j.1365-2222.2011.03742.x
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA 762OR
UT WOS:000290489800002
PM 21561491
ER
PT J
AU Liu, XH
AF Liu, Xuhui
TI Emerging Ideas: Matrix Metalloproteinase-2 in Muscle Atrophy
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID SKELETAL-MUSCLE; HINDLIMB IMMOBILIZATION; EXPRESSION; RECOVERY; RATS
AB Muscle atrophy impacts almost every patient seen for orthopaedic conditions. Unfortunately, no effective treatment is available to date. Matrix metalloproteinases (MMPs), especially MMP-2, are involved in skeletal muscle atrophy. MMP-2 null mice reportedly have substantially reduced muscle atrophy after tendon transection compared with wild-type mice, suggesting MMP-2 plays an important role in muscle atrophy. Although the exact mechanisms remain unknown, a newly-discovered intracellular form of MMP-2 suggests a possible novel mechanism of MMP-2 digesting muscle matrix during muscle atrophy. I propose a new pharmacologic treatment for muscle atrophy using selective MMP-2 inhibitors.
I hypothesize: (1) intracellular MMP-2 plays an important role during muscle atrophy by digesting intramuscular matrix; (2) AP-1 and NFAT signal transduction pathways are responsible for expression and activation of the intracellular MMP-2 during muscle atrophy; and (3) specific MMP-2 inhibitors can serve as a novel pharmacologic strategy in treating disuse-induced muscle atrophy.
Expression and activity of extracellular and intracellular MMP-2 will be determined in a mouse tendon transection model. The role of AP-1 and NFAT signal transduction pathways in MMP-2 transcriptional regulation in muscle atrophy will be determined using chromatin-immunoprecipitation (ChIP) and small interfering RNA (siRNA). I also will test the feasibility of treating muscle atrophy using selective MMP-2 inhibitors.
Understanding the signaling transduction pathway of extracellular and intracellular MMP-2 expression during muscle atrophy may lead to novel treatments for muscle atrophy that preserve the normal physiologic function of MMP-2.
C1 [Liu, Xuhui] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94121 USA.
[Liu, Xuhui] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Liu, XH (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 4150 Clement St,Bldg 2,Room 639, San Francisco, CA 94121 USA.
EM liux@orthosurg.ucsf.edu
FU Orthopaedic Research & Education Foundation; Illinois Bone and Joint
Institute
FX I thank the ORS Grant Writing Workshop for the education provided. I
appreciate my mentors, Drs Hubert T. Kim and David H. Lovett (SFVAMC and
UCSF), for their intensive mentorship. I also thank the Orthopaedic
Research & Education Foundation and the Illinois Bone and Joint
Institute for research support.
NR 10
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD JUN
PY 2011
VL 469
IS 6
BP 1797
EP 1799
DI 10.1007/s11999-010-1726-5
PG 3
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 763PE
UT WOS:000290571400040
PM 21132408
ER
PT J
AU Dohlman, CH
Cade, F
Pfister, R
AF Dohlman, Claes H.
Cade, Fabiano
Pfister, Roswell
TI Chemical Burns to the Eye: Paradigm Shifts in Treatment
SO CORNEA
LA English
DT Editorial Material
ID ALKALI BURNS; TRANSPLANTATION
C1 [Dohlman, Claes H.; Cade, Fabiano] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
[Pfister, Roswell] Eye Res Fdn, Birmingham, AL USA.
RP Dohlman, CH (reprint author), Massachusetts Eye & Eye Infirm, 243 Charles St, Boston, MA 02114 USA.
EM claes_dohlman@meei.harvard.edu
NR 16
TC 9
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3740
J9 CORNEA
JI Cornea
PD JUN
PY 2011
VL 30
IS 6
BP 613
EP 614
DI 10.1097/ICO.0b013e3182012a4f
PG 2
WC Ophthalmology
SC Ophthalmology
GA 762KM
UT WOS:000290475700001
PM 21242777
ER
PT J
AU Yager, PH
Lok, J
Klig, JE
AF Yager, Phoebe H.
Lok, Josephine
Klig, Jean E.
TI Advances in simulation for pediatric critical care and emergency
medicine
SO CURRENT OPINION IN PEDIATRICS
LA English
DT Review
DE high-fidelity simulation; pediatric mock code; resuscitation; simulation
ID MEDICATION ERROR; PERFORMANCE; IMPACT
AB Purpose of review
Routine integration of simulation into healthcare education and practice has gained momentum. Simulation is particularly important to acute and critical care pediatrics, as it offers alternative methods of training for high-risk and/or lower-frequency events in children. This review will discuss the recent advances in simulation education for pediatric critical care and emergency medicine and assess its potential for future growth through these subspecialties.
Recent findings
Research indicates that simulation with a high-fidelity manikin is more realistic than with a simple manikin. Multievent simulation centers, on-site suites and mobile units for in-situ training offer a variety of venues for training. High-fidelity simulation is now used to identify performance gaps, enhance educational curricula and assess core competencies. A landmark study demonstrated improvement in outcomes from in-hospital pediatric cardiopulmonary arrest following the introduction of a pediatric simulation-based mock code program.
Summary
High-fidelity simulation is emerging as a powerful tool for pediatric emergency medicine and critical care education through both individual and team-based training exercises. Programs can be tailored to meet specific institutional needs and budget limitations. As pediatric simulation-based programs evolve, further progress is anticipated in acute and critical care outcomes.
C1 [Yager, Phoebe H.; Lok, Josephine] Massachusetts Gen Hosp Children, Div Pediat Crit Care Med, Boston, MA USA.
[Yager, Phoebe H.; Lok, Josephine; Klig, Jean E.] Harvard Univ, Sch Med, Boston, MA USA.
[Klig, Jean E.] Massachusetts Gen Hosp Children, Div Pediat Emergency Med, Boston, MA USA.
RP Yager, PH (reprint author), Massachusetts Gen Hosp, 175 Cambridge St,CPZS 5, Boston, MA 02114 USA.
EM pyager@partners.org
NR 26
TC 14
Z9 14
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8703
J9 CURR OPIN PEDIATR
JI CURR. OPIN. PEDIATR.
PD JUN
PY 2011
VL 23
IS 3
BP 293
EP 297
DI 10.1097/MOP.0b013e3283464aaf
PG 5
WC Pediatrics
SC Pediatrics
GA 763LH
UT WOS:000290557600006
PM 21494148
ER
PT J
AU Tan, Y
Yamada-Mabuchi, M
Arya, R
St Pierre, S
Tang, W
Tosa, M
Brachmann, C
White, K
AF Tan, Ying
Yamada-Mabuchi, Megumu
Arya, Richa
St Pierre, Susan
Tang, Wei
Tosa, Marie
Brachmann, Carrie
White, Kristin
TI Coordinated expression of cell death genes regulates neuroblast
apoptosis
SO DEVELOPMENT
LA English
DT Article
DE Neuroblast; Drosophila; Apoptosis
ID DROSOPHILA-MELANOGASTER; NERVOUS-SYSTEM; REAPER; PROTEIN; GRIM; HID;
GENOME; METAMORPHOSIS; ACTIVATOR; LINEAGES
AB Properly regulated apoptosis in the developing central nervous system is crucial for normal morphogenesis and homeostasis. In Drosophila, a subset of neural stem cells, or neuroblasts, undergo apoptosis during embryogenesis. Of the 30 neuroblasts initially present in each abdominal hemisegment of the embryonic ventral nerve cord, only three survive into larval life, and these undergo apoptosis in the larvae. Here, we use loss-of-function analysis to demonstrate that neuroblast apoptosis during embryogenesis requires the coordinated expression of the cell death genes grim and reaper, and possibly sickle. These genes are clustered in a 140 kb region of the third chromosome and show overlapping patterns of expression. We show that expression of grim, reaper and sickle in embryonic neuroblasts is controlled by a common regulatory region located between reaper and grim. In the absence of grim and reaper, many neuroblasts survive the embryonic period of cell death and the ventral nerve cord becomes massively hypertrophic. Deletion of grim alone blocks the death of neuroblasts in the larvae. The overlapping activity of these multiple cell death genes suggests that the coordinated regulation of their expression provides flexibility in this crucial developmental process.
C1 [Tan, Ying; Yamada-Mabuchi, Megumu; Arya, Richa; St Pierre, Susan; Tang, Wei; Tosa, Marie; White, Kristin] Harvard Univ, CBRC, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA.
[Brachmann, Carrie] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.
RP White, K (reprint author), Harvard Univ, CBRC, Massachusetts Gen Hosp, Sch Med, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM kristin.white@cbrc2.mgh.harvard.edu
RI White, Kristin/D-7936-2013;
OI Tosa, Marie/0000-0002-9020-5098
FU NIH [GM55568]; Burroughs Wellcome Fund; MGH
FX Thanks to Chris Doe for antibodies and advice, Ginger Carney and Barbara
Taylor for important observations early in the project and the
Bloomington, VDRC and Harvard Exelixis stock centers for fly stocks.
Reena Patel provided technical assistance on the project at early
stages. The work was funded by NIH grant GM55568 (K. W.), a Career Award
in the Biomedical Sciences from the Burroughs Wellcome Fund (C. B.), and
an MGH Fund for Medical Discovery award (Y.T.). Deposited in PMC for
release after 12 months.
NR 51
TC 22
Z9 22
U1 0
U2 5
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0950-1991
J9 DEVELOPMENT
JI Development
PD JUN 1
PY 2011
VL 138
IS 11
BP 2197
EP 2206
DI 10.1242/dev.058826
PG 10
WC Developmental Biology
SC Developmental Biology
GA 761VW
UT WOS:000290430100005
PM 21558369
ER
PT J
AU Lengerke, C
Wingert, R
Beeretz, M
Grauer, M
Schmidt, AG
Konantz, M
Daley, GQ
Davidson, AJ
AF Lengerke, Claudia
Wingert, Rebecca
Beeretz, Michael
Grauer, Matthias
Schmidt, Anne G.
Konantz, Martina
Daley, George Q.
Davidson, Alan J.
TI Interactions between Cdx genes and retinoic acid modulate early
cardiogenesis
SO DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE Cdx; Retinoic acid; Mesoderm; Cardiac; Embryonic stem cells; Zebrafish
ID EMBRYONIC STEM-CELL; PANCREAS DEVELOPMENT; HOX GENES; HEMATOPOIETIC
PROGENITORS; DEVELOPMENTAL REGULATION; ZEBRAFISH EMBRYOGENESIS; MOUSE
EMBRYO; CAUDAL GENE; EXPRESSION; DIFFERENTIATION
AB Cdx transcription factors regulate embryonic positional identities and have crucial roles in anteroposterior patterning (AP) processes of all three germ layers. Previously we have shown that the zebrafish homologues cdx1a and cdx4 redundantly regulate posterior mesodermal derivatives inducing embryonic blood cell fate specification and patterning of the embryonic kidney. Here we hypothesize that cdx factors restrict formation of anterior mesodermal derivatives such as cardiac cells by imposing posterior identity to developing mesodermal cells. We show that ectopic expression of Cdx1 or Cdx4 applied during the brief window of mesoderm patterning in differentiating murine embryonic stem cell (ESC) strongly suppresses cardiac development as assayed by expression of cardiac genes and formation of embryoid bodies (EB) containing "beating" cell clusters. Conversely, in loss-of-function studies performed in cdx-deficient zebrafish embryos, we observed a dose-dependent expansion of tbx5a(+) anterior-lateral plate mesoderm giving rise to cardiac progenitors. However, further cardiac development of these mesodermal cells required additional suppression of the retinoic acid (RA) pathway, possibly due to differential activity of inhibitory RA signals in cdx mutants. Together, our data suggest that cdx proteins affect cardiogenesis by regulating the formation of cardiogenic mesoderm and together with the RA pathway control the early development of cardiac precursor cells. (c) 2011 Elsevier Inc. All rights reserved.
C1 [Lengerke, Claudia; Beeretz, Michael; Grauer, Matthias; Schmidt, Anne G.; Konantz, Martina] Univ Tuebingen Med Ctr II, Dept Hematol & Oncol, D-72076 Tubingen, Germany.
[Wingert, Rebecca; Davidson, Alan J.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Daley, George Q.] Childrens Hosp, Boston, MA 02115 USA.
[Daley, George Q.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Lengerke, C (reprint author), Univ Tuebingen Med Ctr II, Dept Hematol & Oncol, D-72076 Tubingen, Germany.
EM claudia.lengerke@med.uni-tuebingen.de; rwingert@nd.edu; beeretz@gmx.de;
Mat.Grauer@gmx.de; martina.konantz@tuebingen.mpg.de;
George.Daley@childrens.harvard.edu; a.davidson@auckland.ac.nz
OI Lengerke, Claudia/0000-0001-5442-2805
FU Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft [SFB773];
University of Tuebingen; NIH/NIDDK [DK077186]; United States National
Institutes of Health; NIH Roadmap for Medical Research; Burroughs
Wellcome Fund; Leukemia and Lymphoma Society; Howard Hughes Medical
Institute
FX This study was supported by the Max-Eder-Program of the Deutsche
Krebshilfe and grants from the Deutsche Forschungsgemeinschaft SFB773
and the Fortune Program of the University of Tuebingen for C.L; A.J.D is
supported by the NIH/NIDDK (DK077186); G.Q.D. is supported by grants
from the United States National Institutes of Health, the NIH Director's
Pioneer Award of the NIH Roadmap for Medical Research, Clinical
Scientist Awards in Translational Research from the Burroughs Wellcome
Fund and the Leukemia and Lymphoma Society, and the Howard Hughes
Medical Institute.
NR 58
TC 17
Z9 18
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0012-1606
J9 DEV BIOL
JI Dev. Biol.
PD JUN 1
PY 2011
VL 354
IS 1
BP 134
EP 142
DI 10.1016/j.ydbio.2011.03.027
PG 9
WC Developmental Biology
SC Developmental Biology
GA 763IR
UT WOS:000290550500013
PM 21466798
ER
PT J
AU Duntas, LH
Stathatos, N
AF Duntas, Leonidas H.
Stathatos, Nikolaos
TI Cinacalcet as alternative treatment for primary hyperparathyroidism:
achievements and prospects
SO ENDOCRINE
LA English
DT Review
DE Cinacalcet; Calcimimetics; Calcium-sensing receptor; Primary
hyperparathyroidism
ID ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; 3RD INTERNATIONAL WORKSHOP;
SERUM-CALCIUM; SECONDARY HYPERPARATHYROIDISM; POSTMENOPAUSAL WOMEN;
PARATHYROID-HORMONE; HYPERCALCEMIA; CALCIMIMETICS; DIAGNOSIS; RALOXIFENE
AB Primary hyperparathyroidism (pHPT), which most frequently occurs asymptomatically, is a common endocrine disease associated with increased morbidity and mortality. The newly introduced management guidelines as well as the recent availability of the first calcimimetic offer a highly promising therapeutic option for patients with pHPT. Cinacalcet, the first available calcimimetic, increases the sensitivity of the calcium-sensing receptor (CaR) to circulating serum calcium, thereby safely reducing serum calcium and PTH concentrations in patients with mild-to-moderate pHPT, intractable disease, and also parathyroid carcinoma. Cinacalcet has proved efficient in short- and long-term controls of hypercalcemia and, though bone mineral density was not improved, the available data point to cinacalcet as the treatment of choice in non-operable patients with pHPT. These results encompass a wide spectrum of disease severity. Results are pending as to whether cinacalcet decreases mortality and morbidity in pHPT, confirmation of which would conclusively recommend this drug as a valid alternative to surgery.
C1 [Duntas, Leonidas H.] Univ Athens, Evgenidion Hosp, Endocrine Unit, Athens 11528, Greece.
[Stathatos, Nikolaos] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Thyroid Unit, Boston, MA USA.
RP Duntas, LH (reprint author), Univ Athens, Evgenidion Hosp, Endocrine Unit, 20 Papadiamantopoulou Str, Athens 11528, Greece.
EM ledunt@otenet.gr
NR 56
TC 14
Z9 14
U1 0
U2 1
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1355-008X
J9 ENDOCRINE
JI Endocrine
PD JUN
PY 2011
VL 39
IS 3
BP 199
EP 204
DI 10.1007/s12020-011-9452-7
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 762CV
UT WOS:000290450800001
PM 21442382
ER
PT J
AU Kambadakone, AR
Sharma, A
Catalano, OA
Hahn, PF
Sahani, DV
AF Kambadakone, Avinash R.
Sharma, Ashish
Catalano, Onofrio A.
Hahn, Peter F.
Sahani, Dushyant V.
TI Protocol modifications for CT perfusion (CTp) examinations of
abdomen-pelvic tumors: Impact on radiation dose and data processing time
SO EUROPEAN RADIOLOGY
LA English
DT Article
DE CTperfusion; Radiation dose; Abdomino-pelvic tumors; Protocol
ID COMPUTED-TOMOGRAPHY PERFUSION; ADVANCED HEPATOCELLULAR-CARCINOMA;
PERIPHERAL LUNG-CARCINOMA; 64-DETECTOR ROW CT; MEAN TRANSIT-TIME;
COLORECTAL-CANCER; TEMPORAL RESOLUTION; PANCREATIC NECROSIS;
INITIAL-EXPERIENCE; STROKE PATIENTS
AB To evaluate the effect of CT perfusion (CTp) protocol modifications on quantitative perfusion parameters, radiation dose and data processing time.
CTp datasets of 30 patients (21M:9F) with rectal (n = 24) or retroperitoneal (n = 6) tumours were studied. Standard CTp protocol included 50 sec cine-phase (0.5 sec/rotation) and delayed-phase after 70 ml contrast bolus at 5-7 ml/sec. CTp-data was sub-sampled to generate modified datasets (n = 105) with cine-phase(n = 15) alone, varying cine-phase duration (20-40 sec, n = 45) and varying temporal sampling-interval (1-3 sec, n = 45). The estimated CTp parameters (BF,BV,MTT&PS) and radiation dose of standard CTp served as reference for comparison.
CTp with 50 sec cine-phase showed moderate to high correlation with standard CTp for BF&MTT (r = 0.96&0.85) and low correlation for BV (0.75, p = 0.04). Limiting cine-phase duration to 30 sec demonstrated comparable results for BF&MTT, while considerable variation in CTp values existed at 20 sec. There was moderate-to-high correlation of CTp parameters with sampling interval of 1&2 sec (r = 0.83-0.97, p > 0.05), while at 3 sec only BF showed high correlation (r = 0.96, p = 0.05). Increasing sampling interval (47-60%) and reducing cine-phase duration substantially reduced dose(30.8-65%) which paralleled reduced data processing time (3-10 min).
Limiting CTp cine-phase to 30 sec results in comparable BF&MTT values and increasing cine-phase sampling interval to 2 sec provides good correlation for all CTp parameters with substantial dose reduction and improved computational efficiency.
C1 [Kambadakone, Avinash R.; Sharma, Ashish; Catalano, Onofrio A.; Hahn, Peter F.; Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent Radiol, Boston, MA 02114 USA.
[Catalano, Onofrio A.] SDN Ist Ric Diagnost Nucl, Naples, Italy.
RP Sahani, DV (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent Radiol, White Bldg 270,55 Fruit St, Boston, MA 02114 USA.
EM dsahani@partners.org
FU GE Healthcare
FX The study was not supported by any research grant from GE Healthcare.
One of the authors is a consultant for Bracco Diagnostics and has
received research grant from GE Healthcare.
NR 40
TC 17
Z9 21
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-7994
J9 EUR RADIOL
JI Eur. Radiol.
PD JUN
PY 2011
VL 21
IS 6
BP 1293
EP 1300
DI 10.1007/s00330-010-2048-4
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 760OZ
UT WOS:000290334900020
PM 21246200
ER
PT J
AU Tanackovic, G
Ransijn, A
Thibault, P
Abou Elela, S
Klinck, R
Berson, EL
Chabot, B
Rivolta, C
AF Tanackovic, Goranka
Ransijn, Adriana
Thibault, Philippe
Abou Elela, Sherif
Klinck, Roscoe
Berson, Eliot L.
Chabot, Benoit
Rivolta, Carlo
TI PRPF mutations are associated with generalized defects in spliceosome
formation and pre-mRNA splicing in patients with retinitis pigmentosa
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID FACTOR GENE PRPF31; PROTEIN-PROTEIN INTERACTIONS; TARGETED MOUSE MODELS;
TRI-SNRNP; IN-VIVO; SACCHAROMYCES-CEREVISIAE; RETINAL DEGENERATION;
DISEASE MECHANISM; COMPLEX-FORMATION; HUMAN HOMOLOG
AB Proteins PRPF31, PRPF3 and PRPF8 (RP-PRPFs) are ubiquitously expressed components of the spliceosome, a macromolecular complex that processes nearly all pre-mRNAs. Although these spliceosomal proteins are conserved in eukaryotes and are essential for survival, heterozygous mutations in human RP-PRPF genes lead to retinitis pigmentosa, a hereditary disease restricted to the eye. Using cells from patients with 10 different mutations, we show that all clinically relevant RP-PRPF defects affect the stoichiometry of spliceosomal small nuclear RNAs (snRNAs), the protein composition of tri-small nuclear ribonucleoproteins and the kinetics of spliceosome assembly. These mutations cause inefficient splicing in vitro and affect constitutive splicing ex-vivo by impairing the removal of at least 9% of endogenously expressed introns. Alternative splicing choices are also affected when RP-PRPF defects are present. Furthermore, we show that the steady-state levels of snRNAs and processed pre-mRNAs are highest in the retina, indicating a particularly elevated splicing activity. Our results suggest a role for PRPFs defects in the etiology of PRPF-linked retinitis pigmentosa, which appears to be a truly systemic splicing disease. Although these mutations cause widespread and important splicing defects, they are likely tolerated by the majority of human tissues but are critical for retinal cell survival.
C1 [Tanackovic, Goranka; Ransijn, Adriana; Rivolta, Carlo] Univ Lausanne, Dept Med Genet, CH-1005 Lausanne, Switzerland.
[Thibault, Philippe; Abou Elela, Sherif; Klinck, Roscoe; Chabot, Benoit] Univ Sherbrooke, Lab Genom Fonct, Sherbrooke, PQ J1H 5N4, Canada.
[Abou Elela, Sherif; Chabot, Benoit] Univ Sherbrooke, Fac Med & Sci Sante, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada.
[Berson, Eliot L.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA.
RP Rivolta, C (reprint author), Univ Lausanne, Dept Med Genet, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.
EM carlo.rivolta@unil.ch
OI Rivolta, Carlo/0000-0002-0733-9950
FU Swiss National Science Foundation [PMPDA-114446, 320000-121929];
National Institutes of Health [EY00169, P30-EY014104]; Foundation
Fighting Blindness USA; Research to Prevent Blindness (HMS, Department
of Ophthalmology); Canadian Institute of Health Research
FX This work was supported by the Swiss National Science Foundation [grants
PMPDA-114446 from the Marie Heim-Vogtlin Programme (to G. T.) and grant
320000-121929 (to C. R.)]; the National Institutes of Health (grants
EY00169 and P30-EY014104); The Foundation Fighting Blindness USA (to E.
L. B.); by Research to Prevent Blindness (HMS, Department of
Ophthalmology, Unrestricted Grant) and by the Canadian Institute of
Health Research (to B. C.). S. A. E. is Chercheur National du FRSQ. B.
C. is the Canada Research Chair in Functional Genomics.
NR 75
TC 30
Z9 30
U1 1
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUN 1
PY 2011
VL 20
IS 11
BP 2116
EP 2130
DI 10.1093/hmg/ddr094
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 763WG
UT WOS:000290589800004
PM 21378395
ER
PT J
AU Zhu, XF
Young, JH
Fox, E
Keating, BJ
Franceschini, N
Kang, SJ
Tayo, B
Adeyemo, A
Sun, YV
Li, YL
Morrison, A
Newton-Cheh, C
Liu, K
Ganesh, SK
Kutlar, A
Vasan, RS
Dreisbach, A
Wyatt, S
Polak, J
Palmas, W
Musani, S
Taylor, H
Fabsitz, R
Townsend, RR
Dries, D
Glessner, J
Chiang, CWK
Mosley, T
Kardia, S
Curb, D
Hirschhorn, JN
Rotimi, C
Reiner, A
Eaton, C
Rotter, JI
Cooper, RS
Redline, S
Chakravarti, A
Levy, D
AF Zhu, Xiaofeng
Young, J. H.
Fox, Ervin
Keating, Brendan J.
Franceschini, Nora
Kang, Sunjung
Tayo, Bamidele
Adeyemo, Adebowale
Sun, Yun V.
Li, Yali
Morrison, Alanna
Newton-Cheh, Christopher
Liu, Kiang
Ganesh, Santhi K.
Kutlar, Abdullah
Vasan, Ramachandran S.
Dreisbach, Albert
Wyatt, Sharon
Polak, Joseph
Palmas, Walter
Musani, Solomon
Taylor, Herman
Fabsitz, Richard
Townsend, Raymond R.
Dries, Daniel
Glessner, Joseph
Chiang, Charleston W. K.
Mosley, Thomas
Kardia, Sharon
Curb, David
Hirschhorn, Joel N.
Rotimi, Charles
Reiner, Alexander
Eaton, Charles
Rotter, Jerome I.
Cooper, Richard S.
Redline, Susan
Chakravarti, Aravinda
Levy, Daniel
TI Combined admixture mapping and association analysis identifies a novel
blood pressure genetic locus on 5p13: contributions from the CARe
consortium
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; NATRIURETIC PEPTIDE SYSTEM; MULTILOCUS GENOTYPE
DATA; POPULATION-STRUCTURE; QUANTITATIVE TRAITS; ADMIXED POPULATIONS;
AFRICAN-AMERICANS; DISEASE GENES; LINKAGE; HYPERTENSION
AB Admixture mapping based on recently admixed populations is a powerful method to detect disease variants with substantial allele frequency differences in ancestral populations. We performed admixture mapping analysis for systolic blood pressure (SBP) and diastolic blood pressure (DBP), followed by trait-marker association analysis, in 6303 unrelated African-American participants of the Candidate Gene Association Resource (CARe) consortium. We identified five genomic regions (P < 0.001) harboring genetic variants contributing to inter-individual BP variation. In follow-up association analyses, correcting for all tests performed in this study, three loci were significantly associated with SBP and one significantly associated with DBP (P < 10 25). Further analyses suggested that six independent single-nucleotide polymorphisms (SNPs) contributed to the phenotypic variation observed in the admixture mapping analysis. These six SNPs were examined for replication in multiple, large, independent studies of African-Americans [Women's Health Initiative (WHI), Maywood, Genetic Epidemiology Network of Arteriopathy (GENOA) and Howard University Family Study (HUFS)] as well as one native African sample (Nigerian study), with a total replication sample size of 11 882. Meta-analysis of the replication set identified a novel variant (rs7726475) on chromosome 5 between the SUB1 and NPR3 genes, as being associated with SBP and DBP (P < 0.0015 for both); in meta-analyses combining the CARe samples with the replication data, we observed P-values of 4.45 x 10(-7) for SBP and 7.52 x 10(-7) for DBP for rs7726475 that were significant after accounting for all the tests performed. Our study highlights that admixture mapping analysis can help identify genetic variants missed by genome-wide association studies because of drastically reduced number of tests in the whole genome.
C1 [Zhu, Xiaofeng; Kang, Sunjung; Li, Yali] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
[Young, J. H.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Chakravarti, Aravinda] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
[Fox, Ervin; Dreisbach, Albert; Musani, Solomon; Taylor, Herman; Mosley, Thomas] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA.
[Wyatt, Sharon] Univ Mississippi, Med Ctr, Sch Nursing, Jackson, MS 39216 USA.
[Keating, Brendan J.] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.
[Townsend, Raymond R.; Dries, Daniel] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Franceschini, Nora] Univ N Carolina, Dept Epidemiol, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
[Tayo, Bamidele; Cooper, Richard S.] Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA.
[Adeyemo, Adebowale; Rotimi, Charles] NHGRI, Ctr Res Genom & Global Hlth, Bethesda, MD 20892 USA.
[Sun, Yun V.; Kardia, Sharon] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Morrison, Alanna] Univ Texas Houston, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA.
[Newton-Cheh, Christopher] Harvard Univ, Harvard & MIT, Broad Inst, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Redline, Susan] Harvard Univ, Dept Med, Boston, MA 02115 USA.
[Chiang, Charleston W. K.; Hirschhorn, Joel N.] Harvard Univ, Childrens Hosp Boston, Dept Genet, Boston, MA 02115 USA.
[Liu, Kiang] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
[Ganesh, Santhi K.] Univ Michigan Hlth Syst, Div Cardiovasc Med, Ann Arbor, MI USA.
[Kutlar, Abdullah] Med Coll Georgia, Augusta, GA 30912 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Framingham, MA USA.
[Polak, Joseph] Tufts Univ New England Med Ctr, Dept Radiol, Boston, MA USA.
[Palmas, Walter] Columbia Univ, Dept Med, New York, NY USA.
[Fabsitz, Richard] NHLBI, Div Epidemiol & Clin Applicat, Framingham, MA USA.
[Levy, Daniel] NHLBI, Ctr Populat Studies, Framingham, MA USA.
[Glessner, Joseph] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA.
[Curb, David] Pacific Hlth Res Inst, Honolulu, HI USA.
[Reiner, Alexander] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Eaton, Charles] Brown Univ, Div Biol & Med, Providence, RI 02912 USA.
[Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
RP Zhu, XF (reprint author), Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, 2103 Cornell Rd, Cleveland, OH 44106 USA.
EM xiaofeng.zhu@case.edu; aravinda@jhmi.edu
RI Sun, Yan/A-7461-2008;
OI Chiang, Charleston/0000-0002-0668-7865; Ramachandran,
Vasan/0000-0001-7357-5970; Adeyemo, Adebowale/0000-0002-3105-3231
FU National Heart, Lung, and Blood Institute [HL086718]; National
Institutes of Health, National Heart, Lung, and Blood Institute
[HL074166, HL53353, HL087660, HL100245]; National Human Genome Research
Institute [HG003054]; National Heart, Lung, and Blood Institute,
National Institutes of Health; U.S. Department of Health and Human
Services [N01WH22110, 24152, 32100-32102, 32105, 32106, 32108-32109,
32111-32113, 32115, 32118, 32119, 32122, 42107-42126, 42129-42132,
44221]
FX CARe. The authors wish to acknowledge the support of the National Heart,
Lung, and Blood Institute. The following nine parent studies have
contributed parent study data, ancillary study data, and DNA samples
through the Broad Institute (N01-HC-65226) to create this
genotype/phenotype database for wide dissemination to the biomedical
research community: Atherosclerotic Risk in Communities (ARIC):
University of North Carolina at Chapel Hill (N01-HC-55015), Baylor
Medical College (N01-HC-55016), University of Mississippi Medical Center
(N01-HC-55021), University of Minnesota (N01-HC-55019), Johns Hopkins
University (N01-HC-55020), University of Texas, Houston (N01-HC-55017),
University of North Carolina, Forsyth County (N01-HC-55018);
Cardiovascular Health Study (CHS): University of Washington
(N01-HC-85079), Wake Forest University (N01-HC-85080), Johns Hopkins
University (N01-HC-85081), University of Pittsburgh (N01-HC-85082),
University of California, Davis (N01-HC-85083), University of
California, Irvine (N01-H-C-85084), New England Medical Center
(N01-HC-85085), University of Vermont (N01-HC-85086), Georgetown
University (N01-HC-35129), Johns Hopkins University (N01 HC-15103),
University of Wisconsin (N01-HC-75150), Geisinger Clinic (N01-HC-45133),
University of Washington (N01 HC-55222, U01 HL080295); Cleveland Family
Study (CFS): Case Western Reserve University (RO1 HL46380-01-16);
Cooperative Study of Sickle Cell Disease (CSSCD): University of Illinois
(N01-HB-72982, N01-HB-9-7062), Howard University (N01-HB-72991,
N01-HB-97061), University of Miami (N01-HB-72992, N01-HB-97064), Duke
University (N01-HB-72993), George Washington University (N01-HB-72994),
University of Tennessee (N01-H-B-72995, N01-HB-97070), Yale University
(N01-H-B-72996, N01-HB-97072), Children's Hospital-Philadelphia
(N01-HB-72997, N01-HB-97056), University of Chicago (N01-HB-72998,
N01-HB-97053), Medical College of Georgia (N01-HB-73000, N01-HB-97060),
Washington University (N01-HB-73001, N01-HB-97071), Jewish Hospital and
Medical Center of Brooklyn (N01-HB-73002), Trustees of Health and
Hospitals of the City of Boston, Inc. (N01-HB-73003), Children's
Hospital-Oakland (N01-HB-73004, N01-HB-97054), University of Mississippi
(N01-HB-73005), St. Luke's Hospital-New York (N01-HB-73006), Alta
Bates-Herrick Hospital (N01-HB-97051), Columbia University
(N01-HB-97058), St.; Jude's Children's Research Hospital (N01-HB-97066),
Research Foundation, State University of New York-Albany (N01-HB-97068,
N01-HB-97069), New England Research Institute (N01-HB-97073), Interfaith
Medical Center-Brooklyn (N01-HB-97085); Coronary Artery Risk in Young
Adults (CARDIA): University of Alabama at Birmingham (N01-HC-48047),
University of Minnesota (N01-HC-48048), Northwestern University
(N01-HC-48049), Kaiser Foundation Research Institute (N01-HC-48050),
University of Alabama at Birmingham (N01-HC-95095), Tufts-New England
Medical Center (N01-HC-45204), Wake Forest University (N01-HC-45205),
Harbor-UCLA Research and Education Institute (N01-HC-05187), University
of California, Irvine (N01-HC-45134, N01-HC-95100); Framingham Heart
Study (FHS): Boston University (N01-HC-25195); Jackson Heart Study
(JHS): Jackson State University (N01-HC-95170), University of
Mississippi (N01-HC-95171), Tougaloo College (N01-HC-95172);
Multi-Ethnic Study of Atherosclerosis (MESA): University of Washington
(N01-HC-95159), Regents of the University of California (N01-HC-95160),
Columbia University (N01-HC-95161), Johns Hopkins University
(N01-HC-95162), University of Minnesota (N01-HC-95163), Northwestern
Univesity (N01-HC-95164), Wake Forest University (N01-HC-95165),
University of Vermont (N01-HC-95166), New England Medical Center
(N01-HC-95167), Johns Hopkins University (N01-HC-95168), Harbor-UCLA
Research and Education Institute (N01-HC-95169); Sleep Heart Health
Study (SHHS): Johns Hopkins University (U01 HL064360), Case Western
University (U01 HL063463), University of California, Davis (U01
HL053916), University of Arizona (U01 HL053938), University of Minnesota
(relocating in 2006 to University Arizona) (U01 HL053934), University of
Pittsburgh (U01 HL077813), Boston University (U01 HL053941), MedStar
Research Institute (U01 HL063429), Johns Hopkins University (U01
HL053937).; Maywood African-American and Nigeria studies are supported
by the National Institutes of Health, grant numbers HL074166 and HL53353
from the National Heart, Lung, and Blood Institute. Y. L. and X. Z. are
supported by HL086718 from the National Heart, Lung, and Blood Institute
and HG003054 from the National Human Genome Research Institute.; Genetic
Epidemiology Network of Arteriopathy (GENOA) study is supported by the
National Institutes of Health, grant numbers HL087660 and HL100245 from
the National Heart, Lung, and Blood Institute.; The WHI program is
funded by the National Heart, Lung, and Blood Institute, National
Institutes of Health, U.S. Department of Health and Human Services
through contracts N01WH22110, 24152, 32100-32102, 32105, 32106,
32108-32109, 32111-32113, 32115, 32118, 32119, 32122, 42107-42126,
42129-42132, and 44221.
NR 41
TC 39
Z9 41
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUN 1
PY 2011
VL 20
IS 11
BP 2285
EP 2295
DI 10.1093/hmg/ddr113
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 763WG
UT WOS:000290589800018
PM 21422096
ER
PT J
AU Thukkani, N
Williams, JL
Sonnenberg, A
AF Thukkani, Nundhini
Williams, J. Lucas
Sonnenberg, Amnon
TI Epidemiologic Characteristics of Patients with Inflammatory Bowel
Disease Undergoing Colonoscopy
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE colonoscopy; Crohn's disease; epidemiology of inflammatory bowel
disease; ethnic variation; geographic variation; practice patterns;
ulcerative colitis
ID CROHNS-DISEASE; UNITED-STATES; ULCERATIVE-COLITIS; AGE DISTRIBUTION;
APPROPRIATE USE; CORI DATABASE; VITAMIN-D; HOSPITALIZATION; PREVALENCE;
IBD
AB Background: The aim was too describe the demographic characteristics of patients with inflammatory bowel disease (IBD) undergoing colonoscopy.
Methods: The Clinical Outcomes Research Initiative (CORI) maintains a database of endoscopic procedures in diverse clinical practices distributed throughout the US. The data from 2000-2007 were used to analyze the demographic characteristics of patients with Crohn's disease (CD) and ulcerative colitis (UC).
Results: During the period 2000-2007, 4631 patients with CD and 6619 patients with UC were compared to a control population of 826,207 patients without IBD. CD and UC patients were significantly (P < 0.0001) younger than controls: 41.7 +/- 18.4, 47.3 +/- 17.4, 59.2 +/- 14.0 years, respectively. CD and UC were less common among nonwhite than white endoscopy patients: odds ratio (OR) = 0.64 (0.58-0.70) for CD and OR = 0.71 (0.66-0.77) for UC. Endoscopy for IBD was only slightly less common among female than male CD patients (0.94, 0.89-1.00), but significantly less common among female than male UC patients (0.72, 0.68-0.75). Compared with community/private practices, relatively more endoscopies were performed among IBD patients in academic institutions: OR = 1.68 (1.56-1.81) for CD and OR = 27 (1.19-1.36) for UC. The race-, sex-, and age-adjusted rates of CD and UC were both significantly higher in the northern than southern regions of the US, with a significant correlation of r = 0.89, degrees of freedom = 4, P = 0.017 between the geographic distributions of the two diagnoses.
Conclusions: The endoscopy patterns of IBD patients may be influenced in part by the epidemiology of these two diagnoses, as well as by underlying trends in the utilization of colonoscopy.
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
FU NIDDK [UO1 CA 89389-01, U01 DK057132, R33-DK61778-01]; AstraZeneca; Bard
International; Pentax USA; ProVation; Endosoft; GIVEN Imaging; Ethicon
FX Supported with funding from NIDDK UO1 CA 89389-01, NIDDK U01 DK057132
and R33-DK61778-01. In addition, the practice network (CORI) has
received support from the following entities to support the
infrastructure of the practice-based network: AstraZeneca, Bard
International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and
Ethicon. The commercial entities had no involvement in this research.
NR 23
TC 4
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1078-0998
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JUN
PY 2011
VL 17
IS 6
BP 1333
EP 1337
DI 10.1002/ibd.21513
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 761ZQ
UT WOS:000290442400032
PM 21560196
ER
PT J
AU Pariente, B
Cosnes, J
Danese, S
Sandborn, WJ
Lewin, M
Fletcher, JG
Chowers, Y
D'Haens, G
Feagan, BG
Hibi, T
Hommes, DW
Irvine, EJ
Kamm, MA
Loftus, EV
Louis, E
Michetti, P
Munkholm, P
Oresland, T
Panes, J
Peyrin-Biroulet, L
Reinisch, W
Sands, BE
Schoelmerich, J
Schreiber, S
Tilg, H
Travis, S
van Assche, G
Vecchi, M
Mary, JY
Colombel, JF
Lemann, M
AF Pariente, Benjamin
Cosnes, Jacques
Danese, Silvio
Sandborn, William J.
Lewin, Maite
Fletcher, Joel G.
Chowers, Yehuda
D'Haens, Geert
Feagan, Brian G.
Hibi, Toshifumi
Hommes, Daniel W.
Irvine, E. Jan
Kamm, Michael A.
Loftus, Edward V., Jr.
Louis, Edouard
Michetti, Pierre
Munkholm, Pia
Oresland, Tom
Panes, Julian
Peyrin-Biroulet, Laurent
Reinisch, Walter
Sands, Bruce E.
Schoelmerich, Juergen
Schreiber, Stefan
Tilg, Herbert
Travis, Simon
van Assche, Gert
Vecchi, Maurizio
Mary, Jean-Yves
Colombel, Jean-Frederic
Lemann, Marc
TI Development of the Crohn's Disease Digestive Damage Score, the Lemann
Score
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Review
DE Crohn's disease; illness index severity; magnetic resonance imaging
ID INFLAMMATORY-BOWEL-DISEASE; EARLY RHEUMATOID-ARTHRITIS; ENHANCED CT
ENTEROGRAPHY; MAGNETIC-RESONANCE; RADIOLOGIC ABNORMALITIES;
HISTOLOGIC-FINDINGS; MURAL ATTENUATION; CLINICAL-TRIALS; ACTIVITY INDEX;
END-POINTS
AB Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a specific point in time. An instrument to measure cumulative structural damage to the bowel, which may predict long-term disability, is needed. The aim of this article is to outline the methods to develop an instrument that can measure cumulative bowel damage. The project is being conducted by the International Program to develop New Indexes in Crohn's disease (IPNIC) group. This instrument, called the Crohn's Disease Digestive Damage Score (the Lemann score), should take into account damage location, severity, extent, progression, and reversibility, as measured by diagnostic imaging modalities and the history of surgical resection. It should not be "diagnostic modality driven": for each lesion and location, a modality appropriate for the anatomic site (for example: computed tomography or magnetic resonance imaging enterography, and colonoscopy) will be used. A total of 24 centers from 15 countries will be involved in a cross-sectional study, which will include up to 240 patients with stratification according to disease location and duration. At least 120 additional patients will be included in the study to validate the score. The Lemann score is expected to be able to portray a patient's disease course on a double-axis graph, with time as the x-axis, bowel damage severity as the y-axis, and the slope of the line connecting data points as a measure of disease progression. This instrument could be used to assess the effect of various medical therapies on the progression of bowel damage.
C1 [Cosnes, Jacques] Hop St Antoine, Serv Hepatogastroenterol & Nutr, Dept Gastroenterol & Nutr, F-75012 Paris, France.
[Pariente, Benjamin; Lemann, Marc] Hop St Antoine, Dept Hepatogastroenterol, F-75012 Paris, France.
[Danese, Silvio] Inst Clin Humanitas, Dept Gastroenterol, Milan, Italy.
[Sandborn, William J.] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA 92093 USA.
[Lewin, Maite] Hop St Antoine, Dept Radiol, F-75012 Paris, France.
[Fletcher, Joel G.] Mayo Clin, Dept Radiol, Rochester, MN USA.
[Chowers, Yehuda] Rambam Hlth Care Campus, Dept Gastroenterol, Haifa, Israel.
[D'Haens, Geert] Imelda GI Clin Res Ctr, Bonheiden, Belgium.
[Feagan, Brian G.] Univ Western Ontario, Robarts Res Inst, London, ON, Canada.
[Hibi, Toshifumi] Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan.
[Hommes, Daniel W.] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands.
[Irvine, E. Jan] Univ Toronto, Toronto, ON, Canada.
[Irvine, E. Jan] St Michaels Hosp, Div Gastroenterol, Toronto, ON M5B 1W8, Canada.
[Kamm, Michael A.] St Vincents Hosp, Melbourne, Vic, Australia.
[Kamm, Michael A.] Univ Melbourne, Melbourne, Vic, Australia.
[Loftus, Edward V., Jr.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA.
[Louis, Edouard] Univ Liege, Ctr Hosp Univ Liege, Dept Hepatogastroenterol, Liege, Belgium.
[Michetti, Pierre] CHU Vaudois, Dept Gastroenterol & Hepatol, Lausanne, Switzerland.
[Michetti, Pierre] Univ Lausanne, Lausanne, Switzerland.
[Munkholm, Pia] Univ Copenhagen, Herlev Hosp, Dept Med Gastroenterol C, DK-1168 Copenhagen, Denmark.
[Oresland, Tom] Univ Oslo, Akershus Univ Hosp, Dept GI Surg, N-0316 Oslo, Norway.
[Panes, Julian] Hosp Clin Barcelona, Barcelona, Spain.
[Peyrin-Biroulet, Laurent] Ctr Hosp Univ Nancy, Dept Hepatogastroenterol, Vandoeuvre Les Nancy, France.
[Reinisch, Walter] Univ Klin Innere Med III, Vienna, Austria.
[Sands, Bruce E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Crohns & Colitis Ctr, Boston, MA USA.
[Sands, Bruce E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
[Schoelmerich, Juergen] Univ Hosp Frankfurt Main, CEA Hosp Board, Frankfurt, Germany.
[Schreiber, Stefan] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany.
[Tilg, Herbert] Med Univ Innsbruck, Christian Doppler Res Lab Gut Inflammat, Innsbruck, Austria.
[Travis, Simon] John Radcliffe Hosp, Translat Gastroenterol Unit, Oxford OX3 9DU, England.
[van Assche, Gert] Univ Leuven Hosp, Div Gastroenterol, Louvain, Belgium.
[Vecchi, Maurizio] IRCCS Policlin San Donato, Gastroenterol & Gastrointestinal Endoscopy Unit, San Donato Milanese, Italy.
[Vecchi, Maurizio] Univ Milan, San Donato Milanese, Italy.
[Mary, Jean-Yves] Hop St Louis, INSERM, U717, Paris, France.
[Colombel, Jean-Frederic] Ctr Hosp Univ, Hop Huriez, Dept Hepatogastroenterol, Lille, France.
RP Cosnes, J (reprint author), Hop St Antoine, Serv Hepatogastroenterol & Nutr, Dept Gastroenterol & Nutr, 184 Rue Faubourg St Antoine, F-75012 Paris, France.
EM jacques.cosnes@sat.aphp.fr
RI Loftus, Edward/E-8304-2011; Schreiber, Stefan/B-6748-2008; Feagan,
Brian/M-4283-2015;
OI Schreiber, Stefan/0000-0003-2254-7771; Panes, Julian/0000-0002-4971-6902
FU Abbott Laboratories
FX Supported by an educational grant from Abbott Laboratories.
NR 47
TC 188
Z9 194
U1 0
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1078-0998
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JUN
PY 2011
VL 17
IS 6
BP 1415
EP 1422
DI 10.1002/ibd.21506
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 761ZQ
UT WOS:000290442400041
PM 21560202
ER
PT J
AU Foley, JM
Wright, MJ
Gooding, AL
Ettenhofer, M
Kim, M
Choi, M
Castellon, SA
Sadek, J
Heaton, RK
van Gorp, WG
Marcotte, TD
Hinkin, CH
AF Foley, J. M.
Wright, M. J.
Gooding, A. L.
Ettenhofer, M.
Kim, M.
Choi, M.
Castellon, S. A.
Sadek, J.
Heaton, R. K.
van Gorp, W. G.
Marcotte, T. D.
Hinkin, C. H.
TI Operationalization of the updated diagnostic algorithm for classifying
HIV-related cognitive impairment and dementia
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Article
DE HIV; cognitive impairment; classification; dementia
ID NEUROCOGNITIVE DISORDERS; CONFIRMATION; INFECTION
AB Background: This study applies the updated HIV-Associated Neurocognitive Disorders (HAND) diagnostic algorithm.
Methods: Participants were 210 HIV-infected-adults, classified using proposed HAND criteria: HIV-Associated Dementia (HAD), Mild Neurocognitive Disorder (MND), Asymptomatic Neurocognitive Impairment (ANI).
Results: The algorithm yielded: normal = 32.8%, ANI = 21.4%, MND = 34.3%, and HAD = 11.4%. Normal participants performed superior to HAND-defined participants on cognition, and HAD participants performed more poorly on global cognition and executive functioning. Two distinct subgroups of interest emerged: (1) functional decline without cognitive impairment; (2) severe cognitive impairment and minimal functional compromise.
Conclusions: The algorithm discriminates between HIV-infected cognitively impaired individuals. Diagnosis yields two unique profiles requiring further investigation. Findings largely support the algorithm's utility for diagnosing HIV-cognitive-impairment, but suggest distinct subsets of individuals with discrepant cognitive/functional performances that may not be readily apparent by conventional application of HAND diagnosis.
C1 [Foley, J. M.; Wright, M. J.; Ettenhofer, M.; Castellon, S. A.; Hinkin, C. H.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA.
[Gooding, A. L.; Kim, M.; Castellon, S. A.; Hinkin, C. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Choi, M.; Heaton, R. K.; Marcotte, T. D.] UCSD Dept Psychiat, San Diego, CA USA.
[Sadek, J.] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA.
[van Gorp, W. G.] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY USA.
RP Foley, JM (reprint author), 150 S,Huntington Ave, Boston, MA 02130 USA.
EM Jfoley@post.harvard.edu
FU NIMH [R01 MH58522]; VA Merit Review: Aging and HIV/AIDS: Neurocognitive
Sequelae and Functional Consequences
FX This study was conducted at the University of California Los Angeles,
and the West Los Angeles Veteran's Affairs Medical Center and was
supported by: NIMH R01 MH58522, VA Merit Review: Aging and HIV/AIDS:
Neurocognitive Sequelae and Functional Consequences to CHH.
NR 29
TC 4
Z9 5
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD JUN
PY 2011
VL 23
IS 5
BP 835
EP 843
DI 10.1017/S1041610210002085
PG 9
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
Psychology
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA 757TB
UT WOS:000290109500017
PM 21092351
ER
PT J
AU Johnson, JS
Meliton, V
Kim, WK
Lee, KB
Wang, JC
Nguyen, K
Yoo, D
Jung, ME
Atti, E
Tetradis, S
Pereira, RC
Magyar, C
Nargizyan, T
Hahn, TJ
Farouz, F
Thies, S
Parhami, F
AF Johnson, Jared S.
Meliton, Vicente
Kim, Woo Kyun
Lee, Kwang-Bok
Wang, Jeffrey C.
Nguyen, KhanhLinh
Yoo, Dongwon
Jung, Michael E.
Atti, Elisa
Tetradis, Sotirios
Pereira, Renata C.
Magyar, Clara
Nargizyan, Taya
Hahn, Theodore J.
Farouz, Francine
Thies, Scott
Parhami, Farhad
TI Novel Oxysterols Have Pro-Osteogenic and Anti-Adipogenic Effects In
Vitro and Induce Spinal Fusion In Vivo
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE OXYSTEROLS; SPINAL FUSION; BMP2; OSTEOGENESIS; ADIPOGENESIS
ID BONE MORPHOGENETIC PROTEIN-2; MARROW STROMAL CELLS; MESENCHYMAL
PRECURSOR CELLS; OSTEOBLASTIC DIFFERENTIATION; FRACTURE REPAIR; SONIC
HEDGEHOG; GENE-THERAPY; RODENT MODEL; EXPRESSION;
20(S)-HYDROXYCHOLESTEROL
AB Stimulation of bone formation by osteoinductive materials is of great clinical importance in spinal fusion surgery, repair of bone fractures, and in the treatment of osteoporosis. We previously reported that specific naturally occurring oxysterols including 20(S)-hydroxycholesterol (20S) induce the osteogenic differentiation of pluripotent mesenchymal cells, while inhibiting their adipogenic differentiation. Here we report the characterization of two structural analogues of 20S, Oxy34 and Oxy49, which induce the osteogenic and inhibit the adipogenic differentiation of bone marrow stromal cells (MSC) through activation of Hedgehog (Hh) signaling. Treatment of M2-10B4 MSC with Oxy34 or Oxy49 induced the expression of osteogenic differentiation markers Runx2, Osterix (Osx), alkaline phosphatase (ALP), bone sialoprotein (BSP), and osteocalcin (OCN), as well as ALP enzymatic activity and robust mineralization. Treatment with oxysterols together with PPAR gamma activator, troglitazone (Tro), inhibited mRNA expression for adipogenic genes PPAR gamma, LPL, and aP2, and inhibited the formation of adipocytes. Efficacy of Oxy34 and Oxy49 in stimulating bone formation in vivo was assessed using the posterolateral intertransverse process rat spinal fusion model. Rats receiving collagen implants with Oxy 34 or Oxy49 showed comparable osteogenic efficacy to BMP2/collagen implants as measured by radiography, MicroCT, and manual inspection. Histological analysis showed trabecular and cortical bone formation by oxysterols and rhBMP2 within the fusion mass, with robust adipogenesis in BMP2-induced bone and significantly less adipocytes in oxysterol-induced bone. These data suggest that Oxy34 and Oxy49 are effective novel osteoinductive molecules and may be suitable candidates for further development and use in orthopedic indications requiring local bone formation. J. Cell. Biochem. 112: 1673-1684, 2011. (C) 2011 Wiley-Liss, Inc.
C1 [Parhami, Farhad] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Dept Med, Los Angeles, CA 90095 USA.
[Johnson, Jared S.; Lee, Kwang-Bok; Wang, Jeffrey C.] Univ Calif Los Angeles, Dept Orthoped Surg, Los Angeles, CA 90095 USA.
[Nguyen, KhanhLinh; Yoo, Dongwon; Jung, Michael E.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA.
[Atti, Elisa; Tetradis, Sotirios] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Pereira, Renata C.] Univ Calif Los Angeles, Dept Pediat Nephrol, Los Angeles, CA 90024 USA.
[Magyar, Clara] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA.
[Hahn, Theodore J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Hahn, Theodore J.] Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Farouz, Francine; Thies, Scott] Fate Therapeut Inc, San Diego, CA USA.
RP Parhami, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Dept Med, A2-237,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM fparhami@mednet.ucla.edu
FU NIAMS/NIH [RO1AR050426]; Fate Therapeutics, Inc.; Fate Therapeutics,
Inc. (San Diego, CA, USA)
FX Grant sponsor: NIAMS/NIH; Grant number: RO1AR050426; Grant sponsor: Fate
Therapeutics, Inc..; This work was supported by NIAMS/NIH Grant
RO1AR050426 and in part by a sponsored research award from Fate
Therapeutics, Inc. (San Diego, CA, USA).
NR 52
TC 30
Z9 31
U1 1
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUN
PY 2011
VL 112
IS 6
BP 1673
EP 1684
DI 10.1002/jcb.23082
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 762NX
UT WOS:000290487800023
PM 21503957
ER
PT J
AU Sharma, R
Tye, CE
Arun, A
MacDonald, D
Chatterjee, A
Abrazinski, T
Everett, ET
Whitford, GM
Bartlett, JD
AF Sharma, R.
Tye, C. E.
Arun, A.
MacDonald, D.
Chatterjee, A.
Abrazinski, T.
Everett, E. T.
Whitford, G. M.
Bartlett, J. D.
TI Assessment of Dental Fluorosis in Mmp20(+/-) Mice
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE protease/proteinase; gene expression; protein expression; fluoride;
enamel
ID HYPOMATURATION AMELOGENESIS IMPERFECTA; ENDOPLASMIC-RETICULUM STRESS;
IN-VITRO; FLUORIDE; ENAMEL; MMP-20; RAT; SECRETION; MUTATION; ENZYME
AB The molecular mechanisms that underlie dental fluorosis are poorly understood. The retention of enamel proteins hallmarking fluorotic enamel may result from impaired hydrolysis and/or removal of enamel proteins. Previous studies have suggested that partial inhibition of Mmp20 expression is involved in the etiology of dental fluorosis. Here we ask if mice expressing only one functional Mmp20 allele are more susceptible to fluorosis. We demonstrate that Mmp20(+/-) mice express approximately half the amount of MMP20 as do wild-type mice. The Mmp20 heterozygous mice have normal-appearing enamel, with Vickers microhardness values similar to those of wild-type control enamel. Therefore, reduced MMP20 expression is not solely responsible for dental fluorosis. With 50-ppm-fluoride (F-) treatment ad libitum, the Mmp20(+/-) mice had F-tissue levels similar to those of Mmp20(+/+) mice. No significant difference in enamel hardness was observed between the F--treated heterozygous and wild-type mice. Interestingly, we did find a small but significant difference in quantitative fluorescence between these two groups, which may be attributable to slightly higher protein content in the Mmp20(+/-) mouse enamel. We conclude that MMP20 plays a nominal role in dental enamel fluorosis.
C1 [Sharma, R.; Tye, C. E.; Chatterjee, A.; Abrazinski, T.; Bartlett, J. D.] Harvard Univ, Sch Dent Med, Dept Cytokine Biol, Forsyth Inst, Boston, MA 02115 USA.
[Sharma, R.; Tye, C. E.; Chatterjee, A.; Abrazinski, T.; Bartlett, J. D.] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
[Arun, A.; Whitford, G. M.] Med Coll Georgia, Dept Oral Biol & Maxillofacial Pathol, Augusta, GA 30912 USA.
[MacDonald, D.; Everett, E. T.] Univ N Carolina, Dept Pediat Dent, Chapel Hill, NC USA.
[MacDonald, D.; Everett, E. T.] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA.
RP Bartlett, JD (reprint author), Harvard Univ, Sch Dent Med, Dept Cytokine Biol, Forsyth Inst, 188 Longwood Ave, Boston, MA 02115 USA.
EM jbartlett@forsyth.org
RI Sharma, Ramaswamy/F-8401-2012
FU NIDCR [DE018106, DE16276, DE018104]
FX We thank Dr. Henry Margolis and Amy Litman for their enamel surface
roughness determinations. This work was supported by NIDCR grants
DE018106 (JDB), DE16276 (JDB), and DE018104 (ETE).
NR 25
TC 7
Z9 7
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PD JUN
PY 2011
VL 90
IS 6
BP 788
EP 792
DI 10.1177/0022034511398868
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 761ZI
UT WOS:000290441600017
PM 21386097
ER
PT J
AU John, LK
Loewenstein, G
Troxel, AB
Norton, L
Fassbender, JE
Volpp, KG
AF John, Leslie K.
Loewenstein, George
Troxel, Andrea B.
Norton, Laurie
Fassbender, Jennifer E.
Volpp, Kevin G.
TI Financial Incentives for Extended Weight Loss: A Randomized, Controlled
Trial
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE behavioral medicine; obesity; psychology; randomized trials; behavioral
economics
ID REDUCTION; CHOICE; HEALTH
AB BACKGROUND: Previous efforts to use incentives for weight loss have resulted in substantial weight regain after 16 weeks.
OBJECTIVE: To evaluate a longer term weight loss intervention using financial incentives.
DESIGN: A 32-week, three-arm randomized controlled trial of financial incentives for weight loss consisting of a 24-week weight loss phase during which all participants were given a weight loss goal of 1 pound per week, followed by an 8-week maintenance phase.
PARTICIPANTS: Veterans who were patients at the Philadelphia Veterans Affairs Medical Center with BMIs of 30-40.
INTERVENTION: Participants were randomly assigned to participate in either a weight-monitoring program involving a consultation with a dietician and monthly weigh-ins (control condition), or the same program with one of two financial incentive plans. Both incentive arms used deposit contracts (DC) in which participants put their own money at risk (matched 1:1), which they lost if they failed to lose weight. In one incentive arm participants were told that the period after 24 weeks was for weight-loss maintenance; in the other, no such distinction was made.
MAIN MEASURE: Weight loss after 32 weeks.
KEY RESULTS: Results were analyzed using intention-to-treat. There was no difference in weight loss between the incentive arms (P = 0.80). Incentive participants lost more weight than control participants [mean DC = 8.70 pounds, mean control = 1.17, P = 0.04, 95% CI of the difference in means (0.56, 14.50)]. Follow-up data 36 weeks after the 32-week intervention had ended indicated weight regain; the net weight loss between the incentive and control groups was no longer significant (mean DC = 1.2 pounds, 95% CI, -2.58-5.00; mean control = 0.27, 95% CI, -3.77-4.30, P = 0.76).
CONCLUSIONS: Financial incentives produced significant weight loss over an 8-month intervention; however, participants regained weight post-intervention.
C1 [John, Leslie K.; Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA.
[Loewenstein, George; Troxel, Andrea B.; Norton, Laurie; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA.
[Troxel, Andrea B.; Fassbender, Jennifer E.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Troxel, Andrea B.; Fassbender, Jennifer E.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Norton, Laurie; Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Norton, Laurie; Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
RP John, LK (reprint author), Carnegie Mellon Univ, Dept Social & Decis Sci, 208 Porter Hall,5000 Forbes Ave, Pittsburgh, PA 15213 USA.
EM lkjohn@andrew.cmu.edu
OI Troxel, Andrea/0000-0002-1393-3075
FU USDA; Economic Research Service [58-4000-7-0058]; Hewlett Foundation
FX USDA, Economic Research Service (grant no. 58-4000-7-0058) and the
Hewlett Foundation.
NR 20
TC 97
Z9 97
U1 5
U2 33
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2011
VL 26
IS 6
BP 621
EP 626
DI 10.1007/s11606-010-1628-y
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 763RE
UT WOS:000290576600013
PM 21249462
ER
PT J
AU Baggett, TP
Singer, DE
Rao, SR
O'Connell, JJ
Bharel, M
Rigotti, NA
AF Baggett, Travis P.
Singer, Daniel E.
Rao, Sowmya R.
O'Connell, James J.
Bharel, Monica
Rigotti, Nancy A.
TI Food Insufficiency and Health Services Utilization in a National Sample
of Homeless Adults
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE homelessness; food insufficiency; health services utilization
ID NUTRITION EXAMINATION SURVEY; LOGISTIC-REGRESSION; PATIENT POPULATION;
UNITED-STATES; INSECURITY; HUNGER; CARE; EMERGENCY; INDIVIDUALS;
SUFFICIENCY
AB BACKGROUND: Homeless people have high rates of hospitalization and emergency department (ED) use. Obtaining adequate food is a common concern among homeless people and may influence health care utilization.
OBJECTIVE: We tested the hypothesis that food insufficiency is related to higher rates of hospitalization and ED use in a national sample of homeless adults.
DESIGN: We analyzed data from the 2003 Health Care for the Homeless (HCH) User Survey.
PARTICIPANTS: Participants were 966 adults surveyed at 79 HCH clinic sites throughout the US. The study sample was representative of over 436,000 HCH clinic users nationally.
MEASURES: We determined the prevalence and characteristics of food insufficiency among respondents. Using multivariable logistic regression, we examined the association between food insufficiency and four past-year acute health services utilization outcomes: (1) hospitalization for any reason, (2) psychiatric hospitalization, (3) any ED use, and (4) high ED use (>= 4 visits).
RESULTS: Overall, 25% of respondents reported food insufficiency. Among them, 68% went a whole day without eating in the past month. Chronically homeless (p = 0.01) and traumatically victimized (p = 0.001) respondents were more likely to be food insufficient. In multivariable analyses, food insufficiency was associated with significantly greater odds of hospitalization for any reason (AOR 1.59, 95% CI 1.07, 2.36), psychiatric hospitalization (AOR 3.12, 95% CI 1.73, 5.62), and high ED utilization (AOR 2.83, 95% CI 1.32, 6.08).
CONCLUSIONS: One-fourth of homeless adults in this national survey were food insufficient, and this was associated with increased odds of acute health services utilization. Addressing the adverse health services utilization patterns of homeless adults will require attention to the social circumstances that may contribute to this issue.
C1 [Baggett, Travis P.; Singer, Daniel E.; O'Connell, James J.; Bharel, Monica; Rigotti, Nancy A.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Baggett, Travis P.; Singer, Daniel E.; O'Connell, James J.; Bharel, Monica; Rigotti, Nancy A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Baggett, Travis P.; O'Connell, James J.; Bharel, Monica] Boston Hlth Care Homeless Program, Boston, MA USA.
[Rao, Sowmya R.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
RP Baggett, TP (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM tbaggett@partners.org
FU Health Resources and Services Administration of the Department of Health
and Human Services to support the Harvard Medical School [T32HP10251]
FX This study was funded by grant number T32HP10251 from the Health
Resources and Services Administration of the Department of Health and
Human Services to support the Harvard Medical School Fellowship in
General Medicine and Primary Care. The views expressed in this
publication are the opinions of the authors and do not necessarily
reflect the official policies of the US Department of Health and Human
Services or the Health Resources and Services Administration, nor does
mention of the department or agency imply endorsement by the US
government.
NR 54
TC 28
Z9 29
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2011
VL 26
IS 6
BP 627
EP 634
DI 10.1007/s11606-011-1638-4
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 763RE
UT WOS:000290576600014
PM 21279455
ER
PT J
AU Trivedi, RB
Nieuwsma, JA
Williams, JW
AF Trivedi, Ranak B.
Nieuwsma, Jason A.
Williams, John W., Jr.
TI Examination of the Utility of Psychotherapy for Patients with Treatment
Resistant Depression: A Systematic Review
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Review
DE treatment resistant depression; depression treatment; primary care;
psychotherapy
ID RANDOMIZED CONTROLLED-TRIAL; STAR-ASTERISK-D; PRIMARY-CARE PATIENTS;
COGNITIVE-BEHAVIORAL THERAPY; ACUTE MAJOR DEPRESSION; RESIDUAL
DEPRESSION; COLLABORATIVE CARE; COST-EFFECTIVENESS; PSYCHOLOGICAL
INTERVENTIONS; 2ND-STEP TREATMENTS
AB OBJECTIVE: To examine the utility of psychotherapy in managing treatment resistant depression.
DATA SOURCES: PubMed, PsycInfo, Embase, Cochrane Registry of Controlled Clinical Trials, article bibliographies.
REVIEW METHODS: Eligible articles had to be in English and include English-speaking adult outpatients from general medical or mental health clinics. Studies had to be randomized clinical trials (RCT) involving at least one of the following psychotherapy modalities: cognitive therapy, interpersonal therapy, or behavior therapy. Patients were considered treatment resistant if they reported partial or no remission following treatment with an adequate antidepressant dose for >= 6 weeks. Exclusion criteria included receiving psychotherapy at the time of recruitment, and/or comorbid psychiatric conditions unlikely to be treated outside of specialized mental health care (e.g., severe substance abuse). Due to heterogeneity in study designs, a summary estimate of effect was not calculated. Studies were critically analyzed and a qualitative synthesis was conducted.
RESULTS: Of 941 original titles, 13 articles evaluating 7 unique treatment comparisons were included. Psychotherapy was examined as an augmentation to antidepressants in five studies and as substitution treatment in two studies. A total of 592 patients were evaluated (Mean age similar to 40 y; Females = 50-85%; Caucasians >= 75%). The STAR*D trial used an equipoise stratified randomization design; the remaining studies were RCTs. Compared to active management, two good quality trials showed similar benefit from augmenting antidepressants with psychotherapy; one fair quality and one poor quality trial showed benefit from psychotherapy augmentation; and one good and one poor trial found similar benefit from substituting psychotherapy for antidepressants. One fair quality trial showed lithium augmentation to be more beneficial than psychotherapy.
CONCLUSIONS: Review demonstrates the utility of psychotherapy in managing treatment resistant depression. However, evidence is sparse and results are mixed. Given that quality trials are lacking, rigorous clinical trials are recommended to guide practice. In the interim, primary care providers should consider psychotherapy when treating patients with treatment resistant depression.
C1 [Trivedi, Ranak B.] Univ Washington, Sch Publ Hlth, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA.
[Nieuwsma, Jason A.] Duke Univ, Med Ctr, Durham VA MIRECC, Durham, NC USA.
[Williams, John W., Jr.] Duke Univ, Med Ctr, Durham VA Med Ctr, Evidence Based Practice Ctr, Durham, NC USA.
RP Trivedi, RB (reprint author), Univ Washington, Sch Publ Hlth, VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM ranak.trivedi@va.gov
FU Duke University Medical Center; VA Mid-Atlantic MIRECC fellowship; VA
Health Services
FX Dr. Trivedi was partly supported by an AHRQ T-32 fellowship at Duke
University Medical Center, and resources within the VA Puget Sound
Health Care System. Dr. Nieuwsma was partly supported by a VA
Mid-Atlantic MIRECC fellowship. The views and opinions in this
manuscript are those of the authors and do not reflect those of the VA.;
This project was funded by the VA Health Services Research and
Development Evidence Synthesis Program.
NR 51
TC 19
Z9 19
U1 3
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2011
VL 26
IS 6
BP 643
EP 650
DI 10.1007/s11606-010-1608-2
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 763RE
UT WOS:000290576600016
PM 21184287
ER
PT J
AU April, MD
Chiosi, JJ
Paltiel, AD
Sax, PE
Walensky, RP
AF April, Michael D.
Chiosi, John J.
Paltiel, A. David
Sax, Paul E.
Walensky, Rochelle P.
TI Projected Survival Gains from Revising State Laws Requiring Written
Opt-in Consent for HIV Testing
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE HIV; AIDS; screening; modeling; survival analysis
ID MYCOBACTERIUM-AVIUM COMPLEX; PNEUMOCYSTIS-CARINII-PNEUMONIA; MULTIPLE
VIROLOGICAL FAILURES; HEALTH-CARE SETTINGS; UNITED-STATES;
ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; OPPORTUNISTIC INFECTIONS;
HIV-1-INFECTED PATIENTS; PRIMARY PROPHYLAXIS
AB BACKGROUND: Although the Centers for Disease Control and Prevention recommends HIV testing in all settings unless patients refuse (opt-out consent), many state laws require written opt-in consent.
OBJECTIVE: To quantify potential survival gains from passing state laws streamlining HIV testing consent.
DESIGN: We retrieved surveillance data to estimate the current annual HIV diagnosis rate in states with laws requiring written opt-in consent (19.3%). Published data informed the effect of removing that requirement on diagnosis rate (48.5% increase). These parameters then served as input for a model-driven projection of survival based on consent method. Other inputs included undiagnosed HIV prevalence (0.101%); and annual HIV incidence (0.023%).
PATIENTS: Hypothetical cohort of adults (> 13 years) living in written opt-in states.
MEASUREMENTS: Life years gained (LYG).
RESULTS: In the base-case, of the 53,036,383 adult persons living in written opt-in states, 0.66% (350,040) will be infected with HIV. Due to earlier diagnosis, revised consent laws yield 1.5 LYG per HIV-infected person, corresponding to 537,399 LYG among this population. Sensitivity analyses demonstrate that diagnosis rate increases of 24.8-72.3% result in 304,765-724,195 LYG. Net survival gains vanish if the proportion of HIV-infected persons refusing all testing in response to revised laws exceeds 18.2%.
CONCLUSIONS: The potential survival gains of increased testing are substantial, suggesting that state laws requiring opt-in HIV testing should be revised.
C1 [April, Michael D.] Rochelle P Walensky, Div Gen Med, MGH, Boston, MA 02114 USA.
[Walensky, Rochelle P.] Harvard Univ, Sch Med, Ctr AIDS Res CFAR, Boston, MA USA.
[Chiosi, John J.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Paltiel, A. David] Yale Univ, Sch Med, New Haven, CT USA.
[Sax, Paul E.; Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Sax, Paul E.; Walensky, Rochelle P.] Brigham & Womens Hosp, Dept Gen Med, Boston, MA 02115 USA.
RP April, MD (reprint author), Rochelle P Walensky, Div Gen Med, MGH, 50 Staniford St,9th Fl, Boston, MA 02114 USA.
EM Michael_April@hms.harvard.edu
OI Walensky, Rochelle P./0000-0002-8795-379X
FU CEPAC faculty; National Institute of Allergy and Infectious Diseases
[R01 AI058736, P30 AI060354]; National Institute of Mental Health [R01
MH065869, R01 MH073445]; Doris Duke Charitable Foundation; Gilead;
Merck; Tibotec
FX We are indebted to the entire CEPAC faculty for their support. Thanks
especially to Lauren Uhler and Alexis Sypek for their contributions
(MGH, Boston, MA).; National Institute of Allergy and Infectious
Diseases (R01 AI058736, P30 AI060354), the National Institute of Mental
Health (R01 MH065869, R01 MH073445), and the Doris Duke Charitable
Foundation (Clinical Scientist Development Award).; Dr. Paul E. Sax is a
consultant for Abbott, BMS, Gilead, GSK, Merck, Tibotec, and ViiV and
receives grant support from Gilead, Merck, and Tibotec. All other
authors report no disclosures.
NR 46
TC 4
Z9 4
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2011
VL 26
IS 6
BP 661
EP 667
DI 10.1007/s11606-011-1637-5
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 763RE
UT WOS:000290576600019
PM 21286837
ER
PT J
AU Arbiser, JL
Fisher, DE
AF Arbiser, Jack L.
Fisher, David E.
TI Fisetin: A Natural Fist against Melanoma?
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Editorial Material
AB Melanoma has now become the subject of targeted therapies, based upon the high prevalence of B-raf mutations in melanoma. However, while initial responses to B-raf inhibitors are impressive, resistance is extremely common, suggesting that melanoma is not addicted to B-raf. In their report, Syed et al. demonstrate that fisetin, a natural product without well established mechanisms, has activity against melanoma. Their report suggests that "nontargeted therapies" need to become part of our armamentarium against melanoma, given that targeted therapies do not target all of the pathways required for melanoma growth.
C1 [Arbiser, Jack L.] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA.
[Arbiser, Jack L.] Atlanta Vet Adm Hosp, Winship Canc Inst, Atlanta, GA USA.
[Fisher, David E.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
RP Arbiser, JL (reprint author), Emory Univ, Sch Med, Dept Dermatol, WMB 5309,1639 Pierce Dr, Atlanta, GA 30322 USA.
EM jarbise@emory.edu
FU NIAMS NIH HHS [R01-AR043369-15, R01 AR47901, P30 AR42687]
NR 2
TC 4
Z9 4
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD JUN
PY 2011
VL 131
IS 6
BP 1187
EP 1189
DI 10.1038/jid.2011.39
PG 3
WC Dermatology
SC Dermatology
GA 764GD
UT WOS:000290616700005
PM 21566577
ER
PT J
AU Bailey, EE
Kroshinsky, D
AF Bailey, E. E.
Kroshinsky, D.
TI Diagnostic guidelines for cellulitis: Recommendations based on a
retrospective analysis of cellulitis admissions to Massachusetts General
Hospital
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the Medical-Dermatology-Society
CY FEB 03, 2011
CL New Orleans, LA
SP Med Dermatol Soc
C1 [Bailey, E. E.] Columbia Univ, Coll Phys & Surg, New York, NY USA.
[Kroshinsky, D.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD JUN
PY 2011
VL 131
IS 6
MA 4
BP 1390
EP 1390
PG 1
WC Dermatology
SC Dermatology
GA 764GD
UT WOS:000290616700042
ER
PT J
AU Leduc, MS
Lyons, M
Darvishi, K
Walsh, K
Sheehan, S
Amend, S
Cox, A
Orho-Melander, M
Kathiresan, S
Paigen, B
Korstanje, R
AF Leduc, Magalie S.
Lyons, Malcolm
Darvishi, Katayoon
Walsh, Kenneth
Sheehan, Susan
Amend, Sarah
Cox, Allison
Orho-Melander, Marju
Kathiresan, Sekar
Paigen, Beverly
Korstanje, Ron
TI The mouse QTL map helps interpret human genome-wide association studies
for HDL cholesterol
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE genomics; high density lipoprotein; comparative genomics; quantitative
trait loci; mouse model
ID QUANTITATIVE TRAIT LOCI; DENSITY-LIPOPROTEIN CHOLESTEROL;
CORONARY-HEART-DISEASE; CAST/EI INBRED MICE; GENE-EXPRESSION;
BIOINFORMATICS TOOLBOX; INTERCROSS; POPULATION; STRAINS; CROSSES
AB Genome-wide association (GWA) studies represent a powerful strategy for identifying susceptibility genes for complex diseases in human populations but results must be confirmed and replicated. Because of the close homology between mouse and human genomes, the mouse can be used to add evidence to genes suggested by human studies. We used the mouse quantitative trait loci (QTL) map to interpret results from a GWA study for genes associated with plasma HDL cholesterol levels. We first positioned single nucleotide polymorphisms (SNPs) from a human GWA study on the genomic map for mouse HDL QTL. We then used mouse bioinformatics, sequencing, and expression studies to add evidence for one well-known HDL gene (Abca1) and three newly identified genes (Galnt2, Wwox, and Cdh13), thus supporting the results of the human study. For GWA peaks that occur in human haplotype blocks with multiple genes, we examined the homologous regions in the mouse to prioritize the genes using expression, sequencing, and bioinformatics from the mouse model, showing that some genes were unlikely candidates and adding evidence for candidate genes Mvk and Mmab in one haplotype block and Fads1 and Fads2 in the second haplotype block. Our study highlights the value of mouse genetics for evaluating genes found in human GWA studies.-Leduc, M. S., M. Lyons, K. Darvishi, K. Walsh, S. Sheehan, S. Amend, A. Cox, M. Orho-Melander, S. Kathiresan, B. Paigen, and R. Korstanje. The mouse QTL map helps interpret human genome-wide association studies for HDL cholesterol. J. Lipid Res. 2011. 52: 1139-1149.
C1 [Leduc, Magalie S.; Lyons, Malcolm; Darvishi, Katayoon; Walsh, Kenneth; Sheehan, Susan; Amend, Sarah; Cox, Allison; Paigen, Beverly; Korstanje, Ron] Jackson Lab, Bar Harbor, ME 04609 USA.
[Orho-Melander, Marju] Lund Univ, Malmo Univ Hosp, Malmo, Sweden.
[Kathiresan, Sekar] Massachussetts Gen Hosp, Boston, MA USA.
RP Korstanje, R (reprint author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
EM ron.korstanje@jax.org
FU National Institutes of Health [HL077796, HL081162, HL095668]; American
Heart Association; National Cancer Institute [CA034196]; Pfizer; Alnylam
Pharmaceuticals
FX This study was funded by National Institutes of Health grants (HL077796
and HL081162 to B. P., HL095668 to R. K.), the American Heart
Association post-doctoral Fellowship (to M. S. L.), and the National
Cancer Institute Core grant to The Jackson Laboratory (CA034196). Its
contents are solely the responsibility of the authors and do not
necessarily represent the official views of the National Institutes of
Health or other granting agencies. S. Kathiresan has received grant
support from Pfizer and Alnylam Pharmaceuticals and has served on
scientific advisory boards for Pfizer, Merck, and Daiichi Sankyo.
NR 51
TC 17
Z9 17
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD JUN
PY 2011
VL 52
IS 6
BP 1139
EP 1149
DI 10.1194/jlr.M009175
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 763LX
UT WOS:000290559500009
PM 21444760
ER
PT J
AU Stahl, JE
Holt, JK
Gagliano, NJ
AF Stahl, James E.
Holt, Julie K.
Gagliano, Nancy J.
TI Understanding Performance and Behavior of Tightly Coupled Outpatient
Systems Using RFID: Initial Experience
SO JOURNAL OF MEDICAL SYSTEMS
LA English
DT Article
DE RFID; Outpatient; Operations research; System behavior; Time-motion
ID TRACKING SYSTEM; TIME; CARE; PHYSICIANS; WORK; MANAGEMENT; VISITS
AB Understanding how clinical systems actually behave in an era of limited medical resources is critical. The purpose of this study was to determine if a radiofrequency-identification-based indoor positioning system (IPS) could objectively and unobtrusively capture outpatient clinic behavior. Primary outcomes were flowtime, wait time and patient/clinician face time. Two contrasting clinics were evaluated: a primary care clinic (PC) with templated scheduling and an urgent care clinic (UC) with unconstrained visit time and first-in, first-out scheduling. All staff wore transponders throughout the study period. Patients carried transponders from check in to check out. All patients and staff were allowed to opt out. The study was approved by hospital IRB. Standard descriptive and analytic statistical methods were used. Five hundred twenty-six patients (309 patients (PC), 217 patients (UC)) and 38 clinicians (eight (PC) and 30 (UC)) volunteered between April 30 and July 1, 2008. Total FT was not significantly different across clinics. PC wait time was significantly shorter (7.6 min [SD 15.8]) vs. UC (19.7 min [SD 25.3], p < 0.0001), and PC Face time was significantly longer (29.9 min, [SD 19.1] vs. UC (9.8 min [SD 8.5], p < 0.0001). PC Face time distributions reflected template scheduling structure. In contrast, face time distributions in UC had a smooth log normal distribution with a lower mean value. Our study seems to indicate that an IPS can successfully measure important clinic process measures in live clinical outpatient settings and capture behavioral differences across different outpatient organizational structures.
C1 [Stahl, James E.; Holt, Julie K.] MGH Inst Technol Assessment, Boston, MA 02114 USA.
[Gagliano, Nancy J.] Massachusetts Gen Hosp, Massachusetts Gen Phys Org, Boston, MA 02114 USA.
RP Stahl, JE (reprint author), MGH Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.
EM james@mgh-ita.org
FU Massachusetts General Physicians Organization
FX Sponsored by the Massachusetts General Physicians Organization.
NR 30
TC 11
Z9 11
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0148-5598
J9 J MED SYST
JI J. Med. Syst.
PD JUN
PY 2011
VL 35
IS 3
BP 291
EP 297
DI 10.1007/s10916-009-9365-7
PG 7
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 763RL
UT WOS:000290577300002
PM 20703561
ER
PT J
AU Kalva, SP
Somarouthu, B
Hirsch, J
AF Kalva, Sanjeeva P.
Somarouthu, Bhanusupriya
Hirsch, Joshua
TI Inferior vena cava filters for the cerebrovascular patient
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
ID DEEP VENOUS THROMBOSIS; ACUTE ISCHEMIC-STROKE; PULMONARY-EMBOLISM; VEIN
THROMBOSIS; THROMBOEMBOLISM; PREVENTION; EXPERIENCE; UPDATE; CARE
AB Acute cerebrovascular disease is often complicated by deep venous thrombosis and pulmonary embolism. Many of these patients are at high risk of intracranial hemorrhage with therapeutic anticoagulation. These patients may benefit from insertion of inferior vena cava filters. Studies specifically dealing with stroke patients are lacking, but it is the authors' opinion that filters reduce the incidence of pulmonary embolism. There is little evidence to support the use of these devices prophylactically in patients who do not have venous thromboembolism. Retrievable filters are an attractive option but there are concerns about their safety; and if regularly used, a system for successful filter retrieval in all patients should be instituted. The role of concurrent anticoagulation with filters is not clear. However, we believe anticoagulation, in the absence of a contraindication, is beneficial in patients with active venous thromboembolism.
C1 [Kalva, Sanjeeva P.; Somarouthu, Bhanusupriya; Hirsch, Joshua] Massachusetts Gen Hosp, Dept Imaging, Boston, MA 02114 USA.
[Kalva, Sanjeeva P.; Somarouthu, Bhanusupriya; Hirsch, Joshua] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
RP Kalva, SP (reprint author), GRB 297,55 Fruit St, Boston, MA 02114 USA.
EM skalva@partners.org
NR 30
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD JUN
PY 2011
VL 3
IS 2
BP 137
EP 140
DI 10.1136/jnis.2010.003798
PG 4
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA 760DL
UT WOS:000290303800004
PM 21990805
ER
PT J
AU Somarouthu, B
Yeddula, K
Wicky, S
Hirsch, JA
Kalva, SP
AF Somarouthu, Bhanusupriya
Yeddula, Kalpana
Wicky, Stephan
Hirsch, Joshua A.
Kalva, Sanjeeva P.
TI Long-term safety and effectiveness of inferior vena cava filters in
patients with stroke
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
ID FATAL PULMONARY-EMBOLISM; VENOUS THROMBOEMBOLISM; PREVENTION; EXPERIENCE
AB Purpose To assess the long-term safety and clinical effectiveness of inferior vena cava (IVC) filters in patients with stroke.
Method and materials In this institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study, we reviewed the clinical data of patients who had stroke and were treated with an IVC filter from 2002 to 2009. The demographics, clinical data, indications for IVC filter, procedural complications, symptomatic post-filter pulmonary embolism (PE) and deep vein thrombosis (DVT), caval occlusion and incidental, imaging-evident filter-related complications were recorded. Safety was assessed through occurrence of filter-related complications during placement and follow-up. Effectiveness was assessed through occurrence of post-filter fatal and non-fatal PE.
Results During this period, 371 patients (224 male; mean age 67.5 years) with stroke received an IVC filter. The stroke was hemorrhagic in 28%, ischemic in 20%, associated with intracranial malignancy in 21% and trauma in 31%. 235 (63%) patients (PE in 159) had venous thromboembolism on imaging. The indications for IVC filter included contraindication to anticoagulation in 251 (68%), prophylaxis in 83 (22%), added protection in 22 (6%) and complication or failure of anticoagulation in 15 (4%). There was one procedural complication. During a follow-up of 1.74+/-2.36 years, 180 (49%) patients died, three due to post-filter PE and the remainder all due to primary disease. Symptomatic post-filter PE and DVT occurred at a frequency of 15% (54/371) and 16% (60/371), respectively. Of these, 15 (4%) had imaging-proven PE. Three (0.8%) succumbed to post-filter PE. Imaging-proven new or recurrent DVT occurred in 6% and 8%, respectively. Symptomatic caval occlusion was seen in five (5/371, 1.3%).
Conclusion IVC filters have an acceptable safety profile in stroke patients. In our cohort, they were effective in preventing life-threatening PE.
C1 [Somarouthu, Bhanusupriya; Yeddula, Kalpana; Wicky, Stephan; Hirsch, Joshua A.; Kalva, Sanjeeva P.] Massachusetts Gen Hosp, Div Vasc Imaging & Intervent, Dept Imaging, Boston, MA 02114 USA.
[Wicky, Stephan; Hirsch, Joshua A.; Kalva, Sanjeeva P.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Div Neuro Imaging & Intervent, Boston, MA 02114 USA.
RP Kalva, SP (reprint author), Massachusetts Gen Hosp, Div Vasc Imaging & Intervent, Dept Imaging, GRB 297,55 Fruit St, Boston, MA 02114 USA.
EM skalva@partners.org
NR 24
TC 4
Z9 4
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD JUN
PY 2011
VL 3
IS 2
BP 141
EP 146
DI 10.1136/jnis.2010.004564
PG 6
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA 760DL
UT WOS:000290303800005
PM 21990806
ER
PT J
AU White, C
Brugera, C
Hirsch, J
AF White, Christopher
Brugera, Carolyn
Hirsch, Joshua
TI The neurointerventionalist and the AdvaMed Code of Ethics: examining the
doctor-device industry relationship
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
C1 [White, Christopher] AdvaMed, Washington, DE USA.
[Brugera, Carolyn] Micrus Endovasc Corp, San Jose, CA USA.
[Hirsch, Joshua] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP White, C (reprint author), 701 Penn Ave NW,Suite 800, Washington, DC 20004 USA.
EM cwhite@advamed.org
NR 4
TC 2
Z9 2
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD JUN
PY 2011
VL 3
IS 2
BP 204
EP 206
DI 10.1136/jnis.2010.003921
PG 3
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA 760DL
UT WOS:000290303800019
PM 21990820
ER
PT J
AU Sarajarvi, T
Tuusa, JT
Haapasalo, A
Lackman, JJ
Sormunen, R
Helisalmi, S
Roehr, JT
Parrado, AR
Makinen, P
Bertram, L
Soininen, H
Tanzi, RE
Petaja-Repo, UE
Hiltunen, M
AF Sarajarvi, Timo
Tuusa, Jussi T.
Haapasalo, Annakaisa
Lackman, Jarkko J.
Sormunen, Raija
Helisalmi, Seppo
Roehr, Johannes T.
Parrado, Antonio R.
Makinen, Petra
Bertram, Lars
Soininen, Hilkka
Tanzi, Rudolph E.
Petaja-Repo, Ulla E.
Hiltunen, Mikko
TI Cysteine 27 Variant of the delta-Opioid Receptor Affects Amyloid
Precursor Protein Processing through Altered Endocytic Trafficking
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM;
CELL-SURFACE; PHARMACOLOGICAL CHAPERONES; SUBCELLULAR-LOCALIZATION;
MULTIVESICULAR BODIES; DRUG-DEPENDENCE; ALPHA-SECRETASE; BETA
AB Agonist-induced activation of the delta-opioid receptor (delta OR) was recently shown to augment beta- and gamma-secretase activities, which increased the production of beta-amyloid peptide (A beta), known to accumulate in the brain tissues of Alzheimer's disease (AD) patients. Previously, the delta OR variant with a phenylalanine at position 27 (delta OR-Phe27) exhibited more efficient receptor maturation and higher stability at the cell surface than did the less common cysteine (delta OR-Cys27) variant. For this study, we expressed these variants in human SH-SY5Y and HEK293 cells expressing exogenous or endogenous amyloid precursor protein (APP) and assessed the effects on APP processing. Expression of delta OR-Cys27, but not delta OR-Phe27, resulted in a robust accumulation of the APP C83 C-terminal fragment and the APP intracellular domain, while the total soluble APP and, particularly, the beta-amyloid 40 levels were decreased. These changes upon delta OR-Cys27 expression coincided with decreased localization of APP C-terminal fragments in late endosomes and lysosomes. Importantly, a long-term treatment with a subset of delta OR-specific ligands or a c-Src tyrosine kinase inhibitor suppressed the delta OR-Cys27-induced APP phenotype. These data suggest that an increased constitutive internalization and/or concurrent signaling of the delta OR-Cys27 variant affects APP processing through altered endocytic trafficking of APP.
C1 [Sarajarvi, Timo; Haapasalo, Annakaisa; Helisalmi, Seppo; Makinen, Petra; Soininen, Hilkka; Hiltunen, Mikko] Univ Eastern Finland, Inst Clin Med Neurol, FI-70211 Kuopio, Finland.
[Sarajarvi, Timo; Haapasalo, Annakaisa; Helisalmi, Seppo; Makinen, Petra; Soininen, Hilkka; Hiltunen, Mikko] Kuopio Univ Hosp, Dept Neurol, FI-70211 Kuopio, Finland.
[Tuusa, Jussi T.; Lackman, Jarkko J.; Petaja-Repo, Ulla E.] Univ Oulu, Inst Biomed, Dept Anat & Cell Biol, FI-90014 Oulu, Finland.
[Sormunen, Raija] Univ Oulu, Bioctr Oulu, FI-90014 Oulu, Finland.
[Parrado, Antonio R.; Tanzi, Rudolph E.] Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA USA.
[Parrado, Antonio R.; Tanzi, Rudolph E.] Harvard Univ, Sch Med, Boston, MA 02129 USA.
[Roehr, Johannes T.; Bertram, Lars] Max Planck Inst Mol Genet, Dept Vertebrate Genom, Neuropsychiat Genet Grp, D-14195 Berlin, Germany.
RP Hiltunen, M (reprint author), Univ Eastern Finland, Inst Clin Med Neurol, POB 1627, FI-70211 Kuopio, Finland.
EM mikko.hiltunen@uef.fi
RI Bertram, Lars/K-3889-2015
OI Bertram, Lars/0000-0002-0108-124X
FU University of Eastern Finland; Health Research Council of the Academy of
Finland [14133, 127199]; Sigrid Juselius Foundation; Kuopio University
Hospital [5772708]; Nordic Centre of Excellence in Neurodegeneration;
Finnish Cultural Foundation; Cure Alzheimer's Fund; NIA; Finnish Funding
Agency for Technology and Innovation [70048/09]
FX This study was supported by strategic funding from the University of
Eastern Finland and by grants from the Health Research Council of the
Academy of Finland (grant 14133 to A.H. and grant 127199 to H.S., M.H.,
and U.E.P.-R.), the Sigrid Juselius Foundation (to U.E.P.-R. and M.H.),
the Kuopio University Hospital (EVO grant 5772708 to H.S.), the Nordic
Centre of Excellence in Neurodegeneration (to H.S. and M.H.), the
Finnish Cultural Foundation (to J.T.T.), the Cure Alzheimer's Fund and
NIA (to R.E.T.), and the Finnish Funding Agency for Technology and
Innovation (grant 70048/09 to H.S.).
NR 48
TC 16
Z9 16
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUN
PY 2011
VL 31
IS 11
BP 2326
EP 2340
DI 10.1128/MCB.05015-11
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 762KI
UT WOS:000290475100013
PM 21464208
ER
PT J
AU Gerhard, F
Haslinger, R
Pipa, G
AF Gerhard, Felipe
Haslinger, Robert
Pipa, Gordon
TI Applying the Multivariate Time-Rescaling Theorem to Neural Population
Models
SO NEURAL COMPUTATION
LA English
DT Article
ID SPIKE-TRAIN DATA; POINT-PROCESSES; PAIRWISE CORRELATIONS;
STATISTICAL-MODELS; NEURONAL NETWORKS; CELL ASSEMBLIES; FIELD;
INFORMATION; GENERATION; EXCESS
AB Statistical models of neural activity are integral to modern neuroscience. Recently interest has grown in modeling the spiking activity of populations of simultaneously recorded neurons to study the effects of correlations and functional connectivity on neural information processing. However, any statistical model must be validated by an appropriate goodness-of-fit test. Kolmogorov-Smirnov tests based on the time-rescaling theorem have proven to be useful for evaluating point-process-based statistical models of single-neuron spike trains. Here we discuss the extension of the time-rescaling theorem to the multivariate (neural population) case. We show that even in the presence of strong correlations between spike trains, models that neglect couplings between neurons can be erroneously passed by the univariate time-rescaling test. We present the multivariate version of the time-rescaling theorem and provide a practical step-by-step procedure for applying it to testing the sufficiency of neural population models. Using several simple analytically tractable models and more complex simulated and real data sets, we demonstrate that important features of the population activity can be detected only using the multivariate extension of the test.
C1 [Gerhard, Felipe] Ecole Polytech Fed Lausanne, Brain Mind Inst, CH-1015 Lausanne, Switzerland.
[Gerhard, Felipe; Pipa, Gordon] Frankfurt Inst Adv Studies, D-60438 Frankfurt, Germany.
[Haslinger, Robert] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Haslinger, Robert; Pipa, Gordon] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Pipa, Gordon] Univ Osnabruck, Inst Cognit Sci, D-49069 Osnabruck, Germany.
[Pipa, Gordon] Max Planck Inst Brain Res, Dept Neurophysiol, D-60528 Frankfurt, Germany.
RP Gerhard, F (reprint author), Ecole Polytech Fed Lausanne, Brain Mind Inst, CH-1015 Lausanne, Switzerland.
EM felipe.gerhard@epfl.ch; robhh@nmr.mgh.harvard.edu; gpipa@uos.de
RI Pipa, Gordon/M-1813-2014
OI Pipa, Gordon/0000-0002-3416-2652
FU NIH [K25 NS052422-02]; Max Planck Society; EU [PHOCUS, 240763]; Stiftung
Polytechnische Gesellschaft (Frankfurt am Main, Germany); Swiss National
Science Foundation [200020-117975]
FX We are grateful to Sergio Neuenschwander and Bruss Lima for supplying
the macaque V1 recordings discussed in section 3.3. This work was
supported by NIH grant K25 NS052422-02, the Max Planck Society, and EU
Grant PHOCUS, 240763, FP7-ICT-2009-C. F.G. acknowledges partial support
by the Stiftung Polytechnische Gesellschaft (Frankfurt am Main, Germany)
and support by the Swiss National Science Foundation under grant number
200020-117975.
NR 92
TC 6
Z9 6
U1 1
U2 3
PU MIT PRESS
PI CAMBRIDGE
PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA
SN 0899-7667
EI 1530-888X
J9 NEURAL COMPUT
JI Neural Comput.
PD JUN
PY 2011
VL 23
IS 6
BP 1452
EP 1483
PG 32
WC Computer Science, Artificial Intelligence; Neurosciences
SC Computer Science; Neurosciences & Neurology
GA 760CO
UT WOS:000290300400002
PM 21395436
ER
PT J
AU Bartzokis, G
Lu, PH
Tingus, K
Peters, DG
Amar, CP
Tishler, TA
Finn, JP
Villablanca, P
Altshuler, LL
Mintz, J
Neely, E
Connor, JR
AF Bartzokis, George
Lu, Po H.
Tingus, Kathleen
Peters, Douglas G.
Amar, Chetan P.
Tishler, Todd A.
Finn, J. Paul
Villablanca, Pablo
Altshuler, Lori L.
Mintz, Jim
Neely, Elizabeth
Connor, James R.
TI Gender and Iron Genes May Modify Associations Between Brain Iron and
Memory in Healthy Aging
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE memory; iron; gene; sex; dementia; treatment
ID MILD COGNITIVE IMPAIRMENT; ONSET PARKINSONS-DISEASE; POPULATION-BASED
COHORTS; ALZHEIMERS-DISEASE; FERRITIN IRON; RECOGNITION MEMORY; MOUSE
HIPPOCAMPUS; OXIDATIVE STRESS; MAJOR SUBTYPES; SERUM IRON
AB Brain iron increases with age and is abnormally elevated early in the disease process in several neurodegenerative disorders that impact memory including Alzheimer's disease (AD). Higher brain iron levels are associated with male gender and presence of highly prevalent allelic variants in genes encoding for iron metabolism proteins (hemochromatosis H63D (HFE H63D) and transferrin C2 (TfC2)). In this study, we examined whether in healthy older individuals memory performance is associated with increased brain iron, and whether gender and gene variant carrier (IRON+) vs noncarrier (IRON-) status (for HFE H63D/TfC2) modify the associations. Tissue iron deposited in ferritin molecules can be measured in vivo with magnetic resonance imaging utilizing the field-dependent relaxation rate increase (FDRI) method. FDRI was assessed in hippocampus, basal ganglia, and white matter, and IRON+ vs IRON- status was determined in a cohort of 63 healthy older individuals. Three cognitive domains were assessed: verbal memory (delayed recall), working memory/attention, and processing speed. Independent of gene status, worse verbal-memory performance was associated with higher hippocampal iron in men (r = -0.50, p = 0.003) but not in women. Independent of gender, worse verbal working memory performance was associated with higher basal ganglia iron in IRON- group (r = -0.49, p = 0.005) but not in the IRON+ group. Between-group interactions (p = 0.006) were noted for both of these associations. No significant associations with white matter or processing speed were observed. The results suggest that in specific subgroups of healthy older individuals, higher accumulations of iron in vulnerable gray matter regions may adversely impact memory functions and could represent a risk factor for accelerated cognitive decline. Combining genetic and MRI biomarkers may provide opportunities to design primary prevention clinical trials that target high-risk groups. Neuropsychopharmacology (2011) 36, 1375-1384; doi:10.1038/npp.2011.22; published online 9 March 2011
C1 [Bartzokis, George; Peters, Douglas G.; Amar, Chetan P.; Tishler, Todd A.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Bartzokis, George] Univ Calif Los Angeles, Div Brain Mapping, Dept Neurol, Lab Neuroimaging, Los Angeles, CA 90095 USA.
[Bartzokis, George; Peters, Douglas G.; Amar, Chetan P.; Tishler, Todd A.] Greater Los Angeles VA Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Lu, Po H.; Tingus, Kathleen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Finn, J. Paul; Villablanca, Pablo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
[Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Neely, Elizabeth; Connor, James R.] Penn State Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA.
RP Bartzokis, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA.
EM gbar@ucla.edu
RI Bartzokis, George/K-2409-2013
FU NIH [AG027342, MH0266029]; Department of Veterans Affairs; RCS
Alzheimer's Foundation; George M Leader Family
FX This work was supported in part by NIH grants (AG027342 and MH0266029),
the Department of Veterans Affairs, the RCS Alzheimer's Foundation, and
the George M Leader Family. This work was presented in part at the 451st
Annual Winter Conference on Brain Research, Snowbird, Utah, January
2008, and the Alzheimer's Association International Conference on
Alzheimer's Disease (ICAD), Vienna, Austria, July 2009.
NR 105
TC 39
Z9 39
U1 1
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JUN
PY 2011
VL 36
IS 7
BP 1375
EP 1384
DI 10.1038/npp.2011.22
PG 10
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 764GL
UT WOS:000290617500007
PM 21389980
ER
PT J
AU Pan, JQ
Lewis, MC
Ketterman, JK
Clore, EL
Riley, M
Richards, KR
Berry-Scott, E
Liu, XL
Wagner, FF
Holson, EB
Neve, RL
Biechele, TL
Moon, RT
Scolnick, EM
Petryshen, TL
Haggarty, SJ
AF Pan, Jen Q.
Lewis, Michael C.
Ketterman, Josh K.
Clore, Elizabeth L.
Riley, Misha
Richards, Keenan R.
Berry-Scott, Erin
Liu, Xiulin
Wagner, Florence F.
Holson, Edward B.
Neve, Rachael L.
Biechele, Travis L.
Moon, Randall T.
Scolnick, Edward M.
Petryshen, Tracey L.
Haggarty, Stephen J.
TI AKT Kinase Activity Is Required for Lithium to Modulate Mood-Related
Behaviors in Mice
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE lithium; AKT; mania; depression; TCF/LEF; behavior
ID GLYCOGEN-SYNTHASE KINASE-3; IN-VIVO; MOLECULAR-MECHANISM;
DOPAMINE-RECEPTORS; SIGNALING CASCADE; BIPOLAR DISORDER; UP-REGULATION;
RODENT MODEL; MANIA; ACTIVATION
AB Bipolar disorder (BP) is a debilitating psychiatric disorder, affecting similar to 2% of the worldwide population, for which the etiological basis, pathogenesis, and neurocircuitry remain poorly understood. Individuals with BP suffer from recurrent episodes of mania and depression, which are commonly treated with the mood stabilizer lithium. However, nearly half of BP patients do not respond adequately to lithium therapy and the clinically relevant mechanisms of lithium for mood stabilization remain elusive. Here, we modeled lithium responsiveness using cellular assays of glycogen synthase kinase 3 (GSK-3) signaling and mood-related behavioral assays in inbred strains of mice that differ in their response to lithium. We found that activating AKT through phosphosrylation of a key regulatory site (Thr308) was associated with lithium response-activation of signaling pathways downstream of GSK-3 in cells and attenuation of mood-related behaviors in mice-and this response was attenuated by selective and direct inhibition of AKT kinase activity. Conversely, the expression of constitutively active AKT1 in both the cellular and behavioral assays conferred lithium sensitivity. In contrast, selective and direct GSK-3 inhibition by the ATP-competitive inhibitor CHIR99021 bypassed the requirement for AKT activation and modulated behavior in both lithium-responsive and non-responsive mouse strains. These results distinguish the mechanism of action of lithium from direct GSK-3 inhibition both in vivo and in vitro, and highlight the therapeutic potential for selective GSK-3 inhibitors in BP treatment. Neuropsychopharmacology (2011) 36, 1397-1411; doi:10.1038/npp.2011.24; published online 9 March 2011
C1 [Pan, Jen Q.; Lewis, Michael C.; Ketterman, Josh K.; Clore, Elizabeth L.; Riley, Misha; Richards, Keenan R.; Berry-Scott, Erin; Liu, Xiulin; Wagner, Florence F.; Holson, Edward B.; Scolnick, Edward M.; Petryshen, Tracey L.; Haggarty, Stephen J.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.
[Neve, Rachael L.] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA.
[Biechele, Travis L.; Moon, Randall T.] Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Seattle, WA 98195 USA.
[Biechele, Travis L.; Moon, Randall T.] Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA.
[Petryshen, Tracey L.; Haggarty, Stephen J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Petryshen, Tracey L.; Haggarty, Stephen J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Mol Neurogenet Unit, Boston, MA 02114 USA.
[Petryshen, Tracey L.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Haggarty, Stephen J.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
RP Haggarty, SJ (reprint author), Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, 7 Cambridge Ctr, Cambridge, MA 02142 USA.
EM petryshen@chgr.mgh.harvard.edu; haggarty@chgr.mgh.harvard.edu
RI Moon, Randall/B-1743-2014;
OI Moon, Randall/0000-0002-9352-1408; Haggarty, Stephen
J./0000-0002-7872-168X
FU National Institutes of Health [RL1GM084437, RL1CA133834, RL1HG004671,
UL1RR024924, MH087442-01]; Stanley Medical Research Institute
FX We thank Drs Li-Huei Tsai, Daniel Fass, Jon Madison, Pamela Sklar,
Melanie Leussis, and Roy Perlis for critical reading of the paper. We
thank Dr Jennifer Moran for technical assistance with HT-22 cell
genotype analysis. We thank Dr. Michael Moyer for assistance with the
AKT inhibitor experiments. We thank Drs M Mazei-Robison and E Nestler
for providing HSV-AKT1 constructs. This work was supported by grants
from the National Institutes of Health (RL1GM084437 to EMS,
administratively linked to RL1CA133834, RL1HG004671, and UL1RR024924;
MH087442-01 to JP and SJH) and the Stanley Medical Research Institute
(to EMS, SJH, TLP). RTM is an investigator of the HHMI.
NR 50
TC 44
Z9 44
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JUN
PY 2011
VL 36
IS 7
BP 1397
EP 1411
DI 10.1038/npp.2011.24
PG 15
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 764GL
UT WOS:000290617500009
PM 21389981
ER
PT J
AU Chung, JW
Fayad, J
Linthicum, F
Ishiyama, A
Merchant, SN
AF Chung, Jong Woo
Fayad, Jose
Linthicum, Fred
Ishiyama, Akira
Merchant, Saumil N.
TI Histopathology After Endolymphatic Sac Surgery for Meniere's Syndrome
SO OTOLOGY & NEUROTOLOGY
LA English
DT Article
DE Endolymphatic sac surgery; Histopathology; Meniere's syndrome; Temporal
bone; Vertigo
ID TEMPORAL BONE; DOUBLE-BLIND; HYDROPS; DISEASE; SHUNT
AB Background: The putative goal of sac surgery in Meniere's syndrome is to promote the flow of endolymph from the labyrinth to the endolymphatic sac and thereby relieving hydrops. There are scant published histopathologic data whether sac surgery actually accomplishes this goal.
Objective: To determine whether sac surgery relieves hydrops by examining the histopathologic changes in temporal bones obtained from individuals who had undergone sac surgery during life for Meniere's syndrome.
Methods: Temporal bones were examined from 15 patients who had sac surgery. Data on the presence and severity of hydrops, histology of the sac, and whether the procedure relieved vertigo were collected.
Results: The surgery failed to expose the sac in 5 cases; 4 of the 5 had relief from vertigo. The sac was exposed, but the shunt failed to reach the lumen of the sac in 8 cases; 4 of the 8 had relief from vertigo. The shunt was successfully placed within the lumen of the sac in 2 cases; both cases failed to experience relief from vertigo. Endolymphatic hydrops was present in all 15 cases.
Conclusion: Endolymphatic sac surgery does not relieve hydrops in patients with Meniere's syndrome. Yet, sac surgery relieves vertigo in some patients, but the mechanism of such symptomatic relief remains unknown.
C1 [Chung, Jong Woo; Merchant, Saumil N.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
[Ishiyama, Akira] Univ Calif Los Angeles, Los Angeles, CA USA.
[Fayad, Jose; Linthicum, Fred] House Ear Res Inst, Los Angeles, CA USA.
RP Merchant, SN (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.
EM saumil_merchant@meei.harvard.edu
FU National Institute on Deafness and Other Communication Disorders' Human
Temporal Bone Consortium for Research Resource Enhancement [U24 DC
008559]
FX Supported by the National Institute on Deafness and Other Communication
Disorders' Human Temporal Bone Consortium for Research Resource
Enhancement (U24 DC 008559).
NR 14
TC 13
Z9 18
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1531-7129
J9 OTOL NEUROTOL
JI Otol. Neurotol.
PD JUN
PY 2011
VL 32
IS 4
BP 660
EP 664
DI 10.1097/MAO.0b013e31821553ce
PG 5
WC Clinical Neurology; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 763ME
UT WOS:000290560600022
PM 21436748
ER
PT J
AU Hong, TS
Shammas, A
Charron, M
Zukotynski, KA
Drubach, LA
Lim, R
AF Hong, Terence S.
Shammas, Amer
Charron, Martin
Zukotynski, Katherine A.
Drubach, Laura A.
Lim, Ruth
TI Brown adipose tissue F-18-FDG uptake in pediatric PET/CT imaging
SO PEDIATRIC RADIOLOGY
LA English
DT Article
DE PET/CT; Brown adipose tissue; FDG uptake; False-positives; Children
ID UPPER CHEST REGION; FDG UPTAKE; ORAL DIAZEPAM; ADULT HUMANS; USA-FAT;
TEMPERATURE; CHILDREN; MALIGNANCIES; PROTEIN; MUSCLE
AB Positron emission tomography (PET) using [F-18]2-fluoro-2-deoxyglucose (FDG) fused with CT (F-18-FDG PET/CT) has been widely adopted in oncological imaging. However, it is known that benign lesions and other metabolically active tissues, such as brown adipose tissue (BAT), can accumulate F-18-FDG, potentially resulting in false-positive interpretation. Previous studies have reported that F-18-FDG uptake in BAT is more common in children than in adults. We illustrate BAT FDG uptake in various anatomical locations in children and adolescents. We also review what is known about the effects of patient-related physical attributes and environmental temperatures on BAT FDG uptake, and discuss methods used to reduce BAT FDG uptake on F-18-FDG PET.
C1 [Shammas, Amer; Charron, Martin] Hosp Sick Children, Dept Diagnost Imaging, Div Nucl Med, Toronto, ON M5G 1X8, Canada.
[Zukotynski, Katherine A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging,Div Nucl Med, Boston, MA 02115 USA.
[Drubach, Laura A.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Radiol,Div Nucl Med PET, Boston, MA 02115 USA.
[Lim, Ruth] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
RP Shammas, A (reprint author), Hosp Sick Children, Dept Diagnost Imaging, Div Nucl Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM amer.shammas@sickkids.ca
NR 34
TC 3
Z9 3
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0301-0449
J9 PEDIATR RADIOL
JI Pediatr. Radiol.
PD JUN
PY 2011
VL 41
IS 6
BP 759
EP 768
DI 10.1007/s00247-010-1925-y
PG 10
WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging
SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging
GA 763GX
UT WOS:000290544500012
PM 21161205
ER
PT J
AU Giustina, A
Bronstein, MD
Casanueva, FF
Chanson, P
Ghigo, E
Ho, KKY
Klibanski, A
Lamberts, S
Trainer, P
Melmed, S
AF Giustina, A.
Bronstein, M. D.
Casanueva, F. F.
Chanson, P.
Ghigo, E.
Ho, K. K. Y.
Klibanski, A.
Lamberts, S.
Trainer, P.
Melmed, S.
TI Current management practices for acromegaly: an international survey
SO PITUITARY
LA English
DT Article
DE Acromegaly; Questionnaire; Growth hormone; Insulin like growth factor-I;
Somatostatin analogs; Pegvisomant
ID RECEPTOR ANTAGONIST PEGVISOMANT; GROWTH-HORMONE; SOMATOSTATIN ANALOGS;
LONG-TERM; GLUCOSE-HOMEOSTASIS; CONSENSUS STATEMENT; TREATMENT OUTCOMES;
HIGH PREVALENCE; DIAGNOSIS; GUIDELINES
AB To determine whether peer-reviewed consensus statements have changed clinical practice, we surveyed acromegaly care in specialist centers across the globe, and determined the degree of adherence to published consensus guidelines on acromegaly management. Sixty-five acromegaly experts who participated in the 7th Acromegaly Consensus Workshop in March 2009 responded. Results indicated that the most common referring sources for acromegaly patients were other endocrinologists (in 26% of centers), neurosurgeons (25%) and primary care physicians (21%). In sixty-nine percent of patients, biochemical diagnoses were made by evaluating results of a combination of growth hormone (GH) nadir/basal GH and elevated insulin like growth factor-I (IGF-I) levels. In both Europe and the USA, neurosurgery was the treatment of choice for GH-secreting microadenomas and for macroadenomas with compromised visual function. The most widely used criteria for neurosurgical outcome assessment were combined measurements of IGF-I and GH levels after oral glucose tolerance test (OGTT) 3 months after surgery. Ninety-eight percent of respondents stated that primary treatment with somatostatin receptor ligands (SRLs) was indicated at least sometime during the management of acromegaly patients. In nearly all centers (96%), the use of pegvisomant monotherapy was restricted to patients who had failed to achieve biochemical control with SRL therapy. The observation that most centers followed consensus statement recommendations encourages the future utility of these workshops aimed to create uniform management standards for acromegaly.
C1 [Giustina, A.] Univ Brescia, Dept Med & Surg Sci, Endocrine Serv, Montichiari Hosp, I-25018 Montichiari, Italy.
[Bronstein, M. D.] Univ Sao Paulo, Sch Med, Neuroendocrine Unit, Div Endocrinol & Metab, BR-14049 Ribeirao Preto, Brazil.
[Casanueva, F. F.] Univ Santiago de Compostela, Dept Med, Div Endocrinol CHUS, Santiago De Compostela, Spain.
[Chanson, P.] Univ Paris 11, AP HP, Dept Endocrinol & Reprod Dis, Le Kremlin Bicetre, France.
[Ghigo, E.] Univ Turin, Div Endocrinol, Turin, Italy.
[Ho, K. K. Y.] Garvan Inst Med Res, Pituitary Res Unit, Sydney, NSW, Australia.
[Klibanski, A.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
[Klibanski, A.] Harvard Univ, Sch Med, Boston, MA USA.
[Lamberts, S.] Erasmus MC, Dept Internal Med, Div endocrinol, Rotterdam, Netherlands.
[Trainer, P.] Christie Hosp, Dept Endocrinol, Manchester, Lancs, England.
[Melmed, S.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.
RP Giustina, A (reprint author), Univ Brescia, Dept Med & Surg Sci, Endocrine Serv, Montichiari Hosp, Via Ciotti 154, I-25018 Montichiari, Italy.
EM a.giustina@libero.it
RI Ho, Ken/E-5832-2011; Chanson, Philippe/F-8511-2013;
OI Trainer, Peter/0000-0003-0146-3835
FU Ipsen
FX The authors thank the following participants in the Seventh Acromegaly
Consensus Group meeting for their kind participation in this survey in
advance of the meeting: John Ayuk, Birmingham, UK; Ariel Barkan, Ann
Arbor, USA; Albert Beckers, Liege, Belgium; Paolo Beck-Peccoz, Milan,
Italy; Bengt-A ke Bengtsson, Gothenburg, Sweden; Anat Ben-Shlomo, Los
Angeles, USA; Jerome Bertherat, Paris, France; John Bevan, Aberdeen, UK;
Beverly Biller, Boston, USA; Jens Bollerslev, Oslo, Norway; Vivien
Bonert, Los Angeles, USA; Marcello Bronstein, Sao Paulo, Brazil; Thierry
Brue, Marseille, France; Michael Buchfelder, Erlangen, Germany; Philippe
Caron, Toulouse, France; Davide Carvalho, Porto, Portugal; Felipe
Casanueva, Santiago de Compostela, Spain; Franco Cavagnini, Milan,
Italy; Philippe Chanson, Le Kremlin Bicetre, France; David Clemmons,
Chapel Hill, USA; Annamaria Colao, Naples, Italy; Renato Cozzi, Milan,
Italy; Ettore Degli Uberti, Ferrara, Italy; Laura De Marinis, Rome,
Italy; Ernesto De Menis, Italy; Eva Marie Erfurth, Lund, Sweden; Rudolph
Fahlbusch, Hannover, Germany; Diego Ferone, Genoa, Italy; Pamela Freda,
New York, USA; Lawrence Frohman, Chicago, USA; Monica Gadelha, Rio de
Janeiro, Brazil; Rolf Gaillard, Switzerland; Ezio Ghigo, Turin, Italy;
Yona Greenman, Tel Aviv, Israel; Ashley Grossmann, London, UK; Feng Gu,
Beijing, China; Amir Hamrahian, Cleveland, USA; Ian Holdaway, New
Zealand; Ken Ho, Sydney, Australia; Jens Otto Jorgensen, Aarhus,
Denmark; David Kleinberg, New York, USA; Anne Klibanski, Boston, USA;
Steven Lamberts, Rotterdam, Netherlands; Edward Laws, Boston, USA;
Gaetano Lombardi, Naples, Italy; Marco Losa, Milan, Italy; Pietro
Maffei, Padua, Italy; Josef Marek, Prague, Czech Republic; Gherardo
Mazziotti, Mantua, Italy; Moises Mercado, Mexico City, Mexico; Francesco
Minuto, Genoa, Italy; Mark Molitch, Chicago, USA; Pietro Mortini,
Brescia, Italy; Robert Murray, Leeds, UK; Stephan Petersenn, Essen,
Germany; Ferdinand Roelfsema, Netherlands; Richard Ross, Sheffield, UK;
Roberto Salvatori, Baltimore, USA; Janet Schlechte, Iowa City, USA;
Jochen Schopohl, Munich, Germany; Omar Serri, Montreal, Canada; Guenter
Stalla, Munich, Germany; Brooke Swearingen, USA; Mary Lee Vance,
Charlottesville, USA; Aart Jan Van Der Lely, Rotterdam, Netherlands,
Massimo Terzolo, Italy; George Tolis, Greece; John Wass, Oxford, UK;
Susan Webb, Barcelona, Spain; Margaret Wierman, Denver, USA; Sema
Yarman, Istanbul, Turkey. Editorial assistance was provided by John
Clarke and Martin Gilmour (ESP Bioscience) supported by Ipsen.
NR 34
TC 55
Z9 58
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1386-341X
EI 1573-7403
J9 PITUITARY
JI Pituitary
PD JUN
PY 2011
VL 14
IS 2
BP 125
EP 133
DI 10.1007/s11102-010-0269-9
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 763UZ
UT WOS:000290586500004
PM 21063787
ER
PT J
AU Winkfield, KM
Niemierko, A
Bussiere, MR
Crowley, EM
Napolitano, BN
Beaudette, KP
Loeffler, JS
Shih, HA
AF Winkfield, K. M.
Niemierko, A.
Bussiere, M. R.
Crowley, E. M.
Napolitano, B. N.
Beaudette, K. P.
Loeffler, J. S.
Shih, H. A.
TI Modeling Intracranial Second Tumor Risk and Estimates of Clinical
Toxicity with Various Radiation Therapy Techniques For Patients with
Pituitary Adenoma
SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT
LA English
DT Article
DE Pituitary adenoma; Second tumor risk; Conformal radiation therapy;
Radiation toxicity; Proton radiation therapy
ID INTENSITY-MODULATED RADIOTHERAPY; PARANASAL SINUS CANCER; PHOTON
RADIOTHERAPY; PROSTATE-CANCER; PROTON; BRAIN; IRRADIATION; CHILDHOOD;
NEOPLASMS; IMRT
AB This study was designed to estimate the risk of radiation-associated tumors and clinical toxicity in the brain following fractionated radiation treatment of pituitary adenoma. A standard case of a patient with a pituitary adenoma was planned using 8 different dosimetric techniques. Total dose was 50.4 Gy (GyE) at daily fractionation of 1.8 Gy (GyE). All methods utilized the same CT simulation scan with designated target and normal tissue volumes. The excess risk of radiation-associated second tumors in the brain was calculated using the corresponding dose-volume histograms for the whole brain and based on the data published by the United Nation Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) and a risk model proposed by Schneider. The excess number of second tumor cases per 10,000 patients per year following radiation is 9.8 for 2-field photons, 18.4 with 3-field photons, 20.4 with photon intensity modulated radiation therapy (IMRT), and 25 with photon stereotactic radiotherapy (SRT). Proton radiation resulted in the following excess second tumor risks: 2-field = 5.1, 3-field = 12, 4-field = 15, 5-field = 16. Temporal lobe toxicity was highest for the 2-field photon plan. Proton radiation therapy achieves the best therapeutic ratio when evaluating plans for the treatment of pituitary adenoma. Temporal lobe toxicity can be reduced through the use of multiple fields but is achieved at the expense of exposing a larger volume of normal brain to radiation. Limiting the irradiated volume of normal brain by reducing the number of treatment fields is desirable to minimize excess risk of radiation-associated second tumors.
C1 [Winkfield, K. M.; Niemierko, A.; Bussiere, M. R.; Crowley, E. M.; Napolitano, B. N.; Beaudette, K. P.; Loeffler, J. S.; Shih, H. A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Winkfield, KM (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 3, Boston, MA 02114 USA.
EM kwinkfield@partners.org
NR 35
TC 7
Z9 7
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-0346
EI 1533-0338
J9 TECHNOL CANCER RES T
JI Technol. Cancer Res. Treat.
PD JUN
PY 2011
VL 10
IS 3
BP 243
EP 251
PG 9
WC Oncology
SC Oncology
GA 763JX
UT WOS:000290553700004
PM 21517130
ER
PT J
AU Enestvedt, BK
Williams, JL
Sonnenberg, A
AF Enestvedt, B. K.
Williams, J. L.
Sonnenberg, A.
TI Epidemiology and practice patterns of achalasia in a large multi-centre
database
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID UNITED-STATES; BOTULINUM TOXIN; PREVALENCE; CONSORTIUM; HOSPITALIZATION;
COLONOSCOPY; POPULATION; HEMORRHAGE; ENDOSCOPY
AB Background
Due to its rarity, achalasia remains a difficult disease to study.
Aims
To describe the epidemiology of achalasia and practice patterns in its endoscopic management, utilising patient records from a large national database of endoscopic procedures.
Methods
The Clinical Outcomes Research Initiative maintains a database of endoscopic procedures in diverse clinical practices. The data from 89 endoscopy practices distributed throughout the US during 2000-2008 were used to analyse the characteristics and therapy of patients with achalasia.
Results
Among 521 497 upper endoscopies during the study period, we identified 896 patients with achalasia. Compared with the entirety of all other endoscopic diagnoses, achalasia was more common in men than in women (OR = 1.39, CI 1.22-1.59), but similar among nonwhites and whites (OR = 0.87, CI 0.74-1.03). Relatively, more achalasia patients were treated at university than at community practices (OR = 1.52, CI 1.30-1.78). Botox injection was most frequently used as first choice of endoscopic therapy in 41%, followed by balloon dilation in 21%, Savary dilation in 20%, Maloney dilation in 10%, Rigiflex in 4% and other modalities in 4% of patients. One quarter of achalasia patients treated endoscopically underwent a repeat therapy about every 14 months.
Conclusions
Botox has become the primary choice of initial endoscopic therapy in achalasia. Despite their partial deviation from guidelines and recommendations, these endoscopic patterns reflect the current clinical practice in the United States.
C1 [Enestvedt, B. K.; Williams, J. L.; Sonnenberg, A.] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97201 USA.
[Williams, J. L.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
[Sonnenberg, A.] Portland VA Med Ctr, Portland, OR USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-G1,3710 SW S Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
FU NIDDK [UO1 CA 89389-01, U01 DK057132, R33-DK61778-01]; AstraZeneca; Bard
International; Pentax USA; ProVation; Endosoft; GIVEN Imaging; Ethicon
FX Declaration of funding interests: The study was supported with funding
from NIDDK UO1 CA 89389-01, NIDDK U01 DK057132 and R33-DK61778-01. In
addition, the practice network (CORI) has received support from the
following entities to support the infrastructure of the practice based
network: AstraZeneca, Bard International, Pentax USA, ProVation,
Endosoft, GIVEN Imaging and Ethicon. The commercial entities had no
involvement in this research.
NR 31
TC 12
Z9 13
U1 0
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD JUN 1
PY 2011
VL 33
IS 11
BP 1209
EP 1214
DI 10.1111/j.1365-2036.2011.04655.x
PG 6
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 758OL
UT WOS:000290174300004
PM 21480936
ER
PT J
AU Butt, AA
Umbleja, T
Andersen, JW
Chung, RT
Sherman, KE
AF Butt, A. A.
Umbleja, T.
Andersen, J. W.
Chung, R. T.
Sherman, K. E.
CA ACTG A5178 Study Team
TI The incidence, predictors and management of anaemia and its association
with virological response in HCV/HIV coinfected persons treated with
long-term pegylated interferon alfa 2a and ribavirin
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID HEPATITIS-C-VIRUS; CHRONIC KIDNEY-DISEASE; HIV-INFECTED PATIENTS;
HUMAN-IMMUNODEFICIENCY-VIRUS; PLUS RIBAVIRIN; EPOETIN-ALPHA; HEMOGLOBIN;
ZIDOVUDINE; THERAPY; IMPACT
AB Background
The association of anaemia with outcomes in the HCV/HIV coinfected persons undergoing HCV treatment remains unclear.
Aims
To study the incidence, predictors and management of anaemia, and its association with outcomes among persons treated with pegylated interferon and weight-based ribavirin.
Methods
Retrospective analysis of a prospective controlled treatment trial of HCV/HIV coinfection.
Results
Among 329 subjects enrolled, 40% developed anaemia during the first 1218 weeks of treatment (median haemoglobin decrease at week 4: 2.2 g/dL). Among 169 subjects who achieved early virological response and received therapy for 72 weeks, 55% eventually developed anaemia. However, median haemoglobin levels stayed stable after 12-18 weeks of initial therapy. Among these 169 subjects, 45% were prescribed an erythropoiesis stimulating agent (ESA), with 17% receiving it prior to a drop in haemoglobin meeting protocol definition of anaemia. Only 27% completed the study without any ribavirin dose modification. Age >40 years, lower BMI, zidovudine use and lower entry haemoglobin were significant predictors of anaemia in the multi-covariate model. Among all 329, sustained virological response (SVR) rate was similar in those with or without anaemia (23% vs. 30%; P = 0.17) with no evidence of association between anaemia or ESA use and treatment response.
Conclusions
Anaemia is common in HCV/HIV coinfected persons undergoing HCV treatment, and only a minority of them are able to maintain ribavirin dose. Persons with age > 40 years, lower baseline haemoglobin and lower baseline BMI should be monitored carefully. Prescription of erythropoiesis stimulating agent is common, but anaemia or erythropoiesis stimulating agent use is not associated with SVR.
C1 [Butt, A. A.] Univ Pittsburgh, Div Infect Dis, Dept Med, Pittsburgh, PA 15213 USA.
[Umbleja, T.; Andersen, J. W.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Chung, R. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sherman, K. E.] Univ Cincinnati, Div Digest Dis, Cincinnati, OH USA.
RP Butt, AA (reprint author), Univ Pittsburgh, Div Infect Dis, Dept Med, 3601 5th Ave,Suite 3A, Pittsburgh, PA 15213 USA.
EM aabutt@pitt.edu
FU Valeant; DSMB; Tibotec; Roche; Schering; Gilead; Vertex; SciClone; HGS;
National Institute of Allergy and Infectious Diseases [U01AI068636];
National Institute of Mental Health (NIMH), National Institute of Dental
and Craniofacial Research (NIDCR)
FX Declaration of personal interests: AAB received research support from
Valeant. TU declares no conflicts of interest. JWA received support from
DSMB and Tibotec. RTC received research support from Roche and Schering.
KES received research support (to institution) from Roche, Schering,
Gilead, Vertex, SciClone and HGS. He served as a consultant and advisory
board member for BMS, Vertex, SciClone, Anadys, Merck and Valeant, and
served on the DSMB or Endpoint Adjudication Committee for Tibotec and
Pfizer. Declaration of funding interests: This study was supported by
Award Number U01AI068636 from the National Institute of Allergy and
Infectious Diseases and supported by National Institute of Mental Health
(NIMH), National Institute of Dental and Craniofacial Research (NIDCR).
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Allergy and Infectious Diseases or the National Institutes of Health.
NR 26
TC 12
Z9 13
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD JUN 1
PY 2011
VL 33
IS 11
BP 1234
EP 1244
DI 10.1111/j.1365-2036.2011.04648.x
PG 11
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 758OL
UT WOS:000290174300007
PM 21535051
ER
PT J
AU Sreenivasan, R
Bassett, EK
Hoganson, DM
Vacanti, JP
Gleason, KK
AF Sreenivasan, Ramaswamy
Bassett, Erik K.
Hoganson, David M.
Vacanti, Joseph P.
Gleason, Karen K.
TI Ultra-thin, gas permeable free-standing and composite membranes for
microfluidic lung assist devices
SO BIOMATERIALS
LA English
DT Article
DE Lung assist device; Permeable membrane; iCVD; Membrane oxygenator;
Artificial lung
ID CHEMICAL-VAPOR-DEPOSITION; ARTIFICIAL LUNGS; MICROCHANNEL TECHNOLOGIES;
RECTANGULAR CHANNELS; HYDROGEN SEPARATION; MALEIC-ANHYDRIDE; COPOLYMERS;
LAYERS; LIVER; FILMS
AB Membranes for a lung assist device must permit the exchange of gaseous O2 and CO(2) while simultaneously acting as a liquid barrier, so as to prevent leakage of blood and its components from passing from one side to the other. Additionally, these membranes must be capable of being integrated into microfluidic devices possessing a vascular network. In this work, uniform, large-area, ultra-thin, polymeric free-standing membranes (FSMs) and composite membranes (CMs) are reproducibly fabricated by initiated Chemical Vapor Deposition (iCVD). The 5 mu m thick FSMs remained intact during handling and exhibited a CO(2) permeance that was 1.3 times that of the control membrane (8 mu m thick spun-cast membrane of silicone). The CMs consisted of a dense iCVD skin layer (0.5-3 mu m thick) deposited on top of a polytetrafluoroethylene (PTFE) support membrane (20 mu m thick, 100 nm pores). The CMs exhibited CO(2) and O(2) permeance values 50-300 times that of the control membrane. The FSMs were subjected to mechanical testing to assess the impact of the absence of an underlying support structure. The CMs were subjected to liquid barrier tests to ensure that while they were permeable to gases, they acted as barriers to liquids. Both FSMs and CMs were integrated into silicone microfluidic devices and tested for bond integrity. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Sreenivasan, Ramaswamy; Gleason, Karen K.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Bassett, Erik K.; Hoganson, David M.; Vacanti, Joseph P.] Massachusetts Gen Hosp, Lab Tissue Engn & Organ Fabricat, Boston, MA 02114 USA.
RP Gleason, KK (reprint author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM kkg@mit.edu
RI Gleason, Karen/G-1471-2013;
OI Gleason, Karen/0000-0001-6127-1056; Hoganson, David/0000-0002-8141-7793
FU US Army through the Institute for Soldier Nanotechnologies
[DAAD-19-02-D-0002]; U.S. Army Research Office [DAAD-19-02-D-0002]
FX This research was supported in part by the US Army through the Institute
for Soldier Nanotechnologies, under Contract DAAD-19-02-D-0002 with the
U.S. Army Research Office. We would like to thank undergraduate
researchers Alex Mannion and Kelly Desharnais for their assistance with
sample preparations and gas and liquid permeation experiments.
NR 32
TC 14
Z9 15
U1 6
U2 56
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2011
VL 32
IS 16
BP 3883
EP 3889
DI 10.1016/j.biomaterials.2011.02.017
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 758WA
UT WOS:000290196700001
PM 21396705
ER
PT J
AU Kachnic, LA
Li, L
Fournier, L
Ferraiolo, N
Dahm-Daphi, J
Borgmann, K
Willers, H
AF Kachnic, Lisa A.
Li, Li
Fournier, Loreen
Ferraiolo, Natalie
Dahm-Daphi, Jochen
Borgmann, Kerstin
Willers, Henning
TI FANCD2 but not FANCA promotes cellular resistance to type II
topoisomerase poisons
SO CANCER LETTERS
LA English
DT Article
DE Fanconi Anemia; FANCD2; FANCA; Etoposide
ID DOUBLE-STRAND BREAKS; MEDIATED DNA-DAMAGE; ANEMIA PATHWAY;
MONOUBIQUITINATED FANCD2; REPAIR; CANCER; COMPLEX; PROTEIN; BRCA1; CELLS
AB Genetic or epigenetic inactivation of the pathway formed by the Fanconi Anemia (FA) and BRCA proteins occurs in several cancer types, including lung and breast cancer, rendering the affected tumors potentially hypersensitive to DNA crosslinking agents. However, the cytotoxicity of other commonly used cancer therapeutics in cells with FA/BRCA pathway defects remains to be defined. Building on earlier data that implicated BRCA1 and BRCA2 in the repair of DNA damage caused by the topoisomerase II poison etoposide, we studied the role of FANCD2 in mediating resistance to several topoisomerase II poisons. We establish that the loss of FANCD2 increases cell death in response to etoposide. FANCD2 promotes homologous recombination repair (HRR) and prevents DNA double-strand break formation and chromosomal aberrations in etoposide-treated cells. Strikingly, this function of FANCD2 is independent of FANCD2 foci formation and of FANCA, which is a member of the FA core complex upstream of FANCD2 mono-ubiquitination. Thus, FANCD2 appears to promote HRR in a mono-ubiquitination-independent manner in conjunction with BRCA1/2. These data add to an emerging body of evidence indicating that the FA pathway is not linear and that several protein subcomplexes with different functions exist. Our findings are potentially relevant for predicting the sensitivity of lung and breast cancers to etoposide and doxorubicin, respectively. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Kachnic, Lisa A.; Li, Li; Fournier, Loreen; Ferraiolo, Natalie; Willers, Henning] Massachusetts Gen Hosp, Ctr Canc, Dept Radiat Oncol, Lab Cellular & Mol Radiat Oncol, Charlestown, MA 02129 USA.
[Kachnic, Lisa A.] Boston Med Ctr, Dept Radiat Oncol, Boston, MA 02118 USA.
[Dahm-Daphi, Jochen; Borgmann, Kerstin] Univ Med Ctr Hamburg Eppendorf, Lab Radiobiol & Expt Radiat Oncol, D-20246 Hamburg, Germany.
RP Willers, H (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 3,55 Fruit St, Boston, MA 02114 USA.
EM hwillers@partners.org
FU Department of Defense [W81XWH-06-1-0309]; Susan G. Komen for the Cure of
Breast Cancer [BCTR0504040]
FX The authors wish to thank Drs. Grover Bagby, Martin Brown, Alan
D'Andrea, and Markus Grompe for their generous contribution of
materials. The excellent technical assistance of Chake Tokadjian is
acknowledged. This work was supported by the Department of Defense
W81XWH-06-1-0309 (LAK, HW) and Susan G. Komen for the Cure of Breast
Cancer BCTR0504040 (HW).
NR 40
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD JUN 1
PY 2011
VL 305
IS 1
BP 86
EP 93
DI 10.1016/j.canlet.2011.02.030
PG 8
WC Oncology
SC Oncology
GA 758BD
UT WOS:000290133600010
PM 21414716
ER
PT J
AU Choi, WI
Lee, MY
Oh, D
Rho, BH
Hales, CA
AF Choi, Won-Il
Lee, Mi-Young
Oh, Doyeun
Rho, Byung Hak
Hales, Charles A.
TI Estimated Incidence of Acute Pulmonary Embolism in a Korean Hospital
SO CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
LA English
DT Article
DE pulmonary embolism; thromboembolism; incidence
ID DEEP VENOUS THROMBOSIS; FACTOR-V-LEIDEN; THROMBOEMBOLISM; MANAGEMENT
AB Patients with acute pulmonary embolism (PE) were identified retrospectively from patients hospitalized during a 2-year period from 2005 to 2007. Among adult patients (>= 20 years), the incidence of established acute PE was 88 (0.17%) of 50 882 in Dongsan Hospital. The incidence of acute PE at Dongsan Hospital was 26% lower than that at Henry Ford Hospital (P < .01). Among patients more than 50 years of age, PE was more frequent in women (0.32%; 95% CI, 0.24-0.4) than in men (0.15%; 95% CI, 0.1-0.21; P < .01). Among all patients with PE older than 20 years of age, 68 (0.21%) of 31 869 (95% CI, 0.17-0.26) were from the medical service and 18 (0.08%) of 23 139 (95% CI, 0.04-0.11; P <.01) were from the surgical service. The estimated incidence of PE in a university teaching hospital in Korea was 0.17%, it was about two thirds of that in North America.
C1 [Choi, Won-Il] Keimyung Univ, Sch Med, Dept Internal Med, Pulm Unit,Dongsan Hosp, Taegu 700712, South Korea.
[Lee, Mi-Young] Keimyung Univ, Sch Med, Dept Prevent Med, Taegu 700712, South Korea.
[Oh, Doyeun] Pochon CHA Univ, Dept Internal Med, Coll Med, Kyonggi Do, South Korea.
[Rho, Byung Hak] Keimyung Univ, Sch Med, Dongsan Hosp, Dept Diagnost Radiol, Taegu 700712, South Korea.
[Hales, Charles A.] Massachusetts Gen Hosp, Dept Med, Pulm Crit Care Unit, Boston, MA 02114 USA.
[Hales, Charles A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Choi, WI (reprint author), Keimyung Univ, Sch Med, Dept Internal Med, 194 Dongsan Dong, Taegu 700712, South Korea.
EM wichoi@dsmc.or.kr
FU Keimyung University
FX The present research has been conducted by the Bisa Research Grant of
Keimyung University in 2010.
NR 26
TC 6
Z9 6
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1076-0296
J9 CLIN APPL THROMB-HEM
JI Clin. Appl. Thromb.-Hemost.
PD JUN
PY 2011
VL 17
IS 3
BP 297
EP 301
DI 10.1177/1076029610368669
PG 5
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 761GO
UT WOS:000290385700012
PM 20530053
ER
PT J
AU Sorrell, AD
Lee, S
Stolle, C
Ellenhorn, J
Grix, A
Kaelin, WG
Weitzel, JN
AF Sorrell, A. D.
Lee, S.
Stolle, C.
Ellenhorn, J.
Grix, A.
Kaelin, W. G., Jr.
Weitzel, J. N.
TI Clinical and functional properties of novel VHL mutation (X214L)
consistent with Type 2A phenotype and low risk of renal cell carcinoma
SO CLINICAL GENETICS
LA English
DT Article
DE germline mutation; HIF; Jun B; neuroendocrine; pheochromocytoma; von
Hippel Lindau
ID HIPPEL-LINDAU-DISEASE; PHEOCHROMOCYTOMA; TUMOR; CANCER
AB This report describes clinical characteristics in families with a Type 2A phenotype and functional properties of a novel von Hippel Lindau variant (X214L). Pedigrees were analyzed. Analysis of von Hippel Lindau (VHL) coding exons and flanking intronic sequences in DNA from a proband with pheochromocytoma and islet cell tumor was performed. Western blot assays for VHL protein (pVHL), HIF alpha, and Jun B were conducted using VHL null renal clear carcinoma cell lines that were engineered to produce wild-type or X214L mutant pVHL. Pedigree analysis indicated that the variant tracked with disease and the same or similar VHL point mutations were identified in several Type 2A families. The predicted 14 amino acid extended pVHL variant, when reintroduced into VHL null cells, was stable and retained the ability to downregulate HIF alpha in a hydroxylation-dependent manner. In contrast, the variant was defective with respect to downregulation of JunB. pVHL X214L, like other pVHL variants associated with a low risk of clear cell renal carcinoma, largely preserves the ability to downregulate HIF. In contrast, this variant, like other pVHL variants linked to Type 2A disease, fails to suppress JunB. This underscores that JunB may play a role in the pathogenesis of Type 2A VHL disease.
C1 [Sorrell, A. D.; Ellenhorn, J.; Weitzel, J. N.] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Lee, S.; Kaelin, W. G., Jr.] Dana Farber Canc Res Inst, Boston, MA USA.
[Stolle, C.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Grix, A.] Permanente Med Grp Inc, Sacramento, CA USA.
[Kaelin, W. G., Jr.] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Sorrell, AD (reprint author), City Hope Natl Med Ctr, 1500 E Duarte Rd,Machris Bldg Rm 3040, Duarte, CA 91010 USA.
EM asorrell@coh.org
FU NIH through the Division of Clinical Cancer Genetics at the City of Hope
[R25 CA 085771]; General Clinical Research Center from NIH [M01 RR00043]
FX Dr. Sorrell was supported by a NIH funded career development award (R25
CA 085771; PI-J.N. Weitzel) through the Division of Clinical Cancer
Genetics at the City of Hope. This research was also supported in part
by a General Clinical Research Center grant from NIH (M01 RR00043)
awarded to the City of Hope National Medical Center, Duarte, California.
NR 22
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9163
J9 CLIN GENET
JI Clin. Genet.
PD JUN
PY 2011
VL 79
IS 6
BP 539
EP 545
DI 10.1111/j.1399-0004.2010.01464.x
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 759TJ
UT WOS:000290271100008
PM 20560986
ER
PT J
AU Chasson, GS
Timpano, KR
Greenberg, JL
Shaw, A
Singer, T
Wilhelm, S
AF Chasson, Gregory S.
Timpano, Kiara R.
Greenberg, Jennifer L.
Shaw, Ashley
Singer, Tracy
Wilhelm, Sabine
TI Shared social competence impairment: Another link between the
obsessive-compulsive and autism spectrums?
SO CLINICAL PSYCHOLOGY REVIEW
LA English
DT Review
DE Obsessive-Compulsive Spectrum Disorders; Autism Spectrum Disorders;
Social Competence Impairment; Obsessive-Compulsive Disorder; Autism
ID BODY DYSMORPHIC DISORDER; PERVASIVE DEVELOPMENTAL DISORDERS; EMOTION
RECOGNITION DEFICITS; HIGH-FUNCTIONING CHILDREN; ASPERGER-SYNDROME;
GLUTAMATE-RECEPTOR-6 GENE; PSYCHIATRIC-DISORDERS; CHRONIC-SCHIZOPHRENIA;
SYMPTOM PROVOCATION; FACIAL EXPRESSIONS
AB Recently, there has been a growing interest in the phenotypic, pathogenic, and pathophysiological overlap between autism spectrum disorders (ASD) and obsessive-compulsive spectrum disorders (OCSD). However, social competence impairment is one domain of overlap that has received less attention. Codified as one of three diagnostic categories in ASD, pathological social processing has also been demonstrated in OCSD. Yet, to date no reviews have synthesized the research literature on social competence impairments in OCSD, especially impairments that may parallel those found in ASD. The current review set out to examine the extant literature in this area in the service of advancing understanding of shared phenomenology between these two spectrums of conditions. Further, delineation of shared social competence impairments between ASD and OCSD might highlight candidate endophenotypes for further investigation. Ultimately, understanding the links between OCSD and ASD may aid in development of better intervention and prevention strategies, some of which may directly target maladaptive social processing. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Chasson, Gregory S.; Singer, Tracy] Towson Univ, Dept Psychol, Towson, MD 21254 USA.
[Timpano, Kiara R.] Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA.
[Greenberg, Jennifer L.; Shaw, Ashley; Wilhelm, Sabine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Chasson, GS (reprint author), Towson Univ, Dept Psychol, 8000 York Rd, Towson, MD 21254 USA.
EM gchasson@towson.edu; k.timpano@miami.edu; JLGREENBERG@partners.org;
AMSHAW@partners.org; tsinger224@gmail.com; wilhelm@psych.mgh.harvard.edu
RI Timpano, Kiara/C-8760-2012;
OI Timpano, Kiara/0000-0002-0665-8722
NR 102
TC 10
Z9 10
U1 7
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0272-7358
J9 CLIN PSYCHOL REV
JI Clin. Psychol. Rev.
PD JUN
PY 2011
VL 31
IS 4
BP 653
EP 662
DI 10.1016/j.cpr.2011.02.006
PG 10
WC Psychology, Clinical
SC Psychology
GA 755HY
UT WOS:000289920900012
PM 21482323
ER
PT J
AU Najafi-Shoushtari, SH
AF Najafi-Shoushtari, S. Hani
TI MicroRNAs in Cardiometabolic Disease
SO CURRENT ATHEROSCLEROSIS REPORTS
LA English
DT Article
DE microRNAs; Cholesterol; Fatty acids; Metabolism; Atherosclerosis
ID IN-VIVO; CHOLESTEROL HOMEOSTASIS; INFLAMMATORY RESPONSE; LIPID UPTAKE;
EXPRESSION; CELL; ATHEROSCLEROSIS; METABOLISM; MIR-33; SREBP
AB Defects in homeostatic regulation of cholesterol and fatty acids are associated with major cardiometabolic risk factors that are prevalent in type 2 diabetes and atherosclerotic cardiovascular disease. Regulatory input is found at many levels; however, recent findings have revealed pivotal roles for small non-coding RNAs (microRNAs) of the endogenous RNA interference pathway in post-transcriptional control of major regulatory mechanisms underpinning cholesterol and energy homeostasis. In addition, aberrant expression of microRNAs has been implicated in marked pathophysiologic events contributing to the progression and development of atherosclerosis, including loss of endothelial integrity, vascular smooth muscle cell proliferation, neointimal hyperplasia, and foam cell formation. This review surveys the impact of microRNA-mediated regulation in biological processes governing the cholesterol/lipoprotein metabolism, fatty acid beta-oxidation (eg by miR-122 and miR-33), and endothelial dysfunction related to atherosclerosis. Given the current advances in microRNA-based technologies, the clinical potential of microRNAs as novel therapeutic targets is highlighted as new alternative strategies to ameliorate cardiometabolic diseases.
C1 [Najafi-Shoushtari, S. Hani] Harvard Univ, Sch Med, Dept Cell Biol, Charlestown, MA 02129 USA.
[Najafi-Shoushtari, S. Hani] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA.
RP Najafi-Shoushtari, SH (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Charlestown, MA 02129 USA.
EM hnajafi-shoushtari@partners.org
OI Najafi-Shoushtari, Hani/0000-0002-7562-4083
NR 49
TC 18
Z9 18
U1 1
U2 7
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1523-3804
J9 CURR ATHEROSCLER REP
JI Curr. Atherosclerol. Rep.
PD JUN
PY 2011
VL 13
IS 3
BP 202
EP 207
DI 10.1007/s11883-011-0179-y
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 758MB
UT WOS:000290167800002
PM 21461683
ER
PT J
AU Nadeau, KJ
Reusch, JEB
AF Nadeau, Kristen J.
Reusch, Jane E. B.
TI Cardiovascular Function/Dysfunction in Adolescents with Type 1 Diabetes
SO CURRENT DIABETES REPORTS
LA English
DT Article
DE Type 1 diabetes; Youth; Children; Adolescents; Cardiovascular; Cardiac
dysfunction; Diastolic dysfunction; Systolic dysfunction; Insulin
resistance; Glycemic control; Atherosclerosis
ID INTIMA-MEDIA THICKNESS; INSULIN-RESISTANCE; ARTERIAL STIFFNESS;
BLOOD-PRESSURE; RISK-FACTORS; EARLY SIGNS; CHILDREN; MELLITUS;
ATHEROSCLEROSIS; DYSFUNCTION
AB Type 1 diabetes mellitus (T1D) is associated with an increased risk of cardiovascular disease (CVD) that begins in childhood. Youth with T1D develop concerning functional cardiac and vascular defects and evidence of early atherosclerosis, despite modern advancements in risk reduction and glycemic management. Such early defects predict poor long-term outcomes. Women with T1D also have higher CVD risk than expected for unexplained reasons. Insulin resistance (IR) is recently recognized as a prominent factor in T1D youth and adults, but with an atypical clinical phenotype. This IR may contribute to early cardiac and vascular dysfunction and long-term CVD in T1D. A better understanding of potential contributors to cardiovascular dysfunction in T1D youth such as IR and its unique phenotype in T1D, subtle lipid abnormalities, and gender differences is now required to address the current knowledge gaps and to prevent cardiovascular morbidity and mortality in T1D.
C1 [Nadeau, Kristen J.] Univ Colorado, Childrens Hosp, Aurora, CO 80045 USA.
[Reusch, Jane E. B.] Denver VAMC, Denver, CO 80220 USA.
[Reusch, Jane E. B.] Univ Colorado, Denver, CO 80220 USA.
RP Nadeau, KJ (reprint author), Univ Colorado, Childrens Hosp, 13123 E 16th Ave,B265, Aurora, CO 80045 USA.
EM nadeau.kristen@tchden.org; jane.reusch@ucdenver.edu
OI Nadeau, Kristen/0000-0002-0477-3356
FU Amylin; GlaxoSmithKline; Bristol-Myers Squibb; Juvenile Diabetes
Research Foundation [K23 020038, DK61242]; University of Colorado Center
for Women's Health Research [UL1 RR025780]; VA Merit Review [DK57516,
HL14985]; NIH/CRR [UL1 RR025780]
FX We K.J. Nadeau: none; J.E.B. Reusch: has received ITT grant funding from
Amylin, GlaxoSmithKline, and Bristol-Myers Squibb.; We would like to
acknowledge funding from the following sources: KJN (K23 020038Award,
DK61242, Juvenile Diabetes Research Foundation [PI Nadeau]); KJN and
JEBR (UL1 RR025780, University of Colorado Center for Women's Health
Research), JEBR (VA Merit Review, ADA research Award, DK57516, HL14985),
NIH/CRR Colorado CTSI Grant Number UL1 RR025780. We would also like to
acknowledge Amy West for her assistance with literature searches used to
prepare this manuscript.
NR 56
TC 8
Z9 8
U1 0
U2 2
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1534-4827
J9 CURR DIABETES REP
JI Curr. Diabetes Rep.
PD JUN
PY 2011
VL 11
IS 3
BP 185
EP 192
DI 10.1007/s11892-011-0180-4
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 758MN
UT WOS:000290169000006
PM 21336845
ER
PT J
AU Chan, JA
Kulke, MH
AF Chan, Jennifer A.
Kulke, Matthew H.
TI New Treatment Options for Patients with Advanced Neuroendocrine Tumors
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
ID RECEPTOR RADIONUCLIDE THERAPY; MALIGNANT CARCINOID-SYNDROME; PHASE-II;
HEPATIC METASTASES; LIVER METASTASES; OPERATIVE RESECTION; SOMATOSTATIN
ANALOG; ALPHA-INTERFERON; OCTREOTIDE; MANAGEMENT
AB Well- to moderately differentiated neuroendocrine tumors (NET) are a heterogeneous group of malignancies for which a range of therapeutic options have been employed. For patients with localized NET, surgical resection remains the mainstay of treatment. Surgical resection of hepatic metastases or hepatic artery embolization may also be beneficial in patients with hepatic-predominant metastatic disease. Symptoms of hormonal excess, such as carcinoid syndrome and syndromes associated with functional pancreatic NET, can be effectively treated with somatostatin analogs. Systemic treatment options for patients with advanced NET have been limited. Treatment with the somatostatin analog octreotide has been shown to improve progression-free survival in patients with advanced midgut carcinoid tumors, and the potential antiproliferative effect of somatostatin analogs in patients with other NET subtypes is currently under investigation. Patients with advanced pancreatic NET may also respond to treatment with streptozocin or temozolomide-based therapy. In patients with advanced pancreatic NET, randomized, placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with the mTOR inhibitor everolimus is associated with improved progression-free survival. Based on these studies, sunitinib or everolimus should now be considered as therapeutic options in patients with advanced pancreatic NET. Initial phase II studies have also suggested activity associated with VEGF pathway and mTOR inhibitors in patients with advanced carcinoid tumors. Future studies will likely further define the role of these agents in the advanced carcinoid patient population.
C1 [Chan, Jennifer A.; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP Chan, JA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM jang@partners.org
FU Novartis; Bayer/Onyx; Merck
FX J. Chan: consulted for Bayer/Onyx; received grants or has grants pending
from Novartis, Bayer/Onyx, Merck for clinical trial support; and
received payment from Novartis for educational presentations; M. Kulke:
consulted for Pfizer, Novartis, Lexicon, and Ipsen.
NR 54
TC 25
Z9 25
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527-2729
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD JUN
PY 2011
VL 12
IS 2
BP 136
EP 148
DI 10.1007/s11864-011-0148-2
PG 13
WC Oncology
SC Oncology
GA 758NM
UT WOS:000290171500003
PM 21437592
ER
PT J
AU Cappai, G
Songini, M
Doria, A
Cavallerano, JD
Lorenzi, M
AF Cappai, G.
Songini, M.
Doria, A.
Cavallerano, J. D.
Lorenzi, M.
TI Increased prevalence of proliferative retinopathy in patients with type
1 diabetes who are deficient in glucose-6-phosphate dehydrogenase
SO DIABETOLOGIA
LA English
DT Article
DE Diabetic retinopathy; Endothelial nitric oxide synthase; G6PD
deficiency; Oxidative stress; Polyol pathway; Proliferative retinopathy;
Type 1 diabetes
ID G6PD DEFICIENCY; MELLITUS; COMPLICATIONS
AB Impaired activity of the pentose phosphate pathway of glucose metabolism caused by hereditary deficiency of its key regulatory enzyme glucose-6-phosphate dehydrogenase (G6PD) has consequences that may worsen or attenuate the course of diabetic complications. Decreased availability of NADPH can predispose to oxidative stress and endothelial dysfunction, but can also limit the activity of the polyol pathway and cholesterol synthesis. Reduced availability of pentose phosphates for nucleic acid synthesis could impair cell proliferation. We sought to learn in which direction G6PD deficiency affects diabetic retinopathy.
We enrolled patients who were G6PD-deficient or -sufficient with type 1 diabetes of duration 15 years or longer for whom HbA(1c) records were available for at least the previous 3 years. Renal failure and smoking were exclusion criteria. For each participant seven standard field colour photographs were obtained of each eye, and retinopathy was graded in a masked fashion.
The clinical characteristics of the 19 G6PD-deficient patients studied (age 42 +/- 9 years, diabetes duration 24 +/- 6 years, average HbA(1c) over 3 years 6.7 +/- 0.8%) were similar to those of the 35 G6PD-sufficient patients. Almost 90% of patients in both groups had retinopathy; however, proliferative retinopathy was noted solely among G6PD-deficient patients (28%, p = 0.0036 vs G6PD-sufficient). The G6PD-deficient patients also showed a trend for increased frequency of microalbuminuria.
The data suggest that G6PD deficiency accelerates the microvascular complications of diabetes, and that among the consequences of G6PD deficiency those that can enhance the damage caused by diabetes outweigh those that could be protective.
C1 [Lorenzi, M.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA.
[Cappai, G.] Osped San Giovanni di Dio, Ophthalmol Clin, Cagliari, Italy.
[Songini, M.] Osped San Michele, Ctr Diabet, Cagliari, Italy.
[Doria, A.; Cavallerano, J. D.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02114 USA.
[Cavallerano, J. D.] Harvard Univ, Sch Med, Beetham Eye Inst, Boston, MA 02114 USA.
RP Lorenzi, M (reprint author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM mara.lorenzi@schepens.harvard.edu
FU Juvenile Diabetes Research Foundation; Massachusetts Lions Eye Research
Fund
FX We are grateful to M. Fossarello, Director of the Ophthalmology Clinic,
Ospedale San Giovanni di Dio, University of Cagliari for making
available for this study facilities and personnel; S. Pisano of the
Ophthalmology Clinic, Ospedale San Giovanni di Dio for taking the eye
photographs; and F. Mastinu and M. Mastinu for referring patients. The
study was supported by a grant from the Juvenile Diabetes Research
Foundation, a grant-in-aid from the Massachusetts Lions Eye Research
Fund, and a generous donation from B. Shaw to M. Lorenzi.
NR 11
TC 12
Z9 12
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD JUN
PY 2011
VL 54
IS 6
BP 1539
EP 1542
DI 10.1007/s00125-011-2099-3
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 760ML
UT WOS:000290328300032
PM 21380594
ER
PT J
AU Samadi, H
Sultzer, D
AF Samadi, Hossein
Sultzer, David
TI Solanezumab for Alzheimer's disease
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Alzheimer's disease; biomarkers; immunotherapy; monoclonal antibody;
solanezumab; beta-amyloid
ID A-BETA ANTIBODY; AMYLOID-BETA; INTRAVENOUS IMMUNOGLOBULINS;
MONOCLONAL-ANTIBODY; CONTROLLED-TRIAL; DOUBLE-BLIND; MOUSE MODEL;
IMMUNIZATION; PATHOLOGY; SAFETY
AB Areas covered: This paper reviews literature on solanezumab that is available in PubMed from 2008 to 2010, other treatment trials in clinicaltrials.gov and published abstracts from conferences. The article also provides a discussion of the early trials of AN1792 and an overview of the immunotherapies currently in development. The authors provide the reader with a critical appraisal of the to-date clinical trial data on solanezumab and its implications for the broader field of immunotherapies for AD.
Expert opinion: Solanezumab can neutralize soluble A beta beta peptides, which may represent the more neurotoxic of the A beta beta species. Phase II findings support the compound's safety, which has been a concern for some A beta beta immunotherapies. Cerebrospinal and plasma biomarker changes with solanezumab treatment are encouraging. Results of the ongoing Phase III trials will be instrumental in determining the drug's clinical significance.
C1 [Sultzer, David] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90073 USA.
[Sultzer, David] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Samadi, Hossein] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Samadi, Hossein] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA.
RP Sultzer, D (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, 11301 Wilshire Blvd,Bldg 401,Room A215,116AE, Los Angeles, CA 90073 USA.
EM dsultzer@ucla.edu
FU Department of Veterans Affairs (Geriatric Psychiatry Training, Office of
Academic Affiliations; CSRD Merit Review); Eli Lilly and Company
FX The authors are supported in part by the Department of Veterans Affairs
(Geriatric Psychiatry Training, Office of Academic Affiliations; CSR&D
Merit Review). D Sultzer is the principal investigator and H Samadi a
clinical investigator of a Phase III clinical trial of solanezumab
sponsored by Eli Lilly and Company.
NR 55
TC 28
Z9 31
U1 7
U2 35
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1471-2598
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JUN
PY 2011
VL 11
IS 6
BP 787
EP 798
DI 10.1517/14712598.2011.578573
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 760JU
UT WOS:000290321400010
PM 21504387
ER
PT J
AU Bartzokis, G
AF Bartzokis, George
TI Neuroglialpharmacology: white matter pathophysiologies and psychiatric
treatments
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE White matter; oligodendrocyte; neuregulin; ErbB; DISC1; nardilysin;
apolipoprotein; secretase; medication; degeneration; MRI; Review
ID CATECHOL-O-METHYLTRANSFERASE; CENTRAL-NERVOUS-SYSTEM; N-ACETYL-CYSTEINE;
NICOTINIC ACETYLCHOLINE-RECEPTOR; FATTY-ACID-COMPOSITION; POSTMORTEM
ORBITOFRONTAL CORTEX; MILD COGNITIVE IMPAIRMENT;
PLACEBO-CONTROLLED-TRIAL; OLIGODENDROCYTE PRECURSOR CELLS; DORSOLATERAL
PREFRONTAL CORTEX
AB Psychotropic treatments such as second generation or "atypical" antipsychotics are efficacious in a wide spectrum of psychiatric disorders ranging from schizophrenia to depression, bipolar disorder, and autism. These treatments are associated with peripheral metabolic derangements that are often also present in drug-naive patients. Furthermore, altering lipid composition/levels (with omega 3 fatty acids) and ameliorating oxidative toxicities may treat/prevent disease. The above observations are reexamined from the perspective of a myelin-centered model of the human brain. The model proposes that the human brain's extensive myelination required higher metabolic resources that caused evolutionary adaptations resulting in our quadratic (inverted U) myelination trajectory that peaks in the sixth decade of life. It further proposes that optimal brain function depends on exquisite action potential synchronization that myelin makes possible and that myelin's exceptional vulnerability to subtle metabolic/oxidative abnormalities may promote both developmental and degenerative diseases. Available data are integrated herein to suggest that widely used psychotropic treatments have under-appreciated CNS metabolic and neurotransmitter effects on myelination, its plasticity, and repair that may substantially contribute to their mechanisms of action.
C1 [Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA.
[Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Div Brain Mapping, Lab Neuroimaging,Dept Neurol, Los Angeles, CA 90095 USA.
[Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
[Bartzokis, George] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA.
RP Bartzokis, G (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA.
EM gbar@ucla.edu
RI Bartzokis, George/K-2409-2013
FU NIH [MH 0266029, AG027342]; Research and Psychiatry Services of the
Department of Veterans Affairs; RCS Foundation
FX This work was supported in part by NIH grants (MH 0266029; AG027342),
Research and Psychiatry Services of the Department of Veterans Affairs,
and the RCS Foundation. The author thanks Lori L. Altshuler, M.D., and
Keith H. Nuechterlein, Ph.D. for reading the manuscript and providing
suggestions for improving it.
NR 521
TC 23
Z9 23
U1 4
U2 11
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JUN 1
PY 2011
VL 16
BP 2695
EP 2733
DI 10.2741/3881
PG 39
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 757OK
UT WOS:000290097400020
PM 21622204
ER
PT J
AU Zhang, Q
Radisavljevic, ZM
Siroky, MB
Azadzoi, KM
AF Zhang, Q.
Radisavljevic, Z. M.
Siroky, M. B.
Azadzoi, K. M.
TI Dietary antioxidants improve arteriogenic erectile dysfunction
SO INTERNATIONAL JOURNAL OF ANDROLOGY
LA English
DT Article
DE antioxidants; erectile dysfunction; ischaemia; oxidative stress
ID CAVERNOSUM SMOOTH-MUSCLE; E-DEFICIENT MICE; OXIDATIVE STRESS; CORPUS
CAVERNOSUM; NITRIC-OXIDE; LIPID-PEROXIDATION; RED WINE; CONSUMPTION;
ISCHEMIA; SUSCEPTIBILITY
AB P>Most cases of erectile dysfunction (ED) are associated with oxidative stress risk factors such as diabetes mellitus, smoking, hypercholesterolaemia and hypertension. Our goal was to search for markers of oxidative stress in arteriogenic ED and examine the protective role of dietary antioxidants. Atherosclerosis-induced ED was developed in rabbits by balloon de-endothelialization of the iliac arteries. Ballooned and age-matched control animals were assigned into subgroups receiving pomegranate extract antioxidants in drinking water or tap water as placebo. After 8 weeks, penile blood flow and erectile activity were recorded. Erectile tissue relaxation, oxidative products, oxidative stress-responsive genes and structure were examined using organ bath, enzyme immunoassay, quantitative real-time polymerase chain reaction and transmission electron microscopy, respectively. Arterial ballooning caused diffused atherosclerosis, decreased intracavernosal blood flow and led to ED. Impairment of endothelium-dependent relaxation, diffused fibrosis, increased oxidative products, upregulation of superoxide dismutase (SOD) and aldose reductase (AR) gene expression, mitochondrial and endothelial structural damage and increased caveolae were evident in erectile tissues from atherosclerotic animals receiving placebo. Upregulation of antioxidant enzymes SOD and AR failed to protect ischaemic erectile tissue from oxidative injury. Pomegranate extract significantly improved intracavernosal blood flow, erectile activity, smooth muscle relaxation and fibrosis of the atherosclerotic group in comparison with the atherosclerotic group receiving placebo, but did not normalize them to the age-matched control levels. Pomegranate extract appeared more effective in diminishing oxidative products, preventing SOD and AR gene upregulation, and protecting mitochondrial, endothelial and caveolae structural integrity of the atherosclerotic group. Our data suggest the presence of oxidative stress in ED and a more efficient action of antioxidants on molecular and ultrastructural alterations than on distinct functional deficit and structural damage in the ischaemic penis.
C1 [Azadzoi, K. M.] VA Boston Healthcare Syst, Dept Urol & Pathol, Boston, MA 02130 USA.
[Zhang, Q.; Radisavljevic, Z. M.; Siroky, M. B.] VA Boston Healthcare Syst, Dept Urol, Boston, MA 02130 USA.
[Azadzoi, K. M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Azadzoi, KM (reprint author), VA Boston Healthcare Syst, Dept Urol & Pathol, Urol Res 151,150 S Huntington Ave, Boston, MA 02130 USA.
EM kazadzoi@bu.edu
FU Department of Veterans Affairs; POM Wonderful Inc.
FX This work was supported by a Merit Review Grant from the Department of
Veterans Affairs and POM Wonderful Inc.
NR 35
TC 23
Z9 24
U1 3
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0105-6263
J9 INT J ANDROL
JI Int. J. Androl.
PD JUN
PY 2011
VL 34
IS 3
BP 225
EP 235
DI 10.1111/j.1365-2605.2010.01083.x
PG 11
WC Andrology
SC Endocrinology & Metabolism
GA 759UL
UT WOS:000290273900004
PM 20584092
ER
PT J
AU Yeh, Y
Slovik, D
Carter, D
Clapp, M
Churchill, W
Reddy, P
AF Yeh, Y.
Slovik, D.
Carter, D.
Clapp, M.
Churchill, W.
Reddy, P.
TI Intravenous bisphosphonates for post-menopausal osteoporosis: adherence
to a network guideline
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Article
DE adherence; bisphosphonate; guideline; ibandronate; zoledronic acid
ID ZOLEDRONIC ACID; FRACTURES; THERAPY
AB P>What is known and Objective:
An evidence-based guideline on the use of intravenous (i.v.) bisphosphonates in post-menopausal osteoporosis was developed across a healthcare system and approved by clinical experts and Pharmacy and Therapeutics Committees. The objective of the study was to evaluate adherence to the guideline at hospitals in the healthcare system.
Methods:
Post-menopausal women who received i.v. zoledronic acid or i.v. ibandronate for osteoporosis between September 2007 and October 2008 were identified through a data repository that provides patient-level longitudinal information on diagnoses, medications and laboratory tests. Manual review of electronic medical records supplemented the data capture. The guideline recommends use of i.v. bisphosphonates in patients: (i) who have had a recent vertebral or hip fracture; (ii) who cannot stand or sit upright for 30-60 min; (iii) who have oesophageal dysmotility or varices; (iv) who have documented adherence issues or, (v) who failed to tolerate oral bisphosphonates after 12 months. In addition, specific monitoring tests are recommended prior to administration.
Results and Discussion:
Among the 220 women that received an i.v. bisphosphonate (hospitals A/B: n = 92 vs. hospital C: n = 128), 72% met the criteria for use. The results were similar when examined by institution (hospitals A/B 66% vs. hospital C 77%; P = 0 center dot 094). On review of the electronic medical records, an additional reason for using i.v. bisphosphonates was identified: persistent bone loss despite oral bisphosphonate therapy. When this criterion for use was included, the adherence rate increased to 80% (hospitals A/B 72% vs. hospital C 86%; P = 0 center dot 009). Serum calcium and 25-OH vitamin D were performed in 75% (hospitals A/B 77% vs. hospital C 73%; P = 0 center dot 53), and 86% (hospitals A/B 84% vs. hospital C 87%; P = 0 center dot 53) of patients respectively.
What is new and Conclusion:
Adherence to an i.v. bisphosphonates evidence-based guideline was adequate (defined as at least 80%) although room for improvement in meeting the criteria for use at one hospital and for conducting baseline serum calcium levels was noted. A future project is warranted to re-assesses adherence after the measures to improve guideline adherence are implemented.
C1 [Yeh, Y.; Reddy, P.] Partners Healthcare, Partners Ctr Drug Policy, Needham, MA 02494 USA.
[Slovik, D.] Newton Wellesley Hosp, Dept Med, Newton, MA USA.
[Slovik, D.] Massachusetts Gen Hosp, Endocrine Associates, Endocrine Unit, Boston, MA 02114 USA.
[Churchill, W.] Brigham & Womens Hosp, Dept Pharm, Boston, MA 02115 USA.
[Clapp, M.] Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA.
RP Yeh, Y (reprint author), Partners Healthcare, Partners Ctr Drug Policy, 115 4th Ave, Needham, MA 02494 USA.
EM yyeh@partners.org
NR 12
TC 0
Z9 0
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-4727
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD JUN
PY 2011
VL 36
IS 3
BP 342
EP 347
DI 10.1111/j.1365-2710.2010.01186.x
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 760GQ
UT WOS:000290313200009
PM 21545613
ER
PT J
AU Kohen, R
Shofer, JB
Korvatska, O
Petrie, EC
Wang, LY
Schellenberg, GD
Peskind, ER
Wilkinson, CW
AF Kohen, R.
Shofer, J. B.
Korvatska, O.
Petrie, E. C.
Wang, L. Y.
Schellenberg, G. D.
Peskind, E. R.
Wilkinson, C. W.
TI ABCB1 Genotype and CSF beta-Amyloid in Alzheimer Disease
SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
LA English
DT Article
DE Alzheimer disease; dementia; P-glycoprotein; MDR1; ABCB1; association
study
ID BLOOD-BRAIN-BARRIER; P-GLYCOPROTEIN EXPRESSION; MDR1; RESISTANCE;
TRANSPORT; POLYMORPHISMS; PATHOGENESIS; DEPOSITION; RELEVANCE; GENE
AB The ABCB1 gene, coding for the efflux transporter P-glycoprotein (PGP), is a candidate gene for Alzheimer disease (AD). P-glycoprotein is heavily expressed at the blood-brain barrier, where it mediates the efflux of beta-amyloid (A beta) from the brain. In this study, we investigated a possible association between 2 common ABCB1 polymorphisms, G2677T/A (Ala893Ser/Thr) and C3435T, AD, and cerebrospinal fluid (CSF) levels of A beta. No strong evidence for association was found.
C1 [Kohen, R.; Korvatska, O.; Petrie, E. C.; Wang, L. Y.; Schellenberg, G. D.; Peskind, E. R.; Wilkinson, C. W.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Shofer, J. B.; Petrie, E. C.; Wang, L. Y.; Peskind, E. R.] VA Puget Sound Hlth Care Syst, MIRECC, Washington, DC USA.
[Schellenberg, G. D.; Wilkinson, C. W.] Vet Affairs VA Puget Sound Hlth Care Syst, GRECC, Tacoma, WA USA.
RP Kohen, R (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, HSB BB1537,1959 Pacific Ave NE, Seattle, WA 98195 USA.
EM ruko@uw.edu
FU NIH/NIA [P50AG005136]; Northwest Network VISN 20 Mental Illness
Research, Education and Clinical Center (MIRECC); VA Puget Sound
Geriatric Research, Education and Clinical Center (GRECC); Office of
Research and Development Medical Research Service, Department of
Veterans Affairs
FX The authors disclosed receipt of the following financial support for the
research and/or authorship of this article: NIH/NIA grant P50AG005136
and by the Northwest Network VISN 20 Mental Illness Research, Education
and Clinical Center (MIRECC), the VA Puget Sound Geriatric Research,
Education and Clinical Center (GRECC), and the Office of Research and
Development Medical Research Service, Department of Veterans Affairs.
NR 27
TC 6
Z9 7
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0891-9887
J9 J GERIATR PSYCH NEUR
JI J. Geriatr. Psychiatry Neurol.
PD JUN
PY 2011
VL 24
IS 2
BP 63
EP 66
DI 10.1177/0891988711402325
PG 4
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA 759MZ
UT WOS:000290251600001
PM 21478475
ER
PT J
AU Huls, S
Hogen, T
Vassallo, N
Danzer, KM
Hengerer, B
Giese, A
Herms, J
AF Huels, Sandra
Hoegen, Tobias
Vassallo, Neville
Danzer, Karin M.
Hengerer, Bastian
Giese, Armin
Herms, Jochen
TI AMPA-receptor-mediated excitatory synaptic transmission is enhanced by
iron-induced alpha-synuclein oligomers
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE AMPA-receptor; oligomer; Parkinson's disease; synaptic transmission;
synuclein
ID LEWY-BODY-DISEASE; INTENSELY FLUORESCENT TARGETS; ABNORMAL PROTEIN
AGGREGATION; FAMILIAL PARKINSONS-DISEASE; SOLUBLE AMYLOID OLIGOMERS;
HIPPOCAMPAL-NEURONS; PRION PROTEIN; ALZHEIMERS-DISEASE; GLUTAMATE
RELEASE; PRECURSOR PROTEIN
AB P>Aggregated alpha-synuclein (alpha-syn) is a characteristic pathological finding in Parkinson's disease and related disorders, such as dementia with Lewy bodies. Recent evidence suggests that alpha-syn oligomers represent the principal neurotoxic species; however, the pathophysiological mechanisms are still not well understood. Here, we studied the neurophysiological effects of various biophysically-characterized preparations of alpha-syn aggregates on excitatory synaptic transmission in autaptic neuronal cultures. Nanomolar concentrations of large alpha-syn oligomers, generated by incubation with organic solvent and Fe3+ ions, were found to selectivity enhance evoked alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-receptor, but not NMDA-receptor, mediated synaptic transmission within minutes. Moreover, the analysis of spontaneous AMPA-receptor-mediated miniature synaptic currents revealed an augmented frequency. These results collectively indicate that large alpha-syn oligomers alter both pre- and post-synaptic mechanisms of AMPA-receptor-mediated synaptic transmission. The augmented excitatory synaptic transmission may directly contribute to nerve cell death in synucleinopathies. Indeed, already low micromolar glutamate concentrations were found to be toxic in primary cultured neurons incubated with large alpha-syn oligomers. In conclusion, large alpha-syn oligomers enhance both pre- and post-synaptic AMPA-receptor-mediated synaptic transmission, thereby aggravating intracellular calcium dyshomeostasis and contributing to excitotoxic nerve cell death in synucleinopathies.
C1 [Huels, Sandra; Giese, Armin; Herms, Jochen] Univ Munich, Ctr Neuropathol & Prion Res, D-81377 Munich, Germany.
[Hoegen, Tobias] Univ Munich, Dept Neurol, D-81377 Munich, Germany.
[Vassallo, Neville] Univ Malta, Dept Physiol & Biochem, Msida, Malta.
[Danzer, Karin M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Inst Neurodegenerat Dis, Charlestown, MA USA.
[Hengerer, Bastian] Boehringer Ingelheim Pharma GmbH & Co KG, CNS Dis Res, Biberach, Germany.
RP Herms, J (reprint author), Univ Munich, Zentrum Neuropathol, Feodor Lynen Str 23, D-81377 Munich, Germany.
EM jochen.herms@med.uni-muenchen.de
RI Herms, Jochen/D-3518-2011; Giese, Armin/F-3271-2010
OI Giese, Armin/0000-0002-8238-4102
FU DFG [SFB 596]; German Federal Ministry of Education and Research
(Boundesministerium fur Bildung und Forschung) [01EW1006]; University of
Malta [R09-31-309]
FX This work was supported by the DFG (SFB 596) as well as the German
Federal Ministry of Education and Research (Boundesministerium fur
Bildung und Forschung), 01EW1006, ImageNinND to J.H.; Research Grant
(R09-31-309) from the University of Malta to N.V.
NR 53
TC 26
Z9 27
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD JUN
PY 2011
VL 117
IS 5
BP 868
EP 878
DI 10.1111/j.1471-4159.2011.07254.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 759FB
UT WOS:000290225000009
PM 21426349
ER
PT J
AU Hussaini, BE
Treanor, PR
Healey, NA
Lu, XG
Khuri, SF
Thatte, HS
AF Hussaini, Bader E.
Treanor, Patrick R.
Healey, Nancy A.
Lu, Xiu-Gui
Khuri, Shukri F.
Thatte, Hemant S.
TI Multifactorial Comparison of Modified and Conventional Perfusion
Strategies in A Porcine Model of Cardiopulmonary Bypass
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE thromboresistant surfaces; heparin-bonded circuit; CABG; cardiac surgery
ID SYSTEMIC INFLAMMATORY RESPONSE; IN-VITRO MODEL; BLOOD-LOSS; TRANSFUSION
REQUIREMENTS; CARDIAC-SURGERY; HEPARIN; CIRCUITS; ACTIVATION;
COMPLEMENT; LEUKOCYTE
AB Background. Utilization of thromboresistant circuits in cardiopulmonary bypass (CPB) surgery has been controversial. However, due to the advantages associated with these types of circuits, we sought to evaluate the efficacy of use of low-dose heparin in conjunction with thromboresistant surfaces, closed perfusion system, elimination of blood-gas interface, maintenance of hematocrit to > 25%, and systemic normothermia, with respect to the conventional strategy of non-thromboresistant open circuits with high-dose heparin, during 3 h of CPB in an animal model.
Methods. Using an open-chest swine model, animals were placed on CPB for 3 h with additional monitoring for 1 h post-CPB. Pigs were randomized into either a heparin-bonded circuit (HBC) group (n = 10) or a non-HBC (NHB) group (n = 10). Hemodynamic, hematologic, and biochemical parameters and multiphoton microscopy were used to compare the two groups.
Results. Pigs in the HBC group showed a 38.4% reduction in post-CPB blood loss in comparison with the NHB group (P = 0.0007). Additionally, compared with the HBC group, the NHB group exhibited a 32.7% post-CPB reduction in platelets (P < 0.001) and significant increases in alkaline phosphatase, aspartate aminotransferase, and creatine phosphokinase enzymes (P < 0.0202, P = 0.0015, P < 0.0001; respectively). Multiphoton imaging of the arterial filters revealed no entrapment of RBC, WBC, and platelets in the HBC group, while the filters in the NHB group were clogged by these cells.
Conclusion. Utilization of modified perfusion strategy employing low-dose heparin and closed thromboresistant circuits is successful in ameliorating the potential adverse hematologic and pro-inflammatory elements induced with open perfusion system of non-thromboresistant circuits most commonly used in cardiac surgery. Published by Elsevier Inc.
C1 [Hussaini, Bader E.; Treanor, Patrick R.; Healey, Nancy A.; Lu, Xiu-Gui; Khuri, Shukri F.; Thatte, Hemant S.] VA Boston Healthcare Syst, Dept Cardiothorac Surg, Boston, MA USA.
[Hussaini, Bader E.; Lu, Xiu-Gui; Khuri, Shukri F.; Thatte, Hemant S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Hussaini, Bader E.; Lu, Xiu-Gui; Khuri, Shukri F.; Thatte, Hemant S.] Harvard Univ, Sch Med, Boston, MA USA.
RP Thatte, HS (reprint author), VA Boston Healthcare Syst, Dept Surg MC112, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM Hemant_thatte@hms.harvard.edu
FU VA Merit Review; DoD/ONR
FX The authors acknowledge support for this work by VA Merit Review (SKF
and HST), and DoD/ONR grants (HST).
NR 33
TC 1
Z9 1
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD JUN
PY 2011
VL 168
IS 1
BP E7
EP E15
DI 10.1016/j.jss.2010.01.037
PG 9
WC Surgery
SC Surgery
GA 756MQ
UT WOS:000290016200002
PM 20421111
ER
PT J
AU Lee, SH
Jia, SD
Zhu, YN
Utermark, T
Signoretti, S
Loda, M
Schaffhausen, B
Roberts, TM
AF Lee, Sang Hyun
Jia, Shidong
Zhu, Yanni
Utermark, Tamara
Signoretti, Sabina
Loda, Massimo
Schaffhausen, Brian
Roberts, Thomas M.
TI Transgenic Expression of Polyomavirus Middle T Antigen in the Mouse
Prostate Gives Rise to Carcinoma
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CELLS IN-VITRO; INTRAEPITHELIAL NEOPLASIA; GENE-EXPRESSION;
TUMOR-ANTIGEN; MEDIATED TRANSFORMATION; CANCER PROGRESSION;
MAMMARY-TUMORS; BREAST-CANCER; PTEN; MICE
AB The middle T (MT) antigen of polyomavirus has provided fundamental insights into the regulation of mammalian cell growth in vitro and important animal models for the analysis of tumor induction. The mouse mammary tumor virus (MMTV)-MT model of breast cancer has been important for probing the cellular signaling pathways in mammary tumorigenesis. MT itself has no intrinsic enzymatic activity but, rather, transforms by binding to and activating key intracellular signaling molecules, phosphatidylinositol 3-kinase (PI3-kinase) being the best studied of these. Thus, MT mimics a constitutively activated receptor tyrosine kinase (RTK). Our recent work suggests that MT signaling, like that of RTKs, is often quite dependent on cellular context in vitro. Here, we examine contextual effects on signaling in animal models as well. In this study, we generated transgenic mice in which MT is expressed in the mouse prostate under the control of an (ARR) 2-Probasin promoter. All male transgenic mice displayed mouse prostatic intraepithelial neoplasia (mPIN) in the ventral and dorsal/lateral prostate as early as 8 weeks of age. Notably, during the course of tumor development over time, invasive cancer, reactive stroma, and infiltration of inflammatory cells were seen. Transcriptional profiling analyses show regulation of multiple pathways, with marked upregulation of both the NF-kappa B and inflammatory pathways. Comparison of expression profiles of our MT prostate model with those from an MMTV-MT breast model (23) shows both tissue-specific and tissue-independent MT effects. The signature of genes regulated by MT in a tissue-independent manner may have prognostic value.
C1 [Zhu, Yanni; Schaffhausen, Brian] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02112 USA.
[Lee, Sang Hyun; Jia, Shidong; Utermark, Tamara; Roberts, Thomas M.] Dana Farber Canc Inst, Dept Cell Biol, Boston, MA 02115 USA.
[Signoretti, Sabina; Loda, Massimo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Lee, Sang Hyun; Jia, Shidong; Utermark, Tamara; Signoretti, Sabina; Loda, Massimo; Roberts, Thomas M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Schaffhausen, B (reprint author), Tufts Univ, Sch Med, Dept Biochem, Jaharis 606, Boston, MA 02112 USA.
EM brian.schaffhausen@tufts.edu; thomas_roberts@dfci.harvard.edu
FU National Institutes of Health; Prostate Cancer Foundation; Linda and
Arthur Gelb Center for Translational Research; DFHCC Prostate SPORE
FX This work was supported in part by grants from the National Institutes
of Health (T.M.R., B.S., and M.L.), the Prostate Cancer Foundation
(M.L.), the Linda and Arthur Gelb Center for Translational Research
(M.L.), and the DFHCC Prostate SPORE (T.M.R. and M.L.). In compliance
with Harvard Medical School guidelines, we disclose the consulting
relationships: Novartis Pharmaceuticals, Inc. (T.M.R. and M.L.).
NR 73
TC 2
Z9 2
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN
PY 2011
VL 85
IS 11
BP 5581
EP 5592
DI 10.1128/JVI.02609-10
PG 12
WC Virology
SC Virology
GA 760CE
UT WOS:000290298700035
PM 21411524
ER
PT J
AU Seto, D
Chodosh, J
Brister, JR
Jones, MS
AF Seto, Donald
Chodosh, James
Brister, J. Rodney
Jones, Morris S.
CA Adenovirus Res Community
TI Using the Whole-Genome Sequence To Characterize and Name Human
Adenoviruses
SO JOURNAL OF VIROLOGY
LA English
DT Letter
C1 [Seto, Donald] George Mason Univ, Sch Syst Biol, Manassas, VA 20110 USA.
[Chodosh, James] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Howe Lab, Boston, MA 02114 USA.
[Brister, J. Rodney] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA.
[Jones, Morris S.] Calif Dept Publ Hlth, Viral & Rickettsial Dis Lab, Richmond, CA 94804 USA.
RP Seto, D (reprint author), George Mason Univ, Sch Syst Biol, 10900 Univ Blvd,MSN 5B3, Manassas, VA 20110 USA.
EM dseto@gmu.edu
RI Zhang, Qiwei/D-9110-2012; Leppard, Keith/A-1853-2009; Lukashev,
Alexander/G-2777-2013; Kremer, Eric /D-3734-2013; San Martin,
Carmen/A-4074-2010; van Raaij, Mark/B-3678-2009; Greber,
Urs/G-9458-2015;
OI Smith, Jason/0000-0001-6727-5269; Zhang, Qiwei/0000-0002-2770-111X;
Leppard, Keith/0000-0003-2155-7919; Kremer, EJ/0000-0001-6114-7530;
Lukashev, Alexander/0000-0001-7365-0352; San Martin,
Carmen/0000-0001-9799-175X; van Raaij, Mark/0000-0002-4781-1375; Greber,
Urs/0000-0003-2278-120X; Heim, Albert/0000-0002-9447-1561
FU Intramural NIH HHS; NEI NIH HHS [R01 EY013124, EY013124, P30 EY014104,
P30EY014104]
NR 0
TC 48
Z9 55
U1 1
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN
PY 2011
VL 85
IS 11
BP 5701
EP 5702
DI 10.1128/JVI.00354-11
PG 2
WC Virology
SC Virology
GA 760CE
UT WOS:000290298700049
PM 21450823
ER
PT J
AU Shoup, TM
Elmaleh, DR
Brownell, AL
Zhu, A
Guerrero, JL
Fischman, AJ
AF Shoup, Timothy M.
Elmaleh, David R.
Brownell, Anna-Liisa
Zhu, Aijun
Guerrero, J. Luis
Fischman, Alan J.
TI Evaluation of (4-[F-18]Fluorophenyl)triphenylphosphonium Ion. A
Potential Myocardial Blood Flow Agent for PET
SO MOLECULAR IMAGING AND BIOLOGY
LA English
DT Article
DE Myocardial perfusion agent; Positron emission tomography; F-18;
Tetraphenylphosphonium; Mitochondrial damage; membrane potential
ID CORONARY-ARTERY-DISEASE; MITOCHONDRIAL-MEMBRANE; KINETIC-ANALYSIS;
CARCINOMA-CELLS; TRACER; HEARTS; PHOSPHONIUM; CARDIOLOGY; RETENTION;
ELECTRODE
AB The lipophilic cationic compound, (4-[F-18]fluorophenyl)triphenylphosphonium ion (F-18-FTPP) was synthesized and evaluated as a potential positron emission tomography (PET) myocardial perfusion agent.
F-18-FTPP was prepared from (4-nitrophenyl)triphenylphosphonium nitrate and ammonium [F-18]fluoride by nucleophilic aromatic substitution and was purified by high performance liquid chromatography before use. Biodistribution studies were performed in rats at 5, 30, 60 min (five rats per time point). Three rats were evaluated by microPET imaging after injection of F-18-FTPP. In addition, microPET imaging in rabbits (three) was performed before and after occlusion of the left anterior descending (LAD) artery with (NH3)-N-13 (111 MBq) and F-18-FTPP (74 MBq).
Biodistribution data in rats showed rapid blood clearance and high levels of accumulation in the heart; 75:1 heart-to-blood ratio at 30 min. Uptake of radioactivity in the heart was 1.64% ID/G, 1.51% ID/g, and 1.57% ID/g at 5, 30, and 60 min. At 5, 30, and 60 min, lung activity was 0.69% ID/g, 0.03% ID/g, and 0.38% ID/g, and liver uptake was 0.34% ID/g, 0.18% ID/g, and 0.17% ID/g. Heart-to-lung ratios at 5, 30, and 60 min were 2, 5, and 4. Bone accumulation was minimal. MicroPET imaging in both rats and rabbits after injection of F-18-FTPP demonstrated an initial spike of activity in the myocardium corresponding to blood flow followed by a plateau after 1 min. Region of interest analysis of microPET images of normal and LAD-occluded rabbits with (NH3)-N-13 and F-18-FTPP indicated similar distributions of the two tracers in both normal and altered blood flow regions.
The excellent heart-to-blood ratio of F-18-FTPP and its correlation with (NH3)-N-13 distribution in normal and LAD-occluded rabbits suggest that this radiopharmaceutical may have potential as a PET agent for characterizing mitochondrial damage and/or myocardial blood flow.
C1 [Shoup, Timothy M.; Elmaleh, David R.; Brownell, Anna-Liisa; Zhu, Aijun; Guerrero, J. Luis; Fischman, Alan J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Elmaleh, DR (reprint author), Massachusetts Gen Hosp, Dept Radiol, Edwards Bldg B015,55 Fruit St, Boston, MA 02114 USA.
EM delmaleh@partners.org
NR 26
TC 25
Z9 28
U1 3
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1536-1632
J9 MOL IMAGING BIOL
JI Mol. Imaging. Biol.
PD JUN
PY 2011
VL 13
IS 3
BP 511
EP 517
DI 10.1007/s11307-010-0349-2
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 759VT
UT WOS:000290277300013
PM 20563755
ER
PT J
AU Gupta, R
Tayal, AH
Levy, EI
Cheng-Ching, E
Rai, A
Liebeskind, DS
Yoo, AJ
Hsu, DP
Rymer, MM
Zaidat, OO
Lin, R
Natarajan, SK
Nogueira, RG
Nanda, A
Tian, M
Hao, Q
Abou-Chebl, A
Kalia, JS
Nguyen, TN
Chen, M
Jovin, TG
AF Gupta, Rishi
Tayal, Ashis H.
Levy, Elad I.
Cheng-Ching, Esteban
Rai, Ansaar
Liebeskind, David S.
Yoo, Albert J.
Hsu, Daniel P.
Rymer, Marilyn M.
Zaidat, Osama O.
Lin, Ridwan
Natarajan, Sabareesh K.
Nogueira, Raul G.
Nanda, Ashish
Tian, Melissa
Hao, Qing
Abou-Chebl, Alex
Kalia, Junaid S.
Nguyen, Thanh N.
Chen, Michael
Jovin, Tudor G.
TI Intra-arterial Thrombolysis or Stent Placement During Endovascular
Treatment for Acute Ischemic Stroke Leads to the Highest Recanalization
Rate: Results of a Multicenter Retrospective Study
SO NEUROSURGERY
LA English
DT Article
DE Acute stroke; Endovascular stroke; Intra-arterial thrombolysis; Stent
ID TRIAL; THERAPY; IMPACT; MELT
AB BACKGROUND: Reperfusion therapy for acute ischemic stroke (AIS) is rapidly evolving, with the development of multiple endovascular modalities that can be used alone or in combination.
OBJECTIVE: To determine which pharmacologic or mechanical modality may be associated with increased rates of recanalization.
METHODS: A cohort of 1122 patients with AIS involving the anterior circulation treated at 13 stroke centers underwent intra-arterial (IA) therapy within 8 hours of symptom onset. Demographic information, admission National Institutes of Health Stroke Scale (NIHSS), mechanical and pharmacologic treatments used, recanalization grade, and hemorrhagic complications were recorded.
RESULTS: The mean age was 67 +/- 16 years and the median NIHSS was 17. The sites of arterial occlusion before treatment were M1 middle cerebral artery (MCA) in 561 (50%) patients, carotid terminus in 214 (19%) patients, M2 MCA in 171 (15%) patients, tandem occlusions in 141 (13%) patients, and isolated extracranial internal carotid artery occlusion in 35 (3%) patients. Therapeutic interventions included multimodal therapy in 584 (52%) patients, pharmacologic therapy only in 264 (24%) patients, and mechanical therapy only in 274 (24%) patients. Patients treated with multimodal therapy had a significantly higher Thrombolysis in Myocardial Infarction 2 or 3 recanalization rate (435 patients [74%]) compared with pharmacologic therapy only (160 patients, [61%]) or mechanical only therapy (173 patients [63%]), P < .001. In binary logistic regression modeling, independent predictors of Thrombolysis in Myocardial Infarction 2 or 3 recanalization were use of IA thrombolytic OR 1.58 (1.21-2.08), P < .001 and stent deployment 1.91 (1.23-2.96), P < .001.
CONCLUSION: Multimodal therapy has significantly higher recanalization rates compared with pharmacologic or mechanical therapy. Among the individual treatment modalities, stent deployment or IA thrombolytics increase the chance of recanalization.
C1 [Gupta, Rishi; Nogueira, Raul G.] Emory Univ, Sch Med, Marcus Stroke & Neurosci Ctr, Grady Mem Hosp, Atlanta, GA 30303 USA.
[Cheng-Ching, Esteban] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Tayal, Ashis H.; Tian, Melissa] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA.
[Levy, Elad I.; Natarajan, Sabareesh K.] SUNY Buffalo, Buffalo, NY 14260 USA.
[Rai, Ansaar] W Virginia Univ, Morgantown, WV 26506 USA.
[Liebeskind, David S.; Hao, Qing] Univ Calif Los Angeles, UCLA Revascularizat Investigators, Los Angeles, CA USA.
[Liebeskind, David S.; Hao, Qing] Univ Calif Los Angeles, UCLA Stroke Investigators, Los Angeles, CA USA.
[Yoo, Albert J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hsu, Daniel P.; Nanda, Ashish] Univ Hosp, Cleveland, OH USA.
[Rymer, Marilyn M.] St Lukes Brain & Stroke Inst, Kansas City, MO USA.
[Zaidat, Osama O.; Kalia, Junaid S.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Lin, Ridwan; Jovin, Tudor G.] Univ Pittsburgh, Med Ctr, Stroke Inst, Pittsburgh, PA USA.
[Abou-Chebl, Alex] Univ Louisville, Med Ctr, Louisville, KY 40292 USA.
[Nguyen, Thanh N.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Chen, Michael] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
RP Gupta, R (reprint author), Emory Univ, Sch Med, 49 Jesse Hill Jr Dr SE,Fac Off Bldg 393, Atlanta, GA 30303 USA.
EM rishi.gupta@emory.edu
OI Kalia, Junaid/0000-0001-7121-8638
FU Penumbra Corp.
FX R Gupta is a Consultant/Scientific Advisory Board Concentric Medical,
CoAxia Inc., and Rapid Medical; AH Tayal is a Speaker for Genentech and
Boehringer Ingelheim; EI Levy reports Research Grant Boston Scientific
Corporation Research support Micrus Endovascular, Research Support
Abbott Vascular, Research Support EV3, Honoraria Intratech Medical Ltd.
Ownership Interest; Mynx/Access Closure, Ownership Interest TheraSyn
Sensors, Inc, Consultant/Advisory Board; Cordis Neurovascular,
Consultant/Advisory Board; Micrus Endovascular; E Cheng-Ching has no
relevant disclosures to report; A Rai is a Consultant/Scientific
Advisory Board for Concentric Medical; DS Liebskind reports NIH,
Significant, B. Research Grant; Concentric Medical, Inc., Modest, G.
Consultant/Advisory Board; Coaxia, Inc., Modest, G. Consultant/Advisory
Board, AJ Yoo received Research Support Penumbra Corp.; DP Hsu has no
relevant disclosures to report; MM Rymer is a Speaker for Concentric
Medical, Consultant for Genetech; O Zaidat is a Consultant/Scientific
Advisory Board Boston Scientific; R Lin and SK Natarajan do not have
relevant disclosures to report; RG Nogueira is a Consultant and Advisory
Board Concentric Medical, EV3, CoAxia Inc., and Rapid Medical; A Nanda,
M Tian, Q Hao, A Abou-Chebl, JS Kalia, and TN Nguyen have no relevant
disclosures to report; M Chen is a Speaker for Concentric Medical; TG
Jovin is Consultant/Scientific advisory board for CoAxia Inc.,
Concentric Medical, Consultant for EV3. The authors have no personal
financial or institutional interest in any of the drugs, materials, or
devices described in this article.
NR 16
TC 25
Z9 25
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD JUN
PY 2011
VL 68
IS 6
BP 1618
EP 1622
DI 10.1227/NEU.0b013e31820f156c
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 760CK
UT WOS:000290299700063
PM 21336221
ER
PT J
AU Bunyavanich, S
Shargorodsky, J
Celedon, JC
AF Bunyavanich, Supinda
Shargorodsky, Josef
Celedon, Juan C.
TI A meta-analysis of Th2 pathway genetic variants and risk for allergic
rhinitis
SO PEDIATRIC ALLERGY AND IMMUNOLOGY
LA English
DT Article
DE allergic rhinitis; genetic association; polymorphism; Th2; IL13
ID SINGLE NUCLEOTIDE POLYMORPHISMS; JAPANESE CEDAR POLLINOSIS; EOSINOPHIL
PEROXIDASE GENE; EGYPTIAN ATOPIC PATIENTS; INTERLEUKIN-4 RECEPTOR;
HAY-FEVER; ALPHA-SUBUNIT; BIRTH COHORT; IL13 GENE; TOTAL IGE
AB P>There is a significant genetic contribution to allergic rhinitis (AR). Genetic association studies for AR have been performed, but varying results make it challenging to decipher the overall potential effect of specific variants. The Th2 pathway plays an important role in the immunological development of AR. We performed meta-analyses of genetic association studies of variants in Th2 pathway genes and AR. PubMed and Phenopedia were searched by double extraction for original studies on Th2 pathway-related genetic polymorphisms and their associations with AR. A meta-analysis was conducted on each genetic polymorphism with data meeting our predetermined selection criteria. Analyses were performed using both fixed and random effects models, with stratification by age group, ethnicity, and AR definition where appropriate. Heterogeneity and publication bias were assessed. Six independent studies analyzing three candidate polymorphisms and involving a total of 1596 cases and 2892 controls met our inclusion criteria. Overall, the A allele of IL13 single nucleotide polymorphism (SNP) rs20541 was associated with increased odds of AR (estimated OR = 1.2; 95% CI 1.1-1.3, p-value 0.004 in fixed effects model, 95% CI 1.0-1.5, p-value 0.056 in random effects model). The A allele of rs20541 was associated with increased odds of AR in mixed age groups using both fixed effects and random effects modeling. IL13 SNP rs1800925 and IL4R SNP 1801275 did not demonstrate overall associations with AR. We conclude that there is evidence for an overall association between IL13 SNP rs20541 and increased risk of AR, especially in mixed-age populations.
C1 [Bunyavanich, Supinda; Shargorodsky, Josef; Celedon, Juan C.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
[Bunyavanich, Supinda] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
[Bunyavanich, Supinda; Shargorodsky, Josef; Celedon, Juan C.] Harvard Univ, Sch Med, Boston, MA USA.
[Shargorodsky, Josef] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Celedon, Juan C.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Celedon, Juan C.] Brigham & Womens Hosp, Dept Med, Ctr Genom Med, Boston, MA 02115 USA.
[Celedon, Juan C.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15260 USA.
[Celedon, Juan C.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA.
[Celedon, Juan C.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA.
[Celedon, Juan C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15260 USA.
RP Bunyavanich, S (reprint author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.
EM Supinda@post.harvard.edu
FU U.S. National Institutes of Health [K12 HL089990, HL073373, HL079966];
Massachusetts Eye and Ear Infirmary Foundation; [T32 HL007427]
FX SB is supported by U.S. National Institutes of Health grant K12 HL089990
and was supported by T32 HL007427. JS is supported by the Massachusetts
Eye and Ear Infirmary Foundation. JCC is supported by grants HL073373
and HL079966 from the U.S. National Institutes of Health. We would like
to thank Peter J. Castaldi for his technical support.
NR 66
TC 14
Z9 14
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0905-6157
J9 PEDIAT ALLERG IMM-UK
JI Pediatr. Allergy Immunol.
PD JUN
PY 2011
VL 22
IS 4
BP 378
EP 387
DI 10.1111/j.1399-3038.2010.01124.x
PG 10
WC Allergy; Immunology; Pediatrics
SC Allergy; Immunology; Pediatrics
GA 758NH
UT WOS:000290171000006
PM 21309855
ER
PT J
AU Green, JV
Sun, DW
Hafezi-Moghadam, A
Lashkari, K
Murthy, SK
AF Green, James V.
Sun, Dawei
Hafezi-Moghadam, Ali
Lashkari, Kameran
Murthy, Shashi K.
TI Microfluidic pillar array sandwich immunofluorescence assay for ocular
diagnostics
SO BIOMEDICAL MICRODEVICES
LA English
DT Article
DE Microfluidic; Immunoassay; Uveitis; Primary intraocular lymphoma
ID ENDOTOXIN-INDUCED UVEITIS; NERVOUS-SYSTEM LYMPHOMA; PRIMARY INTRAOCULAR
LYMPHOMA; AQUEOUS-HUMOR; INTERLEUKIN-10; RAT; IMMUNOASSAY; CYTOKINES
AB Uveitis and primary intraocular lymphoma (PIOL) are diseases associated with the invasion of lymphocytes into various regions of the eye, accompanied by expression of inflammatory cytokines. While these diseases are very different in terms of survivability and treatment options they have similar symptoms that make accurate diagnosis challenging. Furthermore, the diagnostic yield with state-of-the-art techniques for cell and cytokine analysis of vitreous and aqueous humor samples is under 20% due to inadequate sensitivity. This paper describes a simple sandwich immunofluorescence assay (sIFA) microfluidic device that is capable of identifying important analytes in ocular biopsies as a potential alternative to current diagnostic approaches. Detection is accomplished by capture of the target molecules on antibody-coated, vertical, oval shaped pillars in a microfluidic device followed by a biotinylated detection antibody and finally florescent avidin for target molecule quantification. Cytokine concentration measurements were carried out on aqueous humor samples from rats with endotoxin-induced uveitis as well as human cataract patients. Results correlated well with conventional protein quantification techniques and additionally, measurements from the human samples surpassed detection limits of current state-of-the-art immunoassay techniques. The single-digit femtomolar range of detection of this sIFA system provides lower limits of detection when compared to traditional techniques and allows for the mapping of the cytokine content of vitreous biopsies with detection limits that have yet to be realized using cost effective microfluidics. Furthermore, the relative simplicity of the device design, fabrication and ability to automate makes it easily translatable from the laboratory to a clinical setting.
C1 [Green, James V.; Murthy, Shashi K.] Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA.
[Sun, Dawei; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Lashkari, Kameran] Schepens Eye Res Inst, Boston, MA 02114 USA.
[Sun, Dawei; Hafezi-Moghadam, Ali; Lashkari, Kameran] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Murthy, SK (reprint author), Northeastern Univ, Dept Chem Engn, Boston, MA 02115 USA.
EM smurthy@coe.neu.edu
OI Hafezi-Moghadam, Ali/0000-0002-5336-0697
FU National Science Foundation [CBET-0827868]
FX The authors gratefully acknowledge financial support from the National
Science Foundation through grant CBET-0827868. The authors also thank
Mehdi Abedi for his CFD contributions.
NR 28
TC 9
Z9 9
U1 1
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1387-2176
J9 BIOMED MICRODEVICES
JI Biomed. Microdevices
PD JUN
PY 2011
VL 13
IS 3
BP 573
EP 583
DI 10.1007/s10544-011-9528-4
PG 11
WC Engineering, Biomedical; Nanoscience & Nanotechnology
SC Engineering; Science & Technology - Other Topics
GA 757PG
UT WOS:000290099600017
PM 21461664
ER
PT J
AU Mulligan, JK
Bleier, BS
O'Connell, B
Mulligan, RM
Wagner, C
Schlosser, RJ
AF Mulligan, J. K.
Bleier, B. S.
O'Connell, B.
Mulligan, R. M.
Wagner, C.
Schlosser, R. J.
TI Vitamin D-3 correlates inversely with systemic dendritic cell numbers
and bone erosion in chronic rhinosinusitis with nasal polyps and
allergic fungal rhinosinusitis
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE allergic fungal rhinosinusitis; bone erosion; chronic rhinosinusitis;
dendritic cells; vitamin D
ID 1,25-DIHYDROXYVITAMIN D-3; EPITHELIAL-CELLS; GM-CSF; ASTHMA; EXPRESSION;
DISEASE; PHENOTYPE; MOLECULES; SINUSITIS; RHINITIS
AB P>Vitamin D-3 (VD3) is a steroid hormone that regulates bone health and numerous aspects of immune function and may play a role in respiratory health. We hypothesized that T helper type 2 (Th2) disorders, chronic rhinosinusitis with nasal polyps (CRSwNP) and allergic fungal rhinosinusitis (AFRS) would have VD3 deficiencies, resulting in increased mature dendritic cells (DCs) and bone erosion. We conducted a retrospective study examining VD3 levels in patients with AFRS (n = 14), CRSwNP (n = 9), chronic rhinosinusitis without nasal polyps (CRSsNP) (n = 20) and cerebrospinal fluid leak repair (non-diseased controls) (n = 14) at time of surgery. Circulating immune cell levels were determined by immunostaining and flow cytometric analysis. Plasma VD3 and immune regulatory factors (granulocyte-macrophage colony-stimulating factor and prostaglandin E-2) were measured by enzyme-linked immunosorbent assay. It was observed that CRSwNP and AFRS demonstrated increased circulating DCs, while chronic rhinosinusitis without nasal polyps displayed increased circulating macrophages. CRSwNP and AFRS were to found to have insufficient levels of VD3 which correlated inversely with circulating numbers of mature DCs, DC regulatory factors and bone erosion. CRSsNP displayed no change in circulating DC numbers or VD3 status compared to control, but did display increased numbers of circulating macrophages that was independent of VD3 status. Lastly, VD3 deficiency was associated with more severe bone erosion. Taken together, these results suggest support a role for VD3 as a key player in the immunopathology of CRSwNP and AFRS.
C1 [Mulligan, J. K.; Bleier, B. S.; O'Connell, B.; Mulligan, R. M.; Schlosser, R. J.] Med Univ S Carolina, Div Rhinol & Sinus Surg, Dept Otolaryngol Head & Neck Surg, Charleston, SC USA.
[Mulligan, J. K.; Mulligan, R. M.; Schlosser, R. J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Wagner, C.] Med Univ S Carolina, Dept Pediat, Div Neonatol, Charleston, SC 29425 USA.
[Bleier, B. S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
RP Mulligan, JK (reprint author), MSC 550,135 Rutledge Ave, Charleston, SC 29425 USA.
EM konopa@musc.edu
FU Flight Attendant Medical Research Institute
FX The authors would like to thank Helen Accerbi RN for her technical
assistance with these studies. These studies were supported by grants to
R.J.S. and J.K.M. from the Flight Attendant Medical Research Institute.
NR 39
TC 37
Z9 38
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JUN
PY 2011
VL 164
IS 3
BP 312
EP 320
DI 10.1111/j.1365-2249.2011.04325.x
PG 9
WC Immunology
SC Immunology
GA 755QJ
UT WOS:000289950600003
PM 21401575
ER
EF